<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0//FR" "http://www.w3.org/TR/REC-html40/strict.dtd">
<!-- template_7 -->
<HTML>
  <HEAD>
    <META http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
    <META name="organization" content="ANSM : Agence Nationale de Sécurité du Médicament et des Produit de santé">
    <META name="description" content="Résumé des Caractéristiques du Produit">
    <META name="keywords" content="DOCETAXEL SEACROSS 20 mg/1 ml, solution à diluer pour perfusion, Médicament, Spécialité pharmaceutique, RCP, Résumé des Caractéristiques du Produit, Dénomination, Forme pharmaceutique, Indications, Contre-indications, Effets secondaires">
    <TITLE>Résumé des Caractéristiques du Produit</TITLE>
    <link rel="stylesheet" href="../style/spstyl01.css" type="text/css">
  </HEAD>
  <BODY>
<p class="AmmAnnexeTitre"><a name="RcpTitre">RÉSUMÉ DES CARACTÉRISTIQUES DU PRODUIT</a></p>
<p class="DateNotif">ANSM - Mis à jour le : 15/05/2014</p>
<p class="AmmAnnexeTitre1"><a name="RcpDenomination">1. DENOMINATION DU MEDICAMENT</a></p>
<p class=AmmDenomination>DOCETAXEL SEACROSS 20 mg/1 ml, solution à diluer pour perfusion</p>
<p class="AmmAnnexeTitre1"><a name="RcpCompoQualitQuanti">2. COMPOSITION QUALITATIVE ET QUANTITATIVE</a></p>
<p class=AmmComposition>Chaque ml de solution à diluer contient 20 mg de docétaxel anhydre.</p>
<p class=AmmComposition>Un flacon<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span>1<span style='letter-spacing:-.05pt'> </span><span style='letter-spacing:-.1pt'>m</span>l<span style='letter-spacing:-.1pt'> </span>de<span style='letter-spacing:-.1pt'> </span>solution<span style='letter-spacing:-.3pt'> </span>à diluer<span style='letter-spacing:-.2pt'> </span>contient<span style='letter-spacing:-.25pt'> </span>20<span style='letter-spacing:-.1pt'> m</span>g<span style='letter-spacing:-.05pt'> </span>de<span style='letter-spacing:-.1pt'> </span>docétaxel.</p>
<p class=AmmComposition><u>Excipient</u><span style='letter-spacing:-.6pt'> </span>: Chaque flacon de 1 ml de solution à diluer contient 0,57 ml d’éthanol à 96 % (0,46 g).</p>
<p class=AmmComposition>Pour la liste co<span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>p</span>lète<span style='letter-spacing:-.1pt'> </span>des<span style='letter-spacing:-.15pt'> </span>excipients,<span style='letter-spacing: -.4pt'> </span>voir<span style='letter-spacing:-.15pt'> </span>rubrique<span style='letter-spacing:-.35pt'> </span>6.1.</p>
<p class="AmmAnnexeTitre1"><a name="RcpFormePharm">3. FORME PHARMACEUTIQUE</a></p>
<p class=AmmCorpsTexte><a name="_Toc142278915">Solution<span style='letter-spacing: -.55pt'> </span>à diluer<span style='letter-spacing:-.2pt'> </span>pour<span style='letter-spacing:-.2pt'> </span>perfusion.</a></p>
<p class=AmmCorpsTexte>La solution à diluer est une solution stérile, visqueuse, limpide, incolore à jaune brunâtre.</p>
<p class="AmmAnnexeTitre1"><a name="RcpDonneesCliniques">4. DONNEES CLINIQUES</a></p>
<p class="AmmAnnexeTitre2"><a name="RcpIndicTherap">4.1. Indications thérapeutiques</a></p>
<p class=AmmCorpsTexte><a name="_Toc142278917"><u>Cancer du sein</u></a></p>
<p class=AmmCorpsTexte>Le docétaxel<span style='letter-spacing:-.85pt'> </span>en<span style='letter-spacing:-.1pt'> </span>association<span style='letter-spacing: -.45pt'> </span>à la doxorubicine<span style='letter-spacing:-.55pt'> </span>et au<span style='letter-spacing:-.1pt'> </span>cyclophospha<span style='letter-spacing:-.05pt'>m</span>ide<span style='letter-spacing:-.65pt'> </span>est<span style='letter-spacing:-.1pt'> </span>indiqué<span style='letter-spacing:-.3pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>le traite<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.3pt'> </span>adjuvant<span style='letter-spacing:.05pt'> </span>du<span style='letter-spacing:-.1pt'> </span>:</p>
<p class=AmmListePuces1 style='text-align:justify'><span style='font-family: Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>cancer<span style='letter-spacing:-.25pt'> </span>du<span style='letter-spacing:-.1pt'> </span>sein<span style='letter-spacing:-.15pt'> </span>opérable,<span style='letter-spacing:-.35pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>des<span style='letter-spacing:-.15pt'> </span>patients<span style='letter-spacing:-.3pt'> </span>présentant<span style='letter-spacing:-.4pt'> </span>un<span style='letter-spacing:-.1pt'> </span>envahisse<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.4pt'> </span>ganglionnaire,</p>
<p class=AmmListePuces1 style='text-align:justify'><span style='font-family: Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>cancer<span style='letter-spacing:-.25pt'> </span>du<span style='letter-spacing:-.1pt'> </span>sein<span style='letter-spacing:-.15pt'> </span>opérable,<span style='letter-spacing:-.35pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>des<span style='letter-spacing:-.15pt'> </span>patients<span style='letter-spacing:-.3pt'> </span>ne<span style='letter-spacing:-.1pt'> </span>présentant<span style='letter-spacing:-.4pt'> </span>pas<span style='letter-spacing:-.15pt'> </span>d<span style='letter-spacing:.05pt'>’</span>envahisse<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.05pt'> </span>ganglionnaire.</p>
<p class=AmmCorpsTexte style='margin-top:6.0pt'>Pour<span style='letter-spacing: -.45pt'> </span>des<span style='letter-spacing:-.15pt'> </span>patients<span style='letter-spacing:-.3pt'> </span>avec<span style='letter-spacing:-.2pt'> </span>cancer<span style='letter-spacing:-.25pt'> </span>du<span style='letter-spacing:-.1pt'> </span>sein<span style='letter-spacing:-.15pt'> </span>opérable<span style='letter-spacing:-.35pt'> </span>sa<span style='letter-spacing:.05pt'>n</span>s<span style='letter-spacing: -.1pt'> </span>envahisse<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.4pt'> </span>ganglionnaire,<span style='letter-spacing: -.55pt'> </span>le traite<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.3pt'> </span>adjuvant devra être<span style='letter-spacing: -.15pt'> </span>restreint<span style='letter-spacing:-.35pt'> </span>aux<span style='letter-spacing:-.15pt'> </span>patients<span style='letter-spacing:-.3pt'> </span><span style='letter-spacing:-.05pt'>éligibles</span><span style='letter-spacing:-.3pt'> </span>à une<span style='letter-spacing:-.15pt'> </span>chi<span style='letter-spacing:-.05pt'>m</span>iothérapie<span style='letter-spacing: -.1pt'> </span>selon<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>critères<span style='letter-spacing:-.3pt'> </span>internationale<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.1pt'> </span>établis<span style='letter-spacing:-.25pt'> </span>pour<span style='letter-spacing:-.2pt'> </span>le traite<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.3pt'> </span>initi<span style='letter-spacing:-.1pt'>a</span>l du<span style='letter-spacing:-.1pt'> </span>cancer<span style='letter-spacing:-.25pt'> </span>du<span style='letter-spacing:-.1pt'> </span>sein<span style='letter-spacing:2.4pt'> </span>au<span style='letter-spacing:-.1pt'> </span>stade<span style='letter-spacing:-.2pt'> </span>précoce<span style='letter-spacing:-.3pt'> </span>(voir<span style='letter-spacing:-.2pt'> </span>rubrique 5.1).</p>
<p class=AmmCorpsTexte>Le docétaxel en<span style='letter-spacing:-.1pt'> </span>association<span style='letter-spacing:-.45pt'> </span>à la doxorubicine<span style='letter-spacing: -.55pt'> </span>est<span style='letter-spacing:-.1pt'> </span><span style='letter-spacing:-.05pt'>i</span>ndiqué<span style='letter-spacing:-.25pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>le traite<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.3pt'> </span>du<span style='letter-spacing:-.1pt'> </span>cancer<span style='letter-spacing:-.2pt'> </span>du<span style='letter-spacing:-.1pt'> </span>sein<span style='letter-spacing:-.15pt'> </span>locale<span style='letter-spacing:-.05pt'>m</span>ent avancé<span style='letter-spacing: -.3pt'> </span>ou<span style='letter-spacing:-.1pt'> m</span>étastatique<span style='letter-spacing:-.45pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>patientes<span style='letter-spacing:-.35pt'> </span>n<span style='letter-spacing:-.1pt'>'</span>a<span style='letter-spacing: .1pt'>y</span>ant<span style='letter-spacing:-.05pt'> </span>pas<span style='letter-spacing:-.15pt'> </span>reçu<span style='letter-spacing:-.15pt'> </span>de<span style='letter-spacing:-.1pt'> </span>chi<span style='letter-spacing:-.05pt'>m</span>iothérapie<span style='letter-spacing:-.05pt'> </span>c<span style='letter-spacing:.1pt'>y</span>totoxique<span style='letter-spacing:-.05pt'> </span>antérieure dans<span style='letter-spacing: -.2pt'> </span>cette affection.</p>
<p class=AmmCorpsTexte>Le docétaxel<span style='letter-spacing:-.85pt'> </span>est<span style='letter-spacing:-.1pt'> </span>indiqué<span style='letter-spacing:-.3pt'> </span>en<span style='letter-spacing:-.1pt'> m</span>onothérapie<span style='letter-spacing:-.05pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>le t<span style='letter-spacing:-.05pt'>r</span>aite<span style='letter-spacing: -.05pt'>m</span>ent<span style='letter-spacing:-.1pt'> </span>des<span style='letter-spacing:-.15pt'> </span>patientes<span style='letter-spacing: -.35pt'> </span>atteintes<span style='letter-spacing:-.3pt'> </span>d<span style='letter-spacing:-.05pt'>'</span>un<span style='letter-spacing:-.05pt'> </span>cancer<span style='letter-spacing:-.25pt'> </span>du<span style='letter-spacing:-.1pt'> </span>sein locale<span style='letter-spacing:-.05pt'>m</span>ent avancé<span style='letter-spacing:-.3pt'> </span>ou<span style='letter-spacing:-.1pt'> m</span>étastatique<span style='letter-spacing:-.45pt'> </span>après<span style='letter-spacing:-.2pt'> </span>échec<span style='letter-spacing:-.25pt'> </span>d'une<span style='letter-spacing:-.25pt'> </span>chi<span style='letter-spacing:-.05pt'>m</span>iothérapie<span style='letter-spacing:-.05pt'> </span>c<span style='letter-spacing:.1pt'>y</span>totoxique,<span style='letter-spacing:-.05pt'> </span>a<span style='letter-spacing:.1pt'>y</span>ant<span style='letter-spacing:-.05pt'> </span>co<span style='letter-spacing:-.1pt'>m</span>porté<span style='letter-spacing:-.1pt'> </span>une anthrac<span style='letter-spacing: .1pt'>y</span>cline<span style='letter-spacing:.05pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>un<span style='letter-spacing:-.1pt'> </span>agent<span style='letter-spacing:-.2pt'> </span>alk<span style='letter-spacing:.1pt'>y</span>lant.</p>
<p class=AmmCorpsTexte>Le docétaxel en<span style='letter-spacing:-.1pt'> </span>association<span style='letter-spacing:-.45pt'> </span>au<span style='letter-spacing:-.1pt'> </span>trastuzu<span style='letter-spacing:-.05pt'>m</span>ab<span style='letter-spacing:-.3pt'> </span>est<span style='letter-spacing:-.1pt'> i</span>ndiqué<span style='letter-spacing:-.25pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>le traite<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.3pt'> </span>du<span style='letter-spacing:-.1pt'> </span>cancer<span style='letter-spacing:-.2pt'> </span>du<span style='letter-spacing:-.1pt'> </span>sein <span style='letter-spacing:-.1pt'>m</span>étastatique<span style='letter-spacing:-.4pt'> </span>avec<span style='letter-spacing:-.2pt'> </span>surexpression<span style='letter-spacing:-.6pt'> </span>tu<span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>o</span>rale<span style='letter-spacing:-.1pt'> </span>de<span style='letter-spacing:-.1pt'> </span>HER2,<span style='letter-spacing:-.25pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>patients<span style='letter-spacing:-.3pt'> </span>non<span style='letter-spacing:-.15pt'> </span>prétraités<span style='letter-spacing:-.35pt'> </span>par chi<span style='letter-spacing:-.05pt'>m</span>iothérapie<span style='letter-spacing:.05pt'> </span>pour<span style='letter-spacing:-.2pt'> </span>leur<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span>aladie<span style='letter-spacing:-.25pt'> </span><span style='letter-spacing:-.1pt'>m</span>étastatique.</p>
<p class=AmmCorpsTexte>Le docétaxel en<span style='letter-spacing:-.1pt'> </span>association<span style='letter-spacing:-.45pt'> </span>à la capécitabine<span style='letter-spacing: -.45pt'> </span>est<span style='letter-spacing:-.2pt'> </span>indiqué<span style='letter-spacing:-.3pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>le traite<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing: -.3pt'> </span>du<span style='letter-spacing:-.1pt'> </span>cancer<span style='letter-spacing:-.2pt'> </span>du<span style='letter-spacing:-.1pt'> </span>sein<span style='letter-spacing:-.15pt'> </span>locale<span style='letter-spacing:-.05pt'>m</span>ent avancé ou<span style='letter-spacing:-.1pt'> m</span>étastatique<span style='letter-spacing:-.45pt'> </span>après<span style='letter-spacing:-.2pt'> </span>échec<span style='letter-spacing:-.25pt'> </span>d<span style='letter-spacing:.05pt'>’</span>une<span style='letter-spacing:-.05pt'> </span>chi<span style='letter-spacing:-.05pt'>m</span>iothérapie<span style='letter-spacing:-.05pt'> </span>c<span style='letter-spacing:.1pt'>y</span>totoxique<span style='letter-spacing:-.05pt'> </span>a<span style='letter-spacing:.1pt'>y</span>ant<span style='letter-spacing:-.05pt'> </span>co<span style='letter-spacing:-.1pt'>m</span>porté<span style='letter-spacing:-.1pt'> </span>une<span style='letter-spacing:-.15pt'> </span>anthrac<span style='letter-spacing:.1pt'>y</span>cline.</p>
<p class=AmmCorpsTexte><u>Cancer du pou<span style='letter-spacing:-.1pt'>m</span>on non à petites cellules</u></p>
<p class=AmmCorpsTexte>Le docétaxel est<span style='letter-spacing:-.1pt'> </span>indiqué<span style='letter-spacing:-.3pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>le traite<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing: -.3pt'> </span>du<span style='letter-spacing:-.2pt'> </span>cancer<span style='letter-spacing:-.25pt'> </span>du poumon<span style='letter-spacing: -.45pt'> </span>non<span style='letter-spacing:-.15pt'> </span>à petites<span style='letter-spacing:-.25pt'> </span>cellules<span style='letter-spacing:-.3pt'> </span>locale<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.25pt'> </span>avancé ou<span style='letter-spacing: -.1pt'> m</span>étastatique,<span style='letter-spacing:-.5pt'> </span>après<span style='letter-spacing:-.2pt'> </span>échec<span style='letter-spacing:-.25pt'> </span>d<span style='letter-spacing:-.1pt'>'</span>une<span style='letter-spacing:-.05pt'> </span>chi<span style='letter-spacing:-.05pt'>m</span>iothérapie<span style='letter-spacing: -.05pt'> </span>antérieure.</p>
<p class=AmmCorpsTexte>Le docétaxel en<span style='letter-spacing:-.1pt'> </span>association<span style='letter-spacing:-.45pt'> </span>au<span style='letter-spacing:-.1pt'> </span>cisplatine<span style='letter-spacing:-.35pt'> </span>est<span style='letter-spacing:-.1pt'> </span>indiqué<span style='letter-spacing:-.4pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>le traite<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing: -.3pt'> </span>du<span style='letter-spacing:-.1pt'> </span>cancer<span style='letter-spacing:-.2pt'> </span>bronchique<span style='letter-spacing: -.45pt'> </span>non<span style='letter-spacing:-.15pt'> </span>à petites cellules<span style='letter-spacing:-.3pt'> </span>non<span style='letter-spacing: -.15pt'> </span>résécable,<span style='letter-spacing:-.4pt'> </span>locale<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.25pt'> </span>avancé<span style='letter-spacing:-.3pt'> </span>ou<span style='letter-spacing:-.1pt'> m</span>étas<span style='letter-spacing:-.05pt'>t</span>atique,<span style='letter-spacing:-.35pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>patients<span style='letter-spacing:-.3pt'> </span>n<span style='letter-spacing:-.05pt'>'</span>a<span style='letter-spacing: .1pt'>y</span>ant<span style='letter-spacing:-.05pt'> </span>pas<span style='letter-spacing:-.15pt'> </span>reçu<span style='letter-spacing:-.15pt'> </span>de<span style='letter-spacing:-.1pt'> </span>chi<span style='letter-spacing:-.05pt'>m</span>iothérapie<span style='letter-spacing:.05pt'> </span>antérieure<span style='letter-spacing: -.35pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>cette indication.</p>
<p class=AmmCorpsTexte><u>Cancer de la prostate</u></p>
<p class=AmmCorpsTexte>Le docétaxel<span style='letter-spacing:-.85pt'> </span>en<span style='letter-spacing:-.1pt'> </span>association<span style='letter-spacing: -.45pt'> </span>à la prednisone<span style='letter-spacing:-.45pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>à la p<span style='letter-spacing:-.05pt'>r</span>ednisolone<span style='letter-spacing:-.05pt'> </span>est<span style='letter-spacing:-.1pt'> </span>indiqué<span style='letter-spacing:-.3pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>le traite<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing: -.3pt'> </span>du<span style='letter-spacing:-.1pt'> </span>cancer de la prostate<span style='letter-spacing:-.3pt'> </span><span style='letter-spacing: -.1pt'>m</span>étastatique<span style='letter-spacing:-.4pt'> </span>hor<span style='letter-spacing:-.1pt'>m</span>ono-résistant.</p>
<p class=AmmCorpsTexte><u><sub>Cancer gastrique</sub></u></p>
<p class=AmmCorpsTexte>Le docétaxel,<span style='letter-spacing:-.85pt'> </span>en<span style='letter-spacing:-.1pt'> </span>association<span style='letter-spacing:-.45pt'> </span>avec<span style='letter-spacing:-.2pt'> </span>le cisplatine<span style='letter-spacing:-.4pt'> </span>et le <span style='letter-spacing:-.05pt'>5</span>-fluoro-uracile est<span style='letter-spacing:-.1pt'> </span>indiqué<span style='letter-spacing:-.3pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>le traite<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.3pt'> </span>de l<span style='letter-spacing:.05pt'>’</span>adénocarcino<span style='letter-spacing: -.05pt'>m</span>e gastrique<span style='letter-spacing:-.35pt'> </span><span style='letter-spacing:-.1pt'>m</span>étastatique,<span style='letter-spacing: -.45pt'> </span>y<span style='letter-spacing:.05pt'> </span>co<span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>p</span>ris<span style='letter-spacing:-.1pt'> </span>l<span style='letter-spacing:.05pt'>’</span>adénocarcino<span style='letter-spacing:-.05pt'>m</span>e<span style='letter-spacing:-.05pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la jonction<span style='letter-spacing: -.35pt'> </span>œsogastrique,<span style='letter-spacing:-.55pt'> </span>chez les patients<span style='letter-spacing:-.3pt'> </span>non<span style='letter-spacing:-.15pt'> </span>prétraités<span style='letter-spacing: -.3pt'> </span>par<span style='letter-spacing:-.15pt'> </span>chi<span style='letter-spacing:-.05pt'>m</span>iothérapie<span style='letter-spacing: -.05pt'> </span>pour<span style='letter-spacing:-.2pt'> </span>leur<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span>aladie<span style='letter-spacing:-.25pt'> </span><span style='letter-spacing:-.1pt'>m</span>étastatique.</p>
<p class=AmmCorpsTexte><u>Cancer des voies aéro-digestives supérieures</u></p>
<p class=AmmCorpsTexte>Le docétaxel<span style='letter-spacing:-.85pt'> </span>en<span style='letter-spacing:-.1pt'> </span>association<span style='letter-spacing: -.45pt'> </span>avec<span style='letter-spacing:-.2pt'> </span>le cisplatine<span style='letter-spacing:-.4pt'> </span>et le<span style='letter-spacing:-.1pt'> </span>5-fluoro-uracile<span style='letter-spacing:-.55pt'> </span>est<span style='letter-spacing:-.1pt'> </span>indiqué<span style='letter-spacing:-.3pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>le traite<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing: -.3pt'> </span>d<span style='letter-spacing:.05pt'>’</span>induction des<span style='letter-spacing:-.15pt'> </span>carcino<span style='letter-spacing:-.05pt'>m</span>es<span style='letter-spacing:-.3pt'> </span>épider<span style='letter-spacing:-.05pt'>m</span><span style='letter-spacing:.05pt'>o</span>ïdes<span style='letter-spacing:-.25pt'> </span>locale<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.25pt'> </span>avancés<span style='letter-spacing:-.3pt'> </span>des<span style='letter-spacing:-.15pt'> </span>voies<span style='letter-spacing:-.2pt'> </span>aéro-digestives<span style='letter-spacing: -.6pt'> </span>supérieures.</p>
<p class="AmmAnnexeTitre2"><a name="RcpPosoAdmin">4.2. Posologie et mode d'administration</a></p>
<p class=AmmCorpsTexte><a name="_Toc142278918">L<span style='letter-spacing: -.05pt'>'</span>utilisation du<span style='letter-spacing:-.1pt'> </span>docétaxel<span style='letter-spacing:-.35pt'> </span>doit<span style='letter-spacing:-.15pt'> </span>être<span style='letter-spacing:-.15pt'> </span>réservée<span style='letter-spacing:-.35pt'> </span>aux<span style='letter-spacing:-.15pt'> </span>unités<span style='letter-spacing:-.25pt'> </span>spécialisées<span style='letter-spacing: -.45pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>l<span style='letter-spacing:-.05pt'>'</span>ad<span style='letter-spacing:-.1pt'>m</span>inistration<span style='letter-spacing:-.45pt'> </span>de<span style='letter-spacing:-.1pt'> </span>c<span style='letter-spacing:.1pt'>y</span>totoxiques et le docétaxel<span style='letter-spacing:-.35pt'> </span>doit<span style='letter-spacing:-.15pt'> </span>être<span style='letter-spacing:-.15pt'> </span>ad<span style='letter-spacing:-.1pt'>m</span>inistré<span style='letter-spacing:-.3pt'> </span><span style='letter-spacing:-.1pt'>s</span>ous<span style='letter-spacing:-.05pt'> </span>contrôle<span style='letter-spacing:-.3pt'> </span>d<span style='letter-spacing:-.05pt'>'</span>un<span style='letter-spacing: -.05pt'> </span><span style='letter-spacing:-.1pt'>m</span>édecin<span style='letter-spacing:-.35pt'> </span>qualifié<span style='letter-spacing:-.25pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>l<span style='letter-spacing: -.05pt'>'</span>utilisation<span style='letter-spacing:-.4pt'> </span>des chi<span style='letter-spacing:-.05pt'>m</span>iothérapies anticancéreuses<span style='letter-spacing:-.6pt'> </span>(voir<span style='letter-spacing:-.2pt'> </span>rubrique<span style='letter-spacing:-.35pt'> </span>6.6).</a></p>
<p class=AmmCorpsTexte><u>Posologie reco<span style='letter-spacing:-.1pt'>mm</span>andée</u><span style='letter-spacing:-.2pt'> </span>:</p>
<p class=AmmCorpsTexte>Dans<span style='letter-spacing:-.5pt'> </span>les<span style='letter-spacing:-.1pt'> </span>cancers<span style='letter-spacing:-.3pt'> </span>du<span style='letter-spacing:-.1pt'> </span>sein,<span style='letter-spacing:-.2pt'> </span>du<span style='letter-spacing:-.1pt'> </span>pou<span style='letter-spacing:-.1pt'>m</span>on<span style='letter-spacing:-.15pt'> </span>non<span style='letter-spacing:-.15pt'> </span>à petites<span style='letter-spacing: -.25pt'> </span>cellules,<span style='letter-spacing:-.35pt'> </span>gastrique<span style='letter-spacing:-.35pt'> </span>et des<span style='letter-spacing:-.15pt'> </span>voies<span style='letter-spacing:-.2pt'> </span>aéro-digestives<span style='letter-spacing:-.6pt'> </span>supérieures, et sauf<span style='letter-spacing:-.15pt'> </span>contre-indication,<span style='letter-spacing: -.65pt'> </span>une<span style='letter-spacing:-.15pt'> </span>pré<span style='letter-spacing:-.1pt'>m</span>édication<span style='letter-spacing:-.15pt'> </span>par<span style='letter-spacing:-.15pt'> </span>un<span style='letter-spacing: -.1pt'> </span>corticoïde<span style='letter-spacing:-.35pt'> </span>oral<span style='letter-spacing:-.15pt'> </span>peut<span style='letter-spacing:-.15pt'> </span>être<span style='letter-spacing:-.15pt'> </span>utilisée,<span style='letter-spacing: -.25pt'> </span>tel que<span style='letter-spacing:-.15pt'> </span>la dexa<span style='letter-spacing:-.05pt'>m</span>éthasone<span style='letter-spacing:-.5pt'> </span>à raison<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.1pt'> </span>16<span style='letter-spacing:-.1pt'> m</span>g<span style='letter-spacing:-.05pt'> </span>par<span style='letter-spacing:-.15pt'> </span>jour<span style='letter-spacing:-.15pt'> </span>(par<span style='letter-spacing:-.15pt'> </span>exe<span style='letter-spacing:-.05pt'>m</span>ple:<span style='letter-spacing:-.1pt'> </span>8<span style='letter-spacing:-.05pt'> </span><span style='letter-spacing:-.1pt'>m</span>g<span style='letter-spacing:-.05pt'> </span>2<span style='letter-spacing:-.05pt'> </span>fois<span style='letter-spacing:-.15pt'> </span>par<span style='letter-spacing:-.15pt'> </span>jour)<span style='letter-spacing:-.2pt'> </span>pendant<span style='letter-spacing:-.25pt'> </span>3<span style='letter-spacing:-.05pt'> </span>jours en<span style='letter-spacing:-.35pt'> </span>co<span style='letter-spacing:-.1pt'>mm</span>ençant<span style='letter-spacing:-.3pt'> </span>la veille<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la perfusion<span style='letter-spacing:-.4pt'> </span>du<span style='letter-spacing:-.1pt'> </span>docétaxel<span style='letter-spacing:-.5pt'> </span>(voir rubrique<span style='letter-spacing: -.45pt'> </span>4.4).<span style='letter-spacing:-.2pt'> </span>Une<span style='letter-spacing:-.15pt'> </span>proph<span style='letter-spacing:.1pt'>y</span>laxie<span style='letter-spacing:-.25pt'> </span>par<span style='letter-spacing:-.15pt'> </span>G<span style='letter-spacing:-.05pt'> </span>CSF peut<span style='letter-spacing:-.45pt'> </span>être<span style='letter-spacing:-.15pt'> </span>utilisée<span style='letter-spacing:-.25pt'> </span>pour<span style='letter-spacing:-.2pt'> </span>di<span style='letter-spacing:-.1pt'>m</span>inuer<span style='letter-spacing:-.25pt'> </span>le risque<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing: -.1pt'> </span>toxicité<span style='letter-spacing:-.25pt'> </span>hé<span style='letter-spacing:-.1pt'>m</span>atologique.</p>
<p class=AmmCorpsTexte>Dans<span style='letter-spacing:-.5pt'> </span>le cancer<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la prostate,<span style='letter-spacing:-.35pt'> </span>co<span style='letter-spacing: -.1pt'>m</span><span style='letter-spacing:.05pt'>p</span>te<span style='letter-spacing:-.1pt'> </span>tenu<span style='letter-spacing:-.15pt'> </span>de<span style='letter-spacing:-.25pt'> </span>l’utilisation<span style='letter-spacing: -.4pt'> </span>conco<span style='letter-spacing:-.05pt'>m</span>itan<span style='letter-spacing:-.05pt'>t</span>e<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.1pt'> </span>prednisone<span style='letter-spacing: -.45pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>de<span style='letter-spacing:-.1pt'> </span>prednisolone, la pré<span style='letter-spacing:-.1pt'>m</span>édication<span style='letter-spacing:-.1pt'> </span>orale<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span>dexa<span style='letter-spacing:-.05pt'>m</span>éthasone<span style='letter-spacing:-.5pt'> </span>reco<span style='letter-spacing:-.1pt'>mm</span>andée<span style='letter-spacing:-.35pt'> </span>est<span style='letter-spacing:-.1pt'> </span>de<span style='letter-spacing:-.1pt'> </span>8<span style='letter-spacing:-.05pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>g</span>,<span style='letter-spacing:-.1pt'> </span>12<span style='letter-spacing:-.1pt'> </span>heures,<span style='letter-spacing:-.3pt'> </span>3<span style='letter-spacing:-.05pt'> </span>heures<span style='letter-spacing:-.25pt'> </span>et 1<span style='letter-spacing:-.05pt'> </span>heure<span style='letter-spacing:-.2pt'> </span>avant<span style='letter-spacing:-.2pt'> </span>la perfusion<span style='letter-spacing:-.4pt'> </span>de<span style='letter-spacing: -.15pt'> </span>docétaxel<span style='letter-spacing:-.35pt'> </span>(voir rubrique<span style='letter-spacing:-.6pt'> </span>4.4).</p>
<p class=AmmCorpsTexte>DOCETAXEL SEACROSS est<span style='letter-spacing:-.1pt'> </span>ad<span style='letter-spacing:-.1pt'>m</span>inistré<span style='letter-spacing:-.3pt'> </span>en<span style='letter-spacing:-.1pt'> </span>une<span style='letter-spacing:-.15pt'> </span>perfusion<span style='letter-spacing: -.4pt'> </span>d<span style='letter-spacing:.05pt'>’</span>une<span style='letter-spacing:-.05pt'> </span>heure,<span style='letter-spacing:-.25pt'> </span>toutes<span style='letter-spacing:-.25pt'> </span>les<span style='letter-spacing:-.1pt'> </span>trois<span style='letter-spacing:-.2pt'> </span>se<span style='letter-spacing:-.1pt'>m</span>aines.</p>
<p class=AmmCorpsTexte><i><u>Cancer du sein</u> :</i></p>
<p class=AmmCorpsTexte><span style='letter-spacing:-.1pt'>Dans le traitement adjuvant du cancer du sein opérable avec ou sans envahissement ganglionnaire, la posologie recommandée de docétaxel est de 75 mg/m<sup>2</sup> administrée 1 heure après 50 mg/m</span><sup>2</sup><span style='letter-spacing:-.1pt'> de doxorubicine et 500 mg/m<sup>2</sup> de cyclophosphamide, toutes les 3 semaines pendant 6 cycles (schéma TAC) (cf. Ajustement posologique).</span></p>
<p class=AmmCorpsTexte><span style='letter-spacing:-.1pt'>Pour le traitement des patientes atteintes d’un cancer du sein localement avancé ou métastatique, la posologie recommandée du docétaxel en monothérapie est de 100 mg/m<sup>2</sup>. En première ligne, le docétaxel à la dose recommandée de 75 mg/m</span><sup>2</sup><span style='letter-spacing:-.1pt'> est associé à la doxorubicine (50 mg/m</span><sup>2</sup><span style='letter-spacing:-.1pt'>).</span></p>
<p class=AmmCorpsTexte>En<span style='letter-spacing:-.35pt'> </span>association<span style='letter-spacing:-.45pt'> </span>au<span style='letter-spacing:-.1pt'> </span>trastuzu<span style='letter-spacing:-.05pt'>m</span>ab,<span style='letter-spacing:-.3pt'> </span>la posologie<span style='letter-spacing:-.4pt'> </span>reco<span style='letter-spacing: -.1pt'>mm</span>andée<span style='letter-spacing:-.35pt'> </span>de<span style='letter-spacing:-.1pt'> </span>docétaxel<span style='letter-spacing:-.35pt'> </span>est<span style='letter-spacing:-.1pt'> </span>de<span style='letter-spacing: -.1pt'> </span>100<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.2pt'>m</span><sup>2 </sup>toutes<span style='letter-spacing: -.5pt'> </span>les trois<span style='letter-spacing:-.3pt'> </span>se<span style='letter-spacing:-.1pt'>m</span>aines,<span style='letter-spacing:-.1pt'> </span>associé<span style='letter-spacing:-.3pt'> </span>au<span style='letter-spacing:-.1pt'> </span>trastuzu<span style='letter-spacing:-.05pt'>m</span>ab<span style='letter-spacing:-.3pt'> </span>ad<span style='letter-spacing:-.1pt'>m</span>inistré<span style='letter-spacing:-.3pt'> </span>toutes<span style='letter-spacing:-.3pt'> </span>les<span style='letter-spacing:-.1pt'> </span>se<span style='letter-spacing:-.1pt'>m</span>aines.<span style='letter-spacing:-.1pt'> </span>Dans<span style='letter-spacing:-.2pt'> </span>l<span style='letter-spacing:.05pt'>’</span>étude<span style='letter-spacing:-.05pt'> </span>pivot,<span style='letter-spacing:-.35pt'> </span>la pre<span style='letter-spacing:-.1pt'>m</span>ière<span style='letter-spacing:-.15pt'> </span>perfusion de<span style='letter-spacing: -.1pt'> </span>docétaxel<span style='letter-spacing:-.4pt'> </span>a été effectuée<span style='letter-spacing:-.35pt'> </span>le lende<span style='letter-spacing:-.05pt'>m</span>ain<span style='letter-spacing:-.35pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la pre<span style='letter-spacing:-.1pt'>m</span>ière<span style='letter-spacing:-.15pt'> </span>ad<span style='letter-spacing:-.1pt'>m</span>inistration<span style='letter-spacing:-.45pt'> </span>de<span style='letter-spacing:-.1pt'> </span>trastuzu<span style='letter-spacing:-.05pt'>m</span>ab.<span style='letter-spacing:-.3pt'> </span>Les<span style='letter-spacing:-.15pt'> </span>cures suivantes<span style='letter-spacing: -.35pt'> </span>de docétaxel<span style='letter-spacing:-.4pt'> </span>ont<span style='letter-spacing:-.15pt'> </span>été ad<span style='letter-spacing:-.1pt'>m</span>inistrées<span style='letter-spacing:-.4pt'> </span>i<span style='letter-spacing:-.1pt'>mm</span>édiate<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.2pt'> </span>après<span style='letter-spacing:-.2pt'> </span>la fin<span style='letter-spacing:-.1pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la perfusion<span style='letter-spacing: -.4pt'> </span>du trastuzu<span style='letter-spacing:-.05pt'>m</span>ab<span style='letter-spacing:-.35pt'> </span>si<span style='letter-spacing:-.05pt'> </span>la dose<span style='letter-spacing:-.2pt'> </span>précédente<span style='letter-spacing:-.45pt'> </span>de<span style='letter-spacing:-.1pt'> </span>trastuzu<span style='letter-spacing:-.05pt'>m</span>ab<span style='letter-spacing:-.3pt'> </span>av<span style='letter-spacing:-.1pt'>a</span>it<span style='letter-spacing:-.1pt'> </span>été bien<span style='letter-spacing:-.15pt'> </span>tolérée.<span style='letter-spacing: -.25pt'> </span>Pour<span style='letter-spacing:-.2pt'> </span>la posologie<span style='letter-spacing:-.4pt'> </span>et le <span style='letter-spacing:-.1pt'>m</span>ode d’ad<span style='letter-spacing:-.1pt'>m</span>inistration<span style='letter-spacing:-.4pt'> </span>du<span style='letter-spacing:-.1pt'> </span>trastuzu<span style='letter-spacing:-.05pt'>m</span>ab,<span style='letter-spacing:-.3pt'> </span>voir<span style='letter-spacing:-.15pt'> </span>le résu<span style='letter-spacing:-.1pt'>m</span>é<span style='letter-spacing:-.15pt'> </span>des<span style='letter-spacing:-.15pt'> </span>caractéristiques<span style='letter-spacing:-.55pt'> </span>du<span style='letter-spacing:-.1pt'> </span>produit.</p>
<p class=AmmCorpsTexte>En<span style='letter-spacing:-.35pt'> </span>association<span style='letter-spacing:-.45pt'> </span>à la capécitabine,<span style='letter-spacing: -.45pt'> </span>la posologie<span style='letter-spacing:-.4pt'> </span>reco<span style='letter-spacing:-.1pt'>mm</span>andée<span style='letter-spacing:-.35pt'> </span>du<span style='letter-spacing:-.1pt'> </span>docétaxel<span style='letter-spacing:-.35pt'> </span>est<span style='letter-spacing:-.1pt'> </span>de<span style='letter-spacing:-.1pt'> </span>75<span style='letter-spacing:-.1pt'> m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.15pt'>m</span><sup>2<span style='letter-spacing:.7pt'> </span></sup>toutes<span style='letter-spacing: -.5pt'> </span>les<span style='letter-spacing:-.1pt'> </span>trois se<span style='letter-spacing:-.1pt'>m</span>aines,<span style='letter-spacing:-.1pt'> </span>associé<span style='letter-spacing:-.3pt'> </span>à 1250<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.05pt'>m</span><sup>2 </sup>de<span style='letter-spacing: -.35pt'> </span>capécitabine<span style='letter-spacing:-.45pt'> </span>deux<span style='letter-spacing:-.2pt'> </span>fois<span style='letter-spacing:-.15pt'> </span>par<span style='letter-spacing:-.15pt'> </span>jour<span style='letter-spacing:-.15pt'> </span>(dans<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>30<span style='letter-spacing:-.1pt'> m</span>inutes<span style='letter-spacing:-.3pt'> </span>qui<span style='letter-spacing:-.15pt'> </span>suivent un<span style='letter-spacing:-.1pt'> </span>repas) pendant<span style='letter-spacing: -.3pt'> </span>deux<span style='letter-spacing:-.2pt'> </span>se<span style='letter-spacing:-.1pt'>m</span>aines<span style='letter-spacing:-.1pt'> </span>suivi<span style='letter-spacing:-.2pt'> </span>d’une<span style='letter-spacing:-.25pt'> </span>période<span style='letter-spacing:-.3pt'> </span>sans<span style='letter-spacing:-.15pt'> </span>traite<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.3pt'> </span>d’une<span style='letter-spacing:-.25pt'> </span>se<span style='letter-spacing:-.1pt'>m</span>aine.<span style='letter-spacing:-.1pt'> </span>Pour<span style='letter-spacing:-.2pt'> </span>le calcul<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing: -.1pt'> </span>la dose<span style='letter-spacing:-.2pt'> </span>de capécitabine<span style='letter-spacing:-.45pt'> </span>en<span style='letter-spacing:-.1pt'> </span>fonction<span style='letter-spacing:-.4pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la surface<span style='letter-spacing:-.3pt'> </span>corporelle,<span style='letter-spacing: -.45pt'> </span>voir<span style='letter-spacing:-.15pt'> </span>le résu<span style='letter-spacing:-.1pt'>m</span>é<span style='letter-spacing:-.15pt'> </span>des<span style='letter-spacing:-.15pt'> </span>caractéristiques<span style='letter-spacing: .05pt'> </span>du<span style='letter-spacing:-.1pt'> </span>produit<span style='letter-spacing:-.3pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la capécitabine.</p>
<p class=AmmCorpsTexte><i><u>Cancer du poumon non à<span style='letter-spacing: .05pt'> </span>petites cellules</u> :</i></p>
<p class=AmmCorpsTexte>Chez<span style='letter-spacing:-.5pt'> </span>les<span style='letter-spacing:-.1pt'> </span>patients<span style='letter-spacing:-.3pt'> </span>traités<span style='letter-spacing:-.25pt'> </span>pour<span style='letter-spacing:-.2pt'> </span>un<span style='letter-spacing:-.1pt'> </span>cancer<span style='letter-spacing:-.25pt'> </span>du poumon<span style='letter-spacing: -.45pt'> </span>non<span style='letter-spacing:-.15pt'> </span>à petites<span style='letter-spacing:-.25pt'> </span>cellules<span style='letter-spacing:-.3pt'> </span>et n’a<span style='letter-spacing:.1pt'>y</span>ant<span style='letter-spacing:-.15pt'> </span>reçu<span style='letter-spacing:-.15pt'> </span>aucune chi<span style='letter-spacing:-.05pt'>m</span>iothérapie antérieure,<span style='letter-spacing:-.4pt'> </span>les<span style='letter-spacing:-.1pt'> </span>doses<span style='letter-spacing:-.2pt'> </span>reco<span style='letter-spacing:-.1pt'>mm</span>andées<span style='letter-spacing:-.4pt'> </span>sont<span style='letter-spacing:-.15pt'> </span>de<span style='letter-spacing:-.1pt'> </span>75<span style='letter-spacing:-.1pt'> m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.1pt'>m</span><sup>2</sup><span style='letter-spacing:-.1pt'> </span>de<span style='letter-spacing:-.1pt'> </span>docétaxel<span style='letter-spacing:-.35pt'> </span>suivi<span style='letter-spacing:-.2pt'> </span>i<span style='letter-spacing:-.1pt'>mm</span>édiate<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.2pt'> </span>par 75<span style='letter-spacing:-.1pt'> m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing: -.1pt'>m</span><sup>2</sup><span style='letter-spacing:-.1pt'> </span>de<span style='letter-spacing:-.1pt'> </span>cisplatine<span style='letter-spacing: -.35pt'> </span>en<span style='letter-spacing:-.1pt'> </span>30<span style='letter-spacing:-.05pt'>-</span>60<span style='letter-spacing:-.1pt'> m</span>inutes.<span style='letter-spacing:-.3pt'> </span>Après<span style='letter-spacing:-.25pt'> </span>échec<span style='letter-spacing:-.25pt'> </span>d<span style='letter-spacing:.05pt'>’</span>une<span style='letter-spacing:-.05pt'> </span>chi<span style='letter-spacing:-.05pt'>m</span>iothérapie<span style='letter-spacing:-.05pt'> </span>à base<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span>sels<span style='letter-spacing: -.15pt'> </span>de<span style='letter-spacing:-.1pt'> </span>platine,<span style='letter-spacing:-.3pt'> </span>la dose reco<span style='letter-spacing: -.1pt'>mm</span>andée<span style='letter-spacing:-.35pt'> </span>est<span style='letter-spacing:-.1pt'> </span>de<span style='letter-spacing:-.1pt'> </span>75<span style='letter-spacing:-.1pt'> m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.1pt'>m</span><sup>2</sup><span style='letter-spacing: -.1pt'> </span>de<span style='letter-spacing:-.1pt'> </span>docétaxel<span style='letter-spacing:-.35pt'> </span>en<span style='letter-spacing:-.1pt'> m</span>onothérapie.</p>
<p class=AmmCorpsTexte><i><u><sub>Cancer de la prostate</sub></u><sub> :</sub></i></p>
<p class=AmmCorpsTexte>La<span style='letter-spacing:-.35pt'> </span>posologie<span style='letter-spacing:-.4pt'> </span>reco<span style='letter-spacing:-.1pt'>mm</span>andée<span style='letter-spacing:-.35pt'> </span>du<span style='letter-spacing:-.1pt'> </span>docétaxel<span style='letter-spacing:-.35pt'> </span>est<span style='letter-spacing:-.1pt'> </span>de<span style='letter-spacing:-.1pt'> </span>75<span style='letter-spacing:-.1pt'> m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.15pt'>m</span><sup>2</sup>.<span style='letter-spacing:-.35pt'> </span>La<span style='letter-spacing:-.1pt'> </span>prednisone<span style='letter-spacing:-.45pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>la prednisolone<span style='letter-spacing:-.5pt'> </span>orale<span style='letter-spacing:-.2pt'> </span>est ad<span style='letter-spacing:-.1pt'>m</span>inistrée<span style='letter-spacing:-.25pt'> </span>en<span style='letter-spacing:-.1pt'> </span>continu,<span style='letter-spacing:-.3pt'> </span>à raison<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.1pt'> </span>5<span style='letter-spacing: -.05pt'> </span><span style='letter-spacing:-.1pt'>m</span>g<span style='letter-spacing:-.1pt'> </span>deux<span style='letter-spacing:-.2pt'> </span>fois<span style='letter-spacing:-.15pt'> </span>par<span style='letter-spacing:-.15pt'> </span>jour<span style='letter-spacing:-.15pt'> </span>(voir rubrique<span style='letter-spacing: -.4pt'> </span>5.1).</p>
<p class=AmmCorpsTexte><i><u>Cancer gastrique</u> :</i></p>
<p class=AmmCorpsTexte>La<span style='letter-spacing: -.35pt'> </span>posologie<span style='letter-spacing:-.4pt'> </span>reco<span style='letter-spacing:-.1pt'>mm</span>andée<span style='letter-spacing:-.35pt'> </span>de<span style='letter-spacing:-.1pt'> </span>docétaxel<span style='letter-spacing:-.35pt'> </span>est<span style='letter-spacing:-.1pt'> </span>de<span style='letter-spacing:-.1pt'> </span>75<span style='letter-spacing:-.1pt'> m</span>g/<span style='letter-spacing:-.1pt'>m</span><sup>2</sup><span style='letter-spacing: -.1pt'> </span>suivi<span style='letter-spacing:-.2pt'> </span>le <span style='letter-spacing:-.1pt'>m</span>ê<span style='letter-spacing:-.1pt'>m</span>e<span style='letter-spacing:-.15pt'> </span>jour<span style='letter-spacing:-.15pt'> </span>par<span style='letter-spacing:-.15pt'> </span>une<span style='letter-spacing:-.15pt'> </span>perfusion<span style='letter-spacing:-.4pt'> </span>de<span style='letter-spacing:-.1pt'> </span>1<span style='letter-spacing:-.05pt'> </span>à 3<span style='letter-spacing:-.05pt'> </span>heures de<span style='letter-spacing:-.1pt'> </span>cisplatine<span style='letter-spacing: -.35pt'> </span>à la posologie<span style='letter-spacing:-.4pt'> </span>de<span style='letter-spacing:-.1pt'> </span>75<span style='letter-spacing:-.1pt'> m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.1pt'>m</span><sup>2</sup>.<span style='letter-spacing:-.1pt'> </span>I<span style='letter-spacing:-.1pt'>mm</span>édiate<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.25pt'> </span>après<span style='letter-spacing:-.2pt'> </span>la fin<span style='letter-spacing:-.1pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la perfusion<span style='letter-spacing: -.4pt'> </span>de<span style='letter-spacing:-.1pt'> </span>cisplatine,<span style='letter-spacing:.05pt'> </span>débute<span style='letter-spacing:-.25pt'> </span>la perfusion<span style='letter-spacing:-.4pt'> </span>continue<span style='letter-spacing:-.35pt'> </span>sur<span style='letter-spacing:-.1pt'> </span>5<span style='letter-spacing:-.05pt'> </span>jours<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span>5<span style='letter-spacing:-.05pt'> </span>fluoro-uracile<span style='letter-spacing:-.45pt'> </span>à la posologie<span style='letter-spacing: -.4pt'> </span>de 750<span style='letter-spacing:-.4pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.1pt'>m</span><sup>2</sup>/jour.<span style='letter-spacing: -.1pt'> </span>Le<span style='letter-spacing:-.1pt'> </span>traite<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.3pt'> </span>est<span style='letter-spacing:-.1pt'> </span>répété<span style='letter-spacing:-.25pt'> </span>toutes<span style='letter-spacing:-.25pt'> </span>les<span style='letter-spacing:-.1pt'> </span>3<span style='letter-spacing:-.05pt'> </span>se<span style='letter-spacing:-.1pt'>m</span>aines.<span style='letter-spacing:-.1pt'> </span>Une<span style='letter-spacing:-.15pt'> </span>pré<span style='letter-spacing:-.1pt'>m</span>édication<span style='letter-spacing:-.1pt'> </span>par<span style='letter-spacing:-.15pt'> </span>des<span style='letter-spacing:-.15pt'> </span>anti-<span style='letter-spacing:-.2pt'> </span>é<span style='letter-spacing:-.1pt'>m</span>étiques et une h<span style='letter-spacing: .1pt'>y</span>dratation<span style='letter-spacing:-.05pt'> </span>adéquate<span style='letter-spacing:-.35pt'> </span>préalable<span style='letter-spacing: -.35pt'> </span>à l’ad<span style='letter-spacing:-.1pt'>m</span>inistration<span style='letter-spacing:-.55pt'> </span>de<span style='letter-spacing:-.1pt'> </span>cisplatine<span style='letter-spacing:-.35pt'> </span>devront<span style='letter-spacing:-.3pt'> </span>être<span style='letter-spacing:-.15pt'> </span>réalisées.<span style='letter-spacing:-.35pt'> </span>Une proph<span style='letter-spacing: .1pt'>y</span>laxie<span style='letter-spacing:-.25pt'> </span>par<span style='letter-spacing:-.15pt'> </span>G<span style='letter-spacing:-.05pt'>-</span>CSF devrait<span style='letter-spacing:-.3pt'> </span>être<span style='letter-spacing: -.15pt'> </span>utilisée<span style='letter-spacing:-.3pt'> </span>pour<span style='letter-spacing:-.15pt'> </span>di<span style='letter-spacing:-.1pt'>m</span>inuer<span style='letter-spacing:-.25pt'> </span>le risque<span style='letter-spacing: -.25pt'> </span>de<span style='letter-spacing:-.1pt'> </span>toxicité<span style='letter-spacing:-.25pt'> </span>hé<span style='letter-spacing:-.1pt'>m</span>atologique<span style='letter-spacing:-.45pt'> </span>(Voir aussi<span style='letter-spacing: -.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>ajuste<span style='letter-spacing:-.05pt'>m</span>ents<span style='letter-spacing:-.35pt'> </span>de<span style='letter-spacing:-.1pt'> </span>doses pendant<span style='letter-spacing: -.3pt'> </span>le traite<span style='letter-spacing:-.05pt'>m</span>ent).</p>
<p class=AmmCorpsTexte><i><u>Cancer des voies aéro-<span style='letter-spacing: .05pt'>d</span>igestives supérieures</u> :</i></p>
<p class=AmmCorpsTexte>Les<span style='letter-spacing:-.4pt'> </span>patients<span style='letter-spacing:-.3pt'> </span>doivent<span style='letter-spacing:-.3pt'> </span>recevoir<span style='letter-spacing:-.35pt'> </span>une<span style='letter-spacing:-.15pt'> </span>pré<span style='letter-spacing:-.1pt'>m</span>édication<span style='letter-spacing:-.1pt'> </span>par<span style='letter-spacing:-.15pt'> </span>des<span style='letter-spacing:-.15pt'> </span>anti-é<span style='letter-spacing:-.05pt'>m</span>étiques<span style='letter-spacing:-.25pt'> </span>et une<span style='letter-spacing:-.15pt'> </span>h<span style='letter-spacing:.1pt'>y</span>dratation<span style='letter-spacing:-.05pt'> </span>adéquate<span style='letter-spacing:-.35pt'> </span>(avant et après<span style='letter-spacing:-.2pt'> </span>ad<span style='letter-spacing:-.1pt'>m</span>inistration<span style='letter-spacing: -.45pt'> </span>du<span style='letter-spacing:-.1pt'> </span>cisplatine).<span style='letter-spacing:-.4pt'> </span>Une<span style='letter-spacing:-.15pt'> </span>proph<span style='letter-spacing:.1pt'>y</span>laxie<span style='letter-spacing:-.25pt'> </span>par<span style='letter-spacing:-.15pt'> </span>G-CSF<span style='letter-spacing:-.3pt'> </span>peut<span style='letter-spacing:-.15pt'> </span>être<span style='letter-spacing:-.15pt'> </span>utilisée<span style='letter-spacing:-.3pt'> </span>pour<span style='letter-spacing:-.2pt'> </span>di<span style='letter-spacing:-.1pt'>m</span>inuer<span style='letter-spacing:-.2pt'> </span>le risque<span style='letter-spacing:-.25pt'> </span>de toxicité<span style='letter-spacing:-.3pt'> </span>hé<span style='letter-spacing:-.1pt'>m</span>atologique.<span style='letter-spacing:-.5pt'> </span>Tous<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>patients<span style='letter-spacing:-.3pt'> </span>du<span style='letter-spacing:-.1pt'> </span>bras<span style='letter-spacing: -.15pt'> </span>docétaxel<span style='letter-spacing:-.35pt'> </span>des<span style='letter-spacing:-.15pt'> </span>études<span style='letter-spacing:-.25pt'> </span>TAX323<span style='letter-spacing:-.35pt'> </span>et TAX324<span style='letter-spacing:-.35pt'> </span>ont<span style='letter-spacing:-.15pt'> </span>reçu<span style='letter-spacing:-.15pt'> </span>une proph<span style='letter-spacing: .1pt'>y</span>laxie<span style='letter-spacing:-.2pt'> </span>antibiotique.</p>
<p class=AmmListePuces1 style='text-align:justify'><span style='font-family: Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>Chi<span style='letter-spacing:-.1pt'>m</span>iothérapie<span style='letter-spacing:-.1pt'> </span>d’induction<span style='letter-spacing: -.4pt'> </span>suivie<span style='letter-spacing:-.15pt'> </span>de<span style='letter-spacing:-.1pt'> </span>radiothérapie<span style='letter-spacing: -.5pt'> </span>(TAX323)</p>
<p class=AmmCorpsTexte style='margin-top:6.0pt'>Dans<span style='letter-spacing: -.5pt'> </span>le traite<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.3pt'> </span>d<span style='letter-spacing:.05pt'>’</span>induction<span style='letter-spacing:-.05pt'> </span>des<span style='letter-spacing:-.15pt'> </span>carcino<span style='letter-spacing:-.05pt'>m</span>es<span style='letter-spacing:-.35pt'> </span>épider<span style='letter-spacing:-.05pt'>m</span><span style='letter-spacing:.05pt'>o</span>ïdes<span style='letter-spacing:-.25pt'> </span>locale<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.25pt'> </span>avancés<span style='letter-spacing:-.3pt'> </span>et inopérables<span style='letter-spacing:-.45pt'> </span>des voies aéro-digestives<span style='letter-spacing:-.6pt'> </span>supérieures,<span style='letter-spacing:-.5pt'> </span>la posologie<span style='letter-spacing: -.4pt'> </span>reco<span style='letter-spacing:-.1pt'>mm</span>andée<span style='letter-spacing:-.35pt'> </span>de<span style='letter-spacing:-.1pt'> </span>docétaxel est<span style='letter-spacing:-.45pt'> </span>de<span style='letter-spacing: -.1pt'> </span>75<span style='letter-spacing:-.1pt'> m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.1pt'>m</span><sup>2</sup> en<span style='letter-spacing:-.35pt'> </span>perfusion<span style='letter-spacing: -.4pt'> </span>de<span style='letter-spacing:-.1pt'> </span>1<span style='letter-spacing:-.05pt'> </span>heure,<span style='letter-spacing:-.25pt'> </span>suivi<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span>cisplatine<span style='letter-spacing: -.35pt'> </span>à la<span style='letter-spacing:-.05pt'> </span>posologie<span style='letter-spacing:-.4pt'> </span>de<span style='letter-spacing:-.1pt'> </span>75<span style='letter-spacing:-.1pt'> m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.1pt'>m</span><sup>2</sup><span style='letter-spacing: -.1pt'> </span>en<span style='letter-spacing:-.1pt'> </span>perfusion<span style='letter-spacing:-.4pt'> </span>de<span style='letter-spacing:-.1pt'> </span>1<span style='letter-spacing:-.05pt'> </span>heure<span style='letter-spacing:-.2pt'> </span>à J1,<span style='letter-spacing:-.1pt'> </span>suivi de<span style='letter-spacing: -.1pt'> </span>5<span style='letter-spacing:-.05pt'> </span>fluoro-uracile<span style='letter-spacing:-.45pt'> </span>à la posologie<span style='letter-spacing: -.4pt'> </span>de<span style='letter-spacing:-.1pt'> </span>750<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.1pt'>m</span><sup>2</sup>/jour<span style='letter-spacing:-.05pt'> </span>en<span style='letter-spacing:-.1pt'> </span>perfusion<span style='letter-spacing:-.4pt'> </span>continue<span style='letter-spacing:-.3pt'> </span>sur<span style='letter-spacing:-.1pt'> </span>5<span style='letter-spacing: -.05pt'> </span>jours.<span style='letter-spacing:-.2pt'> </span>Ce sché<span style='letter-spacing:-.1pt'>m</span>a<span style='letter-spacing:-.2pt'> </span>est<span style='letter-spacing:-.1pt'> </span>répété toutes<span style='letter-spacing: -.25pt'> </span>les<span style='letter-spacing:-.1pt'> </span>3<span style='letter-spacing:-.05pt'> </span>se<span style='letter-spacing:-.1pt'>m</span>aines<span style='letter-spacing:-.1pt'> </span>pend<span style='letter-spacing:-.05pt'>a</span>nt<span style='letter-spacing:-.2pt'> </span>4<span style='letter-spacing:-.05pt'> </span>c<span style='letter-spacing:.1pt'>y</span>cles.<span style='letter-spacing:-.05pt'> </span>Après<span style='letter-spacing:-.25pt'> </span>la chi<span style='letter-spacing:-.05pt'>m</span>iothérapie,<span style='letter-spacing:-.1pt'> </span>les<span style='letter-spacing:-.1pt'> </span>patients doivent<span style='letter-spacing:-.3pt'> </span>être<span style='letter-spacing: -.15pt'> </span>traités<span style='letter-spacing:-.25pt'> </span>par radiothérapie.</p>
<p class=AmmListePuces1 style='text-align:justify'><span style='font-family: Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>Chimiothérapie d’induction suivie de chimioradiothérapie (TAX324)</p>
<p class=AmmCorpsTexte style='margin-top:6.0pt'>Dans<span style='letter-spacing: -.5pt'> </span>le traite<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.3pt'> </span>d<span style='letter-spacing:.05pt'>’</span>induction<span style='letter-spacing:-.05pt'> </span>des<span style='letter-spacing:-.15pt'> </span>patients<span style='letter-spacing:-.3pt'> </span>présentant<span style='letter-spacing: -.4pt'> </span>un<span style='letter-spacing:-.1pt'> </span>carcino<span style='letter-spacing:-.05pt'>m</span>e<span style='letter-spacing:-.3pt'> </span>épider<span style='letter-spacing:-.05pt'>m</span><span style='letter-spacing:.05pt'>o</span>ïde<span style='letter-spacing:-.25pt'> </span>locale<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.25pt'> </span>avancé des voies<span style='letter-spacing: -.2pt'> </span>aéro-digestives<span style='letter-spacing:-.6pt'> </span>supérieures<span style='letter-spacing:-.35pt'> </span>(VADS)<span style='letter-spacing:-.35pt'> </span>(non<span style='letter-spacing:-.2pt'> </span>résécable<span style='letter-spacing:-.35pt'> </span>technique<span style='letter-spacing: -.05pt'>m</span>ent,<span style='letter-spacing:-.5pt'> </span>faible<span style='letter-spacing:-.25pt'> </span>probabilité<span style='letter-spacing: .05pt'> </span>de<span style='letter-spacing:-.1pt'> </span>curabilité<span style='letter-spacing:.05pt'> </span>chirurgicale<span style='letter-spacing: -.45pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>préserv<span style='letter-spacing:-.05pt'>a</span>tion<span style='letter-spacing:-.3pt'> </span>d<span style='letter-spacing:.05pt'>’</span>organe),<span style='letter-spacing:-.05pt'> </span>la posologie<span style='letter-spacing:-.4pt'> </span>reco<span style='letter-spacing:-.1pt'>mm</span>andée<span style='letter-spacing:-.35pt'> </span>de<span style='letter-spacing:-.1pt'> </span>docétaxel<span style='letter-spacing:.05pt'> </span>est<span style='letter-spacing:-.1pt'> </span>de<span style='letter-spacing:-.1pt'> </span>75<span style='letter-spacing:-.1pt'> m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.15pt'>m</span><sup>2 </sup>en perfusion<span style='letter-spacing:-.4pt'> </span>intraveineuse<span style='letter-spacing:-.5pt'> </span>de<span style='letter-spacing:-.1pt'> </span>1<span style='letter-spacing:-.05pt'> </span>h<span style='letter-spacing:-.1pt'>e</span>ure<span style='letter-spacing:-.05pt'> </span>à J1,<span style='letter-spacing:-.1pt'> </span>suivi<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span>cisplatine<span style='letter-spacing:-.4pt'> </span>à la posologie<span style='letter-spacing: -.35pt'> </span>de<span style='letter-spacing:-.1pt'> </span>100<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.05pt'>m</span>²<sup><span style='letter-spacing:.7pt'> </span></sup>en<span style='letter-spacing:-.35pt'> </span>perfusion<span style='letter-spacing:-.4pt'> </span>de 30<span style='letter-spacing:-.1pt'> m</span>inutes<span style='letter-spacing:-.3pt'> </span>à 3<span style='letter-spacing:-.05pt'> </span>heures,<span style='letter-spacing:-.3pt'> </span>suivi<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span>5-fluoro-uracile<span style='letter-spacing: -.55pt'> </span>1000<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.1pt'>m</span>²/jour<span style='letter-spacing:-.55pt'> </span>en<span style='letter-spacing:-.1pt'> </span>perfusion<span style='letter-spacing:-.4pt'> </span>continue<span style='letter-spacing:-.3pt'> </span>de<span style='letter-spacing:-.1pt'> </span>J1<span style='letter-spacing: -.1pt'> </span>à J4.<span style='letter-spacing:-.1pt'> </span>Ce sché<span style='letter-spacing:-.1pt'>m</span>a<span style='letter-spacing:-.2pt'> </span>est<span style='letter-spacing:-.1pt'> </span>ad<span style='letter-spacing:-.1pt'>m</span>inistré<span style='letter-spacing:-.3pt'> </span>toutes<span style='letter-spacing:-.25pt'> </span>les<span style='letter-spacing:-.1pt'> </span>3<span style='letter-spacing: -.05pt'> </span>se<span style='letter-spacing:-.1pt'>m</span>aines<span style='letter-spacing:-.1pt'> </span>à raison<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.1pt'> </span>3<span style='letter-spacing: -.05pt'> </span>c<span style='letter-spacing:.1pt'>y</span>cles.<span style='letter-spacing:-.05pt'> </span>Après<span style='letter-spacing:-.25pt'> </span>la chi<span style='letter-spacing:-.05pt'>m</span>iothérapie,<span style='letter-spacing:-.1pt'> </span>les<span style='letter-spacing:-.1pt'> </span>patients doivent<span style='letter-spacing:-.3pt'> </span>être<span style='letter-spacing: -.15pt'> </span>traités<span style='letter-spacing:-.25pt'> </span>par<span style='letter-spacing:-.15pt'> </span>chi<span style='letter-spacing:-.05pt'>m</span>io radiothérapie.</p>
<p class=AmmCorpsTexte>Pour<span style='letter-spacing:-.45pt'> </span>les<span style='letter-spacing:-.1pt'> </span>ajuste<span style='letter-spacing:-.05pt'>m</span>ents<span style='letter-spacing:-.35pt'> </span>posologiques<span style='letter-spacing: -.55pt'> </span>du<span style='letter-spacing:-.1pt'> </span>cisplatine<span style='letter-spacing:-.35pt'> </span>et du<span style='letter-spacing:-.1pt'> </span>5-fluoro-uracile,<span style='letter-spacing:-.6pt'> </span>se<span style='letter-spacing:-.1pt'> </span>référer<span style='letter-spacing:-.25pt'> </span>au<span style='letter-spacing:-.1pt'> </span>résu<span style='letter-spacing:-.1pt'>m</span>é<span style='letter-spacing:-.15pt'> </span>des caractéristiques<span style='letter-spacing:.05pt'> </span>du<span style='letter-spacing:-.1pt'> </span>produit<span style='letter-spacing:-.3pt'> </span>correspondant.</p>
<p class=AmmCorpsTexte><u>Ajuste<span style='letter-spacing:-.1pt'>m</span>ent<span style='letter-spacing:-.1pt'> </span>posologique</u> :</p>
<p class=AmmCorpsTexte><i><u><sub>Généralités</sub></u></i></p>
<p class=AmmCorpsTexte>Le<span style='letter-spacing:-.35pt'> </span>docétaxel<span style='letter-spacing:-.4pt'> </span>ne<span style='letter-spacing:-.1pt'> </span>doit<span style='letter-spacing:-.15pt'> </span>pas<span style='letter-spacing:-.15pt'> </span>être<span style='letter-spacing:-.15pt'> </span>ad<span style='letter-spacing:-.1pt'>m</span>inistré<span style='letter-spacing:-.3pt'> </span>tant<span style='letter-spacing:-.2pt'> </span>que<span style='letter-spacing:-.15pt'> </span>le no<span style='letter-spacing:-.1pt'>m</span>bre<span style='letter-spacing:-.1pt'> </span>de<span style='letter-spacing:-.1pt'> </span>neutrophiles<span style='letter-spacing:-.5pt'> </span>est<span style='letter-spacing:-.1pt'> </span>inférieur<span style='letter-spacing:-.35pt'> </span>à 1500/<span style='letter-spacing:-.1pt'>mm<sup>3</sup></span>.<span style='letter-spacing:-.25pt'> </span>Chez les patientes<span style='letter-spacing: -.35pt'> </span>a<span style='letter-spacing:.1pt'>y</span>ant<span style='letter-spacing:-.05pt'> </span>présenté,<span style='letter-spacing: -.35pt'> </span>pendant<span style='letter-spacing:-.3pt'> </span>le traite<span style='letter-spacing:-.05pt'>me</span>nt<span style='letter-spacing:-.3pt'> </span>par<span style='letter-spacing:-.15pt'> </span>le docétaxel,<span style='letter-spacing: -.35pt'> </span>une<span style='letter-spacing:-.15pt'> </span>neutropénie<span style='letter-spacing:-.4pt'> </span>fébrile,<span style='letter-spacing:-.3pt'> </span>un<span style='letter-spacing:-.1pt'> </span>no<span style='letter-spacing: -.1pt'>m</span>bre de pol<span style='letter-spacing:.1pt'>y</span>nucléaires<span style='letter-spacing:-.1pt'> </span>neutrophiles<span style='letter-spacing: -.5pt'> </span>&lt;500/<span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:-.05pt'>m</span><sup><span style='letter-spacing:-.1pt'>3</span><span style='letter-spacing:.55pt'> </span></sup>pendant<span style='letter-spacing: -.6pt'> </span>plus<span style='letter-spacing:-.15pt'> </span>d<span style='letter-spacing:.05pt'>’</span>une<span style='letter-spacing:-.05pt'> </span>se<span style='letter-spacing:-.1pt'>m</span>aine,<span style='letter-spacing:-.1pt'> </span>des<span style='letter-spacing:-.15pt'> </span>réactions<span style='letter-spacing: -.35pt'> </span>cutanées<span style='letter-spacing:-.35pt'> </span>sévères ou<span style='letter-spacing:-.1pt'> </span>répétées ou<span style='letter-spacing: -.1pt'> </span>une<span style='letter-spacing:-.15pt'> </span>neuropathie<span style='letter-spacing:-.45pt'> </span>périphérique<span style='letter-spacing: -.5pt'> </span>sévè<span style='letter-spacing:.05pt'>r</span>e,<span style='letter-spacing:-.2pt'> </span>la dose<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span>docétaxel<span style='letter-spacing:-.4pt'> </span>doit<span style='letter-spacing:-.15pt'> </span>être<span style='letter-spacing:-.15pt'> </span>réduite<span style='letter-spacing:-.3pt'> </span>de 100<span style='letter-spacing:-.35pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.1pt'>m</span><sup>2 </sup>à<span style='letter-spacing: -.25pt'> </span>75<span style='letter-spacing:-.1pt'> m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.1pt'>m</span>²<sup><span style='letter-spacing:.7pt'> </span></sup>et/ou<span style='letter-spacing: -.4pt'> </span>de<span style='letter-spacing:-.1pt'> </span>75<span style='letter-spacing:-.1pt'> </span>à 60<span style='letter-spacing:-.1pt'> m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.1pt'>m</span><sup>2</sup>.<span style='letter-spacing:-.35pt'> </span>Si<span style='letter-spacing:-.1pt'> </span>ces<span style='letter-spacing:-.15pt'> </span>réactions<span style='letter-spacing: -.35pt'> </span>persistent<span style='letter-spacing:-.4pt'> </span>à 60<span style='letter-spacing:-.1pt'> m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.1pt'>m</span><sup>2</sup>,<span style='letter-spacing: -.1pt'> </span>le traite<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.3pt'> </span>doit être<span style='letter-spacing:.05pt'> </span>interro<span style='letter-spacing:-.05pt'>m</span>pu.</p>
<p class=AmmCorpsTexte><i><u>Traitement adjuvant du cancer du sein</u></i></p>
<p class=AmmCorpsTexte>Une<span style='letter-spacing:-.45pt'> </span>proph<span style='letter-spacing:.1pt'>y</span>laxie<span style='letter-spacing:-.25pt'> </span>pri<span style='letter-spacing:-.1pt'>m</span>aire<span style='letter-spacing:-.1pt'> </span>par<span style='letter-spacing:-.15pt'> </span>G-CSF<span style='letter-spacing:-.3pt'> </span>doit<span style='letter-spacing:-.15pt'> </span>être<span style='letter-spacing:-.15pt'> </span>envisagée,<span style='letter-spacing:-.15pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>patientes<span style='letter-spacing:-.35pt'> </span>qui<span style='letter-spacing:-.15pt'> </span>reçoivent<span style='letter-spacing:-.35pt'> </span>docétaxel, doxorubicine et c<span style='letter-spacing:.1pt'>y</span>clophospha<span style='letter-spacing:-.05pt'>m</span>ide<span style='letter-spacing:-.15pt'> </span>(TAC)<span style='letter-spacing:-.25pt'> </span>en<span style='letter-spacing:-.1pt'> </span>trait<span style='letter-spacing:-.05pt'>e</span><span style='letter-spacing:-.1pt'>m</span>ent<span style='letter-spacing:-.15pt'> </span>adjuvant<span style='letter-spacing:-.35pt'> </span>pour<span style='letter-spacing:-.2pt'> </span>leur<span style='letter-spacing:-.15pt'> </span>cancer<span style='letter-spacing:-.25pt'> </span>du<span style='letter-spacing:-.1pt'> </span>sein.<span style='letter-spacing:-.2pt'> </span>Les<span style='letter-spacing:-.15pt'> </span>patientes présentant<span style='letter-spacing:-.4pt'> </span>une<span style='letter-spacing: -.15pt'> </span>neutropénie<span style='letter-spacing:-.45pt'> </span>fébrile<span style='letter-spacing:-.25pt'> </span>et/ou<span style='letter-spacing:-.2pt'> </span>une<span style='letter-spacing:-.15pt'> </span>infection<span style='letter-spacing: -.3pt'> </span>neutropénique,<span style='letter-spacing:-.6pt'> </span>doivent<span style='letter-spacing:-.25pt'> </span>avoir<span style='letter-spacing:-.2pt'> </span>une<span style='letter-spacing:-.15pt'> </span>réduction de<span style='letter-spacing: -.1pt'> </span>dose<span style='letter-spacing:-.2pt'> </span>de docétaxel<span style='letter-spacing:-.35pt'> </span>à 60<span style='letter-spacing:-.1pt'> m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.1pt'>m</span><sup>2 </sup>pour<span style='letter-spacing:-.45pt'> </span>tous<span style='letter-spacing:-.15pt'> </span>les<span style='letter-spacing:-.1pt'> </span>c<span style='letter-spacing:.1pt'>y</span>cles<span style='letter-spacing:-.05pt'> </span>ultérieurs<span style='letter-spacing:-.4pt'> </span>(voir<span style='letter-spacing:-.2pt'> </span>rubriques<span style='letter-spacing:-.4pt'> </span>4.4<span style='letter-spacing:-.15pt'> </span>et 4.8).</p>
<p class=AmmCorpsTexte>Pour<span style='letter-spacing:-.45pt'> </span>les<span style='letter-spacing:-.1pt'> </span>patientes<span style='letter-spacing:-.35pt'> </span>présentant<span style='letter-spacing:-.4pt'> </span>une<span style='letter-spacing:-.15pt'> </span>sto<span style='letter-spacing:-.1pt'>m</span>atite<span style='letter-spacing:-.1pt'> </span>de<span style='letter-spacing:-.1pt'> </span>grade<span style='letter-spacing:-.2pt'> </span>3<span style='letter-spacing:-.05pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>4,<span style='letter-spacing:-.05pt'> </span>la dose<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing: -.1pt'> </span>docétaxel<span style='letter-spacing:-.35pt'> </span>devrait<span style='letter-spacing:-.3pt'> </span>être<span style='letter-spacing:-.15pt'> </span>di<span style='letter-spacing:-.1pt'>m</span>inuée<span style='letter-spacing:-.25pt'> </span>à 60 <span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.1pt'>m</span><sup>2</sup>.</p>
<p class=AmmCorpsTexte><i><u>En association avec le cisplatine </u></i></p>
<p class=AmmCorpsTexte>Chez<span style='letter-spacing:-.5pt'> </span>les<span style='letter-spacing:-.1pt'> </span>patients<span style='letter-spacing:-.3pt'> </span>a<span style='letter-spacing:.1pt'>y</span>ant<span style='letter-spacing: -.05pt'> </span>reçu<span style='letter-spacing:-.15pt'> </span>une<span style='letter-spacing:-.15pt'> </span>dose<span style='letter-spacing:-.2pt'> </span>initiale<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing:-.1pt'> </span>docétaxel<span style='letter-spacing:-.4pt'> </span>à 75<span style='letter-spacing:-.1pt'> m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.1pt'>m</span><sup>2</sup><span style='letter-spacing:-.1pt'> </span>en<span style='letter-spacing:-.1pt'> </span>association<span style='letter-spacing:-.45pt'> </span>au<span style='letter-spacing:-.1pt'> </span>cisplatine,<span style='letter-spacing:-.4pt'> </span>pour lesquels le nadir<span style='letter-spacing:-.2pt'> </span>du<span style='letter-spacing:-.1pt'> </span>no<span style='letter-spacing:-.1pt'>m</span>bre<span style='letter-spacing:-.1pt'> </span>des<span style='letter-spacing:-.15pt'> </span>plaquett<span style='letter-spacing:-.05pt'>e</span><i>s<span style='letter-spacing:-.3pt'> </span></i>lors<span style='letter-spacing:-.15pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la cure<span style='letter-spacing:-.15pt'> </span>précédente<span style='letter-spacing: -.4pt'> </span>était &lt;25000/<span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:-.15pt'>m</span><sup><span style='letter-spacing:-.1pt'>3</span></sup>,<span style='letter-spacing:-.55pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>présentant une neutropénie<span style='letter-spacing:-.4pt'> </span>fébrile,<span style='letter-spacing:-.3pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>des<span style='letter-spacing:-.15pt'> </span>toxicités<span style='letter-spacing: -.35pt'> </span>sévères<span style='letter-spacing:-.3pt'> </span>non<span style='letter-spacing:-.15pt'> </span>hé<span style='letter-spacing:-.1pt'>m</span>atologiques,<span style='letter-spacing:-.55pt'> </span>la dose<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span>docétaxel<span style='letter-spacing:-.4pt'> </span>doit être<span style='letter-spacing:-.15pt'> </span>réduite<span style='letter-spacing:-.3pt'> </span>à 65 <span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.1pt'>m</span>²<span style='letter-spacing:-.1pt'> </span>lors<span style='letter-spacing:-.15pt'> </span>des<span style='letter-spacing:-.15pt'> </span>c<span style='letter-spacing:.1pt'>y</span>cles<span style='letter-spacing:-.05pt'> </span>suivants.<span style='letter-spacing:-.35pt'> </span>Pour<span style='letter-spacing:-.2pt'> </span>l’ajuste<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.35pt'> </span>posologique<span style='letter-spacing:-.5pt'> </span>du<span style='letter-spacing:-.1pt'> </span>cisplatine,<span style='letter-spacing:-.35pt'> </span>se<span style='letter-spacing:-.1pt'> </span>reporter au<span style='letter-spacing:-.1pt'> </span>résu<span style='letter-spacing: -.1pt'>m</span>é<span style='letter-spacing:-.15pt'> </span>des caractéristiques<span style='letter-spacing:-.55pt'> </span>du<span style='letter-spacing:-.1pt'> </span>produit<span style='letter-spacing:-.3pt'> </span>correspondant.</p>
<p class=AmmCorpsTexte><i><u>En association avec la capécitabine </u></i></p>
<p class=AmmListePuces1 style='text-align:justify'><span style='font-family: Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>Pour<span style='letter-spacing:-.2pt'> </span>l’ajuste<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.35pt'> </span>posologique<span style='letter-spacing:-.5pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la capécit<span style='letter-spacing:-.05pt'>a</span>bine,<span style='letter-spacing: -.3pt'> </span>voir<span style='letter-spacing:-.15pt'> </span>son<span style='letter-spacing:-.15pt'> </span>résu<span style='letter-spacing:-.1pt'>m</span>é<span style='letter-spacing:-.15pt'> </span>des<span style='letter-spacing:-.15pt'> </span>caractéristiques<span style='letter-spacing:-.55pt'> </span>du<span style='letter-spacing:-.1pt'> </span>produit.</p>
<p class=AmmListePuces1 style='text-align:justify'><span style='font-family: Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>Chez<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>patients<span style='letter-spacing:-.3pt'> </span>qui<span style='letter-spacing:-.15pt'> </span>présentent<span style='letter-spacing:-.4pt'> </span>une<span style='letter-spacing:-.15pt'> </span>pre<span style='letter-spacing:-.1pt'>m</span>ière<span style='letter-spacing:-.15pt'> </span>apparition<span style='letter-spacing:-.4pt'> </span>de<span style='letter-spacing:-.1pt'> </span>toxicité<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.1pt'> </span>Grade<span style='letter-spacing:-.25pt'> </span>2,<span style='letter-spacing:-.05pt'> </span>qui<span style='letter-spacing:-.15pt'> </span>persiste<span style='letter-spacing:-.3pt'> </span>jusqu<span style='letter-spacing:.05pt'>’</span>à l<span style='letter-spacing:.05pt'>’</span>ad<span style='letter-spacing:-.1pt'>m</span>inistration<span style='letter-spacing:-.4pt'> </span>suivante<span style='letter-spacing:-.35pt'> </span>de<span style='letter-spacing:-.1pt'> </span>docétaxel<span style='letter-spacing:-.05pt'>/</span>capécitabine,<span style='letter-spacing: -.35pt'> </span>retarder<span style='letter-spacing:-.3pt'> </span>le traite<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.3pt'> </span>jusqu’au<span style='letter-spacing:-.35pt'> </span>retour au<span style='letter-spacing: -.1pt'> </span>Grade 0-1,<span style='letter-spacing:-.15pt'> </span>puis<span style='letter-spacing:-.15pt'> </span>continuer<span style='letter-spacing: -.4pt'> </span>à 100%<span style='letter-spacing:-.25pt'> </span>des<span style='letter-spacing:-.15pt'> </span>posologies<span style='letter-spacing: -.45pt'> </span>initiales.</p>
<p class=AmmListePuces1 style='text-align:justify'><span style='font-family: Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>Chez<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>patients<span style='letter-spacing:-.3pt'> </span>qui<span style='letter-spacing:-.15pt'> </span>présentent<span style='letter-spacing:-.4pt'> </span>une<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:.05pt'>2</span><sup><span style='letter-spacing:-.1pt'>ème </span></sup>apparition<span style='letter-spacing:-.65pt'> </span>de<span style='letter-spacing:-.1pt'> </span>toxicité<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.1pt'> </span>Grade<span style='letter-spacing:-.25pt'> </span>2<span style='letter-spacing:-.05pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>une<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.05pt'>1</span><sup><span style='letter-spacing:-.1pt'>ère </span></sup>apparition<span style='letter-spacing:-.45pt'> </span>de toxicité<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.1pt'> </span>Grade<span style='letter-spacing:-.25pt'> </span>3,<span style='letter-spacing:-.05pt'> </span>quel<span style='letter-spacing:-.15pt'> </span>que<span style='letter-spacing:-.15pt'> </span>soit<span style='letter-spacing:-.15pt'> </span>le stade<span style='letter-spacing:-.2pt'> </span>du<span style='letter-spacing:-.1pt'> </span>c<span style='letter-spacing: .1pt'>y</span>cle<span style='letter-spacing:-.05pt'> </span>de<span style='letter-spacing:-.1pt'> </span>traite<span style='letter-spacing:-.05pt'>m</span>ent,<span style='letter-spacing:-.3pt'> </span>retarder<span style='letter-spacing:-.3pt'> </span>le traite<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.3pt'> </span>jusqu’au retour<span style='letter-spacing: -.25pt'> </span>au Grade<span style='letter-spacing:-.25pt'> </span>0-1,<span style='letter-spacing:-.15pt'> </span>puis<span style='letter-spacing:-.15pt'> </span>reprendre<span style='letter-spacing:-.4pt'> </span>le traite<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.3pt'> </span>avec<span style='letter-spacing:-.2pt'> </span>55<span style='letter-spacing:-.1pt'> m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.05pt'>m</span>²<sup> </sup>de<span style='letter-spacing: -.35pt'> </span>docétaxel.</p>
<p class=AmmListePuces1 style='text-align:justify'><span style='font-family: Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>Pour<span style='letter-spacing:-.2pt'> </span>toute<span style='letter-spacing:-.15pt'> </span>apparition<span style='letter-spacing: -.35pt'> </span>ultérieure<span style='letter-spacing:-.35pt'> </span>de<span style='letter-spacing:-.15pt'> </span>toxicité,<span style='letter-spacing: -.25pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>toute<span style='letter-spacing:-.15pt'> </span>toxicité<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.1pt'> </span>G<span style='letter-spacing: -.05pt'>r</span>ade<span style='letter-spacing:-.05pt'> </span>4,<span style='letter-spacing:-.05pt'> </span>arrêter<span style='letter-spacing:-.25pt'> </span>le traite<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.3pt'> </span>par<span style='letter-spacing:-.15pt'> </span>docétaxel.</p>
<p class=AmmCorpsTexte style='margin-top:6.0pt'>Pour<span style='letter-spacing: -.45pt'> </span>les<span style='letter-spacing:-.1pt'> m</span>odifications<span style='letter-spacing:-.05pt'> </span>de<span style='letter-spacing:-.1pt'> </span>posologie<span style='letter-spacing:-.4pt'> </span>du<span style='letter-spacing:-.1pt'> </span>trastuzu<span style='letter-spacing:-.05pt'>m</span>ab,<span style='letter-spacing:-.3pt'> </span>voir<span style='letter-spacing:-.15pt'> </span>le résu<span style='letter-spacing:-.1pt'>m</span>é<span style='letter-spacing:-.15pt'> </span>des<span style='letter-spacing:-.15pt'> </span>caractéristiques<span style='letter-spacing:-.55pt'> </span>du<span style='letter-spacing:-.1pt'> </span>produit.</p>
<p class=AmmCorpsTexte><i><u>En association avec le cisplatine et le 5 fluoro-uracile </u></i></p>
<p class=AmmCorpsTexte>Si<span style='letter-spacing:-.35pt'> </span>un<span style='letter-spacing:-.1pt'> </span>épisode<span style='letter-spacing:-.3pt'> </span>de<span style='letter-spacing:-.1pt'> </span>neutropénie<span style='letter-spacing:-.4pt'> </span>co<span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>p</span>liquée<span style='letter-spacing:-.1pt'> </span>(fébrile,<span style='letter-spacing:-.3pt'> </span>prolongée<span style='letter-spacing:-.35pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>infection<span style='letter-spacing:-.3pt'> </span>neutropénique)<span style='letter-spacing: -.55pt'> </span>survient<span style='letter-spacing:-.3pt'> </span><span style='letter-spacing:-.1pt'>m</span>algré l’utilisation<span style='letter-spacing: -.4pt'> </span>de<span style='letter-spacing:-.1pt'> </span>G-CSF,<span style='letter-spacing:-.3pt'> </span>la posologie<span style='letter-spacing: -.4pt'> </span>de<span style='letter-spacing:-.1pt'> </span>docétaxel<span style='letter-spacing:-.35pt'> </span>devra<span style='letter-spacing:-.2pt'> </span>être<span style='letter-spacing:-.15pt'> </span>réduite<span style='letter-spacing:-.3pt'> </span>de<span style='letter-spacing:-.1pt'> </span>75<span style='letter-spacing: -.1pt'> </span>à 60<span style='letter-spacing:-.1pt'> m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.1pt'>m</span><sup>2</sup>.</p>
<p class=AmmCorpsTexte>Si<span style='letter-spacing:1.6pt'> </span>d<span style='letter-spacing:.05pt'>’</span>autres<span style='letter-spacing:1.9pt'> </span>épisodes<span style='letter-spacing:1.6pt'> </span>de<span style='letter-spacing:1.85pt'> </span>neutropénie<span style='letter-spacing:1.5pt'> </span>co<span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>p</span>liquée<span style='letter-spacing:1.85pt'> </span>s<span style='letter-spacing:.1pt'>u</span>rviennent,<span style='letter-spacing:1.9pt'> </span>la<span style='letter-spacing:1.95pt'> </span>posologie<span style='letter-spacing:1.55pt'> </span>de<span style='letter-spacing:1.85pt'> </span>docétaxel<span style='letter-spacing:1.5pt'> </span>devra<span style='letter-spacing:1.65pt'> </span>être<span style='letter-spacing:-.15pt'> </span>réduite<span style='letter-spacing:.05pt'> </span>de 60<span style='letter-spacing:-.1pt'> </span>à 45<span style='letter-spacing:-.1pt'> m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.1pt'>m</span><sup>2</sup>.</p>
<p class=AmmCorpsTexte>En<span style='letter-spacing:-.35pt'> </span>cas<span style='letter-spacing:-.15pt'> </span>de<span style='letter-spacing:-.1pt'> </span>thro<span style='letter-spacing:-.1pt'>m</span>bopénie<span style='letter-spacing:-.15pt'> </span>de<span style='letter-spacing:-.1pt'> </span>Grade<span style='letter-spacing:-.25pt'> </span>4,<span style='letter-spacing:-.05pt'> </span>la posologie<span style='letter-spacing:-.4pt'> </span>de<span style='letter-spacing: -.1pt'> </span>docétaxel<span style='letter-spacing:-.35pt'> </span>devra<span style='letter-spacing:-.2pt'> </span>être<span style='letter-spacing:-.15pt'> </span>réduite<span style='letter-spacing:-.3pt'> </span>de<span style='letter-spacing:-.1pt'> </span>75<span style='letter-spacing:-.1pt'> </span>à 60<span style='letter-spacing:-.1pt'> m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.1pt'>m</span><sup>2</sup>.<span style='letter-spacing:-.1pt'> </span>Les ad<span style='letter-spacing:-.1pt'>m</span>inistrations<span style='letter-spacing:-.5pt'> </span>suivantes<span style='letter-spacing:-.35pt'> </span>de<span style='letter-spacing:-.1pt'> </span>docétaxel<span style='letter-spacing:-.4pt'> </span>ne<span style='letter-spacing:-.1pt'> </span>dev<span style='letter-spacing:-.05pt'>r</span>ont<span style='letter-spacing:-.15pt'> </span>reprendre<span style='letter-spacing:-.4pt'> </span>que<span style='letter-spacing:-.15pt'> </span>si<span style='letter-spacing:-.05pt'> </span>le no<span style='letter-spacing:-.1pt'>m</span>bre<span style='letter-spacing:-.1pt'> </span>de<span style='letter-spacing:-.1pt'> </span>pol<span style='letter-spacing:.1pt'>y</span>nucléaires<span style='letter-spacing:-.15pt'> </span>neutrophiles<span style='letter-spacing:.05pt'> </span>est<span style='letter-spacing:-.1pt'> </span>&gt;1500/<span style='letter-spacing:-.1pt'>mm<sup>3</sup></span><sup><span style='letter-spacing:.5pt'> </span></sup>et<span style='letter-spacing:-.25pt'> </span>le no<span style='letter-spacing:-.1pt'>m</span>bre<span style='letter-spacing:-.1pt'> </span>de<span style='letter-spacing:-.1pt'> </span>plaquettes<span style='letter-spacing:-.35pt'> </span>est<span style='letter-spacing:-.1pt'> </span>&gt;100<span style='letter-spacing:-.2pt'> </span>000/<span style='letter-spacing:-.1pt'>mm<sup>3</sup></span>.<span style='letter-spacing:-.45pt'> </span>Si<span style='letter-spacing:-.1pt'> </span>ces<span style='letter-spacing:-.15pt'> </span>toxicités<span style='letter-spacing: -.35pt'> </span>hé<span style='letter-spacing:-.1pt'>m</span>atologiques<span style='letter-spacing:-.4pt'> </span>persistent<span style='letter-spacing: -.4pt'> </span>le traite<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.3pt'> </span>devra<span style='letter-spacing:-.2pt'> </span>être<span style='letter-spacing:-.15pt'> </span>arrêté<span style='letter-spacing:-.25pt'> </span>(voir<span style='letter-spacing:-.1pt'> </span>rubrique<span style='letter-spacing:-.45pt'> </span>4.4).</p>
<p class=AmmCorpsTexte>En<span style='letter-spacing:1.0pt'> </span>cas<span style='letter-spacing:1.2pt'> </span>de<span style='letter-spacing:1.25pt'> </span>toxicités,<span style='letter-spacing:1.0pt'> </span>les<span style='letter-spacing:1.25pt'> </span>ajuste<span style='letter-spacing:-.05pt'>m</span>ents<span style='letter-spacing:1.0pt'> </span>posologiques<span style='letter-spacing:.85pt'> </span>des<span style='letter-spacing:1.2pt'> </span>patients<span style='letter-spacing:1.05pt'> </span>recevant<span style='letter-spacing:1.0pt'> </span>du<span style='letter-spacing:1.25pt'> </span>docétaxel<span style='letter-spacing:.95pt'> </span>en<span style='letter-spacing:1.15pt'> </span>association<span style='letter-spacing:-.45pt'> </span>avec le cisplatine<span style='letter-spacing: -.4pt'> </span>et le 5-fluoro-ur<span style='letter-spacing:-.05pt'>a</span>cile<span style='letter-spacing:-.45pt'> </span>(5-FU)<span style='letter-spacing:-.3pt'> </span>sont<span style='letter-spacing:-.15pt'> </span>les<span style='letter-spacing:-.1pt'> </span>suivantes<span style='letter-spacing:-.35pt'> </span>:</p>
<div align=center>
<table class=AmmCorpsTexteTable border=0 cellspacing=0 cellpadding=0
style='margin-left:-37.1pt;border-collapse:collapse'>
<tr style='height:11.35pt'>
<td width=208 valign=top style='width:155.9pt;border:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:11.35pt'>
<p class=AmmCorpsTexte style='margin-left:9.4pt'><b>Toxicité<span style='letter-spacing:-.65pt'> </span>–<span style='letter-spacing:-.05pt'> </span>grade</b></p>
</td>
<td width=415 valign=top style='width:311.15pt;border:solid black 1.0pt;
border-left:none;padding:0cm 0cm 0cm 0cm;height:11.35pt'>
<p class=AmmCorpsTexte style='margin-left:7.1pt'><b>Ajuste<span style='letter-spacing:-.05pt'>m</span>ents<span style='letter-spacing:-.45pt'> </span>posologiques</b></p>
</td>
</tr>
<tr style='height:11.35pt'>
<td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:11.35pt'>
<p class=AmmCorpsTexte style='margin-left:9.4pt'>Diarrhée<span style='letter-spacing:-.65pt'> </span>–<span style='letter-spacing:-.05pt'> </span>grade<span style='letter-spacing:-.2pt'> </span>3</p>
</td>
<td width=415 valign=top style='width:311.15pt;border:none;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:11.35pt'>
<p class=AmmCorpsTexte style='margin-left:7.1pt'><sub><span style='letter-spacing: .05pt'>1</span></sub><sup><span style='letter-spacing:-.1pt'>er</span> </sup><sub>épisode<span style='letter-spacing:-.55pt'> </span>: réduction<span style='letter-spacing: -.35pt'> </span>de<span style='letter-spacing:-.1pt'> </span>20%<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la dose<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing: -.1pt'> </span>5-FU.</sub></p>
<p class=AmmCorpsTexte style='margin-left:7.1pt'><sub><span style='letter-spacing: .05pt'> </span></sub></p>
</td>
</tr>
<tr style='height:19.0pt'>
<td width=208 valign=top style='width:155.9pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:19.0pt'>
<p class=AmmCorpsTexte style='margin-left:9.4pt'> </p>
</td>
<td width=415 valign=top style='width:311.15pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:19.0pt'>
<p class=AmmCorpsTexte style='margin-left:7.1pt'><span style='letter-spacing: .05pt'>2</span><sup><span style='letter-spacing:-.1pt'>ème</span><span style='letter-spacing:1.7pt'> </span></sup>épisode: réduction<span style='letter-spacing:-.35pt'> </span>de<span style='letter-spacing:-.1pt'> </span>20%<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la dose<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing: -.1pt'> </span>docétaxel.</p>
</td>
</tr>
<tr style='height:11.35pt'>
<td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:11.35pt'>
<p class=AmmCorpsTexte style='margin-left:9.4pt'>Diarrhée<span style='letter-spacing:-.65pt'> </span>–<span style='letter-spacing:-.05pt'> </span>grade<span style='letter-spacing:-.2pt'> </span>4</p>
</td>
<td width=415 valign=top style='width:311.15pt;border:none;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:11.35pt'>
<p class=AmmCorpsTexte style='margin-left:7.1pt'><sub><span style='letter-spacing: .05pt'>1</span></sub><sup><span style='letter-spacing:-.1pt'>er</span> </sup><sub>épisode<span style='letter-spacing:-.6pt'> </span>: réduction<span style='letter-spacing: -.35pt'> </span>de<span style='letter-spacing:-.1pt'> </span>20%<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la<span style='letter-spacing:-.05pt'> </span>dose<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span>docétaxel<span style='letter-spacing:-.35pt'> </span>et de<span style='letter-spacing:-.1pt'> </span>5-FU.</sub></p>
<p class=AmmCorpsTexte style='margin-left:7.1pt'> </p>
</td>
</tr>
<tr style='height:16.6pt'>
<td width=208 valign=top style='width:155.9pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:16.6pt'>
<p class=AmmCorpsTexte style='margin-left:9.4pt'> </p>
</td>
<td width=415 valign=top style='width:311.15pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:16.6pt'>
<p class=AmmCorpsTexte style='margin-left:7.1pt'><span style='letter-spacing: .05pt'>2</span><sup><span style='letter-spacing:-.1pt'>ème</span><span style='letter-spacing:1.7pt'> </span></sup>épisode: arrêt<span style='letter-spacing:-.2pt'> </span>du<span style='letter-spacing:-.1pt'> </span>traite<span style='letter-spacing:-.05pt'>m</span>ent.</p>
</td>
</tr>
<tr style='height:11.35pt'>
<td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:11.35pt'>
<p class=AmmCorpsTexte style='margin-left:9.4pt'>Sto<span style='letter-spacing: -.1pt'>m</span>atites/<span style='letter-spacing:-.05pt'>m</span><span style='letter-spacing:.05pt'>u</span>cites<span style='letter-spacing:-.2pt'> </span>– grade<span style='letter-spacing:-.5pt'> </span>3</p>
</td>
<td width=415 valign=top style='width:311.15pt;border:none;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:11.35pt'>
<p class=AmmCorpsTexte style='margin-left:7.1pt'><sub><span style='letter-spacing: .05pt'>1</span></sub><sup><span style='letter-spacing:-.1pt'>er</span> </sup><sub>épisode: réduction<span style='letter-spacing:-.35pt'> </span>de<span style='letter-spacing:-.1pt'> </span>20%<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la dose<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span>5-FU </sub></p>
</td>
</tr>
<tr style='height:11.35pt'>
<td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:11.35pt'>
<p class=AmmCorpsTexte style='margin-left:9.4pt'> </p>
</td>
<td width=415 valign=top style='width:311.15pt;border:none;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:11.35pt'>
<p class=AmmCorpsTexte style='margin-left:7.1pt'><sub><span style='letter-spacing: .05pt'>2</span></sub><sup><span style='letter-spacing:-.1pt'>ème </span></sup><sub>épisode: arrêt<span style='letter-spacing:-.2pt'> </span>définitif<span style='letter-spacing:-.25pt'> </span>du<span style='letter-spacing:-.1pt'> </span>5-FU<span style='letter-spacing:-.2pt'> </span>seule<span style='letter-spacing:-.05pt'>m</span>ent.</sub></p>
</td>
</tr>
<tr style='height:20.05pt'>
<td width=208 valign=top style='width:155.9pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:20.05pt'>
<p class=AmmCorpsTexte style='margin-left:9.4pt'> </p>
</td>
<td width=415 valign=top style='width:311.15pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:20.05pt'>
<p class=AmmCorpsTexte style='margin-left:7.1pt'><span style='letter-spacing: .05pt'>3</span><sup><span style='letter-spacing:-.1pt'>ème </span></sup>épisode: réduction<span style='letter-spacing:-.35pt'> </span>de<span style='letter-spacing:-.1pt'> </span>20%<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la dose<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span>docétaxel.<sub>.</sub></p>
</td>
</tr>
<tr style='height:11.35pt'>
<td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:11.35pt'>
<p class=AmmCorpsTexte style='margin-left:9.4pt'>Sto<span style='letter-spacing: -.1pt'>m</span>atites/<span style='letter-spacing:-.05pt'>m</span><span style='letter-spacing:.05pt'>u</span>cites<span style='letter-spacing:-.2pt'> </span>– grade<span style='letter-spacing:-.5pt'> </span>4</p>
<p class=AmmCorpsTexte style='margin-left:9.4pt'> </p>
</td>
<td width=415 valign=top style='width:311.15pt;border:none;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:11.35pt'>
<p class=AmmCorpsTexte style='margin-left:7.1pt'><sub><span style='letter-spacing: .05pt'>1</span></sub><sup><span style='letter-spacing:-.1pt'>er</span> </sup><sub>épisode: arrêt<span style='letter-spacing:-.2pt'> </span>définitif<span style='letter-spacing:-.25pt'> </span>du<span style='letter-spacing:-.1pt'> </span>5-FU<span style='letter-spacing:-.2pt'> </span>seule<span style='letter-spacing:-.05pt'>m</span>ent.</sub></p>
</td>
</tr>
<tr style='height:16.95pt'>
<td width=208 valign=top style='width:155.9pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:16.95pt'>
<p class=AmmCorpsTexte> </p>
</td>
<td width=415 valign=top style='width:311.15pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:16.95pt'>
<p class=AmmCorpsTexte style='margin-left:7.1pt'><span style='letter-spacing: .05pt'>2</span><sup><span style='letter-spacing:-.1pt'>ème</span><span style='letter-spacing:1.7pt'> </span></sup>épisode: réduction<span style='letter-spacing:-.35pt'> </span>de<span style='letter-spacing:-.1pt'> </span>20%<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la dose<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing: -.1pt'> </span>docétaxel.</p>
</td>
</tr>
</table>
</div>
<p class=AmmCorpsTexte style='margin-top:6.0pt'>Pour<span style='letter-spacing: -.45pt'> </span>les<span style='letter-spacing:-.1pt'> </span>ajuste<span style='letter-spacing:-.05pt'>m</span>ents<span style='letter-spacing:-.35pt'> </span>posologiques<span style='letter-spacing:-.55pt'> </span>du<span style='letter-spacing:-.1pt'> </span>5-fluoro-uracile<span style='letter-spacing:-.6pt'> </span>et du<span style='letter-spacing:-.1pt'> </span>cisplatine,<span style='letter-spacing:-.35pt'> </span>se<span style='letter-spacing:-.1pt'> </span>référer<span style='letter-spacing:-.25pt'> </span>aux<span style='letter-spacing:-.15pt'> </span>résu<span style='letter-spacing:-.1pt'>m</span>és<span style='letter-spacing:-.15pt'> </span>des caractéristiques<span style='letter-spacing:.05pt'> </span>des<span style='letter-spacing:-.15pt'> </span>produits.</p>
<p class=AmmCorpsTexte>Dans<span style='letter-spacing:-.5pt'> </span>les<span style='letter-spacing:-.1pt'> </span>études<span style='letter-spacing:-.25pt'> </span>pivot<span style='letter-spacing:-.35pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>patients<span style='letter-spacing:-.3pt'> </span>traités<span style='letter-spacing:-.15pt'> </span>par<span style='letter-spacing:-.15pt'> </span>chi<span style='letter-spacing:-.05pt'>m</span>iothérapie<span style='letter-spacing: -.05pt'> </span>d’induction<span style='letter-spacing:-.4pt'> </span>pour<span style='letter-spacing:-.2pt'> </span>un<span style='letter-spacing:-.1pt'> </span>cancer<span style='letter-spacing:-.2pt'> </span>des<span style='letter-spacing:-.15pt'> </span>VADS, et a<span style='letter-spacing:.1pt'>y</span>ant<span style='letter-spacing: -.05pt'> </span>présenté<span style='letter-spacing:-.35pt'> </span>une<span style='letter-spacing:-.15pt'> </span>neutropénie<span style='letter-spacing: -.45pt'> </span>co<span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>p</span>liquée<span style='letter-spacing:-.1pt'> </span>(incluant<span style='letter-spacing:-.3pt'> </span>neutropénie<span style='letter-spacing: -.4pt'> </span>prolongée,<span style='letter-spacing:-.4pt'> </span>neutropénie<span style='letter-spacing:-.45pt'> </span>fébrile<span style='letter-spacing:.05pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>infection),<span style='letter-spacing:.05pt'> </span>une<span style='letter-spacing:-.15pt'> </span>p<span style='letter-spacing:-.05pt'>r</span>oph<span style='letter-spacing:.1pt'>y</span>laxie par<span style='letter-spacing:-.15pt'> </span>G-CSF<span style='letter-spacing: -.3pt'> </span>(ex<span style='letter-spacing:-.15pt'> </span>: du<span style='letter-spacing:-.1pt'> </span>6<sup><span style='letter-spacing:-.1pt'>ème</span><span style='letter-spacing:1.7pt'> </span></sup>au<span style='letter-spacing:-.3pt'> </span>15<sup><span style='letter-spacing:-.1pt'>ème</span><span style='letter-spacing:1.65pt'> </span></sup>jour)<span style='letter-spacing: -.45pt'> </span>était<span style='letter-spacing:.05pt'> </span>reco<span style='letter-spacing:-.1pt'>mm</span>andée<span style='letter-spacing:-.35pt'> </span>pour<span style='letter-spacing:-.2pt'> </span>les c<span style='letter-spacing:.1pt'>y</span>cles<span style='letter-spacing:-.05pt'> </span>suivants.</p>
<p class=AmmCorpsTexte><u>Populations à risque</u> :</p>
<p class=AmmCorpsTexte><i><u><sub>Patients avec insuffisance hépatique</sub></u></i></p>
<p class=AmmCorpsTexte>D<span style='letter-spacing:.05pt'>’</span>après<span style='letter-spacing:-.1pt'> </span>les<span style='letter-spacing:-.1pt'> </span>données<span style='letter-spacing:-.35pt'> </span>phar<span style='letter-spacing:-.1pt'>m</span>acocinétiques<span style='letter-spacing:-.1pt'> </span>relatives<span style='letter-spacing:-.35pt'> </span>au<span style='letter-spacing:-.1pt'> </span>docétaxel<span style='letter-spacing:-.4pt'> </span>à 100<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.1pt'>m</span>²<sup> </sup>ad<span style='letter-spacing: -.1pt'>m</span>inistré<span style='letter-spacing:-.35pt'> </span>en<span style='letter-spacing:-.1pt'> m</span>onothérapie,<span style='letter-spacing: .05pt'> </span>la dose<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span>docétaxel<span style='letter-spacing:-.35pt'> </span>reco<span style='letter-spacing:-.1pt'>mm</span>an<span style='letter-spacing:-.05pt'>d</span>ée<span style='letter-spacing:-.2pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>patients<span style='letter-spacing:-.3pt'> </span>a<span style='letter-spacing:.1pt'>y</span>ant<span style='letter-spacing:-.05pt'> </span>des<span style='letter-spacing:-.15pt'> </span>transa<span style='letter-spacing:-.05pt'>m</span>inases<span style='letter-spacing:-.25pt'> </span>(ALAT<span style='letter-spacing:-.3pt'> </span>et/ou ASAT)<span style='letter-spacing:-.3pt'> </span>supérieures<span style='letter-spacing: -.45pt'> </span>à 1,5 fois<span style='letter-spacing:-.15pt'> </span>la LSN<span style='letter-spacing:-.2pt'> </span>ainsi<span style='letter-spacing:-.2pt'> </span>que<span style='letter-spacing:-.15pt'> </span>des<span style='letter-spacing:-.15pt'> </span>phosphatases<span style='letter-spacing:-.55pt'> </span>alcalines<span style='letter-spacing: -.35pt'> </span>supérieures<span style='letter-spacing:-.45pt'> </span>à 2,5<span style='letter-spacing:-.15pt'> </span>fois<span style='letter-spacing:-.15pt'> </span>la LSN,<span style='letter-spacing:-.2pt'> </span>est<span style='letter-spacing:-.1pt'> </span>de<span style='letter-spacing:-.1pt'> </span>75<span style='letter-spacing:-.1pt'> m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.15pt'>m</span>²<sup> </sup>(voir rubriques<span style='letter-spacing:-.5pt'> </span>4.4<span style='letter-spacing:-.15pt'> </span>et 5.2).<span style='letter-spacing:-.2pt'> </span>Chez<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>patients<span style='letter-spacing:-.3pt'> </span>a<span style='letter-spacing:.1pt'>y</span>ant<span style='letter-spacing: -.05pt'> </span>une<span style='letter-spacing:-.15pt'> </span>bilirubiné<span style='letter-spacing:-.05pt'>m</span>ie<span style='letter-spacing:-.4pt'> </span>&gt;LSN<span style='letter-spacing:-.25pt'> </span>et/ou des<span style='letter-spacing: -.15pt'> </span>ASAT<span style='letter-spacing:-.25pt'> </span>et ALAT<span style='letter-spacing:-.25pt'> </span>3,5<span style='letter-spacing:-.15pt'> </span>fois supérieures<span style='letter-spacing:-.45pt'> </span>à la LSN<span style='letter-spacing:-.2pt'> </span>ainsi<span style='letter-spacing:-.2pt'> </span>que<span style='letter-spacing:-.15pt'> </span>des<span style='letter-spacing:-.15pt'> </span>phosphatases<span style='letter-spacing:-.55pt'> </span>alcalines<span style='letter-spacing: -.35pt'> </span>supérieures à 6<span style='letter-spacing:-.05pt'> </span>fois<span style='letter-spacing:-.15pt'> </span>la LSN,<span style='letter-spacing:-.2pt'> </span>au<span style='letter-spacing:-.05pt'>c</span>une<span style='letter-spacing: -.1pt'> </span>réduction<span style='letter-spacing:-.4pt'> </span>de<span style='letter-spacing:-.1pt'> </span>dose ne<span style='letter-spacing:-.1pt'> </span>peut<span style='letter-spacing:-.15pt'> </span>être<span style='letter-spacing:-.15pt'> </span>reco<span style='letter-spacing:-.1pt'>mm</span>andée<span style='letter-spacing:-.35pt'> </span>et le docétaxel<span style='letter-spacing: -.35pt'> </span>ne<span style='letter-spacing:-.1pt'> </span>doit pas<span style='letter-spacing:-.15pt'> </span>être<span style='letter-spacing:-.15pt'> </span>ad<span style='letter-spacing:-.1pt'>m</span>inistré<span style='letter-spacing:-.3pt'> </span>sauf<span style='letter-spacing:-.15pt'> </span>s<span style='letter-spacing: .05pt'>’</span>il<span style='letter-spacing:-.05pt'> </span>est<span style='letter-spacing:-.1pt'> </span>stricte<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.25pt'> </span>indiqué.</p>
<p class=AmmCorpsTexte>Dans<span style='letter-spacing:-.5pt'> </span>le traite<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.3pt'> </span>de<span style='letter-spacing:-.1pt'> </span>l<span style='letter-spacing:.05pt'>’</span>adénocarcino<span style='letter-spacing:-.05pt'>m</span>e<span style='letter-spacing:-.05pt'> </span>gas<span style='letter-spacing:-.05pt'>t</span>rique,<span style='letter-spacing:-.15pt'> </span>en<span style='letter-spacing:-.1pt'> </span>association<span style='letter-spacing:-.45pt'> </span>avec<span style='letter-spacing:-.2pt'> </span>le cisplatine<span style='letter-spacing:-.4pt'> </span>et le 5-fluoro-uracile,<span style='letter-spacing:-.9pt'> </span>l<span style='letter-spacing:.05pt'>’</span>étude<span style='letter-spacing:-.05pt'> </span>pivot<span style='letter-spacing:-.3pt'> </span>a exclu<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing: -.1pt'> </span>patients<span style='letter-spacing:-.3pt'> </span>présentant<span style='letter-spacing:-.4pt'> </span>un<span style='letter-spacing:-.1pt'> </span>taux<span style='letter-spacing:-.15pt'> </span>de<span style='letter-spacing:-.1pt'> </span>transa<span style='letter-spacing:-.05pt'>m</span>inases<span style='letter-spacing:-.25pt'> </span>(ASAT<span style='letter-spacing:-.3pt'> </span>et/ou ALAT)<span style='letter-spacing:-.6pt'> </span>&gt;1,5<span style='letter-spacing:-.2pt'> </span>fois<span style='letter-spacing:-.15pt'> </span>la LSN<span style='letter-spacing:-.2pt'> </span>associé<span style='letter-spacing:-.3pt'> </span>à des<span style='letter-spacing:-.15pt'> </span>phosphatases<span style='letter-spacing:-.55pt'> </span>alcalines<span style='letter-spacing: -.35pt'> </span>&gt;2,5<span style='letter-spacing:-.2pt'> </span>fois<span style='letter-spacing:-.15pt'> </span>la LSN<span style='letter-spacing:-.2pt'> </span>et un<span style='letter-spacing:-.1pt'> </span>taux<span style='letter-spacing:-.15pt'> </span>de<span style='letter-spacing:-.1pt'> </span>bilirubine<span style='letter-spacing:.05pt'> </span>&gt;1 fois la LSN<span style='letter-spacing:-.2pt'> </span>: en<span style='letter-spacing:-.1pt'> </span>conséquence<span style='letter-spacing:-.5pt'> </span>pour<span style='letter-spacing:-.2pt'> </span>ces<span style='letter-spacing:-.15pt'> </span>patients,<span style='letter-spacing: -.35pt'> </span>aucune<span style='letter-spacing:-.3pt'> </span>réduction<span style='letter-spacing:-.4pt'> </span>de<span style='letter-spacing:-.1pt'> </span>dose<span style='letter-spacing:-.2pt'> </span>ne<span style='letter-spacing:-.1pt'> </span>peut<span style='letter-spacing:-.15pt'> </span>être<span style='letter-spacing:-.15pt'> </span>reco<span style='letter-spacing:-.1pt'>mm</span>andée<span style='letter-spacing:-.2pt'> </span>et le docétaxel<span style='letter-spacing:-.4pt'> </span>ne<span style='letter-spacing:-.1pt'> </span>doit<span style='letter-spacing:-.15pt'> </span>pas<span style='letter-spacing:-.15pt'> </span>être<span style='letter-spacing:-.2pt'> </span>ad<span style='letter-spacing:-.1pt'>m</span>inistré<span style='letter-spacing:-.3pt'> </span>sauf<span style='letter-spacing:-.15pt'> </span>si<span style='letter-spacing:-.05pt'> </span>il est<span style='letter-spacing:-.1pt'> </span>stricte<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.25pt'> </span>indiqué.</p>
<p class=AmmCorpsTexte>On<span style='letter-spacing:-.4pt'> </span>ne<span style='letter-spacing:-.1pt'> </span>dispose<span style='letter-spacing:-.3pt'> </span>d<span style='letter-spacing:.05pt'>’</span>aucune<span style='letter-spacing:-.05pt'> </span>donnée<span style='letter-spacing:-.3pt'> </span>sur<span style='letter-spacing:-.1pt'> </span>les<span style='letter-spacing: -.1pt'> </span>insuffisants<span style='letter-spacing:-.35pt'> </span>hépatiques<span style='letter-spacing:-.45pt'> </span>traités<span style='letter-spacing:-.25pt'> </span>par<span style='letter-spacing:-.15pt'> </span>le docétaxel<span style='letter-spacing:-.4pt'> </span>en<span style='letter-spacing:-.1pt'> </span>association<span style='letter-spacing:-.45pt'> </span>dans les autres<span style='letter-spacing: -.25pt'> </span>indications.</p>
<p class=AmmCorpsTexte><u>Populations pédiatriques</u> :</p>
<p class=AmmCorpsTexte>La<span style='letter-spacing:-.35pt'> </span>tolérance<span style='letter-spacing:-.35pt'> </span>et l’efficacité<span style='letter-spacing: -.4pt'> </span>de<span style='letter-spacing:-.1pt'> </span>docétaxel<span style='letter-spacing:-.55pt'> </span>dans<span style='letter-spacing:-.25pt'> </span>le carcino<span style='letter-spacing:-.05pt'>m</span>e<span style='letter-spacing: -.3pt'> </span>naso-pha<span style='letter-spacing:.1pt'>r</span>yngé<span style='letter-spacing:-.35pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>des<span style='letter-spacing:-.15pt'> </span>enfants<span style='letter-spacing:-.3pt'> </span>âgés<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing: -.1pt'> </span>plus d<span style='letter-spacing:.05pt'>’</span>un <span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>o</span>is<span style='letter-spacing:-.1pt'> </span>et de<span style='letter-spacing:-.1pt'> m</span><span style='letter-spacing:.05pt'>o</span>ins<span style='letter-spacing:-.1pt'> </span>de<span style='letter-spacing:-.1pt'> </span>18<span style='letter-spacing:-.1pt'> </span>ans<span style='letter-spacing:-.15pt'> </span>n<span style='letter-spacing:.05pt'>’</span>est<span style='letter-spacing:-.05pt'> </span>pas<span style='letter-spacing:-.15pt'> </span>encore<span style='letter-spacing:-.25pt'> </span>établi.</p>
<p class=AmmCorpsTexte>L’utilisation<span style='letter-spacing:-.75pt'> </span>de<span style='letter-spacing:-.1pt'> </span>docétaxel<span style='letter-spacing:-.55pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>populations<span style='letter-spacing: -.4pt'> </span>p<span style='letter-spacing:-.1pt'>é</span>diatriques<span style='letter-spacing:-.05pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>le cancer<span style='letter-spacing:-.25pt'> </span>du<span style='letter-spacing: -.1pt'> </span>sein,<span style='letter-spacing:-.2pt'> </span>le cancer<span style='letter-spacing:-.25pt'> </span>du<span style='letter-spacing:-.1pt'> </span>pou<span style='letter-spacing:-.1pt'>m</span>on non<span style='letter-spacing:-.15pt'> </span>à petites<span style='letter-spacing:-.25pt'> </span>cellules,<span style='letter-spacing:-.3pt'> </span>le cancer<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la prost<span style='letter-spacing:-.1pt'>a</span>te,<span style='letter-spacing:-.2pt'> </span>le cancer<span style='letter-spacing:-.25pt'> </span>gastrique,<span style='letter-spacing:-.4pt'> </span>le cancer<span style='letter-spacing:-.25pt'> </span>des<span style='letter-spacing:-.15pt'> </span>voies<span style='letter-spacing:-.2pt'> </span>aéro-<span style='letter-spacing:-.2pt'> </span>digestives supérieures,<span style='letter-spacing:-.5pt'> </span>n’incluant<span style='letter-spacing:-.4pt'> </span>pas<span style='letter-spacing:-.15pt'> </span>les<span style='letter-spacing:-.1pt'> </span>cancers<span style='letter-spacing:-.3pt'> </span>naso-pha<span style='letter-spacing:.1pt'>r</span>yngés<span style='letter-spacing:-.35pt'> </span>t<span style='letter-spacing:.1pt'>y</span>pe<span style='letter-spacing:-.05pt'> </span>II<span style='letter-spacing:-.05pt'> </span>et III<span style='letter-spacing:-.1pt'> </span>peu<span style='letter-spacing: -.15pt'> </span>différenciés,<span style='letter-spacing:-.5pt'> </span>n’est<span style='letter-spacing:-.2pt'> </span>pas pertinent.</p>
<p class=AmmCorpsTexte><i><u>Sujets âgés</u>:</i></p>
<p class=AmmCorpsTexte>Au<span style='letter-spacing:-.4pt'> </span>vu<span style='letter-spacing:-.1pt'> </span>des<span style='letter-spacing:-.15pt'> </span>données<span style='letter-spacing:-.35pt'> </span>de<span style='letter-spacing:-.1pt'> </span>phar<span style='letter-spacing:-.1pt'>m</span>acocinétique<span style='letter-spacing: -.15pt'> </span>de<span style='letter-spacing:-.1pt'> </span>population,<span style='letter-spacing:-.4pt'> </span>aucune<span style='letter-spacing:-.3pt'> </span>précaution<span style='letter-spacing:-.4pt'> </span>particulière<span style='letter-spacing: -.4pt'> </span>n<span style='letter-spacing:-.05pt'>'</span>est<span style='letter-spacing:-.05pt'> </span>à prendre<span style='letter-spacing: -.3pt'> </span>chez le sujet<span style='letter-spacing:-.2pt'> </span>âgé.</p>
<p class=AmmCorpsTexte>En<span style='letter-spacing:-.35pt'> </span>association<span style='letter-spacing:-.45pt'> </span>avec<span style='letter-spacing:-.2pt'> </span>la capécitabine,<span style='letter-spacing:-.45pt'> </span>il est<span style='letter-spacing:-.1pt'> </span>rec<span style='letter-spacing:-.05pt'>o</span><span style='letter-spacing:-.1pt'>mm</span>andé<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.1pt'> </span>réduire<span style='letter-spacing:-.3pt'> </span>à 75%<span style='letter-spacing:-.2pt'> </span>la dose<span style='letter-spacing:-.2pt'> </span>initiale<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing:-.1pt'> </span>capécitabine<span style='letter-spacing:.05pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>sujets<span style='letter-spacing:-.25pt'> </span>âgés<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing: -.1pt'> </span>60<span style='letter-spacing:-.1pt'> </span>ans<span style='letter-spacing:-.15pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>plus<span style='letter-spacing:-.2pt'> </span>(se<span style='letter-spacing:-.1pt'> </span>reporter<span style='letter-spacing:-.3pt'> </span>au<span style='letter-spacing:-.1pt'> </span>résu<span style='letter-spacing:-.1pt'>m</span>é<span style='letter-spacing:-.15pt'> </span>des<span style='letter-spacing:-.15pt'> </span>caractéristiques<span style='letter-spacing: -.6pt'> </span>du<span style='letter-spacing:-.1pt'> </span>produit de capécitabine).</p>
<p class="AmmAnnexeTitre2"><a name="RcpContreIndic">4.3. Contre-indications</a></p>
<p class=AmmListePuces1 style='text-align:justify'><a name="_Toc142278919"><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>H<span style='letter-spacing:.1pt'>y</span>persensibilité<span style='letter-spacing:-.1pt'> </span>à la substance<span style='letter-spacing: -.4pt'> </span>active<span style='letter-spacing:-.25pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>à l<span style='letter-spacing:-.05pt'>'</span>un<span style='letter-spacing:-.1pt'> </span>des<span style='letter-spacing:-.15pt'> </span>excipients </a><span lang=FR-BE>mentionnés à la rubrique 6.1</span>.</p>
<p class=AmmListePuces1 style='text-align:justify'><span style='font-family: Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>Le docétaxel ne doit pas être utilisé chez les patients dont le nombre initial de neutrophiles est &lt;1500/mm<sup>3</sup>.</p>
<p class=AmmListePuces1 style='text-align:justify'><span style='font-family: Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>En l’absence de données disponibles, le docétaxel ne doit pas être administré aux patients présentant une insuffisance hépatique sévère (voir rubriques 4.2 et 4.4).</p>
<p class=AmmListePuces1 style='text-align:justify'><span style='font-family: Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>Tenir compte également des contre-indications des spécialités associées au docétaxel.</p>
<p class="AmmAnnexeTitre2"><a name="RcpMisesEnGarde">4.4. Mises en garde spéciales et précautions d'emploi</a></p>
<p class=AmmCorpsTexte><a name="_Toc142278928">Pour<span style='letter-spacing: -.45pt'> </span>les<span style='letter-spacing:-.1pt'> </span>cancers<span style='letter-spacing:-.3pt'> </span>du<span style='letter-spacing:-.1pt'> </span>sein<span style='letter-spacing:-.15pt'> </span>et du<span style='letter-spacing:-.1pt'> </span>pou<span style='letter-spacing:-.1pt'>m</span>on<span style='letter-spacing:-.15pt'> </span>non<span style='letter-spacing:-.15pt'> </span>à petites<span style='letter-spacing: -.25pt'> </span>cellules,<span style='letter-spacing:-.3pt'> </span>une<span style='letter-spacing:-.15pt'> </span>pré<span style='letter-spacing:-.1pt'>m</span>édication<span style='letter-spacing:-.1pt'> </span>par<span style='letter-spacing:-.15pt'> </span>un<span style='letter-spacing:-.1pt'> </span>corticoïde<span style='letter-spacing: -.35pt'> </span>oral,<span style='letter-spacing:-.2pt'> </span>tel que<span style='letter-spacing:-.15pt'> </span>la dexa<span style='letter-spacing:-.05pt'>m</span>éthasone<span style='letter-spacing:-.5pt'> </span>à raison<span style='letter-spacing:-.3pt'> </span>de<span style='letter-spacing:-.1pt'> </span>16<span style='letter-spacing: -.1pt'> m</span>g<span style='letter-spacing:-.05pt'> </span>par<span style='letter-spacing:-.15pt'> </span>jour<span style='letter-spacing:-.15pt'> </span>(par<span style='letter-spacing:-.15pt'> </span>exe<span style='letter-spacing:-.05pt'>m</span>ple:<span style='letter-spacing:-.1pt'> </span>8<span style='letter-spacing:-.05pt'> </span><span style='letter-spacing:-.1pt'>m</span>g<span style='letter-spacing:-.05pt'> </span>2<span style='letter-spacing:-.05pt'> </span>fois<span style='letter-spacing:-.15pt'> </span>par<span style='letter-spacing:-.15pt'> </span>jour)<span style='letter-spacing:-.2pt'> </span>pendant 3<span style='letter-spacing:-.3pt'> </span>jours<span style='letter-spacing: -.2pt'> </span>en<span style='letter-spacing:-.1pt'> </span>co<span style='letter-spacing:-.1pt'>mm</span>ençant<span style='letter-spacing:-.3pt'> </span>la veille<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la perfusion<span style='letter-spacing: -.45pt'> </span>du<span style='letter-spacing:-.1pt'> </span>docétaxel,<span style='letter-spacing:-.35pt'> </span>sauf<span style='letter-spacing:-.15pt'> </span>contre-indication,<span style='letter-spacing:-.65pt'> </span>peut<span style='letter-spacing:-.15pt'> </span>réduire<span style='letter-spacing:-.3pt'> </span>l’incidence<span style='letter-spacing: .05pt'> </span>et la sévérité<span style='letter-spacing:-.3pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la rétention<span style='letter-spacing: -.3pt'> </span>h<span style='letter-spacing:.1pt'>y</span>drique<span style='letter-spacing:-.05pt'> </span>et<span style='letter-spacing:-.1pt'> </span>la sévérité<span style='letter-spacing:-.3pt'> </span>des<span style='letter-spacing: -.15pt'> </span>réactions<span style='letter-spacing:-.35pt'> </span>d’h<span style='letter-spacing:.1pt'>y</span>persensibilité.<span style='letter-spacing: -.1pt'> </span>Pour<span style='letter-spacing:-.2pt'> </span>le cancer<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la prostate,<span style='letter-spacing:-.35pt'> </span>la pré<span style='letter-spacing:-.1pt'>m</span>édication<span style='letter-spacing:-.15pt'> </span>orale<span style='letter-spacing:-.2pt'> </span>par<span style='letter-spacing:-.15pt'> </span>la<span style='letter-spacing:-.1pt'> </span>dexa<span style='letter-spacing:-.05pt'>m</span>éthasone<span style='letter-spacing:-.5pt'> </span>est<span style='letter-spacing:-.1pt'> </span>de<span style='letter-spacing: -.1pt'> </span>8<span style='letter-spacing:-.05pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>g</span>,<span style='letter-spacing:-.1pt'> </span>12<span style='letter-spacing:-.1pt'> </span>heures,<span style='letter-spacing:-.3pt'> </span>3<span style='letter-spacing:-.05pt'> </span>heures<span style='letter-spacing:-.25pt'> </span>et 1 heure avant la perfusion de docétaxel (voir rubrique 4.2). </a></p>
<p class=AmmCorpsTexte><u>Hématologie</u></p>
<p class=AmmCorpsTexte>La neutropénie est l'effet indésirable le plus fréquent observé avec le docétaxel. Le nadir a été observé en médiane 7 jours après le traitement mais cet intervalle peut être plus court chez les patients prétraités. Une surveillance fréquente de la formule sanguine doit être exercée chez tous les patients traités par le docétaxel. Le traitement par le docétaxel ne doit pas être repris tant que le nombre de neutrophiles n’est pas remonté au moins à 1500/mm<sup>3</sup> (voir rubrique 4.2).</p>
<p class=AmmCorpsTexte>En cas de neutropénie sévère (&lt;500/mm<sup>3 </sup>durant 7 jours ou plus) pendant une cure de docétaxel, il est recommandé de réduire la dose lors des cures suivantes ou de prendre les mesures symptomatiques appropriées (voir rubrique 4.2).</p>
<p class=AmmCorpsTexte>Chez les<span style='letter-spacing:.4pt'> </span>patients<span style='letter-spacing:.2pt'> </span>traités<span style='letter-spacing:.25pt'> </span>par<span style='letter-spacing:.35pt'> </span>docétaxel<span style='letter-spacing:.1pt'> </span>en<span style='letter-spacing:.35pt'> </span>association<span style='letter-spacing:-.05pt'> </span>avec<span style='letter-spacing:.25pt'> </span>le<span style='letter-spacing:.45pt'> </span>cisplatine<span style='letter-spacing: .05pt'> </span>et<span style='letter-spacing:.45pt'> </span>le<span style='letter-spacing:.45pt'> </span>5-fluoro-uracile (protocole<span style='letter-spacing:-.4pt'> </span>TCF), l’ad<span style='letter-spacing: -.05pt'>m</span>inistration<span style='letter-spacing:1.35pt'> </span>de<span style='letter-spacing:1.75pt'> </span>G-CSF<span style='letter-spacing:1.5pt'> </span>en<span style='letter-spacing:1.7pt'> </span>proph<span style='letter-spacing:.1pt'>y</span>laxie<span style='letter-spacing:1.55pt'> </span>p<span style='letter-spacing:-.05pt'>e</span>r<span style='letter-spacing:-.1pt'>m</span>et<span style='letter-spacing:1.75pt'> </span>de<span style='letter-spacing:1.7pt'> </span>réduire<span style='letter-spacing:1.5pt'> </span>la<span style='letter-spacing:1.8pt'> </span>fréquence<span style='letter-spacing:1.4pt'> </span>des<span style='letter-spacing:1.65pt'> </span>neutropénies fébriles<span style='letter-spacing:.75pt'> </span>et<span style='letter-spacing: .75pt'> </span>des<span style='letter-spacing:.75pt'> </span>infections<span style='letter-spacing:.35pt'> </span>neutropéniques.<span style='letter-spacing: .1pt'> </span>Les<span style='letter-spacing:.6pt'> </span>pati<span style='letter-spacing:.05pt'>e</span>nts<span style='letter-spacing:.6pt'> </span>traités<span style='letter-spacing:.5pt'> </span>selon<span style='letter-spacing:.5pt'> </span>le<span style='letter-spacing:.7pt'> </span>protocole<span style='letter-spacing:.3pt'> </span>TCF<span style='letter-spacing:.5pt'> </span>devront<span style='letter-spacing:.4pt'> </span>recevoir<span style='letter-spacing:-.35pt'> </span>du G-CSF en<span style='letter-spacing:1.3pt'> </span>proph<span style='letter-spacing:.1pt'>y</span>laxie pour di<span style='letter-spacing: -.1pt'>m</span>inuer le risque de survenue de neutropénies<span style='letter-spacing:.75pt'> </span>co<span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>p</span>liquées (neutropénie<span style='letter-spacing:.05pt'> </span>fébrile,<span style='letter-spacing:.05pt'> </span>prolongée<span style='letter-spacing:-.4pt'> </span>ou<span style='letter-spacing:-.05pt'> </span>infection<span style='letter-spacing: -.3pt'> </span>neutropénique).</p>
<p class=AmmCorpsTexte>Les<span style='letter-spacing:-.4pt'> </span>patients<span style='letter-spacing:-.3pt'> </span>traités<span style='letter-spacing:-.25pt'> </span>selon<span style='letter-spacing:-.2pt'> </span>le protocole<span style='letter-spacing:-.4pt'> </span>TCF<span style='letter-spacing:-.2pt'> </span>devront<span style='letter-spacing:-.3pt'> </span>faire<span style='letter-spacing:-.2pt'> </span>l’objet<span style='letter-spacing:-.25pt'> </span>d’une<span style='letter-spacing:-.25pt'> </span>surveillance<span style='letter-spacing:-.45pt'> </span>attentive (voir rubriques 4.2<span style='letter-spacing:-.15pt'> </span>et 4.8).</p>
<p class=AmmCorpsTexte>Chez les patients traités par docétaxel en association avec doxorubicine et cyclophosphamide (TAC), la neutropénie fébrile et/ou l’infection neutropénique surviennent à des taux plus faibles quand les patients ont reçu une prophylaxie primaire par G-CSF. Une prophylaxie primaire par G-CSF devrait être évaluée chez des patients recevant le protocole TAC en traitement adjuvant du cancer du sein pour atténuer le risque de complications neutropéniques (neutropénie fébrile, neutropénie prolongée ou infection neutropénique). Les patients recevant le protocole TAC doivent avoir un suivi étroit (voir rubriques 4.2 et 4.8).</p>
<p class=AmmCorpsTexte><u><sub>Réactions d<span style='letter-spacing:-.05pt'>'</span>h<span style='letter-spacing:.1pt'>y</span>persensibilité</sub></u></p>
<p class=AmmCorpsTexte>Les<span style='letter-spacing:-.4pt'> </span>patients<span style='letter-spacing:-.3pt'> </span>doivent<span style='letter-spacing:-.3pt'> </span>être<span style='letter-spacing:-.15pt'> </span>stricte<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.25pt'> </span>surveillés<span style='letter-spacing:-.4pt'> </span>en<span style='letter-spacing:-.05pt'> </span>raison<span style='letter-spacing:-.25pt'> </span>du<span style='letter-spacing:-.1pt'> </span>risque<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.1pt'> </span>réa<span style='letter-spacing:-.05pt'>c</span>tions<span style='letter-spacing:-.1pt'> </span>d’h<span style='letter-spacing:.1pt'>y</span>persensibilité, particulière<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.1pt'> </span>pendant<span style='letter-spacing:-.3pt'> </span>la pre<span style='letter-spacing:-.1pt'>m</span>i<span style='letter-spacing:-.05pt'>è</span>re<span style='letter-spacing:-.2pt'> </span>et la seconde<span style='letter-spacing:-.3pt'> </span>perfusion.<span style='letter-spacing:-.4pt'> </span>Des<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.05pt'>r</span>éactions<span style='letter-spacing:-.05pt'> </span>d<span style='letter-spacing:-.05pt'>'</span>h<span style='letter-spacing: .1pt'>y</span>persensibilité peuvent<span style='letter-spacing:-.3pt'> </span>survenir dans<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing: -.1pt'> m</span>inutes<span style='letter-spacing:-.3pt'> </span>qui<span style='letter-spacing:-.15pt'> </span>suivent<span style='letter-spacing:-.3pt'> </span>le début<span style='letter-spacing:-.2pt'> </span>d<span style='letter-spacing:-.05pt'>'</span>une<span style='letter-spacing:-.05pt'> </span>perfusion<span style='letter-spacing:-.4pt'> </span>du<span style='letter-spacing:-.1pt'> </span>docétaxel<span style='letter-spacing:-.35pt'> </span>; pour<span style='letter-spacing:-.2pt'> </span>cette<span style='letter-spacing:.05pt'> </span>raison<span style='letter-spacing:-.25pt'> </span>le <span style='letter-spacing:-.1pt'>m</span>atériel<span style='letter-spacing:-.05pt'> </span><span style='letter-spacing:-.1pt'>m</span>édical<span style='letter-spacing:.05pt'> </span>approprié<span style='letter-spacing:-.4pt'> </span>doit<span style='letter-spacing:-.15pt'> </span>être<span style='letter-spacing:-.1pt'> </span>disponible<span style='letter-spacing: -.35pt'> </span>pour<span style='letter-spacing:-.3pt'> </span>traiter<span style='letter-spacing:-.2pt'> </span>l’h<span style='letter-spacing:.1pt'>y</span>potension<span style='letter-spacing:-.1pt'> </span>et le bronchospas<span style='letter-spacing: -.1pt'>m</span>e.<span style='letter-spacing:-.5pt'> </span>Les<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span>anifestations<span style='letter-spacing:-.45pt'> </span><span style='letter-spacing:-.1pt'>m</span>ineures, co<span style='letter-spacing:-.1pt'>mm</span>e<span style='letter-spacing: -.1pt'> </span>les<span style='letter-spacing:-.1pt'> </span>bouffées<span style='letter-spacing:-.35pt'> </span>vaso<span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>o</span>trices<span style='letter-spacing:-.2pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>les<span style='letter-spacing:-.1pt'> </span>réactions<span style='letter-spacing:-.35pt'> </span>cutanées<span style='letter-spacing:-.35pt'> </span>localisées,<span style='letter-spacing:-.4pt'> </span>ne<span style='letter-spacing:-.1pt'> </span>justifient<span style='letter-spacing: .05pt'> </span>pas<span style='letter-spacing:-.15pt'> </span>l<span style='letter-spacing:-.05pt'>'</span>interruption<span style='letter-spacing: -.4pt'> </span>du traite<span style='letter-spacing:-.05pt'>m</span>ent.<span style='letter-spacing:-.3pt'> </span>En<span style='letter-spacing:-.1pt'> </span>r<span style='letter-spacing:-.05pt'>e</span>vanche,<span style='letter-spacing:-.05pt'> </span>les<span style='letter-spacing:-.1pt'> </span>réactions<span style='letter-spacing:-.35pt'> </span>sévères,<span style='letter-spacing:-.3pt'> </span>telles une<span style='letter-spacing:-.15pt'> </span>h<span style='letter-spacing:.1pt'>y</span>potension<span style='letter-spacing:-.05pt'> </span>sévère, un<span style='letter-spacing:-.1pt'> </span>bronchospas<span style='letter-spacing:-.1pt'>m</span>e<span style='letter-spacing:-.5pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>un rash/ér<span style='letter-spacing: .1pt'>y</span>thè<span style='letter-spacing:-.1pt'>m</span>e<span style='letter-spacing:-.25pt'> </span>général<span style='letter-spacing:.05pt'>i</span>sé,<span style='letter-spacing:-.3pt'> </span>i<span style='letter-spacing:-.1pt'>m</span>posent<span style='letter-spacing:-.05pt'> </span>l'arrêt<span style='letter-spacing:-.25pt'> </span>i<span style='letter-spacing:-.1pt'>mm</span>édiat<span style='letter-spacing:-.2pt'> </span>du<span style='letter-spacing:-.1pt'> </span>docétaxel<span style='letter-spacing:-.4pt'> </span>et l<span style='letter-spacing:-.05pt'>'</span>instauration<span style='letter-spacing:-.4pt'> </span>d<span style='letter-spacing:-.05pt'>'</span>un<span style='letter-spacing:-.05pt'> </span>traite<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.3pt'> </span>s<span style='letter-spacing:.1pt'>y</span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>p</span>to<span style='letter-spacing:-.1pt'>m</span>atique. Le<span style='letter-spacing: -.1pt'> </span>docé<span style='letter-spacing:-.05pt'>t</span>axel<span style='letter-spacing:-.2pt'> </span>ne<span style='letter-spacing:-.1pt'> </span>doit<span style='letter-spacing:-.15pt'> </span>pas<span style='letter-spacing:-.15pt'> </span>être<span style='letter-spacing:-.15pt'> </span>réad<span style='letter-spacing:-.1pt'>m</span>inistré<span style='letter-spacing:-.4pt'> </span>aux<span style='letter-spacing:-.15pt'> </span>patients<span style='letter-spacing:-.3pt'> </span>a<span style='letter-spacing:.1pt'>y</span>ant présenté<span style='letter-spacing:-.35pt'> </span>des<span style='letter-spacing: -.15pt'> </span>réactions<span style='letter-spacing:-.35pt'> </span>d<span style='letter-spacing:-.05pt'>'</span>h<span style='letter-spacing:.1pt'>y</span>persensibilité<span style='letter-spacing:-.05pt'> </span>sévères.</p>
<p class=AmmCorpsTexte><u>Réactions cutanées</u></p>
<p class=AmmCorpsTexte>Des<span style='letter-spacing:-.4pt'> </span>cas<span style='letter-spacing:-.15pt'> </span>d<span style='letter-spacing:.05pt'>’</span>ér<span style='letter-spacing:.1pt'>y</span>thè<span style='letter-spacing:-.1pt'>m</span>es<span style='letter-spacing:-.15pt'> </span>cutanés<span style='letter-spacing:-.3pt'> </span>localisés<span style='letter-spacing:-.35pt'> </span>aux<span style='letter-spacing:-.15pt'> </span>extré<span style='letter-spacing:-.05pt'>m</span>ités<span style='letter-spacing:-.3pt'> </span>(pau<span style='letter-spacing:-.1pt'>m</span>es<span style='letter-spacing:-.2pt'> </span>des<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span>ains<span style='letter-spacing:-.2pt'> </span>et<span style='letter-spacing:.05pt'> </span>plantes<span style='letter-spacing:-.3pt'> </span>des<span style='letter-spacing:-.15pt'> </span>pieds),<span style='letter-spacing:-.25pt'> </span>acco<span style='letter-spacing:-.05pt'>m</span><span style='letter-spacing:.05pt'>p</span>agnés d<span style='letter-spacing:.05pt'>’</span>œdè<span style='letter-spacing:-.1pt'>m</span>e<span style='letter-spacing:-.05pt'> </span>et suivis<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing: -.1pt'> </span>desqua<span style='letter-spacing:-.1pt'>m</span>ation<span style='letter-spacing:-.45pt'> </span>ont<span style='letter-spacing:-.2pt'> </span>été observés.<span style='letter-spacing:-.35pt'> </span>Des<span style='letter-spacing: -.15pt'> </span>s<span style='letter-spacing:.1pt'>y</span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>p</span>tô<span style='letter-spacing:-.1pt'>m</span>es<span style='letter-spacing:-.05pt'> </span>sévères<span style='letter-spacing:-.3pt'> </span>tels que<span style='letter-spacing:-.15pt'> </span>des éruptions<span style='letter-spacing:-.35pt'> </span>suivies<span style='letter-spacing:-.3pt'> </span>de desqua<span style='letter-spacing:-.1pt'>m</span>ation<span style='letter-spacing:-.45pt'> </span>conduisa<span style='letter-spacing:.05pt'>n</span>t<span style='letter-spacing:-.35pt'> </span>à l’interruption<span style='letter-spacing: -.5pt'> </span>te<span style='letter-spacing:-.05pt'>m</span>poraire ou<span style='letter-spacing:-.1pt'> </span>définitive<span style='letter-spacing: -.35pt'> </span>du<span style='letter-spacing:-.1pt'> </span>traite<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.1pt'> </span>par<span style='letter-spacing:-.15pt'> </span>le docétaxel<span style='letter-spacing: -.4pt'> </span>ont<span style='letter-spacing:-.15pt'> </span>été rapportés<span style='letter-spacing:-.35pt'> </span>(voir rubrique 4.2).</p>
<p class=AmmCorpsTexte><u>Rétention h<span style='letter-spacing:.1pt'>y</span>drique</u></p>
<p class=AmmCorpsTexte>Les<span style='letter-spacing:-.4pt'> </span>patients<span style='letter-spacing:-.3pt'> </span>présentant<span style='letter-spacing: -.4pt'> </span>une<span style='letter-spacing:-.15pt'> </span>rétention<span style='letter-spacing:-.35pt'> </span>h<span style='letter-spacing:.1pt'>y</span>drique<span style='letter-spacing:-.05pt'> </span>sévère<span style='letter-spacing:-.3pt'> </span>telle<span style='letter-spacing:.05pt'> </span>que<span style='letter-spacing:-.15pt'> </span>pleurésie,<span style='letter-spacing: -.4pt'> </span>péricardite<span style='letter-spacing:-.4pt'> </span>et ascite devront<span style='letter-spacing:-.3pt'> </span>être particulière<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.55pt'> </span>surveillés.</p>
<p class=AmmCorpsTexte><u>Patients avec insuffisance hépatique</u></p>
<p class=AmmCorpsTexte>Chez<span style='letter-spacing:-.5pt'> </span>les<span style='letter-spacing:-.1pt'> </span>patients<span style='letter-spacing:-.3pt'> </span>traités<span style='letter-spacing:-.25pt'> </span>par<span style='letter-spacing:-.15pt'> </span>le docétaxel<span style='letter-spacing: -.4pt'> </span>à 100<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.1pt'>m<sup>2</sup></span><sup> </sup>en<span style='letter-spacing:-.35pt'> </span><span style='letter-spacing:-.1pt'>m</span>onothérapie<span style='letter-spacing:-.05pt'> </span>et présentant<span style='letter-spacing: -.4pt'> </span>des<span style='letter-spacing:-.15pt'> </span>taux<span style='letter-spacing:-.15pt'> </span>de<span style='letter-spacing:-.1pt'> </span>transa<span style='letter-spacing:-.05pt'>m</span>inases (ALAT<span style='letter-spacing: -.3pt'> </span>et/ou<span style='letter-spacing:-.2pt'> </span>ASAT)<span style='letter-spacing:-.3pt'> </span>supérieurs<span style='letter-spacing: -.4pt'> </span>à 1,5<span style='letter-spacing:-.15pt'> </span>fois<span style='letter-spacing:-.15pt'> </span>la LSN<span style='letter-spacing:-.2pt'> </span>ainsi<span style='letter-spacing:-.2pt'> </span>que<span style='letter-spacing:-.15pt'> </span>des<span style='letter-spacing:-.15pt'> </span>taux<span style='letter-spacing:-.15pt'> </span>sériques<span style='letter-spacing:-.35pt'> </span>de<span style='letter-spacing:-.1pt'> </span>phosphatases alcalines<span style='letter-spacing:-.35pt'> </span>supérieurs à 2,5<span style='letter-spacing: -.15pt'> </span>fois<span style='letter-spacing:-.15pt'> </span>la LSN,<span style='letter-spacing:-.2pt'> </span>le risque<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.1pt'> </span>développer<span style='letter-spacing: -.45pt'> </span>des<span style='letter-spacing:-.15pt'> </span>effets<span style='letter-spacing:-.2pt'> </span>indésirables<span style='letter-spacing: -.5pt'> </span>sévères tels que<span style='letter-spacing:-.15pt'> </span>décès<span style='letter-spacing:-.2pt'> </span>toxiques,<span style='letter-spacing:-.35pt'> </span>incluant septicé<span style='letter-spacing:-.05pt'>m</span>ies<span style='letter-spacing:-.35pt'> </span>et hé<span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>o</span>rragies<span style='letter-spacing:-.1pt'> </span>gastro-intestinales<span style='letter-spacing:-.7pt'> </span>qui<span style='letter-spacing:-.15pt'> </span>peuvent<span style='letter-spacing:-.3pt'> </span>être fatales,<span style='letter-spacing:-.3pt'> </span>neutropénie<span style='letter-spacing:-.4pt'> </span>fébrile,<span style='letter-spacing:-.3pt'> </span>infections, thr<span style='letter-spacing:-.1pt'>o</span>mb<span style='letter-spacing:-.1pt'>o</span><span style='letter-spacing:.1pt'>c</span>ytopénies,<span style='letter-spacing:-.45pt'> </span>sto<span style='letter-spacing:-.1pt'>m</span>atites<span style='letter-spacing:-.1pt'> </span>et asthénie,<span style='letter-spacing: -.35pt'> </span>est<span style='letter-spacing:-.1pt'> </span>aug<span style='letter-spacing:-.1pt'>m</span>enté.<span style='letter-spacing:-.15pt'> </span>En<span style='letter-spacing:-.1pt'> </span>conséquence, la dose<span style='letter-spacing:-.2pt'> </span>reco<span style='letter-spacing:-.05pt'>m</span><span style='letter-spacing:-.1pt'>m</span>andée<span style='letter-spacing:-.35pt'> </span>de<span style='letter-spacing:-.1pt'> </span>docétaxel<span style='letter-spacing:-.5pt'> </span>chez les<span style='letter-spacing:-.1pt'> </span>patients<span style='letter-spacing:-.3pt'> </span>a<span style='letter-spacing:.1pt'>y</span>ant<span style='letter-spacing:-.05pt'> </span>un<span style='letter-spacing:-.1pt'> </span>bilan<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la fonction<span style='letter-spacing:-.35pt'> </span>hépatique élevé<span style='letter-spacing:-.2pt'> </span>(BFH)<span style='letter-spacing:-.25pt'> </span>est<span style='letter-spacing:-.1pt'> </span>de<span style='letter-spacing:-.1pt'> </span>75<span style='letter-spacing:-.1pt'> m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.15pt'>m</span><sup><span style='letter-spacing:-.1pt'>2</span> <span style='letter-spacing:.7pt'></span></sup>et<span style='letter-spacing: -.2pt'> </span>un<span style='letter-spacing:-.1pt'> </span>bilan<span style='letter-spacing:-.15pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la<span style='letter-spacing:.05pt'> </span>fonction<span style='letter-spacing:.05pt'> </span>h<span style='letter-spacing:-.1pt'>é</span>patique<span style='letter-spacing:-.05pt'> </span>(BFH)<span style='letter-spacing:-.25pt'> </span>doit<span style='letter-spacing:-.15pt'> </span>être<span style='letter-spacing:-.15pt'> </span>fait en<span style='letter-spacing:-.1pt'> </span>début de<span style='letter-spacing:-.1pt'> </span>traite<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.3pt'> </span>et avant<span style='letter-spacing:-.25pt'> </span>chaque<span style='letter-spacing: -.3pt'> </span>cure<span style='letter-spacing:-.15pt'> </span>(voir rubrique 4.2).</p>
<p class=AmmCorpsTexte>Chez<span style='letter-spacing:-.5pt'> </span>les<span style='letter-spacing:-.1pt'> </span>patients<span style='letter-spacing:-.3pt'> </span>avec<span style='letter-spacing:-.2pt'> </span>une<span style='letter-spacing:-.15pt'> </span>bilirubiné<span style='letter-spacing: -.05pt'>m</span>ie<span style='letter-spacing:-.4pt'> </span>&gt;LSN<span style='letter-spacing:-.25pt'> </span>et/ou<span style='letter-spacing:-.2pt'> </span>des<span style='letter-spacing:-.15pt'> </span>ALAT<span style='letter-spacing:-.25pt'> </span>et ASAT<span style='letter-spacing:-.25pt'> </span>3,5<span style='letter-spacing: -.15pt'> </span>fois<span style='letter-spacing:-.15pt'> </span>supérieures<span style='letter-spacing:-.45pt'> </span>à la LSN<span style='letter-spacing:-.2pt'> </span>avec des<span style='letter-spacing:-.15pt'> </span>phosphatases<span style='letter-spacing:-.55pt'> </span>alcalines<span style='letter-spacing:-.35pt'> </span>supérieures<span style='letter-spacing: -.45pt'> </span>à 6<span style='letter-spacing:-.05pt'> </span>f<span style='letter-spacing:.05pt'>o</span>is<span style='letter-spacing:-.05pt'> </span>la LSN,<span style='letter-spacing:-.2pt'> </span>aucune<span style='letter-spacing:-.3pt'> </span>rédu<span style='letter-spacing:-.1pt'>c</span>tion<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span>dose<span style='letter-spacing:-.2pt'> </span>ne<span style='letter-spacing:-.1pt'> </span>peut<span style='letter-spacing:-.15pt'> </span>être reco<span style='letter-spacing:-.1pt'>mm</span>andée<span style='letter-spacing: -.35pt'> </span>et le docétaxel<span style='letter-spacing:-.4pt'> </span>ne<span style='letter-spacing:-.1pt'> </span>devrait<span style='letter-spacing:-.3pt'> </span>pas<span style='letter-spacing:-.2pt'> </span>être<span style='letter-spacing:-.15pt'> </span>ad<span style='letter-spacing:-.1pt'>m</span>inistré<span style='letter-spacing:-.3pt'> </span>sauf<span style='letter-spacing:-.15pt'> </span>s<span style='letter-spacing:.05pt'>’</span>il<span style='letter-spacing:-.05pt'> </span>est<span style='letter-spacing:-.1pt'> </span>stricte<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.25pt'> </span>indiqué.<span style='letter-spacing:-.3pt'> </span>Dans le traite<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.3pt'> </span>de l<span style='letter-spacing:.05pt'>’</span>adénocarcino<span style='letter-spacing:-.05pt'>m</span>e<span style='letter-spacing:-.05pt'> </span>gas<span style='letter-spacing:-.05pt'>t</span>rique<span style='letter-spacing:-.15pt'> </span>en<span style='letter-spacing:-.1pt'> </span>association<span style='letter-spacing:-.45pt'> </span>avec<span style='letter-spacing:-.2pt'> </span>le cisplatine<span style='letter-spacing:-.4pt'> </span>et le 5<span style='letter-spacing:-.3pt'> </span>fluoro-uracile,<span style='letter-spacing: -.5pt'> </span>l<span style='letter-spacing:.05pt'>’</span>étude<span style='letter-spacing:-.05pt'> </span>pivot<span style='letter-spacing:-.25pt'> </span>a exclu<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>pati<span style='letter-spacing:-.05pt'>e</span>nts<span style='letter-spacing:-.15pt'> </span>présentant<span style='letter-spacing: -.4pt'> </span>un<span style='letter-spacing:-.1pt'> </span>taux<span style='letter-spacing:-.15pt'> </span>de<span style='letter-spacing:-.1pt'> </span>transa<span style='letter-spacing:-.05pt'>m</span>inases<span style='letter-spacing:-.25pt'> </span>(ASAT<span style='letter-spacing:-.3pt'> </span>et/ou<span style='letter-spacing:-.2pt'> </span>ALAT) &gt;1,5<span style='letter-spacing: -.2pt'> </span>fois<span style='letter-spacing:-.15pt'> </span>la LSN<span style='letter-spacing:-.2pt'> </span>associé<span style='letter-spacing:-.3pt'> </span>à des<span style='letter-spacing:-.15pt'> </span>phosphatases<span style='letter-spacing:-.55pt'> </span>alcalines<span style='letter-spacing: -.35pt'> </span>&gt;2,5<span style='letter-spacing:-.2pt'> </span>fois<span style='letter-spacing:-.15pt'> </span>la LSN<span style='letter-spacing:-.2pt'> </span>et un<span style='letter-spacing:-.1pt'> </span>taux<span style='letter-spacing:-.15pt'> </span>de<span style='letter-spacing:-.1pt'> </span>bilirubine<span style='letter-spacing:.05pt'> </span>&gt;<span style='letter-spacing:-.05pt'> </span>1<span style='letter-spacing:-.05pt'> </span>fois<span style='letter-spacing:-.15pt'> </span>la LSN<span style='letter-spacing:-.2pt'> </span>: en<span style='letter-spacing:-.1pt'> </span>conséquence<span style='letter-spacing:-.5pt'> </span>pour<span style='letter-spacing:-.2pt'> </span>ces<span style='letter-spacing:-.15pt'> </span>patients,<span style='letter-spacing: -.35pt'> </span>aucune<span style='letter-spacing:-.3pt'> </span>réduction<span style='letter-spacing:-.4pt'> </span>de<span style='letter-spacing:-.1pt'> </span>dose<span style='letter-spacing:-.2pt'> </span>ne<span style='letter-spacing:-.1pt'> </span>peut<span style='letter-spacing:-.15pt'> </span>être<span style='letter-spacing:-.15pt'> </span>reco<span style='letter-spacing:-.1pt'>mm</span>andée<span style='letter-spacing:-.2pt'> </span>et le docétaxel<span style='letter-spacing:-.4pt'> </span>ne<span style='letter-spacing:-.1pt'> </span>devrait pas<span style='letter-spacing: -.15pt'> </span>être<span style='letter-spacing:-.2pt'> </span>ad<span style='letter-spacing:-.1pt'>m</span>inistré<span style='letter-spacing:-.3pt'> </span>sauf<span style='letter-spacing:-.15pt'> </span>si<span style='letter-spacing:-.05pt'> </span>il est<span style='letter-spacing:-.1pt'> </span>stricte<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.25pt'> </span>indiqué.</p>
<p class=AmmCorpsTexte>On<span style='letter-spacing:-.4pt'> </span>ne<span style='letter-spacing:-.1pt'> </span>dispose<span style='letter-spacing:-.3pt'> </span>d<span style='letter-spacing:.05pt'>’</span>aucune<span style='letter-spacing:-.05pt'> </span>donnée<span style='letter-spacing:-.3pt'> </span>sur<span style='letter-spacing:-.1pt'> </span>les<span style='letter-spacing: -.1pt'> </span>insuffisants<span style='letter-spacing:-.35pt'> </span>hépatiques<span style='letter-spacing:-.45pt'> </span>traités<span style='letter-spacing:-.25pt'> </span>par<span style='letter-spacing:-.15pt'> </span>le docétaxel<span style='letter-spacing:-.4pt'> </span>en<span style='letter-spacing:-.1pt'> </span>association<span style='letter-spacing:-.45pt'> </span>dans les autres<span style='letter-spacing: -.25pt'> </span>indications.</p>
<p class=AmmCorpsTexte><u>Patients avec insuffisance rénale</u></p>
<p class=AmmCorpsTexte>Il<span style='letter-spacing:-.3pt'> </span>n’existe<span style='letter-spacing:-.3pt'> </span>aucune<span style='letter-spacing:-.3pt'> </span>donnée<span style='letter-spacing:-.3pt'> </span>disponible<span style='letter-spacing: -.4pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>patients<span style='letter-spacing:-.3pt'> </span>atteints<span style='letter-spacing:-.3pt'> </span>d’insuffisance<span style='letter-spacing:-.55pt'> </span>rénale<span style='letter-spacing:-.25pt'> </span>sévère<span style='letter-spacing:-.25pt'> </span>traités<span style='letter-spacing:-.25pt'> </span>par<span style='letter-spacing:-.15pt'> </span>docétaxel.</p>
<p class=AmmCorpsTexte><u><sub>S<span style='letter-spacing:.1pt'>y</span>stè<span style='letter-spacing:-.1pt'>m</span>e nerveux</sub></u></p>
<p class=AmmCorpsTexte>L’apparition<span style='letter-spacing:-.75pt'> </span>d’une<span style='letter-spacing:-.2pt'> </span>neurotoxicité<span style='letter-spacing: -.55pt'> </span>périphérique<span style='letter-spacing:-.5pt'> </span>sévère<span style='letter-spacing:-.25pt'> </span>i<span style='letter-spacing:-.1pt'>m</span>pose<span style='letter-spacing:-.05pt'> </span>une<span style='letter-spacing:-.15pt'> </span>réduction<span style='letter-spacing:-.4pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la dose<span style='letter-spacing:-.2pt'> </span>(voir rubrique 4.2).</p>
<p class=AmmCorpsTexte><u>Toxicité<span style='letter-spacing:.05pt'> </span>cardiaque</u></p>
<p class=AmmCorpsTexte>Une<span style='letter-spacing:-.45pt'> </span>insuffisance<span style='letter-spacing:-.5pt'> </span>cardiaque<span style='letter-spacing:-.4pt'> </span>a été observée<span style='letter-spacing:-.35pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>des<span style='letter-spacing:-.15pt'> </span>patientes<span style='letter-spacing:-.35pt'> </span>recevant<span style='letter-spacing:-.35pt'> </span>du<span style='letter-spacing:-.1pt'> </span>docétaxel<span style='letter-spacing:-.35pt'> </span>en<span style='letter-spacing:-.1pt'> </span>association<span style='letter-spacing:-.45pt'> </span>avec<span style='letter-spacing:-.2pt'> </span>du trastuzu<span style='letter-spacing:-.05pt'>m</span>ab,<span style='letter-spacing: -.3pt'> </span>en<span style='letter-spacing:-.1pt'> </span>particulier<span style='letter-spacing:-.35pt'> </span>après<span style='letter-spacing:-.2pt'> </span>une<span style='letter-spacing:-.15pt'> </span>chi<span style='letter-spacing:-.05pt'>m</span>iothé<span style='letter-spacing:-.05pt'>r</span>apie<span style='letter-spacing:-.1pt'> </span>contenant<span style='letter-spacing:-.35pt'> </span>une<span style='letter-spacing:-.15pt'> </span>anthrac<span style='letter-spacing:.1pt'>y</span>cline<span style='letter-spacing:-.25pt'> </span>(doxorubicine<span style='letter-spacing:-.5pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>épirubicine). Celle-ci peut<span style='letter-spacing:-.15pt'> </span>être<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span>odérée<span style='letter-spacing:-.1pt'> </span>à sévère,<span style='letter-spacing:-.3pt'> </span>voire<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing: -.1pt'>m</span>ê<span style='letter-spacing:-.1pt'>m</span>e<span style='letter-spacing:-.15pt'> </span>d’issue<span style='letter-spacing:-.3pt'> </span>fatale (voir rubrique 4.8).</p>
<p class=AmmCorpsTexte>Quand<span style='letter-spacing:-.55pt'> </span>les<span style='letter-spacing:-.1pt'> </span>patientes<span style='letter-spacing:-.35pt'> </span>sont<span style='letter-spacing:-.15pt'> </span>susceptibles<span style='letter-spacing:-.5pt'> </span>d<span style='letter-spacing:.05pt'>’</span>être<span style='letter-spacing:-.05pt'> </span>tr<span style='letter-spacing:-.05pt'>a</span>itées<span style='letter-spacing:-.05pt'> </span>par<span style='letter-spacing:-.15pt'> </span>le docétaxel<span style='letter-spacing:-.4pt'> </span>en<span style='letter-spacing: -.1pt'> </span>association<span style='letter-spacing:-.45pt'> </span>avec<span style='letter-spacing:-.2pt'> </span>le trastuzu<span style='letter-spacing: -.05pt'>m</span>ab,<span style='letter-spacing:-.3pt'> </span>elles doivent<span style='letter-spacing:-.3pt'> </span>bénéficier<span style='letter-spacing: -.35pt'> </span>d’une<span style='letter-spacing:-.25pt'> </span>éva<span style='letter-spacing:-.05pt'>l</span>uation<span style='letter-spacing:-.15pt'> </span>cardiaque<span style='letter-spacing:-.35pt'> </span>avant<span style='letter-spacing:-.2pt'> </span>traite<span style='letter-spacing:-.05pt'>m</span>ent.<span style='letter-spacing:-.3pt'> </span>La<span style='letter-spacing:-.1pt'> </span>fonction<span style='letter-spacing:-.35pt'> </span>cardiaque doit<span style='letter-spacing: -.15pt'> </span>être<span style='letter-spacing:2.4pt'> </span>surveillée pendant<span style='letter-spacing:-.3pt'> </span>le trait<span style='letter-spacing:-.1pt'>em</span>ent<span style='letter-spacing:-.15pt'> </span>(ex<span style='letter-spacing:-.15pt'> </span>: tous<span style='letter-spacing:-.15pt'> </span>les<span style='letter-spacing:-.1pt'> </span>trois<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>o</span>is)<span style='letter-spacing:-.1pt'> </span>pour<span style='letter-spacing:-.2pt'> </span>per<span style='letter-spacing:-.1pt'>m</span>ettre<span style='letter-spacing:-.15pt'> </span>d<span style='letter-spacing:.05pt'>’</span>identifier les<span style='letter-spacing:-.1pt'> </span>patientes<span style='letter-spacing: -.3pt'> </span>susceptibles<span style='letter-spacing:-.5pt'> </span>de développ<span style='letter-spacing:-.1pt'>e</span>r<span style='letter-spacing: -.35pt'> </span>un<span style='letter-spacing:-.1pt'> </span>d<span style='letter-spacing:.1pt'>y</span>sfonctionne<span style='letter-spacing: -.05pt'>m</span>ent<span style='letter-spacing:-.15pt'> </span>cardiaque.<span style='letter-spacing:-.35pt'> </span>Pour<span style='letter-spacing:-.2pt'> </span>plus<span style='letter-spacing:-.15pt'> </span>de<span style='letter-spacing:-.1pt'> </span>détails, voir<span style='letter-spacing:-.15pt'> </span>le résu<span style='letter-spacing: -.1pt'>m</span>é<span style='letter-spacing:-.15pt'> </span>des<span style='letter-spacing:-.15pt'> </span>caractéristiques<span style='letter-spacing: -.55pt'> </span>du produit<span style='letter-spacing:-.3pt'> </span>de<span style='letter-spacing:-.1pt'> </span>trastuzu<span style='letter-spacing:-.05pt'>m</span>ab.</p>
<p class=AmmCorpsTexte><u>Divers</u></p>
<p class=AmmCorpsTexte>Des<span style='letter-spacing:-.4pt'> </span><span style='letter-spacing:-.1pt'>m</span>esures<span style='letter-spacing:-.1pt'> </span>contraceptives<span style='letter-spacing:-.6pt'> </span>doivent<span style='letter-spacing:-.3pt'> </span>être<span style='letter-spacing:-.15pt'> </span>prises<span style='letter-spacing:-.25pt'> </span>à la fois<span style='letter-spacing: -.15pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>ho<span style='letter-spacing:-.1pt'>mm</span>es<span style='letter-spacing:-.1pt'> </span>et les<span style='letter-spacing:-.1pt'> </span>fe<span style='letter-spacing:-.1pt'>mm</span>es<span style='letter-spacing:-.1pt'> </span>en<span style='letter-spacing:-.1pt'> </span>cours<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span>traite<span style='letter-spacing:-.05pt'>m</span>ent et poursuivies<span style='letter-spacing:-.45pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>ho<span style='letter-spacing:-.1pt'>mm</span>es<span style='letter-spacing:-.1pt'> </span>au<span style='letter-spacing:-.1pt'> m</span><span style='letter-spacing:.05pt'>o</span>ins<span style='letter-spacing:-.1pt'> </span>6<span style='letter-spacing:-.05pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>o</span>is<span style='letter-spacing:-.1pt'> </span>après<span style='letter-spacing:-.2pt'> </span>la fin<span style='letter-spacing:-.1pt'> </span>du<span style='letter-spacing: -.1pt'> </span>traite<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.3pt'> </span>(voir<span style='letter-spacing:-.2pt'> </span>rubrique 4.6).</p>
<p class=AmmCorpsTexte><u>Précautions particulières<span style='letter-spacing: .05pt'> </span>pour l<span style='letter-spacing:.05pt'>’</span>utilisation en traite<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing: -.1pt'> </span>adjuvant du cancer du sein</u></p>
<p class=AmmCorpsTexte><i><u>Neutropénie compliquée</u></i></p>
<p class=AmmCorpsTexte>Chez<span style='letter-spacing:-.5pt'> </span>les<span style='letter-spacing:-.1pt'> </span>patientes<span style='letter-spacing:-.35pt'> </span>a<span style='letter-spacing:.1pt'>y</span>ant<span style='letter-spacing: -.05pt'> </span>présenté<span style='letter-spacing:-.35pt'> </span>une<span style='letter-spacing:-.15pt'> </span>neutropénie<span style='letter-spacing: -.45pt'> </span>co<span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>p</span>liquée<span style='letter-spacing:-.1pt'> </span>(une<span style='letter-spacing:-.2pt'> </span>neutropénie<span style='letter-spacing: -.4pt'> </span>prolongée,<span style='letter-spacing:-.4pt'> </span>une<span style='letter-spacing:-.15pt'> </span>neutropénie<span style='letter-spacing: .05pt'> </span>fébrile<span style='letter-spacing:-.25pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>une<span style='letter-spacing:-.15pt'> </span>infection),<span style='letter-spacing:-.4pt'> </span>l’utilisation<span style='letter-spacing: -.4pt'> </span>de<span style='letter-spacing:-.1pt'> </span>G-CSF<span style='letter-spacing:-.3pt'> </span>et une<span style='letter-spacing:-.15pt'> </span>réduction<span style='letter-spacing:-.4pt'> </span>de<span style='letter-spacing:-.1pt'> </span>dose<span style='letter-spacing:-.2pt'> </span>devraient<span style='letter-spacing:-.3pt'> </span>être<span style='letter-spacing:-.15pt'> </span>envisagées (voir rubrique 4.2).</p>
<p class=AmmCorpsTexte><i><u>Effets gastro-intestinaux</u></i></p>
<p class=AmmCorpsTexte>Des<span style='letter-spacing:-.4pt'> </span>s<span style='letter-spacing:.1pt'>y</span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>p</span>tô<span style='letter-spacing:-.1pt'>m</span>es<span style='letter-spacing:-.05pt'> </span>tels que<span style='letter-spacing:-.15pt'> </span>douleurs<span style='letter-spacing:-.35pt'> </span>et sensibilité<span style='letter-spacing:-.4pt'> </span>abdo<span style='letter-spacing:-.1pt'>m</span>inales<span style='letter-spacing:-.2pt'> </span>précoces,<span style='letter-spacing:-.35pt'> </span>fièvre,<span style='letter-spacing:-.25pt'> </span>diarrhée,<span style='letter-spacing:-.35pt'> </span>avec<span style='letter-spacing:-.2pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>sans neutropénie,<span style='letter-spacing: .05pt'> </span>peuvent<span style='letter-spacing:-.3pt'> </span>être<span style='letter-spacing:-.15pt'> </span>des<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span>anifestations<span style='letter-spacing: -.55pt'> </span>p<span style='letter-spacing:-.05pt'>r</span>écoces<span style='letter-spacing:-.05pt'> </span>d<span style='letter-spacing:.05pt'>’</span>une<span style='letter-spacing:-.05pt'> </span>toxicité<span style='letter-spacing:-.3pt'> </span>gastro-intestinale<span style='letter-spacing:-.65pt'> </span>sévère<span style='letter-spacing:-.25pt'> </span>et doivent<span style='letter-spacing: -.3pt'> </span>être évalués<span style='letter-spacing:-.3pt'> </span>et traités<span style='letter-spacing:-.25pt'> </span>rapide<span style='letter-spacing:-.05pt'>m</span>ent.</p>
<p class=AmmCorpsTexte><i><u>Insuffisance cardiaque congestive (ICC)</u></i></p>
<p class=AmmCorpsTexte>Les<span style='letter-spacing:-.4pt'> </span>patientes<span style='letter-spacing:-.35pt'> </span>doivent<span style='letter-spacing:-.3pt'> </span>être<span style='letter-spacing:-.15pt'> </span>surveillées<span style='letter-spacing: -.45pt'> </span>pour<span style='letter-spacing:-.2pt'> </span>des<span style='letter-spacing:-.15pt'> </span>s<span style='letter-spacing:.1pt'>y</span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>p</span>tô<span style='letter-spacing:-.1pt'>m</span>es<span style='letter-spacing:-.05pt'> </span>d<span style='letter-spacing:.05pt'>’</span>insuffisance<span style='letter-spacing: -.05pt'> </span>cardiaque<span style='letter-spacing:-.4pt'> </span>congestive<span style='letter-spacing:-.45pt'> </span>pendant le traite<span style='letter-spacing: -.05pt'>m</span>ent<span style='letter-spacing:-.3pt'> </span>et p<span style='letter-spacing:-.1pt'>e</span>ndant<span style='letter-spacing:-.05pt'> </span>la période<span style='letter-spacing:-.3pt'> </span>de<span style='letter-spacing: -.1pt'> </span>suivi.</p>
<p class=AmmCorpsTexte>Chez les patientes traitées par TAC pour un cancer du sein présentant un envahissement ganglionnaire, il a été montré que le risque d’ICC était plus élevé la première année après le traitement (voir rubriques 4.8 et 5.1).</p>
<p class=AmmCorpsTexte><i><u>Leucémie</u></i></p>
<p class=AmmCorpsTexte>Chez<span style='letter-spacing:-.5pt'> </span>les<span style='letter-spacing:-.1pt'> </span>fe<span style='letter-spacing:-.1pt'>mm</span>es<span style='letter-spacing:-.1pt'> </span>traitées<span style='letter-spacing:-.3pt'> </span>par<span style='letter-spacing:-.15pt'> </span>docétaxel,<span style='letter-spacing:-.4pt'> </span>doxorubicine<span style='letter-spacing: -.55pt'> </span>et c<span style='letter-spacing:.1pt'>y</span>clophospha<span style='letter-spacing:-.05pt'>m</span>ide<span style='letter-spacing:-.15pt'> </span>(TAC),<span style='letter-spacing:-.3pt'> </span>le risque<span style='letter-spacing:-.25pt'> </span>de développer une<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.1pt'>y</span>élod<span style='letter-spacing:.1pt'>y</span>splasie<span style='letter-spacing:-.1pt'> </span>secondaire<span style='letter-spacing:-.45pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>une<span style='letter-spacing:-.15pt'> </span>leucé<span style='letter-spacing:-.05pt'>m</span>ie<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.1pt'>y</span>éloïde<span style='letter-spacing:-.1pt'> </span>nécessite<span style='letter-spacing:-.35pt'> </span>un<span style='letter-spacing:-.1pt'> </span>suivi<span style='letter-spacing:-.2pt'> </span>hé<span style='letter-spacing:-.1pt'>m</span>atologique.</p>
<p class=AmmCorpsTexte><i><u>Patientes présentant au moins 4<span style='letter-spacing:.05pt'> </span>ganglions envahis</u></i></p>
<p class=AmmCorpsTexte>Comme le bénéfice observé chez les patientes présentant au moins 4 ganglions envahis n’était pas statistiquement significatif sur la survie sans maladie (SSM) et la survie globale (SG), le rapport bénéfice/risque positif de TAC chez les patientes ayant au moins 4 ganglions envahis n’a pas été complètement démontré par l’analyse finale (cf. paragraphe 5.1.)</p>
<p class=AmmCorpsTexte><i><u>Sujets âgés</u></i></p>
<p class=AmmCorpsTexte>Il<span style='letter-spacing:-.3pt'> </span>existe<span style='letter-spacing:-.25pt'> </span>des<span style='letter-spacing:-.15pt'> </span>données<span style='letter-spacing:-.35pt'> </span>li<span style='letter-spacing:-.05pt'>m</span>itées disponibles<span style='letter-spacing:-.45pt'> </span>sur<span style='letter-spacing:-.1pt'> </span>l<span style='letter-spacing:.05pt'>’</span>utilisation<span style='letter-spacing:-.05pt'> </span>du<span style='letter-spacing:-.1pt'> </span>docétaxel<span style='letter-spacing:-.4pt'> </span>en<span style='letter-spacing:-.1pt'> </span>association<span style='letter-spacing:-.45pt'> </span>avec<span style='letter-spacing:-.2pt'> </span>la doxorubicine<span style='letter-spacing:-.55pt'> </span>et le c<span style='letter-spacing:.1pt'>y</span>clophospha<span style='letter-spacing:-.05pt'>m</span>ide<span style='letter-spacing:-.15pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>des<span style='letter-spacing:-.15pt'> </span>patientes<span style='letter-spacing: -.35pt'> </span>de<span style='letter-spacing:-.1pt'> </span>plus<span style='letter-spacing:-.15pt'> </span>de<span style='letter-spacing:-.1pt'> </span>70<span style='letter-spacing:-.1pt'> </span>ans.</p>
<p class=AmmCorpsTexte>Dans<span style='letter-spacing:-.5pt'> </span>une<span style='letter-spacing:-.15pt'> </span>étude<span style='letter-spacing:-.2pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>le cancer<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.2pt'> </span>la prostate<span style='letter-spacing:2.25pt'> </span>sur<span style='letter-spacing:-.1pt'> </span>les<span style='letter-spacing:-.1pt'> </span>333<span style='letter-spacing:-.15pt'> </span>patients<span style='letter-spacing:-.3pt'> </span>traités<span style='letter-spacing:-.25pt'> </span>avec<span style='letter-spacing:-.2pt'> </span>docétaxel<span style='letter-spacing:-.4pt'> </span>toutes<span style='letter-spacing:-.25pt'> </span>les 3<span style='letter-spacing:-.3pt'> </span>se<span style='letter-spacing:-.1pt'>m</span>aines,<span style='letter-spacing:-.1pt'> </span>209<span style='letter-spacing:-.15pt'> </span>patients<span style='letter-spacing:-.3pt'> </span>étaient<span style='letter-spacing:.05pt'> </span>âgés<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span>65<span style='letter-spacing:-.1pt'> </span>ans<span style='letter-spacing:-.15pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>plus<span style='letter-spacing:-.15pt'> </span>et 68<span style='letter-spacing:-.1pt'> </span>patients<span style='letter-spacing: -.3pt'> </span>étaient<span style='letter-spacing:.05pt'> </span>âgés<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span>plus<span style='letter-spacing:-.15pt'> </span>de<span style='letter-spacing:-.1pt'> </span>75<span style='letter-spacing:-.1pt'> </span>ans.<span style='letter-spacing:-.15pt'> </span>Chez les patients<span style='letter-spacing:-.3pt'> </span>traités<span style='letter-spacing:-.25pt'> </span>par<span style='letter-spacing:-.15pt'> </span>docétaxel<span style='letter-spacing:-.4pt'> </span>toutes<span style='letter-spacing:-.25pt'> </span>les<span style='letter-spacing:-.1pt'> </span>tro<span style='letter-spacing: .05pt'>i</span>s<span style='letter-spacing:-.1pt'> </span>se<span style='letter-spacing:-.1pt'>m</span>aines,<span style='letter-spacing:-.1pt'> </span>le taux<span style='letter-spacing:-.15pt'> </span>d<span style='letter-spacing: .05pt'>’</span>incidence<span style='letter-spacing:-.05pt'> </span>d<span style='letter-spacing:.05pt'>’</span>altérations<span style='letter-spacing: -.05pt'> </span>des<span style='letter-spacing:-.15pt'> </span>ongles attribués au médicament était supérieur d’au moins 10% chez les patients âgés de 65 ans ou plus, au taux observé chez les sujets plus jeunes.</p>
<p class=AmmCorpsTexte>Les taux d’incidence des cas de fièvre, diarrhée, anorexie et œdème périphérique attribués au médicament étaient supérieurs d’au moins 10% chez les patients de 75 ans et plus, aux taux observés chez les sujets de moins de 65 ans.</p>
<p class=AmmCorpsTexte>Dans<span style='letter-spacing:-.5pt'> </span>une<span style='letter-spacing:-.15pt'> </span>étude<span style='letter-spacing:-.2pt'> </span>sur<span style='letter-spacing:-.1pt'> </span>le cancer<span style='letter-spacing:-.25pt'> </span>gastrique,<span style='letter-spacing:-.4pt'> </span>sur<span style='letter-spacing:-.1pt'> </span>les<span style='letter-spacing:-.1pt'> </span>300<span style='letter-spacing:-.2pt'> </span>patients<span style='letter-spacing:-.3pt'> </span>(221<span style='letter-spacing:-.2pt'> </span>patients<span style='letter-spacing:-.3pt'> </span>en<span style='letter-spacing:-.1pt'> </span>phase<span style='letter-spacing:-.25pt'> </span>III<span style='letter-spacing:-.1pt'> </span>et 79<span style='letter-spacing:-.1pt'> </span>patients<span style='letter-spacing: -.3pt'> </span>en<span style='letter-spacing:-.1pt'> </span>phase II) traités<span style='letter-spacing:-.25pt'> </span>par<span style='letter-spacing:-.15pt'> </span>docétaxel<span style='letter-spacing:-.4pt'> </span>en<span style='letter-spacing:-.1pt'> </span>association<span style='letter-spacing:-.45pt'> </span>avec<span style='letter-spacing:-.2pt'> </span>le cisplatine<span style='letter-spacing:-.35pt'> </span>et le 5-fluoro-uracile,<span style='letter-spacing:-.55pt'> </span>74<span style='letter-spacing:-.1pt'> </span>patients<span style='letter-spacing:-.3pt'> </span>étaient âgés<span style='letter-spacing: -.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span>65<span style='letter-spacing:-.1pt'> </span>ans<span style='letter-spacing:-.15pt'> </span>ou plus<span style='letter-spacing:-.15pt'> </span>et 4<span style='letter-spacing: -.05pt'> </span>patients<span style='letter-spacing:-.3pt'> </span>étaient<span style='letter-spacing:.05pt'> </span>âgés<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.15pt'> </span>75<span style='letter-spacing:-.1pt'> </span>ans<span style='letter-spacing:-.15pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>plus.<span style='letter-spacing:-.2pt'> </span>L<span style='letter-spacing:.05pt'>’</span>incidence des<span style='letter-spacing:-.15pt'> </span>effets<span style='letter-spacing: -.2pt'> </span>indésirables<span style='letter-spacing:-.5pt'> </span>graves était supérieure<span style='letter-spacing:-.4pt'> </span>chez les<span style='letter-spacing:-.1pt'> </span>patients<span style='letter-spacing:-.3pt'> </span>âgés<span style='letter-spacing:-.2pt'> </span>co<span style='letter-spacing: -.1pt'>m</span><span style='letter-spacing:.05pt'>p</span>arés<span style='letter-spacing:-.05pt'> </span>aux<span style='letter-spacing:-.15pt'> </span>patients<span style='letter-spacing:-.3pt'> </span>plus<span style='letter-spacing:-.15pt'> </span>jeunes.<span style='letter-spacing:-.3pt'> </span>L’incidence<span style='letter-spacing: -.45pt'> </span>des<span style='letter-spacing:-.15pt'> </span>effets<span style='letter-spacing:-.2pt'> </span>indésirables suivants<span style='letter-spacing:-.35pt'> </span>(quel<span style='letter-spacing:-.2pt'> </span>que<span style='letter-spacing:-.15pt'> </span>soit<span style='letter-spacing:-.15pt'> </span>le grade)<span style='letter-spacing:-.25pt'> </span>léthargie,<span style='letter-spacing:-.35pt'> </span>sto<span style='letter-spacing:-.1pt'>m</span>atites,<span style='letter-spacing:-.1pt'> </span>infections<span style='letter-spacing: -.4pt'> </span>était supérieure<span style='letter-spacing:-.4pt'> </span>d<span style='letter-spacing:.05pt'>’</span>au<span style='letter-spacing:-.05pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>o</span>ins 10%<span style='letter-spacing:-.2pt'> </span>chez<span style='letter-spacing: -.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>patients<span style='letter-spacing:-.3pt'> </span>âgés<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span>65<span style='letter-spacing:-.1pt'> </span>ans<span style='letter-spacing:-.15pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>plus par<span style='letter-spacing:-.15pt'> </span>rapport<span style='letter-spacing: -.3pt'> </span>à celle observée<span style='letter-spacing:-.35pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>sujets<span style='letter-spacing:-.25pt'> </span>plus<span style='letter-spacing:-.15pt'> </span>jeunes.</p>
<p class=AmmCorpsTexte>Les<span style='letter-spacing:-.4pt'> </span>patients<span style='letter-spacing:-.3pt'> </span>âgés<span style='letter-spacing:-.2pt'> </span>traités<span style='letter-spacing:-.25pt'> </span>avec<span style='letter-spacing:-.2pt'> </span>le protocole<span style='letter-spacing:-.4pt'> </span>TCF<span style='letter-spacing: -.15pt'> </span>feront<span style='letter-spacing:-.25pt'> </span>l’objet<span style='letter-spacing:-.2pt'> </span>d’une<span style='letter-spacing:-.25pt'> </span>surveillance<span style='letter-spacing:-.45pt'> </span>attentive. </p>
<p class=AmmCorpsTexte style='margin-bottom:0cm;margin-bottom:.0001pt'>Délétère pour les personnes souffrant d’alcoolisme.</p>
<p class=AmmCorpsTexte>A prendre en compte chez les femmes enceintes ou allaitantes, les enfants et les groupes de patients à haut risque tels que les patients atteints de troubles hépatiques ou d’épilepsie.</p>
<p class=AmmCorpsTexte>La<span style='letter-spacing:-.35pt'> </span>quantité<span style='letter-spacing:-.25pt'> </span>d’alcool<span style='letter-spacing:-.35pt'> </span>contenue<span style='letter-spacing:-.35pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>ce <span style='letter-spacing:-.1pt'>m</span>édica<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.25pt'> </span>peut<span style='letter-spacing:-.15pt'> </span>altérer<span style='letter-spacing:-.25pt'> </span>les<span style='letter-spacing:-.1pt'> </span>effets<span style='letter-spacing:-.2pt'> </span>des<span style='letter-spacing:-.15pt'> </span>autres<span style='letter-spacing:-.25pt'> </span><span style='letter-spacing:-.1pt'>m</span>édica<span style='letter-spacing:-.05pt'>m</span>ents.</p>
<p class=AmmCorpsTexte>La<span style='letter-spacing:-.35pt'> </span>quantité<span style='letter-spacing:-.25pt'> </span>d’alcool<span style='letter-spacing:-.35pt'> </span>contenue<span style='letter-spacing:-.35pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>ce <span style='letter-spacing:-.1pt'>m</span>édica<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.25pt'> </span>peut<span style='letter-spacing:-.15pt'> </span>avoir<span style='letter-spacing:-.2pt'> </span>un<span style='letter-spacing:-.1pt'> </span>effet<span style='letter-spacing:-.2pt'> </span>sur<span style='letter-spacing:-.1pt'> </span>la capacité<span style='letter-spacing: -.3pt'> </span>des<span style='letter-spacing:-.15pt'> </span>patients<span style='letter-spacing:-.3pt'> </span>à conduire ou<span style='letter-spacing: -.1pt'> </span>utiliser<span style='letter-spacing:-.3pt'> </span>des<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span>achines.</p>
<p class=AmmCorpsTexte><i><u>Excipients</u></i></p>
<p class=AmmCorpsTexte>Ce médicament contient environ 55 % vol. d’éthanol (alcool), c’est-à-dire jusqu’à 0,457 g (0,57 ml) d’éthanol à 96 % par flacon, équivalant à 12 ml de bière ou 5 ml de vin par flacon.</p>
<p class="AmmAnnexeTitre2"><a name="RcpInteractions">4.5. Interactions avec d'autres médicaments et autres formes d'interactions</a></p>
<p class=AmmCorpsTexte><a name="_Toc142278925">Des<span style='letter-spacing: -.4pt'> </span>études<span style='letter-spacing:-.2pt'> </span><i>in<span style='letter-spacing:-.1pt'> </span>vitro<span style='letter-spacing:-.2pt'> </span></i>ont<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span>ontré<span style='letter-spacing:-.1pt'> </span>que<span style='letter-spacing:-.15pt'> </span>le <span style='letter-spacing:-.1pt'>m</span>étabolis<span style='letter-spacing: -.05pt'>m</span>e<span style='letter-spacing:-.35pt'> </span>du<span style='letter-spacing:-.1pt'> </span>docétaxel<span style='letter-spacing:-.45pt'> </span>peut<span style='letter-spacing:-.15pt'> </span>être<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span>odifié<span style='letter-spacing:-.1pt'> </span>par<span style='letter-spacing:-.15pt'> </span>l<span style='letter-spacing:-.05pt'>'</span>ad<span style='letter-spacing:-.1pt'>m</span>inistration conco<span style='letter-spacing:-.05pt'>m</span>itante<span style='letter-spacing: .05pt'> </span>de<span style='letter-spacing:-.1pt'> </span>co<span style='letter-spacing:-.1pt'>m</span>posés<span style='letter-spacing:-.1pt'> </span>qui<span style='letter-spacing:-.15pt'> </span>induisent,<span style='letter-spacing: -.35pt'> </span>inhibent<span style='letter-spacing:-.35pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>sont<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span>étabolisés<span style='letter-spacing: -.4pt'> </span>par<span style='letter-spacing:-.15pt'> </span>(et<span style='letter-spacing:-.1pt'> </span>ceux<span style='letter-spacing:-.2pt'> </span>inhibant<span style='letter-spacing:-.3pt'> </span>de<span style='letter-spacing:-.1pt'> m</span>anière co<span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>p</span>étitive)<span style='letter-spacing:-.05pt'> </span>le c<span style='letter-spacing:.1pt'>y</span>tochro<span style='letter-spacing:-.05pt'>m</span>e<span style='letter-spacing:-.05pt'> </span>P450-3A<span style='letter-spacing:-.35pt'> </span>tels que<span style='letter-spacing:-.15pt'> </span>: la ciclosporine,<span style='letter-spacing:-.5pt'> </span>la terfénadine,<span style='letter-spacing:-.4pt'> </span>le kétoconazole,<span style='letter-spacing:-.5pt'> </span>l<span style='letter-spacing:-.05pt'>'</span>ér<span style='letter-spacing:.1pt'>y</span>thro<span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.1pt'>y</span>cine et la troléando<span style='letter-spacing: -.05pt'>m</span><span style='letter-spacing:.1pt'>y</span>ci<span style='letter-spacing:-.05pt'>n</span>e.<span style='letter-spacing:-.4pt'> </span>La<span style='letter-spacing:-.1pt'> </span>prudence<span style='letter-spacing:-.35pt'> </span>s<span style='letter-spacing:-.05pt'>'</span>i<span style='letter-spacing: -.1pt'>m</span>pose<span style='letter-spacing:-.05pt'> </span>donc<span style='letter-spacing:-.2pt'> </span>en<span style='letter-spacing:-.1pt'> </span>cas<span style='letter-spacing:-.15pt'> </span>de<span style='letter-spacing:-.1pt'> </span>traite<span style='letter-spacing:-.05pt'>m</span>ent si<span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>u</span>ltané<span style='letter-spacing:-.05pt'> </span>par<span style='letter-spacing:-.15pt'> </span>le docétaxel<span style='letter-spacing: -.4pt'> </span>et l<span style='letter-spacing:-.05pt'>'</span>un<span style='letter-spacing:-.1pt'> </span>de<span style='letter-spacing:-.1pt'> </span>ces<span style='letter-spacing:-.15pt'> </span>co<span style='letter-spacing:-.1pt'>m</span>posés<span style='letter-spacing:-.1pt'> </span>du<span style='letter-spacing:-.15pt'> </span>fait de<span style='letter-spacing:-.1pt'> </span>la possibilité<span style='letter-spacing:-.4pt'> </span>d<span style='letter-spacing:.05pt'>’</span>interactions<span style='letter-spacing:-.05pt'> </span>significatives.</a></p>
<p class=AmmCorpsTexte>Le<span style='letter-spacing:-.35pt'> </span>docétaxel<span style='letter-spacing:-.4pt'> </span>se<span style='letter-spacing:-.1pt'> </span>lie forte<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing: -.2pt'> </span>aux<span style='letter-spacing:-.15pt'> </span>protéines<span style='letter-spacing:-.35pt'> </span>plas<span style='letter-spacing:-.1pt'>m</span>at<span style='letter-spacing:-.05pt'>i</span>ques<span style='letter-spacing:-.35pt'> </span>(&gt;95%).<span style='letter-spacing:-.35pt'> </span>Bien<span style='letter-spacing:-.2pt'> </span>que<span style='letter-spacing:-.15pt'> </span>les<span style='letter-spacing:-.1pt'> </span>interactions<span style='letter-spacing:-.45pt'> </span>éventuelles<span style='letter-spacing: -.45pt'> </span><i>in vivo<span style='letter-spacing:-.1pt'> </span></i>du docétaxel<span style='letter-spacing:-.4pt'> </span>et de<span style='letter-spacing:-.1pt'> m</span>édica<span style='letter-spacing:-.05pt'>m</span>ents<span style='letter-spacing:-.25pt'> </span>ad<span style='letter-spacing:-.1pt'>m</span>inistrés<span style='letter-spacing:-.35pt'> </span>si<span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>u</span>ltané<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.15pt'> </span>n'aient<span style='letter-spacing:-.25pt'> </span>pas<span style='letter-spacing:-.15pt'> </span>été étudiées<span style='letter-spacing:-.35pt'> </span>for<span style='letter-spacing:-.1pt'>m</span>elle<span style='letter-spacing:-.05pt'>m</span>ent,<span style='letter-spacing:-.1pt'> </span>les<span style='letter-spacing:-.1pt'> </span>interactions<span style='letter-spacing: -.45pt'> </span><i>in vitro<span style='letter-spacing:-.2pt'> </span></i>avec<span style='letter-spacing:-.2pt'> </span>des<span style='letter-spacing:-.15pt'> </span>agents<span style='letter-spacing:-.25pt'> </span>forte<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.2pt'> </span>liés aux<span style='letter-spacing:-.15pt'> </span>protéines,<span style='letter-spacing:-.4pt'> </span>co<span style='letter-spacing:-.1pt'>mm</span>e<span style='letter-spacing:-.1pt'> </span>l<span style='letter-spacing:-.05pt'>'</span>ér<span style='letter-spacing:.1pt'>y</span>thro<span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.1pt'>y</span>cine,<span style='letter-spacing:-.35pt'> </span>la diphenh<span style='letter-spacing: .1pt'>y</span>dra<span style='letter-spacing:-.1pt'>m</span>ine,<span style='letter-spacing:-.3pt'> </span>le propranolo<span style='letter-spacing: -.05pt'>l</span>,<span style='letter-spacing:-.45pt'> </span>la propafénone,<span style='letter-spacing:-.5pt'> </span>la phén<span style='letter-spacing:.1pt'>y</span>toïne,<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>salic<span style='letter-spacing:.1pt'>y</span>lés,<span style='letter-spacing:-.3pt'> </span>le sulfa<span style='letter-spacing:-.1pt'>m</span>éthoxazole<span style='letter-spacing:-.15pt'> </span>et le valproate<span style='letter-spacing: -.3pt'> </span>de<span style='letter-spacing:-.1pt'> </span>sodiu<span style='letter-spacing:-.1pt'>m</span>,<span style='letter-spacing:-.2pt'> </span>n<span style='letter-spacing:-.05pt'>'</span>ont<span style='letter-spacing:-.1pt'> </span>pas<span style='letter-spacing:-.15pt'> </span>affecté<span style='letter-spacing:-.25pt'> </span>la liaison<span style='letter-spacing:-.25pt'> </span>du<span style='letter-spacing:-.1pt'> </span>docétaxel<span style='letter-spacing:-.4pt'> </span>aux<span style='letter-spacing:-.15pt'> </span>protéines<span style='letter-spacing:-.35pt'> </span>plas<span style='letter-spacing:-.1pt'>m</span>atiques. La<span style='letter-spacing:-.1pt'> </span>dexa<span style='letter-spacing: -.05pt'>m</span>éthasone<span style='letter-spacing:-.5pt'> </span>n<span style='letter-spacing:-.05pt'>'</span>a<span style='letter-spacing:-.05pt'> </span>pas<span style='letter-spacing:-.15pt'> </span>davanta<span style='letter-spacing:.05pt'>g</span>e<span style='letter-spacing:-.3pt'> </span>affecté<span style='letter-spacing:-.25pt'> </span>la liaison<span style='letter-spacing:-.25pt'> </span>du docétaxel<span style='letter-spacing:-.4pt'> </span>aux<span style='letter-spacing:-.15pt'> </span>protéines<span style='letter-spacing:-.35pt'> </span>plas<span style='letter-spacing:-.1pt'>m</span>atiques. Le<span style='letter-spacing:-.1pt'> </span>docétaxel<span style='letter-spacing: -.35pt'> </span>n<span style='letter-spacing:-.05pt'>'</span>a<span style='letter-spacing:-.05pt'> </span>pas<span style='letter-spacing:-.15pt'> </span>eu<span style='letter-spacing:-.1pt'> </span>d<span style='letter-spacing:-.05pt'>'</span>influence sur<span style='letter-spacing:-.1pt'> </span>la liaison<span style='letter-spacing: -.25pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la digitoxine.</p>
<p class=AmmCorpsTexte>Les<span style='letter-spacing:-.4pt'> </span>para<span style='letter-spacing:-.1pt'>m</span>ètres<span style='letter-spacing:-.3pt'> </span>phar<span style='letter-spacing:-.1pt'>m</span>acocinétiques<span style='letter-spacing: -.15pt'> </span>du<span style='letter-spacing:-.1pt'> </span>docétaxel,<span style='letter-spacing:-.4pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la doxorubicine<span style='letter-spacing:-.5pt'> </span>et du<span style='letter-spacing:-.1pt'> </span>c<span style='letter-spacing:.1pt'>y</span>clophospha<span style='letter-spacing:-.05pt'>m</span>ide<span style='letter-spacing:-.15pt'> </span>ne<span style='letter-spacing:-.1pt'> </span>sont<span style='letter-spacing:-.15pt'> </span>pas <span style='letter-spacing:-.1pt'>m</span>odifiés<span style='letter-spacing: -.1pt'> </span>par<span style='letter-spacing:-.15pt'> </span>leur<span style='letter-spacing:-.15pt'> </span>co-ad<span style='letter-spacing:-.1pt'>m</span>inistration.<span style='letter-spacing:-.2pt'> </span>Des<span style='letter-spacing:-.15pt'> </span>données<span style='letter-spacing:-.35pt'> </span>li<span style='letter-spacing:-.05pt'>m</span>itées d<span style='letter-spacing:.05pt'>’</span>une<span style='letter-spacing: -.05pt'> </span>étude<span style='letter-spacing:-.2pt'> </span>non<span style='letter-spacing:-.15pt'> </span>contrôlée<span style='letter-spacing: -.3pt'> </span>ont<span style='letter-spacing:-.15pt'> </span>suggéré<span style='letter-spacing:-.3pt'> </span>une interaction<span style='letter-spacing: .05pt'> </span>entre<span style='letter-spacing:-.2pt'> </span>le docétaxel<span style='letter-spacing:-.35pt'> </span>et le carboplati<span style='letter-spacing: -.05pt'>n</span>e.<span style='letter-spacing:-.4pt'> </span>Associé<span style='letter-spacing:-.3pt'> </span>au<span style='letter-spacing:-.1pt'> </span>docétaxel,<span style='letter-spacing:-.4pt'> </span>la clairance<span style='letter-spacing: -.35pt'> </span>du<span style='letter-spacing:-.1pt'> </span>carboplatine<span style='letter-spacing:-.5pt'> </span>est supérieure<span style='letter-spacing: -.4pt'> </span>de<span style='letter-spacing:-.1pt'> </span>50%<span style='letter-spacing:-.2pt'> </span>par r<span style='letter-spacing:-.05pt'>a</span>pport<span style='letter-spacing:-.05pt'> </span>aux<span style='letter-spacing:-.15pt'> </span>valeurs<span style='letter-spacing:-.3pt'> </span>observées<span style='letter-spacing:-.4pt'> </span>précéde<span style='letter-spacing:-.05pt'>m</span><span style='letter-spacing:-.1pt'>m</span>ent<span style='letter-spacing:-.4pt'> </span>pour<span style='letter-spacing:-.2pt'> </span>le carboplatine<span style='letter-spacing: -.45pt'> </span>en<span style='letter-spacing:-.1pt'> m</span>onothérapie.</p>
<p class=AmmCorpsTexte>La<span style='letter-spacing:-.35pt'> </span>phar<span style='letter-spacing:-.1pt'>m</span>acocinétique<span style='letter-spacing: -.15pt'> </span>du<span style='letter-spacing:-.1pt'> </span>docétaxel<span style='letter-spacing:2.15pt'> </span>en<span style='letter-spacing:-.1pt'> </span>présence<span style='letter-spacing:-.35pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la prednisone<span style='letter-spacing:-.45pt'> </span>a été étudiée<span style='letter-spacing:-.3pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>patients<span style='letter-spacing:-.3pt'> </span>atteints de cancer<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la prostate.<span style='letter-spacing: -.35pt'> </span>Le<span style='letter-spacing:-.1pt'> </span>docétaxel<span style='letter-spacing:-.5pt'> </span>est<span style='letter-spacing:-.1pt'> m</span>étabolisé<span style='letter-spacing:-.4pt'> </span>par<span style='letter-spacing:-.15pt'> </span>le c<span style='letter-spacing:.1pt'>y</span>tochro<span style='letter-spacing: -.05pt'>m</span>e<span style='letter-spacing:-.05pt'> </span>CYP3A4<span style='letter-spacing:-.35pt'> </span>et la prednisone<span style='letter-spacing: -.45pt'> </span>est connue<span style='letter-spacing:-.3pt'> </span>pour<span style='letter-spacing:-.2pt'> </span>induire<span style='letter-spacing:-.3pt'> </span>le CYP3A4.<span style='letter-spacing:-.4pt'> </span>Aucun<span style='letter-spacing:-.25pt'> </span>effet<span style='letter-spacing:-.2pt'> </span>statistique<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.5pt'> </span>significatif<span style='letter-spacing:-.4pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la prednisone<span style='letter-spacing:-.45pt'> </span>sur<span style='letter-spacing:-.1pt'> </span>la phar<span style='letter-spacing:-.1pt'>m</span>acocinétique<span style='letter-spacing:-.15pt'> </span>du<span style='letter-spacing:-.1pt'> </span>docétaxel<span style='letter-spacing:-.35pt'> </span>n’a<span style='letter-spacing:-.15pt'> </span>été observé.</p>
<p class=AmmCorpsTexte>Des cas cliniques d’augmentation de la toxicité du docétaxel ont été rapportés en association avec le ritonavir. Le mécanisme de cette interaction est une inhibition du CYP3A4 qui est la principale isoenzyme impliquée dans le métabolisme du doxétaxel par le ritonavir. Par l’extrapolation d’une étude pharmacocinétique chez 7 patients traités par kétoconazole, une réduction posologique du docétaxel de 50% doit être envisagée lorsque les patients nécessitent une co-administration d’un inhibiteur puissant du CYP3A4, tels que les antifongiques azolés, le ritonavir et certains macrolides (clarithromycine, télithromycine).</p>
<p class="AmmAnnexeTitre2"><a name="RcpGrossAllait">4.6. Grossesse et allaitement</a></p>
<p class=AmmAnnexeTitre2Bis>Grossesse</p>
<p class=AmmCorpsTexte>Aucune information sur l’utilisation du docetaxel chez la femme enceinte n’est disponible. Le docétaxel s'est révélé embryotoxique et foetotoxique chez le lapin et le rat, et réduit la fertilité chez le rat. Comme d'autres médicaments cytotoxiques, le docétaxel peut entraîner des dommages fœtaux quand il est administré à la femme enceinte. Par conséquent, le docétaxel ne doit pas être administré au cours de la grossesse sauf si clairement indiqué.</p>
<p class=AmmCorpsTexte>Les femmes en âge de procréer sous docétaxel doivent éviter de tomber enceinte et informer immédiatement le médecin si cela arrivait. </p>
<p class=AmmAnnexeTitre2Bis>Allaitement</p>
<p class=AmmCorpsTexte>Le docétaxel est une substance lipophile mais le passage du docétaxel dans le lait maternel n'est pas connu. Par conséquent, étant donné les risques d’effets indésirables chez le nourrisson, l'allaitement devra être arrêté, durant le traitement par le docétaxel.</p>
<p class=AmmAnnexeTitre2Bis>Fécondité</p>
<p class=AmmCorpsTexte>Une méthode de contraception efficace doit être utilisée pendant le traitement.</p>
<p class=AmmCorpsTexte>Les études précliniques montrent que le docétaxel a des effets génotoxiques et peut altérer la fertilité masculine (voir rubrique 5.3).</p>
<p class=AmmCorpsTexte>Par conséquent, il est déconseillé aux hommes traités par docétaxel de procréer pendant le traitement et jusqu’à 6 mois après. Il est conseillé de se renseigner sur la conservation du sperme avant le traitement.</p>
<p class="AmmAnnexeTitre2"><a name="RcpConduite">4.7. Effets sur l'aptitude à conduire des véhicules et à utiliser des machines</a></p>
<p class=AmmCorpsTexte><a name="_Toc142278929">Les effets sur l’aptitude à conduire des véhicules et à utiliser des machines n’ont pas été étudiés.</a></p>
<p class="AmmAnnexeTitre2"><a name="RcpEffetsIndesirables">4.8. Effets indésirables</a></p>
<p class=AmmCorpsTexte><a name="_Toc142278930"><u>Résumé du profil de tolérance pour toutes les indications</u></a></p>
<p class=AmmCorpsTexte>Des<span style='letter-spacing:-.4pt'> </span>réactions<span style='letter-spacing:-.35pt'> </span>indésirables<span style='letter-spacing: -.5pt'> </span>considérées<span style='letter-spacing:-.45pt'> </span>co<span style='letter-spacing:-.1pt'>mm</span>e<span style='letter-spacing:-.1pt'> </span>étant<span style='letter-spacing:-.2pt'> </span>liées de<span style='letter-spacing:-.1pt'> </span>façon<span style='letter-spacing:-.2pt'> </span>possible<span style='letter-spacing:-.35pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>probable<span style='letter-spacing:-.35pt'> </span>à l<span style='letter-spacing:.05pt'>’</span>ad<span style='letter-spacing:-.1pt'>m</span>inistration<span style='letter-spacing: -.4pt'> </span>de<span style='letter-spacing:-.1pt'> </span>docétaxel<span style='letter-spacing:-.4pt'> </span>ont<span style='letter-spacing:-.15pt'> </span>été rapportées<span style='letter-spacing:-.4pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>:</p>
<p class=AmmListePuces1 style='text-align:justify'><span style='font-family: Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>1312 et 121 patients ayant reçu respectivement 100 mg/m² et 75 mg/m² de docétaxel en monothérapie.</p>
<p class=AmmListePuces1 style='text-align:justify'><span style='font-family: Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>258 patients ayant reçu du docétaxel en association avec la doxorubicine.</p>
<p class=AmmListePuces1 style='text-align:justify'><span style='font-family: Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>406 patients ayant reçu du docétaxel en association avec le cisplatine.</p>
<p class=AmmListePuces1 style='text-align:justify'><span style='font-family: Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>92 patientes ayant reçu du docétaxel en association avec le trastuzumab.</p>
<p class=AmmListePuces1 style='text-align:justify'><span style='font-family: Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>255 patients ayant reçu du docétaxel en association avec la capecitabine.</p>
<p class=AmmListePuces1 style='text-align:justify'><span style='font-family: Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>332 patients ayant reçu du docétaxel en association avec la prednisone ou la prednisolone (les effets indésirables cliniquement important et reliés au traitement sont présentés).</p>
<p class=AmmListePuces1 style='text-align:justify'><span style='font-family: Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>1276 patientes (744 et 532 respectivement dans les études TAX 316 et GEICAM 9805) ayant reçu du docétaxel en association avec la doxorubicine et le cyclophosphamide (les effets indésirables cliniquement importants et reliés au traitement sont présentés ci-dessous).</p>
<p class=AmmListePuces1 style='text-align:justify'><span style='font-family: Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>300 patients présentant un adénocarcinome gastrique (221 patients en phase III et 79 patients en phase II) ayant reçu du docétaxel en association avec le cisplatine et le 5 fluoro-uracile (les effets indésirables cliniquement importants et reliés au traitement sont présentés ci-dessous).</p>
<p class=AmmListePuces1 style='text-align:justify'><span style='font-family: Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>174 et 251 patients présentant un cancer des voies aéro-digestives supérieures et traités par docétaxel en association avec le cisplatine et le 5-fluoro-uracile(les effets indésirables cliniquement importants et reliés au traitement sont présentés ci-dessous).</p>
<p class=AmmCorpsTexte style='margin-top:6.0pt'>Ces<span style='letter-spacing: -.4pt'> </span>événe<span style='letter-spacing:-.05pt'>m</span>ents<span style='letter-spacing:-.25pt'> </span>ont<span style='letter-spacing:-.15pt'> </span>été décrits<span style='letter-spacing:-.25pt'> </span>en<span style='letter-spacing: -.1pt'> </span>utilisant<span style='letter-spacing:-.3pt'> </span>les<span style='letter-spacing:-.1pt'> </span>Critères<span style='letter-spacing:-.3pt'> </span>Co<span style='letter-spacing:-.1pt'>mm</span>uns<span style='letter-spacing: -.1pt'> </span>de<span style='letter-spacing:-.1pt'> </span>Toxicité<span style='letter-spacing:-.3pt'> </span>NCI<span style='letter-spacing:-.15pt'> </span>(grade<span style='letter-spacing:-.25pt'> </span>3<span style='letter-spacing:-.05pt'> </span>=<span style='letter-spacing:-.05pt'> </span>G3<span style='letter-spacing:-.1pt'> </span>; grade<span style='letter-spacing:-.2pt'> </span>3-4<span style='letter-spacing: -.15pt'> </span>= G3/4<span style='letter-spacing:-.2pt'> </span>; grade<span style='letter-spacing:-.2pt'> </span>4<span style='letter-spacing:-.05pt'> </span>=<span style='letter-spacing:-.05pt'> </span>G4)<span style='letter-spacing:-.15pt'> </span>ainsi<span style='letter-spacing:-.2pt'> </span>que<span style='letter-spacing:-.15pt'> </span>les<span style='letter-spacing:-.1pt'> </span>ter<span style='letter-spacing:-.05pt'>m</span>es<span style='letter-spacing:-.1pt'> </span>COSTART<span style='letter-spacing:-.45pt'> </span>et MEDRA.<span style='letter-spacing:-.4pt'> </span></p>
<p class=AmmCorpsTexte>Les<span style='letter-spacing:-.15pt'> </span>fréquences<span style='letter-spacing:-.45pt'> </span>sont<span style='letter-spacing:-.15pt'> </span>définies co<span style='letter-spacing:-.1pt'>mm</span>e : </p>
<div align=center>
<table class=AmmCorpsTexteTable border=0 cellspacing=0 cellpadding=0
style='margin-left:-35.85pt;border-collapse:collapse'>
<tr>
<td width=203 valign=top style='width:152.4pt;padding:0cm 5.4pt 0cm 5.4pt'>
<p class=AmmCorpsTexte style='margin-bottom:0cm;margin-bottom:.0001pt'>Très fréquent</p>
</td>
<td width=388 valign=top style='width:290.7pt;padding:0cm 5.4pt 0cm 5.4pt'>
<p class=AmmCorpsTexte style='margin-bottom:0cm;margin-bottom:.0001pt'>(&#8805; 1/10)</p>
</td>
</tr>
<tr>
<td width=203 valign=top style='width:152.4pt;padding:0cm 5.4pt 0cm 5.4pt'>
<p class=AmmCorpsTexte style='margin-bottom:0cm;margin-bottom:.0001pt'>Fréquent</p>
</td>
<td width=388 valign=top style='width:290.7pt;padding:0cm 5.4pt 0cm 5.4pt'>
<p class=AmmCorpsTexte style='margin-bottom:0cm;margin-bottom:.0001pt'>(&#8805; 1/100 à &lt; 1/10)</p>
</td>
</tr>
<tr>
<td width=203 valign=top style='width:152.4pt;padding:0cm 5.4pt 0cm 5.4pt'>
<p class=AmmCorpsTexte style='margin-bottom:0cm;margin-bottom:.0001pt'>Peu fréquent</p>
</td>
<td width=388 valign=top style='width:290.7pt;padding:0cm 5.4pt 0cm 5.4pt'>
<p class=AmmCorpsTexte style='margin-bottom:0cm;margin-bottom:.0001pt'>&#8805; 1/1000 à &lt; 1/100)</p>
</td>
</tr>
<tr>
<td width=203 valign=top style='width:152.4pt;padding:0cm 5.4pt 0cm 5.4pt'>
<p class=AmmCorpsTexte style='margin-bottom:0cm;margin-bottom:.0001pt'>Rare </p>
</td>
<td width=388 valign=top style='width:290.7pt;padding:0cm 5.4pt 0cm 5.4pt'>
<p class=AmmCorpsTexte style='margin-bottom:0cm;margin-bottom:.0001pt'>(&#8805; 1/10,000 à &lt; 1/1000)</p>
</td>
</tr>
<tr>
<td width=203 valign=top style='width:152.4pt;padding:0cm 5.4pt 0cm 5.4pt'>
<p class=AmmCorpsTexte style='margin-bottom:0cm;margin-bottom:.0001pt'>Très rare </p>
</td>
<td width=388 valign=top style='width:290.7pt;padding:0cm 5.4pt 0cm 5.4pt'>
<p class=AmmCorpsTexte style='margin-bottom:0cm;margin-bottom:.0001pt'>(&lt; 1/10000)</p>
</td>
</tr>
<tr>
<td width=203 valign=top style='width:152.4pt;padding:0cm 5.4pt 0cm 5.4pt'>
<p class=AmmCorpsTexte>Fréquence indéterminée</p>
</td>
<td width=388 valign=top style='width:290.7pt;padding:0cm 5.4pt 0cm 5.4pt'>
<p class=AmmCorpsTexte>(ne peut être estimée sur la base des données disponibles)</p>
</td>
</tr>
</table>
</div>
<p class=AmmCorpsTexte style='margin-top:6.0pt'>Au sein de chaque groupe de fréquence, les effets indésirables doivent être présentés suivant un ordre décroissant de gravité.</p>
<p class=AmmCorpsTexte>Les effets indésirables les plus fréquemment observés lors de l’utilisation du docétaxel en monothérapie sont : neutropénie (réversible et non cumulative ; la médiane d'apparition du nadir ainsi que la durée médiane de neutropénie sévère (&lt;500/mm<sup>3</sup>) ont été de 7 jours), anémie, alopécie, nausées, vomissements, stomatites, diarrhées et asthénie.</p>
<p class=AmmCorpsTexte>La sévérité des effets indésirables du docétaxel peut être majorée lors de l’association avec d’autres cytotoxiques.</p>
<p class=AmmCorpsTexte>Pour l’association avec le trastuzumab, sont présentés les effets indésirables (tous grades) rapportés dans au moins 10% des cas. Une augmentation de l’incidence des effets indésirables graves (40% vs. 31%) et des effets indésirables de grade 4 (34% vs. 23%) a été observée pour l’association avec le trastuzumab par rapport au docétaxel en monothérapie.</p>
<p class=AmmCorpsTexte>Pour l’association avec la capécitabine, les effets indésirables le plus fréquemment rapportés (&#8805;5%) dans un essai de phase III chez des patientes traitées pour un cancer du sein après échec d’un traitement avec une anthracycline sont présentés (voir résumé des caractéristiques de la capécitabine).</p>
<p class=AmmCorpsTexte>Les<span style='letter-spacing:-.4pt'> </span>effets<span style='letter-spacing:-.2pt'> </span>indésirables<span style='letter-spacing: -.5pt'> </span>suivants<span style='letter-spacing:-.35pt'> </span>ont<span style='letter-spacing:-.15pt'> </span>été fréque<span style='letter-spacing: -.05pt'>m</span><span style='letter-spacing:-.1pt'>m</span>ent<span style='letter-spacing:-.35pt'> </span>observés<span style='letter-spacing:-.35pt'> </span>avec<span style='letter-spacing:-.2pt'> </span>docétaxel: </p>
<p class=AmmCorpsTexte><u>Affections du s<span style='letter-spacing:.1pt'>y</span>stè<span style='letter-spacing:-.1pt'>m</span>e i<span style='letter-spacing:-.1pt'>mm</span>unitaire</u> :</p>
<p class=AmmCorpsTexte>Des<span style='letter-spacing:-.4pt'> </span>réactions<span style='letter-spacing:-.35pt'> </span>d’h<span style='letter-spacing:.1pt'>y</span>persensibilité<span style='letter-spacing:-.1pt'> </span>sont<span style='letter-spacing:-.15pt'> </span>générale<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.45pt'> </span>survenues<span style='letter-spacing:-.4pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> m</span>inutes<span style='letter-spacing:-.3pt'> </span>qui<span style='letter-spacing:-.15pt'> </span>suivaient<span style='letter-spacing:-.35pt'> </span>le début d’une<span style='letter-spacing: -.05pt'> </span>perfusion<span style='letter-spacing:-.4pt'> </span>de<span style='letter-spacing:-.1pt'> </span>docétaxel<span style='letter-spacing:-.35pt'> </span>et étaient<span style='letter-spacing:.05pt'> </span>habituell<span style='letter-spacing:-.1pt'>em</span>ent<span style='letter-spacing:-.45pt'> </span>légères<span style='letter-spacing:-.3pt'> </span>à <span style='letter-spacing:-.1pt'>m</span>odérées.<span style='letter-spacing:-.1pt'> </span>Les<span style='letter-spacing:-.15pt'> </span>s<span style='letter-spacing:.1pt'>y</span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>p</span>tô<span style='letter-spacing:-.1pt'>m</span>es<span style='letter-spacing:-.05pt'> </span>les<span style='letter-spacing:-.1pt'> </span>plus fréque<span style='letter-spacing:-.1pt'>mm</span>ent<span style='letter-spacing: -.1pt'> </span>rapportés<span style='letter-spacing:-.35pt'> </span>ont<span style='letter-spacing:-.15pt'> </span>été des<span style='letter-spacing:-.15pt'> </span>flushs,<span style='letter-spacing:-.25pt'> </span>des<span style='letter-spacing:-.15pt'> </span>éruptions<span style='letter-spacing: -.35pt'> </span>avec<span style='letter-spacing:-.2pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>sans<span style='letter-spacing:-.15pt'> </span>prurit,<span style='letter-spacing:-.25pt'> </span>une<span style='letter-spacing:-.15pt'> </span>sensation<span style='letter-spacing:-.35pt'> </span>de<span style='letter-spacing:-.1pt'> </span>constriction<span style='letter-spacing:.05pt'> </span>thoracique,<span style='letter-spacing: -.4pt'> </span>des<span style='letter-spacing:-.15pt'> </span>lo<span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>b</span>algies,<span style='letter-spacing:-.1pt'> </span>une<span style='letter-spacing:-.15pt'> </span>d<span style='letter-spacing:.1pt'>y</span>sp<span style='letter-spacing:-.05pt'>n</span>ée<span style='letter-spacing:-.05pt'> </span>et une<span style='letter-spacing:-.15pt'> </span>fièvre<span style='letter-spacing:-.25pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>des<span style='letter-spacing:-.15pt'> </span>frissons.<span style='letter-spacing:-.35pt'> </span>Des<span style='letter-spacing:-.15pt'> </span>réactions<span style='letter-spacing:-.35pt'> </span>intenses étaient<span style='letter-spacing: .05pt'> </span>caractérisées<span style='letter-spacing:-.45pt'> </span>par<span style='letter-spacing:-.15pt'> </span>une<span style='letter-spacing:-.15pt'> </span>h<span style='letter-spacing:.1pt'>y</span>potension<span style='letter-spacing:-.05pt'> </span>et/ou<span style='letter-spacing:-.2pt'> </span>un<span style='letter-spacing:-.1pt'> </span>bronchospas<span style='letter-spacing: -.1pt'>m</span>e<span style='letter-spacing:-.5pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>un<span style='letter-spacing:-.1pt'> </span>rash/ér<span style='letter-spacing:.1pt'>y</span>thè<span style='letter-spacing:-.05pt'>m</span>e<span style='letter-spacing:-.25pt'> </span>généralisé<span style='letter-spacing: -.35pt'> </span>(voir rubrique 4.4).</p>
<p class=AmmCorpsTexte><u>Affections du s<span style='letter-spacing:.1pt'>y</span>stè<span style='letter-spacing:-.1pt'>m</span>e nerveux</u> :</p>
<p class=AmmCorpsTexte style='margin-bottom:0cm;margin-bottom:.0001pt'>L<span style='letter-spacing:.05pt'>’</span>apparition d<span style='letter-spacing: .05pt'>’</span>une<span style='letter-spacing:-.05pt'> </span>neurotoxicité<span style='letter-spacing:-.55pt'> </span>périphérique<span style='letter-spacing: -.5pt'> </span>sévère<span style='letter-spacing:-.25pt'> </span>nécessite<span style='letter-spacing:-.35pt'> </span>une<span style='letter-spacing:-.15pt'> </span>r<span style='letter-spacing:-.05pt'>é</span>duction<span style='letter-spacing:-.05pt'> </span>de<span style='letter-spacing:-.1pt'> </span>dose<span style='letter-spacing: -.2pt'> </span>(voir rubriques 4.2<span style='letter-spacing:-.35pt'> </span>et<span style='letter-spacing:.05pt'> </span>4.4).</p>
<p class=AmmCorpsTexte>Les<span style='letter-spacing:-.4pt'> </span>signes<span style='letter-spacing:-.25pt'> </span>neurosensoriels<span style='letter-spacing: -.6pt'> </span>légers<span style='letter-spacing:-.25pt'> </span>à <span style='letter-spacing:-.1pt'>m</span>odérés<span style='letter-spacing:-.1pt'> </span>sont<span style='letter-spacing:-.1pt'> </span>caractérisés<span style='letter-spacing: -.45pt'> </span>par<span style='letter-spacing:-.15pt'> </span>des<span style='letter-spacing:-.15pt'> </span>paresthésies,<span style='letter-spacing: -.5pt'> </span>des<span style='letter-spacing:-.15pt'> </span>d<span style='letter-spacing:.1pt'>y</span>sesthésies<span style='letter-spacing:-.05pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>des sensations<span style='letter-spacing:-.4pt'> </span>douloureuses<span style='letter-spacing: -.55pt'> </span>à t<span style='letter-spacing:.1pt'>y</span>pe<span style='letter-spacing:-.05pt'> </span>de<span style='letter-spacing:-.1pt'> </span>brûlure.<span style='letter-spacing:-.3pt'> </span>Les<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span>anifestations<span style='letter-spacing: -.55pt'> </span>neuro<span style='letter-spacing:-.1pt'>m</span>otrices<span style='letter-spacing:-.25pt'> </span>sont<span style='letter-spacing:-.15pt'> </span>principale<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.5pt'> </span>caractérisées par une<span style='letter-spacing:-.15pt'> </span>faiblesse.</p>
<p class=AmmCorpsTexte><u>Affections de la peau et du tissu sous-cutané</u> :</p>
<p class=AmmCorpsTexte>Des<span style='letter-spacing:-.4pt'> </span>réactions<span style='letter-spacing:-.35pt'> </span>cutanées<span style='letter-spacing:-.35pt'> </span>réversibles<span style='letter-spacing:-.45pt'> </span>ont<span style='letter-spacing:-.15pt'> </span>été obse<span style='letter-spacing:.05pt'>r</span>vées<span style='letter-spacing:-.2pt'> </span>et étaient générale<span style='letter-spacing: -.05pt'>m</span>ent<span style='letter-spacing:-.4pt'> </span>considérées<span style='letter-spacing:-.45pt'> </span>co<span style='letter-spacing:-.1pt'>mm</span>e<span style='letter-spacing:-.1pt'> </span>légères<span style='letter-spacing:-.3pt'> </span>à <span style='letter-spacing:-.1pt'>m</span>odérées.<span style='letter-spacing:-.1pt'> </span>Les<span style='letter-spacing:-.15pt'> </span>réactions<span style='letter-spacing:-.35pt'> </span>ont<span style='letter-spacing:-.15pt'> </span>été caractérisées<span style='letter-spacing:-.5pt'> </span>par<span style='letter-spacing:-.15pt'> </span>un<span style='letter-spacing:-.1pt'> </span>rash<span style='letter-spacing:-.15pt'> </span>avec<span style='letter-spacing:-.2pt'> </span>des<span style='letter-spacing:-.15pt'> </span>éruptions<span style='letter-spacing: -.35pt'> </span>localisées<span style='letter-spacing:-.4pt'> </span>principale<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.1pt'> </span>au<span style='letter-spacing:-.1pt'> </span>niveau des<span style='letter-spacing: -.15pt'> </span>pieds<span style='letter-spacing:-.2pt'> </span>et des<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span>ai<span style='letter-spacing:.05pt'>n</span>s<span style='letter-spacing:-.1pt'> </span>(incluant<span style='letter-spacing:-.35pt'> </span>des<span style='letter-spacing:-.15pt'> </span>s<span style='letter-spacing:.1pt'>y</span>ndro<span style='letter-spacing:-.1pt'>m</span>es<span style='letter-spacing:-.05pt'> </span><span style='letter-spacing:-.1pt'>m</span>ains-pieds<span style='letter-spacing:-.45pt'> </span>sévères)<span style='letter-spacing:-.35pt'> </span><span style='letter-spacing:-.1pt'>m</span>ais<span style='letter-spacing: -.15pt'> </span>égale<span style='letter-spacing:-.05pt'>m</span>ent au<span style='letter-spacing:-.1pt'> </span>niveau<span style='letter-spacing:-.25pt'> </span>des<span style='letter-spacing:-.15pt'> </span>bras,<span style='letter-spacing:-.2pt'> </span>du visage ou<span style='letter-spacing: -.1pt'> </span>du<span style='letter-spacing:-.1pt'> </span>thorax,<span style='letter-spacing:-.3pt'> </span>et fréque<span style='letter-spacing:-.1pt'>mm</span>ent<span style='letter-spacing:-.35pt'> </span>associées<span style='letter-spacing: -.35pt'> </span>à un<span style='letter-spacing:-.1pt'> </span>prurit.<span style='letter-spacing:-.25pt'> </span>Ces<span style='letter-spacing:-.15pt'> </span>éruptions sont<span style='letter-spacing:-.15pt'> </span>générale<span style='letter-spacing: -.05pt'>m</span>ent<span style='letter-spacing:-.4pt'> </span>survenues<span style='letter-spacing:-.4pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>la se<span style='letter-spacing:-.1pt'>m</span>aine<span style='letter-spacing: -.1pt'> </span>suivant<span style='letter-spacing:-.3pt'> </span>la perfusion<span style='letter-spacing:-.4pt'> </span>du<span style='letter-spacing:-.1pt'> </span>docétaxel.<span style='letter-spacing:-.4pt'> </span>Des<span style='letter-spacing:-.15pt'> </span>s<span style='letter-spacing:.1pt'>y</span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>p</span>tô<span style='letter-spacing:-.1pt'>m</span>es sévères<span style='letter-spacing:-.3pt'> </span>tels que<span style='letter-spacing:-.15pt'> </span>des<span style='letter-spacing:-.15pt'> </span>éruptions<span style='letter-spacing:-.35pt'> </span>sui<span style='letter-spacing:.05pt'>v</span>ies<span style='letter-spacing:-.1pt'> </span>d’une desqua<span style='letter-spacing: -.1pt'>m</span>ation,<span style='letter-spacing:-.45pt'> </span>conduisant<span style='letter-spacing:-.45pt'> </span>rare<span style='letter-spacing:-.1pt'>m</span>ent<span style='letter-spacing:-.25pt'> </span>à l’interruption<span style='letter-spacing: -.5pt'> </span>provisoire<span style='letter-spacing:-.4pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>définitive<span style='letter-spacing: -.35pt'> </span>du<span style='letter-spacing:-.1pt'> </span>traite<span style='letter-spacing:-.05pt'>me</span>nt<span style='letter-spacing:-.3pt'> </span>par<span style='letter-spacing:-.15pt'> </span>le docétaxel,<span style='letter-spacing: -.35pt'> </span>ont<span style='letter-spacing:-.15pt'> </span>été <span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>o</span>ins<span style='letter-spacing:-.1pt'> </span>fréque<span style='letter-spacing:-.1pt'>mm</span>ent<span style='letter-spacing:-.35pt'> </span>rapportés (voir rubriques<span style='letter-spacing:-.5pt'> </span>4.2<span style='letter-spacing:-.15pt'> </span>et 4.4).<span style='letter-spacing:-.2pt'> </span>Des<span style='letter-spacing: -.15pt'> </span>t<span style='letter-spacing:-.05pt'>r</span>oubles<span style='letter-spacing:-.05pt'> </span>unguéaux<span style='letter-spacing:-.4pt'> </span>sévères<span style='letter-spacing:-.3pt'> </span>sont<span style='letter-spacing:-.15pt'> </span>caractérisés<span style='letter-spacing: -.4pt'> </span>par une h<span style='letter-spacing:.1pt'>y</span>po<span style='letter-spacing:-.05pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>une h<span style='letter-spacing:.1pt'>y</span>perpig<span style='letter-spacing: -.05pt'>m</span>entation<span style='letter-spacing:-.3pt'> </span>des<span style='letter-spacing:-.15pt'> </span>ongles<span style='letter-spacing:-.25pt'> </span>et parfois<span style='letter-spacing:-.3pt'> </span>une<span style='letter-spacing:-.15pt'> </span>douleur<span style='letter-spacing:-.3pt'> </span>et une<span style='letter-spacing:-.15pt'> </span>on<span style='letter-spacing:.1pt'>y</span>chol<span style='letter-spacing:.1pt'>y</span>se.</p>
<p class=AmmCorpsTexte><u>Troubles généraux et ano<span style='letter-spacing: -.1pt'>m</span>alies au site d’ad<span style='letter-spacing:-.1pt'>m</span>inistration</u><span style='letter-spacing:-.4pt'> </span>:</p>
<p class=AmmCorpsTexte style='margin-bottom:0cm;margin-bottom:.0001pt'>Les<span style='letter-spacing:-.4pt'> </span>réactions<span style='letter-spacing:-.35pt'> </span>au<span style='letter-spacing:-.1pt'> </span>site d<span style='letter-spacing:.05pt'>’</span>injection étaient<span style='letter-spacing: .05pt'> </span>gén<span style='letter-spacing:-.1pt'>é</span>rale<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:-.1pt'>m</span>ineures<span style='letter-spacing:-.35pt'> </span>et se<span style='letter-spacing:-.1pt'> m</span>anifestaient<span style='letter-spacing:-.5pt'> </span>par<span style='letter-spacing:-.15pt'> </span>une<span style='letter-spacing:-.15pt'> </span>h<span style='letter-spacing:.1pt'>y</span>perpig<span style='letter-spacing:-.05pt'>m</span>entation,<span style='letter-spacing: .05pt'> </span>une<span style='letter-spacing:-.1pt'> </span>infla<span style='letter-spacing:-.05pt'>m</span><span style='letter-spacing:-.1pt'>m</span>ation,<span style='letter-spacing:-.3pt'> </span>une<span style='letter-spacing:-.1pt'> </span>rougeur<span style='letter-spacing:-.35pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>une<span style='letter-spacing:-.15pt'> </span>sécheresse<span style='letter-spacing: -.4pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la peau,<span style='letter-spacing:-.2pt'> </span>une<span style='letter-spacing:-.15pt'> </span>phlébite<span style='letter-spacing:-.25pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>une<span style='letter-spacing:-.15pt'> </span>extravasation<span style='letter-spacing: .05pt'> </span>et une tu<span style='letter-spacing:-.1pt'>m</span>éfaction<span style='letter-spacing:-.35pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la veine.</p>
<p class=AmmCorpsTexte>La<span style='letter-spacing:-.35pt'> </span>rétention<span style='letter-spacing:-.3pt'> </span>h<span style='letter-spacing:.1pt'>y</span>drique<span style='letter-spacing:-.05pt'> </span>peut<span style='letter-spacing:-.15pt'> </span>se<span style='letter-spacing:-.1pt'> </span>traduire<span style='letter-spacing:-.25pt'> </span>p<span style='letter-spacing:-.05pt'>a</span>r<span style='letter-spacing: -.05pt'> </span>un<span style='letter-spacing:-.1pt'> </span>œdè<span style='letter-spacing:-.1pt'>m</span>e<span style='letter-spacing:-.15pt'> </span>périphérique<span style='letter-spacing:-.45pt'> </span>et,<span style='letter-spacing:-.1pt'> m</span><span style='letter-spacing:.05pt'>o</span>ins<span style='letter-spacing:-.1pt'> </span>fréque<span style='letter-spacing:-.1pt'>mm</span>ent,<span style='letter-spacing:-.35pt'> </span>un<span style='letter-spacing:-.1pt'> </span>épanche<span style='letter-spacing:-.05pt'>m</span>ent pleural,<span style='letter-spacing:-.3pt'> </span>un<span style='letter-spacing: -.1pt'> </span>épanche<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.35pt'> </span>péricardiqu<span style='letter-spacing: -.05pt'>e</span>,<span style='letter-spacing:-.45pt'> </span>une<span style='letter-spacing:-.15pt'> </span>ascite et une<span style='letter-spacing: -.15pt'> </span>prise<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span>poids.<span style='letter-spacing:-.25pt'> </span>L’œdè<span style='letter-spacing:-.1pt'>m</span>e<span style='letter-spacing: -.25pt'> </span>périphérique<span style='letter-spacing:-.45pt'> </span>débute générale<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing: -.4pt'> </span>au<span style='letter-spacing:-.1pt'> </span>niveau<span style='letter-spacing:-.25pt'> </span>des<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:-.05pt'>e</span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>b</span>res<span style='letter-spacing:-.15pt'> </span>inférieurs<span style='letter-spacing: -.4pt'> </span>et peut<span style='letter-spacing:-.15pt'> </span>se<span style='letter-spacing:-.1pt'> </span>généraliser<span style='letter-spacing: -.45pt'> </span>avec<span style='letter-spacing:-.2pt'> </span>une<span style='letter-spacing:-.15pt'> </span>prise de<span style='letter-spacing:-.1pt'> </span>poids<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span>3<span style='letter-spacing:-.05pt'> </span>kg<span style='letter-spacing:-.1pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>plus. La<span style='letter-spacing:-.1pt'> </span>rétention<span style='letter-spacing:-.35pt'> </span>h<span style='letter-spacing:.1pt'>y</span>drique<span style='letter-spacing:-.05pt'> </span>est<span style='letter-spacing:-.1pt'> </span>cu<span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>u</span>lative<span style='letter-spacing:-.1pt'> </span>en<span style='letter-spacing:-.1pt'> </span>incidence<span style='letter-spacing:-.35pt'> </span>et en<span style='letter-spacing:-.1pt'> </span>sévérité<span style='letter-spacing:-.3pt'> </span>(voir rubrique<span style='letter-spacing: .05pt'> </span>4.4).</p>
<p class=AmmAnnexeTitre3><span style='text-decoration:none'>Tableau des effets indésirables dans le cancer du sein pour docétaxel 100 <span style='letter-spacing: -.1pt'>m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.1pt'>m</span>² en <span style='letter-spacing:-.1pt'>m</span>onothérapie</span></p>
<div align=center>
<table class=AmmCorpsTexteTable border=0 cellspacing=0 cellpadding=0 width=665
style='width:498.65pt;border-collapse:collapse'>
<tr style='height:52.1pt'>
<td width=135 valign=top style='width:101.6pt;border:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:52.1pt'>
<p class=AmmCorpsTexte align=left style='margin-left:2.75pt;text-align:left; page-break-after:avoid'><b>Base<span style='letter-spacing:-.45pt'> </span>de<span style='letter-spacing:-.1pt'> </span>données MeDRA des<span style='letter-spacing: -.15pt'> </span>classes<span style='letter-spacing:-.3pt'> </span>de systèmes d’organe</b></p>
</td>
<td width=190 valign=top style='width:142.15pt;border:solid black 1.0pt;
border-left:none;padding:0cm 0cm 0cm 0cm;height:52.1pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.5pt;text-align:left; page-break-after:avoid'><b>Très<span style='letter-spacing:-.45pt'> </span>fréquent</b></p>
</td>
<td width=189 valign=top style='width:142.05pt;border:solid black 1.0pt;
border-left:none;padding:0cm 0cm 0cm 0cm;height:52.1pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.1pt;text-align:left; page-break-after:avoid'><b>Fréquent</b></p>
</td>
<td width=150 valign=top style='width:112.85pt;border:solid black 1.0pt;
border-left:none;padding:0cm 0cm 0cm 0cm;height:52.1pt'>
<p class=AmmCorpsTexte align=left style='margin-left:6.8pt;text-align:left; page-break-after:avoid'><b>Peu<span style='letter-spacing:-.45pt'> </span>fréquent</b></p>
</td>
</tr>
<tr style='height:52.15pt'>
<td width=135 valign=top style='width:101.6pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:52.15pt'>
<p class=AmmCorpsTexte align=left style='margin-left:2.4pt;text-align:left; page-break-after:avoid'>Infections<span style='letter-spacing:-.7pt'> </span>et infestations</p>
</td>
<td width=190 valign=top style='width:142.15pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:52.15pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.5pt;text-align:left; page-break-after:avoid'>Infections<span style='letter-spacing:-.7pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>5,7<span style='letter-spacing:-.05pt'>%</span>; incluant<span style='letter-spacing:-.3pt'> </span>septicé<span style='letter-spacing:-.05pt'>m</span>ie<span style='letter-spacing:-.3pt'> </span>et pneu<span style='letter-spacing:-.1pt'>m</span>onie,<span style='letter-spacing: -.15pt'> </span>d’évolution fatale<span style='letter-spacing:-.25pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>1,7%<span style='letter-spacing:-.2pt'> </span>des cas)</p>
</td>
<td width=189 valign=top style='width:142.05pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:52.15pt'>
<p class=AmmCorpsTexte align=left style='margin-left:3.85pt;text-align:left; page-break-after:avoid'>Infection<span style='letter-spacing:-.65pt'> </span>associée<span style='letter-spacing:-.35pt'> </span>à une neutropénie<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing:-.1pt'> </span>grade<span style='letter-spacing:-.2pt'> </span>4 (G3/4:<span style='letter-spacing: .05pt'> </span>4,6<span style='letter-spacing:-.05pt'>%</span>)</p>
</td>
<td width=150 valign=top style='width:112.85pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:52.15pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.1pt;text-align:left; page-break-after:avoid'> </p>
</td>
</tr>
<tr style='height:41.55pt'>
<td width=135 valign=top style='width:101.6pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:41.55pt'>
<p class=AmmCorpsTexte align=left style='margin-left:2.4pt;text-align:left; page-break-after:avoid'>Affections hé<span style='letter-spacing:-.1pt'>m</span>atologiques<span style='letter-spacing:-.35pt'> </span>et du s<span style='letter-spacing: .1pt'>y</span>stè<span style='letter-spacing:-.1pt'>m</span>e l<span style='letter-spacing:.1pt'>y</span><span style='letter-spacing:-.1pt'>m</span>phatique</p>
</td>
<td width=190 valign=top style='width:142.15pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:41.55pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.5pt;text-align:left; page-break-after:avoid'>Neutropénie<span style='letter-spacing:-.8pt'> </span>(G4:76,4<span style='letter-spacing:-.05pt'>%</span>); Ané<span style='letter-spacing:-.1pt'>m</span>ie<span style='letter-spacing:-.2pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>8,9<span style='letter-spacing:-.05pt'>%</span>); Neutropénie fébrile</p>
</td>
<td width=189 valign=top style='width:142.05pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:41.55pt'>
<p class=AmmCorpsTexte align=left style='margin-left:3.85pt;text-align:left; page-break-after:avoid'>Thro<span style='letter-spacing:-.1pt'>m</span>bopénie<span style='letter-spacing:-.15pt'> </span>(G4:0,2<span style='letter-spacing: -.05pt'>%</span>)</p>
</td>
<td width=150 valign=top style='width:112.85pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:41.55pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.1pt;text-align:left; page-break-after:avoid'> </p>
</td>
</tr>
<tr style='height:28.65pt'>
<td width=135 valign=top style='width:101.6pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:28.65pt'>
<p class=AmmCorpsTexte align=left style='margin-left:2.4pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span>du<span style='letter-spacing:-.1pt'> </span>s<span style='letter-spacing:.1pt'>y</span>stè<span style='letter-spacing:-.1pt'>m</span>e i<span style='letter-spacing:-.1pt'>mm</span>unitaire</p>
</td>
<td width=190 valign=top style='width:142.15pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:28.65pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.5pt;text-align:left'>H<span style='letter-spacing:.1pt'>y</span>persensibilité<span style='letter-spacing: -.05pt'> </span>(G3/4: 5,3<span style='letter-spacing:-.05pt'>%</span>)</p>
</td>
<td width=189 valign=top style='width:142.05pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:28.65pt'>
<p class=AmmCorpsTexte align=left style='margin-left:3.85pt;text-align:left'> </p>
</td>
<td width=150 valign=top style='width:112.85pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:28.65pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.1pt;text-align:left'> </p>
</td>
</tr>
<tr style='height:38.65pt'>
<td width=135 valign=top style='width:101.6pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:38.65pt'>
<p class=AmmCorpsTexte align=left style='margin-left:2.4pt;text-align:left'>Troubles<span style='letter-spacing:-.6pt'> </span>du <span style='letter-spacing:-.1pt'>m</span>étabolis<span style='letter-spacing:-.05pt'>m</span>e<span style='letter-spacing:-.25pt'> </span>et de<span style='letter-spacing:-.1pt'> </span>la nutrition</p>
</td>
<td width=190 valign=top style='width:142.15pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:38.65pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.5pt;text-align:left'>Anorexie</p>
</td>
<td width=189 valign=top style='width:142.05pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:38.65pt'>
<p class=AmmCorpsTexte align=left style='margin-left:3.85pt;text-align:left'> </p>
</td>
<td width=150 valign=top style='width:112.85pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:38.65pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.1pt;text-align:left'> </p>
</td>
</tr>
<tr style='height:67.25pt'>
<td width=135 valign=top style='width:101.6pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:67.25pt'>
<p class=AmmCorpsTexte align=left style='margin-left:2.4pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span>du<span style='letter-spacing:-.1pt'> </span>s<span style='letter-spacing:.1pt'>y</span>stè<span style='letter-spacing:-.1pt'>m</span>e nerveux</p>
</td>
<td width=190 valign=top style='width:142.15pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:67.25pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:5.4pt;margin-bottom:.0001pt;text-align:left'>Neuropathie<span style='letter-spacing:-.8pt'> </span>sensitive périphérique (G3:<span style='letter-spacing:-.45pt'> </span>4,1<span style='letter-spacing:-.05pt'>%</span>);</p>
<p class=AmmCorpsTexte align=left style='margin-left:5.5pt;text-align:left'>Neuropathie <span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>o</span>trice périphérique<span style='letter-spacing:-.45pt'> </span>(G3/4: 4<span style='letter-spacing:-.05pt'>%</span>) ; D<span style='letter-spacing: .1pt'>y</span>sgueusie<span style='letter-spacing:-.1pt'> </span>(sévère 0,07<span style='letter-spacing:-.05pt'>%</span>)</p>
</td>
<td width=189 valign=top style='width:142.05pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:67.25pt'>
<p class=AmmCorpsTexte align=left style='margin-left:3.85pt;text-align:left'> </p>
</td>
<td width=150 valign=top style='width:112.85pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:67.25pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.1pt;text-align:left'> </p>
</td>
</tr>
<tr style='height:20.7pt'>
<td width=135 valign=top style='width:101.6pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:20.7pt'>
<p class=AmmCorpsTexte align=left style='margin-left:2.4pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span>cardiaques</p>
</td>
<td width=190 valign=top style='width:142.15pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:20.7pt'>
<p class=AmmCorpsTexte align=left style='text-align:left'> </p>
</td>
<td width=189 valign=top style='width:142.05pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:20.7pt'>
<p class=AmmCorpsTexte align=left style='margin-left:3.85pt;text-align:left'>Ar<span style='letter-spacing:.1pt'>y</span>th<span style='letter-spacing:-.1pt'>m</span>ie<span style='letter-spacing:-.15pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>0,7<span style='letter-spacing:-.05pt'>%</span>)</p>
</td>
<td width=150 valign=top style='width:112.85pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:20.7pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.1pt;text-align:left'>Insuffisance<span style='letter-spacing:-.8pt'> </span>cardiaque</p>
</td>
</tr>
<tr style='height:42.25pt'>
<td width=135 valign=top style='width:101.6pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:42.25pt'>
<p class=AmmCorpsTexte align=left style='margin-left:2.4pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span>vasculaires</p>
</td>
<td width=190 valign=top style='width:142.15pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:42.25pt'>
<p class=AmmCorpsTexte align=left style='text-align:left'> </p>
</td>
<td width=189 valign=top style='width:142.05pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:42.25pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:3.95pt;margin-bottom:.0001pt;text-align:left'>H<span style='letter-spacing:.1pt'>y</span>potension; </p>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:3.95pt;margin-bottom:.0001pt;text-align:left'>H<span style='letter-spacing:.1pt'>y</span>pertension; </p>
<p class=AmmCorpsTexte align=left style='margin-left:3.85pt;text-align:left'>Hé<span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>o</span>rragie</p>
</td>
<td width=150 valign=top style='width:112.85pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:42.25pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.1pt;text-align:left'> </p>
</td>
</tr>
<tr style='height:56.35pt'>
<td width=135 valign=top style='width:101.6pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:56.35pt'>
<p class=AmmCorpsTexte align=left style='margin-left:2.4pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span>respiratoires, thoraciques et <span style='letter-spacing:-.1pt'>m</span>édiastinales</p>
</td>
<td width=190 valign=top style='width:142.15pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:56.35pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.1pt;text-align:left'>D<span style='letter-spacing:.1pt'>y</span>spnée<span style='letter-spacing:-.1pt'> </span>(sévère<span style='letter-spacing:-.3pt'> </span>: 2,7<span style='letter-spacing:-.05pt'>%</span>)</p>
</td>
<td width=189 valign=top style='width:142.05pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:56.35pt'>
<p class=AmmCorpsTexte align=left style='margin-left:3.85pt;text-align:left'> </p>
</td>
<td width=150 valign=top style='width:112.85pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:56.35pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.1pt;text-align:left'> </p>
</td>
</tr>
<tr style='height:70.6pt'>
<td width=135 valign=top style='width:101.6pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:70.6pt'>
<p class=AmmCorpsTexte align=left style='margin-left:2.4pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span>gastro- intestinales</p>
</td>
<td width=190 valign=top style='width:142.15pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:70.6pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.1pt;text-align:left'>Sto<span style='letter-spacing:-.1pt'>m</span>atite<span style='letter-spacing:-.1pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>5,3%); Diarrhée (G3/4:<span style='letter-spacing:-.25pt'> </span>4%); Nausées (G3/4:<span style='letter-spacing:-.25pt'> </span>4%); Vo<span style='letter-spacing: -.1pt'>m</span>isse<span style='letter-spacing:-.1pt'>m</span>ents<span style='letter-spacing:-.1pt'> </span>(G3/4: 3<span style='letter-spacing: -.05pt'>%</span>)</p>
</td>
<td width=189 valign=top style='width:142.05pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:70.6pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:3.95pt;margin-bottom:.0001pt;text-align:left'>Constipation<span style='letter-spacing:-.8pt'> </span>(sévère: 0,2<span style='letter-spacing: -.05pt'>%</span>);<span style='letter-spacing:-.15pt'> </span>Douleur abdo<span style='letter-spacing:-.1pt'>m</span>inale (sévère:1<span style='letter-spacing: -.05pt'>%</span>);</p>
<p class=AmmCorpsTexte align=left style='margin-left:3.85pt;text-align:left'>Hé<span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>o</span>rragies<span style='letter-spacing:-.15pt'> </span>gastro- intestinales (sévère:0,3<span style='letter-spacing:-.05pt'>%</span>)</p>
</td>
<td width=150 valign=top style='width:112.85pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:70.6pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.1pt;text-align:left'>Œsophagite<span style='letter-spacing:-.75pt'> </span>(sévère: 0,4<span style='letter-spacing: -.05pt'>%</span>)</p>
</td>
</tr>
<tr style='height:64.1pt'>
<td width=135 valign=top style='width:101.6pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:64.1pt'>
<p class=AmmCorpsTexte align=left style='margin-left:2.4pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la peau<span style='letter-spacing:-.2pt'> </span>et du<span style='letter-spacing: -.1pt'> </span>tissu<span style='letter-spacing:-.2pt'> </span>sous-cutané</p>
</td>
<td width=190 valign=top style='width:142.15pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:64.1pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:7.1pt;margin-bottom:.0001pt;text-align:left'>Alopécie;</p>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:7.1pt;margin-bottom:.0001pt;text-align:left'>Réactions cutanées<span style='letter-spacing:-.35pt'> </span>(G3/4:<span style='letter-spacing:.05pt'> </span>5,9<span style='letter-spacing:-.05pt'>%</span>); </p>
<p class=AmmCorpsTexte align=left style='margin-left:7.1pt;text-align:left'>Altération des<span style='letter-spacing:-.15pt'> </span>ongles (sévère : 2,6%)</p>
</td>
<td width=189 valign=top style='width:142.05pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:64.1pt'>
<p class=AmmCorpsTexte align=left style='margin-left:3.85pt;text-align:left'> </p>
</td>
<td width=150 valign=top style='width:112.85pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:64.1pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.1pt;text-align:left'> </p>
</td>
</tr>
<tr style='height:44.45pt'>
<td width=135 valign=top style='width:101.6pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:44.45pt'>
<p class=AmmCorpsTexte align=left style='margin-left:2.4pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>u</span>sculo- squelettiques et s<span style='letter-spacing:.1pt'>y</span>sté<span style='letter-spacing:-.1pt'>m</span>iques</p>
</td>
<td width=190 valign=top style='width:142.15pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:44.45pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.1pt;text-align:left'>M<span style='letter-spacing:.1pt'>y</span>algie<span style='letter-spacing:-.1pt'> </span>(sévère<span style='letter-spacing:-.3pt'> </span>: 1,4%)</p>
</td>
<td width=189 valign=top style='width:142.05pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:44.45pt'>
<p class=AmmCorpsTexte align=left style='margin-left:3.85pt;text-align:left'>Arthralgie</p>
</td>
<td width=150 valign=top style='width:112.85pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:44.45pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.1pt;text-align:left'> </p>
</td>
</tr>
<tr style='height:57.15pt'>
<td width=135 valign=top style='width:101.6pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:57.15pt'>
<p class=AmmCorpsTexte align=left style='margin-left:2.4pt;text-align:left'>Troubles<span style='letter-spacing:-.65pt'> </span>généraux<span style='letter-spacing: -.35pt'> </span>et ano<span style='letter-spacing:-.1pt'>m</span>alies<span style='letter-spacing:-.15pt'> </span>au<span style='letter-spacing:-.1pt'> </span>site d’ad<span style='letter-spacing:-.1pt'>m</span>inistration</p>
</td>
<td width=190 valign=top style='width:142.15pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:57.15pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:7.1pt;margin-bottom:.0001pt;text-align:left'>Rétention<span style='letter-spacing:-.65pt'> </span>h<span style='letter-spacing:.1pt'>y</span>drique (sévère: 6,5%); </p>
<p class=AmmCorpsTexte align=left style='margin-left:7.1pt;text-align:left'>Asthénie (sévère:11,2<span style='letter-spacing:-.05pt'>%</span>); Douleurs</p>
</td>
<td width=189 valign=top style='width:142.05pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:57.15pt'>
<p class=AmmCorpsTexte align=left style='margin-left:3.85pt;text-align:left'>Réaction<span style='letter-spacing:-.65pt'> </span>au<span style='letter-spacing:-.1pt'> </span>site d’injection; Douleur<span style='letter-spacing:-.6pt'> </span>thoracique d’origine<span style='letter-spacing:.05pt'> </span>non<span style='letter-spacing:-.15pt'> </span>cardiaque (sévère: 0,4%)</p>
</td>
<td width=150 valign=top style='width:112.85pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:57.15pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.1pt;text-align:left'> </p>
</td>
</tr>
<tr style='height:99.45pt'>
<td width=135 valign=top style='width:101.6pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:99.45pt'>
<p class=AmmCorpsTexte align=left style='margin-left:2.4pt;text-align:left'>Investigations</p>
</td>
<td width=190 valign=top style='width:142.15pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:99.45pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:7.1pt;margin-bottom:.0001pt;text-align:left'> </p>
</td>
<td width=189 valign=top style='width:142.05pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:99.45pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:7.1pt;margin-bottom:.0001pt;text-align:left'>Elévation de la bilirubine (G3/4 &lt;5%);</p>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:7.1pt;margin-bottom:.0001pt;text-align:left'>Elévation des phosphatases alcalines (G3/4 &lt;4%); Elévation des ASAT (G3/4 &lt;3%); </p>
<p class=AmmCorpsTexte align=left style='margin-left:3.85pt;text-align:left'>Elévation des ALAT (G3/4 &lt;2%)</p>
</td>
<td width=150 valign=top style='width:112.85pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:99.45pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.1pt;text-align:left'> </p>
</td>
</tr>
</table>
</div>
<p class=AmmCorpsTexte style='margin-top:6.0pt;line-height:10.0pt;text-autospace: none'><b><u><span style='font-size:10.0pt;font-family:Arial'>Description de certains effets indésirables dans le cancer du sein pour docetaxel 100 mg/m² en monothérapie</span></u></b></p>
<p class=AmmCorpsTexte style='margin-top:6.0pt'><u>Affections hématologiques et du système lymphatique</u><span style='letter-spacing:-.05pt'> </span>:</p>
<p class=AmmCorpsTexte>Rare<span style='letter-spacing:-.45pt'> </span>: épisodes<span style='letter-spacing:-.35pt'> </span>hé<span style='letter-spacing: -.1pt'>m</span><span style='letter-spacing:.05pt'>o</span>rragiques<span style='letter-spacing:-.1pt'> </span>associés<span style='letter-spacing:-.35pt'> </span>à <span style='letter-spacing:.05pt'>d</span>es<span style='letter-spacing: -.05pt'> </span>thro<span style='letter-spacing:-.1pt'>m</span>bopénies<span style='letter-spacing:-.15pt'> </span>de<span style='letter-spacing:-.1pt'> </span>grade<span style='letter-spacing:-.2pt'> </span>3/4.</p>
<p class=AmmCorpsTexte><u>Affections du système nerveux</u><span style='letter-spacing:-.05pt'> </span>:</p>
<p class=AmmCorpsTexte>Les<span style='letter-spacing:-.4pt'> </span>données<span style='letter-spacing:-.35pt'> </span>sur<span style='letter-spacing:-.1pt'> </span>la réversibilité<span style='letter-spacing:-.45pt'> </span>sont<span style='letter-spacing:-.15pt'> </span>disponibles<span style='letter-spacing: -.45pt'> </span>pour<span style='letter-spacing:-.2pt'> </span>35,3%<span style='letter-spacing:-.25pt'> </span>des<span style='letter-spacing:-.15pt'> </span>patients<span style='letter-spacing:-.3pt'> </span>a<span style='letter-spacing:.1pt'>y</span>ant<span style='letter-spacing:-.05pt'> </span>eu<span style='letter-spacing:-.1pt'> </span>des<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span>anifestations neurotoxiques à la suite<span style='letter-spacing:-.2pt'> </span>du<span style='letter-spacing:-.1pt'> </span>traite<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.3pt'> </span>par<span style='letter-spacing:-.15pt'> </span>docéta<span style='letter-spacing:.05pt'>x</span>el<span style='letter-spacing:-.25pt'> </span>en<span style='letter-spacing:-.1pt'> m</span>onothérapie<span style='letter-spacing: -.05pt'> </span>à raison<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.1pt'> </span>100<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.1pt'>m</span>².<span style='letter-spacing:-.1pt'> </span>Ces<span style='letter-spacing:-.15pt'> </span>effets ont<span style='letter-spacing: -.15pt'> </span>été spontané<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.35pt'> </span>réversibles<span style='letter-spacing: -.45pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>3<span style='letter-spacing:-.05pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>o</span>is.</p>
<p class=AmmCorpsTexte><u>Affections de la peau et du tissu sous-cuta<span style='letter-spacing:-.05pt'>n</span>é</u> :</p>
<p class=AmmCorpsTexte>Très<span style='letter-spacing:-.45pt'> </span>rare<span style='letter-spacing:-.15pt'> </span>: 1<span style='letter-spacing:-.05pt'> </span>cas<span style='letter-spacing:-.15pt'> </span>d<span style='letter-spacing:.05pt'>’</span>alopécie non<span style='letter-spacing:-.15pt'> </span>réversible<span style='letter-spacing:-.4pt'> </span>à la fin<span style='letter-spacing:-.1pt'> </span>de<span style='letter-spacing:-.15pt'> </span>l<span style='letter-spacing: .05pt'>’</span>étude.<span style='letter-spacing:-.05pt'> </span>73%<span style='letter-spacing:-.2pt'> </span>des<span style='letter-spacing:-.15pt'> </span>réactions<span style='letter-spacing:-.35pt'> </span>cutanées<span style='letter-spacing:-.35pt'> </span>ont<span style='letter-spacing:-.15pt'> </span>été réversibles<span style='letter-spacing:-.45pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>21<span style='letter-spacing:-.1pt'> </span>jours.</p>
<p class=AmmCorpsTexte><i><u>Troubles généraux et anomalies au site d’administration</u></i><i> :</i></p>
<p class=AmmCorpsTexte>Pour la rétention hydrique, la dose cumulative médiane à l’arrêt du traitement était supérieure à 1 000 mg/m² et le temps médian de réversibilité était de 16,4 semaines (intervalle de 0 à 42 semaines). L’apparition de la rétention hydrique modérée à sévère est retardée (dose cumulative médiane :</p>
<p class=AmmCorpsTexte>818,9 mg/m²) chez les patients ayant reçu une prémédication par rapport aux patients qui n’en ont pas reçu (dose cumulative médiane : 489,7 mg/m²); toutefois, cette manifestation a été rapportée chez certains patients pendant les premiers cycles de traitement.</p>
<p class=AmmCorpsTexte><b><u>Docétaxel 75 <span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.1pt'>m</span>² en <span style='letter-spacing:-.1pt'>m</span>onothérapie</u></b></p>
<div align=center>
<table class=AmmCorpsTexteTable border=0 cellspacing=0 cellpadding=0
style='margin-left:5.15pt;border-collapse:collapse'>
<tr style='height:39.2pt'>
<td width=217 valign=top style='width:162.7pt;border:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:39.2pt'>
<p class=AmmCorpsTexte style='margin-left:4.65pt'><b>Base<span style='letter-spacing:-.45pt'> </span>de<span style='letter-spacing:-.1pt'> </span>données<span style='letter-spacing:-.35pt'> </span>MeDRA<span style='letter-spacing:-.35pt'> </span>des classes de<span style='letter-spacing:-.1pt'> </span>système<span style='letter-spacing:-.35pt'> </span>d’organe</b></p>
</td>
<td width=217 valign=top style='width:162.8pt;border:solid black 1.0pt;
border-left:none;padding:0cm 0cm 0cm 0cm;height:39.2pt'>
<p class=AmmCorpsTexte style='margin-left:4.95pt'><b>Très<span style='letter-spacing:-.45pt'> </span>fréquent</b></p>
</td>
<td width=217 valign=top style='width:162.8pt;border:solid black 1.0pt;
border-left:none;padding:0cm 0cm 0cm 0cm;height:39.2pt'>
<p class=AmmCorpsTexte style='margin-left:5.2pt'><b>Fréquent</b></p>
</td>
</tr>
<tr style='height:13.2pt'>
<td width=217 valign=top style='width:162.7pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:13.2pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.65pt;text-align:left'>Infections<span style='letter-spacing:-.7pt'> </span>et infestations</p>
</td>
<td width=217 valign=top style='width:162.8pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:13.2pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.95pt;text-align:left'>Infections<span style='letter-spacing:-.7pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>5<span style='letter-spacing:-.05pt'>%</span>)</p>
</td>
<td width=217 valign=top style='width:162.8pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:13.2pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.2pt;text-align:left'> </p>
</td>
</tr>
<tr style='height:38.65pt'>
<td width=217 valign=top style='width:162.7pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:38.65pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.65pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span>hé<span style='letter-spacing:-.1pt'>m</span>atologiques<span style='letter-spacing:-.5pt'> </span>et du s<span style='letter-spacing:.1pt'>y</span>stè<span style='letter-spacing:-.1pt'>m</span>e l<span style='letter-spacing:.1pt'>y</span><span style='letter-spacing:-.1pt'>m</span>phatique</p>
</td>
<td width=217 valign=top style='width:162.8pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:38.65pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:4.8pt;margin-bottom:.0001pt;text-align:left'>Neutropénie<span style='letter-spacing:-.75pt'> </span>(G4:<span style='letter-spacing:-.2pt'> </span>54,2<span style='letter-spacing:-.05pt'>%</span>); </p>
<p class=AmmCorpsTexte align=left style='margin-left:4.95pt;text-align:left'>Ané<span style='letter-spacing:-.1pt'>m</span>ie (G3/4:<span style='letter-spacing: -.25pt'> </span>10,8<span style='letter-spacing:-.05pt'>%</span>); Thro<span style='letter-spacing:-.1pt'>m</span>bopénie<span style='letter-spacing:.05pt'> </span>(G4:<span style='letter-spacing:-.2pt'> </span>1,7<span style='letter-spacing:-.05pt'>%</span>)</p>
</td>
<td width=217 valign=top style='width:162.8pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:38.65pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.2pt;text-align:left'>Neutropénie<span style='letter-spacing:-.8pt'> </span>fébrile</p>
</td>
</tr>
<tr style='height:25.9pt'>
<td width=217 valign=top style='width:162.7pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:25.9pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.65pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span>du<span style='letter-spacing:-.1pt'> </span>s<span style='letter-spacing:.1pt'>y</span>stè<span style='letter-spacing:-.1pt'>m</span>e i<span style='letter-spacing:-.1pt'>mm</span>unitaire</p>
</td>
<td width=217 valign=top style='width:162.8pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:25.9pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.95pt;text-align:left'> </p>
</td>
<td width=217 valign=top style='width:162.8pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:25.9pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.2pt;text-align:left'>H<span style='letter-spacing:.1pt'>y</span>persensibilité<span style='letter-spacing: -.1pt'> </span>(ja<span style='letter-spacing:-.05pt'>m</span>ais<span style='letter-spacing:-.1pt'> </span>sévère)</p>
</td>
</tr>
<tr style='height:25.9pt'>
<td width=217 valign=top style='width:162.7pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:25.9pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.65pt;text-align:left'>Troubles<span style='letter-spacing:-.65pt'> </span>du<span style='letter-spacing:-.1pt'> m</span>étabolis<span style='letter-spacing:-.05pt'>m</span>e<span style='letter-spacing:-.35pt'> </span>et de<span style='letter-spacing:-.1pt'> </span>la nutrition</p>
</td>
<td width=217 valign=top style='width:162.8pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:25.9pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.95pt;text-align:left'>Anorexie</p>
</td>
<td width=217 valign=top style='width:162.8pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:25.9pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.2pt;text-align:left'> </p>
</td>
</tr>
<tr style='height:25.9pt'>
<td width=217 valign=top style='width:162.7pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:25.9pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.65pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span>du<span style='letter-spacing:-.1pt'> </span>s<span style='letter-spacing:.1pt'>y</span>stè<span style='letter-spacing:-.1pt'>m</span>e<span style='letter-spacing:-.05pt'> </span>nerveux</p>
</td>
<td width=217 valign=top style='width:162.8pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:25.9pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.95pt;text-align:left'>Neuropathie<span style='letter-spacing:-.8pt'> </span>sensitive périphérique<span style='letter-spacing:.05pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>0,8<span style='letter-spacing:-.05pt'>%</span>)</p>
</td>
<td width=217 valign=top style='width:162.8pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:25.9pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.2pt;text-align:left'>Neuropathie<span style='letter-spacing:-.8pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>o</span>trice périphérique<span style='letter-spacing:-.45pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>2,5<span style='letter-spacing:-.05pt'>%</span>)</p>
</td>
</tr>
<tr style='height:13.2pt'>
<td width=217 valign=top style='width:162.7pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:13.2pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.65pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span>cardiaques</p>
</td>
<td width=217 valign=top style='width:162.8pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:13.2pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.95pt;text-align:left'> </p>
</td>
<td width=217 valign=top style='width:162.8pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:13.2pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.2pt;text-align:left'>Ar<span style='letter-spacing:.1pt'>y</span>th<span style='letter-spacing:-.1pt'>m</span>ie<span style='letter-spacing:-.15pt'> </span>(ja<span style='letter-spacing:-.05pt'>m</span>ais<span style='letter-spacing:-.1pt'> </span>sévère);</p>
</td>
</tr>
<tr style='height:13.2pt'>
<td width=217 valign=top style='width:162.7pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:13.2pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.65pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span>vasculaires</p>
</td>
<td width=217 valign=top style='width:162.8pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:13.2pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.95pt;text-align:left'> </p>
</td>
<td width=217 valign=top style='width:162.8pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:13.2pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.2pt;text-align:left'>H<span style='letter-spacing:.1pt'>y</span>potension</p>
</td>
</tr>
<tr style='height:51.35pt'>
<td width=217 valign=top style='width:162.7pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:51.35pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.65pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span>gastro-intestinales</p>
</td>
<td width=217 valign=top style='width:162.8pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:51.35pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:4.8pt;margin-bottom:.0001pt;text-align:left'>Nausées<span style='letter-spacing:-.6pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>3,3%); </p>
<p class=AmmCorpsTexte align=left style='margin-left:4.95pt;text-align:left'>Sto<span style='letter-spacing:-.1pt'>m</span>atite<span style='letter-spacing:.05pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>1,7%); Vo<span style='letter-spacing:-.1pt'>m</span>isse<span style='letter-spacing:-.1pt'>m</span>ents<span style='letter-spacing:-.1pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>0,8%); Diarrhée (G3/4:<span style='letter-spacing:-.25pt'> </span>1,7<span style='letter-spacing:-.05pt'>%</span>)</p>
</td>
<td width=217 valign=top style='width:162.8pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:51.35pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.2pt;text-align:left'>Constipation</p>
</td>
</tr>
<tr style='height:25.9pt'>
<td width=217 valign=top style='width:162.7pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:25.9pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.65pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la peau<span style='letter-spacing:-.2pt'> </span>et du<span style='letter-spacing: -.1pt'> </span>tissu sous-cutané</p>
</td>
<td width=217 valign=top style='width:162.8pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:25.9pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:4.8pt;margin-bottom:.0001pt;text-align:left'>Alopécie;</p>
<p class=AmmCorpsTexte align=left style='margin-left:4.95pt;text-align:left'>Réactions<span style='letter-spacing:-.7pt'> </span>cutanées<span style='letter-spacing: -.35pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>0,8%)</p>
</td>
<td width=217 valign=top style='width:162.8pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:25.9pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.2pt;text-align:left'>Altération<span style='letter-spacing:-.7pt'> </span>des<span style='letter-spacing:-.15pt'> </span>ongles (sévère<span style='letter-spacing:-.55pt'> </span>: 0,8%)</p>
</td>
</tr>
<tr style='height:25.9pt'>
<td width=217 valign=top style='width:162.7pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:25.9pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.65pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>u</span>sculo- squelettiques et s<span style='letter-spacing:.1pt'>y</span>sté<span style='letter-spacing:-.1pt'>m</span>iques</p>
</td>
<td width=217 valign=top style='width:162.8pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:25.9pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.95pt;text-align:left'> </p>
</td>
<td width=217 valign=top style='width:162.8pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:25.9pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.2pt;text-align:left'>M<span style='letter-spacing:.1pt'>y</span>algie</p>
</td>
</tr>
<tr style='height:51.35pt'>
<td width=217 valign=top style='width:162.7pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:51.35pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.65pt;text-align:left'>Troubles<span style='letter-spacing:-.65pt'> </span>généraux<span style='letter-spacing: -.35pt'> </span>et ano<span style='letter-spacing:-.1pt'>m</span>alies<span style='letter-spacing:-.15pt'> </span>au site d<span style='letter-spacing: .05pt'>’</span>ad<span style='letter-spacing:-.1pt'>m</span>inistration</p>
</td>
<td width=217 valign=top style='width:162.8pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:51.35pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:4.8pt;margin-bottom:.0001pt;text-align:left'>Asthénie<span style='letter-spacing:-.65pt'> </span>(sévère<span style='letter-spacing: -.3pt'> </span>: 12,4%); Rétention<span style='letter-spacing:.05pt'> </span>h<span style='letter-spacing:.1pt'>y</span>drique<span style='letter-spacing:-.05pt'> </span>(sévère:</p>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:4.8pt;margin-bottom:.0001pt;text-align:left'>0,8<span style='letter-spacing:-.05pt'>%</span>);</p>
<p class=AmmCorpsTexte align=left style='margin-left:4.95pt;text-align:left'>Douleurs</p>
</td>
<td width=217 valign=top style='width:162.8pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:51.35pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.2pt;text-align:left'> </p>
</td>
</tr>
<tr style='height:30.2pt'>
<td width=217 valign=top style='width:162.7pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:30.2pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.65pt;text-align:left'>Investigations</p>
</td>
<td width=217 valign=top style='width:162.8pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:30.2pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.95pt;text-align:left'> </p>
</td>
<td width=217 valign=top style='width:162.8pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:30.2pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.2pt;text-align:left'>Elévation<span style='letter-spacing:-.6pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la bilirubine (G3/4<span style='letter-spacing:-.5pt'> </span>&lt;2<span style='letter-spacing:-.05pt'>%</span>)</p>
</td>
</tr>
</table>
</div>
<p class=AmmCorpsTexte style='margin-top:6.0pt'><b>Tableau des effets indésirables dans le cancer du sein pour docétaxel<sub> 75 <span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.1pt'>m</span>² en association avec la doxorubicine</sub></b></p>
<div align=center>
<table class=AmmCorpsTexteTable border=0 cellspacing=0 cellpadding=0
style='margin-left:-17.3pt;border-collapse:collapse'>
<tr style='height:52.1pt'>
<td width=183 valign=top style='width:137.55pt;border:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:52.1pt'>
<p class=AmmCorpsTexte style='margin-left:8.95pt'><b>Base<span style='letter-spacing:-.45pt'> </span>de<span style='letter-spacing:-.1pt'> </span>données MeDRA des<span style='letter-spacing:-.15pt'> </span>classes<span style='letter-spacing:-.3pt'> </span>de système d’organe</b></p>
</td>
<td width=171 valign=top style='width:128.1pt;border:solid black 1.0pt;
border-left:none;padding:0cm 0cm 0cm 0cm;height:52.1pt'>
<p class=AmmCorpsTexte style='margin-left:6.05pt'><b>Très<span style='letter-spacing:-.45pt'> </span>fréquent</b></p>
</td>
<td width=151 valign=top style='width:4.0cm;border:solid black 1.0pt;
border-left:none;padding:0cm 0cm 0cm 0cm;height:52.1pt'>
<p class=AmmCorpsTexte style='margin-left:5.55pt'><b>Fréquent</b></p>
</td>
<td width=138 valign=top style='width:103.65pt;border:solid black 1.0pt;
border-left:none;padding:0cm 0cm 0cm 0cm;height:52.1pt'>
<p class=AmmCorpsTexte style='margin-left:5.55pt'><b>Peu<span style='letter-spacing:-.45pt'> </span>fréquent</b></p>
</td>
</tr>
<tr style='height:13.2pt'>
<td width=183 valign=top style='width:137.55pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:13.2pt'>
<p class=AmmCorpsTexte align=left style='margin-left:9.3pt;text-align:left'>Infections<span style='letter-spacing:-.7pt'> </span>et infestations</p>
</td>
<td width=171 valign=top style='width:128.1pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:13.2pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.6pt;text-align:left'>Infection<span style='letter-spacing:-.6pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>7,8<span style='letter-spacing:-.05pt'>%</span>)</p>
</td>
<td width=151 valign=top style='width:4.0cm;border-top:none;border-left:none;
border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0cm 0cm 0cm 0cm;
height:13.2pt'>
<p class=AmmCorpsTexte align=left style='text-align:left'> </p>
</td>
<td width=138 valign=top style='width:103.65pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:13.2pt'>
<p class=AmmCorpsTexte align=left style='text-align:left'> </p>
</td>
</tr>
<tr style='height:76.8pt'>
<td width=183 valign=top style='width:137.55pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:76.8pt'>
<p class=AmmCorpsTexte align=left style='margin-left:9.3pt;text-align:left'>Affections hé<span style='letter-spacing:-.1pt'>m</span>atologiques<span style='letter-spacing:-.35pt'> </span>et du s<span style='letter-spacing: .1pt'>y</span>stè<span style='letter-spacing:-.1pt'>m</span>e l<span style='letter-spacing:.1pt'>y</span><span style='letter-spacing:-.1pt'>m</span>phatique</p>
</td>
<td width=171 valign=top style='width:128.1pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:76.8pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:7.65pt;margin-bottom:.0001pt;text-align:left'>Neutropénie<span style='letter-spacing:-.8pt'> </span>(G4:</p>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:7.65pt;margin-bottom:.0001pt;text-align:left'>91,7<span style='letter-spacing:-.05pt'>%</span>);<span style='letter-spacing:-.2pt'> </span>Ané<span style='letter-spacing:-.1pt'>m</span>ie<span style='letter-spacing:-.15pt'> </span>(G3/4:</p>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:7.65pt;margin-bottom:.0001pt;text-align:left'>9,4<span style='letter-spacing:-.05pt'>%</span>);</p>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:7.65pt;margin-bottom:.0001pt;text-align:left'>Neutropénie<span style='letter-spacing:-.8pt'> </span>fébrile; Thro<span style='letter-spacing: -.1pt'>m</span>bopénie<span style='letter-spacing:.05pt'> </span>(G4:</p>
<p class=AmmCorpsTexte align=left style='margin-left:7.6pt;text-align:left'>0,8<span style='letter-spacing:-.05pt'>%</span>)</p>
</td>
<td width=151 valign=top style='width:4.0cm;border-top:none;border-left:none;
border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0cm 0cm 0cm 0cm;
height:76.8pt'>
<p class=AmmCorpsTexte align=left style='text-align:left'> </p>
</td>
<td width=138 valign=top style='width:103.65pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:76.8pt'>
<p class=AmmCorpsTexte align=left style='margin-left:11.4pt;text-align:left'> </p>
</td>
</tr>
<tr style='height:25.9pt'>
<td width=183 valign=top style='width:137.55pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:25.9pt'>
<p class=AmmCorpsTexte align=left style='margin-left:9.3pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span>du<span style='letter-spacing:-.1pt'> </span>s<span style='letter-spacing:.1pt'>y</span>stè<span style='letter-spacing:-.1pt'>m</span>e i<span style='letter-spacing:-.1pt'>mm</span>unitaire</p>
</td>
<td width=171 valign=top style='width:128.1pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:25.9pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.6pt;text-align:left'> </p>
</td>
<td width=151 valign=top style='width:4.0cm;border-top:none;border-left:none;
border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0cm 0cm 0cm 0cm;
height:25.9pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.95pt;text-align:left'>H<span style='letter-spacing:.1pt'>y</span>persensibilité<span style='letter-spacing: -.05pt'> </span>(G3/4:1,2<span style='letter-spacing:-.05pt'>%</span>)</p>
</td>
<td width=138 valign=top style='width:103.65pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:25.9pt'>
<p class=AmmCorpsTexte align=left style='margin-left:11.4pt;text-align:left'> </p>
</td>
</tr>
<tr style='height:26.9pt'>
<td width=183 valign=top style='width:137.55pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:26.9pt'>
<p class=AmmCorpsTexte align=left style='margin-left:9.3pt;text-align:left'>Troubles<span style='letter-spacing:-.6pt'> </span>du <span style='letter-spacing:-.1pt'>m</span>étabolis<span style='letter-spacing:-.05pt'>m</span>e<span style='letter-spacing:-.25pt'> </span>et de<span style='letter-spacing:-.1pt'> </span>la nutrition</p>
</td>
<td width=171 valign=top style='width:128.1pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:26.9pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.6pt;text-align:left'> </p>
</td>
<td width=151 valign=top style='width:4.0cm;border-top:none;border-left:none;
border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0cm 0cm 0cm 0cm;
height:26.9pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.95pt;text-align:left'>Anorexie</p>
</td>
<td width=138 valign=top style='width:103.65pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:26.9pt'>
<p class=AmmCorpsTexte align=left style='margin-left:11.4pt;text-align:left'> </p>
</td>
</tr>
<tr style='height:38.65pt'>
<td width=183 valign=top style='width:137.55pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:38.65pt'>
<p class=AmmCorpsTexte align=left style='margin-left:9.3pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span>du<span style='letter-spacing:-.1pt'> </span>s<span style='letter-spacing:.1pt'>y</span>stè<span style='letter-spacing:-.1pt'>m</span>e nerveux</p>
</td>
<td width=171 valign=top style='width:128.1pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:38.65pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.6pt;text-align:left'>Neuropathie<span style='letter-spacing:-.8pt'> </span>sensitive périphérique<span style='letter-spacing:.05pt'> </span>(G3:<span style='letter-spacing:-.2pt'> </span>0,4<span style='letter-spacing:-.05pt'>%</span>)</p>
</td>
<td width=151 valign=top style='width:4.0cm;border-top:none;border-left:none;
border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0cm 0cm 0cm 0cm;
height:38.65pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.95pt;text-align:left'>Neuropathie<span style='letter-spacing:-.8pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>o</span>trice périphérique<span style='letter-spacing:-.45pt'> </span>(G3/4:0,4<span style='letter-spacing: -.05pt'>%</span>)</p>
</td>
<td width=138 valign=top style='width:103.65pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:38.65pt'>
<p class=AmmCorpsTexte align=left style='margin-left:11.4pt;text-align:left'> </p>
</td>
</tr>
<tr style='height:38.65pt'>
<td width=183 valign=top style='width:137.55pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:38.65pt'>
<p class=AmmCorpsTexte align=left style='margin-left:9.3pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span>cardiaques</p>
</td>
<td width=171 valign=top style='width:128.1pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:38.65pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.6pt;text-align:left'> </p>
</td>
<td width=151 valign=top style='width:4.0cm;border-top:none;border-left:none;
border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0cm 0cm 0cm 0cm;
height:38.65pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.95pt;text-align:left'>Insuffisance<span style='letter-spacing:-.8pt'> </span>cardiaque; Ar<span style='letter-spacing: .1pt'>y</span>th<span style='letter-spacing:-.1pt'>m</span>ie<span style='letter-spacing:-.05pt'> </span>(ja<span style='letter-spacing:-.05pt'>m</span>ais<span style='letter-spacing:-.1pt'> </span>sévère)</p>
</td>
<td width=138 valign=top style='width:103.65pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:38.65pt'>
<p class=AmmCorpsTexte align=left style='margin-left:11.4pt;text-align:left'> </p>
</td>
</tr>
<tr style='height:13.2pt'>
<td width=183 valign=top style='width:137.55pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:13.2pt'>
<p class=AmmCorpsTexte align=left style='margin-left:9.3pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span>vasculaires</p>
</td>
<td width=171 valign=top style='width:128.1pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:13.2pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.6pt;text-align:left'> </p>
</td>
<td width=151 valign=top style='width:4.0cm;border-top:none;border-left:none;
border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0cm 0cm 0cm 0cm;
height:13.2pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.95pt;text-align:left'> </p>
</td>
<td width=138 valign=top style='width:103.65pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:13.2pt'>
<p class=AmmCorpsTexte align=left style='margin-left:11.4pt;text-align:left'>H<span style='letter-spacing:.1pt'>y</span>potension</p>
</td>
</tr>
<tr style='height:64.1pt'>
<td width=183 valign=top style='width:137.55pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:64.1pt'>
<p class=AmmCorpsTexte align=left style='margin-left:9.3pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span>gastro- intestinales</p>
</td>
<td width=171 valign=top style='width:128.1pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:64.1pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:7.65pt;margin-bottom:.0001pt;text-align:left'>Nausées<span style='letter-spacing:-.6pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>5%); Sto<span style='letter-spacing:-.1pt'>m</span>atite<span style='letter-spacing:.05pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>7,8%); Diarrhée (G3/4:<span style='letter-spacing:-.25pt'> </span>6,2<span style='letter-spacing:-.05pt'>%</span>); Vo<span style='letter-spacing:-.1pt'>m</span>isse<span style='letter-spacing:-.1pt'>m</span>ents<span style='letter-spacing:-.1pt'> </span>(G3/4:</p>
<p class=AmmCorpsTexte align=left style='margin-left:7.6pt;text-align:left'>5<span style='letter-spacing:-.05pt'>%</span>); Constipation</p>
</td>
<td width=151 valign=top style='width:4.0cm;border-top:none;border-left:none;
border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0cm 0cm 0cm 0cm;
height:64.1pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.95pt;text-align:left'> </p>
</td>
<td width=138 valign=top style='width:103.65pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:64.1pt'>
<p class=AmmCorpsTexte align=left style='margin-left:11.4pt;text-align:left'> </p>
</td>
</tr>
<tr style='height:64.1pt'>
<td width=183 valign=top style='width:137.55pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:64.1pt'>
<p class=AmmCorpsTexte align=left style='margin-left:9.3pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la peau<span style='letter-spacing:-.2pt'> </span>et du<span style='letter-spacing: -.1pt'> </span>tissu<span style='letter-spacing:-.2pt'> </span>sous-cutané</p>
</td>
<td width=171 valign=top style='width:128.1pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:64.1pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:7.65pt;margin-bottom:.0001pt;text-align:left'>Alopécie;</p>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:7.65pt;margin-bottom:.0001pt;text-align:left'>Altération<span style='letter-spacing:-.7pt'> </span>des<span style='letter-spacing:-.15pt'> </span>ongles (sévère: 0,4%); </p>
<p class=AmmCorpsTexte align=left style='margin-left:7.6pt;text-align:left'>Réactions cutanées (ja<span style='letter-spacing:-.05pt'>m</span>ais sévères)</p>
</td>
<td width=151 valign=top style='width:4.0cm;border-top:none;border-left:none;
border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0cm 0cm 0cm 0cm;
height:64.1pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.95pt;text-align:left'> </p>
</td>
<td width=138 valign=top style='width:103.65pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:64.1pt'>
<p class=AmmCorpsTexte align=left style='margin-left:11.4pt;text-align:left'> </p>
</td>
</tr>
<tr style='height:38.65pt'>
<td width=183 valign=top style='width:137.55pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:38.65pt'>
<p class=AmmCorpsTexte align=left style='margin-left:9.3pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>u</span>sculo- squelettiques et s<span style='letter-spacing:.1pt'>y</span>sté<span style='letter-spacing:-.1pt'>m</span>iques</p>
</td>
<td width=171 valign=top style='width:128.1pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:38.65pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.6pt;text-align:left'> </p>
</td>
<td width=151 valign=top style='width:4.0cm;border-top:none;border-left:none;
border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0cm 0cm 0cm 0cm;
height:38.65pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.95pt;text-align:left'>M<span style='letter-spacing:.1pt'>y</span>algie</p>
</td>
<td width=138 valign=top style='width:103.65pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:38.65pt'>
<p class=AmmCorpsTexte align=left style='margin-left:11.4pt;text-align:left'> </p>
</td>
</tr>
<tr style='height:64.1pt'>
<td width=183 valign=top style='width:137.55pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:64.1pt'>
<p class=AmmCorpsTexte align=left style='margin-left:9.3pt;text-align:left'>Troubles<span style='letter-spacing:-.65pt'> </span>généraux<span style='letter-spacing: -.35pt'> </span>et ano<span style='letter-spacing:-.1pt'>m</span>alies<span style='letter-spacing:-.15pt'> </span>au<span style='letter-spacing:-.1pt'> </span>site d’ad<span style='letter-spacing:-.1pt'>m</span>inistration</p>
</td>
<td width=171 valign=top style='width:128.1pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:64.1pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:7.65pt;margin-bottom:.0001pt;text-align:left'>Asthénie<span style='letter-spacing:-.65pt'> </span>(sévère<span style='letter-spacing: -.3pt'> </span>:</p>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:7.65pt;margin-bottom:.0001pt;text-align:left'>8,1<span style='letter-spacing:-.05pt'>%</span>);</p>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:7.65pt;margin-bottom:.0001pt;text-align:left'>Rétention<span style='letter-spacing:-.65pt'> </span>h<span style='letter-spacing:.1pt'>y</span>drique (sévère: 1.2%); </p>
<p class=AmmCorpsTexte align=left style='margin-left:7.6pt;text-align:left'>Douleurs</p>
</td>
<td width=151 valign=top style='width:4.0cm;border-top:none;border-left:none;
border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0cm 0cm 0cm 0cm;
height:64.1pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.95pt;text-align:left'>Réactions<span style='letter-spacing:-.7pt'> </span>au<span style='letter-spacing:-.1pt'> </span>site d’injection</p>
</td>
<td width=138 valign=top style='width:103.65pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:64.1pt'>
<p class=AmmCorpsTexte align=left style='margin-left:11.4pt;text-align:left'> </p>
</td>
</tr>
<tr style='height:64.1pt'>
<td width=183 valign=top style='width:137.55pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:64.1pt'>
<p class=AmmCorpsTexte align=left style='margin-left:9.3pt;text-align:left'>Investigations</p>
</td>
<td width=171 valign=top style='width:128.1pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:64.1pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.6pt;text-align:left'> </p>
</td>
<td width=151 valign=top style='width:4.0cm;border-top:none;border-left:none;
border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0cm 0cm 0cm 0cm;
height:64.1pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.95pt;text-align:left'>Aug<span style='letter-spacing:-.1pt'>m</span>entation<span style='letter-spacing: -.15pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la bilirubine<span style='letter-spacing:-.35pt'> </span>(G3/4&lt;2,5%); Aug<span style='letter-spacing:-.1pt'>m</span>entation<span style='letter-spacing: .05pt'> </span>des phosphatases alcalines (G3/4&lt;2,5<span style='letter-spacing: -.05pt'>%</span>)</p>
</td>
<td width=138 valign=top style='width:103.65pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:64.1pt'>
<p class=AmmCorpsTexte align=left style='margin-left:11.4pt;text-align:left'>Aug<span style='letter-spacing:-.1pt'>m</span>entation<span style='letter-spacing: -.15pt'> </span>des ASAT (G3/4&lt;1<span style='letter-spacing:-.05pt'>%</span>); Aug<span style='letter-spacing:-.1pt'>m</span>entation<span style='letter-spacing: .05pt'> </span>des ALAT (G3/4&lt;1<span style='letter-spacing:-.05pt'>%</span>)</p>
</td>
</tr>
</table>
</div>
<p class=AmmCorpsTexte style='margin-top:6.0pt;page-break-after:avoid'><b>Tableau des effets indésirables dans le cancer du sein pour docétaxel 75 <span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.1pt'>m</span>² en association avec le cisplatine</b></p>
<table class=AmmCorpsTexteTable border=0 cellspacing=0 cellpadding=0
style='margin-left:.25pt;border-collapse:collapse'>
<tr style='height:52.1pt'>
<td width=160 valign=top style='width:120.0pt;border:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:52.1pt'>
<p class=AmmCorpsTexte style='margin-left:7.1pt;page-break-after:avoid'><b>Base de données MeDRA des classes de système d’organe</b></p>
</td>
<td width=153 valign=top style='width:115.05pt;border:solid black 1.0pt;
border-left:none;padding:0cm 0cm 0cm 0cm;height:52.1pt'>
<p class=AmmCorpsTexte style='margin-left:7.6pt;page-break-after:avoid'><b>Très<span style='letter-spacing:-.45pt'> </span>fréquent</b></p>
</td>
<td width=153 valign=top style='width:115.05pt;border:solid black 1.0pt;
border-left:none;padding:0cm 0cm 0cm 0cm;height:52.1pt'>
<p class=AmmCorpsTexte style='margin-left:5.95pt;page-break-after:avoid'><b>Fréquent</b></p>
</td>
<td width=153 valign=top style='width:115.05pt;border:solid black 1.0pt;
border-left:none;padding:0cm 0cm 0cm 0cm;height:52.1pt'>
<p class=AmmCorpsTexte style='margin-left:4.3pt;page-break-after:avoid'><b>Peu<span style='letter-spacing:-.45pt'> </span>fréquent</b></p>
</td>
</tr>
<tr style='height:13.2pt'>
<td width=160 valign=top style='width:120.0pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:13.2pt'>
<p class=AmmCorpsTexte style='margin-left:7.1pt;page-break-after:avoid'>Infections<span style='letter-spacing:-.7pt'> </span>et infestations</p>
</td>
<td width=153 valign=top style='width:115.05pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:13.2pt'>
<p class=AmmCorpsTexte style='margin-left:7.6pt;page-break-after:avoid'>Infection<span style='letter-spacing:-.6pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>5,7<span style='letter-spacing:-.05pt'>%</span>)</p>
</td>
<td width=153 valign=top style='width:115.05pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:13.2pt'>
<p class=AmmCorpsTexte> </p>
</td>
<td width=153 valign=top style='width:115.05pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:13.2pt'>
<p class=AmmCorpsTexte> </p>
</td>
</tr>
<tr style='height:64.1pt'>
<td width=160 valign=top style='width:120.0pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:64.1pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.1pt;text-align:left; page-break-after:avoid'>Affections hé<span style='letter-spacing:-.1pt'>m</span>atologiques<span style='letter-spacing:-.35pt'> </span>et du s<span style='letter-spacing: .1pt'>y</span>stè<span style='letter-spacing:-.1pt'>m</span>e l<span style='letter-spacing:.1pt'>y</span><span style='letter-spacing:-.1pt'>m</span>phatique</p>
</td>
<td width=153 valign=top style='width:115.05pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:64.1pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:7.65pt;margin-bottom:.0001pt;text-align:left; page-break-after:avoid'>Neutropénie<span style='letter-spacing:-.8pt'> </span>(G4:</p>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:7.65pt;margin-bottom:.0001pt;text-align:left; page-break-after:avoid'>51,5<span style='letter-spacing:-.05pt'>%</span>);<span style='letter-spacing:-.2pt'> </span>Ané<span style='letter-spacing:-.1pt'>m</span>ie<span style='letter-spacing:-.15pt'> </span>(G3/4:</p>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:7.65pt;margin-bottom:.0001pt;text-align:left; page-break-after:avoid'>6,9<span style='letter-spacing:-.05pt'>%</span>); </p>
<p class=AmmCorpsTexte align=left style='margin-left:7.6pt;text-align:left; page-break-after:avoid'>Thro<span style='letter-spacing:-.1pt'>m</span>bopénie (G4:0,5<span style='letter-spacing:-.05pt'>%</span>)</p>
</td>
<td width=153 valign=top style='width:115.05pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:64.1pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.95pt;text-align:left; page-break-after:avoid'>Neutropénie<span style='letter-spacing:-.8pt'> </span>fébrile</p>
</td>
<td width=153 valign=top style='width:115.05pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:64.1pt'>
<p class=AmmCorpsTexte align=left style='text-align:left;page-break-after: avoid'> </p>
</td>
</tr>
<tr style='height:25.9pt'>
<td width=160 valign=top style='width:120.0pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:25.9pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.1pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span>du<span style='letter-spacing:-.1pt'> </span>s<span style='letter-spacing:.1pt'>y</span>stè<span style='letter-spacing:-.1pt'>m</span>e i<span style='letter-spacing:-.1pt'>mm</span>unitaire</p>
</td>
<td width=153 valign=top style='width:115.05pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:25.9pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:7.65pt;margin-bottom:.0001pt;text-align:left'>H<span style='letter-spacing:.1pt'>y</span>persensibilité<span style='letter-spacing: -.05pt'> </span>(G3/4:</p>
<p class=AmmCorpsTexte align=left style='margin-left:7.6pt;text-align:left'>2,5<span style='letter-spacing:-.05pt'>%</span>)</p>
</td>
<td width=153 valign=top style='width:115.05pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:25.9pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.95pt;text-align:left'> </p>
</td>
<td width=153 valign=top style='width:115.05pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:25.9pt'>
<p class=AmmCorpsTexte align=left style='text-align:left'> </p>
</td>
</tr>
<tr style='height:38.65pt'>
<td width=160 valign=top style='width:120.0pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:38.65pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.1pt;text-align:left'>Troubles<span style='letter-spacing:-.6pt'> </span>du <span style='letter-spacing:-.1pt'>m</span>étabolis<span style='letter-spacing:-.05pt'>m</span>e<span style='letter-spacing:-.25pt'> </span>et de<span style='letter-spacing:-.1pt'> </span>la nutrition</p>
</td>
<td width=153 valign=top style='width:115.05pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:38.65pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.6pt;text-align:left'>Anorexie</p>
</td>
<td width=153 valign=top style='width:115.05pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:38.65pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.95pt;text-align:left'> </p>
</td>
<td width=153 valign=top style='width:115.05pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:38.65pt'>
<p class=AmmCorpsTexte align=left style='text-align:left'> </p>
</td>
</tr>
<tr style='height:76.8pt'>
<td width=160 valign=top style='width:120.0pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:76.8pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.1pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span>du<span style='letter-spacing:-.1pt'> </span>s<span style='letter-spacing:.1pt'>y</span>stè<span style='letter-spacing:-.1pt'>m</span>e nerveux</p>
</td>
<td width=153 valign=top style='width:115.05pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:76.8pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:7.65pt;margin-bottom:.0001pt;text-align:left'>Neuropathie<span style='letter-spacing:-.8pt'> </span>sensitive périphérique<span style='letter-spacing:.05pt'> </span>(G3:</p>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:7.65pt;margin-bottom:.0001pt;text-align:left'>3,7<span style='letter-spacing:-.05pt'>%</span>);</p>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:7.65pt;margin-bottom:.0001pt;text-align:left'>Neuropathie<span style='letter-spacing:-.8pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>o</span>trice périphérique<span style='letter-spacing:-.45pt'> </span>(G3/4:</p>
<p class=AmmCorpsTexte align=left style='margin-left:7.6pt;text-align:left'>2<span style='letter-spacing:-.05pt'>%</span>)</p>
</td>
<td width=153 valign=top style='width:115.05pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:76.8pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.95pt;text-align:left'> </p>
</td>
<td width=153 valign=top style='width:115.05pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:76.8pt'>
<p class=AmmCorpsTexte align=left style='text-align:left'> </p>
</td>
</tr>
<tr style='height:13.2pt'>
<td width=160 valign=top style='width:120.0pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:13.2pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.1pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span>cardiaques</p>
</td>
<td width=153 valign=top style='width:115.05pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:13.2pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.6pt;text-align:left'> </p>
</td>
<td width=153 valign=top style='width:115.05pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:13.2pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.95pt;text-align:left'>Ar<span style='letter-spacing:.1pt'>y</span>th<span style='letter-spacing:-.1pt'>m</span>ie<span style='letter-spacing:-.15pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>0,7<span style='letter-spacing:-.05pt'>%</span>)</p>
</td>
<td width=153 valign=top style='width:115.05pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:13.2pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.3pt;text-align:left'>Insuffisance<span style='letter-spacing:-.8pt'> </span>cardiaque</p>
</td>
</tr>
<tr style='height:25.9pt'>
<td width=160 valign=top style='width:120.0pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:25.9pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.1pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span>vasculaires</p>
</td>
<td width=153 valign=top style='width:115.05pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:25.9pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.6pt;text-align:left'> </p>
</td>
<td width=153 valign=top style='width:115.05pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:25.9pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:5.95pt;margin-bottom:.0001pt;text-align:left'>H<span style='letter-spacing:.1pt'>y</span>potension<span style='letter-spacing: -.1pt'> </span>(G3/4:</p>
<p class=AmmCorpsTexte align=left style='margin-left:5.95pt;text-align:left'>0,7<span style='letter-spacing:-.05pt'>%</span>)</p>
</td>
<td width=153 valign=top style='width:115.05pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:25.9pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.3pt;text-align:left'> </p>
</td>
</tr>
<tr style='height:76.4pt'>
<td width=160 valign=top style='width:120.0pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:76.4pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.1pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span>gastro- intestinales</p>
</td>
<td width=153 valign=top style='width:115.05pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:76.4pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:7.65pt;margin-bottom:.0001pt;text-align:left'>Nausées<span style='letter-spacing:-.6pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>9,6%); Vo<span style='letter-spacing:-.1pt'>m</span>isse<span style='letter-spacing:-.1pt'>m</span>ents<span style='letter-spacing:-.1pt'> </span>(G3/4:</p>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:7.65pt;margin-bottom:.0001pt;text-align:left'>7,6<span style='letter-spacing:-.05pt'>%</span>);<span style='letter-spacing:-.15pt'> </span></p>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:7.65pt;margin-bottom:.0001pt;text-align:left'>Diarrhée<span style='letter-spacing:-.35pt'> </span>(G3/4:</p>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:7.65pt;margin-bottom:.0001pt;text-align:left'>6,4<span style='letter-spacing:-.4pt'> </span>%);<span style='letter-spacing:-.15pt'> </span></p>
<p class=AmmCorpsTexte align=left style='margin-left:7.6pt;text-align:left'>Sto<span style='letter-spacing:-.1pt'>m</span>atite (G3/4:<span style='letter-spacing: -.55pt'> </span>2<span style='letter-spacing:-.05pt'>%</span>)</p>
</td>
<td width=153 valign=top style='width:115.05pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:76.4pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.95pt;text-align:left'>Constipation</p>
</td>
<td width=153 valign=top style='width:115.05pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:76.4pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.3pt;text-align:left'> </p>
</td>
</tr>
<tr style='height:64.1pt'>
<td width=160 valign=top style='width:120.0pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:64.1pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.1pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la peau<span style='letter-spacing:-.2pt'> </span>et du<span style='letter-spacing: -.1pt'> </span>tissu<span style='letter-spacing:-.2pt'> </span>sous-cutané</p>
</td>
<td width=153 valign=top style='width:115.05pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:64.1pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:7.65pt;margin-bottom:.0001pt;text-align:left'>Alopécie;</p>
<p class=AmmCorpsTexte align=left style='margin-left:7.6pt;text-align:left'>Altération<span style='letter-spacing:-.7pt'> </span>des<span style='letter-spacing:-.15pt'> </span>ongles (sévère : 0,7%); Réactions cutanées (G3/4:<span style='letter-spacing:.05pt'> </span>0,2<span style='letter-spacing:-.05pt'>%</span>)</p>
</td>
<td width=153 valign=top style='width:115.05pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:64.1pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.95pt;text-align:left'> </p>
</td>
<td width=153 valign=top style='width:115.05pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:64.1pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.3pt;text-align:left'> </p>
</td>
</tr>
<tr style='height:38.65pt'>
<td width=160 valign=top style='width:120.0pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:38.65pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.1pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>u</span>sculo- squelettiques et s<span style='letter-spacing:.1pt'>y</span>sté<span style='letter-spacing:-.1pt'>m</span>iques</p>
</td>
<td width=153 valign=top style='width:115.05pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:38.65pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.6pt;text-align:left'>M<span style='letter-spacing:.1pt'>y</span>algie<span style='letter-spacing:-.1pt'> </span>(sévère:<span style='letter-spacing:-.3pt'> </span>0,5%)</p>
</td>
<td width=153 valign=top style='width:115.05pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:38.65pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.95pt;text-align:left'> </p>
</td>
<td width=153 valign=top style='width:115.05pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:38.65pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.3pt;text-align:left'> </p>
</td>
</tr>
<tr style='height:64.1pt'>
<td width=160 valign=top style='width:120.0pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:64.1pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.1pt;text-align:left'>Troubles<span style='letter-spacing:-.65pt'> </span>généraux<span style='letter-spacing: -.35pt'> </span>et ano<span style='letter-spacing:-.1pt'>m</span>alies<span style='letter-spacing:-.15pt'> </span>au<span style='letter-spacing:-.1pt'> </span>site d’ad<span style='letter-spacing:-.1pt'>m</span>inistration</p>
</td>
<td width=153 valign=top style='width:115.05pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:64.1pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:7.65pt;margin-bottom:.0001pt;text-align:left'>Asthénie<span style='letter-spacing:-.65pt'> </span>(sévère<span style='letter-spacing: -.3pt'> </span>:</p>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:7.65pt;margin-bottom:.0001pt;text-align:left'>9,9<span style='letter-spacing:-.05pt'>%</span>);</p>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:7.65pt;margin-bottom:.0001pt;text-align:left'>Rétention<span style='letter-spacing:-.65pt'> </span>h<span style='letter-spacing:.1pt'>y</span>drique (sévère: 0,7%);<span style='letter-spacing:-.25pt'> </span></p>
<p class=AmmCorpsTexte align=left style='margin-left:7.6pt;text-align:left'>Fièvre (G3/4:<span style='letter-spacing:-.25pt'> </span>1,2<span style='letter-spacing: -.05pt'>%</span>)</p>
</td>
<td width=153 valign=top style='width:115.05pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:64.1pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.95pt;text-align:left'>Réactions<span style='letter-spacing:-.7pt'> </span>au<span style='letter-spacing:-.1pt'> </span>site d’injection; Douleurs</p>
</td>
<td width=153 valign=top style='width:115.05pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:64.1pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.3pt;text-align:left'> </p>
</td>
</tr>
<tr style='height:64.1pt'>
<td width=160 valign=top style='width:120.0pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:64.1pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.1pt;text-align:left'>Investigations</p>
</td>
<td width=153 valign=top style='width:115.05pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:64.1pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.6pt;text-align:left'> </p>
</td>
<td width=153 valign=top style='width:115.05pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:64.1pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.95pt;text-align:left'>Aug<span style='letter-spacing:-.1pt'>m</span>entation<span style='letter-spacing: -.15pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la bilirubine<span style='letter-spacing:-.35pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>2,1%); Aug<span style='letter-spacing:-.1pt'>m</span>entation<span style='letter-spacing:.05pt'> </span>des<span style='letter-spacing:-.15pt'> </span>ALAT (G3/4<span style='letter-spacing:-.25pt'> </span>: 1,3<span style='letter-spacing: -.05pt'>%</span>)</p>
</td>
<td width=153 valign=top style='width:115.05pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:64.1pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.3pt;text-align:left'>Aug<span style='letter-spacing:-.1pt'>m</span>entation<span style='letter-spacing: -.15pt'> </span>des ASAT (G3/4<span style='letter-spacing:-.25pt'> </span>: 0,5<span style='letter-spacing:-.05pt'>%</span>); Aug<span style='letter-spacing: -.1pt'>m</span>entation<span style='letter-spacing:.05pt'> </span>des phosphatases alcalines (G3/4 :<span style='letter-spacing:.05pt'> </span>0,3<span style='letter-spacing:-.05pt'>%</span>)</p>
</td>
</tr>
</table>
<p class=AmmCorpsTexte style='margin-top:6.0pt;page-break-after:avoid'><b>Tableau des effets indésirables dans le cancer du sein pour docétaxel<sub> 100 <span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.1pt'>m</span>² en association avec le trastuzu<span style='letter-spacing:-.05pt'>m</span>ab</sub></b></p>
<div align=center>
<table class=AmmCorpsTexteTable border=0 cellspacing=0 cellpadding=0
style='margin-left:-11.3pt;border-collapse:collapse'>
<tr style='height:39.2pt'>
<td width=226 valign=top style='width:169.8pt;border:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:39.2pt'>
<p class=AmmCorpsTexte style='margin-left:5.95pt;page-break-after:avoid'><b>Base<span style='letter-spacing:-.45pt'> </span>de<span style='letter-spacing:-.1pt'> </span>données<span style='letter-spacing:-.35pt'> </span>MeDRA<span style='letter-spacing:-.35pt'> </span>des classes de<span style='letter-spacing:-.1pt'> </span>système<span style='letter-spacing:-.35pt'> </span>d’organe</b></p>
</td>
<td width=205 valign=top style='width:153.45pt;border:solid black 1.0pt;
border-left:none;padding:0cm 0cm 0cm 0cm;height:39.2pt'>
<p class=AmmCorpsTexte style='margin-left:6.25pt;page-break-after:avoid'><b>Très<span style='letter-spacing:-.45pt'> </span>fréquent</b></p>
</td>
<td width=205 valign=top style='width:153.45pt;border:solid black 1.0pt;
border-left:none;padding:0cm 0cm 0cm 0cm;height:39.2pt'>
<p class=AmmCorpsTexte style='margin-left:8.7pt;page-break-after:avoid'><b>Fréquent</b></p>
</td>
</tr>
<tr style='height:76.8pt'>
<td width=226 valign=top style='width:169.8pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:76.8pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.95pt;text-align:left; page-break-after:avoid'>Affections<span style='letter-spacing:-.7pt'> </span>hé<span style='letter-spacing:-.1pt'>m</span>atologiques<span style='letter-spacing: -.5pt'> </span>et du s<span style='letter-spacing:.1pt'>y</span>stè<span style='letter-spacing:-.1pt'>m</span>e l<span style='letter-spacing:.1pt'>y</span><span style='letter-spacing:-.1pt'>m</span>phatique</p>
</td>
<td width=205 valign=top style='width:153.45pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:76.8pt'>
<p class=AmmCorpsTexte align=left style='margin-left:6.25pt;text-align:left; page-break-after:avoid'>Neutropénie<span style='letter-spacing:-.75pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>32<span style='letter-spacing:-.05pt'>%</span>); Neutropénie fébrile<span style='letter-spacing:-.25pt'> </span>(incluant<span style='letter-spacing:-.35pt'> </span>la neutropénie<span style='letter-spacing: -.45pt'> </span>associée<span style='letter-spacing:-.35pt'> </span>à de<span style='letter-spacing:-.1pt'> </span>la fièvre et à l’utilisation<span style='letter-spacing:-.45pt'> </span>d’antibiotiques)<span style='letter-spacing: .05pt'> </span>ou neutropénie<span style='letter-spacing:-.45pt'> </span>avec sepsis</p>
</td>
<td width=205 valign=top style='width:153.45pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:76.8pt'>
<p class=AmmCorpsTexte align=left style='margin-left:8.7pt;text-align:left; page-break-after:avoid'> </p>
</td>
</tr>
<tr style='height:25.9pt'>
<td width=226 valign=top style='width:169.8pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:25.9pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.95pt;text-align:left'>Troubles<span style='letter-spacing:-.65pt'> </span>du<span style='letter-spacing:-.1pt'> m</span>étabolis<span style='letter-spacing:-.05pt'>m</span>e<span style='letter-spacing:-.35pt'> </span>et de<span style='letter-spacing:-.1pt'> </span>la nutrition</p>
</td>
<td width=205 valign=top style='width:153.45pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:25.9pt'>
<p class=AmmCorpsTexte align=left style='margin-left:6.25pt;text-align:left'>Anorexie</p>
</td>
<td width=205 valign=top style='width:153.45pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:25.9pt'>
<p class=AmmCorpsTexte align=left style='margin-left:8.7pt;text-align:left'> </p>
</td>
</tr>
<tr style='height:18.0pt'>
<td width=226 valign=top style='width:169.8pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:18.0pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.95pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span>ps<span style='letter-spacing:.1pt'>y</span>chiatriques</p>
</td>
<td width=205 valign=top style='width:153.45pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:18.0pt'>
<p class=AmmCorpsTexte align=left style='margin-left:6.25pt;text-align:left'>Inso<span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>n</span>ie</p>
</td>
<td width=205 valign=top style='width:153.45pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:18.0pt'>
<p class=AmmCorpsTexte align=left style='margin-left:8.7pt;text-align:left'> </p>
</td>
</tr>
<tr style='height:28.2pt'>
<td width=226 valign=top style='width:169.8pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:28.2pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.95pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span>du<span style='letter-spacing:-.1pt'> </span>s<span style='letter-spacing:.1pt'>y</span>stè<span style='letter-spacing:-.1pt'>m</span>e<span style='letter-spacing:-.05pt'> </span>nerveux</p>
</td>
<td width=205 valign=top style='width:153.45pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:28.2pt'>
<p class=AmmCorpsTexte align=left style='margin-left:6.25pt;text-align:left'>Paresthésie;<span style='letter-spacing:-.75pt'> </span>Céphalée; D<span style='letter-spacing: .1pt'>y</span>sgueusie; H<span style='letter-spacing:.1pt'>y</span>poesthésie</p>
</td>
<td width=205 valign=top style='width:153.45pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:28.2pt'>
<p class=AmmCorpsTexte align=left style='margin-left:8.7pt;text-align:left'> </p>
</td>
</tr>
<tr style='height:25.9pt'>
<td width=226 valign=top style='width:169.8pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:25.9pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.95pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span>oculaires</p>
</td>
<td width=205 valign=top style='width:153.45pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:25.9pt'>
<p class=AmmCorpsTexte align=left style='margin-left:6.25pt;text-align:left'>Aug<span style='letter-spacing:-.1pt'>m</span>entation<span style='letter-spacing: -.15pt'> </span>du<span style='letter-spacing:-.1pt'> </span>lar<span style='letter-spacing:-.05pt'>m</span>oie<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.1pt'> </span>; Conjonctivite</p>
</td>
<td width=205 valign=top style='width:153.45pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:25.9pt'>
<p class=AmmCorpsTexte align=left style='margin-left:8.7pt;text-align:left'> </p>
</td>
</tr>
<tr style='height:16.2pt'>
<td width=226 valign=top style='width:169.8pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:16.2pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.95pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span>cardiaques</p>
</td>
<td width=205 valign=top style='width:153.45pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:16.2pt'>
<p class=AmmCorpsTexte align=left style='margin-left:6.25pt;text-align:left'> </p>
</td>
<td width=205 valign=top style='width:153.45pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:16.2pt'>
<p class=AmmCorpsTexte align=left style='margin-left:8.7pt;text-align:left'>Insuffisance<span style='letter-spacing:-.8pt'> </span>cardiaque</p>
</td>
</tr>
<tr style='height:20.7pt'>
<td width=226 valign=top style='width:169.8pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:20.7pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.95pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span>vasculaires</p>
</td>
<td width=205 valign=top style='width:153.45pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:20.7pt'>
<p class=AmmCorpsTexte align=left style='margin-left:6.25pt;text-align:left'>L<span style='letter-spacing:.1pt'>y</span><span style='letter-spacing:-.1pt'>m</span>phoedè<span style='letter-spacing:-.05pt'>m</span>e</p>
</td>
<td width=205 valign=top style='width:153.45pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:20.7pt'>
<p class=AmmCorpsTexte align=left style='margin-left:8.7pt;text-align:left'> </p>
</td>
</tr>
<tr style='height:51.35pt'>
<td width=226 valign=top style='width:169.8pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:51.35pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.95pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span>respiratoires, thoraciques et <span style='letter-spacing:-.1pt'>m</span>édiastinales</p>
</td>
<td width=205 valign=top style='width:153.45pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:51.35pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:6.25pt;margin-bottom:.0001pt;text-align:left'>Epistaxis;<span style='letter-spacing:-.65pt'> </span>Douleurs<span style='letter-spacing: -.35pt'> </span>phar<span style='letter-spacing:.1pt'>y</span>ngo- lar<span style='letter-spacing:.1pt'>y</span>ngée;<span style='letter-spacing:.05pt'> </span>Rhinophar<span style='letter-spacing:.1pt'>y</span>ngite; D<span style='letter-spacing:.1pt'>y</span>spnée;</p>
<p class=AmmCorpsTexte align=left style='margin-left:6.25pt;text-align:left'>Toux;<span style='letter-spacing:-.5pt'> </span>Rhinorrhée</p>
</td>
<td width=205 valign=top style='width:153.45pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:51.35pt'>
<p class=AmmCorpsTexte align=left style='margin-left:8.7pt;text-align:left'> </p>
</td>
</tr>
<tr style='height:51.35pt'>
<td width=226 valign=top style='width:169.8pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:51.35pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.95pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span>gastro-intestinales</p>
</td>
<td width=205 valign=top style='width:153.45pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:51.35pt'>
<p class=AmmCorpsTexte align=left style='margin-left:6.25pt;text-align:left'>Nausées;<span style='letter-spacing:-.65pt'> </span>Diarrhée; Vo<span style='letter-spacing: -.1pt'>m</span>isse<span style='letter-spacing:-.1pt'>m</span>ents; Constipation; Sto<span style='letter-spacing:-.1pt'>m</span>atite;<span style='letter-spacing:.05pt'> </span>D<span style='letter-spacing:.1pt'>y</span>spepsie;<span style='letter-spacing:-.05pt'> </span>Douleurs abdo<span style='letter-spacing: -.1pt'>m</span>inales</p>
</td>
<td width=205 valign=top style='width:153.45pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:51.35pt'>
<p class=AmmCorpsTexte align=left style='margin-left:8.7pt;text-align:left'> </p>
</td>
</tr>
<tr style='height:31.7pt'>
<td width=226 valign=top style='width:169.8pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:31.7pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.95pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la peau<span style='letter-spacing:-.2pt'> </span>et du<span style='letter-spacing: -.1pt'> </span>tissu sous-cutané</p>
</td>
<td width=205 valign=top style='width:153.45pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:31.7pt'>
<p class=AmmCorpsTexte align=left style='margin-left:6.25pt;text-align:left'>Alopécie;<span style='letter-spacing:-.7pt'> </span>Er<span style='letter-spacing:.1pt'>y</span>thè<span style='letter-spacing:-.1pt'>m</span>e;<span style='letter-spacing:-.2pt'> </span>Rash; Altération des<span style='letter-spacing:-.15pt'> </span>ongles</p>
</td>
<td width=205 valign=top style='width:153.45pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:31.7pt'>
<p class=AmmCorpsTexte align=left style='margin-left:8.7pt;text-align:left'> </p>
</td>
</tr>
<tr style='height:38.65pt'>
<td width=226 valign=top style='width:169.8pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:38.65pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.95pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>u</span>sculo- squelettiques et s<span style='letter-spacing:.1pt'>y</span>sté<span style='letter-spacing:-.1pt'>m</span>iques</p>
</td>
<td width=205 valign=top style='width:153.45pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:38.65pt'>
<p class=AmmCorpsTexte align=left style='margin-left:6.25pt;text-align:left'>M<span style='letter-spacing:.1pt'>y</span>algie;<span style='letter-spacing:-.1pt'> </span>Arthralgie;<span style='letter-spacing:-.45pt'> </span>Douleurs des extré<span style='letter-spacing:-.05pt'>m</span>ités;<span style='letter-spacing: -.2pt'> </span>Douleurs osseuses, Douleurs<span style='letter-spacing:-.35pt'> </span>dorsales</p>
</td>
<td width=205 valign=top style='width:153.45pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:38.65pt'>
<p class=AmmCorpsTexte align=left style='margin-left:8.7pt;text-align:left'> </p>
</td>
</tr>
<tr style='height:64.1pt'>
<td width=226 valign=top style='width:169.8pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:64.1pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.95pt;text-align:left'>Troubles<span style='letter-spacing:-.65pt'> </span>généraux<span style='letter-spacing: -.35pt'> </span>et ano<span style='letter-spacing:-.1pt'>m</span>alies<span style='letter-spacing:-.15pt'> </span>au site d<span style='letter-spacing: .05pt'>’</span>ad<span style='letter-spacing:-.1pt'>m</span>inistration</p>
</td>
<td width=205 valign=top style='width:153.45pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:64.1pt'>
<p class=AmmCorpsTexte align=left style='margin-left:6.25pt;text-align:left'>Asthénie;<span style='letter-spacing:-.65pt'> </span>Œdè<span style='letter-spacing:-.1pt'>m</span>e<span style='letter-spacing:-.2pt'> </span>périphérique; Fièvre; Fatigue;<span style='letter-spacing:-.35pt'> </span>Infla<span style='letter-spacing:-.05pt'>m</span><span style='letter-spacing:-.1pt'>m</span>ation<span style='letter-spacing:-.35pt'> </span>des <span style='letter-spacing:-.1pt'>m</span>uqueuses;<span style='letter-spacing:-.1pt'> </span>Douleurs;<span style='letter-spacing: -.4pt'> </span>s<span style='letter-spacing:.1pt'>y</span>ndro<span style='letter-spacing:-.1pt'>m</span>e pseudo-grippal;<span style='letter-spacing: -.65pt'> </span>Douleur thoracique;<span style='letter-spacing:-.4pt'> </span>Frissons</p>
</td>
<td width=205 valign=top style='width:153.45pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:64.1pt'>
<p class=AmmCorpsTexte align=left style='margin-left:8.7pt;text-align:left'>Léthargie</p>
</td>
</tr>
<tr style='height:18.0pt'>
<td width=226 valign=top style='width:169.8pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:18.0pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.95pt;text-align:left'>Investigations</p>
</td>
<td width=205 valign=top style='width:153.45pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:18.0pt'>
<p class=AmmCorpsTexte align=left style='margin-left:6.25pt;text-align:left'>Aug<span style='letter-spacing:-.1pt'>m</span>entation<span style='letter-spacing: -.15pt'> </span>du<span style='letter-spacing:-.1pt'> </span>poids</p>
</td>
<td width=205 valign=top style='width:153.45pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:18.0pt'>
<p class=AmmCorpsTexte align=left style='margin-left:8.7pt;text-align:left'> </p>
</td>
</tr>
</table>
</div>
<p class=AmmCorpsTexte style='margin-top:6.0pt;line-height:10.0pt;text-autospace: none'><b><span style='font-size:10.0pt;font-family:Arial'>Description de certains effets indésirables dans le cancer du sein pour docetaxel 100 mg/m² en association avec le trastuzumab</span></b></p>
<p class=AmmCorpsTexte style='margin-top:6.0pt'><u>Affections hématologiques et du système lymphatique</u><span style='letter-spacing:-.05pt'> </span>:</p>
<p class=AmmCorpsTexte>Très<span style='letter-spacing:-.45pt'> </span>fréquent<span style='letter-spacing:-.35pt'> </span>: la toxicité<span style='letter-spacing: -.3pt'> </span>hé<span style='letter-spacing:-.1pt'>m</span>atologique<span style='letter-spacing:-.45pt'> </span>a été plus<span style='letter-spacing: -.15pt'> </span>élevée<span style='letter-spacing:-.25pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>patientes<span style='letter-spacing:-.35pt'> </span>recevant<span style='letter-spacing:-.35pt'> </span>du<span style='letter-spacing:-.1pt'> </span>trastuzu<span style='letter-spacing:-.05pt'>m</span>ab<span style='letter-spacing:-.3pt'> </span>et du docétaxel<span style='letter-spacing:-.4pt'> </span>que<span style='letter-spacing:-.15pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>celles recevant<span style='letter-spacing:-.35pt'> </span>du<span style='letter-spacing: -.1pt'> </span>docétaxel<span style='letter-spacing:-.4pt'> </span>seul<span style='letter-spacing:-.15pt'> </span>(neutropénie<span style='letter-spacing: -.45pt'> </span>G<span style='letter-spacing:-.05pt'> </span>3/4<span style='letter-spacing:-.15pt'> </span>: 32%<span style='letter-spacing:-.2pt'> </span>vs.22%,<span style='letter-spacing:-.3pt'> </span>selon<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>critères NCI-CTC).<span style='letter-spacing: -.45pt'> </span>Il<span style='letter-spacing:-.05pt'> </span>est<span style='letter-spacing:-.1pt'> </span>possible<span style='letter-spacing:-.35pt'> </span>que<span style='letter-spacing:-.15pt'> </span>ces<span style='letter-spacing:-.15pt'> </span>chiffres<span style='letter-spacing:-.3pt'> </span>soient<span style='letter-spacing:-.25pt'> </span>sous-esti<span style='letter-spacing:-.1pt'>m</span>és<span style='letter-spacing:-.35pt'> </span>puisque<span style='letter-spacing:-.3pt'> </span>selon<span style='letter-spacing:-.2pt'> </span>la for<span style='letter-spacing:-.1pt'>m</span>ule<span style='letter-spacing: -.1pt'> </span>sanguine au<span style='letter-spacing:-.1pt'> </span>nadir,<span style='letter-spacing:-.25pt'> </span>le docétaxel<span style='letter-spacing: -.35pt'> </span>en<span style='letter-spacing:-.1pt'> m</span>onothérap<span style='letter-spacing:-.05pt'>i</span>e<span style='letter-spacing:-.1pt'> </span>à la dose<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing: -.1pt'> </span>100<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.1pt'>m</span>²<span style='letter-spacing:-.1pt'> </span>est<span style='letter-spacing:-.1pt'> </span>connu<span style='letter-spacing:-.25pt'> </span>pour<span style='letter-spacing:-.2pt'> </span>provoquer<span style='letter-spacing:-.4pt'> </span>une<span style='letter-spacing:-.15pt'> </span>neutropénie<span style='letter-spacing:.05pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>97%<span style='letter-spacing:-.2pt'> </span>des patients,<span style='letter-spacing: -.35pt'> </span>76%<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span>gra<span style='letter-spacing:.05pt'>d</span>e<span style='letter-spacing:-.15pt'> </span>4.<span style='letter-spacing:-.05pt'> </span>L’incidence<span style='letter-spacing:-.45pt'> </span>des<span style='letter-spacing:-.15pt'> </span>neutropénies<span style='letter-spacing:-.5pt'> </span>fébriles/neutropénie<span style='letter-spacing:-.75pt'> </span>avec<span style='letter-spacing:-.2pt'> </span>sepsis<span style='letter-spacing:-.25pt'> </span>était égale<span style='letter-spacing: -.05pt'>m</span>ent<span style='letter-spacing:-.2pt'> </span>aug<span style='letter-spacing:-.1pt'>m</span>entée<span style='letter-spacing:-.15pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>patientes<span style='letter-spacing:-.35pt'> </span>traitées<span style='letter-spacing:-.3pt'> </span>par<span style='letter-spacing:-.15pt'> </span>le trastuzu<span style='letter-spacing:-.05pt'>m</span>ab<span style='letter-spacing:-.3pt'> </span>en association au<span style='letter-spacing:-.1pt'> </span>docétaxel<span style='letter-spacing:-.4pt'> </span>par<span style='letter-spacing:-.15pt'> </span>rapport<span style='letter-spacing:-.3pt'> </span>à celles traitées<span style='letter-spacing: -.3pt'> </span>par<span style='letter-spacing:-.15pt'> </span>le docétaxel<span style='letter-spacing:-.4pt'> </span>seul<span style='letter-spacing:-.15pt'> </span>(23%<span style='letter-spacing:-.2pt'> </span>vs.<span style='letter-spacing:-.1pt'> </span>17%).</p>
<p class=AmmCorpsTexte><u>Affections cardiaques</u> :</p>
<p class=AmmCorpsTexte>Une<span style='letter-spacing:-.45pt'> </span>insuffisance<span style='letter-spacing:-.5pt'> </span>cardiaque<span style='letter-spacing:-.4pt'> </span>s<span style='letter-spacing:.1pt'>y</span><span style='letter-spacing: -.1pt'>m</span><span style='letter-spacing:.05pt'>p</span>to<span style='letter-spacing:-.1pt'>m</span>atique<span style='letter-spacing:-.25pt'> </span>a été<span style='letter-spacing:.05pt'> </span>rapportée<span style='letter-spacing:-.4pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>2,2%<span style='letter-spacing:-.2pt'> </span>des<span style='letter-spacing:-.15pt'> </span>patientes<span style='letter-spacing:-.35pt'> </span>a<span style='letter-spacing:.1pt'>y</span>ant<span style='letter-spacing:-.05pt'> </span>reçu<span style='letter-spacing:-.15pt'> </span>du<span style='letter-spacing:-.1pt'> </span>docétaxel associé<span style='letter-spacing: -.3pt'> </span>au<span style='letter-spacing:-.1pt'> </span>trastuzu<span style='letter-spacing:-.05pt'>m</span>ab,<span style='letter-spacing:-.3pt'> </span>par<span style='letter-spacing:-.15pt'> </span>rapport<span style='letter-spacing:-.3pt'> </span>à 0%<span style='letter-spacing:-.2pt'> </span>des<span style='letter-spacing:-.15pt'> </span>patientes<span style='letter-spacing: -.35pt'> </span>a<span style='letter-spacing:.1pt'>y</span>ant<span style='letter-spacing:-.05pt'> </span>reçu<span style='letter-spacing:-.15pt'> </span>du<span style='letter-spacing:-.1pt'> </span>docétaxel<span style='letter-spacing:-.4pt'> </span>seul.<span style='letter-spacing:-.2pt'> </span>Dans le bras<span style='letter-spacing:-.15pt'> </span>docétaxel associé<span style='letter-spacing: -.3pt'> </span>au<span style='letter-spacing:-.1pt'> </span>trastuzu<span style='letter-spacing:-.05pt'>m</span>ab,<span style='letter-spacing:-.35pt'> </span>64%<span style='letter-spacing:-.2pt'> </span>des<span style='letter-spacing:-.15pt'> </span>patientes<span style='letter-spacing:-.35pt'> </span>avaient<span style='letter-spacing:-.3pt'> </span>reçu<span style='letter-spacing:-.15pt'> </span>auparavant<span style='letter-spacing:-.45pt'> </span>une<span style='letter-spacing:-.15pt'> </span>anthrac<span style='letter-spacing:.1pt'>y</span>cline en<span style='letter-spacing:-.1pt'> </span>traite<span style='letter-spacing:-.05pt'>m</span>ent adjuvant, par<span style='letter-spacing:-.15pt'> </span>rapport<span style='letter-spacing:-.3pt'> </span>à 55%<span style='letter-spacing:-.2pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>le bras<span style='letter-spacing:-.15pt'> </span>docétaxel<span style='letter-spacing:-.4pt'> </span>seul.</p>
<p class=AmmCorpsTexte><b>Tableau des effets indésirables dans le cancer du sein pour docétaxel 75 <span style='letter-spacing: -.1pt'>m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.1pt'>m</span>² en association avec la capécitabine</b></p>
<div align=center>
<table class=AmmCorpsTexteTable border=0 cellspacing=0 cellpadding=0
style='margin-left:5.15pt;border-collapse:collapse'>
<tr style='height:39.2pt'>
<td width=204 valign=top style='width:153.35pt;border:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:39.2pt'>
<p class=AmmCorpsTexte style='margin-left:9.3pt;page-break-after:avoid'><b>Base<span style='letter-spacing:-.45pt'> </span>de<span style='letter-spacing:-.1pt'> </span>données<span style='letter-spacing:-.35pt'> </span>MeDRA<span style='letter-spacing:-.35pt'> </span>des classes de<span style='letter-spacing:-.1pt'> </span>système<span style='letter-spacing:-.35pt'> </span>d’organe</b></p>
</td>
<td width=205 valign=top style='width:153.45pt;border:solid black 1.0pt;
border-left:none;padding:0cm 0cm 0cm 0cm;height:39.2pt'>
<p class=AmmCorpsTexte style='margin-left:4.8pt;page-break-after:avoid'><b>Très<span style='letter-spacing:-.45pt'> </span>fréquent</b></p>
</td>
<td width=235 valign=top style='width:175.9pt;border:solid black 1.0pt;
border-left:none;padding:0cm 0cm 0cm 0cm;height:39.2pt'>
<p class=AmmCorpsTexte style='margin-left:7.25pt;page-break-after:avoid'><b>Fréquent</b></p>
</td>
</tr>
<tr style='height:25.9pt'>
<td width=204 valign=top style='width:153.35pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:25.9pt'>
<p class=AmmCorpsTexte align=left style='margin-left:9.3pt;text-align:left'>Infections<span style='letter-spacing:-.7pt'> </span>et infestations</p>
</td>
<td width=205 valign=top style='width:153.45pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:25.9pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.8pt;text-align:left'> </p>
</td>
<td width=235 valign=top style='width:175.9pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:25.9pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.25pt;text-align:left'>Candidoses<span style='letter-spacing:-.75pt'> </span>buccales<span style='letter-spacing: -.35pt'> </span>(G3/4: &lt;1%)</p>
</td>
</tr>
<tr style='height:31.05pt'>
<td width=204 valign=top style='width:153.35pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:31.05pt'>
<p class=AmmCorpsTexte align=left style='margin-left:9.3pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span>hé<span style='letter-spacing:-.1pt'>m</span>atologiques<span style='letter-spacing:-.5pt'> </span>et du s<span style='letter-spacing:.1pt'>y</span>stè<span style='letter-spacing:-.1pt'>m</span>e l<span style='letter-spacing:.1pt'>y</span><span style='letter-spacing:-.1pt'>m</span>phatique</p>
</td>
<td width=205 valign=top style='width:153.45pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:31.05pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.8pt;text-align:left'>Neutropénie<span style='letter-spacing:-.75pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>63<span style='letter-spacing:-.05pt'>%</span>); Ané<span style='letter-spacing:-.1pt'>m</span>ie (G3/4:<span style='letter-spacing: -.25pt'> </span>10<span style='letter-spacing:-.05pt'>%</span>)</p>
</td>
<td width=235 valign=top style='width:175.9pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:31.05pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.25pt;text-align:left'>Thro<span style='letter-spacing:-.1pt'>m</span>bopénie<span style='letter-spacing:-.15pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>3<span style='letter-spacing:-.05pt'>%</span>)</p>
</td>
</tr>
<tr style='height:33.55pt'>
<td width=204 valign=top style='width:153.35pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:33.55pt'>
<p class=AmmCorpsTexte align=left style='margin-left:9.3pt;text-align:left'>Troubles<span style='letter-spacing:-.65pt'> </span>du<span style='letter-spacing:-.1pt'> m</span>étabolis<span style='letter-spacing:-.05pt'>m</span>e<span style='letter-spacing:-.35pt'> </span>et de<span style='letter-spacing:-.1pt'> </span>la nutrition</p>
</td>
<td width=205 valign=top style='width:153.45pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:33.55pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.8pt;text-align:left'>Anorexie<span style='letter-spacing:-.65pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>1<span style='letter-spacing:-.05pt'>%</span>); Di<span style='letter-spacing:-.1pt'>m</span>inution<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span>l’appétit</p>
</td>
<td width=235 valign=top style='width:175.9pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:33.55pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.25pt;text-align:left'>Désh<span style='letter-spacing:.1pt'>y</span><span style='letter-spacing:.05pt'>d</span>ratation<span style='letter-spacing:-.2pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>2<span style='letter-spacing:-.05pt'>%</span>)</p>
</td>
</tr>
<tr style='height:49.55pt'>
<td width=204 valign=top style='width:153.35pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:49.55pt'>
<p class=AmmCorpsTexte align=left style='margin-left:9.3pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span>du<span style='letter-spacing:-.1pt'> </span>s<span style='letter-spacing:.1pt'>y</span>stè<span style='letter-spacing:-.1pt'>m</span>e<span style='letter-spacing:-.05pt'> </span>nerveux</p>
</td>
<td width=205 valign=top style='width:153.45pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:49.55pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.8pt;text-align:left'>D<span style='letter-spacing:.1pt'>y</span>sgueusie<span style='letter-spacing:-.1pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>&lt;1<span style='letter-spacing:-.05pt'>%</span>); Paresthésie<span style='letter-spacing: -.45pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>&lt;1%)</p>
</td>
<td width=235 valign=top style='width:175.9pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:49.55pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:7.35pt;margin-bottom:.0001pt;text-align:left'>Vertiges<span style='letter-spacing:-.6pt'> </span>;</p>
<p class=AmmCorpsTexte align=left style='margin-left:7.25pt;text-align:left'>Céphalées<span style='letter-spacing:-.7pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>&lt;1%); Neuropathie périphérique</p>
</td>
</tr>
<tr style='height:21.1pt'>
<td width=204 valign=top style='width:153.35pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:21.1pt'>
<p class=AmmCorpsTexte align=left style='margin-left:9.3pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span>oculaires</p>
</td>
<td width=205 valign=top style='width:153.45pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:21.1pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.8pt;text-align:left'>Aug<span style='letter-spacing:-.1pt'>m</span>entation<span style='letter-spacing: -.15pt'> </span>du<span style='letter-spacing:-.1pt'> </span>lar<span style='letter-spacing:-.05pt'>m</span>oie<span style='letter-spacing:-.05pt'>m</span>ent</p>
</td>
<td width=235 valign=top style='width:175.9pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:21.1pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.25pt;text-align:left'> </p>
</td>
</tr>
<tr style='height:38.65pt'>
<td width=204 valign=top style='width:153.35pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:38.65pt'>
<p class=AmmCorpsTexte align=left style='margin-left:9.3pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span>respiratoires, thoraciques et <span style='letter-spacing:-.1pt'>m</span>édiastinales</p>
</td>
<td width=205 valign=top style='width:153.45pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:38.65pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:4.8pt;margin-bottom:.0001pt;text-align:left'>Douleurs<span style='letter-spacing:-.65pt'> </span>phar<span style='letter-spacing:.1pt'>y</span>ngo-lar<span style='letter-spacing:.1pt'>y</span>ngées</p>
<p class=AmmCorpsTexte align=left style='margin-left:4.8pt;text-align:left'>(G3/4:<span style='letter-spacing:-.55pt'> </span>2<span style='letter-spacing:-.05pt'>%</span>)</p>
</td>
<td width=235 valign=top style='width:175.9pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:38.65pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.25pt;text-align:left'>D<span style='letter-spacing:.1pt'>y</span>spnée<span style='letter-spacing:-.1pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>1<span style='letter-spacing:-.05pt'>%</span>); Toux<span style='letter-spacing:.05pt'> </span>(G3/4:<span style='letter-spacing: -.2pt'> </span>&lt;1<span style='letter-spacing:-.05pt'>%</span>); Epistaxis<span style='letter-spacing:-.35pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>&lt;1<span style='letter-spacing:-.05pt'>%</span>)</p>
</td>
</tr>
<tr style='height:98.1pt'>
<td width=204 valign=top style='width:153.35pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:98.1pt'>
<p class=AmmCorpsTexte align=left style='margin-left:9.3pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span>gastro-intestinal<span style='letter-spacing: -.05pt'>e</span>s</p>
</td>
<td width=205 valign=top style='width:153.45pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:98.1pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:4.8pt;margin-bottom:.0001pt;text-align:left'>Sto<span style='letter-spacing:-.1pt'>m</span>atite<span style='letter-spacing:-.1pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>18%);</p>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:4.8pt;margin-bottom:.0001pt;text-align:left'>Diarrhée (G3/4:<span style='letter-spacing:-.25pt'> </span>14<span style='letter-spacing: -.05pt'>%</span>);<span style='letter-spacing:-.1pt'> </span></p>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:4.8pt;margin-bottom:.0001pt;text-align:left'>Nausées (G3/4: 6%);<span style='letter-spacing:-.2pt'> </span>Vo<span style='letter-spacing:-.1pt'>m</span>isse<span style='letter-spacing:-.1pt'>m</span>ents (G3/4:<span style='letter-spacing:-.1pt'> </span>4%); Constipation<span style='letter-spacing:.05pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>1<span style='letter-spacing:-.05pt'>%</span>); Douleurs abdo<span style='letter-spacing:-.1pt'>m</span>inales<span style='letter-spacing:-.2pt'> </span>(G3/4:</p>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:4.8pt;margin-bottom:.0001pt;text-align:left'>2%);<span style='letter-spacing:-.45pt'> </span></p>
<p class=AmmCorpsTexte align=left style='margin-left:4.8pt;text-align:left'>D<span style='letter-spacing:.1pt'>y</span>spepsie</p>
</td>
<td width=235 valign=top style='width:175.9pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:98.1pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.25pt;text-align:left'>Douleurs<span style='letter-spacing:-.65pt'> </span>épigastriques; Sécheresse de<span style='letter-spacing:-.1pt'> </span>la bouche</p>
</td>
</tr>
<tr style='height:64.05pt'>
<td width=204 valign=top style='width:153.35pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:64.05pt'>
<p class=AmmCorpsTexte align=left style='margin-left:9.3pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la peau<span style='letter-spacing:-.2pt'> </span>et du<span style='letter-spacing: -.1pt'> </span>tissu sous-cutané</p>
</td>
<td width=205 valign=top style='width:153.45pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:64.05pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:4.8pt;margin-bottom:.0001pt;text-align:left'>S<span style='letter-spacing:.1pt'>y</span>ndro<span style='letter-spacing:-.1pt'>m</span>e<span style='letter-spacing:-.05pt'> </span><span style='letter-spacing:-.1pt'>m</span>ain-pieds<span style='letter-spacing:-.4pt'> </span>(G3/4:</p>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:4.8pt;margin-bottom:.0001pt;text-align:left'>24%) ;</p>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:4.8pt;margin-bottom:.0001pt;text-align:left'>Alopécie<span style='letter-spacing:-.65pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>6<span style='letter-spacing:-.05pt'>%</span>);</p>
<p class=AmmCorpsTexte align=left style='margin-left:4.8pt;text-align:left'>Altération<span style='letter-spacing:-.65pt'> </span>des<span style='letter-spacing:-.15pt'> </span>ongles<span style='letter-spacing:-.25pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>2<span style='letter-spacing:-.05pt'>%</span>)</p>
</td>
<td width=235 valign=top style='width:175.9pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:64.05pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:4.8pt;margin-bottom:.0001pt;text-align:left'>Dermatites;</p>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:4.8pt;margin-bottom:.0001pt;text-align:left'>Eruption érythémateuse (G3/4: &lt;1%);</p>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:4.8pt;margin-bottom:.0001pt;text-align:left'>Décoloration des ongles; Onycholyse (G3/4: 1%)</p>
</td>
</tr>
<tr style='height:41.55pt'>
<td width=204 valign=top style='width:153.35pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:41.55pt'>
<p class=AmmCorpsTexte align=left style='margin-left:9.3pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>u</span>sculo- squelettiques et s<span style='letter-spacing:.1pt'>y</span>sté<span style='letter-spacing:-.1pt'>m</span>iques</p>
</td>
<td width=205 valign=top style='width:153.45pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:41.55pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.8pt;text-align:left'>M<span style='letter-spacing:.1pt'>y</span>algie<span style='letter-spacing:-.05pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>2<span style='letter-spacing:-.05pt'>%</span>); Arthralgie (G3/4:<span style='letter-spacing:-.25pt'> </span>1%)</p>
</td>
<td width=235 valign=top style='width:175.9pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:41.55pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:4.8pt;margin-bottom:.0001pt;text-align:left'>Douleurs<span style='letter-spacing:-.65pt'> </span>des<span style='letter-spacing:-.15pt'> </span>extré<span style='letter-spacing:-.05pt'>m</span>ités<span style='letter-spacing:-.2pt'> </span>(G3/4: &lt;1%);</p>
<p class=AmmCorpsTexte align=left style='margin-left:7.25pt;text-align:left'>Douleurs<span style='letter-spacing:-.65pt'> </span>dorsales<span style='letter-spacing: -.35pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>1<span style='letter-spacing:-.05pt'>%</span>);</p>
</td>
</tr>
<tr style='height:64.1pt'>
<td width=204 valign=top style='width:153.35pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:64.1pt'>
<p class=AmmCorpsTexte align=left style='margin-left:9.3pt;text-align:left'>Troubles<span style='letter-spacing:-.65pt'> </span>généraux<span style='letter-spacing: -.35pt'> </span>et ano<span style='letter-spacing:-.1pt'>m</span>alies<span style='letter-spacing:-.15pt'> </span>au site d<span style='letter-spacing: .05pt'>’</span>ad<span style='letter-spacing:-.1pt'>m</span>inistration</p>
</td>
<td width=205 valign=top style='width:153.45pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:64.1pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:4.8pt;margin-bottom:.0001pt;text-align:left'>Asthénie<span style='letter-spacing:-.65pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>3<span style='letter-spacing:-.05pt'>%</span>); Fièvre (G3/4:<span style='letter-spacing:-.25pt'> </span>1<span style='letter-spacing:-.05pt'>%</span>);</p>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:4.8pt;margin-bottom:.0001pt;text-align:left'>Fatigue/<span style='letter-spacing:-.6pt'> </span>faiblesse<span style='letter-spacing: -.35pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>5%); Œdè<span style='letter-spacing:-.1pt'>m</span>e périphérique<span style='letter-spacing: -.45pt'> </span>(G3/4:</p>
<p class=AmmCorpsTexte align=left style='margin-left:4.8pt;text-align:left'>1<span style='letter-spacing:-.05pt'>%</span>);</p>
</td>
<td width=235 valign=top style='width:175.9pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:64.1pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.25pt;text-align:left'>Léthargie; Douleurs</p>
</td>
</tr>
<tr style='height:38.65pt'>
<td width=204 valign=top style='width:153.35pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:38.65pt'>
<p class=AmmCorpsTexte align=left style='margin-left:9.3pt;text-align:left'>Investigations</p>
</td>
<td width=205 valign=top style='width:153.45pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:38.65pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.8pt;text-align:left'> </p>
</td>
<td width=235 valign=top style='width:175.9pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:38.65pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.25pt;text-align:left'>Di<span style='letter-spacing:-.1pt'>m</span>inution<span style='letter-spacing:-.3pt'> </span>du<span style='letter-spacing:-.1pt'> </span>poids; Aug<span style='letter-spacing:-.1pt'>m</span>entation<span style='letter-spacing: .05pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la bilirubine (G3/4 :<span style='letter-spacing:.05pt'> </span>9<span style='letter-spacing: -.05pt'>%</span>)</p>
</td>
</tr>
</table>
</div>
<p class=AmmCorpsTexte style='margin-top:6.0pt;page-break-after:avoid'><b>Tableau des effets indésirables dans le cancer du sein pour docétaxel 75 <span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.1pt'>m</span>² en association avec la prednisone ou la prednisolone</b></p>
<div align=center>
<table class=AmmCorpsTexteTable border=0 cellspacing=0 cellpadding=0
style='margin-left:5.15pt;border-collapse:collapse'>
<tr style='height:39.2pt'>
<td width=217 valign=top style='width:162.7pt;border:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:39.2pt'>
<p class=AmmCorpsTexte style='margin-left:4.65pt;page-break-after:avoid'><b>Base<span style='letter-spacing:-.45pt'> </span>de<span style='letter-spacing:-.1pt'> </span>données<span style='letter-spacing:-.35pt'> </span>MeDRA<span style='letter-spacing:-.35pt'> </span>des classes de<span style='letter-spacing:-.1pt'> </span>système<span style='letter-spacing:-.35pt'> </span>d’organe</b></p>
</td>
<td width=217 valign=top style='width:162.8pt;border:solid black 1.0pt;
border-left:none;padding:0cm 0cm 0cm 0cm;height:39.2pt'>
<p class=AmmCorpsTexte style='margin-left:4.95pt;page-break-after:avoid'><b>Très<span style='letter-spacing:-.45pt'> </span>fréquent</b></p>
</td>
<td width=217 valign=top style='width:162.8pt;border:solid black 1.0pt;
border-left:none;padding:0cm 0cm 0cm 0cm;height:39.2pt'>
<p class=AmmCorpsTexte style='margin-left:5.2pt;page-break-after:avoid'><b>Fréquent</b></p>
</td>
</tr>
<tr style='height:22.25pt'>
<td width=217 valign=top style='width:162.7pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:22.25pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.65pt;text-align:left; page-break-after:avoid'>Infections<span style='letter-spacing:-.7pt'> </span>et infestations</p>
</td>
<td width=217 valign=top style='width:162.8pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:22.25pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.95pt;text-align:left; page-break-after:avoid'>Infection<span style='letter-spacing:-.65pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>3,3<span style='letter-spacing:-.05pt'>%</span>)</p>
</td>
<td width=217 valign=top style='width:162.8pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:22.25pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.2pt;text-align:left; page-break-after:avoid'> </p>
</td>
</tr>
<tr style='height:35.25pt'>
<td width=217 valign=top style='width:162.7pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:35.25pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.65pt;text-align:left; page-break-after:avoid'>Affections<span style='letter-spacing:-.7pt'> </span>hé<span style='letter-spacing:-.1pt'>m</span>atologiques<span style='letter-spacing: -.5pt'> </span>et du s<span style='letter-spacing:.1pt'>y</span>stè<span style='letter-spacing:-.1pt'>m</span>e l<span style='letter-spacing:.1pt'>y</span><span style='letter-spacing:-.1pt'>m</span>phatique</p>
</td>
<td width=217 valign=top style='width:162.8pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:35.25pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.95pt;text-align:left; page-break-after:avoid'>Neutropénie<span style='letter-spacing:-.75pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>32<span style='letter-spacing:-.05pt'>%</span>); Ané<span style='letter-spacing:-.1pt'>m</span>ie (G3/4:<span style='letter-spacing:-.25pt'> </span>4,9<span style='letter-spacing:-.05pt'>%</span>)</p>
</td>
<td width=217 valign=top style='width:162.8pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:35.25pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.2pt;text-align:left; page-break-after:avoid'>Thro<span style='letter-spacing:-.1pt'>m</span>bopénie;<span style='letter-spacing:-.15pt'> </span>(G3/4:<span style='letter-spacing:-.2pt'> </span>0,6<span style='letter-spacing:-.05pt'>%</span>); Neutropénie fébrile</p>
</td>
</tr>
<tr style='height:20.95pt'>
<td width=217 valign=top style='width:162.7pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:20.95pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.65pt;text-align:left; page-break-after:avoid'>Affections<span style='letter-spacing:-.7pt'> </span>du<span style='letter-spacing:-.1pt'> </span>s<span style='letter-spacing:.1pt'>y</span>stè<span style='letter-spacing:-.1pt'>m</span>e i<span style='letter-spacing:-.1pt'>mm</span>unitaire</p>
</td>
<td width=217 valign=top style='width:162.8pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:20.95pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.95pt;text-align:left; page-break-after:avoid'> </p>
</td>
<td width=217 valign=top style='width:162.8pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:20.95pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.2pt;text-align:left; page-break-after:avoid'>H<span style='letter-spacing:.1pt'>y</span>persensibilité<span style='letter-spacing:-.1pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>0,6%)</p>
</td>
</tr>
<tr style='height:28.25pt'>
<td width=217 valign=top style='width:162.7pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:28.25pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.65pt;text-align:left; page-break-after:avoid'>Troubles<span style='letter-spacing:-.65pt'> </span>du<span style='letter-spacing:-.1pt'> m</span>étabolis<span style='letter-spacing: -.05pt'>m</span>e<span style='letter-spacing:-.35pt'> </span>et de<span style='letter-spacing:-.1pt'> </span>la nutrition</p>
</td>
<td width=217 valign=top style='width:162.8pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:28.25pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.95pt;text-align:left; page-break-after:avoid'>Anorexie<span style='letter-spacing:-.65pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>0,6<span style='letter-spacing:-.05pt'>%</span>)</p>
</td>
<td width=217 valign=top style='width:162.8pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:28.25pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.2pt;text-align:left; page-break-after:avoid'> </p>
</td>
</tr>
<tr style='height:42.15pt'>
<td width=217 valign=top style='width:162.7pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:42.15pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.65pt;text-align:left; page-break-after:avoid'>Affections<span style='letter-spacing:-.7pt'> </span>du<span style='letter-spacing:-.1pt'> </span>s<span style='letter-spacing:.1pt'>y</span>stè<span style='letter-spacing:-.1pt'>m</span>e<span style='letter-spacing:-.05pt'> </span>nerveux</p>
</td>
<td width=217 valign=top style='width:162.8pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:42.15pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:4.8pt;margin-bottom:.0001pt;text-align:left; page-break-after:avoid'>Neuropathie<span style='letter-spacing:-.8pt'> </span>sensitive périphérique<span style='letter-spacing:.05pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>1,2<span style='letter-spacing:-.05pt'>%</span>);</p>
<p class=AmmCorpsTexte align=left style='margin-left:4.95pt;text-align:left; page-break-after:avoid'>D<span style='letter-spacing:.1pt'>y</span>sgueusie (G3/4:<span style='letter-spacing:-.25pt'> </span>0<span style='letter-spacing: -.05pt'>%</span>)</p>
</td>
<td width=217 valign=top style='width:162.8pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:42.15pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.2pt;text-align:left; page-break-after:avoid'>Neuropathie<span style='letter-spacing:-.8pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>o</span>trice périphérique<span style='letter-spacing:-.45pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>0<span style='letter-spacing:-.05pt'>%</span>)</p>
</td>
</tr>
<tr style='height:35.0pt'>
<td width=217 valign=top style='width:162.7pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:35.0pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.65pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span>oculaires</p>
</td>
<td width=217 valign=top style='width:162.8pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:35.0pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.95pt;text-align:left'> </p>
</td>
<td width=217 valign=top style='width:162.8pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:35.0pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.2pt;text-align:left'>Aug<span style='letter-spacing:-.1pt'>m</span>entation<span style='letter-spacing: -.15pt'> </span>du<span style='letter-spacing:-.1pt'> </span>lar<span style='letter-spacing:-.05pt'>m</span>oie<span style='letter-spacing:-.05pt'>m</span>ent (G3/4:<span style='letter-spacing:-.5pt'> </span>0,6<span style='letter-spacing: -.05pt'>%</span>)</p>
</td>
</tr>
<tr style='height:38.65pt'>
<td width=217 valign=top style='width:162.7pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:38.65pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.65pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span>cardiaques</p>
</td>
<td width=217 valign=top style='width:162.8pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:38.65pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.95pt;text-align:left'> </p>
</td>
<td width=217 valign=top style='width:162.8pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:38.65pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.2pt;text-align:left'>Di<span style='letter-spacing:-.1pt'>m</span>inution<span style='letter-spacing:-.35pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la fraction d’éjection<span style='letter-spacing:.05pt'> </span>ventriculaire<span style='letter-spacing: -.45pt'> </span>gauche (G3/4:<span style='letter-spacing:.05pt'> </span>0,3<span style='letter-spacing:-.05pt'>%</span>)</p>
</td>
</tr>
<tr style='height:38.65pt'>
<td width=217 valign=top style='width:162.7pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:38.65pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.65pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span>respiratoires, thoraciques et <span style='letter-spacing:-.1pt'>m</span>édiastinales</p>
</td>
<td width=217 valign=top style='width:162.8pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:38.65pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.95pt;text-align:left'> </p>
</td>
<td width=217 valign=top style='width:162.8pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:38.65pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:5.1pt;margin-bottom:.0001pt;text-align:left'>Epistaxis<span style='letter-spacing:-.65pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>0<span style='letter-spacing:-.05pt'>%</span>); </p>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:5.1pt;margin-bottom:.0001pt;text-align:left'>D<span style='letter-spacing:.1pt'>y</span>spnée (G3/4:<span style='letter-spacing: -.25pt'> </span>0,6<span style='letter-spacing:-.05pt'>%</span>);</p>
<p class=AmmCorpsTexte align=left style='margin-left:5.2pt;text-align:left'>Toux<span style='letter-spacing:.05pt'> </span>(G3/4:<span style='letter-spacing:-.2pt'> </span>0<span style='letter-spacing:-.05pt'>%</span>)</p>
</td>
</tr>
<tr style='height:64.1pt'>
<td width=217 valign=top style='width:162.7pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:64.1pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.65pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span>gastro-intestinales</p>
</td>
<td width=217 valign=top style='width:162.8pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:64.1pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:4.8pt;margin-bottom:.0001pt;text-align:left; page-break-after:avoid'>Nausées<span style='letter-spacing:-.6pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>2,4%); </p>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:4.8pt;margin-bottom:.0001pt;text-align:left; page-break-after:avoid'>Diarrhée (G3/4:<span style='letter-spacing:-.25pt'> </span>1,2<span style='letter-spacing:-.05pt'>%</span>); Sto<span style='letter-spacing:-.1pt'>m</span>atite/Phar<span style='letter-spacing:.1pt'>y</span>ngite (G3/4:</p>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:4.8pt;margin-bottom:.0001pt;text-align:left; page-break-after:avoid'>0,9%);</p>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:4.8pt;margin-bottom:.0001pt;text-align:left; page-break-after:avoid'>Vo<span style='letter-spacing:-.1pt'>m</span>isse<span style='letter-spacing:-.1pt'>m</span>ents<span style='letter-spacing:-.25pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>1,2%)</p>
</td>
<td width=217 valign=top style='width:162.8pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:64.1pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.2pt;text-align:left'> </p>
</td>
</tr>
<tr style='height:38.65pt'>
<td width=217 valign=top style='width:162.7pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:38.65pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.65pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la peau<span style='letter-spacing:-.2pt'> </span>et du<span style='letter-spacing: -.1pt'> </span>tissu sous-cutané</p>
</td>
<td width=217 valign=top style='width:162.8pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:38.65pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:4.8pt;margin-bottom:.0001pt;text-align:left; page-break-after:avoid'>Alopécie;</p>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:4.8pt;margin-bottom:.0001pt;text-align:left; page-break-after:avoid'>Altération des ongles (jamais sévère)</p>
</td>
<td width=217 valign=top style='width:162.8pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:38.65pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:4.8pt;margin-bottom:.0001pt;text-align:left; page-break-after:avoid'>Eruption<span style='letter-spacing:-.6pt'> </span>avec<span style='letter-spacing:-.15pt'> </span>desqua<span style='letter-spacing:-.1pt'>m</span>ation </p>
<p class=AmmCorpsTexte align=left style='margin-left:5.2pt;text-align:left'>(G3/4:<span style='letter-spacing:-.5pt'> </span>0,3<span style='letter-spacing:-.05pt'>%</span>)</p>
</td>
</tr>
<tr style='height:30.95pt'>
<td width=217 valign=top style='width:162.7pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:30.95pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.65pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>u</span>sculo- squelettiques et s<span style='letter-spacing:.1pt'>y</span>sté<span style='letter-spacing:-.1pt'>m</span>iques</p>
</td>
<td width=217 valign=top style='width:162.8pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:30.95pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.95pt;text-align:left'> </p>
</td>
<td width=217 valign=top style='width:162.8pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:30.95pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.2pt;text-align:left'>Arthralgie<span style='letter-spacing:-.65pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>0,3<span style='letter-spacing:-.05pt'>%</span>); M<span style='letter-spacing:.1pt'>y</span>algie<span style='letter-spacing:.05pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>0,3<span style='letter-spacing:-.05pt'>%</span>)</p>
</td>
</tr>
<tr style='height:38.65pt'>
<td width=217 valign=top style='width:162.7pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:38.65pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.65pt;text-align:left'>Troubles<span style='letter-spacing:-.65pt'> </span>généraux<span style='letter-spacing: -.35pt'> </span>et ano<span style='letter-spacing:-.1pt'>m</span>alies<span style='letter-spacing:-.15pt'> </span>au site d<span style='letter-spacing: .05pt'>’</span>ad<span style='letter-spacing:-.1pt'>m</span>inistration</p>
</td>
<td width=217 valign=top style='width:162.8pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:38.65pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:4.8pt;margin-bottom:.0001pt;text-align:left'>Fatigue<span style='letter-spacing:-.55pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>3,9<span style='letter-spacing:-.05pt'>%</span>); </p>
<p class=AmmCorpsTexte align=left style='margin-left:4.95pt;text-align:left'>Rétention<span style='letter-spacing:.05pt'> </span>h<span style='letter-spacing:.1pt'>y</span>drique (sévère : 0,6%)</p>
</td>
<td width=217 valign=top style='width:162.8pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:38.65pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.2pt;text-align:left'> </p>
</td>
</tr>
</table>
</div>
<p class=AmmCorpsTexte style='margin-top:6.0pt;page-break-after:avoid'><b>Tableau des effets indésirables dans le cancer du sein pour le Traite<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.1pt'> </span>adjuvant avec docétaxel 75 <span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.1pt'>m</span>² en association avec la doxorubicine et le c<span style='letter-spacing:.1pt'>y</span>clophospha<span style='letter-spacing:-.05pt'>m</span>ide<span style='letter-spacing:-.1pt'> </span>chez des patients avec cancer du sein avec envahisse<span style='letter-spacing: -.05pt'>m</span>ent ganglionnaire<span style='letter-spacing:.05pt'> </span>(TAX 316) et sans envahisse<span style='letter-spacing:-.05pt'>m</span>ent ganglionnaire<span style='letter-spacing:.05pt'> </span>(GEICAM 9805) – données poolées</b></p>
<div align=center>
<table class=AmmCorpsTexteTable border=0 cellspacing=0 cellpadding=0 width=666
style='width:499.15pt;margin-left:-11.3pt;border-collapse:collapse'>
<tr style='height:39.2pt'>
<td width=170 colspan=2 valign=top style='width:127.3pt;border:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:39.2pt'>
<p class=AmmCorpsTexte style='margin-left:5.95pt;page-break-after:avoid'><b>Base<span style='letter-spacing:-.45pt'> </span>de données Medra<span style='letter-spacing: -.1pt'> </span>des<span style='letter-spacing:-.15pt'> </span>classes<span style='letter-spacing:-.3pt'> </span>de système d’organe</b></p>
</td>
<td width=178 colspan=2 valign=top style='width:133.3pt;border:solid black 1.0pt;
border-left:none;padding:0cm 0cm 0cm 0cm;height:39.2pt'>
<p class=AmmCorpsTexte style='margin-left:3.6pt;page-break-after:avoid'><b>Très<span style='letter-spacing:-.45pt'> </span>fréquent</b></p>
</td>
<td width=157 colspan=2 valign=top style='width:117.4pt;border:solid black 1.0pt;
border-left:none;padding:0cm 0cm 0cm 0cm;height:39.2pt'>
<p class=AmmCorpsTexte style='margin-left:3.45pt;page-break-after:avoid'><b>Fréquent</b></p>
</td>
<td width=152 colspan=2 valign=top style='width:114.05pt;border:solid black 1.0pt;
border-left:none;padding:0cm 0cm 0cm 0cm;height:39.2pt'>
<p class=AmmCorpsTexte style='margin-left:4.2pt;page-break-after:avoid'><b>Peu<span style='letter-spacing:-.45pt'> </span>fréquent</b></p>
</td>
<td style='border:none;padding:0cm 0cm 0cm 0cm' width=9><p class='AmmCorpsTexte'> </td>
</tr>
<tr style='height:41.65pt'>
<td width=170 colspan=2 valign=top style='width:127.3pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:41.65pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.95pt;text-align:left; page-break-after:avoid'>Infections<span style='letter-spacing:-.7pt'> </span>et infestations</p>
</td>
<td width=178 colspan=2 valign=top style='width:133.3pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:41.65pt'>
<p class=AmmCorpsTexte align=left style='margin-left:3.6pt;text-align:left; page-break-after:avoid'>Infection<span style='letter-spacing:-.6pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>2,4<span style='letter-spacing:-.05pt'>%</span>); Infection neutropénique (G3/4 :<span style='letter-spacing:.05pt'> </span>2,7<span style='letter-spacing:-.05pt'>%</span>).</p>
</td>
<td width=157 colspan=2 valign=top style='width:117.4pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:41.65pt'>
<p class=AmmCorpsTexte align=left style='margin-left:3.45pt;text-align:left; page-break-after:avoid'> </p>
</td>
<td width=152 colspan=2 valign=top style='width:114.05pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:41.65pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.2pt;text-align:left; page-break-after:avoid'> </p>
</td>
<td style='border:none;padding:0cm 0cm 0cm 0cm' width=9><p class='AmmCorpsTexte'> </td>
</tr>
<tr style='height:91.2pt'>
<td width=170 colspan=2 valign=top style='width:127.3pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:91.2pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.95pt;text-align:left; page-break-after:avoid'>Affections hé<span style='letter-spacing:-.1pt'>m</span>atologiques<span style='letter-spacing:-.35pt'> </span>et du s<span style='letter-spacing: .1pt'>y</span>stè<span style='letter-spacing:-.1pt'>m</span>e l<span style='letter-spacing:.1pt'>y</span><span style='letter-spacing:-.1pt'>m</span>phatique</p>
</td>
<td width=178 colspan=2 valign=top style='width:133.3pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:91.2pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:3.7pt;margin-bottom:.0001pt;text-align:left; page-break-after:avoid'>Ané<span style='letter-spacing:-.1pt'>m</span>ie<span style='letter-spacing:-.2pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>3<span style='letter-spacing:-.05pt'>%</span>); Neutropénie (G3/4:</p>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:3.7pt;margin-bottom:.0001pt;text-align:left; page-break-after:avoid'>59,2<span style='letter-spacing:-.05pt'>%</span>);<span style='letter-spacing:-.15pt'> </span></p>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:3.7pt;margin-bottom:.0001pt;text-align:left; page-break-after:avoid'>Thro<span style='letter-spacing:-.1pt'>m</span>bopénie (G3/4:<span style='letter-spacing:.05pt'> </span>1,6<span style='letter-spacing: -.05pt'>%</span>); Neutropénie fébrile<span style='letter-spacing:-.25pt'> </span>(G3/4 : non<span style='letter-spacing:-.15pt'> </span>déter<span style='letter-spacing: -.05pt'>m</span>iné)</p>
</td>
<td width=157 colspan=2 valign=top style='width:117.4pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:91.2pt'>
<p class=AmmCorpsTexte align=left style='margin-left:3.45pt;text-align:left; page-break-after:avoid'> </p>
</td>
<td width=152 colspan=2 valign=top style='width:114.05pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:91.2pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.2pt;text-align:left; page-break-after:avoid'> </p>
</td>
<td style='border:none;padding:0cm 0cm 0cm 0cm' width=9><p class='AmmCorpsTexte'> </td>
</tr>
<tr style='height:28.0pt'>
<td width=170 colspan=2 valign=top style='width:127.3pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:28.0pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.95pt;text-align:left; page-break-after:avoid'>Affections<span style='letter-spacing:-.7pt'> </span>du<span style='letter-spacing:-.1pt'> </span>s<span style='letter-spacing:.1pt'>y</span>stè<span style='letter-spacing:-.1pt'>m</span>e i<span style='letter-spacing:-.1pt'>mm</span>unitaire</p>
</td>
<td width=178 colspan=2 valign=top style='width:133.3pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:28.0pt'>
<p class=AmmCorpsTexte align=left style='margin-left:3.6pt;text-align:left; page-break-after:avoid'> </p>
</td>
<td width=157 colspan=2 valign=top style='width:117.4pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:28.0pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:3.7pt;margin-bottom:.0001pt;text-align:left; page-break-after:avoid'>H<span style='letter-spacing:.1pt'>y</span>persensibilité<span style='letter-spacing:-.05pt'> </span>(G3/4:</p>
<p class=AmmCorpsTexte align=left style='margin-left:3.45pt;text-align:left; page-break-after:avoid'>0,6<span style='letter-spacing:-.05pt'>%</span>)</p>
</td>
<td width=152 colspan=2 valign=top style='width:114.05pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:28.0pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.2pt;text-align:left; page-break-after:avoid'> </p>
</td>
<td style='border:none;padding:0cm 0cm 0cm 0cm' width=9><p class='AmmCorpsTexte'> </td>
</tr>
<tr style='height:38.65pt'>
<td width=170 colspan=2 valign=top style='width:127.3pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:38.65pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.95pt;text-align:left; page-break-after:avoid'>Troubles<span style='letter-spacing:-.6pt'> </span>du <span style='letter-spacing:-.1pt'>m</span>étabolis<span style='letter-spacing: -.05pt'>m</span>e<span style='letter-spacing:-.25pt'> </span>et de<span style='letter-spacing:-.1pt'> </span>la nutrition</p>
</td>
<td width=178 colspan=2 valign=top style='width:133.3pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:38.65pt'>
<p class=AmmCorpsTexte align=left style='margin-left:3.6pt;text-align:left; page-break-after:avoid'>Anorexie<span style='letter-spacing:-.65pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>1,5<span style='letter-spacing:-.05pt'>%</span>)</p>
</td>
<td width=157 colspan=2 valign=top style='width:117.4pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:38.65pt'>
<p class=AmmCorpsTexte align=left style='margin-left:3.45pt;text-align:left; page-break-after:avoid'> </p>
</td>
<td width=152 colspan=2 valign=top style='width:114.05pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:38.65pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.2pt;text-align:left; page-break-after:avoid'> </p>
</td>
<td style='border:none;padding:0cm 0cm 0cm 0cm' width=9><p class='AmmCorpsTexte'> </td>
</tr>
<tr style='height:48.95pt'>
<td width=170 colspan=2 valign=top style='width:127.3pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:48.95pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.95pt;text-align:left; page-break-after:avoid'>Affections<span style='letter-spacing:-.7pt'> </span>du<span style='letter-spacing:-.1pt'> </span>s<span style='letter-spacing:.1pt'>y</span>stè<span style='letter-spacing:-.1pt'>m</span>e nerveux</p>
</td>
<td width=178 colspan=2 valign=top style='width:133.3pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:48.95pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:3.7pt;margin-bottom:.0001pt;text-align:left; page-break-after:avoid'>D<span style='letter-spacing:.1pt'>y</span>sgueusie<span style='letter-spacing:-.1pt'> </span>(G3/4<span style='letter-spacing:-.15pt'>: 0.6%);</span></p>
<p class=AmmCorpsTexte align=left style='margin-left:3.6pt;text-align:left; page-break-after:avoid'><span style='letter-spacing:-.15pt'>Neuropathie sensitive périphérique (G3/4: </span>&lt;0,1%)</p>
</td>
<td width=157 colspan=2 valign=top style='width:117.4pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:48.95pt'>
<p class=AmmCorpsTexte align=left style='margin-left:3.45pt;text-align:left; page-break-after:avoid'>Neuropathie<span style='letter-spacing:-.8pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>o</span>trice périphérique (G3/4:<span style='letter-spacing:-.55pt'> </span>0<span style='letter-spacing:-.05pt'>%</span>);</p>
</td>
<td width=152 colspan=2 valign=top style='width:114.05pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:48.95pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:3.7pt;margin-bottom:.0001pt;text-align:left; page-break-after:avoid'>S<span style='letter-spacing:.1pt'>y</span>ncope<span style='letter-spacing:-.05pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>0<span style='letter-spacing:-.05pt'>%</span>) Neurotoxicité<span style='letter-spacing:.05pt'> </span>(<span style='letter-spacing:-.15pt'>G3/4 : 0%)</span></p>
<p class=AmmCorpsTexte align=left style='margin-left:4.2pt;text-align:left; page-break-after:avoid'><span style='letter-spacing:-.15pt'>Somnolence (G3/4 : </span>0<span style='letter-spacing:-.05pt'>%</span>)</p>
</td>
<td style='border:none;padding:0cm 0cm 0cm 0cm' width=9><p class='AmmCorpsTexte'> </td>
</tr>
<tr style='height:33.95pt'>
<td width=170 colspan=2 valign=top style='width:127.3pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:33.95pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.95pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span>oculaires</p>
</td>
<td width=178 colspan=2 valign=top style='width:133.3pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:33.95pt'>
<p class=AmmCorpsTexte align=left style='margin-left:3.6pt;text-align:left'>Conjonctivite<span style='letter-spacing:-.8pt'> </span>(G3/4: &lt;0,1%)</p>
</td>
<td width=157 colspan=2 valign=top style='width:117.4pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:33.95pt'>
<p class=AmmCorpsTexte align=left style='margin-left:3.45pt;text-align:left'>Lar<span style='letter-spacing:-.05pt'>m</span>oie<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.15pt'> </span>(G3/4: &lt;0,1%);</p>
</td>
<td width=152 colspan=2 valign=top style='width:114.05pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:33.95pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.2pt;text-align:left'> </p>
</td>
<td style='border:none;padding:0cm 0cm 0cm 0cm' width=9><p class='AmmCorpsTexte'> </td>
</tr>
<tr style='height:21.0pt'>
<td width=170 colspan=2 valign=top style='width:127.3pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:21.0pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.95pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span>cardiaques</p>
</td>
<td width=178 colspan=2 valign=top style='width:133.3pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:21.0pt'>
<p class=AmmCorpsTexte align=left style='margin-left:3.6pt;text-align:left'> </p>
</td>
<td width=157 colspan=2 valign=top style='width:117.4pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:21.0pt'>
<p class=AmmCorpsTexte align=left style='margin-left:3.45pt;text-align:left'>Ar<span style='letter-spacing:.1pt'>y</span>th<span style='letter-spacing:-.1pt'>m</span>ie<span style='letter-spacing:-.15pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>0,2<span style='letter-spacing:-.05pt'>%</span>);</p>
</td>
<td width=152 colspan=2 valign=top style='width:114.05pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:21.0pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.2pt;text-align:left'> </p>
</td>
<td style='border:none;padding:0cm 0cm 0cm 0cm' width=9><p class='AmmCorpsTexte'> </td>
</tr>
<tr style='height:33.5pt'>
<td width=170 colspan=2 valign=top style='width:127.3pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:33.5pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.95pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span>vasculaires</p>
</td>
<td width=178 colspan=2 valign=top style='width:133.3pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:33.5pt'>
<p class=AmmCorpsTexte align=left style='margin-left:3.6pt;text-align:left'>Vasodilatation<span style='letter-spacing:-.9pt'> </span>(G3/4: 0.5<span style='letter-spacing: -.05pt'>%</span>);</p>
</td>
<td width=157 colspan=2 valign=top style='width:117.4pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:33.5pt'>
<p class=AmmCorpsTexte align=left style='margin-left:3.45pt;text-align:left'>H<span style='letter-spacing:.1pt'>y</span>potension<span style='letter-spacing: -.1pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>0<span style='letter-spacing:-.05pt'>%</span>) Phlébite<span style='letter-spacing: .05pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>0<span style='letter-spacing:-.05pt'>%</span>)</p>
</td>
<td width=152 colspan=2 valign=top style='width:114.05pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:33.5pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.2pt;text-align:left'>L<span style='letter-spacing:.1pt'>y</span><span style='letter-spacing:-.1pt'>m</span>phoedè<span style='letter-spacing:-.05pt'>m</span>e<span style='letter-spacing:-.05pt'> </span>(G3/4: 0<span style='letter-spacing:-.05pt'>%</span>)</p>
</td>
<td style='border:none;padding:0cm 0cm 0cm 0cm' width=9><p class='AmmCorpsTexte'> </td>
</tr>
<tr style='height:42.45pt'>
<td width=170 colspan=2 valign=top style='width:127.3pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:42.45pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.95pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span>respiratoires, thoraciques et <span style='letter-spacing:-.1pt'>m</span>édiastinales</p>
</td>
<td width=178 colspan=2 valign=top style='width:133.3pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:42.45pt'>
<p class=AmmCorpsTexte align=left style='margin-left:3.6pt;text-align:left'> </p>
</td>
<td width=157 colspan=2 valign=top style='width:117.4pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:42.45pt'>
<p class=AmmCorpsTexte align=left style='margin-left:3.45pt;text-align:left'>Toux<span style='letter-spacing:-.45pt'> </span>(G3/4:<span style='letter-spacing:-.2pt'> </span>0<span style='letter-spacing:-.05pt'>%</span>)</p>
</td>
<td width=152 colspan=2 valign=top style='width:114.05pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:42.45pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.2pt;text-align:left'> </p>
</td>
<td style='border:none;padding:0cm 0cm 0cm 0cm' width=9><p class='AmmCorpsTexte'> </td>
</tr>
<tr style='height:89.5pt'>
<td width=170 colspan=2 valign=top style='width:127.3pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:89.5pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.95pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span>gastro- intestinales</p>
</td>
<td width=178 colspan=2 valign=top style='width:133.3pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:89.5pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:3.7pt;margin-bottom:.0001pt;text-align:left; page-break-after:avoid'>Nausées<span style='letter-spacing:-.6pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>5,0%); Sto<span style='letter-spacing: -.1pt'>m</span>atite<span style='letter-spacing:.05pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>6,0%); Vo<span style='letter-spacing: -.1pt'>m</span>isse<span style='letter-spacing:-.1pt'>m</span>ents<span style='letter-spacing:-.1pt'> </span>(G3/4:</p>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:3.7pt;margin-bottom:.0001pt;text-align:left; page-break-after:avoid'><span style='letter-spacing:-.15pt'>4,2%); Diarrhées (G3/4:</span></p>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:3.7pt;margin-bottom:.0001pt;text-align:left; page-break-after:avoid'><span style='letter-spacing:-.15pt'>3,4%);</span></p>
<p class=AmmCorpsTexte align=left style='margin-left:3.6pt;text-align:left'>Constipation<span style='letter-spacing:-.75pt'> </span>(G3/4: 0,5<span style='letter-spacing: -.05pt'>%</span>)</p>
</td>
<td width=157 colspan=2 valign=top style='width:117.4pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:89.5pt'>
<p class=AmmCorpsTexte align=left style='margin-left:3.45pt;text-align:left'>Douleurs<span style='letter-spacing:-.65pt'> </span><span style='letter-spacing:-.15pt'>abdominales </span>(G3/4:<span style='letter-spacing:-.5pt'> </span>0,4<span style='letter-spacing:-.05pt'>%</span>)</p>
</td>
<td width=152 colspan=2 valign=top style='width:114.05pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:89.5pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.2pt;text-align:left'> </p>
</td>
<td style='border:none;padding:0cm 0cm 0cm 0cm' width=9><p class='AmmCorpsTexte'> </td>
</tr>
<tr style='height:76.8pt'>
<td width=170 colspan=2 valign=top style='width:127.3pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:76.8pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.95pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la peau<span style='letter-spacing:-.2pt'> </span>et du<span style='letter-spacing: -.1pt'> </span>tissu<span style='letter-spacing:-.2pt'> </span>sous-cutané</p>
</td>
<td width=178 colspan=2 valign=top style='width:133.3pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:76.8pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:3.7pt;margin-bottom:.0001pt;text-align:left; page-break-after:avoid'>Alopécie<span style='letter-spacing:-.65pt'> </span>(G3/4: <span style='letter-spacing:-.15pt'>&lt;0,1%);</span></p>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:3.7pt;margin-bottom:.0001pt;text-align:left; page-break-after:avoid'><span style='letter-spacing:-.15pt'>Toxicité cutanée (G3/4:</span></p>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:3.7pt;margin-bottom:.0001pt;text-align:left; page-break-after:avoid'>0,6<span style='letter-spacing:-.05pt'>%</span>);</p>
<p class=AmmCorpsTexte align=left style='margin-left:3.6pt;text-align:left'><span style='letter-spacing:-.15pt'>Altération des ongles </span>(G3/4:<span style='letter-spacing:-.5pt'> </span>0,4<span style='letter-spacing:-.05pt'>%</span>)</p>
</td>
<td width=157 colspan=2 valign=top style='width:117.4pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:76.8pt'>
<p class=AmmCorpsTexte align=left style='margin-left:3.45pt;text-align:left'> </p>
</td>
<td width=152 colspan=2 valign=top style='width:114.05pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:76.8pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.2pt;text-align:left'> </p>
</td>
<td style='border:none;padding:0cm 0cm 0cm 0cm' width=9><p class='AmmCorpsTexte'> </td>
</tr>
<tr style='height:38.65pt'>
<td width=170 colspan=2 valign=top style='width:127.3pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:38.65pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.95pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>u</span>sculo- squelettiques et s<span style='letter-spacing:.1pt'>y</span>sté<span style='letter-spacing:-.1pt'>m</span>iques</p>
</td>
<td width=178 colspan=2 valign=top style='width:133.3pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:38.65pt'>
<p class=AmmCorpsTexte align=left style='margin-left:3.6pt;text-align:left'>M<span style='letter-spacing:.1pt'>y</span>algie<span style='letter-spacing:-.05pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>0,7<span style='letter-spacing:-.05pt'>%</span>); Arthralgie<span style='letter-spacing: .05pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>0,2<span style='letter-spacing:-.05pt'>%</span>)</p>
</td>
<td width=157 colspan=2 valign=top style='width:117.4pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:38.65pt'>
<p class=AmmCorpsTexte align=left style='margin-left:3.45pt;text-align:left'> </p>
</td>
<td width=152 colspan=2 valign=top style='width:114.05pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:38.65pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.2pt;text-align:left'> </p>
</td>
<td style='border:none;border-bottom:solid black 1.0pt' width=9><p class='AmmCorpsTexte'> </td>
</tr>
<tr style='height:39.2pt'>
<td style='border:none;padding:0cm 0cm 0cm 0cm' width=9><p class='AmmCorpsTexte'> </td>
<td width=170 colspan=2 valign=top style='width:127.3pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:39.2pt'>
<p class=AmmCorpsTexte style='margin-left:2.4pt;page-break-after:avoid'><b>Base<span style='letter-spacing:-.45pt'> </span>de<span style='letter-spacing:-.1pt'> </span>données Medra<span style='letter-spacing:-.1pt'> </span>des<span style='letter-spacing: -.15pt'> </span>classes<span style='letter-spacing:-.3pt'> </span>de système d’organe</b></p>
</td>
<td width=178 colspan=2 valign=top style='width:133.3pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:39.2pt'>
<p class=AmmCorpsTexte style='margin-left:7.15pt;page-break-after:avoid'><b>Très<span style='letter-spacing:-.45pt'> </span>fréquent</b></p>
</td>
<td width=157 colspan=2 valign=top style='width:117.4pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:39.2pt'>
<p class=AmmCorpsTexte style='margin-left:7.0pt;page-break-after:avoid'><b>Fréquent</b></p>
</td>
<td width=152 colspan=2 valign=top style='width:114.05pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:39.2pt'>
<p class=AmmCorpsTexte style='margin-left:7.75pt;page-break-after:avoid'><b>Peu<span style='letter-spacing:-.45pt'> </span>fréquent</b></p>
</td>
</tr>
<tr style='height:38.65pt'>
<td style='border:none;padding:0cm 0cm 0cm 0cm' width=9><p class='AmmCorpsTexte'> </td>
<td width=170 colspan=2 valign=top style='width:127.3pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:38.65pt'>
<p class=AmmCorpsTexte align=left style='margin-left:2.4pt;text-align:left; page-break-after:avoid'>Affections<span style='letter-spacing:-.7pt'> </span>des<span style='letter-spacing:-.15pt'> </span>organes de reproduction<span style='letter-spacing:-.45pt'> </span>et<span style='letter-spacing:.05pt'> </span>du sein</p>
</td>
<td width=178 colspan=2 valign=top style='width:133.3pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:38.65pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.15pt;text-align:left; page-break-after:avoid'>A<span style='letter-spacing:-.1pt'>m</span>énorrhée<span style='letter-spacing:-.1pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>non déter<span style='letter-spacing:-.05pt'>m</span>iné);</p>
</td>
<td width=157 colspan=2 valign=top style='width:117.4pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:38.65pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.0pt;text-align:left; page-break-after:avoid'> </p>
</td>
<td width=152 colspan=2 valign=top style='width:114.05pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:38.65pt'>
<p class=AmmCorpsTexte align=left style='text-align:left;page-break-after: avoid'> </p>
</td>
</tr>
<tr style='height:76.8pt'>
<td style='border:none;padding:0cm 0cm 0cm 0cm' width=9><p class='AmmCorpsTexte'> </td>
<td width=170 colspan=2 valign=top style='width:127.3pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:76.8pt'>
<p class=AmmCorpsTexte align=left style='margin-left:2.4pt;text-align:left'>Troubles<span style='letter-spacing:-.65pt'> </span>généraux<span style='letter-spacing: -.35pt'> </span>et ano<span style='letter-spacing:-.1pt'>m</span>alies<span style='letter-spacing:-.15pt'> </span>au<span style='letter-spacing:-.1pt'> </span>site d’ad<span style='letter-spacing:-.1pt'>m</span>inistration</p>
</td>
<td width=178 colspan=2 valign=top style='width:133.3pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:76.8pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:7.1pt;margin-bottom:.0001pt;text-align:left'>Asthénie<span style='letter-spacing:-.65pt'> </span>(G3/4: 10,0<span style='letter-spacing: -.05pt'>%</span>);</p>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:7.1pt;margin-bottom:.0001pt;text-align:left'>Fièvre<span style='letter-spacing:-.5pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>non déter<span style='letter-spacing:-.05pt'>m</span>iné);</p>
<p class=AmmCorpsTexte align=left style='margin-left:7.15pt;text-align:left'>Œdè<span style='letter-spacing:-.1pt'>m</span>e<span style='letter-spacing:-.2pt'> </span>périphérique (G3/4:<span style='letter-spacing:-.5pt'> </span>0,2<span style='letter-spacing: -.05pt'>%</span>)</p>
</td>
<td width=157 colspan=2 valign=top style='width:117.4pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:76.8pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.0pt;text-align:left'> </p>
</td>
<td width=152 colspan=2 valign=top style='width:114.05pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:76.8pt'>
<p class=AmmCorpsTexte align=left style='text-align:left'> </p>
</td>
</tr>
<tr style='height:50.55pt'>
<td style='border:none;padding:0cm 0cm 0cm 0cm' width=9><p class='AmmCorpsTexte'> </td>
<td width=170 colspan=2 valign=top style='width:127.3pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:50.55pt'>
<p class=AmmCorpsTexte align=left style='margin-left:2.4pt;text-align:left'>Investigations</p>
</td>
<td width=178 colspan=2 valign=top style='width:133.3pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:50.55pt'>
<p class=AmmCorpsTexte align=left style='text-align:left'> </p>
</td>
<td width=157 colspan=2 valign=top style='width:117.4pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:50.55pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:7.1pt;margin-bottom:.0001pt;text-align:left'>Prise<span style='letter-spacing:-.45pt'> </span>de<span style='letter-spacing:-.1pt'> </span>poids<span style='letter-spacing:-.2pt'> </span>(G3/4: 0<span style='letter-spacing: -.05pt'>%</span>)</p>
<p class=AmmCorpsTexte align=left style='margin-left:7.0pt;text-align:left'>Perte<span style='letter-spacing:-.5pt'> </span>de<span style='letter-spacing:-.1pt'> </span>poids<span style='letter-spacing:-.2pt'> </span>((G3/4: 0,2<span style='letter-spacing: -.05pt'>%</span>);</p>
</td>
<td width=152 colspan=2 valign=top style='width:114.05pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:50.55pt'>
<p class=AmmCorpsTexte align=left style='text-align:left'> </p>
</td>
</tr>
<tr height=0>
<td width=9 style='border:none'></td>
<td width=160 style='border:none'></td>
<td width=9 style='border:none'></td>
<td width=168 style='border:none'></td>
<td width=9 style='border:none'></td>
<td width=147 style='border:none'></td>
<td width=9 style='border:none'></td>
<td width=143 style='border:none'></td>
<td width=9 style='border:none'></td>
</tr>
</table>
</div>
<p class=AmmCorpsTexte style='margin-top:6.0pt'>Description de certains effets indésirables pour le traitement adjuvant avec docetaxel 75 mg/m² en association avec la doxorubicine et le cyclophosphamide chez des patients avec cancer du sein avec envahissement ganglionnaire (TAX 316) et sans envahissement ganglionnaire (GEICAM 9805)</p>
<p class=AmmCorpsTexte><u>Affections du système nerveux</u><span style='letter-spacing:-.05pt'> </span>:</p>
<p class=AmmCorpsTexte>Sur 84 patientes ayant présenté une neuropathie sensitive périphérique à la fin de la chimiothérapie, dans l’étude cancer du sein avec envahissement ganglionnaire (TAX316), les troubles neurosensoriels persistaient encore chez 10 patientes après le suivi.</p>
<p class=AmmCorpsTexte><u>Affections cardiaques</u> :</p>
<p class=AmmCorpsTexte>Dans l’étude TAX316, 26 patientes dans le bras TAC (3,5%) et 17 patientes dans le bras FAC (2,3%) présentaient une insuffisance cardiaque congestive. Une insuffisance cardiaque congestive a été <span lang=ES>diagnostiquée chez toutes les patientes, plus de 30 jours après la période de traitement, à l’exception d’une patiente dans chaque bras. Deux patientes dans le bras TAC et 4 patientes dans le bras FAC sont </span>décédées à cause d’une insuffisance cardiaque.</p>
<p class=AmmCorpsTexte><u>Affections de la peau et du tissu sous-cutané</u><span style='letter-spacing:-.1pt'> </span>:</p>
<p class=AmmCorpsTexte style='margin-bottom:0cm;margin-bottom:.0001pt'><span lang=ES>Dans l’étude TAX316, des alopécies persistantes ont été rapportées pendant la période de suivi après la fin de la chimiothérapie, chez 687 patientes TAC et 645 patientes FAC.</span></p>
<p class=AmmCorpsTexte><span lang=ES>A la fin de la période de suivi, des alopécies persistaient chez 29 patientes TAC (4,2%) et 16 patientes </span>FAC (2,4%).</p>
<p class=AmmCorpsTexte><u>Affections des organes de reproduction et du sein</u><i> :</i></p>
<p class=AmmCorpsTexte><span lang=ES>Dans l’étude TAX316, s</span>ur<span style='letter-spacing:-.4pt'> </span>les<span style='letter-spacing:-.1pt'> </span>202<span style='letter-spacing:-.15pt'> </span>patientes<span style='letter-spacing: -.35pt'> </span>a<span style='letter-spacing:.1pt'>y</span>ant<span style='letter-spacing:-.05pt'> </span>présenté<span style='letter-spacing:-.35pt'> </span>une<span style='letter-spacing:-.15pt'> </span>a<span style='letter-spacing: -.1pt'>m</span>énorrhée à la fin<span style='letter-spacing:-.1pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la chi<span style='letter-spacing:-.05pt'>m</span>iothérapie,<span style='letter-spacing:-.1pt'> </span>l<span style='letter-spacing:.05pt'>’</span>a<span style='letter-spacing:-.1pt'>m</span>énorrhée<span style='letter-spacing:-.05pt'> </span>persistait encore<span style='letter-spacing:-.25pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>121<span style='letter-spacing:-.15pt'> </span>patientes<span style='letter-spacing:-.35pt'> </span>après<span style='letter-spacing:-.2pt'> </span>le suivi.</p>
<p class=AmmCorpsTexte><u>Troubles généraux et anomalies au site d’administration</u> :</p>
<p class=AmmCorpsTexte style='margin-bottom:0cm;margin-bottom:.0001pt'><span lang=ES>Dans l’étude TAX316, sur les 119 patientes ayant présenté un oedème périphérique dans le bras TAC, l’oedème périphérique persistait encore chez 19 patientes et sur les 23 patientes ayant présenté un oedème périphérique dans le bras FAC, l’oedème périphérique persistait encore chez 4 patientes.</span></p>
<p class=AmmCorpsTexte><span lang=ES>Dans l’étude GEICAM 9805, sur les 5 patientes ayant présenté un lymphoedème à la fin de la chimiothérapie, le lymphoedème persistait encore chez 4 patientes après le suivi.</span></p>
<p class=AmmCorpsTexte><u>Leucémie aigue / Syndrome myélodysplasique</u> :</p>
<p class=AmmCorpsTexte><span lang=ES>Après un suivi de 10 ans dans l’étude TAX316, une leucémie aigue a été rapportée chez 4 patientes TAC sur 744 et chez 1 patiente FAC sur 736. Un syndrome myélodysplasique a été rapporté chez 2 patientes TAC sur 744 et 1 patiente FAC sur 736.</span></p>
<p class=AmmCorpsTexte>Après<span style='letter-spacing:-.5pt'> </span>un<span style='letter-spacing:-.1pt'> </span>suivi<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:-.1pt'>m</span>édian<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.1pt'> </span>77<span style='letter-spacing:-.1pt'> m</span><span style='letter-spacing:.05pt'>o</span>is,<span style='letter-spacing:-.1pt'> </span>une patiente sur<span style='letter-spacing:-.1pt'> </span>532<span style='letter-spacing:-.15pt'> </span>a<span style='letter-spacing:.1pt'>y</span>ant<span style='letter-spacing:-.05pt'> </span>reçu<span style='letter-spacing:-.15pt'> </span>l<span style='letter-spacing:.05pt'>’</span>association<span style='letter-spacing: -.05pt'> </span>docétaxel,<span style='letter-spacing:-.4pt'> </span>doxorubicine<span style='letter-spacing:-.5pt'> </span>et c<span style='letter-spacing:.1pt'>y</span>clophospha<span style='letter-spacing:-.05pt'>m</span>ide<span style='letter-spacing:-.15pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>l<span style='letter-spacing:.05pt'>’</span>étude<span style='letter-spacing:-.05pt'> </span>GEICAM 9805 a présenté<span style='letter-spacing:-.35pt'> </span>une<span style='letter-spacing:-.15pt'> </span>leucé<span style='letter-spacing:-.05pt'>m</span>ie<span style='letter-spacing:-.2pt'> </span>aigue<span style='letter-spacing:-.2pt'> </span>(0,2%).<span style='letter-spacing:-.2pt'> </span>Aucun<span style='letter-spacing:-.25pt'> </span>cas n<span style='letter-spacing:.05pt'>’</span>a été rapporté<span style='letter-spacing: -.35pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>des<span style='letter-spacing:-.15pt'> </span>patientes<span style='letter-spacing: -.35pt'> </span>a<span style='letter-spacing:.1pt'>y</span>ant<span style='letter-spacing:-.05pt'> </span>reçu<span style='letter-spacing:-.15pt'> </span>l<span style='letter-spacing:.05pt'>’</span>association<span style='letter-spacing: -.05pt'> </span>fluoro-uracile,<span style='letter-spacing:-.45pt'> </span>doxorubicine<span style='letter-spacing:.05pt'> </span>et c<span style='letter-spacing:.1pt'>y</span>clophospha<span style='letter-spacing:-.05pt'>m</span>ide. Aucun s<span style='letter-spacing: .1pt'>y</span>ndro<span style='letter-spacing:-.1pt'>m</span>e<span style='letter-spacing:-.05pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.1pt'>y</span>élod<span style='letter-spacing:.1pt'>y</span>splasique<span style='letter-spacing:-.1pt'> </span>n’a<span style='letter-spacing:-.15pt'> </span>été<span style='letter-spacing:.05pt'> </span>diagnostiqué<span style='letter-spacing: -.45pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>l’un<span style='letter-spacing:-.15pt'> </span>des deux<span style='letter-spacing:-.2pt'> </span>groupes<span style='letter-spacing:-.3pt'> </span>de<span style='letter-spacing:-.1pt'> </span>traite<span style='letter-spacing:-.05pt'>m</span>ent.</p>
<p class=AmmCorpsTexte><i>Complications neutropéniques</i></p>
<p class=AmmCorpsTexte>Le<span style='letter-spacing: -.35pt'> </span>tableau<span style='letter-spacing:-.25pt'> </span>ci-dessous<span style='letter-spacing:-.4pt'> </span><span style='letter-spacing:-.1pt'>m</span>ontre<span style='letter-spacing:-.1pt'> </span>que<span style='letter-spacing:-.15pt'> </span>l’incidence<span style='letter-spacing:-.4pt'> </span>des<span style='letter-spacing:-.15pt'> </span>n<span style='letter-spacing:-.05pt'>e</span>utropénies<span style='letter-spacing: -.05pt'> </span>de<span style='letter-spacing:-.1pt'> </span>Grade<span style='letter-spacing:-.25pt'> </span>4,<span style='letter-spacing:2.4pt'> </span>des<span style='letter-spacing:-.15pt'> </span>neutropénies<span style='letter-spacing: -.5pt'> </span>fébriles<span style='letter-spacing:-.3pt'> </span>et des infections<span style='letter-spacing:-.4pt'> </span>neutropéniques<span style='letter-spacing:-.6pt'> </span>di<span style='letter-spacing:-.1pt'>m</span>inue<span style='letter-spacing:-.2pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>des<span style='letter-spacing:-.1pt'> </span>patientes<span style='letter-spacing:-.35pt'> </span>a<span style='letter-spacing:.1pt'>y</span>ant<span style='letter-spacing: -.05pt'> </span>reçu<span style='letter-spacing:-.15pt'> </span>une<span style='letter-spacing:-.15pt'> </span>proph<span style='letter-spacing:.1pt'>y</span>laxie<span style='letter-spacing:-.25pt'> </span>pri<span style='letter-spacing:-.1pt'>m</span>aire<span style='letter-spacing:-.1pt'> </span>par<span style='letter-spacing:-.15pt'> </span>G-CSF après a<span style='letter-spacing:-.1pt'>m</span>ende<span style='letter-spacing: -.05pt'>m</span>ent<span style='letter-spacing:-.1pt'> </span>du<span style='letter-spacing:-.1pt'> </span>protocole,<span style='letter-spacing: -.4pt'> </span>rendant<span style='letter-spacing:-.3pt'> </span>c<span style='letter-spacing:-.05pt'>e</span>tte<span style='letter-spacing:.05pt'> </span>proph<span style='letter-spacing:.1pt'>y</span>laxie<span style='letter-spacing:-.2pt'> </span>obligatoire<span style='letter-spacing:-.45pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>le groupe<span style='letter-spacing:-.3pt'> </span>TAC<span style='letter-spacing: -.2pt'> </span>–<span style='letter-spacing:-.05pt'> </span>Etude GEICAM.</p>
<p class=AmmCorpsTexte>Les<span style='letter-spacing:-.4pt'> </span>co<span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>p</span>lications<span style='letter-spacing:-.1pt'> </span>neutropéniques<span style='letter-spacing: -.6pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>des<span style='letter-spacing:-.15pt'> </span>patientes<span style='letter-spacing: -.35pt'> </span>recevant<span style='letter-spacing:-.35pt'> </span>le protocole<span style='letter-spacing:-.4pt'> </span>TAC<span style='letter-spacing: -.2pt'> </span>avec<span style='letter-spacing:-.2pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>sans proph<span style='letter-spacing: .1pt'>y</span>laxie pri<span style='letter-spacing:-.1pt'>m</span>aire<span style='letter-spacing:-.1pt'> </span>par<span style='letter-spacing:-.15pt'> </span>G-CSF<span style='letter-spacing:-.3pt'> </span>(GEICAM<span style='letter-spacing:-.45pt'> </span>9805).</p>
<div align=center>
<table class=AmmCorpsTexteTable border=0 cellspacing=0 cellpadding=0
style='margin-left:5.15pt;border-collapse:collapse'>
<tr style='height:26.9pt'>
<td width=204 valign=top style='width:153.35pt;border:solid black 1.0pt;
border-bottom:none;padding:0cm 0cm 0cm 0cm;height:26.9pt'>
<p class=AmmCorpsTexte> </p>
</td>
<td width=205 valign=top style='width:153.45pt;border-top:solid black 1.0pt;
border-left:none;border-bottom:none;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:26.9pt'>
<p class=AmmCorpsTexte><b>Sans prophylaxie primaire par G-CSF (n=111)</b></p>
</td>
<td width=205 valign=top style='width:153.45pt;border-top:solid black 1.0pt;
border-left:none;border-bottom:none;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:26.9pt'>
<p class=AmmCorpsTexte><b>Avec prophylaxie primaire par G-CSF (n=421)</b></p>
</td>
</tr>
<tr style='height:20.95pt'>
<td width=204 valign=top style='width:153.35pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:20.95pt'>
<p class=AmmCorpsTexte> </p>
</td>
<td width=205 valign=top style='width:153.45pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:20.95pt'>
<p class=AmmCorpsTexte><b>n(%)</b></p>
</td>
<td width=205 valign=top style='width:153.45pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:20.95pt'>
<p class=AmmCorpsTexte><b>n(%)</b></p>
</td>
</tr>
<tr style='height:13.2pt'>
<td width=204 valign=top style='width:153.35pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:13.2pt'>
<p class=AmmCorpsTexte>Neutropénie<span style='letter-spacing:-.75pt'> </span>(Grade<span style='letter-spacing:-.3pt'> </span>4)</p>
</td>
<td width=205 valign=top style='width:153.45pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:13.2pt'>
<p class=AmmCorpsTexte>104 (93,7)</p>
</td>
<td width=205 valign=top style='width:153.45pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:13.2pt'>
<p class=AmmCorpsTexte>135 (32,1)</p>
</td>
</tr>
<tr style='height:13.2pt'>
<td width=204 valign=top style='width:153.35pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:13.2pt'>
<p class=AmmCorpsTexte>Neutropénie<span style='letter-spacing:-.75pt'> </span>fébrile</p>
</td>
<td width=205 valign=top style='width:153.45pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:13.2pt'>
<p class=AmmCorpsTexte>28 (25,2)</p>
</td>
<td width=205 valign=top style='width:153.45pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:13.2pt'>
<p class=AmmCorpsTexte>23 (5,5)</p>
</td>
</tr>
<tr style='height:13.2pt'>
<td width=204 valign=top style='width:153.35pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:13.2pt'>
<p class=AmmCorpsTexte>Infection<span style='letter-spacing:-.6pt'> </span>neutropénique</p>
</td>
<td width=205 valign=top style='width:153.45pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:13.2pt'>
<p class=AmmCorpsTexte>14 (12,6)</p>
</td>
<td width=205 valign=top style='width:153.45pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:13.2pt'>
<p class=AmmCorpsTexte>21 (5,0)</p>
</td>
</tr>
<tr style='height:16.15pt'>
<td width=204 valign=top style='width:153.35pt;border-top:none;border-left:
solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:16.15pt'>
<p class=AmmCorpsTexte>Infection<span style='letter-spacing:-.6pt'> </span>neutropénique</p>
</td>
<td width=205 valign=top style='width:153.45pt;border:none;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:16.15pt'>
<p class=AmmCorpsTexte>2 (1,8)</p>
</td>
<td width=205 valign=top style='width:153.45pt;border:none;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:16.15pt'>
<p class=AmmCorpsTexte>5 (1,2)</p>
</td>
</tr>
<tr style='height:25.9pt'>
<td width=204 valign=top style='width:153.35pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:25.9pt'>
<p class=AmmCorpsTexte>(Grade<span style='letter-spacing:-.55pt'> </span>3-4)</p>
</td>
<td width=205 valign=top style='width:153.45pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:25.9pt'>
<p class=AmmCorpsTexte> </p>
</td>
<td width=205 valign=top style='width:153.45pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:25.9pt'>
<p class=AmmCorpsTexte> </p>
</td>
</tr>
</table>
</div>
<p class=AmmCorpsTexte style='margin-top:6.0pt'><b>Tableau des effets indésirables dans l’adénocarcinome gastrique pour docétaxel 75 <span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.1pt'>m</span>² en association avec le cisplatine<span style='letter-spacing:.05pt'> </span>et le 5-fluoro-uracile dans l<span style='letter-spacing:.05pt'>’</span>adénocarcino<span style='letter-spacing: -.05pt'>m</span>e gastrique</b></p>
<div align=center>
<table class=AmmCorpsTexteTable border=0 cellspacing=0 cellpadding=0
style='margin-left:-16.0pt;border-collapse:collapse'>
<tr style='height:26.3pt'>
<td width=233 valign=top style='width:174.5pt;border:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:26.3pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.0pt;text-align:left'><b>Base<span style='letter-spacing:-.45pt'> </span>de<span style='letter-spacing:-.1pt'> </span>données<span style='letter-spacing:-.35pt'> </span>MeDRA<span style='letter-spacing:-.35pt'> </span>des classes de<span style='letter-spacing:-.1pt'> </span>système<span style='letter-spacing:-.35pt'> </span>d’organe</b></p>
</td>
<td width=188 valign=top style='width:141.35pt;border:solid black 1.0pt;
border-left:none;padding:0cm 0cm 0cm 0cm;height:26.3pt'>
<p class=AmmCorpsTexte align=left style='margin-left:6.7pt;text-align:left'><b>Très<span style='letter-spacing:-.45pt'> </span>fréquent</b></p>
</td>
<td width=221 valign=top style='width:165.55pt;border:solid black 1.0pt;
border-left:none;padding:0cm 0cm 0cm 0cm;height:26.3pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.1pt;text-align:left'><b>Fréquent</b></p>
</td>
</tr>
<tr style='height:31.8pt'>
<td width=233 valign=top style='width:174.5pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:31.8pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.0pt;text-align:left'>Infections<span style='letter-spacing:-.7pt'> </span>et infestations</p>
</td>
<td width=188 valign=top style='width:141.35pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:31.8pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:6.7pt;margin-bottom:.0001pt;text-align:left'>Infection<span style='letter-spacing:-.65pt'> </span>neutropénique;</p>
<p class=AmmCorpsTexte align=left style='margin-left:6.7pt;text-align:left'>Infection<span style='letter-spacing:.05pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>11,7<span style='letter-spacing:-.05pt'>%</span>)</p>
</td>
<td width=221 valign=top style='width:165.55pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:31.8pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.1pt;text-align:left'> </p>
</td>
</tr>
<tr style='height:51.35pt'>
<td width=233 valign=top style='width:174.5pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:51.35pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.0pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span>hé<span style='letter-spacing:-.1pt'>m</span>atologiques<span style='letter-spacing:-.5pt'> </span>et du s<span style='letter-spacing:.1pt'>y</span>stè<span style='letter-spacing:-.1pt'>m</span>e l<span style='letter-spacing:.1pt'>y</span><span style='letter-spacing:-.1pt'>m</span>phatique</p>
</td>
<td width=188 valign=top style='width:141.35pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:51.35pt'>
<p class=AmmCorpsTexte align=left style='margin-left:6.7pt;text-align:left'>Ané<span style='letter-spacing:-.1pt'>m</span>ie<span style='letter-spacing:-.2pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>20,9<span style='letter-spacing:-.05pt'>%</span>); Neutropénie<span style='letter-spacing:.05pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>83,2<span style='letter-spacing:-.05pt'>%</span>); Thro<span style='letter-spacing:-.1pt'>m</span>bopénie<span style='letter-spacing: .05pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>8,8<span style='letter-spacing:-.05pt'>%</span>); Neutropénie fébrile</p>
</td>
<td width=221 valign=top style='width:165.55pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:51.35pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.1pt;text-align:left'> </p>
</td>
</tr>
<tr style='height:25.9pt'>
<td width=233 valign=top style='width:174.5pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:25.9pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.0pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span>du<span style='letter-spacing:-.1pt'> </span>s<span style='letter-spacing:.1pt'>y</span>stè<span style='letter-spacing:-.1pt'>m</span>e i<span style='letter-spacing:-.1pt'>mm</span>unitaire</p>
</td>
<td width=188 valign=top style='width:141.35pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:25.9pt'>
<p class=AmmCorpsTexte align=left style='margin-left:6.7pt;text-align:left'>H<span style='letter-spacing:.1pt'>y</span>persensibilité<span style='letter-spacing: -.1pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>1,7%)</p>
</td>
<td width=221 valign=top style='width:165.55pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:25.9pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.1pt;text-align:left'> </p>
</td>
</tr>
<tr style='height:28.4pt'>
<td width=233 valign=top style='width:174.5pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:28.4pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.0pt;text-align:left'>Troubles<span style='letter-spacing:-.65pt'> </span>du<span style='letter-spacing:-.1pt'> m</span>étabolis<span style='letter-spacing:-.05pt'>m</span>e<span style='letter-spacing:-.35pt'> </span>et de<span style='letter-spacing:-.1pt'> </span>la nutrition</p>
</td>
<td width=188 valign=top style='width:141.35pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:28.4pt'>
<p class=AmmCorpsTexte align=left style='margin-left:6.7pt;text-align:left'>Anorexie<span style='letter-spacing:-.65pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>11,7<span style='letter-spacing:-.05pt'>%</span>)</p>
</td>
<td width=221 valign=top style='width:165.55pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:28.4pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.1pt;text-align:left'> </p>
</td>
</tr>
<tr style='height:38.65pt'>
<td width=233 valign=top style='width:174.5pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:38.65pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.0pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span>du<span style='letter-spacing:-.1pt'> </span>s<span style='letter-spacing:.1pt'>y</span>stè<span style='letter-spacing:-.1pt'>m</span>e<span style='letter-spacing:-.05pt'> </span>nerveux</p>
</td>
<td width=188 valign=top style='width:141.35pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:38.65pt'>
<p class=AmmCorpsTexte align=left style='margin-left:6.7pt;text-align:left'>Neuropathie<span style='letter-spacing:-.8pt'> </span>sensitive périphérique<span style='letter-spacing:.05pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>8,7<span style='letter-spacing:-.05pt'>%</span>)</p>
</td>
<td width=221 valign=top style='width:165.55pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:38.65pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.1pt;text-align:left'>Vertiges<span style='letter-spacing:-.6pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>2,3<span style='letter-spacing:-.05pt'>%</span>); Neuropathie <span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>o</span>trice périphérique<span style='letter-spacing:-.45pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>1,3<span style='letter-spacing:-.05pt'>%</span>)</p>
</td>
</tr>
<tr style='height:31.5pt'>
<td width=233 valign=top style='width:174.5pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:31.5pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.0pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span>oculaires</p>
</td>
<td width=188 valign=top style='width:141.35pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:31.5pt'>
<p class=AmmCorpsTexte align=left style='margin-left:6.7pt;text-align:left'> </p>
</td>
<td width=221 valign=top style='width:165.55pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:31.5pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.1pt;text-align:left'>Aug<span style='letter-spacing:-.1pt'>m</span>entation<span style='letter-spacing: -.15pt'> </span>du<span style='letter-spacing:-.1pt'> </span>lar<span style='letter-spacing:-.05pt'>m</span>oie<span style='letter-spacing:-.05pt'>m</span>ent (G3/4:<span style='letter-spacing:-.55pt'> </span>0<span style='letter-spacing: -.05pt'>%</span>)</p>
</td>
</tr>
<tr style='height:16.3pt'>
<td width=233 valign=top style='width:174.5pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:16.3pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.0pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span>de<span style='letter-spacing:-.1pt'> </span>l’oreille<span style='letter-spacing:-.25pt'> </span>et du lab<span style='letter-spacing: .1pt'>y</span>rinthe</p>
</td>
<td width=188 valign=top style='width:141.35pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:16.3pt'>
<p class=AmmCorpsTexte align=left style='margin-left:6.7pt;text-align:left'> </p>
</td>
<td width=221 valign=top style='width:165.55pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:16.3pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.1pt;text-align:left'>Troubles<span style='letter-spacing:-.6pt'> </span>de<span style='letter-spacing:-.1pt'> </span>l’audition<span style='letter-spacing:-.35pt'> </span>(G3/4: 0<span style='letter-spacing: -.05pt'>%</span>)</p>
</td>
</tr>
<tr style='height:16.7pt'>
<td width=233 valign=top style='width:174.5pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:16.7pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.0pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span>cardiaques</p>
</td>
<td width=188 valign=top style='width:141.35pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:16.7pt'>
<p class=AmmCorpsTexte align=left style='margin-left:6.7pt;text-align:left'> </p>
</td>
<td width=221 valign=top style='width:165.55pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:16.7pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.1pt;text-align:left'>Ar<span style='letter-spacing:.1pt'>y</span>th<span style='letter-spacing:-.1pt'>m</span>ie<span style='letter-spacing:-.15pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>1,0<span style='letter-spacing:-.05pt'>%</span>)</p>
</td>
</tr>
<tr style='height:64.1pt'>
<td width=233 valign=top style='width:174.5pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:64.1pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.0pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span>gastro-intestinales</p>
</td>
<td width=188 valign=top style='width:141.35pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:64.1pt'>
<p class=AmmCorpsTexte align=left style='margin-left:6.7pt;text-align:left'>Diarrhée<span style='letter-spacing:-.65pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>19,7%); Nausées (G3/4: 16%); Sto<span style='letter-spacing:-.1pt'>m</span>atite<span style='letter-spacing:.05pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>23,7%);<span style='letter-spacing:-.3pt'> </span>Vo<span style='letter-spacing:-.1pt'>m</span>isse<span style='letter-spacing:-.1pt'>m</span>ents (G3/4:<span style='letter-spacing:-.25pt'> </span>14,3%)</p>
</td>
<td width=221 valign=top style='width:165.55pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:64.1pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.1pt;text-align:left'>Constipation<span style='letter-spacing:-.75pt'> </span>(G3/4:<span style='letter-spacing:-.2pt'> </span>1.0<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing: -.05pt'>%</span>); Douleurs<span style='letter-spacing:-.35pt'> </span>gastro-intestinales (G3/4:<span style='letter-spacing:.05pt'> </span>1,0<span style='letter-spacing: -.05pt'>%</span>); Œsophagite/d<span style='letter-spacing:.1pt'>y</span>sphagie/ od<span style='letter-spacing:.1pt'>y</span>nophagie<span style='letter-spacing: .05pt'> </span>(G3/4:<span style='letter-spacing:-.2pt'> </span>0,7<span style='letter-spacing:-.05pt'>%</span>)</p>
</td>
</tr>
<tr style='height:64.1pt'>
<td width=233 valign=top style='width:174.5pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:64.1pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.0pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la peau<span style='letter-spacing:-.2pt'> </span>et du<span style='letter-spacing: -.1pt'> </span>tissu sous-cutané</p>
</td>
<td width=188 valign=top style='width:141.35pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:64.1pt'>
<p class=AmmCorpsTexte align=left style='margin-left:6.7pt;text-align:left'>Alopécie<span style='letter-spacing:-.65pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>4,0<span style='letter-spacing:-.05pt'>%</span>)</p>
</td>
<td width=221 valign=top style='width:165.55pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:64.1pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.1pt;text-align:left'>Rash,<span style='letter-spacing:-.5pt'> </span>démangeaison (G3/4: 0,7%); Altération des ongles (G3/4: 0,7<span style='letter-spacing:-.05pt'>%</span>); Desqua<span style='letter-spacing:-.1pt'>m</span>ation<span style='letter-spacing:-.5pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>0<span style='letter-spacing:-.05pt'>%</span>)</p>
</td>
</tr>
<tr style='height:64.1pt'>
<td width=233 valign=top style='width:174.5pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:64.1pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.0pt;text-align:left'>Troubles<span style='letter-spacing:-.65pt'> </span>généraux<span style='letter-spacing: -.35pt'> </span>et ano<span style='letter-spacing:-.1pt'>m</span>alies<span style='letter-spacing:-.15pt'> </span>au site d<span style='letter-spacing: .05pt'>’</span>ad<span style='letter-spacing:-.1pt'>m</span>inistration</p>
</td>
<td width=188 valign=top style='width:141.35pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:64.1pt'>
<p class=AmmCorpsTexte align=left style='margin-left:6.7pt;text-align:left'>Léthargie<span style='letter-spacing:-.6pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>19,0<span style='letter-spacing:-.05pt'>%</span>);<span style='letter-spacing:-.15pt'> </span>Fièvre (G3/4: 2,3%); Rétention hydrique (sévère/menaçant le pronostic<span style='letter-spacing:-.35pt'> </span>vital: 1%)</p>
</td>
<td width=221 valign=top style='width:165.55pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:64.1pt'>
<p class=AmmCorpsTexte align=left style='text-align:left'> </p>
</td>
</tr>
</table>
</div>
<p class=AmmCorpsTexte> </p>
<p class=AmmCorpsTexte><b><u>Description de certains effets indésirables dans l’adénocarcinome gastrique pour docetaxel 75 mg/m² en association avec le cisplatine et le 5-fluorouracile</u></b></p>
<p class=AmmCorpsTexte><u>Affections hématologiques et du système lymphatique</u><span style='letter-spacing:-.05pt'> </span>:</p>
<p class=AmmCorpsTexte>La<span style='letter-spacing:-.35pt'> </span>neutropénie<span style='letter-spacing:-.4pt'> </span>fébrile<span style='letter-spacing:-.25pt'> </span>et l’infection<span style='letter-spacing:-.35pt'> </span>neutropénique<span style='letter-spacing:-.5pt'> </span>surviennent<span style='letter-spacing: -.45pt'> </span>respective<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.4pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>17,2%<span style='letter-spacing:-.25pt'> </span>et 13,5% des<span style='letter-spacing: -.4pt'> </span>patients<span style='letter-spacing:-.3pt'> </span>sans<span style='letter-spacing:-.15pt'> </span>tenir<span style='letter-spacing:-.2pt'> </span>co<span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>p</span>te<span style='letter-spacing:-.1pt'> </span>de<span style='letter-spacing:-.1pt'> </span>l’utilisation<span style='letter-spacing:-.4pt'> </span>du<span style='letter-spacing:-.1pt'> </span>G-CSF.<span style='letter-spacing:-.3pt'> </span>Le<span style='letter-spacing:-.1pt'> </span>G-CSF<span style='letter-spacing:-.3pt'> </span>a été utilisé<span style='letter-spacing: -.25pt'> </span>en<span style='letter-spacing:-.1pt'> </span>proph<span style='letter-spacing:.1pt'>y</span>laxie<span style='letter-spacing:-.25pt'> </span>secondaire chez 19,3%<span style='letter-spacing:-.25pt'> </span>des<span style='letter-spacing:-.15pt'> </span>patients<span style='letter-spacing:-.3pt'> </span>(10,7%<span style='letter-spacing:-.3pt'> </span>des<span style='letter-spacing:-.15pt'> </span>c<span style='letter-spacing:.1pt'>y</span>cles<span style='letter-spacing:-.05pt'> </span>de<span style='letter-spacing:-.1pt'> </span>chi<span style='letter-spacing:-.05pt'>m</span>iothérapie).<span style='letter-spacing: -.05pt'> </span>La<span style='letter-spacing:-.1pt'> </span>neutropénie<span style='letter-spacing:-.45pt'> </span>fébrile<span style='letter-spacing:-.25pt'> </span>et l’infection<span style='letter-spacing:.05pt'> </span>neutropénique<span style='letter-spacing:-.5pt'> </span>surviennent<span style='letter-spacing: -.45pt'> </span>respective<span style='letter-spacing:-.05pt'>m</span>e<span style='letter-spacing:.05pt'>n</span>t<span style='letter-spacing:-.4pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>12,1%<span style='letter-spacing:-.25pt'> </span>et 3,4%<span style='letter-spacing:-.2pt'> </span>des<span style='letter-spacing: -.15pt'> </span>patients<span style='letter-spacing:-.3pt'> </span>a<span style='letter-spacing:.1pt'>y</span>ant<span style='letter-spacing:-.05pt'> </span>reçu<span style='letter-spacing:-.15pt'> </span>du G-CSF<span style='letter-spacing:-.55pt'> </span>en<span style='letter-spacing:-.1pt'> </span>proph<span style='letter-spacing:.1pt'>y</span>laxie<span style='letter-spacing:-.2pt'> </span>et chez<span style='letter-spacing:-.2pt'> </span>15,6%<span style='letter-spacing: -.25pt'> </span>et 12,9%<span style='letter-spacing:-.25pt'> </span>des<span style='letter-spacing:-.15pt'> </span>pati<span style='letter-spacing:-.05pt'>e</span>nts<span style='letter-spacing:-.15pt'> </span>n’a<span style='letter-spacing:.1pt'>y</span>ant<span style='letter-spacing:-.15pt'> </span>pas<span style='letter-spacing:-.15pt'> </span>reçu<span style='letter-spacing:-.15pt'> </span>de<span style='letter-spacing:-.1pt'> </span>G-CSF<span style='letter-spacing:-.3pt'> </span>(voir rubrique 4.2).</p>
<p class=AmmCorpsTexte><b>Tableau des effets indésirables dans le cancer des voies aéro-digestives supérieures pour Docétaxel 75 <span style='letter-spacing: -.1pt'>m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.1pt'>m</span>² en association avec le cisplati<span style='letter-spacing:-.1pt'>n</span>e et le 5-fluoro-uracile dans les cancers des voies aéro-digestives supérieures</b></p>
<p class=AmmCorpsTexte><b><u>Chi<span style='letter-spacing:-.1pt'>m</span>iothérapie<span style='letter-spacing:-.1pt'> </span>d’induction<span style='letter-spacing: -.4pt'> </span>suivie<span style='letter-spacing:-.15pt'> </span>de<span style='letter-spacing:-.1pt'> </span>radiothérapie<span style='letter-spacing: -.5pt'> </span>(TAX323)</u></b></p>
<div align=center>
<table class=AmmCorpsTexteTable border=0 cellspacing=0 cellpadding=0 width=677
style='width:507.75pt;margin-left:-11.3pt;border-collapse:collapse'>
<tr style='height:43.4pt'>
<td width=206 colspan=2 valign=top style='width:154.65pt;border:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:43.4pt'>
<p class=AmmCorpsTexte align=left style='margin-left:1.75pt;text-align:left'><b>Base<span style='letter-spacing:-.45pt'> </span>de<span style='letter-spacing:-.1pt'> </span>données MeDRA des<span style='letter-spacing:-.15pt'> </span>classes<span style='letter-spacing:-.3pt'> </span>de système d’organe</b></p>
</td>
<td width=176 colspan=2 valign=top style='width:131.65pt;border:solid black 1.0pt;
border-left:none;padding:0cm 0cm 0cm 0cm;height:43.4pt'>
<p class=AmmCorpsTexte align=left style='margin-left:1.75pt;text-align:left'><b>Très<span style='letter-spacing:-.45pt'> </span>fréquent</b></p>
</td>
<td width=194 colspan=2 valign=top style='width:145.7pt;border:solid black 1.0pt;
border-left:none;padding:0cm 0cm 0cm 0cm;height:43.4pt'>
<p class=AmmCorpsTexte align=left style='margin-left:2.8pt;text-align:left'><b>Fréquent</b></p>
</td>
<td width=100 colspan=2 valign=top style='width:75.25pt;border:solid black 1.0pt;
border-left:none;padding:0cm 0cm 0cm 0cm;height:43.4pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.1pt;text-align:left'><b>Peu<span style='letter-spacing:-.45pt'> </span>fréquent</b></p>
</td>
<td style='border:none;padding:0cm 0cm 0cm 0cm' width=1><p class='AmmCorpsTexte'> </td>
</tr>
<tr style='height:29.8pt'>
<td width=206 colspan=2 valign=top style='width:154.65pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:29.8pt'>
<p class=AmmCorpsTexte align=left style='margin-left:1.75pt;text-align:left'>Infections<span style='letter-spacing:-.7pt'> </span>et infestations</p>
</td>
<td width=176 colspan=2 valign=top style='width:131.65pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:29.8pt'>
<p class=AmmCorpsTexte align=left style='margin-left:1.75pt;text-align:left'>Infections<span style='letter-spacing:-.7pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>6,3<span style='letter-spacing:-.05pt'>%</span>)<span style='letter-spacing:-.15pt'> </span>; Infections neutropéniques</p>
</td>
<td width=194 colspan=2 valign=top style='width:145.7pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:29.8pt'>
<p class=AmmCorpsTexte align=left style='margin-left:2.8pt;text-align:left'> </p>
</td>
<td width=100 colspan=2 valign=top style='width:75.25pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:29.8pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.1pt;text-align:left'> </p>
</td>
<td style='border:none;padding:0cm 0cm 0cm 0cm' width=1><p class='AmmCorpsTexte'> </td>
</tr>
<tr style='height:28.1pt'>
<td width=206 colspan=2 valign=top style='width:154.65pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:28.1pt'>
<p class=AmmCorpsTexte align=left style='margin-left:1.75pt;text-align:left'>Tu<span style='letter-spacing:-.1pt'>m</span>eurs<span style='letter-spacing:-.25pt'> </span>bénignes<span style='letter-spacing:-.35pt'> </span>et <span style='letter-spacing:-.1pt'>m</span>alignes<span style='letter-spacing:-.3pt'> </span>(incluant k<span style='letter-spacing:.1pt'>y</span>stes et pol<span style='letter-spacing:.1pt'>y</span><span style='letter-spacing:.05pt'>p</span>es)</p>
</td>
<td width=176 colspan=2 valign=top style='width:131.65pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:28.1pt'>
<p class=AmmCorpsTexte align=left style='margin-left:1.75pt;text-align:left'> </p>
</td>
<td width=194 colspan=2 valign=top style='width:145.7pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:28.1pt'>
<p class=AmmCorpsTexte align=left style='margin-left:2.8pt;text-align:left'>Douleur<span style='letter-spacing:-.6pt'> </span>cancéreuse (G3/4:<span style='letter-spacing: -.5pt'> </span>0,6<span style='letter-spacing:-.05pt'>%</span>)</p>
</td>
<td width=100 colspan=2 valign=top style='width:75.25pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:28.1pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.1pt;text-align:left'> </p>
</td>
<td style='border:none;padding:0cm 0cm 0cm 0cm' width=1><p class='AmmCorpsTexte'> </td>
</tr>
<tr style='height:42.25pt'>
<td width=206 colspan=2 valign=top style='width:154.65pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:42.25pt'>
<p class=AmmCorpsTexte align=left style='margin-left:1.75pt;text-align:left'>Affections hé<span style='letter-spacing:-.1pt'>m</span>atologiques<span style='letter-spacing:-.35pt'> </span>et du s<span style='letter-spacing: .1pt'>y</span>stè<span style='letter-spacing:-.1pt'>m</span>e l<span style='letter-spacing:.1pt'>y</span><span style='letter-spacing:-.1pt'>m</span>phatique</p>
</td>
<td width=176 colspan=2 valign=top style='width:131.65pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:42.25pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:1.75pt;margin-bottom:.0001pt;text-align:left'>Neutropénie<span style='letter-spacing:-.8pt'> </span>(G3/4: 76,3<span style='letter-spacing: -.05pt'>%</span>)<span style='letter-spacing:-.15pt'> </span>;</p>
<p class=AmmCorpsTexte align=left style='margin-left:1.75pt;text-align:left'>Anémie (G3/4: 9,2%) ; Thrombopénie (G3/4: 5,2<span style='letter-spacing:-.05pt'>%</span>)</p>
</td>
<td width=194 colspan=2 valign=top style='width:145.7pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:42.25pt'>
<p class=AmmCorpsTexte align=left style='margin-left:2.8pt;text-align:left'>Neutropénie<span style='letter-spacing:-.8pt'> </span>fébrile</p>
</td>
<td width=100 colspan=2 valign=top style='width:75.25pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:42.25pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.1pt;text-align:left'> </p>
</td>
<td style='border:none;padding:0cm 0cm 0cm 0cm' width=1><p class='AmmCorpsTexte'> </td>
</tr>
<tr style='height:21.6pt'>
<td width=206 colspan=2 valign=top style='width:154.65pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:21.6pt'>
<p class=AmmCorpsTexte align=left style='margin-left:1.75pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span>du<span style='letter-spacing:-.1pt'> </span>s<span style='letter-spacing:.1pt'>y</span>stè<span style='letter-spacing:-.1pt'>m</span>e i<span style='letter-spacing:-.1pt'>mm</span>unitaire</p>
</td>
<td width=176 colspan=2 valign=top style='width:131.65pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:21.6pt'>
<p class=AmmCorpsTexte align=left style='margin-left:1.75pt;text-align:left'> </p>
</td>
<td width=194 colspan=2 valign=top style='width:145.7pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:21.6pt'>
<p class=AmmCorpsTexte align=left style='margin-left:2.8pt;text-align:left'>H<span style='letter-spacing:.1pt'>y</span>persensibilité<span style='letter-spacing: -.1pt'> </span>(ja<span style='letter-spacing:-.05pt'>m</span>ais sévère)</p>
</td>
<td width=100 colspan=2 valign=top style='width:75.25pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:21.6pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.1pt;text-align:left'> </p>
</td>
<td style='border:none;padding:0cm 0cm 0cm 0cm' width=1><p class='AmmCorpsTexte'> </td>
</tr>
<tr style='height:30.05pt'>
<td width=206 colspan=2 valign=top style='width:154.65pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:30.05pt'>
<p class=AmmCorpsTexte align=left style='margin-left:1.75pt;text-align:left'>Troubles<span style='letter-spacing:-.6pt'> </span>du <span style='letter-spacing:-.1pt'>m</span>étabolis<span style='letter-spacing:-.05pt'>m</span>e<span style='letter-spacing:-.25pt'> </span>et de<span style='letter-spacing:-.1pt'> </span>la nutrition</p>
</td>
<td width=176 colspan=2 valign=top style='width:131.65pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:30.05pt'>
<p class=AmmCorpsTexte align=left style='margin-left:1.75pt;text-align:left'>Anorexie<span style='letter-spacing:-.65pt'> </span>(G3/4<span style='letter-spacing:-.25pt'> </span>: 0,6<span style='letter-spacing:-.05pt'>%</span>)</p>
</td>
<td width=194 colspan=2 valign=top style='width:145.7pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:30.05pt'>
<p class=AmmCorpsTexte align=left style='margin-left:2.8pt;text-align:left'> </p>
</td>
<td width=100 colspan=2 valign=top style='width:75.25pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:30.05pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.1pt;text-align:left'> </p>
</td>
<td style='border:none;padding:0cm 0cm 0cm 0cm' width=1><p class='AmmCorpsTexte'> </td>
</tr>
<tr style='height:40.6pt'>
<td width=206 colspan=2 valign=top style='width:154.65pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:40.6pt'>
<p class=AmmCorpsTexte align=left style='margin-left:1.75pt;text-align:left'>Affection<span style='letter-spacing:-.65pt'> </span>du<span style='letter-spacing:-.1pt'> </span>s<span style='letter-spacing:.1pt'>y</span>stè<span style='letter-spacing:-.1pt'>m</span>e nerveux</p>
</td>
<td width=176 colspan=2 valign=top style='width:131.65pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:40.6pt'>
<p class=AmmCorpsTexte align=left style='margin-left:1.75pt;text-align:left'>D<span style='letter-spacing:.1pt'>y</span>sgueusie/Paros<span style='letter-spacing: -.1pt'>m</span>ie<span style='letter-spacing:-.1pt'> </span>; Neuropathie<span style='letter-spacing:-.5pt'> </span>sensitive périphérique<span style='letter-spacing:.05pt'> </span>(G3/4: 0,6<span style='letter-spacing: -.05pt'>%</span>)</p>
</td>
<td width=194 colspan=2 valign=top style='width:145.7pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:40.6pt'>
<p class=AmmCorpsTexte align=left style='margin-left:2.8pt;text-align:left'>Vertige</p>
</td>
<td width=100 colspan=2 valign=top style='width:75.25pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:40.6pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.1pt;text-align:left'> </p>
</td>
<td style='border:none;padding:0cm 0cm 0cm 0cm' width=1><p class='AmmCorpsTexte'> </td>
</tr>
<tr style='height:28.4pt'>
<td width=206 colspan=2 valign=top style='width:154.65pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:28.4pt'>
<p class=AmmCorpsTexte align=left style='margin-left:1.75pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span>oculaires</p>
</td>
<td width=176 colspan=2 valign=top style='width:131.65pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:28.4pt'>
<p class=AmmCorpsTexte align=left style='margin-left:1.75pt;text-align:left'> </p>
</td>
<td width=194 colspan=2 valign=top style='width:145.7pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:28.4pt'>
<p class=AmmCorpsTexte align=left style='margin-left:2.8pt;text-align:left'>Aug<span style='letter-spacing:-.1pt'>m</span>entation<span style='letter-spacing: -.15pt'> </span>du lar<span style='letter-spacing:-.05pt'>m</span>oie<span style='letter-spacing:-.05pt'>m</span>ent ; Conjonctivite</p>
</td>
<td width=100 colspan=2 valign=top style='width:75.25pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:28.4pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.1pt;text-align:left'> </p>
</td>
<td style='border:none;padding:0cm 0cm 0cm 0cm' width=1><p class='AmmCorpsTexte'> </td>
</tr>
<tr style='height:28.9pt'>
<td width=206 colspan=2 valign=top style='width:154.65pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:28.9pt'>
<p class=AmmCorpsTexte align=left style='margin-left:1.75pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span>de<span style='letter-spacing:-.1pt'> </span>l’oreille<span style='letter-spacing:-.25pt'> </span>et du<span style='letter-spacing:-.1pt'> </span>lab<span style='letter-spacing:.1pt'>y</span>rinthe</p>
</td>
<td width=176 colspan=2 valign=top style='width:131.65pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:28.9pt'>
<p class=AmmCorpsTexte align=left style='margin-left:1.75pt;text-align:left'> </p>
</td>
<td width=194 colspan=2 valign=top style='width:145.7pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:28.9pt'>
<p class=AmmCorpsTexte align=left style='margin-left:2.8pt;text-align:left'>Troubles<span style='letter-spacing:-.6pt'> </span>de<span style='letter-spacing:-.1pt'> </span>l’audition</p>
</td>
<td width=100 colspan=2 valign=top style='width:75.25pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:28.9pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.1pt;text-align:left'> </p>
</td>
<td style='border:none;padding:0cm 0cm 0cm 0cm' width=1><p class='AmmCorpsTexte'> </td>
</tr>
<tr style='height:30.7pt'>
<td width=206 colspan=2 valign=top style='width:154.65pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:30.7pt'>
<p class=AmmCorpsTexte align=left style='margin-left:1.75pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span>cardiaques</p>
</td>
<td width=176 colspan=2 valign=top style='width:131.65pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:30.7pt'>
<p class=AmmCorpsTexte align=left style='margin-left:1.75pt;text-align:left'> </p>
</td>
<td width=194 colspan=2 valign=top style='width:145.7pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:30.7pt'>
<p class=AmmCorpsTexte align=left style='margin-left:2.8pt;text-align:left'>Isché<span style='letter-spacing:-.1pt'>m</span>ie<span style='letter-spacing:-.25pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.1pt'>y</span>ocardique (G3/4:<span style='letter-spacing:-.5pt'> </span>1,7<span style='letter-spacing: -.05pt'>%</span>)</p>
</td>
<td width=100 colspan=2 valign=top style='width:75.25pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:30.7pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.1pt;text-align:left'>Ar<span style='letter-spacing:.1pt'>y</span>th<span style='letter-spacing:-.1pt'>m</span>ie<span style='letter-spacing:-.15pt'> </span>(G3/4: 0,6<span style='letter-spacing: -.05pt'>%</span>)</p>
</td>
<td style='border:none;padding:0cm 0cm 0cm 0cm' width=1><p class='AmmCorpsTexte'> </td>
</tr>
<tr style='height:18.3pt'>
<td width=206 colspan=2 valign=top style='width:154.65pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:18.3pt'>
<p class=AmmCorpsTexte align=left style='margin-left:1.75pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span>vasculaires</p>
</td>
<td width=176 colspan=2 valign=top style='width:131.65pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:18.3pt'>
<p class=AmmCorpsTexte align=left style='margin-left:1.75pt;text-align:left'> </p>
</td>
<td width=194 colspan=2 valign=top style='width:145.7pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:18.3pt'>
<p class=AmmCorpsTexte align=left style='margin-left:2.8pt;text-align:left'>Troubles<span style='letter-spacing:-.65pt'> </span>veineux<span style='letter-spacing: -.25pt'> </span>(G3/4<span style='letter-spacing:-.25pt'> </span>: 0,6<span style='letter-spacing:-.05pt'>%</span>)</p>
</td>
<td width=100 colspan=2 valign=top style='width:75.25pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:18.3pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.1pt;text-align:left'> </p>
</td>
<td style='border:none;padding:0cm 0cm 0cm 0cm' width=1><p class='AmmCorpsTexte'> </td>
</tr>
<tr style='height:85.2pt'>
<td width=206 colspan=2 valign=top style='width:154.65pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:85.2pt'>
<p class=AmmCorpsTexte align=left style='margin-left:1.75pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span>gastro- intestinales</p>
</td>
<td width=176 colspan=2 valign=top style='width:131.65pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:85.2pt'>
<p class=AmmCorpsTexte align=left style='margin-left:1.75pt;text-align:left'>Nausées<span style='letter-spacing:-.6pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>0,6%)<span style='letter-spacing:-.25pt'> </span>; Sto<span style='letter-spacing:-.1pt'>m</span>atite<span style='letter-spacing:-.1pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>4,0%)<span style='letter-spacing:-.25pt'> </span>; Diarrhées<span style='letter-spacing: -.4pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>2,9%)<span style='letter-spacing:-.25pt'> </span>; Vo<span style='letter-spacing:-.1pt'>m</span>isse<span style='letter-spacing:-.1pt'>m</span>ents<span style='letter-spacing:-.25pt'> </span>(G3/4: 0,6<span style='letter-spacing:-.05pt'>%</span>)</p>
</td>
<td width=194 colspan=2 valign=top style='width:145.7pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:85.2pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:2.85pt;margin-bottom:.0001pt;text-align:left'>Constipation ; Œsophagite/dysphagie/ odynophagie (G3/4 : 0,6%) ; Douleur abdominale ; </p>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:2.85pt;margin-bottom:.0001pt;text-align:left'>Dyspepsie ; </p>
<p class=AmmCorpsTexte align=left style='margin-left:2.8pt;text-align:left'>Hémorragie gastro- intestinale<span style='letter-spacing:.05pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>0,6<span style='letter-spacing:-.05pt'>%</span>)</p>
</td>
<td width=100 colspan=2 valign=top style='width:75.25pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:85.2pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.1pt;text-align:left'> </p>
</td>
<td style='border:none;padding:0cm 0cm 0cm 0cm' width=1><p class='AmmCorpsTexte'> </td>
</tr>
<tr style='height:28.3pt'>
<td width=206 colspan=2 valign=top style='width:154.65pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:28.3pt'>
<p class=AmmCorpsTexte align=left style='margin-left:1.75pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la peau<span style='letter-spacing:-.2pt'> </span>et du<span style='letter-spacing: -.1pt'> </span>tissu<span style='letter-spacing:-.2pt'> </span>sous-cutané</p>
</td>
<td width=176 colspan=2 valign=top style='width:131.65pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:28.3pt'>
<p class=AmmCorpsTexte align=left style='margin-left:1.75pt;text-align:left'>Alopécie<span style='letter-spacing:-.65pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>10,9<span style='letter-spacing:-.05pt'>%</span>)</p>
</td>
<td width=194 colspan=2 valign=top style='width:145.7pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:28.3pt'>
<p class=AmmCorpsTexte align=left style='margin-left:2.8pt;text-align:left'>Rash<span style='letter-spacing:-.45pt'> </span>avec<span style='letter-spacing:-.2pt'> </span>prurit<span style='letter-spacing:-.2pt'> </span>; Peau sèche<span style='letter-spacing:-.2pt'> </span>; Desqua<span style='letter-spacing: -.1pt'>m</span>ation (G3/4: 0,6<span style='letter-spacing:-.05pt'>%</span>)</p>
</td>
<td width=100 colspan=2 valign=top style='width:75.25pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:28.3pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.1pt;text-align:left'> </p>
</td>
<td style='border:none;padding:0cm 0cm 0cm 0cm' width=1><p class='AmmCorpsTexte'> </td>
</tr>
<tr style='height:13.2pt'>
<td width=206 colspan=2 valign=top style='width:154.65pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:13.2pt'>
<p class=AmmCorpsTexte align=left style='margin-left:1.75pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>u</span>sculo-</p>
</td>
<td width=176 colspan=2 valign=top style='width:131.65pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:13.2pt'>
<p class=AmmCorpsTexte align=left style='margin-left:1.75pt;text-align:left'> </p>
</td>
<td width=194 colspan=2 valign=top style='width:145.7pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:13.2pt'>
<p class=AmmCorpsTexte align=left style='margin-left:2.8pt;text-align:left'>M<span style='letter-spacing:.1pt'>y</span>algies<span style='letter-spacing:-.1pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>0,6<span style='letter-spacing:-.05pt'>%</span>)</p>
</td>
<td width=100 colspan=2 valign=top style='width:75.25pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:13.2pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.1pt;text-align:left'> </p>
</td>
<td style='border:none;border-bottom:solid black 1.0pt' width=1><p class='AmmCorpsTexte'> </td>
</tr>
<tr style='height:25.9pt'>
<td style='border:none;padding:0cm 0cm 0cm 0cm' width=1><p class='AmmCorpsTexte'> </td>
<td width=206 colspan=2 valign=top style='width:154.65pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:25.9pt'>
<p class=AmmCorpsTexte align=left style='margin-left:1.75pt;text-align:left'>squelettiques<span style='letter-spacing:-.8pt'> </span>et s<span style='letter-spacing:.1pt'>y</span>sté<span style='letter-spacing:-.1pt'>m</span>iques</p>
</td>
<td width=176 colspan=2 valign=top style='width:131.65pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:25.9pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.05pt;text-align:left'> </p>
</td>
<td width=194 colspan=2 valign=top style='width:145.7pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:25.9pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.1pt;text-align:left'> </p>
</td>
<td width=100 colspan=2 valign=top style='width:75.25pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:25.9pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.1pt;text-align:left'> </p>
</td>
</tr>
<tr style='height:51.35pt'>
<td style='border:none;padding:0cm 0cm 0cm 0cm' width=1><p class='AmmCorpsTexte'> </td>
<td width=206 colspan=2 valign=top style='width:154.65pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:51.35pt'>
<p class=AmmCorpsTexte align=left style='margin-left:1.75pt;text-align:left'>Troubles<span style='letter-spacing:-.65pt'> </span>généraux<span style='letter-spacing: -.35pt'> </span>et ano<span style='letter-spacing:-.1pt'>m</span>alies<span style='letter-spacing:-.15pt'> </span>au<span style='letter-spacing:-.1pt'> </span>site d’ad<span style='letter-spacing:-.1pt'>m</span>inistration</p>
</td>
<td width=176 colspan=2 valign=top style='width:131.65pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:51.35pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.05pt;text-align:left'>Léthargie (G3/4 : 3,4%) ; Fièvre (G3/4: 0,6%) ; Rétention hydrique ; Œdème</p>
</td>
<td width=194 colspan=2 valign=top style='width:145.7pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:51.35pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.1pt;text-align:left'> </p>
</td>
<td width=100 colspan=2 valign=top style='width:75.25pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:51.35pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.1pt;text-align:left'> </p>
</td>
</tr>
<tr style='height:13.2pt'>
<td style='border:none;padding:0cm 0cm 0cm 0cm' width=1><p class='AmmCorpsTexte'> </td>
<td width=206 colspan=2 valign=top style='width:154.65pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:13.2pt'>
<p class=AmmCorpsTexte style='margin-left:1.75pt'>Investigations</p>
</td>
<td width=176 colspan=2 valign=top style='width:131.65pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:13.2pt'>
<p class=AmmCorpsTexte style='margin-left:5.05pt'> </p>
</td>
<td width=194 colspan=2 valign=top style='width:145.7pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:13.2pt'>
<p class=AmmCorpsTexte>Aug<span style='letter-spacing:-.1pt'>m</span>entation<span style='letter-spacing:-.15pt'> </span>du<span style='letter-spacing:-.1pt'> </span>poids</p>
</td>
<td width=100 colspan=2 valign=top style='width:75.25pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:13.2pt'>
<p class=AmmCorpsTexte> </p>
</td>
</tr>
<tr height=0>
<td width=1 style='border:none'></td>
<td width=206 style='border:none'></td>
<td width=1 style='border:none'></td>
<td width=175 style='border:none'></td>
<td width=1 style='border:none'></td>
<td width=194 style='border:none'></td>
<td width=1 style='border:none'></td>
<td width=100 style='border:none'></td>
<td width=1 style='border:none'></td>
</tr>
</table>
</div>
<p class=AmmCorpsTexte><b><u>Chi<span style='letter-spacing:-.1pt'>m</span>iothérapie<span style='letter-spacing: -.1pt'> </span>d’induction<span style='letter-spacing:-.4pt'> </span>suivie<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.1pt'> </span>chi<span style='letter-spacing:-.05pt'>m</span>io radiothérapie<span style='letter-spacing: -.05pt'> </span>(TAX324)</u></b></p>
<div align=center>
<table class=AmmCorpsTexteTable border=0 cellspacing=0 cellpadding=0
style='margin-left:-16.4pt;border-collapse:collapse'>
<tr style='height:39.2pt'>
<td width=184 valign=top style='width:137.7pt;border:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:39.2pt'>
<p class=AmmCorpsTexte style='margin-left:6.15pt;page-break-after:avoid'><b>Base<span style='letter-spacing:-.45pt'> </span>de<span style='letter-spacing:-.1pt'> </span>données MeDRA des<span style='letter-spacing:-.15pt'> </span>classes<span style='letter-spacing:-.3pt'> </span>de système d’organe</b></p>
</td>
<td width=155 valign=top style='width:116.0pt;border:solid black 1.0pt;
border-left:none;padding:0cm 0cm 0cm 0cm;height:39.2pt'>
<p class=AmmCorpsTexte style='margin-left:3.1pt;page-break-after:avoid'><b>Très<span style='letter-spacing:-.45pt'> </span>fréquent</b></p>
</td>
<td width=155 valign=top style='width:116.0pt;border:solid black 1.0pt;
border-left:none;padding:0cm 0cm 0cm 0cm;height:39.2pt'>
<p class=AmmCorpsTexte style='margin-left:7.6pt;page-break-after:avoid'><b>Fréquent</b></p>
</td>
<td width=155 valign=top style='width:116.0pt;border:solid black 1.0pt;
border-left:none;padding:0cm 0cm 0cm 0cm;height:39.2pt'>
<p class=AmmCorpsTexte style='margin-left:5.0pt;page-break-after:avoid'><b>Peu<span style='letter-spacing:-.45pt'> </span>fréquent</b></p>
</td>
</tr>
<tr style='height:28.6pt'>
<td width=184 valign=top style='width:137.7pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:28.6pt'>
<p class=AmmCorpsTexte align=left style='margin-left:6.15pt;text-align:left'>Infections<span style='letter-spacing:-.7pt'> </span>et infestations</p>
</td>
<td width=155 valign=top style='width:116.0pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:28.6pt'>
<p class=AmmCorpsTexte align=left style='margin-left:3.1pt;text-align:left'>Infection<span style='letter-spacing:-.6pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>3,6<span style='letter-spacing:-.05pt'>%</span>)</p>
</td>
<td width=155 valign=top style='width:116.0pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:28.6pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.6pt;text-align:left'>Infection<span style='letter-spacing:-.6pt'> </span>avec neutropénie</p>
</td>
<td width=155 valign=top style='width:116.0pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:28.6pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.0pt;text-align:left'> </p>
</td>
</tr>
<tr style='height:42.5pt'>
<td width=184 valign=top style='width:137.7pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:42.5pt'>
<p class=AmmCorpsTexte align=left style='margin-left:6.15pt;text-align:left'>Tu<span style='letter-spacing:-.1pt'>m</span>eurs<span style='letter-spacing:-.25pt'> </span>bénignes, <span style='letter-spacing:-.1pt'>m</span>alignes<span style='letter-spacing:-.25pt'> </span>et non<span style='letter-spacing:-.15pt'> </span>précisé (incluant k<span style='letter-spacing:.1pt'>y</span>stes<span style='letter-spacing:-.05pt'> </span>et pol<span style='letter-spacing:.1pt'>y</span><span style='letter-spacing:.05pt'>p</span>es)</p>
</td>
<td width=155 valign=top style='width:116.0pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:42.5pt'>
<p class=AmmCorpsTexte align=left style='margin-left:3.1pt;text-align:left'> </p>
</td>
<td width=155 valign=top style='width:116.0pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:42.5pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.6pt;text-align:left'>Douleur<span style='letter-spacing:-.6pt'> </span>cancéreuse (G3/4:<span style='letter-spacing: -.5pt'> </span>1,2<span style='letter-spacing:-.05pt'>%</span>)</p>
</td>
<td width=155 valign=top style='width:116.0pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:42.5pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.0pt;text-align:left'> </p>
</td>
</tr>
<tr style='height:71.4pt'>
<td width=184 valign=top style='width:137.7pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:71.4pt'>
<p class=AmmCorpsTexte align=left style='margin-left:6.15pt;text-align:left'>Affections hé<span style='letter-spacing:-.1pt'>m</span>atologiques<span style='letter-spacing:-.35pt'> </span>et du s<span style='letter-spacing: .1pt'>y</span>stè<span style='letter-spacing:-.1pt'>m</span>e l<span style='letter-spacing:.1pt'>y</span><span style='letter-spacing:-.1pt'>m</span>phatique</p>
</td>
<td width=155 valign=top style='width:116.0pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:71.4pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:3.1pt;margin-bottom:.0001pt;text-align:left'>Neutropénie<span style='letter-spacing:-.8pt'> </span>(G3/4: 83,5%); </p>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:3.1pt;margin-bottom:.0001pt;text-align:left'>Anémie (G3/4 : 12,4%); Thrombopénie (G3/4: 4,0%) ; </p>
<p class=AmmCorpsTexte align=left style='margin-left:3.1pt;text-align:left'>Neutropénie<span style='letter-spacing:-.5pt'> </span>fébrile</p>
</td>
<td width=155 valign=top style='width:116.0pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:71.4pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.6pt;text-align:left'> </p>
</td>
<td width=155 valign=top style='width:116.0pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:71.4pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.0pt;text-align:left'> </p>
</td>
</tr>
<tr style='height:25.9pt'>
<td width=184 valign=top style='width:137.7pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:25.9pt'>
<p class=AmmCorpsTexte align=left style='margin-left:6.15pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span>du<span style='letter-spacing:-.1pt'> </span>s<span style='letter-spacing:.1pt'>y</span>stè<span style='letter-spacing:-.1pt'>m</span>e i<span style='letter-spacing:-.1pt'>mm</span>unitaire</p>
</td>
<td width=155 valign=top style='width:116.0pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:25.9pt'>
<p class=AmmCorpsTexte align=left style='margin-left:3.1pt;text-align:left'> </p>
</td>
<td width=155 valign=top style='width:116.0pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:25.9pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.6pt;text-align:left'> </p>
</td>
<td width=155 valign=top style='width:116.0pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:25.9pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.0pt;text-align:left'>H<span style='letter-spacing:.1pt'>y</span>persensibilité</p>
</td>
</tr>
<tr style='height:30.5pt'>
<td width=184 valign=top style='width:137.7pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:30.5pt'>
<p class=AmmCorpsTexte align=left style='margin-left:6.15pt;text-align:left'>Troubles<span style='letter-spacing:-.6pt'> </span>du <span style='letter-spacing:-.1pt'>m</span>étabolis<span style='letter-spacing:-.05pt'>m</span>e<span style='letter-spacing:-.25pt'> </span>et de<span style='letter-spacing:-.1pt'> </span>la nutrition</p>
</td>
<td width=155 valign=top style='width:116.0pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:30.5pt'>
<p class=AmmCorpsTexte align=left style='margin-left:3.1pt;text-align:left'>Anorexie<span style='letter-spacing:-.65pt'> </span>(G3/4: 12,0<span style='letter-spacing: -.05pt'>%</span>)</p>
</td>
<td width=155 valign=top style='width:116.0pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:30.5pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.6pt;text-align:left'> </p>
</td>
<td width=155 valign=top style='width:116.0pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:30.5pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.0pt;text-align:left'> </p>
</td>
</tr>
<tr style='height:64.1pt'>
<td width=184 valign=top style='width:137.7pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:64.1pt'>
<p class=AmmCorpsTexte align=left style='margin-left:6.15pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span>du<span style='letter-spacing:-.1pt'> </span>s<span style='letter-spacing:.1pt'>y</span>stè<span style='letter-spacing:-.1pt'>m</span>e nerveux</p>
</td>
<td width=155 valign=top style='width:116.0pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:64.1pt'>
<p class=AmmCorpsTexte align=left style='margin-left:3.1pt;text-align:left'>D<span style='letter-spacing:.1pt'>y</span>sgueusie/paros<span style='letter-spacing: -.05pt'>m</span>ie (G3/4:<span style='letter-spacing:-.2pt'> </span>0,4<span style='letter-spacing:-.05pt'>%</span>); Neuropathie sensitive périphérique<span style='letter-spacing:.05pt'> </span>(G3/4<span style='letter-spacing:-.25pt'> </span>: 1,2<span style='letter-spacing:-.05pt'>%</span>)</p>
</td>
<td width=155 valign=top style='width:116.0pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:64.1pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.6pt;text-align:left'>Vertiges<span style='letter-spacing:-.6pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>2,0<span style='letter-spacing:-.05pt'>%</span>)<span style='letter-spacing:-.15pt'> </span>; Neuropathie<span style='letter-spacing: -.5pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>o</span>trice périphérique<span style='letter-spacing:-.45pt'> </span>(G3/4<span style='letter-spacing:-.25pt'> </span>: 0,4<span style='letter-spacing:-.05pt'>%</span>)</p>
</td>
<td width=155 valign=top style='width:116.0pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:64.1pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.0pt;text-align:left'> </p>
</td>
</tr>
<tr style='height:25.9pt'>
<td width=184 valign=top style='width:137.7pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:25.9pt'>
<p class=AmmCorpsTexte align=left style='margin-left:6.15pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span>oculaires</p>
</td>
<td width=155 valign=top style='width:116.0pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:25.9pt'>
<p class=AmmCorpsTexte align=left style='margin-left:3.1pt;text-align:left'> </p>
</td>
<td width=155 valign=top style='width:116.0pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:25.9pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.6pt;text-align:left'>Aug<span style='letter-spacing:-.1pt'>m</span>entation<span style='letter-spacing: -.15pt'> </span>du lar<span style='letter-spacing:-.05pt'>m</span>oie<span style='letter-spacing:-.05pt'>m</span>ent</p>
</td>
<td width=155 valign=top style='width:116.0pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:25.9pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.0pt;text-align:left'>Conjonctivite</p>
</td>
</tr>
<tr style='height:29.35pt'>
<td width=184 valign=top style='width:137.7pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:29.35pt'>
<p class=AmmCorpsTexte align=left style='margin-left:6.15pt;text-align:left'>Affections de l’oreille et du labyrinthe</p>
</td>
<td width=155 valign=top style='width:116.0pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:29.35pt'>
<p class=AmmCorpsTexte align=left style='margin-left:3.1pt;text-align:left'>Trouble<span style='letter-spacing:-.55pt'> </span>de<span style='letter-spacing:-.05pt'> </span>l’audition (G3/4:<span style='letter-spacing:-.5pt'> </span>1,2<span style='letter-spacing: -.05pt'>%</span>)</p>
</td>
<td width=155 valign=top style='width:116.0pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:29.35pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.6pt;text-align:left'> </p>
</td>
<td width=155 valign=top style='width:116.0pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:29.35pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.0pt;text-align:left'> </p>
</td>
</tr>
<tr style='height:14.2pt'>
<td width=184 valign=top style='width:137.7pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:14.2pt'>
<p class=AmmCorpsTexte align=left style='margin-left:6.15pt;text-align:left'>Affections cardiaques</p>
</td>
<td width=155 valign=top style='width:116.0pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:14.2pt'>
<p class=AmmCorpsTexte align=left style='margin-left:3.1pt;text-align:left'> </p>
</td>
<td width=155 valign=top style='width:116.0pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:14.2pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.6pt;text-align:left'>Ar<span style='letter-spacing:.1pt'>y</span>th<span style='letter-spacing:-.1pt'>m</span>ie<span style='letter-spacing:-.15pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>2,0<span style='letter-spacing:-.05pt'>%</span>)</p>
</td>
<td width=155 valign=top style='width:116.0pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:14.2pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.0pt;text-align:left'>Isché<span style='letter-spacing:-.1pt'>m</span>ie<span style='letter-spacing:-.25pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.1pt'>y</span>ocardique</p>
</td>
</tr>
<tr style='height:14.4pt'>
<td width=184 valign=top style='width:137.7pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:14.4pt'>
<p class=AmmCorpsTexte align=left style='margin-left:6.15pt;text-align:left'>Affections vasculaires</p>
</td>
<td width=155 valign=top style='width:116.0pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:14.4pt'>
<p class=AmmCorpsTexte align=left style='margin-left:3.1pt;text-align:left'> </p>
</td>
<td width=155 valign=top style='width:116.0pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:14.4pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.6pt;text-align:left'> </p>
</td>
<td width=155 valign=top style='width:116.0pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:14.4pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.0pt;text-align:left'>Troubles<span style='letter-spacing:-.65pt'> </span>veineux</p>
</td>
</tr>
<tr style='height:119.35pt'>
<td width=184 valign=top style='width:137.7pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:119.35pt'>
<p class=AmmCorpsTexte align=left style='margin-left:6.15pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span>gastro- intestinales</p>
</td>
<td width=155 valign=top style='width:116.0pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:119.35pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:3.1pt;margin-bottom:.0001pt;text-align:left'>Nausées<span style='letter-spacing:-.6pt'> </span>(G3/4: 13,9%); Stomatite (G3/4: 20,7%); Vomissements (G3/4: 8,4%);</p>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:3.1pt;margin-bottom:.0001pt;text-align:left'>Diarrhées (G3/4: 6,8%); Oesophagite/dysphagie/odynophagie (G3/4: 12,0%);</p>
<p class=AmmCorpsTexte align=left style='margin-left:3.1pt;text-align:left'>Constipation (G3/4 : 0,4<span style='letter-spacing:-.05pt'>%</span>)</p>
</td>
<td width=155 valign=top style='width:116.0pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:119.35pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:7.6pt;margin-bottom:.0001pt;text-align:left'>D<span style='letter-spacing:.1pt'>y</span>spepsie<span style='letter-spacing:-.1pt'> </span>(G3/4: 0,8%); Douleurs gastro- intestinales (G3/4 : 1,2%);</p>
<p class=AmmCorpsTexte align=left style='margin-left:7.6pt;text-align:left'>Hémorragie gastro- intestinale (G3/4: 0,4%)</p>
</td>
<td width=155 valign=top style='width:116.0pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:119.35pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.0pt;text-align:left'> </p>
</td>
</tr>
<tr style='height:28.2pt'>
<td width=184 valign=top style='width:137.7pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:28.2pt'>
<p class=AmmCorpsTexte align=left style='margin-left:6.15pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la peau<span style='letter-spacing:-.2pt'> </span>et du<span style='letter-spacing: -.1pt'> </span>tissu<span style='letter-spacing:-.2pt'> </span>sous-cutané</p>
</td>
<td width=155 valign=top style='width:116.0pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:28.2pt'>
<p class=AmmCorpsTexte align=left style='margin-left:3.1pt;text-align:left'>Alopécie<span style='letter-spacing:-.65pt'> </span>(G3/4<span style='letter-spacing:-.25pt'> </span>: 4,0<span style='letter-spacing:-.05pt'>%</span>)<span style='letter-spacing:-.15pt'> </span>; Rash<span style='letter-spacing:-.45pt'> </span>avec<span style='letter-spacing:-.2pt'> </span>prurit</p>
</td>
<td width=155 valign=top style='width:116.0pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:28.2pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.6pt;text-align:left'>Peau<span style='letter-spacing:-.45pt'> </span>sèche<span style='letter-spacing:-.2pt'> </span>; Desqua<span style='letter-spacing:-.1pt'>m</span>ation</p>
</td>
<td width=155 valign=top style='width:116.0pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:28.2pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.0pt;text-align:left'> </p>
</td>
</tr>
<tr style='height:31.8pt'>
<td width=184 valign=top style='width:137.7pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:31.8pt'>
<p class=AmmCorpsTexte align=left style='margin-left:6.15pt;text-align:left'>Affections<span style='letter-spacing:-.7pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>u</span>sculo- squelettiques et s<span style='letter-spacing:.1pt'>y</span>sté<span style='letter-spacing:-.1pt'>m</span>iques</p>
</td>
<td width=155 valign=top style='width:116.0pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:31.8pt'>
<p class=AmmCorpsTexte align=left style='margin-left:3.1pt;text-align:left'> </p>
</td>
<td width=155 valign=top style='width:116.0pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:31.8pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.6pt;text-align:left'>M<span style='letter-spacing:.1pt'>y</span>algies<span style='letter-spacing:-.1pt'> </span>(G3/4:<span style='letter-spacing:-.25pt'> </span>0,4<span style='letter-spacing:-.05pt'>%</span>)</p>
</td>
<td width=155 valign=top style='width:116.0pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:31.8pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.0pt;text-align:left'> </p>
</td>
</tr>
<tr style='height:63.25pt'>
<td width=184 valign=top style='width:137.7pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:63.25pt'>
<p class=AmmCorpsTexte align=left style='margin-left:6.15pt;text-align:left'>Troubles<span style='letter-spacing:-.65pt'> </span>généraux<span style='letter-spacing: -.35pt'> </span>et ano<span style='letter-spacing:-.1pt'>m</span>alies<span style='letter-spacing:-.15pt'> </span>au<span style='letter-spacing:-.1pt'> </span>site d’ad<span style='letter-spacing:-.1pt'>m</span>inistration</p>
</td>
<td width=155 valign=top style='width:116.0pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:63.25pt'>
<p class=AmmCorpsTexte align=left style='margin-left:3.1pt;text-align:left'>Léthargie<span style='letter-spacing:-.6pt'> </span>(G3/4: 4,0%) ; Fièvre (G3/4: 3,6%) ; Rétention hydrique (G3/4: 1,2%) ; Œdèmes (G3/4: 1,2%)</p>
</td>
<td width=155 valign=top style='width:116.0pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:63.25pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.6pt;text-align:left'> </p>
</td>
<td width=155 valign=top style='width:116.0pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:63.25pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.0pt;text-align:left'> </p>
</td>
</tr>
<tr style='height:13.2pt'>
<td width=184 valign=top style='width:137.7pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:13.2pt'>
<p class=AmmCorpsTexte align=left style='margin-left:6.15pt;text-align:left'>Investigations</p>
</td>
<td width=155 valign=top style='width:116.0pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:13.2pt'>
<p class=AmmCorpsTexte align=left style='margin-left:3.1pt;text-align:left'>Perte<span style='letter-spacing:-.5pt'> </span>de<span style='letter-spacing:-.1pt'> </span>poids</p>
</td>
<td width=155 valign=top style='width:116.0pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:13.2pt'>
<p class=AmmCorpsTexte align=left style='text-align:left'> </p>
</td>
<td width=155 valign=top style='width:116.0pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:13.2pt'>
<p class=AmmCorpsTexte align=left style='margin-left:5.0pt;text-align:left'>Aug<span style='letter-spacing:-.1pt'>m</span>entation<span style='letter-spacing: -.15pt'> </span>du<span style='letter-spacing:-.05pt'> </span>poids</p>
</td>
</tr>
</table>
</div>
<p class=AmmCorpsTexte style='margin-top:6.0pt'><b><u><sub>Autres effets indésirables observés après la <span style='letter-spacing:-.1pt'>m</span>ise<span style='letter-spacing:-.1pt'> </span>sur le <span style='letter-spacing:-.1pt'>m</span>arché</sub></u><sub><span style='letter-spacing:-.15pt'> </span>:</sub></b></p>
<p class=AmmCorpsTexte><u>Tumeurs bénignes et malignes (incluant kystes et polypes)</u><span style='letter-spacing:.05pt'> </span>:</p>
<p class=AmmCorpsTexte>Des<span style='letter-spacing:-.4pt'> </span>cas<span style='letter-spacing:-.15pt'> </span>de<span style='letter-spacing:-.1pt'> </span>leucé<span style='letter-spacing:-.05pt'>m</span>ies<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.1pt'>y</span>éloïdes<span style='letter-spacing:-.1pt'> </span>aigües<span style='letter-spacing:-.25pt'> </span>et de<span style='letter-spacing:-.1pt'> </span>s<span style='letter-spacing: .1pt'>y</span>ndro<span style='letter-spacing:-.1pt'>m</span>es<span style='letter-spacing:-.05pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.1pt'>y</span>élod<span style='letter-spacing:.1pt'>y</span>splasiques<span style='letter-spacing:-.1pt'> </span>ont<span style='letter-spacing:-.15pt'> </span>été rapportés<span style='letter-spacing:-.35pt'> </span>avec le docétaxel<span style='letter-spacing:-.4pt'> </span>en<span style='letter-spacing:-.1pt'> </span>association<span style='letter-spacing:-.45pt'> </span>avec<span style='letter-spacing:-.2pt'> </span>d<span style='letter-spacing:.05pt'>’</span>aut<span style='letter-spacing:-.05pt'>r</span>es<span style='letter-spacing:-.05pt'> </span>antinéoplasiques<span style='letter-spacing: -.6pt'> </span>et/ou<span style='letter-spacing:-.2pt'> </span>une<span style='letter-spacing:-.15pt'> </span>radiothérapie.</p>
<p class=AmmCorpsTexte><u>Affections hématologiques et du système lymphatique</u><span style='letter-spacing:-.05pt'> </span>:</p>
<p class=AmmCorpsTexte>Une<span style='letter-spacing:-.45pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.1pt'>y</span>elosuppression<span style='letter-spacing: -.1pt'> </span>et d<span style='letter-spacing:.05pt'>’</span>autres<span style='letter-spacing:-.05pt'> </span>effets<span style='letter-spacing:-.2pt'> </span>indésirables<span style='letter-spacing:-.5pt'> </span>hé<span style='letter-spacing:-.1pt'>m</span>atologiques<span style='letter-spacing: -.5pt'> </span>ont<span style='letter-spacing:-.15pt'> </span>été rapportés.<span style='letter-spacing:-.4pt'> </span>Des<span style='letter-spacing:-.15pt'> </span>cas<span style='letter-spacing:-.15pt'> </span>de coagulation intravasculaire<span style='letter-spacing:-.55pt'> </span>dissé<span style='letter-spacing:-.1pt'>m</span>inée<span style='letter-spacing:-.2pt'> </span>(CIVD),<span style='letter-spacing:-.35pt'> </span>souvent<span style='letter-spacing:-.3pt'> </span>associés<span style='letter-spacing:-.35pt'> </span>à un<span style='letter-spacing:-.1pt'> </span>sepsis<span style='letter-spacing:-.25pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>une<span style='letter-spacing:-.15pt'> </span>défaillance <span style='letter-spacing: -.1pt'>m</span><span style='letter-spacing:.05pt'>u</span>ltiviscérale,<span style='letter-spacing:.05pt'> </span>ont<span style='letter-spacing:-.15pt'> </span>été rapportés.</p>
<p class=AmmCorpsTexte><u>Affections du système immunitaire</u> :</p>
<p class=AmmCorpsTexte>Quelques<span style='letter-spacing:-.65pt'> </span>cas<span style='letter-spacing:-.15pt'> </span>de<span style='letter-spacing:-.1pt'> </span>chocs<span style='letter-spacing:-.25pt'> </span>anaph<span style='letter-spacing:.1pt'>y</span>lactiques<span style='letter-spacing:-.25pt'> </span>parfois<span style='letter-spacing:-.3pt'> </span>fatals<span style='letter-spacing:-.2pt'> </span>ont<span style='letter-spacing:-.15pt'> </span>été rapportés.</p>
<p class=AmmCorpsTexte><u>Affections du système nerveux</u><span style='letter-spacing:-.05pt'> </span>:</p>
<p class=AmmCorpsTexte>De<span style='letter-spacing:-.4pt'> </span>rares<span style='letter-spacing:-.2pt'> </span>cas<span style='letter-spacing:-.15pt'> </span>de<span style='letter-spacing:-.1pt'> </span>convulsion<span style='letter-spacing: -.45pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>de<span style='letter-spacing:-.1pt'> </span>perte<span style='letter-spacing:-.2pt'> </span>transitoire<span style='letter-spacing:-.4pt'> </span>de<span style='letter-spacing:-.1pt'> </span>conscience<span style='letter-spacing:-.45pt'> </span>ont<span style='letter-spacing:-.15pt'> </span>été observés<span style='letter-spacing:-.35pt'> </span>à la suite<span style='letter-spacing:-.2pt'> </span>de l<span style='letter-spacing:.05pt'>’</span>ad<span style='letter-spacing:-.1pt'>m</span>inistration<span style='letter-spacing: -.4pt'> </span>du<span style='letter-spacing:-.1pt'> </span>docétaxel.<span style='letter-spacing:-.35pt'> </span>Ces<span style='letter-spacing:-.15pt'> </span>réactions<span style='letter-spacing:-.35pt'> </span>app<span style='letter-spacing:-.1pt'>a</span>raissent<span style='letter-spacing:-.15pt'> </span>parfois<span style='letter-spacing:-.3pt'> </span>au<span style='letter-spacing:-.1pt'> </span>cours<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la perfusion<span style='letter-spacing:-.4pt'> </span>du <span style='letter-spacing: -.1pt'>m</span>édica<span style='letter-spacing:-.05pt'>m</span>ent.</p>
<p class=AmmCorpsTexte><u>Affections oculaires</u> :</p>
<p class=AmmCorpsTexte>De<span style='letter-spacing:-.4pt'> </span>très<span style='letter-spacing:-.15pt'> </span>rares<span style='letter-spacing:-.2pt'> </span>cas<span style='letter-spacing:-.15pt'> </span>de<span style='letter-spacing:-.1pt'> </span>troubles<span style='letter-spacing:-.3pt'> </span>visuels<span style='letter-spacing:-.3pt'> </span>transitoires<span style='letter-spacing:-.45pt'> </span>(flashs,<span style='letter-spacing:-.3pt'> </span>scintille<span style='letter-spacing:-.05pt'>m</span>ents,<span style='letter-spacing:-.45pt'> </span>scoto<span style='letter-spacing:-.1pt'>m</span>es)<span style='letter-spacing:-.2pt'> </span>se<span style='letter-spacing:-.1pt'> </span>produisant<span style='letter-spacing:-.4pt'> </span>t<span style='letter-spacing:.1pt'>y</span>pique<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.1pt'> </span>au cours<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing: -.1pt'> </span>la perfusion<span style='letter-spacing:-.4pt'> </span>du<span style='letter-spacing:-.1pt'> </span>produit<span style='letter-spacing:-.3pt'> </span>et en<span style='letter-spacing:-.1pt'> </span>association<span style='letter-spacing:-.45pt'> </span>avec<span style='letter-spacing:-.2pt'> </span>des<span style='letter-spacing:-.15pt'> </span>réactions<span style='letter-spacing: -.35pt'> </span>d<span style='letter-spacing:.05pt'>’</span>h<span style='letter-spacing:.1pt'>y</span>persensibilité<span style='letter-spacing: -.05pt'> </span>ont été rapportés.<span style='letter-spacing:-.4pt'> </span>Ces effets<span style='letter-spacing:-.2pt'> </span>sont<span style='letter-spacing: -.15pt'> </span>réversibles<span style='letter-spacing:-.45pt'> </span>à l<span style='letter-spacing:-.05pt'>'</span>arrêt<span style='letter-spacing:-.15pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la perfusion.<span style='letter-spacing:-.4pt'> </span>De<span style='letter-spacing:-.1pt'> </span>rares<span style='letter-spacing:-.2pt'> </span>cas<span style='letter-spacing:-.15pt'> </span>de<span style='letter-spacing:-.1pt'> </span>lar<span style='letter-spacing:-.05pt'>m</span>oie<span style='letter-spacing:-.05pt'>m</span>ent, avec<span style='letter-spacing: -.45pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>sans<span style='letter-spacing:-.15pt'> </span>conjonctivite,<span style='letter-spacing: -.5pt'> </span>et d<span style='letter-spacing:.05pt'>’</span>obstruction<span style='letter-spacing:-.05pt'> </span>du<span style='letter-spacing:-.1pt'> </span>canal<span style='letter-spacing:-.2pt'> </span>lacr<span style='letter-spacing:.1pt'>y</span><span style='letter-spacing:-.1pt'>m</span>al<span style='letter-spacing:-.15pt'> </span>avec<span style='letter-spacing:-.2pt'> </span>lar<span style='letter-spacing:-.05pt'>m</span>oie<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.1pt'> </span>inte<span style='letter-spacing:-.05pt'>m</span><span style='letter-spacing:.05pt'>p</span>estif<span style='letter-spacing:-.15pt'> </span>ont<span style='letter-spacing:-.15pt'> </span>été rapportés.</p>
<p class=AmmCorpsTexte><u>Affections de l’oreille et du labyrinthe</u> :</p>
<p class=AmmCorpsTexte>De<span style='letter-spacing:-.4pt'> </span>rares<span style='letter-spacing:-.2pt'> </span>cas<span style='letter-spacing:-.15pt'> </span>d<span style='letter-spacing:.05pt'>’</span>ototoxicité, de<span style='letter-spacing: -.1pt'> </span>troubles<span style='letter-spacing:-.3pt'> </span>de<span style='letter-spacing:-.1pt'> </span>l<span style='letter-spacing:.05pt'>’</span>au<span style='letter-spacing:-.05pt'>d</span>ition<span style='letter-spacing:-.05pt'> </span>et/ou<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span>perte<span style='letter-spacing:-.2pt'> </span>auditive<span style='letter-spacing:-.25pt'> </span>ont<span style='letter-spacing:-.15pt'> </span>été rapportés.</p>
<p class=AmmCorpsTexte><u>Affections cardiaques</u> :</p>
<p class=AmmCorpsTexte>De<span style='letter-spacing:-.4pt'> </span>rares<span style='letter-spacing:-.2pt'> </span>cas<span style='letter-spacing:-.15pt'> </span>d<span style='letter-spacing:.05pt'>’</span>infarctus<span style='letter-spacing:-.05pt'> </span>du<span style='letter-spacing:-.1pt'> m</span><span style='letter-spacing: .1pt'>y</span>ocarde<span style='letter-spacing:-.1pt'> </span>ont<span style='letter-spacing:-.15pt'> </span>été rapportés.</p>
<p class=AmmCorpsTexte><u>Affections vasculaires</u> :</p>
<p class=AmmCorpsTexte>Des<span style='letter-spacing:-.4pt'> </span>effets<span style='letter-spacing:-.2pt'> </span>thro<span style='letter-spacing:-.1pt'>m</span>boem<span style='letter-spacing:-.1pt'>b</span>oliques<span style='letter-spacing:-.15pt'> </span>veineux<span style='letter-spacing:-.3pt'> </span>ont<span style='letter-spacing:-.15pt'> </span>rare<span style='letter-spacing:-.1pt'>m</span>ent<span style='letter-spacing:-.25pt'> </span>été rapportés.</p>
<p class=AmmCorpsTexte><u>Affections respiratoires, thoraciques et médiastinales</u> :</p>
<p class=AmmCorpsTexte><span style='letter-spacing:-.2pt'>Un syndrome de détresse respiratoire aiguë, et des cas de pneumopathie interstitielle et de fibrose pulmonaire parfois fatals ont été rarement rapportés. De rares cas de pneumopathie radique ont été rapportés chez les patients recevant une radiothérapie concomitante.</span></p>
<p class=AmmCorpsTexte><u>Affections gastro-intestinales</u> :</p>
<p class=AmmCorpsTexte>De<span style='letter-spacing:-.4pt'> </span>rares<span style='letter-spacing:-.2pt'> </span>cas<span style='letter-spacing:-.15pt'> </span>de<span style='letter-spacing:-.1pt'> </span>désh<span style='letter-spacing:.1pt'>y</span><span style='letter-spacing:.05pt'>d</span>ratation<span style='letter-spacing:-.2pt'> </span>suite<span style='letter-spacing:-.2pt'> </span>à des<span style='letter-spacing:-.15pt'> </span>évène<span style='letter-spacing:-.05pt'>m</span>ents<span style='letter-spacing:-.3pt'> </span>gastro-intestinaux,<span style='letter-spacing: -.7pt'> </span>des<span style='letter-spacing:-.1pt'> </span>perforations<span style='letter-spacing:-.5pt'> </span>intestinales, des colites<span style='letter-spacing:-.25pt'> </span>isché<span style='letter-spacing:-.05pt'>m</span>iques,<span style='letter-spacing:-.2pt'> </span>des<span style='letter-spacing:-.1pt'> </span>colites<span style='letter-spacing:-.25pt'> </span>et entérocolites<span style='letter-spacing: -.55pt'> </span>en<span style='letter-spacing:-.1pt'> </span>période<span style='letter-spacing:-.3pt'> </span>de<span style='letter-spacing:-.1pt'> </span>neutropénie<span style='letter-spacing:-.45pt'> </span>ont<span style='letter-spacing:-.15pt'> </span>été signalés.<span style='letter-spacing:-.35pt'> </span>De<span style='letter-spacing: -.1pt'> </span>rares cas d<span style='letter-spacing:.05pt'>’</span>iléus<span style='letter-spacing:-.05pt'> </span>et d<span style='letter-spacing:.05pt'>’</span>occlusion<span style='letter-spacing:-.05pt'> </span>intestinale<span style='letter-spacing: -.35pt'> </span>ont<span style='letter-spacing:-.15pt'> </span>été rapportés.</p>
<p class=AmmCorpsTexte><u>Affections hépatobiliaires</u> :</p>
<p class=AmmCorpsTexte>De<span style='letter-spacing:-.4pt'> </span>très<span style='letter-spacing:-.15pt'> </span>rares<span style='letter-spacing:-.2pt'> </span>cas<span style='letter-spacing:-.15pt'> </span>d<span style='letter-spacing:.05pt'>’</span>hépatites<span style='letter-spacing:-.05pt'> </span>parfois<span style='letter-spacing:-.3pt'> </span>fatales<span style='letter-spacing:-.25pt'> </span>ont<span style='letter-spacing:-.15pt'> </span>é<span style='letter-spacing:-.05pt'>t</span>é rapportés,<span style='letter-spacing:-.4pt'> </span>essentielle<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.5pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>patients<span style='letter-spacing:-.3pt'> </span>avec<span style='letter-spacing:-.2pt'> </span>des<span style='letter-spacing:-.15pt'> </span>atteintes hépatiques<span style='letter-spacing:-.45pt'> </span>pré-existantes.</p>
<p class=AmmCorpsTexte><u>Affections de la peau et du tissu sous-cutané</u><span style='letter-spacing:-.1pt'> </span>:</p>
<p class=AmmCorpsTexte>De très rares cas de lupus érythémateux cutané et d'éruptions bulleuses tel qu'un érythème polymorphe, un syndrome de Stevens-Johnson, un syndrome de Lyell, ont été rapportés avec le docétaxel. Dans certains cas, d'autres facteurs concomitants peuvent avoir contribué au développement de ces effets. Des modifications cutanées de type sclérodermie généralement précédées par un lymphoedème périphérique ont été rapportées avec le docétaxel. Des cas d’alopécie persistante ont été rapportés.</p>
<p class=AmmCorpsTexte><u><span style='letter-spacing:-.2pt'>Affections rénales et urinaires</span></u><span style='letter-spacing:-.2pt'> :</span></p>
<p class=AmmCorpsTexte style='margin-bottom:0cm;margin-bottom:.0001pt'><span style='letter-spacing:-.2pt'>Des cas d’insuffisance rénale ont été rapportés.</span></p>
<p class=AmmCorpsTexte><span style='letter-spacing:-.2pt'>Dans environ 20% de ces cas, il n’y avait aucun facteur de risque d’insuffisance rénale aigüe telle qu’une administration concomitante de médicaments néphrotoxiques ou de troubles gastrointestinaux.</span></p>
<p class=AmmCorpsTexte><u>Troubles généraux et anomalies au site d’administration</u> :</p>
<p class=AmmCorpsTexte style='margin-bottom:0cm;margin-bottom:.0001pt'>Des<span style='letter-spacing:-.4pt'> </span>phéno<span style='letter-spacing:-.1pt'>m</span>ènes<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.1pt'> </span>réactivation<span style='letter-spacing:-.4pt'> </span>de<span style='letter-spacing:-.1pt'> </span>réact<span style='letter-spacing:-.05pt'>i</span>on<span style='letter-spacing:-.1pt'> </span>radique<span style='letter-spacing:-.3pt'> </span>ont<span style='letter-spacing:-.15pt'> </span>été rare<span style='letter-spacing:-.1pt'>m</span>ent<span style='letter-spacing: -.25pt'> </span>rapportés.</p>
<p class=AmmCorpsTexte>Les<span style='letter-spacing:-.4pt'> </span>cas<span style='letter-spacing:-.15pt'> </span>de<span style='letter-spacing:-.1pt'> </span>rétention<span style='letter-spacing:-.3pt'> </span>h<span style='letter-spacing:.1pt'>y</span>drique<span style='letter-spacing:-.05pt'> </span>n<span style='letter-spacing:.05pt'>’</span>étaient pas<span style='letter-spacing:-.15pt'> </span>acco<span style='letter-spacing: -.05pt'>m</span><span style='letter-spacing:.05pt'>p</span>agnés<span style='letter-spacing:-.2pt'> </span>d<span style='letter-spacing:.05pt'>’</span>épisodes<span style='letter-spacing:-.05pt'> </span>aigus<span style='letter-spacing:-.2pt'> </span>d<span style='letter-spacing:.05pt'>’</span>oligurie<span style='letter-spacing:-.05pt'> </span>ou d’h<span style='letter-spacing:.1pt'>y</span>potension. Une<span style='letter-spacing:-.15pt'> </span>désh<span style='letter-spacing:.1pt'>y</span><span style='letter-spacing:.05pt'>d</span>ratation<span style='letter-spacing:-.15pt'> </span>et un<span style='letter-spacing:-.1pt'> </span>œdè<span style='letter-spacing:-.1pt'>m</span>e<span style='letter-spacing:-.15pt'> </span>pul<span style='letter-spacing:-.1pt'>m</span>onaire<span style='letter-spacing:-.15pt'> </span>ont<span style='letter-spacing:-.15pt'> </span>rare<span style='letter-spacing:-.1pt'>m</span>ent<span style='letter-spacing:-.25pt'> </span>été rapportés.</p>
<p class=AmmCorpsTexte><b><u>Déclaration des effets indésirables suspectés</u></b></p>
<p class=AmmCorpsTexte>La déclaration des effets indésirables suspectés après autorisation du médicament est importante. Elle permet une surveillance continue du rapport bénéfice/risque du médicament. Les professionnels de santé déclarent tout effet indésirable suspecté via le système national de déclaration : Agence nationale de sécurité du médicament et des produits de santé (Ansm) et réseau des Centres Régionaux de Pharmacovigilance - Site internet:<span style='color:red'> </span><span lang=PT>www.ansm.sante.fr.</span></p>
<p class="AmmAnnexeTitre2"><a name="RcpSurdosage">4.9. Surdosage</a></p>
<p class=AmmCorpsTexte><a name="_Toc142278931">Quelques<span style='letter-spacing:-.65pt'> </span>cas<span style='letter-spacing:-.15pt'> </span>de<span style='letter-spacing:-.1pt'> </span>surdosage<span style='letter-spacing:-.4pt'> </span>ont<span style='letter-spacing:-.15pt'> </span>été rapportés.<span style='letter-spacing:-.4pt'> </span>Il<span style='letter-spacing:-.05pt'> </span>n<span style='letter-spacing:.05pt'>’</span>e<span style='letter-spacing:.05pt'>x</span>iste<span style='letter-spacing:-.05pt'> </span>pas<span style='letter-spacing:-.15pt'> </span>d<span style='letter-spacing:.05pt'>’</span>antidote<span style='letter-spacing:-.05pt'> </span>connu<span style='letter-spacing:-.25pt'> </span>en<span style='letter-spacing:-.1pt'> </span>cas<span style='letter-spacing:-.15pt'> </span>de<span style='letter-spacing:-.1pt'> </span>surdosage<span style='letter-spacing:-.4pt'> </span>par<span style='letter-spacing:-.15pt'> </span>le docétaxel.<span style='letter-spacing:-.35pt'> </span>En<span style='letter-spacing:-.1pt'> </span>cas<span style='letter-spacing:-.15pt'> </span>de<span style='letter-spacing:-.1pt'> </span>surdosage,<span style='letter-spacing:-.4pt'> </span>le patient<span style='letter-spacing: -.25pt'> </span>d<span style='letter-spacing:-.05pt'>o</span>it<span style='letter-spacing:-.05pt'> </span>être<span style='letter-spacing:-.15pt'> </span>ad<span style='letter-spacing:-.1pt'>m</span>is<span style='letter-spacing:-.15pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>une<span style='letter-spacing:-.15pt'> </span>unité<span style='letter-spacing:-.2pt'> </span>spécialisée<span style='letter-spacing: -.45pt'> </span>afin<span style='letter-spacing:-.15pt'> </span>de<span style='letter-spacing:-.1pt'> </span>surveiller étroite<span style='letter-spacing: -.05pt'>m</span>ent les<span style='letter-spacing:-.1pt'> </span>fonctions<span style='letter-spacing:-.35pt'> </span>vitales.<span style='letter-spacing:-.3pt'> </span>En<span style='letter-spacing:-.1pt'> </span>cas<span style='letter-spacing: -.15pt'> </span>de<span style='letter-spacing:-.1pt'> </span>surdosage<span style='letter-spacing:-.4pt'> </span>une<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span>ajoration<span style='letter-spacing:-.4pt'> </span>des<span style='letter-spacing:-.15pt'> </span>effets<span style='letter-spacing:-.2pt'> </span>indésirables<span style='letter-spacing: -.5pt'> </span>pourra être<span style='letter-spacing:-.15pt'> </span>observée.<span style='letter-spacing:-.4pt'> </span>Les principales<span style='letter-spacing: -.45pt'> </span>co<span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>p</span>lications<span style='letter-spacing:-.1pt'> </span>prévisibles<span style='letter-spacing:-.45pt'> </span>d’un<span style='letter-spacing:-.2pt'> </span>surdosage<span style='letter-spacing:-.4pt'> </span>se<span style='letter-spacing:-.1pt'> </span>traduiraient<span style='letter-spacing:-.4pt'> </span>par<span style='letter-spacing:-.15pt'> </span>une<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.1pt'>y</span>élosuppression, une<span style='letter-spacing: -.15pt'> </span>neurotoxicité<span style='letter-spacing:.05pt'> </span>périphérique<span style='letter-spacing:-.45pt'> </span>et une<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing: .05pt'>u</span>cite.<span style='letter-spacing:-.1pt'> </span>Les<span style='letter-spacing:-.15pt'> </span>patients<span style='letter-spacing:-.3pt'> </span>doivent<span style='letter-spacing:-.3pt'> </span>recevoir<span style='letter-spacing:-.35pt'> </span>du G-CSF<span style='letter-spacing:-.55pt'> </span>à titre thérapeutique<span style='letter-spacing:-.5pt'> </span>dès<span style='letter-spacing:-.15pt'> </span>que<span style='letter-spacing:-.15pt'> </span>possible<span style='letter-spacing:-.35pt'> </span>ap<span style='letter-spacing:.05pt'>r</span>ès<span style='letter-spacing:-.1pt'> </span>la découverte<span style='letter-spacing: -.45pt'> </span>du<span style='letter-spacing:-.1pt'> </span>surdosage.<span style='letter-spacing:-.4pt'> </span>D’autres<span style='letter-spacing:-.35pt'> </span><span style='letter-spacing:-.1pt'>m</span>esures s<span style='letter-spacing:.1pt'>y</span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>p</span>to<span style='letter-spacing:-.1pt'>m</span>atiques<span style='letter-spacing:-.25pt'> </span>appropriées<span style='letter-spacing: -.45pt'> </span>doivent<span style='letter-spacing:-.3pt'> </span>être<span style='letter-spacing:-.15pt'> </span>prises,<span style='letter-spacing:-.25pt'> </span>si<span style='letter-spacing:-.05pt'> </span>besoin.</a></p>
<p class="AmmAnnexeTitre1"><a name="RcpPropPharmacologie">5. PROPRIETES PHARMACOLOGIQUES</a></p>
<p class="AmmAnnexeTitre2"><a name="RcpPropPharmacodynamie">5.1. Propriétés pharmacodynamiques</a></p>
<p class=AmmCorpsTexte><a name="_Toc142278933"><b>Classe<span style='letter-spacing: -.55pt'> </span>phar<span style='letter-spacing:-.1pt'>m</span>acothérapeutique<span style='letter-spacing:-.15pt'> </span>: Taxanes<span style='letter-spacing: -.35pt'> </span>-<span style='letter-spacing:-.05pt'> </span>Code<span style='letter-spacing:-.2pt'> </span>ATC<span style='letter-spacing:-.2pt'> </span>: L01CD02</b></a></p>
<p class=AmmCorpsTexte style='margin-bottom:0cm;margin-bottom:.0001pt'><u>Mécanisme d’action</u></p>
<p class=AmmCorpsTexte>Le<span style='letter-spacing:-.35pt'> </span>docétaxel est un agent antinéoplasique qui agit en favorisant l’assemblage de la tubuline en microtubules stables et en inhibant leur dépolymérisation conduisant à une diminution marquée de la tubuline libre. La fixation du docétaxel aux microtubules<span style='letter-spacing:-.4pt'> </span>ne<span style='letter-spacing:-.1pt'> m</span>odifie<span style='letter-spacing:-.1pt'> </span>pas<span style='letter-spacing:-.15pt'> </span>le no<span style='letter-spacing:-.1pt'>m</span>bre<span style='letter-spacing:-.1pt'> </span>de<span style='letter-spacing:-.1pt'> </span>protofila<span style='letter-spacing:-.05pt'>m</span>ents.</p>
<p class=AmmCorpsTexte><i>In<span style='letter-spacing:-.35pt'> </span>vitro</i>,<span style='letter-spacing:-.2pt'> </span>le docétaxel<span style='letter-spacing: -.4pt'> </span>désorganise<span style='letter-spacing:-.45pt'> </span>le réseau<span style='letter-spacing:-.25pt'> </span>intrac<span style='letter-spacing:-.05pt'>e</span>llulaire<span style='letter-spacing:-.2pt'> </span>des<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span>icrotubules,<span style='letter-spacing: -.5pt'> </span>qui<span style='letter-spacing:-.15pt'> </span>est<span style='letter-spacing:-.1pt'> </span>essentiel<span style='letter-spacing:-.35pt'> </span>aux<span style='letter-spacing:-.15pt'> </span>fonctions vitales<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la <span style='letter-spacing:-.1pt'>m</span>itose<span style='letter-spacing: -.1pt'> </span>et de<span style='letter-spacing:-.1pt'> </span>l'interphase.</p>
<p class=AmmCorpsTexte style='margin-bottom:0cm;margin-bottom:.0001pt'><u>Effets pharmacodynamiques</u></p>
<p class=AmmCorpsTexte>Le docétaxel s’est révélé cytotoxique<span style='letter-spacing:-.05pt'> </span><i>in<span style='letter-spacing:-.1pt'> </span>vitro<span style='letter-spacing:-.2pt'> </span></i>sur<span style='letter-spacing:-.1pt'> </span>plusieurs<span style='letter-spacing:-.35pt'> </span>lignées<span style='letter-spacing:-.3pt'> </span>cellulaires<span style='letter-spacing: -.4pt'> </span>tu<span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>o</span>rales<span style='letter-spacing:-.1pt'> m</span><span style='letter-spacing:.05pt'>u</span>rines<span style='letter-spacing:-.1pt'> </span>et hu<span style='letter-spacing:-.1pt'>m</span>aines ainsi<span style='letter-spacing: -.2pt'> </span>que<span style='letter-spacing:-.15pt'> </span>sur<span style='letter-spacing:-.1pt'> </span>des<span style='letter-spacing:-.15pt'> </span>cellules<span style='letter-spacing:-.3pt'> </span>tu<span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>o</span>rales<span style='letter-spacing:-.1pt'> </span>hu<span style='letter-spacing:-.1pt'>m</span>aines<span style='letter-spacing:-.1pt'> </span>fraîche<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.35pt'> </span>excisées,<span style='letter-spacing:-.35pt'> </span>lors<span style='letter-spacing:-.15pt'> </span>des<span style='letter-spacing:-.15pt'> </span>essais<span style='letter-spacing:-.25pt'> </span>clonogéniques qui<span style='letter-spacing:-.15pt'> </span>ont<span style='letter-spacing:-.15pt'> </span>été effectués.<span style='letter-spacing: -.4pt'> </span>Le<span style='letter-spacing:-.1pt'> </span>docétaxel<span style='letter-spacing:-.4pt'> </span>pénètre<span style='letter-spacing:-.3pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>cellules<span style='letter-spacing:-.3pt'> </span>à des<span style='letter-spacing:-.15pt'> </span>concentrations<span style='letter-spacing:-.6pt'> </span>élevées et y<span style='letter-spacing: .05pt'> </span>persiste<span style='letter-spacing:-.3pt'> </span>pendant<span style='letter-spacing:-.3pt'> </span>une<span style='letter-spacing:-.15pt'> </span>durée prolongée.<span style='letter-spacing:-.4pt'> </span>Le<span style='letter-spacing: -.15pt'> </span>docétaxel<span style='letter-spacing:-.4pt'> </span>s<span style='letter-spacing:.05pt'>’</span>est<span style='letter-spacing:-.05pt'> </span>par<span style='letter-spacing:-.15pt'> </span>ailleurs<span style='letter-spacing:-.3pt'> </span>révélé<span style='letter-spacing:-.25pt'> </span>actif sur<span style='letter-spacing:-.1pt'> </span>beaucoup <span style='letter-spacing:-.1pt'>m</span>ais<span style='letter-spacing:-.15pt'> </span>pas<span style='letter-spacing:-.15pt'> </span>sur<span style='letter-spacing:-.1pt'> </span>toutes<span style='letter-spacing:-.25pt'> </span>les<span style='letter-spacing:-.1pt'> </span>lignées<span style='letter-spacing:-.3pt'> </span>cellulaires<span style='letter-spacing: .05pt'> </span>surexpri<span style='letter-spacing:-.1pt'>m</span>ant<span style='letter-spacing:-.35pt'> </span>la gl<span style='letter-spacing:.1pt'>y</span>coprotéine<span style='letter-spacing:-.45pt'> </span><i>p </i>codée<span style='letter-spacing: -.25pt'> </span>par<span style='letter-spacing:-.15pt'> </span>le gène<span style='letter-spacing:-.2pt'> </span>de <span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>u</span>ltirésistance.<span style='letter-spacing: -.1pt'> </span><i>In<span style='letter-spacing:-.1pt'> </span>viv<span style='letter-spacing:.05pt'>o</span></i>,<span style='letter-spacing:-.1pt'> </span>l’activité<span style='letter-spacing:.05pt'> </span>du<span style='letter-spacing:-.1pt'> </span>docétaxel<span style='letter-spacing:-.35pt'> </span>est indépendante<span style='letter-spacing: -.5pt'> </span>des<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span>odalités<span style='letter-spacing:-.1pt'> </span>d’ad<span style='letter-spacing:-.1pt'>m</span>inistration<span style='letter-spacing:-.55pt'> </span>et les<span style='letter-spacing:-.1pt'> </span>expéri<span style='letter-spacing:-.05pt'>m</span>entations<span style='letter-spacing:-.55pt'> </span>ont<span style='letter-spacing:-.15pt'> </span>révélé<span style='letter-spacing:-.25pt'> </span>un<span style='letter-spacing:-.1pt'> </span>large<span style='letter-spacing:-.2pt'> </span>spectre<span style='letter-spacing:-.3pt'> </span>antitu<span style='letter-spacing:-.05pt'>m</span><span style='letter-spacing:.05pt'>o</span>ral vis-à-vis<span style='letter-spacing: -.35pt'> </span>de<span style='letter-spacing:-.1pt'> </span>tu<span style='letter-spacing:-.1pt'>m</span>eurs<span style='letter-spacing:-.2pt'> </span>greffées<span style='letter-spacing:-.3pt'> </span>avancées,<span style='letter-spacing:-.4pt'> </span>d’origine<span style='letter-spacing:.05pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>u</span>rine<span style='letter-spacing:-.05pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>hu<span style='letter-spacing:-.1pt'>m</span>aine.</p>
<p class=AmmCorpsTexte style='margin-bottom:0cm;margin-bottom:.0001pt'><u>Efficacité et tolérance cliniques</u></p>
<p class=AmmCorpsTexte style='margin-top:6.0pt'><i><u><sub>Cancer du sein</sub></u></i></p>
<p class=AmmCorpsTexte><i>Le<span style='letter-spacing:-.35pt'> </span>docétaxel en association<span style='letter-spacing:-.45pt'> </span>avec<span style='letter-spacing:-.2pt'> </span>la<span style='letter-spacing:-.1pt'> </span>doxorubicine<span style='letter-spacing:-.55pt'> </span>et le cyclophosphamide<span style='letter-spacing:-.75pt'> </span>:<span style='letter-spacing:-.05pt'> </span>traitement<span style='letter-spacing:-.4pt'> </span>adjuvant</i></p>
<p class=AmmCorpsTexte style='margin-bottom:0cm;margin-bottom:.0001pt'><u>Patientes présentant un cancer du sein opérable avec envahisse<span style='letter-spacing: -.05pt'>m</span>ent ganglionnaire<span style='letter-spacing:.05pt'> </span>(TAX 316)</u> </p>
<p class=AmmCorpsTexte>L’utilisation de docétaxel en traitement adjuvant chez des patientes présentant un cancer du sein opérable avec envahissement ganglionnaire et un indice de performance de Karnofski supérieur ou égal à 80%, ayant entre 18 et 70 ans, s’appuie sur une étude randomisée multicentrique ouverte. Après stratification selon le nombre de ganglions lymphatiques envahis (1-3,4+), 1491 patientes ont été randomisées et ont reçu soit docétaxel 75 mg/m² administré une heure après 50 mg/m² de doxorubicine et 500 mg/m² de cyclophosphamide (bras TAC), soit 50 mg/m² de doxorubicine suivie par 500 mg/m² de fluoro-uracile et 500 mg/m² de cyclophosphamide (bras FAC). Les deux traitements ont été administrés toutes les 3 semaines pendant 6 cycles. Le docétaxel été administré en perfusion d’une heure, les autres médicaments ayant été administrés en bolus intraveineux le premier jour. Du G-CSF a été administré en prophylaxie secondaire chez les patientes ayant présenté une neutropénie compliquée (une neutropénie fébrile, une neutropénie prolongée ou une infection). Les patientes du bras TAC ont reçu une prophylaxie antibiotique par 500 mg de ciprofloxacine par voie orale deux fois par jour pendant 10 jours, en commençant le 5<sup>ème</sup> jour de chaque cycle, ou équivalent. Dans les deux bras, après le dernier cycle de chimiothérapie, les patientes présentant des récepteurs positifs aux estrogènes et/ou à la progestérone ont reçu 20 mg par jour de tamoxifène pendant 5 ans. Une radiothérapie adjuvante a été prescrite suivant les recommandations en vigueur dans les centres participants et a été administré à 69% des patientes du bras TAC et 72% des patientes du bras FAC.</p>
<p class=AmmCorpsTexte style='margin-bottom:0cm;margin-bottom:.0001pt; page-break-after:avoid'>Deux analyses intermédiaires et une analyse finale ont été réalisées. La première analyse intermédiaire a été planifiée 3 ans après la date à laquelle la moitié des inclusions était réalisée. La seconde analyse intermédiaire a été faite après enregistrement de 400 évènements de survie sans maladie, ce qui a permis un suivi médian de 55 mois. L’analyse finale a été réalisée quand toutes les patientes avaient fait leur visite de suivi à 10 ans (sauf apparition d’évènements de SSM ou patientes perdues du vue).</p>
<p class=AmmCorpsTexte style='margin-bottom:0cm;margin-bottom:.0001pt'>La survie sans maladie (SSM) était le critère principal d’efficacité et la survie globale (SG) était le critère secondaire d’efficacité.</p>
<p class=AmmCorpsTexte>Une analyse finale a été réalisée avec un suivi médian réel de 96 mois. Une survie sans rechute significativement plus longue dans le bras TAC par rapport au bras FAC a été démontrée. L’incidence des rechutes à 10 ans a été diminuée dans le bras TAC par rapport au bras FAC (39% versus 45% respectivement), soit une réduction du risque absolu de rechute de 6% (p = 0,0043). </p>
<p class=AmmCorpsTexte>La survie globale à 10 ans a été significativement augmentée dans le bras TAC par rapport au bras FAC (76% versus 69% respectivement), soit une réduction du risque absolu de décès de 7% (p = 0,002). Comme le bénéfice observé chez des patientes ayant au moins 4 ganglions envahis n’était pas statistiquement significatif en terme de SSM et de SG, le rapport bénéfice/risque positif en faveur de TAC chez les patientes avec au moins 4 ganglions envahis, n’a pas été complètement démontré à l’analyse finale.</p>
<p class=AmmCorpsTexte>Globalement, les résultats de l’étude démontrent un rapport bénéfice/risque positif pour TAC comparé à FAC.</p>
<p class=AmmCorpsTexte>Des sous-groupes des patientes traitées par TAC, stratifiés selon des facteurs pronostics majeurs définis prospectivement ont été analysés</p>
<div align=center>
<table class=AmmCorpsTexteTable border=0 cellspacing=0 cellpadding=0 width=650
style='width:487.25pt;margin-left:71.85pt;border-collapse:collapse'>
<tr style='height:14.4pt'>
<td width=142 valign=top style='width:106.3pt;border:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:14.4pt'>
<p class=AmmCorpsTexte align=left style='margin-top:.2pt;margin-right:22.85pt; margin-bottom:0cm;margin-left:0cm;margin-bottom:.0001pt;text-align:left; line-height:102%;text-autospace:none'><b><span style='font-size:10.0pt; line-height:102%;font-family:Arial'> </span></b></p>
</td>
<td width=95 valign=top style='width:71.45pt;border:solid black 1.0pt;
border-left:none;padding:0cm 0cm 0cm 0cm;height:14.4pt'>
<p class=AmmCorpsTexte align=center style='margin-top:.2pt;margin-right:5.45pt; margin-bottom:0cm;margin-left:0cm;margin-bottom:.0001pt;text-align:center; line-height:102%;text-autospace:none'><b><span style='font-size:10.0pt; line-height:102%;font-family:Arial'> </span></b></p>
</td>
<td width=207 colspan=3 valign=top style='width:155.25pt;border:solid black 1.0pt;
border-left:none;padding:0cm 0cm 0cm 0cm;height:14.4pt'>
<p class=AmmCorpsTexte style='margin-top:.2pt;line-height:11.45pt;text-autospace: none'><b><span style='font-size:10.0pt;font-family:Arial'>Survie sans rechute</span></b></p>
</td>
<td width=206 colspan=3 valign=top style='width:154.25pt;border:solid black 1.0pt;
border-left:none;padding:0cm 0cm 0cm 0cm;height:14.4pt'>
<p class=AmmCorpsTexte align=center style='margin-top:.2pt;margin-right:16.45pt; margin-bottom:0cm;margin-left:0cm;margin-bottom:.0001pt;text-align:center; text-autospace:none'><b><span style='font-size:10.0pt;font-family:Arial'>Survie globale</span></b></p>
</td>
</tr>
<tr style='height:29.8pt'>
<td width=142 valign=top style='width:106.3pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:29.8pt'>
<p class=AmmCorpsTexte align=left style='margin-top:.2pt;margin-right:22.85pt; margin-bottom:0cm;margin-left:0cm;margin-bottom:.0001pt;text-align:left; line-height:102%;text-autospace:none'><b><span style='font-size:10.0pt; line-height:102%;font-family:Arial'>Sous-groupe<span style='letter-spacing: .05pt'> </span>de patientes</span></b></p>
</td>
<td width=95 valign=top style='width:71.45pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:29.8pt'>
<p class=AmmCorpsTexte align=center style='margin-top:.2pt;margin-right:5.45pt; margin-bottom:0cm;margin-left:0cm;margin-bottom:.0001pt;text-align:center; line-height:102%;text-autospace:none'><b><span style='font-size:10.0pt; line-height:102%;font-family:Arial'>Nombre de patientes</span></b></p>
</td>
<td width=65 valign=top style='width:48.5pt;border-top:none;border-left:none;
border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0cm 0cm 0cm 0cm;
height:29.8pt'>
<p class=AmmCorpsTexte align=center style='margin-top:.25pt;text-align:center; text-autospace:none'><b><span style='font-size:10.0pt;font-family:Arial'>Risque Relatif*</span></b></p>
</td>
<td width=76 valign=top style='width:57.1pt;border-top:none;border-left:none;
border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0cm 0cm 0cm 0cm;
height:29.8pt'>
<p class=AmmCorpsTexte align=left style='margin-top:.2pt;margin-right:0cm; margin-bottom:0cm;margin-left:7.5pt;margin-bottom:.0001pt;text-align:left; text-autospace:none'><b><span style='font-size:10.0pt;font-family:Arial'>IC 95%</span></b></p>
</td>
<td width=66 valign=top style='width:49.65pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:29.8pt'>
<p class=AmmCorpsTexte align=left style='margin-top:.2pt;margin-right:5.25pt; margin-bottom:0cm;margin-left:0cm;margin-bottom:.0001pt;text-align:left; text-autospace:none'><b><span style='font-size:10.0pt;font-family:Arial'> p<span style='letter-spacing:.05pt'> </span>=</span></b></p>
</td>
<td width=61 valign=top style='width:45.85pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:29.8pt'>
<p class=AmmCorpsTexte align=center style='margin-top:.25pt;text-align:center; text-autospace:none'><b><span style='font-size:10.0pt;font-family:Arial'>Risque Relatif*</span></b></p>
</td>
<td width=76 valign=top style='width:56.75pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:29.8pt'>
<p class=AmmCorpsTexte align=center style='margin-top:.2pt;text-align:center; text-autospace:none'><b><span style='font-size:10.0pt;font-family:Arial'>IC<span style='letter-spacing:.05pt'> </span>95%</span></b></p>
</td>
<td width=69 valign=top style='width:51.65pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:29.8pt'>
<p class=AmmCorpsTexte align=center style='margin-top:.2pt;margin-right:16.45pt; margin-bottom:0cm;margin-left:0cm;margin-bottom:.0001pt;text-align:center; text-autospace:none'><b><span style='font-size:10.0pt;font-family:Arial'>p<span style='letter-spacing:.05pt'> </span>=</span></b></p>
</td>
</tr>
<tr style='height:12.9pt'>
<td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:12.9pt'>
<p class=AmmCorpsTexte align=left style='margin-top:.2pt;margin-right:20.85pt; margin-bottom:0cm;margin-left:0cm;margin-bottom:.0001pt;text-align:left; line-height:102%;text-autospace:none'><b><span style='font-size:10.0pt; line-height:102%;font-family:Arial'>No<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing:.05pt'> </span>gangli<span style='letter-spacing:.05pt'>o</span>ns</span></b></p>
</td>
<td width=95 valign=top style='width:71.45pt;border:none;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:12.9pt'>
<p class=AmmCorpsTexte style='line-height:10.0pt;text-autospace:none'><span style='font-size:10.0pt;font-family:Arial'> </span></p>
</td>
<td width=65 valign=top style='width:48.5pt;border:none;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:12.9pt'>
<p class=AmmCorpsTexte style='line-height:10.0pt;text-autospace:none'><span style='font-size:10.0pt;font-family:Arial'> </span></p>
</td>
<td width=76 valign=top style='width:57.1pt;border:none;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:12.9pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.5pt;text-align:left; line-height:10.0pt;text-autospace:none'><span style='font-size:10.0pt; font-family:Arial'> </span></p>
</td>
<td width=66 valign=top style='width:49.65pt;border:none;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:12.9pt'>
<p class=AmmCorpsTexte align=left style='text-align:left;line-height:10.0pt; text-autospace:none'><span style='font-size:10.0pt;font-family:Arial'> </span></p>
</td>
<td width=61 valign=top style='width:45.85pt;border:none;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:12.9pt'>
<p class=AmmCorpsTexte style='line-height:10.0pt;text-autospace:none'><span style='font-size:10.0pt;font-family:Arial'> </span></p>
</td>
<td width=76 valign=top style='width:56.75pt;border:none;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:12.9pt'>
<p class=AmmCorpsTexte style='line-height:10.0pt;text-autospace:none'><span style='font-size:10.0pt;font-family:Arial'> </span></p>
</td>
<td width=69 valign=top style='width:51.65pt;border:none;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:12.9pt'>
<p class=AmmCorpsTexte style='line-height:10.0pt;text-autospace:none'><span style='font-size:10.0pt;font-family:Arial'> </span></p>
</td>
</tr>
<tr style='height:11.35pt'>
<td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:11.35pt'>
<p class=AmmCorpsTexte align=left style='margin-top:.2pt;margin-right:20.85pt; margin-bottom:0cm;margin-left:0cm;margin-bottom:.0001pt;text-align:left; line-height:102%;text-autospace:none'><b><span style='font-size:10.0pt; line-height:102%;font-family:Arial'>envahis</span></b></p>
<p class=AmmCorpsTexte style='margin-top:.2pt;margin-right:20.85pt;margin-bottom: 0cm;margin-left:0cm;margin-bottom:.0001pt;line-height:102%;text-autospace: none'><b><span style='font-size:10.0pt;line-height:102%;font-family:Arial'> </span></b></p>
</td>
<td width=95 valign=top style='width:71.45pt;border:none;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:11.35pt'>
<p class=AmmCorpsTexte style='line-height:10.0pt;text-autospace:none'><span style='font-size:10.0pt;font-family:Arial'> </span></p>
</td>
<td width=65 valign=top style='width:48.5pt;border:none;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:11.35pt'>
<p class=AmmCorpsTexte style='line-height:10.0pt;text-autospace:none'><span style='font-size:10.0pt;font-family:Arial'> </span></p>
</td>
<td width=76 valign=top style='width:57.1pt;border:none;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:11.35pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.5pt;text-align:left; line-height:10.0pt;text-autospace:none'><span style='font-size:10.0pt; font-family:Arial'> </span></p>
</td>
<td width=66 valign=top style='width:49.65pt;border:none;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:11.35pt'>
<p class=AmmCorpsTexte align=left style='text-align:left;line-height:10.0pt; text-autospace:none'><span style='font-size:10.0pt;font-family:Arial'> </span></p>
</td>
<td width=61 valign=top style='width:45.85pt;border:none;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:11.35pt'>
<p class=AmmCorpsTexte style='line-height:10.0pt;text-autospace:none'><span style='font-size:10.0pt;font-family:Arial'> </span></p>
</td>
<td width=76 valign=top style='width:56.75pt;border:none;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:11.35pt'>
<p class=AmmCorpsTexte style='line-height:10.0pt;text-autospace:none'><span style='font-size:10.0pt;font-family:Arial'> </span></p>
</td>
<td width=69 valign=top style='width:51.65pt;border:none;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:11.35pt'>
<p class=AmmCorpsTexte style='line-height:10.0pt;text-autospace:none'><span style='font-size:10.0pt;font-family:Arial'> </span></p>
</td>
</tr>
<tr style='height:38.05pt'>
<td width=142 valign=top style='width:106.3pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:38.05pt'>
<p class=AmmCorpsTexte style='line-height:11.3pt;text-autospace:none'><span style='font-size:10.0pt;font-family:Arial;letter-spacing:.05pt'>To</span><span style='font-size:10.0pt;font-family:Arial'>tal</span></p>
<p class=AmmCorpsTexte style='margin-top:.2pt;text-autospace:none'><span style='font-size:10.0pt;font-family:Arial;letter-spacing:.05pt'>1-3</span></p>
<p class=AmmCorpsTexte style='margin-top:.2pt;text-autospace:none'><span style='font-size:10.0pt;font-family:Arial;letter-spacing:.05pt'>4+</span></p>
</td>
<td width=95 valign=top style='width:71.45pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:38.05pt'>
<p class=AmmCorpsTexte align=center style='margin-right:16.2pt;text-align:center; text-autospace:none'><span style='font-size:10.0pt;font-family:Arial; letter-spacing:.05pt'>745</span></p>
<p class=AmmCorpsTexte align=center style='margin-top:.2pt;margin-right:16.2pt; margin-bottom:0cm;margin-left:0cm;margin-bottom:.0001pt;text-align:center; text-autospace:none'><span style='font-size:10.0pt;font-family:Arial; letter-spacing:.05pt'>467</span></p>
<p class=AmmCorpsTexte align=center style='margin-top:.2pt;margin-right:16.2pt; margin-bottom:0cm;margin-left:0cm;margin-bottom:.0001pt;text-align:center; text-autospace:none'><span style='font-size:10.0pt;font-family:Arial; letter-spacing:.05pt'>278</span></p>
</td>
<td width=65 valign=top style='width:48.5pt;border-top:none;border-left:none;
border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0cm 0cm 0cm 0cm;
height:38.05pt'>
<p class=AmmCorpsTexte align=center style='margin-right:16.1pt;text-align:center; text-autospace:none'><span style='font-size:10.0pt;font-family:Arial; letter-spacing:.05pt'>0,80</span></p>
<p class=AmmCorpsTexte align=center style='margin-top:.2pt;margin-right:16.15pt; margin-bottom:0cm;margin-left:0cm;margin-bottom:.0001pt;text-align:center; text-autospace:none'><span style='font-size:10.0pt;font-family:Arial; letter-spacing:.05pt'>0,72</span></p>
<p class=AmmCorpsTexte align=center style='margin-top:.2pt;margin-right:16.1pt; margin-bottom:0cm;margin-left:0cm;margin-bottom:.0001pt;text-align:center; text-autospace:none'><span style='font-size:10.0pt;font-family:Arial; letter-spacing:.05pt'>0,87</span></p>
</td>
<td width=76 valign=top style='width:57.1pt;border-top:none;border-left:none;
border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0cm 0cm 0cm 0cm;
height:38.05pt'>
<p class=AmmCorpsTexte align=left style='margin-left:7.5pt;text-align:left; text-autospace:none'><span style='font-size:10.0pt;font-family:Arial; letter-spacing:.05pt'>0,68-0,93</span></p>
<p class=AmmCorpsTexte align=left style='margin-top:.2pt;margin-right:0cm; margin-bottom:0cm;margin-left:7.5pt;margin-bottom:.0001pt;text-align:left; text-autospace:none'><span style='font-size:10.0pt;font-family:Arial; letter-spacing:.05pt'>0,58-0,91</span></p>
<p class=AmmCorpsTexte align=left style='margin-top:.2pt;margin-right:0cm; margin-bottom:0cm;margin-left:7.5pt;margin-bottom:.0001pt;text-align:left; text-autospace:none'><span style='font-size:10.0pt;font-family:Arial; letter-spacing:.05pt'>0,70-1,09</span></p>
</td>
<td width=66 valign=top style='width:49.65pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:38.05pt'>
<p class=AmmCorpsTexte align=left style='text-align:left;text-autospace:none'><span style='font-size:10.0pt;font-family:Arial;letter-spacing:.05pt'> 0,0043</span></p>
<p class=AmmCorpsTexte align=left style='margin-top:.2pt;text-align:left; text-autospace:none'><span style='font-size:10.0pt;font-family:Arial; letter-spacing:.05pt'> 0,0047</span></p>
<p class=AmmCorpsTexte align=left style='margin-top:.2pt;text-align:left; text-autospace:none'><span style='font-size:10.0pt;font-family:Arial; letter-spacing:.05pt'> 0,2290</span></p>
</td>
<td width=61 valign=top style='width:45.85pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:38.05pt'>
<p class=AmmCorpsTexte align=center style='margin-right:16.65pt;text-align:center; text-autospace:none'><span style='font-size:10.0pt;font-family:Arial; letter-spacing:.05pt'>0,74</span></p>
<p class=AmmCorpsTexte align=center style='margin-top:.2pt;margin-right:16.7pt; margin-bottom:0cm;margin-left:0cm;margin-bottom:.0001pt;text-align:center; text-autospace:none'><span style='font-size:10.0pt;font-family:Arial; letter-spacing:.05pt'>0,62</span></p>
<p class=AmmCorpsTexte align=center style='margin-top:.2pt;margin-right:16.65pt; margin-bottom:0cm;margin-left:0cm;margin-bottom:.0001pt;text-align:center; text-autospace:none'><span style='font-size:10.0pt;font-family:Arial; letter-spacing:.05pt'>0,87</span></p>
</td>
<td width=76 valign=top style='width:56.75pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:38.05pt'>
<p class=AmmCorpsTexte align=center style='text-align:center;text-autospace:none'><span style='font-size:10.0pt;font-family:Arial;letter-spacing:.05pt'>0,61-0,90 </span></p>
<p class=AmmCorpsTexte align=center style='margin-top:.2pt;text-align:center; text-autospace:none'><span style='font-size:10.0pt;font-family:Arial; letter-spacing:.05pt'>0,46-0,82 </span></p>
<p class=AmmCorpsTexte align=center style='margin-top:.2pt;text-align:center; text-autospace:none'><span style='font-size:10.0pt;font-family:Arial; letter-spacing:.05pt'>0,67-1,12</span></p>
</td>
<td width=69 valign=top style='width:51.65pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:38.05pt'>
<p class=AmmCorpsTexte align=center style='margin-left:1.9pt;text-align:center; text-autospace:none'><span style='font-size:10.0pt;font-family:Arial; letter-spacing:.05pt'>0,0020</span></p>
<p class=AmmCorpsTexte align=center style='margin-top:.2pt;margin-right:0cm; margin-bottom:0cm;margin-left:1.9pt;margin-bottom:.0001pt;text-align:center; text-autospace:none'><span style='font-size:10.0pt;font-family:Arial; letter-spacing:.05pt'>0,0008</span></p>
<p class=AmmCorpsTexte align=center style='margin-top:.2pt;margin-right:0cm; margin-bottom:0cm;margin-left:1.9pt;margin-bottom:.0001pt;text-align:center; text-autospace:none'><span style='font-size:10.0pt;font-family:Arial; letter-spacing:.05pt'>0,2746</span></p>
</td>
</tr>
</table>
</div>
<p class=AmmCorpsTexte>*Un<span style='letter-spacing:-.45pt'> </span>risque<span style='letter-spacing:-.25pt'> </span>relatif<span style='letter-spacing:-.25pt'> </span>inférieur<span style='letter-spacing:-.35pt'> </span>à 1<span style='letter-spacing:-.05pt'> </span>signifie<span style='letter-spacing:-.3pt'> </span>que<span style='letter-spacing:-.15pt'> </span>TAC<span style='letter-spacing:-.25pt'> </span>est<span style='letter-spacing:-.1pt'> </span>associé<span style='letter-spacing:-.3pt'> </span>à une<span style='letter-spacing:-.15pt'> </span>survie<span style='letter-spacing:-.25pt'> </span>sans<span style='letter-spacing:-.15pt'> </span>rechute<span style='letter-spacing:-.3pt'> </span>et une<span style='letter-spacing:-.15pt'> </span>survie globale<span style='letter-spacing:-.5pt'> </span>plus<span style='letter-spacing:-.15pt'> </span>longue<span style='letter-spacing:-.25pt'> </span>que<span style='letter-spacing:-.15pt'> </span>FAC.</p>
<p class=AmmCorpsTexte><u>Patientes<span style='letter-spacing:-.65pt'> </span>présentant<span style='letter-spacing:-.4pt'> </span>un<span style='letter-spacing:-.1pt'> </span>cancer<span style='letter-spacing:-.25pt'> </span>du<span style='letter-spacing:-.1pt'> </span>sein<span style='letter-spacing:-.15pt'> </span>opérable<span style='letter-spacing:-.35pt'> </span>sans<span style='letter-spacing:-.15pt'> </span>envahisse<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.4pt'> </span>ganglionnaire<span style='letter-spacing:-.55pt'> </span>éligible<span style='letter-spacing:-.25pt'> </span>à une chi<span style='letter-spacing:-.05pt'>m</span>iothérapie<span style='letter-spacing:.05pt'> </span>(GEICAM<span style='letter-spacing:-.45pt'> </span>9805)</u></p>
<p class=AmmCorpsTexte>L<span style='letter-spacing:.05pt'>’</span>utilisation de<span style='letter-spacing:-.1pt'> </span>docétaxel<span style='letter-spacing: -.55pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>le traite<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.3pt'> </span>a<span style='letter-spacing:-.05pt'>d</span>juvant<span style='letter-spacing:-.05pt'> </span>des<span style='letter-spacing:-.15pt'> </span>patientes<span style='letter-spacing:-.35pt'> </span>atteintes<span style='letter-spacing: -.3pt'> </span>d<span style='letter-spacing:.05pt'>’</span>un<span style='letter-spacing:-.05pt'> </span>cancer<span style='letter-spacing:-.25pt'> </span>du<span style='letter-spacing:-.1pt'> </span>sein<span style='letter-spacing: -.15pt'> </span>opérable sans envahisse<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.4pt'> </span>ganglionnaire<span style='letter-spacing: -.5pt'> </span>éligible<span style='letter-spacing:-.3pt'> </span>à une<span style='letter-spacing:-.15pt'> </span>chi<span style='letter-spacing:-.05pt'>m</span>iothérapie<span style='letter-spacing:-.1pt'> </span>s<span style='letter-spacing:.05pt'>’</span>appuie<span style='letter-spacing:-.05pt'> </span>sur<span style='letter-spacing:-.1pt'> </span>les<span style='letter-spacing:-.1pt'> </span>données<span style='letter-spacing:-.35pt'> </span>d<span style='letter-spacing:.05pt'>’</span>une étude <span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>u</span>lticentrique<span style='letter-spacing:-.05pt'> </span>ouverte<span style='letter-spacing:-.3pt'> </span>rando<span style='letter-spacing:-.1pt'>m</span>isée.<span style='letter-spacing:-.3pt'> </span>1060<span style='letter-spacing:-.2pt'> </span>patientes<span style='letter-spacing:-.3pt'> </span>ont<span style='letter-spacing:-.15pt'> </span>été rando<span style='letter-spacing:-.1pt'>m</span>isées<span style='letter-spacing: -.25pt'> </span>pour<span style='letter-spacing:-.2pt'> </span>recevoir<span style='letter-spacing:-.35pt'> </span>soit<span style='letter-spacing:-.15pt'> </span>docétaxel 75 <span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.1pt'>m</span>² ad<span style='letter-spacing:-.1pt'>m</span>inistré<span style='letter-spacing:-.3pt'> </span>une<span style='letter-spacing:-.15pt'> </span>heure<span style='letter-spacing:-.2pt'> </span>après<span style='letter-spacing:-.2pt'> </span>50<span style='letter-spacing:-.1pt'> m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.1pt'>m</span>²<span style='letter-spacing:-.1pt'> </span>de<span style='letter-spacing:-.1pt'> </span>doxorubicine<span style='letter-spacing: -.5pt'> </span>et 500<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.1pt'>m</span>²<span style='letter-spacing:-.1pt'> </span>de<span style='letter-spacing:-.1pt'> </span>c<span style='letter-spacing:.1pt'>y</span>clophospha<span style='letter-spacing:-.05pt'>m</span>ide<span style='letter-spacing:-.1pt'> </span>(539<span style='letter-spacing:-.2pt'> </span>patientes dans<span style='letter-spacing: -.2pt'> </span>le bras<span style='letter-spacing:-.1pt'> </span>TAC),<span style='letter-spacing:-.25pt'> </span>soit<span style='letter-spacing:-.15pt'> </span>doxorubicine<span style='letter-spacing:-.5pt'> </span>50<span style='letter-spacing:-.1pt'> m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.1pt'>m</span>²<span style='letter-spacing:-.1pt'> </span>suivie<span style='letter-spacing:-.25pt'> </span>par 500<span style='letter-spacing:-.4pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.1pt'>m</span>²<span style='letter-spacing:-.1pt'> </span>de<span style='letter-spacing:-.1pt'> </span>fluoro-uracile<span style='letter-spacing: -.45pt'> </span>et 500<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.1pt'>m</span>²<span style='letter-spacing:-.1pt'> </span>de<span style='letter-spacing:-.1pt'> </span>c<span style='letter-spacing:.1pt'>y</span>clopho<span style='letter-spacing:-.05pt'>s</span>pha<span style='letter-spacing:-.1pt'>m</span>ide<span style='letter-spacing:-.15pt'> </span>(521<span style='letter-spacing:-.2pt'> </span>patientes<span style='letter-spacing:-.35pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>le bras<span style='letter-spacing:-.15pt'> </span>FAC).<span style='letter-spacing: -.25pt'> </span>Ces<span style='letter-spacing:-.15pt'> </span>patientes présentaient<span style='letter-spacing:-.5pt'> </span>de<span style='letter-spacing:-.1pt'> </span>patientes<span style='letter-spacing:-.35pt'> </span>présentaient<span style='letter-spacing:-.5pt'> </span>un<span style='letter-spacing:-.1pt'> </span>cancer<span style='letter-spacing:-.25pt'> </span>du<span style='letter-spacing:-.1pt'> </span>sein<span style='letter-spacing: -.15pt'> </span>opérable<span style='letter-spacing:-.35pt'> </span>sans<span style='letter-spacing:-.15pt'> </span>envahisse<span style='letter-spacing: -.05pt'>m</span>ent<span style='letter-spacing:-.4pt'> </span>ganglionnaire<span style='letter-spacing:.05pt'> </span>avec<span style='letter-spacing:-.2pt'> </span>un<span style='letter-spacing:-.1pt'> </span>haut risque<span style='letter-spacing: -.25pt'> </span>de<span style='letter-spacing:-.1pt'> </span>rechute<span style='letter-spacing:-.25pt'> </span>selon<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>critères<span style='letter-spacing:-.3pt'> </span>de<span style='letter-spacing:-.1pt'> </span>St<span style='letter-spacing: -.1pt'> </span>Gallen<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.1pt'> </span>1998<span style='letter-spacing:-.2pt'> </span>(taille tu<span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>o</span>rale&gt;2cm<span style='letter-spacing:-.15pt'> </span>et/ou<span style='letter-spacing:-.2pt'> </span>RE<span style='letter-spacing:-.15pt'> </span>négatif et RP négatif et/ou un grade<span style='letter-spacing:-.2pt'> </span>histologique<span style='letter-spacing: -.45pt'> </span>élevé<span style='letter-spacing:-.2pt'> </span>(grade<span style='letter-spacing:-.25pt'> </span>2<span style='letter-spacing:-.05pt'> </span>à 3)<span style='letter-spacing:-.1pt'> </span>et/ou<span style='letter-spacing: -.2pt'> </span>âge &lt;35<span style='letter-spacing:-.4pt'> </span>ans).<span style='letter-spacing:-.2pt'> </span>Les<span style='letter-spacing:-.15pt'> </span>deux<span style='letter-spacing:-.2pt'> </span>traite<span style='letter-spacing:-.05pt'>m</span>ents<span style='letter-spacing:-.3pt'> </span>ont<span style='letter-spacing:-.15pt'> </span>été ad<span style='letter-spacing:-.1pt'>m</span>inistrés<span style='letter-spacing: -.35pt'> </span>toutes<span style='letter-spacing:-.25pt'> </span>les<span style='letter-spacing:-.1pt'> </span>3<span style='letter-spacing:-.05pt'> </span>se<span style='letter-spacing:-.1pt'>m</span>aines<span style='letter-spacing:-.1pt'> </span>pendant<span style='letter-spacing:-.3pt'> </span>6<span style='letter-spacing:-.05pt'> </span>c<span style='letter-spacing:.1pt'>y</span>cles.<span style='letter-spacing:-.05pt'> </span>Docétaxel a été ad<span style='letter-spacing:-.1pt'>m</span>inistré<span style='letter-spacing:-.3pt'> </span>en<span style='letter-spacing:-.1pt'> </span>perfusion<span style='letter-spacing:-.4pt'> </span>d’une<span style='letter-spacing:-.25pt'> </span>heure,<span style='letter-spacing:-.25pt'> </span>les<span style='letter-spacing:-.1pt'> </span>autres<span style='letter-spacing:-.25pt'> </span><span style='letter-spacing:-.1pt'>m</span>édica<span style='letter-spacing:-.05pt'>m</span>ents<span style='letter-spacing:-.25pt'> </span>a<span style='letter-spacing:.1pt'>y</span>ant<span style='letter-spacing:-.05pt'> </span>été ad<span style='letter-spacing:-.1pt'>m</span>inistrés<span style='letter-spacing: -.35pt'> </span>en bolus<span style='letter-spacing:-.2pt'> </span>intraveineux<span style='letter-spacing:-.5pt'> </span>le pre<span style='letter-spacing:-.1pt'>m</span>ier<span style='letter-spacing:-.15pt'> </span>jour<span style='letter-spacing:-.15pt'> </span>toutes<span style='letter-spacing:-.25pt'> </span>les<span style='letter-spacing:-.1pt'> </span>trois<span style='letter-spacing:-.2pt'> </span>se<span style='letter-spacing:-.1pt'>m</span>aines.<span style='letter-spacing:-.1pt'> </span>Une<span style='letter-spacing:-.15pt'> </span>proph<span style='letter-spacing:.1pt'>y</span>laxie<span style='letter-spacing:-.25pt'> </span>pri<span style='letter-spacing:-.1pt'>m</span>aire<span style='letter-spacing:-.1pt'> </span>par<span style='letter-spacing:-.15pt'> </span>G-CSF<span style='letter-spacing:-.3pt'> </span>a été reco<span style='letter-spacing:-.1pt'>mm</span>andée<span style='letter-spacing:-.35pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>le bras TAC après<span style='letter-spacing:-.2pt'> </span>rando<span style='letter-spacing:-.1pt'>m</span>isation<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.1pt'> </span>230<span style='letter-spacing: -.15pt'> </span>patientes.<span style='letter-spacing:-.35pt'> </span>L’incidence<span style='letter-spacing:-.45pt'> </span>des<span style='letter-spacing:-.15pt'> </span>neutropénies Grade<span style='letter-spacing:-.25pt'> </span>4,<span style='letter-spacing: -.05pt'> </span>des<span style='letter-spacing:-.15pt'> </span>neutropénies<span style='letter-spacing:-.5pt'> </span>fébriles,<span style='letter-spacing:-.3pt'> </span>et<span style='letter-spacing:.05pt'> </span>des<span style='letter-spacing: -.15pt'> </span>infections<span style='letter-spacing:-.4pt'> </span>neutropéniques<span style='letter-spacing:-.6pt'> </span>a été di<span style='letter-spacing:-.1pt'>m</span>inuée<span style='letter-spacing:-.25pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>les patientes<span style='letter-spacing:-.35pt'> </span>a<span style='letter-spacing: .1pt'>y</span>ant<span style='letter-spacing:-.05pt'> </span>reçu<span style='letter-spacing:-.15pt'> </span>une<span style='letter-spacing:-.15pt'> </span>proph<span style='letter-spacing:.1pt'>y</span>laxie<span style='letter-spacing:-.25pt'> </span>pri<span style='letter-spacing:-.1pt'>m</span>aire<span style='letter-spacing:-.1pt'> </span>par<span style='letter-spacing:-.15pt'> </span>G-CSF (voir<span style='letter-spacing: -.2pt'> </span>rubrique<span style='letter-spacing:-.35pt'> </span>4.8).<span style='letter-spacing:-.2pt'> </span>Dans<span style='letter-spacing:-.2pt'> </span>chacun<span style='letter-spacing:-.3pt'> </span>des<span style='letter-spacing:-.15pt'> </span>bras, après<span style='letter-spacing:-.2pt'> </span>le dernier<span style='letter-spacing:-.3pt'> </span>c<span style='letter-spacing:.1pt'>y</span>cle<span style='letter-spacing:-.05pt'> </span>de<span style='letter-spacing:-.1pt'> </span>chi<span style='letter-spacing:-.05pt'>m</span>iothérapie,<span style='letter-spacing: -.1pt'> </span><span style='letter-spacing:-.05pt'>l</span>es<span style='letter-spacing:-.1pt'> </span>patientes<span style='letter-spacing:-.35pt'> </span>a<span style='letter-spacing:.1pt'>y</span>ant<span style='letter-spacing: -.05pt'> </span>des tu<span style='letter-spacing:-.1pt'>m</span>eurs<span style='letter-spacing:-.2pt'> </span>RE+<span style='letter-spacing:-.2pt'> </span>et/ou<span style='letter-spacing:-.2pt'> </span>RP+<span style='letter-spacing:-.2pt'> </span>ont<span style='letter-spacing:-.15pt'> </span>reçu 20<span style='letter-spacing:-.1pt'>m</span>g<span style='letter-spacing:-.1pt'> </span>ta<span style='letter-spacing:-.05pt'>m</span>oxifène une<span style='letter-spacing:-.15pt'> </span>fois<span style='letter-spacing: -.15pt'> </span>par<span style='letter-spacing:-.15pt'> </span>jour<span style='letter-spacing:-.2pt'> </span>pendant<span style='letter-spacing:-.3pt'> </span>5<span style='letter-spacing:-.05pt'> </span>ans.<span style='letter-spacing: -.15pt'> </span>Une<span style='letter-spacing:-.15pt'> </span>radiothérapie<span style='letter-spacing:-.5pt'> </span>adjuvante<span style='letter-spacing:-.4pt'> </span>a été ad<span style='letter-spacing:-.1pt'>m</span>inistrée<span style='letter-spacing:-.35pt'> </span>selon<span style='letter-spacing:-.2pt'> </span>les reco<span style='letter-spacing:-.1pt'>mm</span>andations<span style='letter-spacing:-.5pt'> </span>en<span style='letter-spacing:-.1pt'> </span>vigueur<span style='letter-spacing:-.3pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>différen<span style='letter-spacing:.05pt'>t</span>s<span style='letter-spacing:-.3pt'> </span>centres<span style='letter-spacing:-.3pt'> </span>investigateurs<span style='letter-spacing:-.55pt'> </span>et a été donnée<span style='letter-spacing:-.3pt'> </span>chez<span style='letter-spacing: -.2pt'> </span>57,3%<span style='letter-spacing:-.25pt'> </span>des patientes a<span style='letter-spacing:.1pt'>y</span>ant<span style='letter-spacing:-.05pt'> </span>reçu<span style='letter-spacing:-.15pt'> </span>le protocole<span style='letter-spacing: -.4pt'> </span>TAC<span style='letter-spacing:-.2pt'> </span>et chez<span style='letter-spacing:-.25pt'> </span>51,2%<span style='letter-spacing:-.25pt'> </span>des<span style='letter-spacing:-.15pt'> </span>patientes<span style='letter-spacing:-.35pt'> </span>a<span style='letter-spacing:.1pt'>y</span>ant<span style='letter-spacing:-.05pt'> </span>reçu<span style='letter-spacing:-.15pt'> </span>le protocole<span style='letter-spacing:-.4pt'> </span>FAC.</p>
<p class=AmmCorpsTexte>La médiane de suivi a été de 77 mois. Une survie sans rechute significativement plus longue dans le bras TAC par rapport au bras FAC a été démontrée.<span style='letter-spacing:-.1pt'> </span>Les<span style='letter-spacing:-.15pt'> </span>patientes<span style='letter-spacing: -.35pt'> </span>traitées<span style='letter-spacing:-.3pt'> </span>par<span style='letter-spacing:-.15pt'> </span>TAC<span style='letter-spacing:-.2pt'> </span>ont<span style='letter-spacing:-.15pt'> </span>eu<span style='letter-spacing:-.1pt'> </span>32%<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span>réduction de<span style='letter-spacing:-.1pt'> </span>l<span style='letter-spacing:.05pt'>’</span>incidence de<span style='letter-spacing:-.1pt'> </span>rechute<span style='letter-spacing: -.3pt'> </span>co<span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>p</span>arée<span style='letter-spacing:-.1pt'> </span>à celle observée<span style='letter-spacing:-.35pt'> </span>chez<span style='letter-spacing:2.35pt'> </span>les<span style='letter-spacing:-.1pt'> </span>patientes<span style='letter-spacing:-.35pt'> </span>traitées<span style='letter-spacing:-.3pt'> </span>par<span style='letter-spacing:-.15pt'> </span>FAC<span style='letter-spacing:-.2pt'> </span>(hazard<span style='letter-spacing:.05pt'> </span>ratio=0,68,<span style='letter-spacing:-.4pt'> </span>95%<span style='letter-spacing:-.2pt'> </span>IC<span style='letter-spacing:-.1pt'> </span>(0,49-0,93), p=0,01).<span style='letter-spacing:-.35pt'> </span>La<span style='letter-spacing: -.1pt'> </span>survie<span style='letter-spacing:-.25pt'> </span>globale<span style='letter-spacing:-.3pt'> </span>(SG)<span style='letter-spacing:-.2pt'> </span>était<span style='letter-spacing:.05pt'> </span>égale<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.2pt'> </span>plus<span style='letter-spacing:-.15pt'> </span>longue<span style='letter-spacing:-.25pt'> </span>dans le bras<span style='letter-spacing: -.15pt'> </span>TAC,<span style='letter-spacing:-.2pt'> </span>avec<span style='letter-spacing:-.2pt'> </span>une<span style='letter-spacing:-.15pt'> </span>réduction<span style='letter-spacing:-.4pt'> </span>du<span style='letter-spacing:-.1pt'> </span>risque<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.05pt'> </span>décès<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span>24%<span style='letter-spacing:-.2pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>patientes<span style='letter-spacing:-.35pt'> </span>traitées<span style='letter-spacing:-.3pt'> </span>par<span style='letter-spacing:-.15pt'> </span>TAC,<span style='letter-spacing:-.2pt'> </span>par rapport<span style='letter-spacing:-.3pt'> </span>au<span style='letter-spacing: -.1pt'> </span>bras<span style='letter-spacing:-.15pt'> </span>FAC<span style='letter-spacing:-.2pt'> </span>(hazard<span style='letter-spacing:-.3pt'> </span>ratio=0,76,<span style='letter-spacing:-.45pt'> </span>95%<span style='letter-spacing:-.2pt'> </span>IC (<span style='letter-spacing:.05pt'>0</span>,46-1,26) p=0,29).<span style='letter-spacing:-.3pt'> </span>Cepend<span style='letter-spacing:-.05pt'>a</span>nt<span style='letter-spacing:-.3pt'> </span>la<span style='letter-spacing:.05pt'> </span>distribution<span style='letter-spacing: -.4pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la survie<span style='letter-spacing:-.25pt'> </span>globale<span style='letter-spacing:-.25pt'> </span>n’a<span style='letter-spacing:-.15pt'> </span>pas<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span>ontré<span style='letter-spacing:-.1pt'> </span>de<span style='letter-spacing:-.1pt'> </span>différence<span style='letter-spacing:-.4pt'> </span>significative<span style='letter-spacing: -.45pt'> </span>dans les<span style='letter-spacing:-.1pt'> </span>2<span style='letter-spacing:-.05pt'> </span>groupes.</p>
<p class=AmmCorpsTexte>Les<span style='letter-spacing:-.4pt'> </span>résultats<span style='letter-spacing:-.35pt'> </span>ont<span style='letter-spacing:-.15pt'> </span>été anal<span style='letter-spacing:.1pt'>y</span>sés<span style='letter-spacing: -.15pt'> </span>en<span style='letter-spacing:-.1pt'> </span>sous-groupe<span style='letter-spacing:-.5pt'> </span>selon<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>facteurs<span style='letter-spacing:-.3pt'> </span>de<span style='letter-spacing:-.1pt'> </span>pronostic<span style='letter-spacing:-.35pt'> </span><span style='letter-spacing:-.1pt'>m</span>ajeurs<span style='letter-spacing:-.25pt'> </span>prédéfinis<span style='letter-spacing: -.45pt'> </span>des<span style='letter-spacing:-.15pt'> </span>patientes traitées<span style='letter-spacing:-.3pt'> </span>par<span style='letter-spacing: -.15pt'> </span>TAC<span style='letter-spacing:-.2pt'> </span>(voir<span style='letter-spacing:-.2pt'> </span>tableau<span style='letter-spacing:-.3pt'> </span>ci-dessous)<span style='letter-spacing:-.45pt'> </span>:</p>
<p class=AmmCorpsTexte>Anal<span style='letter-spacing:.1pt'>y</span>se<span style='letter-spacing:-.2pt'> </span>en<span style='letter-spacing:-.1pt'> </span>sous-groupe<span style='letter-spacing: -.5pt'> </span>de<span style='letter-spacing:-.1pt'> </span>l<span style='letter-spacing:.05pt'>’</span>étude<span style='letter-spacing:-.05pt'> </span>du<span style='letter-spacing:-.1pt'> </span>traite<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.35pt'> </span>adjuvant<span style='letter-spacing:-.35pt'> </span>des<span style='letter-spacing:-.15pt'> </span>patientes<span style='letter-spacing:-.3pt'> </span>présentant<span style='letter-spacing: -.4pt'> </span>un<span style='letter-spacing:-.1pt'> </span>cancer<span style='letter-spacing:-.25pt'> </span>du<span style='letter-spacing:-.1pt'> </span>sein<span style='letter-spacing:-.15pt'> </span>sans envahisse<span style='letter-spacing: -.05pt'>m</span>ent<span style='letter-spacing:-.4pt'> </span>ganglionnaire<span style='letter-spacing:-.55pt'> </span>(anal<span style='letter-spacing:.1pt'>y</span>se<span style='letter-spacing:-.2pt'> </span>en<span style='letter-spacing:-.1pt'> </span>Intention<span style='letter-spacing:-.35pt'> </span>de<span style='letter-spacing:-.1pt'> </span>Traiter)</p>
<div align=center>
<table class=AmmCorpsTexteTable border=0 cellspacing=0 cellpadding=0
style='margin-left:-11.2pt;border-collapse:collapse'>
<tr style='height:13.4pt'>
<td width=153 rowspan=2 valign=top style='width:115.05pt;border:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:13.4pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.85pt;text-align:left; page-break-after:avoid'><b>Sous-groupe<span style='letter-spacing:-.85pt'> </span>de patientes</b></p>
</td>
<td width=153 rowspan=2 valign=top style='width:115.05pt;border:solid black 1.0pt;
border-left:none;padding:0cm 0cm 0cm 0cm;height:13.4pt'>
<p class=AmmCorpsTexte align=left style='margin-left:10.25pt;text-align:left; page-break-after:avoid'><b>Nombre<span style='letter-spacing:-.65pt'> </span>de<span style='letter-spacing:-.1pt'> </span>patientes dans le groupe<span style='letter-spacing:-.3pt'> </span>TAC</b></p>
</td>
<td width=307 colspan=2 valign=top style='width:230.15pt;border:solid black 1.0pt;
border-left:none;padding:0cm 0cm 0cm 0cm;height:13.4pt'>
<p class=AmmCorpsTexte align=left style='margin-left:8.6pt;text-align:left; page-break-after:avoid'><b>Survie<span style='letter-spacing:-.55pt'> </span>sans<span style='letter-spacing:-.2pt'> </span>progression</b></p>
</td>
</tr>
<tr style='height:13.4pt'>
<td width=153 valign=top style='width:115.05pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:13.4pt'>
<p class=AmmCorpsTexte align=left style='margin-left:8.6pt;text-align:left; page-break-after:avoid'><b>Ha<span style='letter-spacing:-.05pt'>z</span><span style='letter-spacing:.05pt'>a</span>rd<span style='letter-spacing:-.15pt'> </span>ratio*</b></p>
</td>
<td width=153 valign=top style='width:115.1pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:13.4pt'>
<p class=AmmCorpsTexte align=left style='margin-left:6.95pt;text-align:left; page-break-after:avoid'><b>95%<span style='letter-spacing:-.45pt'> IC</span></b></p>
</td>
</tr>
<tr style='height:13.4pt'>
<td width=153 valign=top style='width:115.05pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:13.4pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.85pt;text-align:left; page-break-after:avoid'><b>Globale</b></p>
</td>
<td width=153 valign=top style='width:115.05pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:13.4pt'>
<p class=AmmCorpsTexte align=left style='margin-left:10.25pt;text-align:left; page-break-after:avoid'><span style='letter-spacing:.05pt'>539</span></p>
</td>
<td width=153 valign=top style='width:115.05pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:13.4pt'>
<p class=AmmCorpsTexte align=left style='margin-left:8.6pt;text-align:left; page-break-after:avoid'><span style='letter-spacing:.05pt'>0,68</span></p>
</td>
<td width=153 valign=top style='width:115.1pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:13.4pt'>
<p class=AmmCorpsTexte align=left style='margin-left:6.95pt;text-align:left; page-break-after:avoid'><span style='letter-spacing:.05pt'>0,49-0,93</span></p>
</td>
</tr>
<tr style='height:38.8pt'>
<td width=153 valign=top style='width:115.05pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:38.8pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:4.8pt;margin-bottom:.0001pt;text-align:left; page-break-after:avoid'><b>Age<span style='letter-spacing:-.45pt'> </span>Catégorie1</b></p>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:4.8pt;margin-bottom:.0001pt;text-align:left; page-break-after:avoid'>&lt;50ans</p>
<p class=AmmCorpsTexte align=left style='margin-left:4.85pt;text-align:left; page-break-after:avoid'>&gt;50ans</p>
</td>
<td width=153 valign=top style='width:115.05pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:38.8pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:10.25pt;margin-bottom:.0001pt;text-align:left; page-break-after:avoid'> </p>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:10.25pt;margin-bottom:.0001pt;text-align:left; page-break-after:avoid'><span style='letter-spacing:.05pt'>260</span></p>
<p class=AmmCorpsTexte align=left style='margin-left:10.25pt;text-align:left; page-break-after:avoid'><span style='letter-spacing:.05pt'>279</span></p>
</td>
<td width=153 valign=top style='width:115.05pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:38.8pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:8.6pt;margin-bottom:.0001pt;text-align:left; page-break-after:avoid'> </p>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:8.6pt;margin-bottom:.0001pt;text-align:left; page-break-after:avoid'>0,67</p>
<p class=AmmCorpsTexte align=left style='margin-left:8.6pt;text-align:left; page-break-after:avoid'><span style='letter-spacing:.05pt'>0,67</span></p>
</td>
<td width=153 valign=top style='width:115.1pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:38.8pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:6.95pt;margin-bottom:.0001pt;text-align:left; page-break-after:avoid'> </p>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:6.95pt;margin-bottom:.0001pt;text-align:left; page-break-after:avoid'>0,43-1,05</p>
<p class=AmmCorpsTexte align=left style='margin-left:6.95pt;text-align:left; page-break-after:avoid'>0,43-1,05</p>
</td>
</tr>
<tr style='height:38.8pt'>
<td width=153 valign=top style='width:115.05pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:38.8pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:4.8pt;margin-bottom:.0001pt;text-align:left; page-break-after:avoid'><b>Age<span style='letter-spacing:-.45pt'> </span>Catégorie2</b></p>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:4.8pt;margin-bottom:.0001pt;text-align:left; page-break-after:avoid'>&lt;35ans</p>
<p class=AmmCorpsTexte align=left style='margin-left:4.85pt;text-align:left; page-break-after:avoid'>&gt;35ans</p>
</td>
<td width=153 valign=top style='width:115.05pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:38.8pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:10.25pt;margin-bottom:.0001pt;text-align:left; page-break-after:avoid'> </p>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:10.25pt;margin-bottom:.0001pt;text-align:left; page-break-after:avoid'>42</p>
<p class=AmmCorpsTexte align=left style='margin-left:10.25pt;text-align:left; page-break-after:avoid'><span style='letter-spacing:.05pt'>497</span></p>
</td>
<td width=153 valign=top style='width:115.05pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:38.8pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:8.6pt;margin-bottom:.0001pt;text-align:left; page-break-after:avoid'> </p>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:8.6pt;margin-bottom:.0001pt;text-align:left; page-break-after:avoid'>0,31</p>
<p class=AmmCorpsTexte align=left style='margin-left:8.6pt;text-align:left; page-break-after:avoid'><span style='letter-spacing:.05pt'>0,73</span></p>
</td>
<td width=153 valign=top style='width:115.1pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:38.8pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:6.95pt;margin-bottom:.0001pt;text-align:left; page-break-after:avoid'> </p>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:6.95pt;margin-bottom:.0001pt;text-align:left; page-break-after:avoid'>0,11-0,89</p>
<p class=AmmCorpsTexte align=left style='margin-left:6.95pt;text-align:left; page-break-after:avoid'>0,52-1,01</p>
</td>
</tr>
<tr style='height:63.15pt'>
<td width=153 valign=top style='width:115.05pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:63.15pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:4.8pt;margin-bottom:.0001pt;text-align:left; page-break-after:avoid'><b>Statut<span style='letter-spacing:-.55pt'> </span>des<span style='letter-spacing:-.15pt'> </span>récepteurs</b></p>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:4.8pt;margin-bottom:.0001pt;text-align:left; page-break-after:avoid'><b>hor<span style='letter-spacing:-.1pt'>m</span>onaux </b></p>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:4.8pt;margin-bottom:.0001pt;text-align:left; page-break-after:avoid'>Négatif </p>
<p class=AmmCorpsTexte align=left style='margin-left:4.85pt;text-align:left; page-break-after:avoid'>Positif</p>
</td>
<td width=153 valign=top style='width:115.05pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:63.15pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:10.25pt;margin-bottom:.0001pt;text-align:left; page-break-after:avoid'> </p>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:10.25pt;margin-bottom:.0001pt;text-align:left; page-break-after:avoid'> </p>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:10.25pt;margin-bottom:.0001pt;text-align:left; page-break-after:avoid'>195</p>
<p class=AmmCorpsTexte align=left style='margin-left:10.25pt;text-align:left; page-break-after:avoid'><span style='letter-spacing:.05pt'>344</span></p>
</td>
<td width=153 valign=top style='width:115.05pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:63.15pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left;page-break-after:avoid'> </p>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left;page-break-after:avoid'> </p>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:10.25pt;margin-bottom:.0001pt;text-align:left; page-break-after:avoid'>0,7</p>
<p class=AmmCorpsTexte align=left style='margin-left:8.6pt;text-align:left; page-break-after:avoid'><span style='letter-spacing:.05pt'>0,62</span></p>
</td>
<td width=153 valign=top style='width:115.1pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:63.15pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left;page-break-after:avoid'> </p>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left;page-break-after:avoid'> </p>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:6.95pt;margin-bottom:.0001pt;text-align:left; page-break-after:avoid'>0,45-1,1</p>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:6.95pt;margin-bottom:.0001pt;text-align:left; page-break-after:avoid'>0,4-0,97</p>
</td>
</tr>
<tr style='height:38.8pt'>
<td width=153 valign=top style='width:115.05pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:38.8pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:4.8pt;margin-bottom:.0001pt;text-align:left; page-break-after:avoid'><b>Taille<span style='letter-spacing:-.5pt'> </span>tumorale</b></p>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:4.8pt;margin-bottom:.0001pt;text-align:left; page-break-after:avoid'>&lt;2cm</p>
<p class=AmmCorpsTexte align=left style='margin-left:4.85pt;text-align:left; page-break-after:avoid'>&gt;2cm</p>
</td>
<td width=153 valign=top style='width:115.05pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:38.8pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:10.25pt;margin-bottom:.0001pt;text-align:left; page-break-after:avoid'> </p>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:10.25pt;margin-bottom:.0001pt;text-align:left; page-break-after:avoid'>285</p>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:10.25pt;margin-bottom:.0001pt;text-align:left; page-break-after:avoid'>254</p>
</td>
<td width=153 valign=top style='width:115.05pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:38.8pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:8.6pt;margin-bottom:.0001pt;text-align:left; page-break-after:avoid'> </p>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:8.6pt;margin-bottom:.0001pt;text-align:left; page-break-after:avoid'>0,69</p>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:8.6pt;margin-bottom:.0001pt;text-align:left; page-break-after:avoid'>0,68</p>
</td>
<td width=153 valign=top style='width:115.1pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:38.8pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:6.95pt;margin-bottom:.0001pt;text-align:left; page-break-after:avoid'> </p>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:6.95pt;margin-bottom:.0001pt;text-align:left; page-break-after:avoid'>0,43-1,1</p>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:6.95pt;margin-bottom:.0001pt;text-align:left; page-break-after:avoid'>0,45-1,04</p>
</td>
</tr>
<tr style='height:38.8pt'>
<td width=153 valign=top style='width:115.05pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:38.8pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.85pt;text-align:left'><b>Grade<span style='letter-spacing:-.55pt'> </span>histologique </b>Grade 1<span style='letter-spacing:-.05pt'> </span>(inclus<span style='letter-spacing: -.25pt'> </span>grade non évalué)</p>
</td>
<td width=153 valign=top style='width:115.05pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:38.8pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:10.25pt;margin-bottom:.0001pt;text-align:left'> </p>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:10.25pt;margin-bottom:.0001pt;text-align:left'>64</p>
</td>
<td width=153 valign=top style='width:115.05pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:38.8pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:8.6pt;margin-bottom:.0001pt;text-align:left'> </p>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:8.6pt;margin-bottom:.0001pt;text-align:left'>0,79</p>
</td>
<td width=153 valign=top style='width:115.1pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:38.8pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:6.95pt;margin-bottom:.0001pt;text-align:left'> </p>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:6.95pt;margin-bottom:.0001pt;text-align:left'>0,24-2,6</p>
</td>
</tr>
<tr style='height:28.0pt'>
<td width=153 valign=top style='width:115.05pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:28.0pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:4.8pt;margin-bottom:.0001pt;text-align:left'><b>Grade 2</b></p>
<p class=AmmCorpsTexte align=left style='margin-left:4.85pt;text-align:left'><b>Grade 3</b></p>
</td>
<td width=153 valign=top style='width:115.05pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:28.0pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:10.25pt;margin-bottom:.0001pt;text-align:left'>216</p>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:10.25pt;margin-bottom:.0001pt;text-align:left'>259</p>
</td>
<td width=153 valign=top style='width:115.05pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:28.0pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:8.6pt;margin-bottom:.0001pt;text-align:left'>0,77</p>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:8.6pt;margin-bottom:.0001pt;text-align:left'>0,59</p>
</td>
<td width=153 valign=top style='width:115.1pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:28.0pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:6.95pt;margin-bottom:.0001pt;text-align:left'>0,46-1,3</p>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:6.95pt;margin-bottom:.0001pt;text-align:left'>0,39-0,9</p>
</td>
</tr>
<tr style='height:38.8pt'>
<td width=153 valign=top style='width:115.05pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:38.8pt'>
<p class=AmmCorpsTexte align=left style='margin-left:4.85pt;text-align:left'><b>Statut ménopause Pré-ménopause Post-ménopause</b></p>
</td>
<td width=153 valign=top style='width:115.05pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:38.8pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:10.25pt;margin-bottom:.0001pt;text-align:left'> </p>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:10.25pt;margin-bottom:.0001pt;text-align:left'>285</p>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:10.25pt;margin-bottom:.0001pt;text-align:left'>254</p>
</td>
<td width=153 valign=top style='width:115.05pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:38.8pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:8.6pt;margin-bottom:.0001pt;text-align:left'> </p>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:8.6pt;margin-bottom:.0001pt;text-align:left'>0,64</p>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:8.6pt;margin-bottom:.0001pt;text-align:left'>0,72</p>
</td>
<td width=153 valign=top style='width:115.1pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:38.8pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:6.95pt;margin-bottom:.0001pt;text-align:left'> </p>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:6.95pt;margin-bottom:.0001pt;text-align:left'>0,40-1</p>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:6.95pt;margin-bottom:.0001pt;text-align:left'>0,47-1,12</p>
</td>
</tr>
</table>
</div>
<p class=AmmCorpsTexte>*un<span style='letter-spacing:-.4pt'> </span>hazard<span style='letter-spacing:-.25pt'> </span>ratio<span style='letter-spacing:-.2pt'> </span>(TAC/FAC)<span style='letter-spacing:-.5pt'> </span>inférieur<span style='letter-spacing:-.35pt'> </span>à 1<span style='letter-spacing:-.05pt'> </span>indique<span style='letter-spacing:-.3pt'> </span>qu<span style='letter-spacing:-.1pt'> </span>TAC<span style='letter-spacing:-.2pt'> </span>est<span style='letter-spacing:-.1pt'> </span>associé<span style='letter-spacing:-.3pt'> </span>à une<span style='letter-spacing:-.15pt'> </span>survie<span style='letter-spacing:-.25pt'> </span>sans<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span>aladie<span style='letter-spacing:-.25pt'> </span>plus longue<span style='letter-spacing:-.55pt'> </span>co<span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>p</span>aré<span style='letter-spacing:-.1pt'> </span>à TAC.</p>
<p class=AmmCorpsTexte>Anal<span style='letter-spacing:.1pt'>y</span>ses<span style='letter-spacing:-.2pt'> </span>exploratoires<span style='letter-spacing: -.5pt'> </span>en<span style='letter-spacing:-.1pt'> </span>sous-groupe<span style='letter-spacing:-.5pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la survie<span style='letter-spacing:-.25pt'> </span>sans<span style='letter-spacing: -.15pt'> </span><span style='letter-spacing:-.1pt'>m</span>aladie<span style='letter-spacing:-.25pt'> </span>des<span style='letter-spacing:-.15pt'> </span>patientes<span style='letter-spacing:-.35pt'> </span>relevant<span style='letter-spacing:-.3pt'> </span>des<span style='letter-spacing:-.15pt'> </span>critères d’indication<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la chi<span style='letter-spacing:-.05pt'>m</span>iothérapie<span style='letter-spacing:-.05pt'> </span>de<span style='letter-spacing:-.1pt'> </span>St<span style='letter-spacing:-.1pt'> </span>Gallen<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.2pt'> </span>2009<span style='letter-spacing:-.2pt'> </span>–<span style='letter-spacing:-.05pt'> </span>(population<span style='letter-spacing: -.4pt'> </span>en<span style='letter-spacing:-.1pt'> </span>intention<span style='letter-spacing:-.3pt'> </span>de<span style='letter-spacing:-.1pt'> </span>traiter)<span style='letter-spacing:-.2pt'> </span>ont<span style='letter-spacing:-.15pt'> </span>été réalisées et présentées<span style='letter-spacing:-.4pt'> </span>ci-dessous<span style='letter-spacing:-.4pt'> </span>:</p>
<div align=center>
<table class=AmmCorpsTexteTable border=0 cellspacing=0 cellpadding=0
style='margin-left:-11.2pt;border-collapse:collapse'>
<tr style='height:25.9pt'>
<td width=145 valign=top style='width:108.5pt;border:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:25.9pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:4.85pt;margin-bottom:.0001pt;text-align:left'> </p>
</td>
<td width=123 valign=top style='width:92.0pt;border:solid black 1.0pt;
border-left:none;padding:0cm 0cm 0cm 0cm;height:25.9pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:4.9pt;margin-bottom:.0001pt;text-align:left'><b>TAC</b></p>
</td>
<td width=123 valign=top style='width:92.1pt;border:solid black 1.0pt;
border-left:none;padding:0cm 0cm 0cm 0cm;height:25.9pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:5.05pt;margin-bottom:.0001pt;text-align:left'><b>FAC</b></p>
</td>
<td width=132 valign=top style='width:98.85pt;border:solid black 1.0pt;
border-left:none;padding:0cm 0cm 0cm 0cm;height:25.9pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:5.1pt;margin-bottom:.0001pt;text-align:left'><b>Hazard<span style='letter-spacing:-.55pt'> </span>ratio</b></p>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:5.1pt;margin-bottom:.0001pt;text-align:left'><b>(TAC/FAC)</b></p>
</td>
<td width=114 valign=top style='width:85.25pt;border:solid black 1.0pt;
border-left:none;padding:0cm 0cm 0cm 0cm;height:25.9pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:5.2pt;margin-bottom:.0001pt;text-align:left'><b> </b></p>
</td>
</tr>
<tr style='height:13.2pt'>
<td width=145 valign=top style='width:108.5pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:13.2pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:4.85pt;margin-bottom:.0001pt;text-align:left'>Sous-groupes</p>
</td>
<td width=123 valign=top style='width:92.0pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:13.2pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:4.9pt;margin-bottom:.0001pt;text-align:left'>(n=539)</p>
</td>
<td width=123 valign=top style='width:92.1pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:13.2pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:5.05pt;margin-bottom:.0001pt;text-align:left'>(N=521)</p>
</td>
<td width=132 valign=top style='width:98.85pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:13.2pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:5.1pt;margin-bottom:.0001pt;text-align:left'>(95%<span style='letter-spacing:-.5pt'> </span>IC)</p>
</td>
<td width=114 valign=top style='width:85.25pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:13.2pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:5.2pt;margin-bottom:.0001pt;text-align:left'>Valeur<span style='letter-spacing:-.55pt'> </span>de<span style='letter-spacing:-.1pt'> </span>p</p>
</td>
</tr>
<tr style='height:43.25pt'>
<td width=145 valign=top style='width:108.5pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:43.25pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:4.85pt;margin-bottom:.0001pt;text-align:left'>Confor<span style='letter-spacing:-.1pt'>m</span>ité<span style='letter-spacing:-.3pt'> </span>à l’indication<span style='letter-spacing:-.4pt'> </span>d’une chi<span style='letter-spacing:-.05pt'>m</span>iothérapie<sup>a</sup></p>
</td>
<td width=123 valign=top style='width:92.0pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:43.25pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:4.9pt;margin-bottom:.0001pt;text-align:left'> </p>
</td>
<td width=123 valign=top style='width:92.1pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:43.25pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:5.05pt;margin-bottom:.0001pt;text-align:left'> </p>
</td>
<td width=132 valign=top style='width:98.85pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:43.25pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:5.1pt;margin-bottom:.0001pt;text-align:left'> </p>
</td>
<td width=114 valign=top style='width:85.25pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:43.25pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:5.2pt;margin-bottom:.0001pt;text-align:left'> </p>
</td>
</tr>
<tr style='height:24.4pt'>
<td width=145 valign=top style='width:108.5pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:24.4pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:4.85pt;margin-bottom:.0001pt;text-align:left'>Non</p>
</td>
<td width=123 valign=top style='width:92.0pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:24.4pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:4.9pt;margin-bottom:.0001pt;text-align:left'><span style='letter-spacing:.05pt'>18/214 </span>(8.4%)</p>
</td>
<td width=123 valign=top style='width:92.1pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:24.4pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:5.05pt;margin-bottom:.0001pt;text-align:left'><span style='letter-spacing:.05pt'>26/227 </span>(11.5<span style='letter-spacing: -.05pt'>%</span>)</p>
</td>
<td width=132 valign=top style='width:98.85pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:24.4pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:5.1pt;margin-bottom:.0001pt;text-align:left'>0.796<span style='letter-spacing:-.45pt'> </span>(0.434<span style='letter-spacing:-.2pt'> </span>- 1.459)</p>
</td>
<td width=114 valign=top style='width:85.25pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:24.4pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:5.2pt;margin-bottom:.0001pt;text-align:left'><span style='letter-spacing:.05pt'>0.4593</span></p>
</td>
</tr>
<tr style='height:20.5pt'>
<td width=145 valign=top style='width:108.5pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:20.5pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:4.85pt;margin-bottom:.0001pt;text-align:left'>Oui</p>
</td>
<td width=123 valign=top style='width:92.0pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:20.5pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:4.9pt;margin-bottom:.0001pt;text-align:left'><span style='letter-spacing:.05pt'>48/325 </span>(14.8<span style='letter-spacing: -.05pt'>%</span>)</p>
</td>
<td width=123 valign=top style='width:92.1pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:20.5pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:5.05pt;margin-bottom:.0001pt;text-align:left'><span style='letter-spacing:.05pt'>69/294 </span>(23.5<span style='letter-spacing: -.05pt'>%</span>)</p>
</td>
<td width=132 valign=top style='width:98.85pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:20.5pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:5.1pt;margin-bottom:.0001pt;text-align:left'>0.606<span style='letter-spacing:-.45pt'> </span>(0.42<span style='letter-spacing:-.15pt'> </span>- 0.877)</p>
</td>
<td width=114 valign=top style='width:85.25pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:20.5pt'>
<p class=AmmCorpsTexte align=left style='margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:5.2pt;margin-bottom:.0001pt;text-align:left'><span style='letter-spacing:.05pt'>0.0072</span></p>
</td>
</tr>
</table>
</div>
<p class=AmmCorpsTexte style='margin-bottom:0cm;margin-bottom:.0001pt'>TAC =<span style='letter-spacing:.05pt'> </span>docétaxel,<span style='letter-spacing: .05pt'> </span>doxorubicine<span style='letter-spacing:.05pt'> </span>et c<span style='letter-spacing:-.05pt'>y</span>clophospha<span style='letter-spacing: -.1pt'>m</span>ide</p>
<p class=AmmCorpsTexte style='margin-bottom:0cm;margin-bottom:.0001pt'>FAC =<span style='letter-spacing:.05pt'> </span>5-fluoro-uracile,<span style='letter-spacing: .05pt'> </span>doxorubicine<span style='letter-spacing:.05pt'> </span>et c<span style='letter-spacing:-.05pt'>y</span>clophosph<span style='letter-spacing: -.1pt'>a</span>mide</p>
<p class=AmmCorpsTexte style='margin-bottom:0cm;margin-bottom:.0001pt'>IC = intervalle<span style='letter-spacing:.05pt'> </span>de confiance;<span style='letter-spacing:-.05pt'> </span>RE<span style='letter-spacing:.05pt'> </span>=<span style='letter-spacing:.05pt'> </span>récepteurs<span style='letter-spacing: .05pt'> </span>aux<span style='letter-spacing:.05pt'> </span>œstrogènes</p>
<p class=AmmCorpsTexte style='margin-bottom:0cm;margin-bottom:.0001pt'>RP =<span style='letter-spacing:.05pt'> </span>récepteurs<span style='letter-spacing: .05pt'> </span>à<span style='letter-spacing:.05pt'> </span>la<span style='letter-spacing:.05pt'> </span>progestérone</p>
<p class=AmmCorpsTexte><sup>a <span style='letter-spacing:.95pt'></span></sup>RE/RP-<span style='letter-spacing:.05pt'>n</span>é<span style='letter-spacing:.05pt'>g</span>atif <span style='letter-spacing:.05pt'>o</span>u<span style='letter-spacing:.05pt'> </span>Gra<span style='letter-spacing:.05pt'>d</span>e 3<span style='letter-spacing: .05pt'> o</span>u<span style='letter-spacing:.05pt'> </span>taille t<span style='letter-spacing:.05pt'>u</span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>o</span>rale &gt;5<span style='letter-spacing:.05pt'> </span>cm</p>
<p class=AmmCorpsTexte>Le<span style='letter-spacing:-.35pt'> </span>hazard<span style='letter-spacing:-.25pt'> </span>ratio<span style='letter-spacing:-.2pt'> </span>a été esti<span style='letter-spacing:-.05pt'>m</span>é<span style='letter-spacing: -.15pt'> </span>selon<span style='letter-spacing:-.2pt'> </span>le <span style='letter-spacing:-.1pt'>m</span>odèle<span style='letter-spacing:-.1pt'> </span>p<span style='letter-spacing:-.1pt'>r</span>oportionnel de<span style='letter-spacing: -.1pt'> </span>Cox<span style='letter-spacing:-.15pt'> </span>avec<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span>groupe<span style='letter-spacing:-.3pt'> </span>co<span style='letter-spacing:-.1pt'>mm</span>e<span style='letter-spacing:-.1pt'> </span>facteur.</p>
<p class=AmmCorpsTexte><i>Le<span style='letter-spacing:-.35pt'> </span>docétaxel</i> <i>en monothérapie</i></p>
<p class=AmmCorpsTexte>Deux<span style='letter-spacing:-.5pt'> </span>études<span style='letter-spacing:-.25pt'> </span>co<span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>p</span>aratives<span style='letter-spacing:-.1pt'> </span>rando<span style='letter-spacing:-.1pt'>m</span>isées<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.1pt'> </span>phase<span style='letter-spacing:-.25pt'> </span>III<span style='letter-spacing:-.1pt'> </span>ont<span style='letter-spacing:-.15pt'> </span>été conduites<span style='letter-spacing: -.4pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>des<span style='letter-spacing:-.15pt'> </span>patientes<span style='letter-spacing: -.35pt'> </span>atteintes<span style='letter-spacing:-.35pt'> </span>de<span style='letter-spacing:-.1pt'> </span>cancer du sein<span style='letter-spacing: -.15pt'> </span><span style='letter-spacing:-.1pt'>m</span>étastatique.<span style='letter-spacing:-.5pt'> </span>Elles<span style='letter-spacing:-.2pt'> </span>ont<span style='letter-spacing:-.15pt'> </span>été ré<span style='letter-spacing:-.1pt'>a</span>lisées<span style='letter-spacing:-.1pt'> </span>respective<span style='letter-spacing: -.05pt'>m</span>ent<span style='letter-spacing:-.4pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>326<span style='letter-spacing:-.15pt'> </span>patientes<span style='letter-spacing:-.35pt'> </span>en<span style='letter-spacing:-.1pt'> </span>échec<span style='letter-spacing:-.25pt'> </span>d<span style='letter-spacing:-.05pt'>'</span>un<span style='letter-spacing:-.05pt'> </span>agent alk<span style='letter-spacing: .1pt'>y</span>lant<span style='letter-spacing:-.1pt'> </span>et chez 392<span style='letter-spacing:-.15pt'> </span>patientes<span style='letter-spacing: -.35pt'> </span>en<span style='letter-spacing:-.1pt'> </span>échec<span style='letter-spacing:-.25pt'> </span>d<span style='letter-spacing:-.05pt'>'</span>une<span style='letter-spacing:-.1pt'> </span>anthrac<span style='letter-spacing:.1pt'>y</span>cline.<span style='letter-spacing:-.3pt'> </span>Dans<span style='letter-spacing:-.2pt'> </span>ces<span style='letter-spacing:-.15pt'> </span>études<span style='letter-spacing:-.25pt'> </span>cliniques,<span style='letter-spacing:-.4pt'> </span>le docétaxel<span style='letter-spacing:-.4pt'> </span>a été ad<span style='letter-spacing:-.1pt'>m</span>inistré<span style='letter-spacing:-.3pt'> </span>selon le sché<span style='letter-spacing: -.1pt'>m</span>a<span style='letter-spacing:-.2pt'> </span>posologique<span style='letter-spacing:-.5pt'> </span>reco<span style='letter-spacing:-.1pt'>mm</span>andé<span style='letter-spacing:-.3pt'> </span>de<span style='letter-spacing:-.1pt'> </span>100<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.1pt'>m</span>²<span style='letter-spacing:-.1pt'> </span>toutes<span style='letter-spacing:-.25pt'> </span>les 3<span style='letter-spacing:-.3pt'> </span>se<span style='letter-spacing:-.1pt'>m</span>aines.</p>
<p class=AmmCorpsTexte>Après<span style='letter-spacing:-.5pt'> </span>échec<span style='letter-spacing:-.25pt'> </span>d'une<span style='letter-spacing:-.2pt'> </span>chi<span style='letter-spacing:-.05pt'>m</span>iothérapie<span style='letter-spacing:-.1pt'> </span>a<span style='letter-spacing:.1pt'>y</span>ant<span style='letter-spacing:-.05pt'> </span>co<span style='letter-spacing:-.1pt'>m</span>porté<span style='letter-spacing:-.1pt'> </span>un<span style='letter-spacing:-.15pt'> </span>agent<span style='letter-spacing:-.2pt'> </span>alk<span style='letter-spacing:.1pt'>y</span>lant,<span style='letter-spacing:-.1pt'> </span>le docétaxel<span style='letter-spacing: -.4pt'> </span>a été co<span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>p</span>aré<span style='letter-spacing:-.1pt'> </span>à la doxorubicine<span style='letter-spacing:-.55pt'> </span>(75<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.1pt'>m</span>²<span style='letter-spacing:-.1pt'> </span>toutes<span style='letter-spacing:-.25pt'> </span>les<span style='letter-spacing:-.1pt'> </span>3<span style='letter-spacing: -.05pt'> </span>se<span style='letter-spacing:-.1pt'>m</span>aines).<span style='letter-spacing:-.1pt'> </span>Sans<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:-.1pt'>m</span>odifier<span style='letter-spacing:-.1pt'> </span>la survie<span style='letter-spacing:-.25pt'> </span>globale<span style='letter-spacing:-.3pt'> </span>(docétaxel<span style='letter-spacing: -.35pt'> </span>15<span style='letter-spacing:-.1pt'> m</span><span style='letter-spacing:.05pt'>o</span>is<span style='letter-spacing:-.1pt'> </span>versus doxorubicine<span style='letter-spacing:-.5pt'> </span>14<span style='letter-spacing:-.1pt'> m</span><span style='letter-spacing:.05pt'>o</span>is,<span style='letter-spacing:-.1pt'> </span>p<span style='letter-spacing:-.05pt'> </span>=<span style='letter-spacing:-.05pt'> </span>0,38)<span style='letter-spacing:-.2pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>la<span style='letter-spacing:.05pt'> </span>survie<span style='letter-spacing:-.15pt'> </span>sans<span style='letter-spacing:-.15pt'> </span>progression<span style='letter-spacing:-.45pt'> </span>(docétaxel<span style='letter-spacing: -.4pt'> </span>27<span style='letter-spacing:-.1pt'> </span>se<span style='letter-spacing:-.1pt'>m</span>aines<span style='letter-spacing:-.1pt'> </span>versus<span style='letter-spacing:-.25pt'> </span>doxorubicine<span style='letter-spacing: .05pt'> </span>23 se<span style='letter-spacing:-.1pt'>m</span>aines,<span style='letter-spacing:-.1pt'> </span>p<span style='letter-spacing:-.05pt'> </span>=<span style='letter-spacing:-.05pt'> </span>0,54),<span style='letter-spacing:-.25pt'> </span>le docétaxel<span style='letter-spacing:2.1pt'> </span>aug<span style='letter-spacing:-.1pt'>m</span>ente<span style='letter-spacing:-.15pt'> </span>le taux<span style='letter-spacing:-.15pt'> </span>de<span style='letter-spacing: -.1pt'> </span>r<span style='letter-spacing:-.1pt'>é</span>ponse<span style='letter-spacing:-.05pt'> </span>(52%<span style='letter-spacing:-.2pt'> </span>versus<span style='letter-spacing:-.25pt'> </span>37<span style='letter-spacing:-.05pt'>%</span>, p<span style='letter-spacing:-.3pt'> </span>=<span style='letter-spacing:-.05pt'> </span>0,01)<span style='letter-spacing:-.2pt'> </span>et réduit<span style='letter-spacing:-.2pt'> </span>le délai<span style='letter-spacing:-.15pt'> </span>d<span style='letter-spacing:-.05pt'>'</span>obtention de<span style='letter-spacing:-.1pt'> </span>la réponse<span style='letter-spacing: -.3pt'> </span>(12<span style='letter-spacing:-.15pt'> </span>se<span style='letter-spacing:-.1pt'>m</span>aines<span style='letter-spacing:-.1pt'> </span>versus<span style='letter-spacing:-.25pt'> </span>23<span style='letter-spacing:-.1pt'> </span>se<span style='letter-spacing:-.1pt'>m</span>aines,<span style='letter-spacing:-.1pt'> </span>p<span style='letter-spacing:-.05pt'> </span>=<span style='letter-spacing:-.05pt'> </span>0,007).<span style='letter-spacing:-.3pt'> </span>Trois patients sous<span style='letter-spacing: -.2pt'> </span>docétaxel<span style='letter-spacing:-.35pt'> </span>(2<span style='letter-spacing:-.05pt'>%</span>)<span style='letter-spacing:-.1pt'> </span>ont<span style='letter-spacing:-.15pt'> </span>arrêté<span style='letter-spacing:-.25pt'> </span>le t<span style='letter-spacing:-.1pt'>r</span>aite<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.1pt'> </span>en<span style='letter-spacing:-.1pt'> </span>raison<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.1pt'> </span>rét<span style='letter-spacing: -.1pt'>e</span>ntion<span style='letter-spacing:-.05pt'> </span>h<span style='letter-spacing:.1pt'>y</span>drique tandis<span style='letter-spacing: -.2pt'> </span>que 15<span style='letter-spacing:-.35pt'> </span>patients<span style='letter-spacing:-.25pt'> </span>sous<span style='letter-spacing:-.2pt'> </span>doxorubicine<span style='letter-spacing:-.5pt'> </span>(9<span style='letter-spacing:-.05pt'>%</span>)<span style='letter-spacing:-.1pt'> </span>ont<span style='letter-spacing:-.15pt'> </span>arrêté<span style='letter-spacing:-.25pt'> </span>le traite<span style='letter-spacing: -.05pt'>m</span>ent<span style='letter-spacing:-.3pt'> </span>en<span style='letter-spacing:-.15pt'> </span>raison<span style='letter-spacing:-.25pt'> </span>d<span style='letter-spacing:-.05pt'>'</span>une<span style='letter-spacing: -.05pt'> </span>toxicité<span style='letter-spacing:-.25pt'> </span>cardiaque (3<span style='letter-spacing:-.35pt'> </span>insuffisances<span style='letter-spacing:-.5pt'> </span>cardiaques<span style='letter-spacing: -.45pt'> </span>congestives<span style='letter-spacing:-.45pt'> </span>d<span style='letter-spacing:-.05pt'>'</span>évolution<span style='letter-spacing: -.05pt'> </span>fatale).</p>
<p class=AmmCorpsTexte>Chez les patientes en échec d'une chimiothérapie avec anthracycline, le docétaxel a été comparé à une association à base de mitomycine C et vinblastine (12 mg/m² toutes les 6 semaines et 6 mg/m² toutes les 3 semaines). Le docétaxel accroit le taux de réponse (33% versus 12%, p &lt;0,0001), la survie sans progression (19 semaines versus 11 semaines, p = 0,0004) et la survie globale (11 mois versus 9 mois, p =<span style='letter-spacing: -.05pt'> </span>0,01).</p>
<p class=AmmCorpsTexte>Au<span style='letter-spacing:-.4pt'> </span>cours<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span>ces<span style='letter-spacing:-.15pt'> </span>deux<span style='letter-spacing:-.2pt'> </span>études<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.1pt'> </span>phase<span style='letter-spacing:-.25pt'> </span>III,<span style='letter-spacing:-.1pt'> </span>le profil<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing: -.1pt'> </span>tolérance<span style='letter-spacing:-.35pt'> </span>de<span style='letter-spacing:-.1pt'> </span>docétaxel<span style='letter-spacing:-.4pt'> </span>a été <span style='letter-spacing:.05pt'></span>co<span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>p</span>arable<span style='letter-spacing:-.1pt'> </span>à celui<span style='letter-spacing:-.2pt'> </span>observé dans<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>études<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.1pt'> </span>phase<span style='letter-spacing:-.25pt'> </span>II<span style='letter-spacing:-.05pt'> </span>(voir rubrique<span style='letter-spacing:-.45pt'> </span>4.8).</p>
<p class=AmmCorpsTexte style='margin-bottom:0cm;margin-bottom:.0001pt'>Une<span style='letter-spacing:-.45pt'> </span>étude<span style='letter-spacing:-.2pt'> </span>ouverte<span style='letter-spacing:-.3pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>u</span>lticentrique<span style='letter-spacing: -.05pt'> </span>rando<span style='letter-spacing:-.1pt'>m</span>isée<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.1pt'> </span>phase<span style='letter-spacing:-.25pt'> </span>III<span style='letter-spacing:-.1pt'> </span>a été réalisée<span style='letter-spacing:-.3pt'> </span>pour<span style='letter-spacing:-.2pt'> </span>co<span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>p</span>arer<span style='letter-spacing:-.1pt'> </span>docétaxel<span style='letter-spacing:-.4pt'> </span>en <span style='letter-spacing:-.1pt'>m</span>onothérapie au<span style='letter-spacing:-.1pt'> </span>paclitaxel<span style='letter-spacing: -.35pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>le traite<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.35pt'> </span>du<span style='letter-spacing:-.1pt'> </span>cancer<span style='letter-spacing:-.25pt'> </span>du<span style='letter-spacing:-.1pt'> </span>sein<span style='letter-spacing: -.15pt'> </span>locale<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.25pt'> </span>avancé<span style='letter-spacing:-.3pt'> </span>ou<span style='letter-spacing:-.1pt'> m</span>étastatique<span style='letter-spacing:-.45pt'> </span>chez les patients<span style='letter-spacing: -.3pt'> </span>a<span style='letter-spacing:.1pt'>y</span>ant<span style='letter-spacing:-.05pt'> </span>reçu<span style='letter-spacing:-.15pt'> </span>préalable<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.45pt'> </span>une<span style='letter-spacing:-.15pt'> </span>chi<span style='letter-spacing:-.1pt'>m</span>iothérapie<span style='letter-spacing:-.1pt'> </span>à base<span style='letter-spacing:-.2pt'> </span>d<span style='letter-spacing:.05pt'>’</span>anthrac<span style='letter-spacing:.1pt'>y</span>cline.<span style='letter-spacing:-.05pt'> </span>Un<span style='letter-spacing:-.1pt'> </span>total de 449<span style='letter-spacing:-.4pt'> </span>patients<span style='letter-spacing:-.3pt'> </span>ont<span style='letter-spacing:-.15pt'> </span>été rando<span style='letter-spacing:-.1pt'>m</span>isés<span style='letter-spacing: -.25pt'> </span>pour<span style='letter-spacing:-.2pt'> </span>recevoir,<span style='letter-spacing:-.35pt'> </span>soit<span style='letter-spacing:-.15pt'> </span>100<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.1pt'>m</span>²<span style='letter-spacing:-.1pt'> </span>de<span style='letter-spacing:-.1pt'> </span>docétaxel<span style='letter-spacing:-.35pt'> </span>en<span style='letter-spacing:-.1pt'> m</span>onothérapie<span style='letter-spacing:-.05pt'> </span>en<span style='letter-spacing:-.1pt'> </span>perfusion d’une heure,<span style='letter-spacing:-.25pt'> </span>soit<span style='letter-spacing:-.15pt'> </span>175<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.1pt'>m</span>²<span style='letter-spacing:-.1pt'> </span>de<span style='letter-spacing:-.1pt'> </span>paclitaxel<span style='letter-spacing: -.35pt'> </span>en<span style='letter-spacing:-.1pt'> </span>perfusion<span style='letter-spacing:-.4pt'> </span>de<span style='letter-spacing:-.1pt'> </span>3<span style='letter-spacing:-.05pt'> </span>heures.<span style='letter-spacing:-.3pt'> </span>Les<span style='letter-spacing:-.15pt'> </span>deux<span style='letter-spacing:-.2pt'> </span>traite<span style='letter-spacing:-.05pt'>m</span>ents<span style='letter-spacing:-.3pt'> </span>ont<span style='letter-spacing:-.15pt'> </span>été ad<span style='letter-spacing:-.1pt'>m</span>inistrés<span style='letter-spacing: -.35pt'> </span>toutes<span style='letter-spacing:-.25pt'> </span>les trois<span style='letter-spacing:-.2pt'> </span>se<span style='letter-spacing:-.1pt'>m</span>aines.</p>
<p class=AmmCorpsTexte style='margin-bottom:0cm;margin-bottom:.0001pt'>Sans<span style='letter-spacing:-.45pt'> </span><span style='letter-spacing:-.1pt'>m</span>odifier<span style='letter-spacing:-.1pt'> </span>l’objectif<span style='letter-spacing: -.3pt'> </span>pri<span style='letter-spacing:-.1pt'>m</span>aire<span style='letter-spacing:-.1pt'> </span>(taux<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span>répo<span style='letter-spacing:-.05pt'>n</span>se<span style='letter-spacing:-.2pt'> </span>global<span style='letter-spacing:-.25pt'> </span>: 32%<span style='letter-spacing:-.2pt'> </span>vs<span style='letter-spacing:-.1pt'> </span>25<span style='letter-spacing:-.05pt'>%</span>,<span style='letter-spacing:-.1pt'> </span>p<span style='letter-spacing:-.05pt'> </span>=<span style='letter-spacing:-.05pt'> </span>0,10),<span style='letter-spacing:-.25pt'> </span>le docétaxel<span style='letter-spacing:-.35pt'> </span>a prolongé<span style='letter-spacing:-.35pt'> </span>le te<span style='letter-spacing:-.05pt'>m</span><span style='letter-spacing:.05pt'>p</span>s<span style='letter-spacing:-.05pt'> </span><span style='letter-spacing:-.1pt'>m</span>édian<span style='letter-spacing:-.25pt'> </span>jusqu<span style='letter-spacing:.05pt'>’</span>à<span style='letter-spacing:-.2pt'> </span>progression<span style='letter-spacing:-.45pt'> </span>(24,6<span style='letter-spacing:-.2pt'> </span>vs<span style='letter-spacing:-.1pt'> </span>15,6<span style='letter-spacing:-.15pt'> </span>se<span style='letter-spacing:-.1pt'>m</span>aines<span style='letter-spacing:-.1pt'> </span>; p<span style='letter-spacing:-.05pt'> </span>&lt;0,01)<span style='letter-spacing: -.25pt'> </span>et la survie<span style='letter-spacing:-.25pt'> </span><span style='letter-spacing:-.1pt'>m</span>édiane<span style='letter-spacing:-.3pt'> </span>(15,3 vs<span style='letter-spacing:-.1pt'> </span>12,7<span style='letter-spacing: -.15pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>o</span>is<span style='letter-spacing:-.1pt'> </span>;<span style='letter-spacing:.05pt'> </span>p =<span style='letter-spacing:-.05pt'> </span>0,03). </p>
<p class=AmmCorpsTexte>Plus<span style='letter-spacing:-.45pt'> </span>d’effets<span style='letter-spacing:-.3pt'> </span>indésirables<span style='letter-spacing: -.5pt'> </span>de<span style='letter-spacing:-.1pt'> </span>grade<span style='letter-spacing:-.2pt'> </span>3/4<span style='letter-spacing:-.15pt'> </span>ont<span style='letter-spacing:-.15pt'> </span>été<span style='letter-spacing:.05pt'> </span>observés<span style='letter-spacing:-.35pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>le bras<span style='letter-spacing:-.15pt'> </span>docétaxel<span style='letter-spacing:-.35pt'> </span>en<span style='letter-spacing:-.1pt'> m</span>onothérapie (55,4%)<span style='letter-spacing:-.6pt'> </span>par<span style='letter-spacing: -.15pt'> </span>rapport<span style='letter-spacing:-.3pt'> </span>au<span style='letter-spacing:-.1pt'> </span>bras<span style='letter-spacing:-.15pt'> </span>paclitaxel<span style='letter-spacing:-.35pt'> </span>(23,0%).</p>
<p class=AmmCorpsTexte><i>Le<span style='letter-spacing:-.35pt'> </span>docétaxel</i> <i>en association<span style='letter-spacing:-.45pt'> </span>à<span style='letter-spacing:-.05pt'> </span>la<span style='letter-spacing:-.1pt'> </span>doxorubicine</i></p>
<p class=AmmCorpsTexte>Une étude randomisée de phase III, incluant 429 patientes non traitées auparavant pour un cancer métastatique, a été réalisée avec la doxorubicine (50 mg/m²) associée au docétaxel (75 mg/m²) (bras AT) versus la doxorubicine (60 mg/m²) associée au cyclophosphamide (600 mg/m²) (bras AC). Les<span style='letter-spacing:-.15pt'> </span>deux traite<span style='letter-spacing:-.05pt'>m</span>ents<span style='letter-spacing:-.3pt'> </span>ont<span style='letter-spacing:-.15pt'> </span>été ad<span style='letter-spacing:-.1pt'>m</span>inistrés<span style='letter-spacing:-.35pt'> </span>au<span style='letter-spacing:-.1pt'> </span>jour<span style='letter-spacing:-.15pt'> </span>J1<span style='letter-spacing:-.1pt'> </span>toutes<span style='letter-spacing:-.25pt'> </span>les<span style='letter-spacing:-.1pt'> </span>trois<span style='letter-spacing:-.2pt'> </span>se<span style='letter-spacing:-.1pt'>m</span>aines.</p>
<p class=AmmListePuces1 style='text-align:justify'><span style='font-family: Symbol'>·<span style='font:7.0pt "Times New Roman"'>                   </span></span>Le<span style='letter-spacing:-.1pt'> </span>te<span style='letter-spacing:-.05pt'>m</span><span style='letter-spacing:.05pt'>p</span>s<span style='letter-spacing:-.05pt'> </span>jusqu<span style='letter-spacing:-.05pt'>'</span>à<span style='letter-spacing:-.2pt'> </span>progression<span style='letter-spacing: -.45pt'> </span>(TTP)<span style='letter-spacing:-.25pt'> </span>était signific<span style='letter-spacing:-.05pt'>a</span>tive<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.3pt'> </span>plus<span style='letter-spacing:-.15pt'> </span>long<span style='letter-spacing:-.2pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>le bras<span style='letter-spacing:-.15pt'> </span>AT<span style='letter-spacing: -.15pt'> </span>que<span style='letter-spacing:-.15pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>le bras AC,<span style='letter-spacing: -.15pt'> </span>p<span style='letter-spacing:-.05pt'> </span>=<span style='letter-spacing:-.05pt'> </span>0,0138<span style='letter-spacing:-.25pt'> </span>: 37,3<span style='letter-spacing:-.15pt'> </span>se<span style='letter-spacing:-.1pt'>m</span>aines<span style='letter-spacing:-.1pt'> </span>(IC<span style='letter-spacing:-.15pt'> </span>95<span style='letter-spacing:-.05pt'>%</span>:<span style='letter-spacing:-.1pt'> </span>33,4–42,1)<span style='letter-spacing: -.45pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>le bras<span style='letter-spacing:-.15pt'> </span>AT<span style='letter-spacing:-.15pt'> </span>versus 31,9<span style='letter-spacing:-.45pt'> </span>se<span style='letter-spacing: -.1pt'>m</span>aines<span style='letter-spacing:-.1pt'> </span>(IC<span style='letter-spacing:-.15pt'> </span>95<span style='letter-spacing:-.05pt'>%</span>:<span style='letter-spacing:-.1pt'> </span>27,4–36,0)<span style='letter-spacing: -.45pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>le bras<span style='letter-spacing:-.15pt'> </span>AC.</p>
<p class=AmmListePuces1 style='text-align:justify'><span style='font-family: Symbol'>·<span style='font:7.0pt "Times New Roman"'>                   </span></span>Le taux de réponse global était significativement plus élevé dans le bras AT que dans le bras AC, p = 0,009 : 59,3% (IC 95% : 52,8–65,9) dans le bras AT versus 46,5% (IC95%: 39,8–53,2) dans le bras AC.</p>
<p class=AmmCorpsTexte style='margin-top:6.0pt'>Dans<span style='letter-spacing: -.5pt'> </span>cette étude,<span style='letter-spacing:-.25pt'> </span>il a été retrouvé<span style='letter-spacing:-.35pt'> </span>plus<span style='letter-spacing: -.15pt'> </span>fréque<span style='letter-spacing:-.1pt'>mm</span>ent<span style='letter-spacing:-.4pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>le bras<span style='letter-spacing:-.15pt'> </span>AT<span style='letter-spacing: -.15pt'> </span>que<span style='letter-spacing:-.15pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>le bras<span style='letter-spacing:-.15pt'> </span>AC,<span style='letter-spacing:-.15pt'> </span>une<span style='letter-spacing:-.15pt'> </span>neutropénie<span style='letter-spacing: .05pt'> </span>sévère (90%<span style='letter-spacing:-.2pt'> </span>versus<span style='letter-spacing:-.25pt'> </span>68,6<span style='letter-spacing:-.05pt'>%</span>),<span style='letter-spacing:-.15pt'> </span>une<span style='letter-spacing:-.15pt'> </span>neutropénie<span style='letter-spacing:-.45pt'> </span>fébrile<span style='letter-spacing:-.2pt'> </span>(33,3%<span style='letter-spacing:-.3pt'> </span>ver<span style='letter-spacing:-.05pt'>s</span>us<span style='letter-spacing:-.15pt'> </span>10<span style='letter-spacing:-.05pt'>%</span>),<span style='letter-spacing:-.1pt'> </span>une<span style='letter-spacing:-.15pt'> </span>infection<span style='letter-spacing: -.35pt'> </span>(8% versus<span style='letter-spacing:-.25pt'> </span>2,4<span style='letter-spacing:-.05pt'>%</span>),<span style='letter-spacing:-.15pt'> </span>une<span style='letter-spacing:-.15pt'> </span>diarrhée<span style='letter-spacing:.05pt'> </span>(7,5%<span style='letter-spacing:-.25pt'> </span>versus<span style='letter-spacing:-.25pt'> </span>1,4<span style='letter-spacing:-.05pt'>%</span>),<span style='letter-spacing:-.15pt'> </span>une<span style='letter-spacing:-.15pt'> </span>asthénie<span style='letter-spacing:-.3pt'> </span>(8,5%<span style='letter-spacing:-.25pt'> </span>versus<span style='letter-spacing:-.25pt'> </span>2,4<span style='letter-spacing:-.05pt'>%</span>),<span style='letter-spacing:-.15pt'> </span>une<span style='letter-spacing:-.15pt'> </span>douleur<span style='letter-spacing:-.3pt'> </span>(2,8% versus<span style='letter-spacing: -.25pt'> </span>0%).<span style='letter-spacing:-.2pt'> </span>Par<span style='letter-spacing:-.15pt'> </span>ailleurs,<span style='letter-spacing: -.3pt'> </span>il a été <span style='letter-spacing:-.1pt'>m</span>is<span style='letter-spacing:-.1pt'> </span>en évi<span style='letter-spacing:.05pt'>d</span>ence<span style='letter-spacing:-.1pt'> </span>plus<span style='letter-spacing:-.15pt'> </span>fréque<span style='letter-spacing:-.1pt'>mm</span>ent<span style='letter-spacing:-.35pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>le bras<span style='letter-spacing:-.15pt'> </span>AC<span style='letter-spacing:-.15pt'> </span>que<span style='letter-spacing: -.15pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>le bras<span style='letter-spacing:-.15pt'> </span>AT,<span style='letter-spacing:-.15pt'> </span>une<span style='letter-spacing:-.15pt'> </span>ané<span style='letter-spacing:-.1pt'>m</span>ie<span style='letter-spacing:-.15pt'> </span>sévère<span style='letter-spacing:-.25pt'> </span>(15,8%<span style='letter-spacing:-.3pt'> </span>versus<span style='letter-spacing:-.25pt'> </span>8,5<span style='letter-spacing:-.05pt'>%</span>)<span style='letter-spacing:-.15pt'> </span>et une plus<span style='letter-spacing: -.15pt'> </span>grande<span style='letter-spacing:-.25pt'> </span>incidence<span style='letter-spacing:-.3pt'> </span>de<span style='letter-spacing:-.1pt'> </span>toxicité<span style='letter-spacing:-.3pt'> </span>cardiaque<span style='letter-spacing:-.4pt'> </span>sévère : insuffisance<span style='letter-spacing:-.5pt'> </span>cardiaque<span style='letter-spacing:-.4pt'> </span>congestive<span style='letter-spacing: -.45pt'> </span>(3,<span style='letter-spacing:.05pt'>8</span>%<span style='letter-spacing:-.1pt'> </span>versus<span style='letter-spacing:-.25pt'> </span>2,8%),<span style='letter-spacing:-.25pt'> </span>baisse absolue<span style='letter-spacing:-.3pt'> </span>de<span style='letter-spacing:-.1pt'> </span>FEVG<span style='letter-spacing:-.25pt'> </span>&#8805;20%<span style='letter-spacing: -.05pt'> </span>(13,1%<span style='letter-spacing:-.3pt'> </span>versus 6,1%),<span style='letter-spacing:-.25pt'> </span>baisse<span style='letter-spacing:-.25pt'> </span>absolue<span style='letter-spacing:-.3pt'> </span>de<span style='letter-spacing:-.1pt'> </span>FEVG<span style='letter-spacing:-.2pt'> </span>&#8805;30%<span style='letter-spacing:-.05pt'> </span>(6,2%<span style='letter-spacing:-.25pt'> </span>versus<span style='letter-spacing:-.25pt'> </span>1,1%).<span style='letter-spacing:-.25pt'> </span>Des<span style='letter-spacing:-.15pt'> </span>décès toxiques<span style='letter-spacing:-.35pt'> </span>ont<span style='letter-spacing: -.15pt'> </span>été observés<span style='letter-spacing:-.35pt'> </span>chez 1<span style='letter-spacing:-.05pt'> </span>patient<span style='letter-spacing:-.25pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>le bras<span style='letter-spacing:-.15pt'> </span>AT<span style='letter-spacing:-.15pt'> </span>(insuffisance<span style='letter-spacing:-.5pt'> </span>cardiaque<span style='letter-spacing:-.45pt'> </span>congestive)<span style='letter-spacing:-.45pt'> </span>et chez<span style='letter-spacing:-.2pt'> </span>4<span style='letter-spacing:-.05pt'> </span>patients dans<span style='letter-spacing:-.2pt'> </span>le bras<span style='letter-spacing: -.15pt'> </span>AC (1<span style='letter-spacing:-.35pt'> </span>par<span style='letter-spacing:-.15pt'> </span>choc<span style='letter-spacing:-.2pt'> </span>septique<span style='letter-spacing:-.35pt'> </span>et 3<span style='letter-spacing:-.05pt'> </span>par<span style='letter-spacing:-.15pt'> </span>insuffisance<span style='letter-spacing: -.5pt'> </span>cardiaque<span style='letter-spacing:-.4pt'> </span>congestive).</p>
<p class=AmmCorpsTexte>Dans<span style='letter-spacing:-.5pt'> </span>les<span style='letter-spacing:-.1pt'> </span>2<span style='letter-spacing:-.05pt'> </span>bras,<span style='letter-spacing:-.2pt'> </span>la qualité<span style='letter-spacing: -.25pt'> </span>de<span style='letter-spacing:-.1pt'> </span>vie<span style='letter-spacing:-.1pt'> </span>évaluée<span style='letter-spacing:-.3pt'> </span>à l<span style='letter-spacing:-.05pt'>'</span>aide<span style='letter-spacing:-.25pt'> </span>du<span style='letter-spacing:-.1pt'> </span>questionnaire<span style='letter-spacing:-.55pt'> </span>EORTC<span style='letter-spacing:-.35pt'> </span>était co<span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>p</span>arable<span style='letter-spacing:-.1pt'> </span>et stable<span style='letter-spacing:-.25pt'> </span>pendant le traite<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.3pt'> </span>et la période<span style='letter-spacing:-.3pt'> </span>de<span style='letter-spacing: -.1pt'> </span>suivi.</p>
<p class=AmmCorpsTexte><i>Le<span style='letter-spacing:-.35pt'> </span>docétaxel</i> <i>en association avec le trastuzumab</i></p>
<p class=AmmCorpsTexte>Le<span style='letter-spacing:-.35pt'> </span>docétaxel<span style='letter-spacing:-.4pt'> </span>en<span style='letter-spacing:-.1pt'> </span>association<span style='letter-spacing:-.45pt'> </span>avec<span style='letter-spacing:-.2pt'> </span>le trastuzu<span style='letter-spacing:-.05pt'>m</span>ab<span style='letter-spacing: -.4pt'> </span>a été évalué<span style='letter-spacing:-.25pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>des<span style='letter-spacing:-.15pt'> </span>patientes<span style='letter-spacing:-.35pt'> </span>présentant<span style='letter-spacing: -.4pt'> </span>un<span style='letter-spacing:-.1pt'> </span>cancer<span style='letter-spacing:-.25pt'> </span>du sein <span style='letter-spacing:-.1pt'>m</span>étastatique<span style='letter-spacing:-.4pt'> </span>avec<span style='letter-spacing:-.2pt'> </span>surexpression<span style='letter-spacing:-.55pt'> </span>tu<span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>o</span>rale<span style='letter-spacing:-.1pt'> </span>de<span style='letter-spacing:-.2pt'> </span>HER2,<span style='letter-spacing:-.25pt'> </span>n<span style='letter-spacing:.05pt'>’</span>a<span style='letter-spacing:.1pt'>y</span>ant<span style='letter-spacing:-.05pt'> </span>pas<span style='letter-spacing:-.15pt'> </span>reçu<span style='letter-spacing:-.15pt'> </span>de<span style='letter-spacing:-.1pt'> </span>chi<span style='letter-spacing:-.05pt'>m</span>iothérapie<span style='letter-spacing: -.05pt'> </span>pour<span style='letter-spacing:-.2pt'> </span>leur <span style='letter-spacing:-.1pt'>m</span>aladie <span style='letter-spacing:-.1pt'>m</span>étastatique.<span style='letter-spacing:-.45pt'> </span>Cent<span style='letter-spacing:-.2pt'> </span>quatre-vingt<span style='letter-spacing:-.55pt'> </span>six<span style='letter-spacing:-.1pt'> </span>patientes<span style='letter-spacing:-.3pt'> </span>ont<span style='letter-spacing:-.15pt'> </span>été rando<span style='letter-spacing:-.1pt'>m</span>isées<span style='letter-spacing: -.25pt'> </span>pour<span style='letter-spacing:-.2pt'> </span>recevoir<span style='letter-spacing:-.35pt'> </span>du<span style='letter-spacing:-.1pt'> </span>docétaxel<span style='letter-spacing:.05pt'> </span>(100<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.1pt'>m</span>²)<span style='letter-spacing:-.1pt'> </span>avec<span style='letter-spacing:-.2pt'> </span>ou sans<span style='letter-spacing:-.15pt'> </span>trastuzu<span style='letter-spacing:-.05pt'>m</span>ab<span style='letter-spacing:-.3pt'> </span>; 60%<span style='letter-spacing:-.3pt'> </span>des<span style='letter-spacing:-.15pt'> </span>patientes<span style='letter-spacing: -.35pt'> </span>avaient<span style='letter-spacing:-.3pt'> </span>reçu<span style='letter-spacing:-.15pt'> </span>une<span style='letter-spacing:-.15pt'> </span>chi<span style='letter-spacing:-.05pt'>m</span>iothérapie<span style='letter-spacing: -.1pt'> </span>adjuvante à base<span style='letter-spacing:-.2pt'> </span>d<span style='letter-spacing:.05pt'>’</span>anthrac<span style='letter-spacing:.1pt'>y</span>cline.<span style='letter-spacing:-.05pt'> </span>Le docétaxel<span style='letter-spacing: -.4pt'> </span>associé<span style='letter-spacing:-.15pt'> </span>au<span style='letter-spacing:-.1pt'> </span>trastuzu<span style='letter-spacing:-.05pt'>m</span>ab<span style='letter-spacing:-.3pt'> </span>a été efficace<span style='letter-spacing: -.3pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>patientes<span style='letter-spacing:-.35pt'> </span>qu’elles aient,<span style='letter-spacing:-.2pt'> </span>auparavant,<span style='letter-spacing:-.4pt'> </span>reçu<span style='letter-spacing:-.15pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>non<span style='letter-spacing:-.15pt'> </span>des anthrac<span style='letter-spacing:.05pt'>y</span>clines<span style='letter-spacing: -.3pt'> </span>en<span style='letter-spacing:-.1pt'> </span>traite<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.3pt'> </span>adjuvant.<span style='letter-spacing:-.35pt'> </span>Dans<span style='letter-spacing:-.2pt'> </span>cette étude<span style='letter-spacing:-.2pt'> </span>pivot,<span style='letter-spacing: .05pt'> </span>la principale<span style='letter-spacing:-.35pt'> </span><span style='letter-spacing:-.1pt'>m</span>éthode<span style='letter-spacing:-.3pt'> </span>utilisée<span style='letter-spacing:-.25pt'> </span>pour<span style='letter-spacing:-.25pt'> </span>déter<span style='letter-spacing:-.05pt'>m</span>iner<span style='letter-spacing:-.2pt'> </span>la positivité<span style='letter-spacing:-.35pt'> </span>de<span style='letter-spacing: -.1pt'> </span>HER2<span style='letter-spacing:-.25pt'> </span>a été l<span style='letter-spacing:.05pt'>’</span>i<span style='letter-spacing:-.1pt'>mm</span>unohistochi<span style='letter-spacing:-.05pt'>m</span>ie<span style='letter-spacing:-.05pt'> </span>(IHC).<span style='letter-spacing:-.25pt'> </span>Pour<span style='letter-spacing:-.2pt'> </span>une<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span>inorité<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.1pt'> </span>p<span style='letter-spacing:-.05pt'>a</span>tientes,<span style='letter-spacing:-.05pt'> </span>c<span style='letter-spacing:.05pt'>’</span>est<span style='letter-spacing: -.05pt'> </span>la Fluorescence in-situ H<span style='letter-spacing:.1pt'>y</span>bridation<span style='letter-spacing:-.05pt'> </span>(FISH) qui<span style='letter-spacing: -.15pt'> </span>a été utilisée.<span style='letter-spacing:-.3pt'> </span>Dans<span style='letter-spacing:-.2pt'> </span>cette étude<span style='letter-spacing: -.2pt'> </span>87%<span style='letter-spacing:-.25pt'> </span>des<span style='letter-spacing:-.15pt'> </span>patientes<span style='letter-spacing: -.35pt'> </span>étaient IHC<span style='letter-spacing:-.15pt'> </span>3+,<span style='letter-spacing:-.15pt'> </span>et 95%<span style='letter-spacing:-.2pt'> </span>des patientes<span style='letter-spacing:-.35pt'> </span>incluses étaient IHC<span style='letter-spacing:-.15pt'> </span>3+<span style='letter-spacing:-.1pt'> </span>et/ou<span style='letter-spacing:-.2pt'> </span>FISH<span style='letter-spacing:-.2pt'> </span>positive.<span style='letter-spacing:-.35pt'> </span>Les<span style='letter-spacing:-.15pt'> </span>résult<span style='letter-spacing:-.05pt'>a</span>ts<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span>l<span style='letter-spacing:.05pt'>’</span>efficacité sont<span style='letter-spacing:-.15pt'> </span>résu<span style='letter-spacing: -.1pt'>m</span>és<span style='letter-spacing:-.15pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>le tableau suivant :</p>
<div align=center>
<table class=AmmCorpsTexteTable border=1 cellspacing=0 cellpadding=0
style='margin-left:3.5pt;border-collapse:collapse;border:none'>
<thead>
<tr style='height:12.0pt'>
<td width=231 valign=top style='width:173.25pt;border:solid windowtext 1.0pt;
border-bottom:none black 1.0pt;padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmTableauTitre1 align=left style='margin:0cm;margin-bottom:.0001pt; text-align:left;page-break-after:avoid'>Paramètres</p>
</td>
<td width=224 valign=top style='width:168.15pt;border-top:solid windowtext 1.0pt;
border-left:none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmTableauTitre1 align=center style='margin:0cm;margin-bottom:.0001pt; text-align:center;page-break-after:avoid'>Docétaxel plus trastuzumab<sup>1</sup></p>
</td>
<td width=224 valign=top style='width:168.15pt;border-top:solid windowtext 1.0pt;
border-left:none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmTableauTitre1 align=center style='margin:0cm;margin-bottom:.0001pt; text-align:center;page-break-after:avoid'>Docétaxel</p>
</td>
<td style='height:12.0pt;border:none' width=0 height=16></td>
</tr>
<tr style='height:24.0pt'>
<td width=231 valign=top style='width:173.25pt;border-top:none;border-left:
solid windowtext 1.0pt;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:24.0pt'>
<p class=AmmTableauTitre1> </p>
</td>
<td width=224 valign=top style='width:168.15pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:24.0pt'>
<p class=AmmTableauTitre1 align=center style='margin:0cm;margin-bottom:.0001pt; text-align:center;page-break-after:avoid'>n=92</p>
</td>
<td width=224 valign=top style='width:168.15pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:24.0pt'>
<p class=AmmTableauTitre1 align=center style='margin:0cm;margin-bottom:.0001pt; text-align:center;page-break-after:avoid'>n=94</p>
</td>
<td style='height:24.0pt;border:none' width=0 height=32></td>
</tr>
<tr style='height:12.0pt'>
<td width=231 valign=top style='width:173.25pt;border-top:none;border-left:
solid windowtext 1.0pt;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left;page-break-after:avoid'>Taux de réponse </p>
</td>
<td width=224 valign=top style='width:168.15pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center;page-break-after:avoid'>61 % (50-71)</p>
</td>
<td width=224 valign=top style='width:168.15pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center;page-break-after:avoid'>34 % (25-45)</p>
</td>
<td style='height:12.0pt;border:none' width=0 height=16></td>
</tr>
<tr style='height:12.0pt'>
<td width=231 valign=top style='width:173.25pt;border-top:none;border-left:
solid windowtext 1.0pt;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left;page-break-after:avoid'>(IC 95 %)</p>
</td>
<td width=224 valign=top style='width:168.15pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center;page-break-after:avoid'> </p>
</td>
<td width=224 valign=top style='width:168.15pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center;page-break-after:avoid'> </p>
</td>
<td style='height:12.0pt;border:none' width=0 height=16></td>
</tr>
<tr style='height:12.0pt'>
<td width=231 valign=top style='width:173.25pt;border-top:none;border-left:
solid windowtext 1.0pt;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left;page-break-after:avoid'>Durée<span style='letter-spacing: -.5pt'> </span><span style='letter-spacing:-.1pt'>m</span>édiane<span style='letter-spacing:-.3pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la réponse</p>
</td>
<td width=224 valign=top style='width:168.15pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left;page-break-after:avoid'> </p>
</td>
<td width=224 valign=top style='width:168.15pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left;page-break-after:avoid'> </p>
</td>
<td style='height:12.0pt;border:none' width=0 height=16></td>
</tr>
<tr style='height:12.0pt'>
<td width=231 valign=top style='width:173.25pt;border-top:none;border-left:
solid windowtext 1.0pt;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>(mois)</p>
</td>
<td width=224 valign=top style='width:168.15pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'>11,4 (9,2-15,0)</p>
</td>
<td width=224 valign=top style='width:168.15pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'>5.1 (4,4-6,2)</p>
</td>
<td style='height:12.0pt;border:none' width=0 height=16></td>
</tr>
<tr style='height:12.0pt'>
<td width=231 valign=top style='width:173.25pt;border-top:none;border-left:
solid windowtext 1.0pt;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>(95 % CI)</p>
</td>
<td width=224 valign=top style='width:168.15pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'> </p>
</td>
<td width=224 valign=top style='width:168.15pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'> </p>
</td>
<td style='height:12.0pt;border:none' width=0 height=16></td>
</tr>
<tr style='height:12.0pt'>
<td width=231 valign=top style='width:173.25pt;border-top:none;border-left:
solid windowtext 1.0pt;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>Temps médian jusqu'à progression (mois)</p>
</td>
<td width=224 valign=top style='width:168.15pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'>10,6 (7,6-12,9)</p>
</td>
<td width=224 valign=top style='width:168.15pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'>5.7(5,0-6,5)</p>
</td>
<td style='height:12.0pt;border:none' width=0 height=16></td>
</tr>
<tr style='height:12.0pt'>
<td width=231 valign=top style='width:173.25pt;border-top:none;border-left:
solid windowtext 1.0pt;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>(IC 95 %)</p>
</td>
<td width=224 valign=top style='width:168.15pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'> </p>
</td>
<td width=224 valign=top style='width:168.15pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'> </p>
</td>
<td style='height:12.0pt;border:none' width=0 height=16></td>
</tr>
<tr style='height:12.0pt'>
<td width=231 valign=top style='width:173.25pt;border-top:none;border-left:
solid windowtext 1.0pt;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>Durée médiane de survie</p>
</td>
<td width=224 valign=top style='width:168.15pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'> </p>
</td>
<td width=224 valign=top style='width:168.15pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'> </p>
</td>
<td style='height:12.0pt;border:none' width=0 height=16></td>
</tr>
<tr style='height:12.0pt'>
<td width=231 valign=top style='width:173.25pt;border-top:none;border-left:
solid windowtext 1.0pt;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>(mois)</p>
</td>
<td width=224 valign=top style='width:168.15pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'>30.5<sup>2</sup></p>
</td>
<td width=224 valign=top style='width:168.15pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'>22,1<sup>2</sup></p>
</td>
<td style='height:12.0pt;border:none' width=0 height=16></td>
</tr>
<tr style='height:11.5pt'>
<td width=231 valign=top style='width:173.25pt;border:solid windowtext 1.0pt;
border-top:none;padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>(IC 95 %)</p>
</td>
<td width=224 valign=top style='width:168.15pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'>(26,8-na)</p>
</td>
<td width=224 valign=top style='width:168.15pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'>(17,6-28,9)</p>
</td>
<td style='height:11.5pt;border:none' width=0 height=15></td>
</tr>
</thead>
</table>
</div>
<p class=AmmCorpsTexte style='margin-bottom:0cm;margin-bottom:.0001pt'>“na”<span style='letter-spacing:-.45pt'> </span>indique<span style='letter-spacing:-.3pt'> </span>qu<span style='letter-spacing:.05pt'>’</span>il<span style='letter-spacing: -.1pt'> </span>n<span style='letter-spacing:.05pt'>’</span>a<span style='letter-spacing:-.05pt'> </span>pas<span style='letter-spacing:-.15pt'> </span>pu<span style='letter-spacing:-.1pt'> </span>être<span style='letter-spacing:-.15pt'> </span>esti<span style='letter-spacing:-.05pt'>m</span>é<span style='letter-spacing:-.15pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>qu<span style='letter-spacing:.05pt'>’</span>il<span style='letter-spacing:-.1pt'> </span>n<span style='letter-spacing:.05pt'>’</span>a<span style='letter-spacing:-.05pt'> </span>pas<span style='letter-spacing:-.15pt'> </span>encore<span style='letter-spacing:-.25pt'> </span>été atteint.</p>
<p class=AmmCorpsTexte style='margin-bottom:0cm;margin-bottom:.0001pt'><sup>1 <span style='letter-spacing:.8pt'></span></sup><sub>Anal<span style='letter-spacing: .1pt'>y</span>se<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span>toute<span style='letter-spacing:-.2pt'> </span>la population<span style='letter-spacing:-.45pt'> </span>(en<span style='letter-spacing:-.15pt'> </span>intention<span style='letter-spacing: -.3pt'> </span>de<span style='letter-spacing:-.1pt'> </span>traiter)</sub></p>
<p class=AmmCorpsTexte><sup>2 <span style='letter-spacing:1.5pt'></span></sup>Médiane<span style='letter-spacing:-.65pt'> </span>de<span style='letter-spacing:-.1pt'> </span>survie<span style='letter-spacing:-.25pt'> </span>esti<span style='letter-spacing:-.05pt'>m</span>ée</p>
<p class=AmmCorpsTexte><i>Le<span style='letter-spacing:-.35pt'> </span>docétaxel</i> <i>en<span style='letter-spacing:-.1pt'> </span>association<span style='letter-spacing:-.45pt'> </span>avec<span style='letter-spacing:-.2pt'> </span>la<span style='letter-spacing:-.1pt'> </span>capécitabine</i></p>
<p class=AmmCorpsTexte>Les données d’une étude multicentrique, randomisée, contrôlée de phase III justifient l'emploi de docétaxel en association avec la capécitabine pour le traitement du cancer du sein localement avancé ou métastatique après échec d’une chimiothérapie à base d’anthracycline. Dans cet essai, 255 patients ont été randomisés pour recevoir 75 mg/m<sup>2</sup> de docétaxel en perfusion intraveineuse de 1 heure toutes les 3 semaines et 1250 mg/m² deux fois par jour de capécitabine pendant 2 semaines, suivi d'une période sans traitement d'une semaine. 256 patients ont été randomisés pour recevoir le docétaxel seul (100 mg/m<sup>2</sup> en perfusion intraveineuse de 1 heure toutes les 3 semaines). La survie était supérieure dans le bras avec l’association docétaxel/capécitabine (p = 0,0126). La survie médiane était de 442 jours (association) versus 352 jours (docétaxel seul). Le taux de réponse global dans la population randomisée (évaluation par l'investigateur) était de 41,6% (association) vs 29,7% (docétaxel seul) ; p = 0,0058. Le temps jusqu’à progression était supérieur dans l’association docétaxel/capécitabine (p&lt;0,0001). Le temps médian jusqu’à progression était de 186 jours (association) vs 128 jours (docétaxel seul).</p>
<p class=AmmCorpsTexte><i><u><sub>Cancer bronchopulmonaire non à<span style='letter-spacing:.05pt'> </span>petites cellules</sub></u></i></p>
<p class=AmmCorpsTexte><i>Patients<span style='letter-spacing:-.6pt'> </span>ayant<span style='letter-spacing:-.2pt'> </span>reçu<span style='letter-spacing:-.2pt'> </span>une<span style='letter-spacing:-.15pt'> </span>chimiothérapie<span style='letter-spacing: -.6pt'> </span>antérieure<span style='letter-spacing:-.4pt'> </span>avec<span style='letter-spacing:-.2pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>sans<span style='letter-spacing:-.2pt'> </span>radiothérapie</i></p>
<p class=AmmCorpsTexte style='margin-bottom:0cm;margin-bottom:.0001pt'>Lors<span style='letter-spacing:-.45pt'> </span>d<span style='letter-spacing:-.05pt'>'</span>une<span style='letter-spacing:-.05pt'> </span>étude<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span>phase<span style='letter-spacing:2.3pt'> </span>III<span style='letter-spacing:-.1pt'> </span>conduite<span style='letter-spacing:-.35pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>des<span style='letter-spacing:-.15pt'> </span>p<span style='letter-spacing:-.05pt'>a</span>tients<span style='letter-spacing:-.05pt'> </span>préalable<span style='letter-spacing: -.05pt'>m</span>ent<span style='letter-spacing:-.45pt'> </span>traités,<span style='letter-spacing:-.25pt'> </span>le te<span style='letter-spacing:-.05pt'>m</span><span style='letter-spacing:.05pt'>p</span>s<span style='letter-spacing:-.05pt'> </span>jusqu<span style='letter-spacing:-.05pt'>'</span>à<span style='letter-spacing:-.2pt'> </span>progression<span style='letter-spacing:-.45pt'> </span>(12,3 se<span style='letter-spacing:-.1pt'>m</span>aines<span style='letter-spacing:-.1pt'> </span>versus<span style='letter-spacing:-.25pt'> </span>7<span style='letter-spacing:-.05pt'> </span>se<span style='letter-spacing: -.1pt'>m</span>aines)<span style='letter-spacing:-.1pt'> </span>et la survie<span style='letter-spacing:-.25pt'> </span>globale<span style='letter-spacing:-.3pt'> </span>étaient<span style='letter-spacing:.05pt'> </span>significative<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.5pt'> </span>supérieurs<span style='letter-spacing:-.4pt'> </span>pour le docétaxel<span style='letter-spacing: -.35pt'> </span>à la dose de<span style='letter-spacing:-.1pt'> </span>75<span style='letter-spacing:-.1pt'> m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.1pt'>m</span>²<span style='letter-spacing:-.1pt'> </span>co<span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>p</span>aré<span style='letter-spacing:-.1pt'> </span>aux<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:-.1pt'>m</span>eilleurs<span style='letter-spacing:-.35pt'> </span>traite<span style='letter-spacing:-.05pt'>m</span>ents<span style='letter-spacing:-.3pt'> </span>palliatifs.<span style='letter-spacing: -.35pt'> </span>La<span style='letter-spacing:-.1pt'> </span>survie<span style='letter-spacing:-.25pt'> </span>à 1<span style='letter-spacing:-.05pt'> </span>an<span style='letter-spacing:-.1pt'> </span>était égale<span style='letter-spacing: -.05pt'>m</span>ent<span style='letter-spacing:-.2pt'> </span>significative<span style='letter-spacing:-.05pt'>m</span>ent supérieure<span style='letter-spacing: -.4pt'> </span>avec<span style='letter-spacing:-.2pt'> </span>le docétaxel<span style='letter-spacing:-.4pt'> </span>(40%)<span style='letter-spacing:-.25pt'> </span>co<span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>p</span>arés<span style='letter-spacing:-.1pt'> </span>aux<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span>eilleurs<span style='letter-spacing:-.35pt'> </span>traite<span style='letter-spacing:-.05pt'>m</span>ents<span style='letter-spacing:-.1pt'> </span>palliatifs<span style='letter-spacing: -.35pt'> </span>(16%).</p>
<p class=AmmCorpsTexte style='margin-bottom:0cm;margin-bottom:.0001pt'>L<span style='letter-spacing:-.05pt'>'</span>utilisation d<span style='letter-spacing: -.05pt'>'</span>analgésiques <span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>o</span>rphiniques<span style='letter-spacing: -.1pt'> </span>(p<span style='letter-spacing:-.1pt'> </span>&lt;<span style='letter-spacing:-.05pt'> </span>0,01),<span style='letter-spacing:-.25pt'> </span>d<span style='letter-spacing:-.05pt'>'</span>analgésiques non<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>o</span>rphiniques<span style='letter-spacing: -.1pt'> </span>(p<span style='letter-spacing:-.1pt'> </span>&lt;<span style='letter-spacing:-.05pt'> </span>0,01),<span style='letter-spacing:-.25pt'> </span>d<span style='letter-spacing:-.05pt'>'</span>autres traite<span style='letter-spacing:-.05pt'>m</span>ents<span style='letter-spacing:-.3pt'> </span>liés aux<span style='letter-spacing:-.15pt'> </span>pathologies<span style='letter-spacing:-.45pt'> </span>(p<span style='letter-spacing:-.1pt'> </span>=<span style='letter-spacing:-.05pt'> </span>0,06)<span style='letter-spacing:-.2pt'> </span>et de<span style='letter-spacing:-.1pt'> </span>radiothérapie<span style='letter-spacing:-.5pt'> </span>(p<span style='letter-spacing:-.1pt'> </span>&lt;<span style='letter-spacing:-.05pt'> </span>0,01)<span style='letter-spacing:-.2pt'> </span>étaient<span style='letter-spacing:.05pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>o</span>indre<span style='letter-spacing:-.1pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>les patients<span style='letter-spacing: -.3pt'> </span>traités par<span style='letter-spacing:-.15pt'> </span>docétaxel<span style='letter-spacing:-.4pt'> </span>à la dose<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span>75<span style='letter-spacing: -.1pt'> m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.1pt'>m</span>²<span style='letter-spacing:-.1pt'> </span>co<span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>p</span>aré<span style='letter-spacing:-.1pt'> </span>à ceux<span style='letter-spacing:-.2pt'> </span>traités<span style='letter-spacing:-.25pt'> </span>par<span style='letter-spacing:-.15pt'> </span>les<span style='letter-spacing:-.1pt'> m</span>eilleurs<span style='letter-spacing:-.35pt'> </span>traite<span style='letter-spacing:-.05pt'>m</span>ents<span style='letter-spacing:-.1pt'> </span>palliatifs.</p>
<p class=AmmCorpsTexte>Le<span style='letter-spacing:-.35pt'> </span>taux<span style='letter-spacing:-.15pt'> </span>de<span style='letter-spacing:-.1pt'> </span>réponse<span style='letter-spacing:-.3pt'> </span>global<span style='letter-spacing:-.25pt'> </span>était de<span style='letter-spacing:-.1pt'> </span>6,8%<span style='letter-spacing:-.2pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>p<span style='letter-spacing:-.05pt'>a</span>tients<span style='letter-spacing:-.05pt'> </span>évaluables,<span style='letter-spacing: -.45pt'> </span>et la durée<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:-.1pt'>m</span>édiane<span style='letter-spacing:-.3pt'> </span>des<span style='letter-spacing:-.15pt'> </span>réponses<span style='letter-spacing:-.35pt'> </span>était de 26,1<span style='letter-spacing:-.15pt'> </span>se<span style='letter-spacing:-.1pt'>m</span>aines.</p>
<p class=AmmCorpsTexte><i>Le<span style='letter-spacing:-.35pt'> </span>docétaxel</i> <i>en<span style='letter-spacing:-.1pt'> </span>association<span style='letter-spacing:-.45pt'> </span>aux<span style='letter-spacing:-.15pt'> </span>sels<span style='letter-spacing:-.15pt'> </span>de<span style='letter-spacing:-.1pt'> </span>platine<span style='letter-spacing:-.3pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>patients<span style='letter-spacing:-.3pt'> </span>n’ayant<span style='letter-spacing:-.3pt'> </span>pas<span style='letter-spacing:-.15pt'> </span>reçu<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span>chimiothérapie antérieure</i></p>
<p class=AmmCorpsTexte>Lors<span style='letter-spacing:-.45pt'> </span>d<span style='letter-spacing:.05pt'>’</span>une<span style='letter-spacing:-.05pt'> </span>étude<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span>phase<span style='letter-spacing:-.25pt'> </span>III<span style='letter-spacing:-.1pt'> </span>rando<span style='letter-spacing:-.1pt'>m</span>isée,<span style='letter-spacing:-.25pt'> </span>1218<span style='letter-spacing:-.2pt'> </span>pati<span style='letter-spacing:-.05pt'>e</span>nts<span style='letter-spacing:-.15pt'> </span>présentant<span style='letter-spacing: -.4pt'> </span>un<span style='letter-spacing:-.1pt'> </span>cancer<span style='letter-spacing:-.25pt'> </span>du poumon<span style='letter-spacing: -.45pt'> </span>non<span style='letter-spacing:-.15pt'> </span>à petites<span style='letter-spacing:-.25pt'> </span>cellules non<span style='letter-spacing: -.15pt'> </span>résécable<span style='letter-spacing:-.35pt'> </span>de<span style='letter-spacing:-.1pt'> </span>stade<span style='letter-spacing:-.2pt'> </span>IIIB<span style='letter-spacing:-.15pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>IV,<span style='letter-spacing:-.15pt'> </span>avec<span style='letter-spacing:-.2pt'> </span>un<span style='letter-spacing:-.15pt'> </span>indice<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.1pt'> </span>perfor<span style='letter-spacing:-.1pt'>m</span>ance<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.1pt'> </span>Karnofski<span style='letter-spacing:-.3pt'> </span>de<span style='letter-spacing:-.1pt'> </span>70%<span style='letter-spacing: -.2pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>plus, et n’a<span style='letter-spacing:.1pt'>y</span>ant<span style='letter-spacing:-.15pt'> </span>pas reçu<span style='letter-spacing:-.15pt'> </span>de<span style='letter-spacing: -.1pt'> </span>chi<span style='letter-spacing:-.05pt'>m</span>iothérapie<span style='letter-spacing:-.1pt'> </span>antérieure<span style='letter-spacing: -.4pt'> </span>pour<span style='letter-spacing:-.2pt'> </span>cette indic<span style='letter-spacing:-.05pt'>a</span>tion,<span style='letter-spacing:-.2pt'> </span>ont<span style='letter-spacing:-.15pt'> </span>été inclus<span style='letter-spacing: -.25pt'> </span>soit<span style='letter-spacing:-.15pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>le bras<span style='letter-spacing:-.15pt'> </span>docétaxel<span style='letter-spacing:-.35pt'> </span>(T)<span style='letter-spacing:-.15pt'> </span>75<span style='letter-spacing:-.1pt'> m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.1pt'>m</span>²<span style='letter-spacing:-.1pt'> </span>en perfusion<span style='letter-spacing: -.4pt'> </span>d<span style='letter-spacing:.05pt'>’</span>une<span style='letter-spacing:-.05pt'> </span>heure<span style='letter-spacing:-.2pt'> </span>i<span style='letter-spacing:-.1pt'>mm</span>édiate<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.2pt'> </span>suivie<span style='letter-spacing:-.25pt'> </span>par<span style='letter-spacing:-.15pt'> </span>du<span style='letter-spacing: -.1pt'> </span>cisplatine<span style='letter-spacing:-.35pt'> </span>(Cis)<span style='letter-spacing:-.2pt'> </span>à 75<span style='letter-spacing:-.35pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.1pt'>m</span>²<span style='letter-spacing:-.1pt'> </span>en<span style='letter-spacing:-.1pt'> </span>30-60<span style='letter-spacing:-.25pt'> </span><span style='letter-spacing:-.1pt'>m</span>inutes<span style='letter-spacing:-.3pt'> </span>toutes<span style='letter-spacing:-.25pt'> </span>les<span style='letter-spacing:-.1pt'> </span>3<span style='letter-spacing:-.05pt'> </span>se<span style='letter-spacing:-.1pt'>m</span>aines<span style='letter-spacing:-.1pt'> </span>(TCis),<span style='letter-spacing:-.3pt'> </span>soit<span style='letter-spacing:-.15pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>le bras<span style='letter-spacing:-.15pt'> </span>docétaxel<span style='letter-spacing:-.35pt'> </span>75<span style='letter-spacing:-.1pt'> m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.1pt'>m</span>²<span style='letter-spacing:-.1pt'> </span>en<span style='letter-spacing:-.1pt'> </span>perfusion d<span style='letter-spacing: .05pt'>’</span>une<span style='letter-spacing:-.05pt'> </span>heure<span style='letter-spacing:-.2pt'> </span>en<span style='letter-spacing:-.1pt'> </span>association<span style='letter-spacing:-.4pt'> </span>au<span style='letter-spacing:-.1pt'> </span>carboplatine<span style='letter-spacing:-.45pt'> </span>(Cb)<span style='letter-spacing:-.2pt'> </span>(AUC<span style='letter-spacing:-.25pt'> </span>6<span style='letter-spacing:-.05pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.1pt'>m</span>l<span style='letter-spacing:-.1pt'> </span>x<span style='letter-spacing:-.05pt'> </span><span style='letter-spacing:-.1pt'>m</span>in)<span style='letter-spacing:-.15pt'> </span>en<span style='letter-spacing:-.1pt'> </span>30-60<span style='letter-spacing:-.25pt'> </span><span style='letter-spacing:-.1pt'>m</span>inutes<span style='letter-spacing:-.3pt'> </span>toutes les<span style='letter-spacing: -.1pt'> </span>3 se<span style='letter-spacing:-.1pt'>m</span>aines, soit<span style='letter-spacing:-.15pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>le bras<span style='letter-spacing:-.15pt'> </span>vinorelbine<span style='letter-spacing:-.45pt'> </span>(V)<span style='letter-spacing:-.15pt'> </span>25<span style='letter-spacing:-.1pt'> m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.1pt'>m</span>²<span style='letter-spacing:-.1pt'> </span>ad<span style='letter-spacing:-.1pt'>m</span>inistrée<span style='letter-spacing:-.35pt'> </span>en<span style='letter-spacing:-.1pt'> </span>6-10<span style='letter-spacing: -.2pt'> </span><span style='letter-spacing:-.1pt'>m</span>inutes<span style='letter-spacing:-.3pt'> </span>à J<span style='letter-spacing:-.05pt'> </span>1, J<span style='letter-spacing:-.3pt'> </span>8,<span style='letter-spacing:-.05pt'> </span>J<span style='letter-spacing:-.05pt'> </span>15<span style='letter-spacing: -.1pt'> </span>et J<span style='letter-spacing:-.05pt'> </span>22<span style='letter-spacing:-.1pt'> </span>suivi<span style='letter-spacing:-.2pt'> </span>par<span style='letter-spacing:-.15pt'> </span>du<span style='letter-spacing:-.1pt'> </span>cisplatine<span style='letter-spacing:-.35pt'> </span>à 100<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing: .05pt'>g</span>/<span style='letter-spacing:-.1pt'>m</span>²<span style='letter-spacing:-.1pt'> </span>ad<span style='letter-spacing:-.1pt'>m</span>inistré<span style='letter-spacing:-.3pt'> </span>à J<span style='letter-spacing:-.05pt'> </span>1<span style='letter-spacing:-.05pt'> </span>du<span style='letter-spacing:-.1pt'> </span>c<span style='letter-spacing:.1pt'>y</span>cle,<span style='letter-spacing:-.05pt'> </span>répété<span style='letter-spacing:-.25pt'> </span>toutes<span style='letter-spacing:-.25pt'> </span>les 4<span style='letter-spacing:-.3pt'> </span>se<span style='letter-spacing:-.1pt'>m</span>aines<span style='letter-spacing:-.1pt'> </span>(VCis).</p>
<p class=AmmCorpsTexte>Les<span style='letter-spacing:-.4pt'> </span>données<span style='letter-spacing:-.35pt'> </span>de<span style='letter-spacing:-.1pt'> </span>survie,<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.1pt'> </span>te<span style='letter-spacing:-.05pt'>m</span><span style='letter-spacing:.05pt'>p</span>s<span style='letter-spacing:-.05pt'> </span><span style='letter-spacing:-.1pt'>m</span>édian<span style='letter-spacing:-.25pt'> </span>jusqu<span style='letter-spacing:.05pt'>’</span>à<span style='letter-spacing:-.2pt'> </span>progression<span style='letter-spacing: -.45pt'> </span>et de<span style='letter-spacing:-.1pt'> </span>taux<span style='letter-spacing:-.15pt'> </span>de<span style='letter-spacing:-.1pt'> </span>réponse<span style='letter-spacing:-.3pt'> </span>sont<span style='letter-spacing:-.15pt'> </span>présentées,<span style='letter-spacing:-.45pt'> </span>pour deux bras<span style='letter-spacing: -.15pt'> </span>de<span style='letter-spacing:-.1pt'> </span>l<span style='letter-spacing:.05pt'>’</span>étude,<span style='letter-spacing:-.05pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>le tableau<span style='letter-spacing:-.25pt'> </span>ci-dessous<span style='letter-spacing: -.4pt'> </span>:</p>
<table class=AmmCorpsTexteTable border=0 cellspacing=0 cellpadding=0
style='margin-left:7.85pt;border-collapse:collapse'>
<tr style='height:36.0pt'>
<td width=232 valign=top style='width:173.9pt;border:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:36.0pt'>
<p class=AmmCorpsTexte> </p>
</td>
<td width=60 valign=top style='width:45.3pt;border:solid black 1.0pt;
border-left:none;padding:0cm 0cm 0cm 0cm;height:36.0pt'>
<p class=AmmCorpsTexte style='margin-top:0cm;margin-right:0cm;margin-bottom: 0cm;margin-left:2.8pt;margin-bottom:.0001pt;page-break-after:avoid'><b>TCis</b></p>
<p class=AmmCorpsTexte style='margin-left:2.8pt;page-break-after:avoid'><b>n<span style='letter-spacing:-.25pt'> </span>= 408</b></p>
</td>
<td width=72 colspan=2 valign=top style='width:53.95pt;border:solid black 1.0pt;
border-left:none;padding:0cm 0cm 0cm 0cm;height:36.0pt'>
<p class=AmmCorpsTexte style='margin-top:0cm;margin-right:0cm;margin-bottom: 0cm;margin-left:3.5pt;margin-bottom:.0001pt'><b>VCis</b></p>
<p class=AmmCorpsTexte style='margin-left:3.5pt;page-break-after:avoid'><b>n<span style='letter-spacing:-.25pt'> </span>= 404</b></p>
</td>
<td width=265 colspan=2 valign=top style='width:198.55pt;border:solid black 1.0pt;
border-left:none;padding:0cm 0cm 0cm 0cm;height:36.0pt'>
<p class=AmmCorpsTexte style='margin-left:3.5pt;page-break-after:avoid'><b>Anal<span style='letter-spacing:.1pt'>y</span>se<span style='letter-spacing:-.2pt'> </span>statistique</b></p>
</td>
</tr>
<tr style='height:14.45pt'>
<td width=232 valign=top style='width:173.9pt;border-top:none;border-left:
solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:14.45pt'>
<p class=AmmCorpsTexte style='margin-left:6.6pt;page-break-after:avoid'>Survie<span style='letter-spacing:-.55pt'> </span>globale (objectif<span style='letter-spacing:-.6pt'> </span>pri<span style='letter-spacing:-.1pt'>m</span>aire)<span style='letter-spacing:-.1pt'> </span>: </p>
</td>
<td width=60 valign=top style='width:45.3pt;border:none;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:14.45pt'>
<p class=AmmCorpsTexte style='margin-left:2.8pt;page-break-after:avoid'> </p>
</td>
<td width=71 valign=top style='width:53.2pt;border:none;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:14.45pt'>
<p class=AmmCorpsTexte style='margin-left:7.1pt;page-break-after:avoid'> </p>
</td>
<td width=265 colspan=2 valign=top style='width:198.55pt;border:none;
border-right:solid black 1.0pt;padding:0cm 0cm 0cm 0cm;height:14.45pt'>
<p class=AmmCorpsTexte style='margin-left:3.5pt;page-break-after:avoid'> </p>
</td>
<td style='border:none;padding:0cm 0cm 0cm 0cm' width=1><p class='AmmCorpsTexte'> </td>
</tr>
<tr style='height:27.25pt'>
<td width=232 valign=top style='width:173.9pt;border-top:none;border-left:
solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:27.25pt'>
<p class=AmmCorpsTexte style='margin-top:0cm;margin-right:0cm;margin-bottom: 7.2pt;margin-left:6.6pt;page-break-after:avoid'>Survie médiane (mois)</p>
</td>
<td width=60 valign=top style='width:45.3pt;border:none;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:27.25pt'>
<p class=AmmCorpsTexte style='margin-top:0cm;margin-right:0cm;margin-bottom: 7.2pt;margin-left:2.8pt;page-break-after:avoid'><span style='letter-spacing: .05pt'>11,3</span></p>
</td>
<td width=71 valign=top style='width:53.2pt;border:none;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:27.25pt'>
<p class=AmmCorpsTexte style='margin-top:0cm;margin-right:0cm;margin-bottom: 7.2pt;margin-left:7.1pt;page-break-after:avoid'><span style='letter-spacing: .05pt'>10,1</span></p>
</td>
<td width=265 colspan=2 valign=top style='width:198.55pt;border:none;
border-right:solid black 1.0pt;padding:0cm 0cm 0cm 0cm;height:27.25pt'>
<p class=AmmCorpsTexte style='margin-top:0cm;margin-right:0cm;margin-bottom: 7.2pt;margin-left:3.4pt;page-break-after:avoid'>Risque<span style='letter-spacing: -.55pt'> </span>relatif<span style='letter-spacing:-.2pt'> </span>: 1,122 <span style='letter-spacing:-.05pt'>[</span>IC97, 2% :<span style='letter-spacing: .05pt'> </span>0,937<span style='letter-spacing:-.15pt'> </span>;<span style='letter-spacing:.05pt'> </span>1,342<span style='letter-spacing:-.1pt'>]</span>*</p>
</td>
<td style='border:none;padding:0cm 0cm 0cm 0cm' width=1><p class='AmmCorpsTexte'> </td>
</tr>
<tr style='height:29.1pt'>
<td width=232 valign=top style='width:173.9pt;border-top:none;border-left:
solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:29.1pt'>
<p class=AmmCorpsTexte style='margin-top:0cm;margin-right:0cm;margin-bottom: 7.2pt;margin-left:6.6pt;page-break-after:avoid'>Taux de Survie à 1<span style='letter-spacing:-.05pt'> </span>an<span style='letter-spacing:-.1pt'> </span>(<span style='letter-spacing:-.05pt'>%</span>)</p>
</td>
<td width=60 valign=top style='width:45.3pt;border:none;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:29.1pt'>
<p class=AmmCorpsTexte style='margin-top:0cm;margin-right:0cm;margin-bottom: 7.2pt;margin-left:2.8pt;page-break-after:avoid'><span style='letter-spacing: .05pt'>46</span></p>
</td>
<td width=71 valign=top style='width:53.2pt;border:none;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:29.1pt'>
<p class=AmmCorpsTexte style='margin-top:0cm;margin-right:0cm;margin-bottom: 7.2pt;margin-left:7.1pt;page-break-after:avoid'><span style='letter-spacing: .05pt'>41</span></p>
</td>
<td width=265 colspan=2 valign=top style='width:198.55pt;border:none;
border-right:solid black 1.0pt;padding:0cm 0cm 0cm 0cm;height:29.1pt'>
<p class=AmmCorpsTexte style='margin-top:0cm;margin-right:0cm;margin-bottom: 7.2pt;margin-left:3.5pt;page-break-after:avoid'>Différence<span style='letter-spacing:-.7pt'> </span>entre<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>traite<span style='letter-spacing:-.05pt'>m</span>ents<span style='letter-spacing:-.3pt'> </span>: 5,4% <span style='letter-spacing:-.05pt'>[</span>IC95% :<span style='letter-spacing:.05pt'> </span>-1,1<span style='letter-spacing:-.1pt'> </span>;<span style='letter-spacing:.05pt'> </span>12,0]</p>
</td>
<td style='border:none;padding:0cm 0cm 0cm 0cm' width=1><p class='AmmCorpsTexte'> </td>
</tr>
<tr style='height:28.85pt'>
<td width=232 valign=top style='width:173.9pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:28.85pt'>
<p class=AmmCorpsTexte style='margin-left:6.6pt;page-break-after:avoid'>Taux de Survie<span style='letter-spacing:-.25pt'> </span>à 2<span style='letter-spacing:-.05pt'> </span>ans<span style='letter-spacing:-.15pt'> </span>(<span style='letter-spacing:-.05pt'>%</span>)</p>
</td>
<td width=60 valign=top style='width:45.3pt;border:none;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:28.85pt'>
<p class=AmmCorpsTexte style='margin-left:2.8pt;page-break-after:avoid'><span style='letter-spacing:.05pt'>21</span></p>
</td>
<td width=71 valign=top style='width:53.2pt;border:none;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:28.85pt'>
<p class=AmmCorpsTexte style='margin-left:7.1pt;page-break-after:avoid'><span style='letter-spacing:.05pt'>14</span></p>
</td>
<td width=265 colspan=2 valign=top style='width:198.55pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:28.85pt'>
<p class=AmmCorpsTexte style='margin-left:3.5pt;page-break-after:avoid'>Différence<span style='letter-spacing:-.7pt'> </span>entre<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>traite<span style='letter-spacing:-.05pt'>m</span>ents<span style='letter-spacing:-.3pt'> </span>: 6,2% <span style='letter-spacing:-.05pt'>[</span>IC95% :<span style='letter-spacing:.05pt'> </span>0,2<span style='letter-spacing:-.1pt'> </span>;<span style='letter-spacing:.05pt'> </span>12,3]</p>
</td>
<td style='border:none;border-bottom:solid black 1.0pt' width=1><p class='AmmCorpsTexte'> </td>
</tr>
<tr style='height:26.3pt'>
<td width=232 valign=top style='width:173.9pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:26.3pt'>
<p class=AmmCorpsTexte style='margin-left:6.6pt;page-break-after:avoid'>Te<span style='letter-spacing:-.05pt'>m</span><span style='letter-spacing:.05pt'>p</span>s <span style='letter-spacing:-.1pt'>m</span>édian<span style='letter-spacing: 2.45pt'> </span>jusqu<span style='letter-spacing:.05pt'>’</span>à<span style='letter-spacing:2.5pt'> </span>progression (se<span style='letter-spacing: -.1pt'>m</span>aines)</p>
</td>
<td width=60 valign=top style='width:45.3pt;border:solid black 1.0pt;
border-left:none;padding:0cm 0cm 0cm 0cm;height:26.3pt'>
<p class=AmmCorpsTexte style='margin-left:2.8pt;page-break-after:avoid'>22,0</p>
</td>
<td width=72 colspan=2 valign=top style='width:53.95pt;border:solid black 1.0pt;
border-left:none;padding:0cm 0cm 0cm 0cm;height:26.3pt'>
<p class=AmmCorpsTexte style='margin-left:7.1pt;page-break-after:avoid'>23,0</p>
</td>
<td width=265 colspan=2 valign=top style='width:198.55pt;border:solid black 1.0pt;
border-left:none;padding:0cm 0cm 0cm 0cm;height:26.3pt'>
<p class=AmmCorpsTexte style='margin-left:3.5pt;page-break-after:avoid'>Risque<span style='letter-spacing:-.5pt'> </span>relatif<span style='letter-spacing:-.2pt'> </span>:<span style='letter-spacing:.05pt'> </span>1,032 <span style='letter-spacing:-.05pt'>[</span>IC95% :<span style='letter-spacing: .05pt'> </span>0,876<span style='letter-spacing:-.15pt'> </span>;<span style='letter-spacing:.05pt'> </span>1,216]</p>
</td>
</tr>
<tr style='height:38.8pt'>
<td width=232 valign=top style='width:173.9pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:38.8pt'>
<p class=AmmCorpsTexte style='margin-left:6.6pt'>Taux<span style='letter-spacing: -.5pt'> </span>de<span style='letter-spacing:-.1pt'> </span>réponse<span style='letter-spacing:-.3pt'> </span>global<span style='letter-spacing:-.25pt'> </span>(<span style='letter-spacing:-.05pt'>%</span>)</p>
</td>
<td width=60 valign=top style='width:45.3pt;border-top:none;border-left:none;
border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0cm 0cm 0cm 0cm;
height:38.8pt'>
<p class=AmmCorpsTexte style='margin-left:2.8pt'>31,6</p>
</td>
<td width=72 colspan=2 valign=top style='width:53.95pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:38.8pt'>
<p class=AmmCorpsTexte style='margin-left:7.1pt'>24,5</p>
</td>
<td width=265 colspan=2 valign=top style='width:198.55pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:38.8pt'>
<p class=AmmCorpsTexte style='margin-left:3.5pt'>Différence<span style='letter-spacing:-.7pt'> </span>entre<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>traite<span style='letter-spacing:-.05pt'>m</span>ents<span style='letter-spacing:-.3pt'> </span>: 7,1% <span style='letter-spacing:-.05pt'>[</span>IC95% :<span style='letter-spacing:.05pt'> </span>0,7<span style='letter-spacing:-.1pt'> </span>;<span style='letter-spacing:.05pt'> </span>13,5]</p>
</td>
</tr>
<tr height=0>
<td width=232 style='border:none'></td>
<td width=60 style='border:none'></td>
<td width=71 style='border:none'></td>
<td width=1 style='border:none'></td>
<td width=264 style='border:none'></td>
<td width=1 style='border:none'></td>
</tr>
</table>
<p class=AmmCorpsTexte>*Corrigé<span style='letter-spacing:-.65pt'> </span>pour<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>co<span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>p</span>araisons<span style='letter-spacing:-.1pt'> m</span><span style='letter-spacing:.05pt'>u</span>ltiples<span style='letter-spacing:-.1pt'> </span>et ajusté<span style='letter-spacing:-.25pt'> </span>pour<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>facteurs<span style='letter-spacing:-.3pt'> </span>de<span style='letter-spacing:-.1pt'> </span>stratification<span style='letter-spacing:-.45pt'> </span>(état de<span style='letter-spacing:-.1pt'> </span>la <span style='letter-spacing:-.1pt'>m</span>aladie et<span style='letter-spacing:-.25pt'> </span>zone<span style='letter-spacing:-.2pt'> </span>géographique<span style='letter-spacing:-.55pt'> </span>du<span style='letter-spacing:-.1pt'> </span>traite<span style='letter-spacing:-.05pt'>m</span>ent),<span style='letter-spacing:-.35pt'> </span>basé<span style='letter-spacing:-.2pt'> </span>sur<span style='letter-spacing:-.1pt'> </span>la population<span style='letter-spacing: -.45pt'> </span>de<span style='letter-spacing:-.1pt'> </span>patients<span style='letter-spacing:-.3pt'> </span>évaluables.</p>
<p class=AmmCorpsTexte>Les<span style='letter-spacing:-.4pt'> </span>objectifs<span style='letter-spacing:-.35pt'> </span>secondaires<span style='letter-spacing: -.45pt'> </span>incluent<span style='letter-spacing:-.3pt'> </span>la <span style='letter-spacing:-.1pt'>m</span>odification<span style='letter-spacing: -.05pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la douleur,<span style='letter-spacing:-.35pt'> </span>le score<span style='letter-spacing:-.2pt'> </span>global<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.1pt'> </span>qualité<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span>vie<span style='letter-spacing: -.1pt'> </span>évalué par l<span style='letter-spacing:.05pt'>’</span>EuroQoL-5D,<span style='letter-spacing:-.05pt'> </span>l<span style='letter-spacing:.05pt'>’</span>échelle<span style='letter-spacing:-.05pt'> </span>des<span style='letter-spacing:-.15pt'> </span>s<span style='letter-spacing:.1pt'>y</span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>p</span>tô<span style='letter-spacing:-.1pt'>m</span>es<span style='letter-spacing:-.05pt'> </span>du<span style='letter-spacing:-.1pt'> </span>cancer<span style='letter-spacing:-.25pt'> </span>bronchique<span style='letter-spacing: -.45pt'> </span>(LCSS)<span style='letter-spacing:-.3pt'> </span>et les<span style='letter-spacing:-.1pt'> </span>change<span style='letter-spacing:-.05pt'>m</span>ents<span style='letter-spacing:-.4pt'> </span>de l’indice<span style='letter-spacing: -.3pt'> </span>de perfor<span style='letter-spacing:-.1pt'>m</span>ance<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.1pt'> </span>Karnofsk<span style='letter-spacing:.1pt'>i</span>.<span style='letter-spacing:-.35pt'> </span>Ces<span style='letter-spacing:-.15pt'> </span>résultats<span style='letter-spacing: -.35pt'> </span>confir<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.3pt'> </span>ceux<span style='letter-spacing:-.2pt'> </span>obtenus<span style='letter-spacing:-.3pt'> </span>pour<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>objectifs<span style='letter-spacing:-.35pt'> </span>pri<span style='letter-spacing:-.1pt'>m</span>aires.</p>
<p class=AmmCorpsTexte>L<span style='letter-spacing:.05pt'>’</span>association<span style='letter-spacing:-.05pt'> </span>docétaxel-Carboplatine<span style='letter-spacing:-.9pt'> </span>n<span style='letter-spacing:.05pt'>’</span>a<span style='letter-spacing:-.05pt'> </span><span style='letter-spacing:-.1pt'>m</span>ontré<span style='letter-spacing:-.1pt'> </span>ni<span style='letter-spacing:-.1pt'> </span>équivalence<span style='letter-spacing:-.45pt'> </span>ni<span style='letter-spacing:-.1pt'> </span>non-infériorité<span style='letter-spacing:-.55pt'> </span>en<span style='letter-spacing:-.1pt'> </span>ter<span style='letter-spacing:-.05pt'>m</span>e d<span style='letter-spacing:.05pt'>’</span>efficacité,<span style='letter-spacing:-.05pt'> </span>co<span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>p</span>arée<span style='letter-spacing:-.1pt'> </span>au<span style='letter-spacing:-.1pt'> </span>traite<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.3pt'> </span>de<span style='letter-spacing:-.1pt'> </span>référence<span style='letter-spacing:-.35pt'> </span>Vcis.</p>
<p class=AmmCorpsTexte><i><u><sub>Cancer de la prostate</sub></u></i></p>
<p class=AmmCorpsTexte>La<span style='letter-spacing:-.35pt'> </span>tolérance<span style='letter-spacing:-.35pt'> </span>et l<span style='letter-spacing:.05pt'>’</span>efficacité<span style='letter-spacing:-.05pt'> </span>de<span style='letter-spacing:-.1pt'> </span>docétaxel<span style='letter-spacing:-.4pt'> </span>en<span style='letter-spacing:-.1pt'> </span>associ<span style='letter-spacing:-.15pt'>a</span>tion<span style='letter-spacing:-.25pt'> </span>avec<span style='letter-spacing:-.2pt'> </span>la prednisone<span style='letter-spacing: -.45pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>la prednisolone<span style='letter-spacing:-.5pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>patients atteints<span style='letter-spacing: -.3pt'> </span>d<span style='letter-spacing:.05pt'>’</span>un<span style='letter-spacing:-.05pt'> </span>cancer<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la prostate<span style='letter-spacing:-.3pt'> </span><span style='letter-spacing:-.1pt'>m</span>étas<span style='letter-spacing:-.1pt'>t</span>atique<span style='letter-spacing:-.3pt'> </span>hor<span style='letter-spacing:-.1pt'>m</span>ono-résistant<span style='letter-spacing: -.15pt'> </span>ont<span style='letter-spacing:-.15pt'> </span>été évaluées<span style='letter-spacing:-.35pt'> </span>lors<span style='letter-spacing:-.15pt'> </span>d<span style='letter-spacing:.05pt'>’</span>une<span style='letter-spacing:-.05pt'> </span>étude de<span style='letter-spacing:-.1pt'> </span>Phase<span style='letter-spacing: -.25pt'> </span>III rando<span style='letter-spacing:-.1pt'>m</span>isée<span style='letter-spacing:-.25pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>u</span>lticentrique.<span style='letter-spacing: -.05pt'> </span>Un<span style='letter-spacing:-.1pt'> </span>total de<span style='letter-spacing:-.1pt'> </span>1006<span style='letter-spacing:-.2pt'> </span>patients<span style='letter-spacing:-.3pt'> </span>avec<span style='letter-spacing:-.2pt'> </span>un<span style='letter-spacing:-.1pt'> </span>score<span style='letter-spacing:-.2pt'> </span>de Karnofski<span style='letter-spacing:-.6pt'> </span>&#8805;60<span style='letter-spacing:-.05pt'> </span>ont<span style='letter-spacing:-.15pt'> </span>été rando<span style='letter-spacing:-.1pt'>m</span>isés<span style='letter-spacing: -.25pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>groupes<span style='letter-spacing:-.3pt'> </span>de<span style='letter-spacing:-.1pt'> </span>traite<span style='letter-spacing:-.05pt'>m</span>ents<span style='letter-spacing:-.3pt'> </span>suivants<span style='letter-spacing:-.35pt'> </span>:</p>
<p class=AmmListePuces1 style='text-align:justify'><span style='font-family: Symbol'>·<span style='font:7.0pt "Times New Roman"'>                   </span></span>Le<span style='letter-spacing:-.35pt'> </span>docétaxel 75<span style='letter-spacing:-.1pt'> m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.1pt'>m</span>²<span style='letter-spacing:-.1pt'> </span>toutes<span style='letter-spacing:-.25pt'> </span>les<span style='letter-spacing:-.1pt'> </span>trois<span style='letter-spacing:-.2pt'> </span>se<span style='letter-spacing:-.1pt'>m</span>aines<span style='letter-spacing:-.1pt'> </span>pendant<span style='letter-spacing:-.3pt'> </span>10<span style='letter-spacing:-.1pt'> </span>c<span style='letter-spacing: .1pt'>y</span>cles.</p>
<p class=AmmListePuces1 style='text-align:justify'><span style='font-family: Symbol'>·<span style='font:7.0pt "Times New Roman"'>                   </span></span>Le<span style='letter-spacing:-.35pt'> </span>docétaxel<span style='letter-spacing:-.4pt'> </span>30<span style='letter-spacing:-.1pt'> m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.1pt'>m</span>²<span style='letter-spacing:-.1pt'> </span>ad<span style='letter-spacing:-.1pt'>m</span>inistré<span style='letter-spacing:-.3pt'> </span>toutes<span style='letter-spacing:-.25pt'> </span>les<span style='letter-spacing:-.1pt'> </span>se<span style='letter-spacing: -.1pt'>m</span>aines<span style='letter-spacing:-.1pt'> </span>pendant<span style='letter-spacing:-.3pt'> </span>5<span style='letter-spacing:-.05pt'> </span>se<span style='letter-spacing:-.1pt'>m</span>aines<span style='letter-spacing:-.1pt'> </span>suivi<span style='letter-spacing:-.2pt'>es d’une </span>se<span style='letter-spacing: -.1pt'>m</span>aine<span style='letter-spacing:-.1pt'> </span>de<span style='letter-spacing:-.1pt'> </span>repos pendant<span style='letter-spacing: -.3pt'> </span>5<span style='letter-spacing:-.05pt'> </span>c<span style='letter-spacing:.1pt'>y</span>cles.</p>
<p class=AmmListePuces1 style='text-align:justify'><span style='font-family: Symbol'>·<span style='font:7.0pt "Times New Roman"'>                   </span></span>Mitoxantrone<span style='letter-spacing:-.55pt'> </span>12<span style='letter-spacing:-.1pt'> m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.1pt'>m</span>²<span style='letter-spacing:-.1pt'> </span>toutes<span style='letter-spacing:-.25pt'> </span>les<span style='letter-spacing:-.1pt'> </span>trois<span style='letter-spacing:-.2pt'> </span>se<span style='letter-spacing:-.1pt'>m</span>aines<span style='letter-spacing:-.1pt'> </span>pendant<span style='letter-spacing:-.3pt'> </span>10<span style='letter-spacing:-.1pt'> </span>c<span style='letter-spacing: .1pt'>y</span>cles.</p>
<p class=AmmCorpsTexte style='margin-top:6.0pt'>Dans<span style='letter-spacing: -.5pt'> </span>les<span style='letter-spacing:-.1pt'> </span>3<span style='letter-spacing:-.05pt'> </span>groupes<span style='letter-spacing:-.3pt'> </span>de<span style='letter-spacing:-.1pt'> </span>traite<span style='letter-spacing:-.05pt'>m</span>ent,<span style='letter-spacing:-.3pt'> </span>la<span style='letter-spacing:.05pt'> </span>prednisone<span style='letter-spacing: -.4pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>la<span style='letter-spacing:.05pt'> </span>prednisolone<span style='letter-spacing: -.55pt'> </span>était ad<span style='letter-spacing:-.1pt'>m</span>inistrée<span style='letter-spacing:-.35pt'> </span>en<span style='letter-spacing:-.1pt'> </span>continu<span style='letter-spacing:-.3pt'> </span>à raison<span style='letter-spacing:-.25pt'> </span>de 5<span style='letter-spacing:-.05pt'> </span><span style='letter-spacing: -.1pt'>m</span>g<span style='letter-spacing:-.05pt'> </span>deux<span style='letter-spacing:-.2pt'> </span>fois<span style='letter-spacing:-.15pt'> </span>par<span style='letter-spacing:-.15pt'> </span>jour.</p>
<p class=AmmCorpsTexte>Il<span style='letter-spacing:-.3pt'> </span>a été dé<span style='letter-spacing:-.1pt'>m</span>ontré<span style='letter-spacing:-.1pt'> </span>une<span style='letter-spacing:-.15pt'> </span>survie<span style='letter-spacing:-.25pt'> </span>globale<span style='letter-spacing:-.3pt'> </span>significative<span style='letter-spacing:-.1pt'>m</span>ent<span style='letter-spacing:-.5pt'> </span>plus<span style='letter-spacing:-.15pt'> </span>longue<span style='letter-spacing:-.25pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>patients<span style='letter-spacing:-.3pt'> </span>a<span style='letter-spacing:.1pt'>y</span>ant<span style='letter-spacing: -.05pt'> </span>reçu<span style='letter-spacing:-.15pt'> </span>du<span style='letter-spacing:-.1pt'> </span>docétaxel toutes<span style='letter-spacing: -.25pt'> </span>les<span style='letter-spacing:-.1pt'> </span>trois<span style='letter-spacing:-.2pt'> </span>se<span style='letter-spacing:-.1pt'>m</span>aines<span style='letter-spacing:-.1pt'> </span>en<span style='letter-spacing:-.1pt'> </span>co<span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>p</span>araison<span style='letter-spacing:-.1pt'> </span>à<span style='letter-spacing:.05pt'> </span>celle des<span style='letter-spacing:-.15pt'> </span>patients<span style='letter-spacing: -.3pt'> </span>du<span style='letter-spacing:-.1pt'> </span>bras<span style='letter-spacing:-.15pt'> </span>contrôle,<span style='letter-spacing: -.35pt'> </span>traités<span style='letter-spacing:-.25pt'> </span>par<span style='letter-spacing:-.15pt'> </span>la <span style='letter-spacing:-.1pt'>m</span>itoxantrone.<span style='letter-spacing:-.05pt'> </span>La différence<span style='letter-spacing: -.35pt'> </span>en<span style='letter-spacing:-.1pt'> </span>gain<span style='letter-spacing:-.15pt'> </span>de<span style='letter-spacing:-.1pt'> </span>survie<span style='letter-spacing:-.25pt'> </span>o<span style='letter-spacing:-.05pt'>b</span>servée<span style='letter-spacing:-.05pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>le bras<span style='letter-spacing:-.15pt'> </span>docétaxel<span style='letter-spacing:-.4pt'> </span>hebdo<span style='letter-spacing:-.1pt'>m</span>adaire<span style='letter-spacing:-.25pt'> </span>n’a<span style='letter-spacing:-.15pt'> </span>pas<span style='letter-spacing:-.15pt'> </span>été statistique<span style='letter-spacing: -.05pt'>m</span>ent significative<span style='letter-spacing:-.5pt'> </span>co<span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>p</span>arée<span style='letter-spacing:-.1pt'> </span>au<span style='letter-spacing:-.1pt'> </span>bras<span style='letter-spacing:-.15pt'> </span>contrôle.<span style='letter-spacing: -.35pt'> </span>Les<span style='letter-spacing:-.15pt'> </span>critères<span style='letter-spacing:-.3pt'> </span>d’efficacité<span style='letter-spacing: -.45pt'> </span>pour<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>bras<span style='letter-spacing:-.15pt'> </span>docétaxel co<span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>p</span>arés<span style='letter-spacing:-.1pt'> </span>au<span style='letter-spacing:-.1pt'> </span>bras contrôle<span style='letter-spacing:-.35pt'> </span>sont<span style='letter-spacing: -.15pt'> </span>résu<span style='letter-spacing:-.1pt'>m</span>és<span style='letter-spacing:-.15pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>le tableau<span style='letter-spacing:-.3pt'> </span>ci-dessous<span style='letter-spacing:-.4pt'> </span>:</p>
<div align=center>
<table class=AmmCorpsTexteTable border=1 cellspacing=0 cellpadding=0 width=638
style='width:478.7pt;margin-left:15.9pt;border-collapse:collapse;border:none'>
<thead>
<tr style='height:11.5pt'>
<td width=211 valign=top style='width:158.6pt;border:solid windowtext 1.0pt;
border-left:solid black 1.0pt;padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmTableauTitre1 align=left style='margin:0cm;margin-bottom:.0001pt; text-align:left;page-break-after:avoid'>Critères</p>
</td>
<td width=152 valign=top style='width:113.85pt;border:solid windowtext 1.0pt;
border-left:none;padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmTableauTitre1 align=left style='margin:0cm;margin-bottom:.0001pt; text-align:left;page-break-after:avoid'>docétaxel toutes les 3 semaines</p>
</td>
<td width=152 valign=top style='width:114.1pt;border:solid windowtext 1.0pt;
border-left:none;padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmTableauTitre1 align=left style='margin:0cm;margin-bottom:.0001pt; text-align:left;page-break-after:avoid'>docétaxel toutes les semaines</p>
</td>
<td width=123 valign=top style='width:92.15pt;border-top:solid windowtext 1.0pt;
border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmTableauTitre1 align=left style='margin:0cm;margin-bottom:.0001pt; text-align:left;page-break-after:avoid'>Mitoxantrone toutes les trois semaines</p>
</td>
</tr>
<tr style='height:11.5pt'>
<td width=211 valign=top style='width:158.6pt;border-top:none;border-left:
solid black 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left;page-break-after:avoid'> </p>
</td>
<td width=152 valign=top style='width:113.85pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left;page-break-after:avoid'> </p>
</td>
<td width=152 valign=top style='width:114.1pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left;page-break-after:avoid'> </p>
</td>
<td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left;page-break-after:avoid'> </p>
</td>
</tr>
<tr style='height:11.5pt'>
<td width=211 valign=top style='width:158.6pt;border-top:none;border-left:
solid black 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left;page-break-after:avoid'>Nombre de patients</p>
</td>
<td width=152 valign=top style='width:113.85pt;border:none;border-right:
solid windowtext 1.0pt;padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center;page-break-after:avoid'>335</p>
</td>
<td width=152 valign=top style='width:114.1pt;border:none;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center;page-break-after:avoid'>334</p>
</td>
<td width=123 valign=top style='width:92.15pt;border:none;border-right:solid black 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center;page-break-after:avoid'>337</p>
</td>
</tr>
<tr style='height:11.5pt'>
<td width=211 valign=top style='width:158.6pt;border-top:none;border-left:
solid black 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left;page-break-after:avoid'>Survie médiane (mois) IC 95 %</p>
</td>
<td width=152 valign=top style='width:113.85pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center;page-break-after:avoid'>18,9 (17,0-21,2)</p>
</td>
<td width=152 valign=top style='width:114.1pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center;page-break-after:avoid'>17,4 (15,7-19,0)</p>
</td>
<td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center;page-break-after:avoid'>16,5 (14,4-18,6)</p>
</td>
</tr>
<tr style='height:11.5pt'>
<td width=211 valign=top style='width:158.6pt;border-top:none;border-left:
solid black 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left;page-break-after:avoid'>Risque relatif IC 95 %</p>
</td>
<td width=152 valign=top style='width:113.85pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center;page-break-after:avoid'>0,761 (0,619-0,936)</p>
</td>
<td width=152 valign=top style='width:114.1pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center;page-break-after:avoid'>0,912 (0,747-1,113)</p>
</td>
<td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center;page-break-after:avoid'>-</p>
</td>
</tr>
<tr style='height:11.5pt'>
<td width=211 valign=top style='width:158.6pt;border-top:none;border-left:
solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left;page-break-after:avoid'>Valeur du p<sup>†</sup>*</p>
</td>
<td width=152 valign=top style='width:113.85pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center;page-break-after:avoid'>0,0094</p>
</td>
<td width=152 valign=top style='width:114.1pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center;page-break-after:avoid'>0,3624</p>
</td>
<td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center;page-break-after:avoid'>-</p>
</td>
</tr>
<tr style='height:11.5pt'>
<td width=211 valign=top style='width:158.6pt;border-top:none;border-left:
solid black 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left;page-break-after:avoid'>Nombre de patients</p>
</td>
<td width=152 valign=top style='width:113.85pt;border:none;border-right:
solid windowtext 1.0pt;padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center;page-break-after:avoid'>291</p>
</td>
<td width=152 valign=top style='width:114.1pt;border:none;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center;page-break-after:avoid'>282</p>
</td>
<td width=123 valign=top style='width:92.15pt;border:none;border-right:solid black 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center;page-break-after:avoid'>300</p>
</td>
</tr>
<tr style='height:11.5pt'>
<td width=211 valign=top style='width:158.6pt;border-top:none;border-left:
solid black 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left;page-break-after:avoid'>Taux de réponse du PSA** (%)</p>
</td>
<td width=152 valign=top style='width:113.85pt;border:none;border-right:
solid windowtext 1.0pt;padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center;page-break-after:avoid'>45,4 (39,5-51,3)</p>
</td>
<td width=152 valign=top style='width:114.1pt;border:none;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center;page-break-after:avoid'>47,9 (41,9-53,.9)</p>
</td>
<td width=123 valign=top style='width:92.15pt;border:none;border-right:solid black 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center;page-break-after:avoid'>31,7 (26,4-37,3)</p>
</td>
</tr>
<tr style='height:11.5pt'>
<td width=211 valign=top style='width:158.6pt;border-top:none;border-left:
solid black 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left;page-break-after:avoid'>IC 95 %</p>
</td>
<td width=152 valign=top style='width:113.85pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center;page-break-after:avoid'> </p>
</td>
<td width=152 valign=top style='width:114.1pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center;page-break-after:avoid'> </p>
</td>
<td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center;page-break-after:avoid'> </p>
</td>
</tr>
<tr style='height:11.5pt'>
<td width=211 valign=top style='width:158.6pt;border-top:none;border-left:
solid black 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left;page-break-after:avoid'>Valeur du p*</p>
</td>
<td width=152 valign=top style='width:113.85pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center;page-break-after:avoid'>0,0005</p>
</td>
<td width=152 valign=top style='width:114.1pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center;page-break-after:avoid'>&lt;0,0001</p>
</td>
<td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center;page-break-after:avoid'>-</p>
</td>
</tr>
<tr style='height:11.5pt'>
<td width=211 valign=top style='width:158.6pt;border-top:none;border-left:
solid black 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left;page-break-after:avoid'>Nombre de patients</p>
</td>
<td width=152 valign=top style='width:113.85pt;border:none;border-right:
solid windowtext 1.0pt;padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center;page-break-after:avoid'>153</p>
</td>
<td width=152 valign=top style='width:114.1pt;border:none;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center;page-break-after:avoid'>154</p>
</td>
<td width=123 valign=top style='width:92.15pt;border:none;border-right:solid black 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center;page-break-after:avoid'>157</p>
</td>
</tr>
<tr style='height:11.5pt'>
<td width=211 valign=top style='width:158.6pt;border-top:none;border-left:
solid black 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left;page-break-after:avoid'>Taux de réponse à la douleur (%)</p>
</td>
<td width=152 valign=top style='width:113.85pt;border:none;border-right:
solid windowtext 1.0pt;padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center;page-break-after:avoid'>34,6 (27,1-42,7)</p>
</td>
<td width=152 valign=top style='width:114.1pt;border:none;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center;page-break-after:avoid'>31,2 (24,0-39,1)</p>
</td>
<td width=123 valign=top style='width:92.15pt;border:none;border-right:solid black 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center;page-break-after:avoid'>21,7 (15,5-28,9)</p>
</td>
</tr>
<tr style='height:11.5pt'>
<td width=211 valign=top style='width:158.6pt;border-top:none;border-left:
solid black 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left;page-break-after:avoid'>IC 95 %</p>
</td>
<td width=152 valign=top style='width:113.85pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center;page-break-after:avoid'> </p>
</td>
<td width=152 valign=top style='width:114.1pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center;page-break-after:avoid'> </p>
</td>
<td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center;page-break-after:avoid'> </p>
</td>
</tr>
<tr style='height:11.5pt'>
<td width=211 valign=top style='width:158.6pt;border-top:none;border-left:
solid black 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left;page-break-after:avoid'>Valeur du p*</p>
</td>
<td width=152 valign=top style='width:113.85pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center;page-break-after:avoid'>0,0107</p>
</td>
<td width=152 valign=top style='width:114.1pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center;page-break-after:avoid'>0,0798</p>
</td>
<td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center;page-break-after:avoid'>-</p>
</td>
</tr>
<tr style='height:11.5pt'>
<td width=211 valign=top style='width:158.6pt;border-top:none;border-left:
solid black 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left;page-break-after:avoid'>Nombre de patients</p>
</td>
<td width=152 valign=top style='width:113.85pt;border:none;border-right:
solid windowtext 1.0pt;padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center;page-break-after:avoid'>141</p>
</td>
<td width=152 valign=top style='width:114.1pt;border:none;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center;page-break-after:avoid'>134</p>
</td>
<td width=123 valign=top style='width:92.15pt;border:none;border-right:solid black 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center;page-break-after:avoid'>137</p>
</td>
</tr>
<tr style='height:11.5pt'>
<td width=211 valign=top style='width:158.6pt;border-top:none;border-left:
solid black 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left;page-break-after:avoid'>Taux de réponse tumoral (%)</p>
</td>
<td width=152 valign=top style='width:113.85pt;border:none;border-right:
solid windowtext 1.0pt;padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center;page-break-after:avoid'>12,1 (7,2-18,6)</p>
</td>
<td width=152 valign=top style='width:114.1pt;border:none;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center;page-break-after:avoid'>8,2 (4,2-14,2)</p>
</td>
<td width=123 valign=top style='width:92.15pt;border:none;border-right:solid black 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center;page-break-after:avoid'>6,6 (3,0-12,1)</p>
</td>
</tr>
<tr style='height:11.5pt'>
<td width=211 valign=top style='width:158.6pt;border-top:none;border-left:
solid black 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left;page-break-after:avoid'>IC 95 %</p>
</td>
<td width=152 valign=top style='width:113.85pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center;page-break-after:avoid'> </p>
</td>
<td width=152 valign=top style='width:114.1pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'> </p>
</td>
<td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center;page-break-after:avoid'> </p>
</td>
</tr>
<tr style='height:11.5pt'>
<td width=211 valign=top style='width:158.6pt;border-top:none;border-left:
solid black 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left;page-break-after:avoid'>Valeur du p*</p>
</td>
<td width=152 valign=top style='width:113.85pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center;page-break-after:avoid'>0,1112</p>
</td>
<td width=152 valign=top style='width:114.1pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center;page-break-after:avoid'>0,5853</p>
</td>
<td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center;page-break-after:avoid'>-</p>
</td>
</tr>
</thead>
</table>
</div>
<p class=AmmCorpsTexte style='margin-bottom:0cm;margin-bottom:.0001pt'><b><i><sup>† <span style='letter-spacing:.8pt'></span></sup></i></b><i>Test<span style='letter-spacing:-.25pt'> </span>log<span style='letter-spacing:-.15pt'> </span>rank<span style='letter-spacing:-.2pt'> </span>stratifié</i></p>
<p class=AmmCorpsTexte style='margin-bottom:0cm;margin-bottom:.0001pt'><i>*Seuil<span style='letter-spacing:-.5pt'> </span>de<span style='letter-spacing:-.1pt'> </span>signification<span style='letter-spacing:-.5pt'> </span>statistique<span style='letter-spacing: -.4pt'> </span>=<span style='letter-spacing:-.05pt'> </span>0,0175</i></p>
<p class=AmmCorpsTexte><i>**PSA:<span style='letter-spacing:-.6pt'> </span>antigène<span style='letter-spacing:-.35pt'> </span>spécifique<span style='letter-spacing: -.4pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la<span style='letter-spacing:-.1pt'> </span>prostate</i></p>
<p class=AmmCorpsTexte>Etant<span style='letter-spacing:-.45pt'> </span>donné<span style='letter-spacing:-.25pt'> </span>que<span style='letter-spacing:-.15pt'> </span>l<span style='letter-spacing:.05pt'>’</span>ad<span style='letter-spacing:-.1pt'>m</span>inistration<span style='letter-spacing:-.35pt'> </span>hebdo<span style='letter-spacing:-.1pt'>m</span>adaire<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.15pt'> </span>docétaxel<span style='letter-spacing:-.35pt'> </span>a présenté<span style='letter-spacing: -.35pt'> </span>un<span style='letter-spacing:-.1pt'> </span>profil<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span>tolérance<span style='letter-spacing:-.35pt'> </span>sensible<span style='letter-spacing:-.05pt'>m</span>ent <span style='letter-spacing:-.1pt'>m</span>eilleur<span style='letter-spacing: -.3pt'> </span>que<span style='letter-spacing:-.15pt'> </span>le docétaxel<span style='letter-spacing:-.4pt'> </span>toutes<span style='letter-spacing:-.25pt'> </span>les<span style='letter-spacing:-.1pt'> </span>trois<span style='letter-spacing:-.2pt'> </span>se<span style='letter-spacing:-.1pt'>m</span>aines,<span style='letter-spacing:-.1pt'> </span>il est<span style='letter-spacing:-.1pt'> </span>possible<span style='letter-spacing:-.35pt'> </span>que<span style='letter-spacing:-.15pt'> </span>certains<span style='letter-spacing:-.3pt'> </span>patients<span style='letter-spacing:-.3pt'> </span>puissent bénéficier<span style='letter-spacing:-.4pt'> </span>de ce sché<span style='letter-spacing:-.1pt'>m</span>a.</p>
<p class=AmmCorpsTexte>En<span style='letter-spacing:-.35pt'> </span>ter<span style='letter-spacing:-.05pt'>m</span>es<span style='letter-spacing:-.1pt'> </span>de<span style='letter-spacing:-.1pt'> </span>qualité<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.1pt'> </span>vie,<span style='letter-spacing: -.15pt'> </span>il n’y<span style='letter-spacing:-.05pt'> </span>a pas<span style='letter-spacing:-.15pt'> </span>de<span style='letter-spacing:-.1pt'> </span>différ<span style='letter-spacing:-.05pt'>e</span>nce<span style='letter-spacing:-.2pt'> </span>statistique<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.5pt'> </span>significative<span style='letter-spacing:-.5pt'> </span>entre<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>groupes<span style='letter-spacing:-.3pt'> </span>de traite<span style='letter-spacing:-.05pt'>m</span>ent.</p>
<p class=AmmCorpsTexte><i><u><sub>Adénocarcinome gastrique</sub></u></i></p>
<p class=AmmCorpsTexte>L<span style='letter-spacing:.05pt'>’</span>étude<span style='letter-spacing:-.05pt'> </span>ouverte,<span style='letter-spacing:-.3pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing: .05pt'>u</span>lticentrique,<span style='letter-spacing:-.05pt'> </span>rando<span style='letter-spacing:-.1pt'>m</span>isée<span style='letter-spacing:-.25pt'> </span>a été ré<span style='letter-spacing:-.05pt'>a</span>lisée<span style='letter-spacing: -.1pt'> </span>pour<span style='letter-spacing:-.2pt'> </span>évaluer<span style='letter-spacing:-.3pt'> </span>la tolérance<span style='letter-spacing: -.35pt'> </span>et l<span style='letter-spacing:.05pt'>’</span>efficacité du<span style='letter-spacing:-.1pt'> </span>docétaxel<span style='letter-spacing:.05pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>le traite<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.3pt'> </span>de<span style='letter-spacing:-.1pt'> </span>l’adénocarcino<span style='letter-spacing: -.05pt'>m</span>e<span style='letter-spacing:-.6pt'> </span>gas<span style='letter-spacing:-.05pt'>t</span>rique<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span>étastatique,<span style='letter-spacing:-.45pt'> </span>y<span style='letter-spacing:.05pt'> </span>co<span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>p</span>ris<span style='letter-spacing:-.1pt'> </span>l<span style='letter-spacing:.05pt'>’</span>adénocarcino<span style='letter-spacing:-.05pt'>m</span>e<span style='letter-spacing:-.05pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la jonction œsogastrique,<span style='letter-spacing:-.55pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>patients<span style='letter-spacing:-.3pt'> </span>non<span style='letter-spacing:-.15pt'> </span>p<span style='letter-spacing: -.05pt'>r</span>étraités<span style='letter-spacing:-.05pt'> </span>par<span style='letter-spacing:-.15pt'> </span>chi<span style='letter-spacing:-.05pt'>m</span>iothérapie<span style='letter-spacing:-.1pt'> </span>pour<span style='letter-spacing:-.2pt'> </span>leur<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span>aladie<span style='letter-spacing:-.25pt'> </span><span style='letter-spacing:-.1pt'>m</span>étastatique.</p>
<p class=AmmCorpsTexte>Au<span style='letter-spacing:-.4pt'> </span>total 445<span style='letter-spacing:-.15pt'> </span>patients<span style='letter-spacing:-.3pt'> </span>avec<span style='letter-spacing:-.2pt'> </span>un<span style='letter-spacing: -.1pt'> </span>indice<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.1pt'> </span>perfor<span style='letter-spacing:-.1pt'>m</span>ance<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.1pt'> </span>Karnofski<span style='letter-spacing:-.3pt'> </span>&gt;70<span style='letter-spacing:-.15pt'> </span>ont<span style='letter-spacing:-.15pt'> </span>reçu<span style='letter-spacing:-.15pt'> </span>soit<span style='letter-spacing:-.15pt'> </span>:</p>
<p class=AmmListePuces1 style='text-align:justify'><span style='font-family: Symbol'>·<span style='font:7.0pt "Times New Roman"'>                   </span></span>docétaxel<span style='letter-spacing:2.15pt'> </span>(T)<span style='letter-spacing:-.15pt'> </span>75<span style='letter-spacing:-.1pt'> m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.1pt'>m</span>²<span style='letter-spacing:-.1pt'> </span>à J1<span style='letter-spacing:-.1pt'> </span>en<span style='letter-spacing:-.1pt'> </span>association<span style='letter-spacing: -.45pt'> </span>avec<span style='letter-spacing:-.25pt'> </span>cisplatine<span style='letter-spacing:-.4pt'> </span>(C)<span style='letter-spacing:-.15pt'> </span>75<span style='letter-spacing:-.1pt'> m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.1pt'>m</span>²<span style='letter-spacing:-.1pt'> </span>à J1<span style='letter-spacing:-.1pt'> </span>et 5-fluoro-uracile (F)<span style='letter-spacing:-.4pt'> </span>750<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.1pt'>m</span>²<span style='letter-spacing:-.1pt'> </span>par<span style='letter-spacing:-.15pt'> </span>jour<span style='letter-spacing:-.15pt'> </span>pendant<span style='letter-spacing:-.25pt'> </span>5<span style='letter-spacing:-.05pt'> </span>jours<span style='letter-spacing:-.2pt'> </span>; </p>
<p class=AmmListePuces1 style='text-align:justify'><span style='font-family: Symbol'>·<span style='font:7.0pt "Times New Roman"'>                   </span></span>cisplatine<span style='letter-spacing:-.35pt'> </span>(C)<span style='letter-spacing:-.15pt'> </span>100<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.1pt'>m</span>²<span style='letter-spacing:-.1pt'> </span>à J1<span style='letter-spacing:-.1pt'> </span>et 5-fluoro-uracile(F)<span style='letter-spacing:-.1pt'> </span>1000<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.1pt'>m</span>²<span style='letter-spacing:-.1pt'> </span>par<span style='letter-spacing:-.15pt'> </span>jour<span style='letter-spacing:-.15pt'> </span>pendant<span style='letter-spacing:-.3pt'> </span>5<span style='letter-spacing:-.05pt'> </span>jours.</p>
<p class=AmmCorpsTexte style='margin-top:6.0pt'>La durée d’un cycle de traitement était de 3 semaines pour le bras TCF et 4 semaines pour le bras CF. Le nombre médian de cycles administrés par patient était de 6 (intervalle : 1-16) pour le bras TCF comparé à 4 (intervalle : 1-12) pour le bras CF.</p>
<p class=AmmCorpsTexte>Le<span style='letter-spacing:-.35pt'> </span>critère<span style='letter-spacing:-.25pt'> </span>principal<span style='letter-spacing: -.35pt'> </span>de<span style='letter-spacing:-.1pt'> </span>cette étude<span style='letter-spacing:-.2pt'> </span>était le t<span style='letter-spacing: -.15pt'>e</span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>p</span>s<span style='letter-spacing:-.1pt'> </span>jusqu<span style='letter-spacing:.05pt'>’</span>à<span style='letter-spacing:-.2pt'> </span>progression.<span style='letter-spacing:-.5pt'> </span>La<span style='letter-spacing:-.1pt'> </span>réduction<span style='letter-spacing:-.35pt'> </span>du<span style='letter-spacing:-.1pt'> </span>risque<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.1pt'> </span>progression était<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing: -.1pt'> </span>32,1%<span style='letter-spacing:-.25pt'> </span>et était<span style='letter-spacing:.05pt'> </span>associé<span style='letter-spacing:-.3pt'> </span>à un<span style='letter-spacing:-.1pt'> </span>te<span style='letter-spacing: -.05pt'>m</span><span style='letter-spacing:.05pt'>p</span>s<span style='letter-spacing:-.05pt'> </span>jusqu<span style='letter-spacing:.05pt'>’</span>à<span style='letter-spacing:-.2pt'> </span>progression<span style='letter-spacing: -.45pt'> </span>significative<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.5pt'> </span>plus<span style='letter-spacing:-.15pt'> </span>long<span style='letter-spacing:-.2pt'> </span>(p =<span style='letter-spacing:-.05pt'> </span>0,0004)<span style='letter-spacing:-.3pt'> </span>en<span style='letter-spacing:-.1pt'> </span>faveur<span style='letter-spacing:-.25pt'> </span>du bras<span style='letter-spacing:-.15pt'> </span>TCF.</p>
<p class=AmmCorpsTexte>La<span style='letter-spacing: -.35pt'> </span>survie<span style='letter-spacing:-.25pt'> </span>globale<span style='letter-spacing:-.3pt'> </span>était égale<span style='letter-spacing: -.05pt'>m</span>ent<span style='letter-spacing:-.2pt'> </span>significative<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.5pt'> </span>plus<span style='letter-spacing:-.15pt'> </span>longue<span style='letter-spacing:-.25pt'> </span>(p<span style='letter-spacing:-.1pt'> </span>=<span style='letter-spacing: -.05pt'> </span>0,0201)<span style='letter-spacing:-.3pt'> </span>en<span style='letter-spacing:-.1pt'> </span>faveur<span style='letter-spacing:-.25pt'> </span>du<span style='letter-spacing:-.1pt'> </span>bras<span style='letter-spacing: -.15pt'> </span>TCF<span style='letter-spacing:-.2pt'> </span>avec une réduction<span style='letter-spacing:-.35pt'> </span>du<span style='letter-spacing: -.1pt'> </span>risque<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.1pt'> m</span><span style='letter-spacing:.05pt'>o</span>r<span style='letter-spacing:-.05pt'>t</span>alité<span style='letter-spacing:-.1pt'> </span>de<span style='letter-spacing:-.1pt'> </span>22,7%.<span style='letter-spacing:-.3pt'> </span>Les<span style='letter-spacing:-.15pt'> </span>résultats<span style='letter-spacing: -.35pt'> </span>d<span style='letter-spacing:.05pt'>’</span><span style='letter-spacing:-.05pt'>e</span>fficacité<span style='letter-spacing: -.4pt'> </span>sont<span style='letter-spacing:-.15pt'> </span>résu<span style='letter-spacing:-.1pt'>m</span>és<span style='letter-spacing:-.15pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>le tableau<span style='letter-spacing: -.25pt'> </span>suivant<span style='letter-spacing:-.3pt'> </span>:</p>
<p class=AmmCorpsTexte><u>Efficacité<span style='letter-spacing:.05pt'> </span>du docétaxel dans le traite<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.1pt'> </span>des patients atteints<span style='letter-spacing:-.25pt'> </span>d’un adénocarcino<span style='letter-spacing:-.05pt'>m</span>e gastrique</u></p>
<div align=center>
<table class=AmmCorpsTexteTable border=1 cellspacing=0 cellpadding=0
style='margin-left:3.5pt;border-collapse:collapse;border:none'>
<thead>
<tr style='height:12.0pt'>
<td width=397 valign=top style='width:297.4pt;border:solid windowtext 1.0pt;
border-bottom:none black 1.0pt;padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmTableauTitre1 align=left style='margin:0cm;margin-bottom:.0001pt; text-align:left;page-break-after:avoid'>Critères</p>
</td>
<td width=133 valign=top style='width:99.65pt;border-top:solid windowtext 1.0pt;
border-left:none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmTableauTitre1 align=center style='margin:0cm;margin-bottom:.0001pt; text-align:center;page-break-after:avoid'>TCF</p>
</td>
<td width=133 valign=top style='width:99.65pt;border-top:solid windowtext 1.0pt;
border-left:none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmTableauTitre1 align=center style='margin:0cm;margin-bottom:.0001pt; text-align:center;page-break-after:avoid'>CF</p>
</td>
<td style='height:12.0pt;border:none' width=0 height=16></td>
</tr>
<tr style='height:24.0pt'>
<td width=397 valign=top style='width:297.4pt;border-top:none;border-left:
solid windowtext 1.0pt;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:24.0pt'>
<p class=AmmTableauTitre1> </p>
</td>
<td width=133 valign=top style='width:99.65pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:24.0pt'>
<p class=AmmTableauTitre1 align=center style='margin:0cm;margin-bottom:.0001pt; text-align:center;page-break-after:avoid'>n=221</p>
</td>
<td width=133 valign=top style='width:99.65pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:24.0pt'>
<p class=AmmTableauTitre1 align=center style='margin:0cm;margin-bottom:.0001pt; text-align:center;page-break-after:avoid'>n=224</p>
</td>
<td style='height:24.0pt;border:none' width=0 height=32></td>
</tr>
<tr>
<td width=397 valign=top style='width:297.4pt;border-top:none;border-left:
solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left;page-break-after:avoid'>Temps médian jusqu'à progression (mois)</p>
</td>
<td width=133 valign=top style='width:99.65pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center;page-break-after:avoid'>5,6</p>
</td>
<td width=133 valign=top style='width:99.65pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center;page-break-after:avoid'>3,7</p>
</td>
<td style='border:none' width=0><p class='AmmCorpsTexte'> </td>
</tr>
<tr style='height:12.0pt'>
<td width=397 valign=top style='width:297.4pt;border-top:none;border-left:
solid windowtext 1.0pt;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left;page-break-after:avoid'>(95 % IC)</p>
</td>
<td width=133 valign=top style='width:99.65pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center;page-break-after:avoid'>(4,86-5,91)</p>
</td>
<td width=133 valign=top style='width:99.65pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center;page-break-after:avoid'>(3,45-4,47)</p>
</td>
<td style='height:12.0pt;border:none' width=0 height=16></td>
</tr>
<tr>
<td width=397 valign=top style='width:297.4pt;border-top:none;border-left:
solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left;page-break-after:avoid'>Risque relatif</p>
</td>
<td width=266 colspan=2 valign=top style='width:199.3pt;border:none;
border-right:solid windowtext 1.0pt;padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center;page-break-after:avoid'>1,473</p>
</td>
<td style='border:none' width=0><p class='AmmCorpsTexte'> </td>
</tr>
<tr>
<td width=397 valign=top style='width:297.4pt;border-top:none;border-left:
solid windowtext 1.0pt;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left;page-break-after:avoid'>(95 % IC)</p>
</td>
<td width=266 colspan=2 valign=top style='width:199.3pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center;page-break-after:avoid'>(1,189-1,825)</p>
</td>
<td style='border:none' width=0><p class='AmmCorpsTexte'> </td>
</tr>
<tr>
<td width=397 valign=top style='width:297.4pt;border-top:none;border-left:
solid windowtext 1.0pt;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left;page-break-after:avoid'>* valeur de p</p>
</td>
<td width=266 colspan=2 valign=top style='width:199.3pt;border-top:none;
border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center;page-break-after:avoid'>0,0004</p>
</td>
<td style='border:none' width=0><p class='AmmCorpsTexte'> </td>
</tr>
<tr style='height:12.0pt'>
<td width=397 valign=top style='width:297.4pt;border-top:none;border-left:
solid windowtext 1.0pt;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left;page-break-after:avoid'>Survie médiane (mois)</p>
</td>
<td width=133 valign=top style='width:99.65pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center;page-break-after:avoid'>9,2</p>
</td>
<td width=133 valign=top style='width:99.65pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center;page-break-after:avoid'>8,6</p>
</td>
<td style='height:12.0pt;border:none' width=0 height=16></td>
</tr>
<tr style='height:12.0pt'>
<td width=397 valign=top style='width:297.4pt;border-top:none;border-left:
solid windowtext 1.0pt;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left;page-break-after:avoid'>(95 % IC)</p>
</td>
<td width=133 valign=top style='width:99.65pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center;page-break-after:avoid'>(8,38-10,58)</p>
</td>
<td width=133 valign=top style='width:99.65pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center;page-break-after:avoid'>(7,16-9,46)</p>
</td>
<td style='height:12.0pt;border:none' width=0 height=16></td>
</tr>
<tr style='height:12.0pt'>
<td width=397 valign=top style='width:297.4pt;border-top:none;border-left:
solid windowtext 1.0pt;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left;page-break-after:avoid'>Estimation à 2 ans (%)</p>
</td>
<td width=133 valign=top style='width:99.65pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center;page-break-after:avoid'>18,4</p>
</td>
<td width=133 valign=top style='width:99.65pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center;page-break-after:avoid'>8,8</p>
</td>
<td style='height:12.0pt;border:none' width=0 height=16></td>
</tr>
<tr>
<td width=397 valign=top style='width:297.4pt;border-top:none;border-left:
solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left;page-break-after:avoid'>Risque relatif</p>
</td>
<td width=266 colspan=2 valign=top style='width:199.3pt;border:none;
border-right:solid windowtext 1.0pt;padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center;page-break-after:avoid'>1,293</p>
</td>
<td style='border:none' width=0><p class='AmmCorpsTexte'> </td>
</tr>
<tr>
<td width=397 valign=top style='width:297.4pt;border-top:none;border-left:
solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left;page-break-after:avoid'>(95 % IC)</p>
</td>
<td width=266 colspan=2 valign=top style='width:199.3pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center;page-break-after:avoid'>(1,041-1,606)</p>
</td>
<td style='border:none' width=0><p class='AmmCorpsTexte'> </td>
</tr>
<tr>
<td width=397 valign=top style='width:297.4pt;border:solid windowtext 1.0pt;
border-top:none;padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left;page-break-after:avoid'>*valeur de p</p>
</td>
<td width=266 colspan=2 valign=top style='width:199.3pt;border-top:none;
border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center;page-break-after:avoid'>0,0201</p>
</td>
<td style='border:none' width=0><p class='AmmCorpsTexte'> </td>
</tr>
<tr>
<td width=397 valign=top style='width:297.4pt;border-top:none;border-left:
solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>Taux de réponse global (RC+RP) (%)</p>
</td>
<td width=133 valign=top style='width:99.65pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'>36,7</p>
</td>
<td width=133 valign=top style='width:99.65pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'>25,4</p>
</td>
<td style='border:none' width=0><p class='AmmCorpsTexte'> </td>
</tr>
<tr>
<td width=397 valign=top style='width:297.4pt;border:solid windowtext 1.0pt;
border-top:none;padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>valeur de p</p>
</td>
<td width=266 colspan=2 valign=top style='width:199.3pt;border-top:none;
border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'>0,0106</p>
</td>
<td style='border:none' width=0><p class='AmmCorpsTexte'> </td>
</tr>
<tr>
<td width=397 valign=top style='width:297.4pt;border:solid windowtext 1.0pt;
border-top:none;padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>Taux de progression de la maladie</p>
</td>
<td width=133 valign=top style='width:99.65pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'>16,7</p>
</td>
<td width=133 valign=top style='width:99.65pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'>25,9</p>
</td>
<td style='border:none' width=0><p class='AmmCorpsTexte'> </td>
</tr>
</thead>
</table>
</div>
<p class=AmmCorpsTexte><sup>* </sup><sub>test<span style='letter-spacing:-.25pt'> </span>log<span style='letter-spacing:-.15pt'> </span>rank<span style='letter-spacing:-.2pt'> </span>stratifié</sub></p>
<p class=AmmCorpsTexte>Des<span style='letter-spacing:-.4pt'> </span>anal<span style='letter-spacing:.1pt'>y</span>ses<span style='letter-spacing:-.15pt'> </span>en<span style='letter-spacing:-.1pt'> </span>sous<span style='letter-spacing:-.2pt'> </span>groupe<span style='letter-spacing:-.3pt'> </span>en<span style='letter-spacing:-.1pt'> </span>fonction<span style='letter-spacing:-.35pt'> </span>de<span style='letter-spacing:-.1pt'> </span>l<span style='letter-spacing:.05pt'>’</span>âge,<span style='letter-spacing:-.05pt'> </span>du<span style='letter-spacing:-.1pt'> </span>sexe<span style='letter-spacing:-.2pt'> </span>et de<span style='letter-spacing:-.1pt'> </span>la race<span style='letter-spacing: -.15pt'> </span>ethnique<span style='letter-spacing:-.35pt'> </span>étaient<span style='letter-spacing:.05pt'> </span>en<span style='letter-spacing:-.1pt'> </span>faveur<span style='letter-spacing:-.25pt'> </span>du<span style='letter-spacing:-.1pt'> </span>bras TCF par rapport au bras CF.</p>
<p class=AmmCorpsTexte>Une analyse actualisée de la survie réalisée avec un suivi médian de 41,6 mois a montré que la différence en faveur du bras TCF n’est alors plus statistiquement significative et que le bénéfice du bras TCF sur le bras CF se situe nettement entre le 18ème et le 30ème mois de suivi.</p>
<p class=AmmCorpsTexte>Globalement, la qualité de vie et le bénéfice clinique étaient en faveur d’une amélioration pour le bras TCF.</p>
<p class=AmmCorpsTexte>Le temps écoulé jusqu’à détérioration définitive de 5% de l’état de santé global déterminé par le questionnaire de qualité de vie (QLQ C30) (p = 0,0121) ainsi que le temps écoulé jusqu’à l’aggravation définitive de l’indice de<span style='letter-spacing:-.1pt'> </span>perfor<span style='letter-spacing:-.1pt'>m</span>ance<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span>Karnofski<span style='letter-spacing:-.3pt'> </span>(p<span style='letter-spacing:-.1pt'> </span>=<span style='letter-spacing: -.05pt'> </span>0,0088)<span style='letter-spacing:-.3pt'> </span>étaient<span style='letter-spacing:.05pt'> </span>plus<span style='letter-spacing:-.15pt'> </span>long<span style='letter-spacing:-.2pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>le bras<span style='letter-spacing:-.15pt'> </span>TCF<span style='letter-spacing: -.2pt'> </span>par<span style='letter-spacing:-.15pt'> </span>rapport<span style='letter-spacing:-.3pt'> </span>bras<span style='letter-spacing:-.15pt'> </span>CF.</p>
<p class=AmmCorpsTexte><i><u><sub>Cancers des Voies Aér<span style='letter-spacing: .05pt'>o</span>-digestives supérieures</sub></u></i></p>
<p class=AmmListePuces1 style='text-align:justify'><span style='font-family: Symbol'>·<span style='font:7.0pt "Times New Roman"'>                   </span></span>Chi<span style='letter-spacing:-.1pt'>m</span>iothérapie<span style='letter-spacing:-.1pt'> </span>d’induction<span style='letter-spacing: -.4pt'> </span>suivie<span style='letter-spacing:-.15pt'> </span>de<span style='letter-spacing:-.1pt'> </span>radiothérapie<span style='letter-spacing: -.5pt'> </span>(TAX323)</p>
<p class=AmmCorpsTexte>L<span style='letter-spacing:.05pt'>’</span>efficacité et la tolérance<span style='letter-spacing:-.35pt'> </span>du<span style='letter-spacing:-.1pt'> </span>docétaxel<span style='letter-spacing:-.4pt'> </span>en<span style='letter-spacing:-.1pt'> </span>tr<span style='letter-spacing: -.15pt'>a</span>ite<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.15pt'> </span>d<span style='letter-spacing:.05pt'>’</span>induction<span style='letter-spacing:-.05pt'> </span>des<span style='letter-spacing:-.15pt'> </span>patients<span style='letter-spacing:-.3pt'> </span>présentant<span style='letter-spacing: -.4pt'> </span>un<span style='letter-spacing:-.1pt'> </span>carcino<span style='letter-spacing:-.05pt'>m</span>e épider<span style='letter-spacing:-.05pt'>m</span><span style='letter-spacing:.05pt'>o</span>ïde<span style='letter-spacing:-.25pt'> </span>des<span style='letter-spacing:-.15pt'> </span>voies<span style='letter-spacing:-.2pt'> </span>aéro-digestives<span style='letter-spacing:-.6pt'> </span>supérieures<span style='letter-spacing: -.45pt'> </span><span style='letter-spacing:.05pt'>(</span>VADS)<span style='letter-spacing:-.05pt'> </span>ont<span style='letter-spacing:-.15pt'> </span>été évaluées<span style='letter-spacing:-.35pt'> </span>au<span style='letter-spacing: -.1pt'> </span>cours<span style='letter-spacing:-.2pt'> </span>d<span style='letter-spacing:.05pt'>’</span>une<span style='letter-spacing:-.05pt'> </span>étude<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span>phase III <span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing: .05pt'>u</span>lticentrique,<span style='letter-spacing:-.05pt'> </span>rando<span style='letter-spacing:-.1pt'>m</span>isée,<span style='letter-spacing:-.25pt'> </span>en<span style='letter-spacing:-.1pt'> </span>ouvert<span style='letter-spacing:-.25pt'> </span>(TAX<span style='letter-spacing:-.25pt'> </span>323).<span style='letter-spacing:-.2pt'> </span>Dans<span style='letter-spacing:-.2pt'> </span>cette<span style='letter-spacing:.05pt'> </span>étude,<span style='letter-spacing:-.25pt'> </span>358<span style='letter-spacing:-.15pt'> </span>patients<span style='letter-spacing:-.3pt'> </span>présentant<span style='letter-spacing: -.4pt'> </span>un carcino<span style='letter-spacing:-.05pt'>m</span>e épider<span style='letter-spacing:-.05pt'>m</span><span style='letter-spacing:.05pt'>o</span>ïde<span style='letter-spacing:-.25pt'> </span>des<span style='letter-spacing:-.15pt'> </span>VADS,<span style='letter-spacing:-.3pt'> </span>locale<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.25pt'> </span>avancé<span style='letter-spacing:-.3pt'> </span>et inopérable,<span style='letter-spacing:-.45pt'> </span>et un<span style='letter-spacing:-.1pt'> </span>état général<span style='letter-spacing: -.3pt'> </span>(échelle<span style='letter-spacing:-.3pt'> </span>OMS) de<span style='letter-spacing:-.1pt'> </span>0<span style='letter-spacing:-.05pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>1,<span style='letter-spacing:-.05pt'> </span>étaient<span style='letter-spacing:.05pt'> </span>rando<span style='letter-spacing:-.1pt'>m</span>isés<span style='letter-spacing:-.25pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>l<span style='letter-spacing:.05pt'>’</span>un<span style='letter-spacing:-.05pt'> d</span>es<span style='letter-spacing:-.05pt'> </span>deux<span style='letter-spacing:-.2pt'> </span>bras<span style='letter-spacing:-.15pt'> </span>de<span style='letter-spacing:-.1pt'> </span>traite<span style='letter-spacing:-.05pt'>m</span>ent.<span style='letter-spacing:-.3pt'> </span>Les<span style='letter-spacing:-.15pt'> </span>patients<span style='letter-spacing:-.3pt'> </span>du<span style='letter-spacing:-.1pt'> </span>bras<span style='letter-spacing: -.15pt'> </span>docétaxel<span style='letter-spacing:.05pt'> </span>ont<span style='letter-spacing:-.15pt'> </span>reçu<span style='letter-spacing:-.15pt'> </span>du<span style='letter-spacing:-.1pt'> </span>docétaxel<span style='letter-spacing:-.35pt'> </span>(T)<span style='letter-spacing:-.15pt'> </span>75 <span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.15pt'>m</span>²<sup> <span style='letter-spacing:.7pt'></span></sup>suivi<span style='letter-spacing:-.45pt'> </span>de<span style='letter-spacing:-.1pt'> </span>cisplatine<span style='letter-spacing:-.35pt'> </span>(P)<span style='letter-spacing:-.1pt'> </span>75<span style='letter-spacing:-.1pt'> m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.1pt'>m<sup>2</sup></span><sup> </sup>suivi<span style='letter-spacing:-.45pt'> </span>de<span style='letter-spacing:-.1pt'> </span>5-fluoro-uracile (F) 750<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing: -.1pt'>m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.1pt'>m<sup>2</sup></span>/jour<span style='letter-spacing: -.55pt'> </span>en<span style='letter-spacing:-.1pt'> </span>perfusion<span style='letter-spacing:-.4pt'> </span>continue pendant<span style='letter-spacing: -.3pt'> </span>5<span style='letter-spacing:-.05pt'> </span>jours.<span style='letter-spacing:-.2pt'> </span>Ce<span style='letter-spacing:-.1pt'> </span>sché<span style='letter-spacing:-.1pt'>m</span>a<span style='letter-spacing:-.2pt'> </span>était<span style='letter-spacing:.05pt'> </span>ad<span style='letter-spacing:-.1pt'>m</span>inistré<span style='letter-spacing:-.3pt'> </span>toutes<span style='letter-spacing:-.25pt'> </span>les<span style='letter-spacing:-.1pt'> </span>3<span style='letter-spacing: -.05pt'> </span>se<span style='letter-spacing:-.1pt'>m</span>aines à raison<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.1pt'> </span>4<span style='letter-spacing:-.05pt'> </span>c<span style='letter-spacing:.1pt'>y</span>cles<span style='letter-spacing:-.05pt'> </span>sous<span style='letter-spacing:-.2pt'> </span>réserve<span style='letter-spacing:-.3pt'> </span>qu<span style='letter-spacing:.05pt'>’</span>une<span style='letter-spacing:-.1pt'> </span>réponse au<span style='letter-spacing: -.1pt'> m</span><span style='letter-spacing:.05pt'>o</span>ins<span style='letter-spacing:-.1pt'> m</span>ineure<span style='letter-spacing:-.3pt'> </span>(&#8805;<span style='letter-spacing:-.05pt'> </span>25%<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span>réduction<span style='letter-spacing:-.35pt'> </span>de la<span style='letter-spacing:-.25pt'> </span>taille<span style='letter-spacing:.05pt'> </span>bidi<span style='letter-spacing:-.05pt'>m</span>ensionnelle<span style='letter-spacing: -.55pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la tu<span style='letter-spacing:-.1pt'>m</span>eur)<span style='letter-spacing:-.2pt'> </span>ait été obse<span style='letter-spacing:-.05pt'>r</span>vée<span style='letter-spacing: -.2pt'> </span>après<span style='letter-spacing:-.2pt'> </span>2<span style='letter-spacing:-.05pt'> </span>c<span style='letter-spacing:.1pt'>y</span>cles.<span style='letter-spacing:-.05pt'> </span>Les<span style='letter-spacing:-.15pt'> </span>patients<span style='letter-spacing:-.3pt'> </span>dont<span style='letter-spacing:-.2pt'> </span>la tu<span style='letter-spacing:-.1pt'>m</span>eur<span style='letter-spacing: -.15pt'> </span>n’a<span style='letter-spacing:-.15pt'> </span>pas progressé<span style='letter-spacing:-.4pt'> </span>à la fin<span style='letter-spacing:-.1pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la chi<span style='letter-spacing:-.05pt'>m</span>iothérapie<span style='letter-spacing: -.1pt'> </span>ont<span style='letter-spacing:-.15pt'> </span>débuté<span style='letter-spacing:-.25pt'> </span>entre<span style='letter-spacing:-.2pt'> </span>4<span style='letter-spacing:-.05pt'> </span>et 7<span style='letter-spacing:-.05pt'> </span>se<span style='letter-spacing:-.1pt'>m</span>aines<span style='letter-spacing:-.1pt'> </span>après<span style='letter-spacing:-.2pt'> </span>celle-ci<span style='letter-spacing:.05pt'> </span>une<span style='letter-spacing:-.15pt'> </span>radiothérapie<span style='letter-spacing:.05pt'> </span>(RT) d’une<span style='letter-spacing: -.25pt'> </span>durée<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span>7<span style='letter-spacing:-.05pt'> </span>se<span style='letter-spacing:-.1pt'>m</span>aines,<span style='letter-spacing:-.1pt'> </span>confor<span style='letter-spacing:-.1pt'>m</span>é<span style='letter-spacing:-.1pt'>m</span>ent<span style='letter-spacing:-.3pt'> </span>aux<span style='letter-spacing:-.1pt'> </span>reco<span style='letter-spacing:-.1pt'>mm</span>and<span style='letter-spacing:-.05pt'>a</span>tions<span style='letter-spacing:-.25pt'> </span>en<span style='letter-spacing:-.1pt'> </span>vigueur<span style='letter-spacing:-.3pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>les centres<span style='letter-spacing:-.3pt'> </span>participants (TPF/RT).<span style='letter-spacing:-.4pt'> </span>Les<span style='letter-spacing:-.15pt'> </span>patients<span style='letter-spacing:-.3pt'> </span>du<span style='letter-spacing:-.1pt'> </span>bras<span style='letter-spacing:-.15pt'> </span>co<span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>p</span>arateur<span style='letter-spacing:-.1pt'> </span>ont<span style='letter-spacing:-.15pt'> </span>reçu<span style='letter-spacing:-.15pt'> </span>du<span style='letter-spacing:-.1pt'> </span>cisplatine<span style='letter-spacing:-.35pt'> </span>(P)<span style='letter-spacing:-.1pt'> </span>100<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.1pt'>m<sup>2</sup></span><sup><span style='letter-spacing:.7pt'> </span></sup>suivi<span style='letter-spacing: -.45pt'> </span>de<span style='letter-spacing:-.1pt'> </span>5-fluoro-uracile(F) 1000<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing: -.1pt'>m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.1pt'>m</span>²/jour<span style='letter-spacing:-.55pt'> </span>en<span style='letter-spacing:-.1pt'> </span>perfusion<span style='letter-spacing:-.4pt'> </span>continue<span style='letter-spacing:-.3pt'> </span>pendant<span style='letter-spacing:-.3pt'> </span>5<span style='letter-spacing:-.05pt'> </span>jours.<span style='letter-spacing:-.2pt'> </span>Ce<span style='letter-spacing:-.1pt'> </span>sché<span style='letter-spacing: -.1pt'>m</span>a<span style='letter-spacing:-.2pt'> </span>était ad<span style='letter-spacing:-.1pt'>m</span>inistré<span style='letter-spacing:-.3pt'> </span>toutes<span style='letter-spacing:-.25pt'> </span>les<span style='letter-spacing:-.1pt'> </span>3<span style='letter-spacing:-.05pt'> </span>se<span style='letter-spacing:-.1pt'>m</span>aines<span style='letter-spacing:-.1pt'> </span>à raison de<span style='letter-spacing:-.1pt'> </span>4<span style='letter-spacing: -.05pt'> </span>c<span style='letter-spacing:.1pt'>y</span>cles<span style='letter-spacing:-.05pt'> </span>sous<span style='letter-spacing:-.2pt'> </span>réserve<span style='letter-spacing:-.3pt'> </span>qu<span style='letter-spacing:.05pt'>’</span>une<span style='letter-spacing:-.1pt'> </span>réponse<span style='letter-spacing:-.3pt'> </span>au<span style='letter-spacing:-.1pt'> m</span><span style='letter-spacing: .05pt'>o</span>ins <span style='letter-spacing:-.1pt'>m</span>ineure<span style='letter-spacing:-.3pt'> </span>(&#8805;<span style='letter-spacing:-.05pt'> </span>25<span style='letter-spacing:-.1pt'> </span>%<span style='letter-spacing: -.1pt'> </span>de<span style='letter-spacing:-.1pt'> </span>réduction<span style='letter-spacing:-.35pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la taille<span style='letter-spacing:.05pt'> </span>bidi<span style='letter-spacing: -.05pt'>m</span>ensionn<span style='letter-spacing:-.1pt'>e</span>lle<span style='letter-spacing:-.4pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la tu<span style='letter-spacing:-.1pt'>m</span>eur)<span style='letter-spacing: -.2pt'> </span>ait été observée<span style='letter-spacing:-.35pt'> </span>après<span style='letter-spacing:-.2pt'> </span>2<span style='letter-spacing:-.05pt'> </span>c<span style='letter-spacing:.1pt'>y</span>cles.</p>
<p class=AmmCorpsTexte>Les<span style='letter-spacing:-.4pt'> </span>patients<span style='letter-spacing:-.3pt'> </span>dont<span style='letter-spacing:-.2pt'> </span>la tu<span style='letter-spacing:-.1pt'>m</span>eur<span style='letter-spacing: -.15pt'> </span>n<span style='letter-spacing:.05pt'>’</span>a<span style='letter-spacing:-.05pt'> </span>pas<span style='letter-spacing:-.15pt'> </span>progressée<span style='letter-spacing:-.45pt'> </span>à la fin<span style='letter-spacing:-.1pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la chi<span style='letter-spacing:-.05pt'>m</span>iothérapie,<span style='letter-spacing: -.05pt'> </span>ont<span style='letter-spacing:-.15pt'> </span>débuté<span style='letter-spacing:-.25pt'> </span>entre<span style='letter-spacing:-.2pt'> </span>4<span style='letter-spacing:-.05pt'> </span>et 7<span style='letter-spacing:-.3pt'> </span>se<span style='letter-spacing:-.1pt'>m</span>aines<span style='letter-spacing:-.1pt'> </span>après<span style='letter-spacing:-.2pt'> </span>celle-ci, une<span style='letter-spacing: -.15pt'> </span>radiothérapie<span style='letter-spacing:-.55pt'> </span>(RT)<span style='letter-spacing:-.2pt'> </span>d’une<span style='letter-spacing:-.25pt'> </span>durée<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span>7<span style='letter-spacing:-.05pt'> </span>se<span style='letter-spacing:-.1pt'>m</span>aines,<span style='letter-spacing:-.1pt'> </span>confor<span style='letter-spacing:-.1pt'>m</span>é<span style='letter-spacing:-.1pt'>m</span>ent<span style='letter-spacing:-.4pt'> </span>aux reco<span style='letter-spacing:-.1pt'>mm</span>andations<span style='letter-spacing:-.35pt'> </span>en<span style='letter-spacing:-.1pt'> </span>vigueur<span style='letter-spacing:-.3pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>centres<span style='letter-spacing:-.3pt'> </span>participa<span style='letter-spacing:.05pt'>n</span>ts<span style='letter-spacing:-.35pt'> </span>(PF/RT).<span style='letter-spacing:-.35pt'> </span>La<span style='letter-spacing:-.1pt'> </span>radiothérapie<span style='letter-spacing:-.5pt'> </span>locorégionale<span style='letter-spacing: -.5pt'> </span>est<span style='letter-spacing:-.1pt'> </span>réalisée soit<span style='letter-spacing:-.15pt'> </span>par<span style='letter-spacing:-.15pt'> </span>radiothérapie<span style='letter-spacing:-.5pt'> </span>conventionnelle<span style='letter-spacing: -.6pt'> </span>(1,8<span style='letter-spacing:-.1pt'> </span>G<span style='letter-spacing:.1pt'>y</span>–2,0<span style='letter-spacing:-.05pt'> </span>Gy par<span style='letter-spacing:-.15pt'> </span>jour,<span style='letter-spacing: -.2pt'> </span>5<span style='letter-spacing:-.05pt'> </span>jours<span style='letter-spacing:-.2pt'> </span>par<span style='letter-spacing:-.15pt'> </span>se<span style='letter-spacing:-.1pt'>m</span>aine,<span style='letter-spacing:-.1pt'> </span>pour<span style='letter-spacing:-.2pt'> </span>une<span style='letter-spacing:-.15pt'> </span>dose totale<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing: -.1pt'> </span>66<span style='letter-spacing:-.1pt'> </span>à 70<span style='letter-spacing:-.1pt'> </span>G),<span style='letter-spacing:-.15pt'> </span>soit<span style='letter-spacing:-.15pt'> </span>par<span style='letter-spacing:-.15pt'> </span>radiothérapie<span style='letter-spacing:-.55pt'> </span>accélérée/h<span style='letter-spacing: .1pt'>y</span>perfractionnée<span style='letter-spacing:-.4pt'> </span>(2<span style='letter-spacing:-.1pt'> </span>fois<span style='letter-spacing:-.15pt'> </span>par<span style='letter-spacing:-.15pt'> </span>jour,<span style='letter-spacing:-.2pt'> </span>avec<span style='letter-spacing:-.2pt'> </span>un<span style='letter-spacing:-.1pt'> m</span>ini<span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>u</span>m<span style='letter-spacing:-.15pt'> </span>de<span style='letter-spacing:-.1pt'> </span>6<span style='letter-spacing:-.05pt'> </span>heures<span style='letter-spacing:-.25pt'> </span>entre<span style='letter-spacing:-.2pt'> </span>2 séances,<span style='letter-spacing:-.35pt'> </span>5<span style='letter-spacing:-.05pt'> </span>jours<span style='letter-spacing:-.2pt'> </span>par<span style='letter-spacing:-.15pt'> </span>se<span style='letter-spacing:-.1pt'>m</span>aine).<span style='letter-spacing:-.1pt'> </span>Un<span style='letter-spacing:-.1pt'> </span>total de<span style='letter-spacing:-.1pt'> </span>70<span style='letter-spacing:-.1pt'> </span>Gy était reco<span style='letter-spacing:-.1pt'>mm</span>andé<span style='letter-spacing:-.3pt'> </span>pour<span style='letter-spacing:-.2pt'> </span>la radiothérapie<span style='letter-spacing: -.5pt'> </span>accélérée<span style='letter-spacing:.05pt'> </span>et 74<span style='letter-spacing:-.1pt'> </span>Gy pour la radiothérapie<span style='letter-spacing:-.5pt'> </span>h<span style='letter-spacing:.1pt'>y</span>perfractionnée.</p>
<p class=AmmCorpsTexte>Une<span style='letter-spacing:-.45pt'> </span>chirurgie<span style='letter-spacing:-.35pt'> </span>était autorisée<span style='letter-spacing: -.35pt'> </span>après<span style='letter-spacing:-.2pt'> </span>la chi<span style='letter-spacing:-.05pt'>m</span>iothérapie,<span style='letter-spacing: -.1pt'> </span>avant<span style='letter-spacing:-.2pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>après<span style='letter-spacing:-.2pt'> </span>la radiothérapie.</p>
<p class=AmmCorpsTexte>Les<span style='letter-spacing:-.4pt'> </span>patients<span style='letter-spacing:-.3pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>le bras<span style='letter-spacing:-.15pt'> </span>TPF<span style='letter-spacing:-.15pt'> </span>ont<span style='letter-spacing:-.15pt'> </span>reçu<span style='letter-spacing:-.15pt'> </span>une prophylaxie antibiotique par ciprofloxacine 500 mg par voie orale 2 fois par jour pendant 10 jours, en commençant le 5ème jour de chaque cycle ou équivalent. La survie sans progression (SSP), critère principal de cette étude, a été significativement plus longue<span style='letter-spacing:-.25pt'> </span>dans le bras<span style='letter-spacing:-.15pt'> </span>TPF<span style='letter-spacing: -.15pt'> </span>par rapport<span style='letter-spacing:-.3pt'> </span>au<span style='letter-spacing:-.1pt'> </span>bras<span style='letter-spacing:-.15pt'> </span>PF,<span style='letter-spacing:-.15pt'> </span>p<span style='letter-spacing:-.05pt'> </span>=<span style='letter-spacing:-.05pt'> </span>0,0042<span style='letter-spacing:-.25pt'> </span>(<span style='letter-spacing:-.1pt'>m</span>édiane : 11,4<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>o</span>is<span style='letter-spacing:-.1pt'> </span>versus<span style='letter-spacing:-.25pt'> </span>8,3<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>o</span>is<span style='letter-spacing:-.1pt'> </span>respective<span style='letter-spacing: -.05pt'>m</span>ent) avec<span style='letter-spacing:-.2pt'> </span>un<span style='letter-spacing:-.1pt'> </span>suivi<span style='letter-spacing:-.2pt'> </span>global <span style='letter-spacing:-.1pt'>m</span>édian de<span style='letter-spacing: -.1pt'> </span>33,7<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>o</span>is.</p>
<p class=AmmCorpsTexte>La<span style='letter-spacing:-.35pt'> </span>survie<span style='letter-spacing:-.25pt'> </span>globale<span style='letter-spacing:-.3pt'> </span><span style='letter-spacing:-.1pt'>m</span>édiane<span style='letter-spacing: -.3pt'> </span>a été égale<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.2pt'> </span>significative<span style='letter-spacing: -.05pt'>m</span>ent<span style='letter-spacing:-.5pt'> </span>plus<span style='letter-spacing:-.15pt'> </span>longue<span style='letter-spacing:-.25pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>le bras<span style='letter-spacing:-.15pt'> </span>TPF<span style='letter-spacing:-.15pt'> </span>par<span style='letter-spacing:-.15pt'> </span>rapport<span style='letter-spacing:-.3pt'> </span>au bras<span style='letter-spacing:-.15pt'> </span>PF (18,6<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>o</span>is<span style='letter-spacing:-.1pt'> </span>versus<span style='letter-spacing:-.25pt'> </span>14,5<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>o</span>is<span style='letter-spacing:-.1pt'> </span>respective<span style='letter-spacing: -.1pt'>m</span>ent)<span style='letter-spacing:-.4pt'> </span>avec<span style='letter-spacing:-.2pt'> </span>une<span style='letter-spacing:-.15pt'> </span>réduction<span style='letter-spacing:-.4pt'> </span>relative<span style='letter-spacing:-.3pt'> </span>du<span style='letter-spacing:-.1pt'> </span>risque<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.1pt'> m</span><span style='letter-spacing:.05pt'>o</span>rtalité<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing:-.1pt'> </span>28%,<span style='letter-spacing: -.2pt'> </span>p<span style='letter-spacing:-.05pt'> </span>= 0,0128.<span style='letter-spacing:-.3pt'> </span>Les<span style='letter-spacing:-.15pt'> </span>résultats<span style='letter-spacing:-.35pt'> </span>d<span style='letter-spacing:.05pt'>’</span>eff<span style='letter-spacing:-.05pt'>i</span>cacité<span style='letter-spacing:-.05pt'> </span>sont<span style='letter-spacing:-.15pt'> </span>présentés<span style='letter-spacing:-.35pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>le tableau<span style='letter-spacing:-.3pt'> </span>ci-dessous.</p>
<p class=AmmCorpsTexte><u>Efficacité<span style='letter-spacing:.05pt'> </span>du docétaxel<span style='letter-spacing:.05pt'> </span>dans le traite<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.2pt'> </span>d<span style='letter-spacing:.05pt'>’</span>induction des patients présentant un carcino<span style='letter-spacing:-.05pt'>m</span>e</u> <u>épider<span style='letter-spacing:-.05pt'>m</span><span style='letter-spacing:.05pt'>o</span>ïde, locale<span style='letter-spacing:-.05pt'>m</span>ent avancé et inopérable, des voies aéro-digestives supérieures.</u> <u>(Anal<span style='letter-spacing: .1pt'>y</span>se en intention de traiter)</u></p>
<table class=AmmCorpsTexteTable border=1 cellspacing=0 cellpadding=0
style='margin-left:3.5pt;border-collapse:collapse;border:none'>
<thead>
<tr style='height:12.0pt'>
<td width=408 valign=top style='width:305.7pt;border:solid windowtext 1.0pt;
border-bottom:none black 1.0pt;padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmTableauTitre1 align=left style='margin:0cm;margin-bottom:.0001pt; text-align:left'>Critères d'évaluation</p>
</td>
<td width=149 valign=top style='width:112.1pt;border-top:solid windowtext 1.0pt;
border-left:none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmTableauTitre1 align=center style='margin:0cm;margin-bottom:.0001pt; text-align:center'>docétaxel + Cis +</p>
</td>
<td width=122 valign=top style='width:91.7pt;border-top:solid windowtext 1.0pt;
border-left:none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmTableauTitre1 align=center style='margin:0cm;margin-bottom:.0001pt; text-align:center'>Cis+5-FU</p>
</td>
<td style='height:12.0pt;border:none' width=0 height=16></td>
</tr>
<tr style='height:24.0pt'>
<td width=408 valign=top style='width:305.7pt;border-top:none;border-left:
solid windowtext 1.0pt;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:24.0pt'>
<p class=AmmTableauTitre1> </p>
</td>
<td width=149 valign=top style='width:112.1pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:24.0pt'>
<p class=AmmTableauTitre1 align=center style='margin:0cm;margin-bottom:.0001pt; text-align:center'>5-FU</p>
</td>
<td width=122 valign=top style='width:91.7pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:24.0pt'>
<p class=AmmTableauTitre1 align=center style='margin:0cm;margin-bottom:.0001pt; text-align:center'> </p>
</td>
<td style='height:24.0pt;border:none' width=0 height=32></td>
</tr>
<tr style='height:24.0pt'>
<td width=408 valign=top style='width:305.7pt;border-top:none;border-left:
solid windowtext 1.0pt;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:24.0pt'>
<p class=AmmTableauTitre1> </p>
</td>
<td width=149 valign=top style='width:112.1pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:24.0pt'>
<p class=AmmTableauTitre1 align=center style='margin:0cm;margin-bottom:.0001pt; text-align:center'>n=177</p>
</td>
<td width=122 valign=top style='width:91.7pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:24.0pt'>
<p class=AmmTableauTitre1 align=center style='margin:0cm;margin-bottom:.0001pt; text-align:center'>n=181</p>
</td>
<td style='height:24.0pt;border:none' width=0 height=32></td>
</tr>
<tr style='height:12.0pt'>
<td width=408 valign=top style='width:305.7pt;border-top:none;border-left:
solid windowtext 1.0pt;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>Médiane de survie sans progression (mois)</p>
</td>
<td width=149 valign=top style='width:112.1pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'>11,4</p>
</td>
<td width=122 valign=top style='width:91.7pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'>8,3</p>
</td>
<td style='height:12.0pt;border:none' width=0 height=16></td>
</tr>
<tr style='height:12.0pt'>
<td width=408 valign=top style='width:305.7pt;border-top:none;border-left:
solid windowtext 1.0pt;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>(95 %CI)</p>
</td>
<td width=149 valign=top style='width:112.1pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'>(10,1-14,0)</p>
</td>
<td width=122 valign=top style='width:91.7pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'>(7,4-9,1)</p>
</td>
<td style='height:12.0pt;border:none' width=0 height=16></td>
</tr>
<tr>
<td width=408 valign=top style='width:305.7pt;border-top:none;border-left:
solid windowtext 1.0pt;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>Risque relatif ajusté</p>
</td>
<td width=272 colspan=2 valign=top style='width:203.8pt;border:none;
border-right:solid windowtext 1.0pt;padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'>0,70</p>
</td>
<td style='border:none' width=0><p class='AmmCorpsTexte'> </td>
</tr>
<tr>
<td width=408 valign=top style='width:305.7pt;border-top:none;border-left:
solid windowtext 1.0pt;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>(IC 95 %)</p>
</td>
<td width=272 colspan=2 valign=top style='width:203.8pt;border:none;
border-right:solid windowtext 1.0pt;padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'>(0,55-0,89)</p>
</td>
<td style='border:none' width=0><p class='AmmCorpsTexte'> </td>
</tr>
<tr>
<td width=408 valign=top style='width:305.7pt;border-top:none;border-left:
solid windowtext 1.0pt;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>*valeur de p</p>
</td>
<td width=272 colspan=2 valign=top style='width:203.8pt;border-top:none;
border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'>0,0042</p>
</td>
<td style='border:none' width=0><p class='AmmCorpsTexte'> </td>
</tr>
<tr style='height:12.0pt'>
<td width=408 valign=top style='width:305.7pt;border-top:none;border-left:
solid windowtext 1.0pt;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>Médiane de survie (mois)</p>
</td>
<td width=149 valign=top style='width:112.1pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'>18,6</p>
</td>
<td width=122 valign=top style='width:91.7pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'>14,5</p>
</td>
<td style='height:12.0pt;border:none' width=0 height=16></td>
</tr>
<tr style='height:12.0pt'>
<td width=408 valign=top style='width:305.7pt;border-top:none;border-left:
solid windowtext 1.0pt;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>(95 %CI)</p>
</td>
<td width=149 valign=top style='width:112.1pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'>(15,7-24,0)</p>
</td>
<td width=122 valign=top style='width:91.7pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'>(11,6-18,7)</p>
</td>
<td style='height:12.0pt;border:none' width=0 height=16></td>
</tr>
<tr>
<td width=408 valign=top style='width:305.7pt;border-top:none;border-left:
solid windowtext 1.0pt;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>Risque relatif</p>
</td>
<td width=272 colspan=2 valign=top style='width:203.8pt;border:none;
border-right:solid windowtext 1.0pt;padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'>0,72</p>
</td>
<td style='border:none' width=0><p class='AmmCorpsTexte'> </td>
</tr>
<tr>
<td width=408 valign=top style='width:305.7pt;border-top:none;border-left:
solid windowtext 1.0pt;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>(95 %CI)</p>
</td>
<td width=272 colspan=2 valign=top style='width:203.8pt;border:none;
border-right:solid windowtext 1.0pt;padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'>(0,56-0,93)</p>
</td>
<td style='border:none' width=0><p class='AmmCorpsTexte'> </td>
</tr>
<tr>
<td width=408 valign=top style='width:305.7pt;border-top:none;border-left:
solid windowtext 1.0pt;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>**valeur de p</p>
</td>
<td width=272 colspan=2 valign=top style='width:203.8pt;border-top:none;
border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'>0,0128</p>
</td>
<td style='border:none' width=0><p class='AmmCorpsTexte'> </td>
</tr>
<tr style='height:12.0pt'>
<td width=408 valign=top style='width:305.7pt;border-top:none;border-left:
solid windowtext 1.0pt;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>Réponse objective à la chimiothérapie (%)</p>
</td>
<td width=149 valign=top style='width:112.1pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'>67,8</p>
</td>
<td width=122 valign=top style='width:91.7pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'>53,6</p>
</td>
<td style='height:12.0pt;border:none' width=0 height=16></td>
</tr>
<tr style='height:12.0pt'>
<td width=408 valign=top style='width:305.7pt;border-top:none;border-left:
solid windowtext 1.0pt;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>(IC 95 %)</p>
</td>
<td width=149 valign=top style='width:112.1pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'>(60,4-74,6)</p>
</td>
<td width=122 valign=top style='width:91.7pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'>(46,0-61,0)</p>
</td>
<td style='height:12.0pt;border:none' width=0 height=16></td>
</tr>
<tr>
<td width=408 valign=top style='width:305.7pt;border-top:none;border-left:
solid windowtext 1.0pt;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>***valeur de p</p>
</td>
<td width=272 colspan=2 valign=top style='width:203.8pt;border-top:none;
border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'>0,006</p>
</td>
<td style='border:none' width=0><p class='AmmCorpsTexte'> </td>
</tr>
<tr style='height:12.0pt'>
<td width=408 valign=top style='width:305.7pt;border-top:none;border-left:
solid windowtext 1.0pt;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>Réponse objective au traitement</p>
</td>
<td width=149 valign=top style='width:112.1pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'>72,3</p>
</td>
<td width=122 valign=top style='width:91.7pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'>58,6</p>
</td>
<td style='height:12.0pt;border:none' width=0 height=16></td>
</tr>
<tr style='height:12.0pt'>
<td width=408 valign=top style='width:305.7pt;border-top:none;border-left:
solid windowtext 1.0pt;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>[chimiothérapie +/- radiothérapie] (%)</p>
</td>
<td width=149 valign=top style='width:112.1pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'>(65,1-78,8)</p>
</td>
<td width=122 valign=top style='width:91.7pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'>(51,0-65,8)</p>
</td>
<td style='height:12.0pt;border:none' width=0 height=16></td>
</tr>
<tr>
<td width=408 valign=top style='width:305.7pt;border-top:none;border-left:
solid windowtext 1.0pt;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>(IC 95 %)</p>
</td>
<td width=272 colspan=2 valign=top style='width:203.8pt;border:none;
border-right:solid windowtext 1.0pt;padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'> </p>
</td>
<td style='border:none' width=0><p class='AmmCorpsTexte'> </td>
</tr>
<tr>
<td width=408 valign=top style='width:305.7pt;border-top:none;border-left:
solid windowtext 1.0pt;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>***valeur de p</p>
</td>
<td width=272 colspan=2 valign=top style='width:203.8pt;border-top:none;
border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'>0,006</p>
</td>
<td style='border:none' width=0><p class='AmmCorpsTexte'> </td>
</tr>
<tr style='height:12.0pt'>
<td width=408 valign=top style='width:305.7pt;border-top:none;border-left:
solid windowtext 1.0pt;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte style='margin-bottom:0cm;margin-bottom:.0001pt'>Durée médiane de réponse au traitement</p>
</td>
<td width=149 valign=top style='width:112.1pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'>n=128</p>
</td>
<td width=122 valign=top style='width:91.7pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'>n=106</p>
</td>
<td style='height:12.0pt;border:none' width=0 height=16></td>
</tr>
<tr style='height:12.0pt'>
<td width=408 valign=top style='width:305.7pt;border-top:none;border-left:
solid windowtext 1.0pt;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>[chimiothérapie +/- radiothérapie (mois)]</p>
</td>
<td width=149 valign=top style='width:112.1pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'>15,7</p>
</td>
<td width=122 valign=top style='width:91.7pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'>11,7</p>
</td>
<td style='height:12.0pt;border:none' width=0 height=16></td>
</tr>
<tr style='height:12.0pt'>
<td width=408 valign=top style='width:305.7pt;border-top:none;border-left:
solid windowtext 1.0pt;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>(IC 95 %)</p>
</td>
<td width=149 valign=top style='width:112.1pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'>(13,4-24,6)</p>
</td>
<td width=122 valign=top style='width:91.7pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'>(10,2-17,4)</p>
</td>
<td style='height:12.0pt;border:none' width=0 height=16></td>
</tr>
<tr>
<td width=408 valign=top style='width:305.7pt;border-top:none;border-left:
solid windowtext 1.0pt;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>Risque relatif</p>
</td>
<td width=272 colspan=2 valign=top style='width:203.8pt;border:none;
border-right:solid windowtext 1.0pt;padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'>0,72</p>
</td>
<td style='border:none' width=0><p class='AmmCorpsTexte'> </td>
</tr>
<tr>
<td width=408 valign=top style='width:305.7pt;border-top:none;border-left:
solid windowtext 1.0pt;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>(IC 95 %)</p>
</td>
<td width=272 colspan=2 valign=top style='width:203.8pt;border:none;
border-right:solid windowtext 1.0pt;padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'>(0,52-0,99)</p>
</td>
<td style='border:none' width=0><p class='AmmCorpsTexte'> </td>
</tr>
<tr>
<td width=408 valign=top style='width:305.7pt;border:solid windowtext 1.0pt;
border-top:none;padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>**valeur de p</p>
</td>
<td width=272 colspan=2 valign=top style='width:203.8pt;border-top:none;
border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'>0,0457</p>
</td>
<td style='border:none' width=0><p class='AmmCorpsTexte'> </td>
</tr>
</thead>
</table>
<p class=AmmCorpsTexte style='margin-bottom:0cm;margin-bottom:.0001pt'>Un<span style='letter-spacing:-.4pt'> </span>risque<span style='letter-spacing:-.25pt'> </span>relatif<span style='letter-spacing:-.25pt'> </span>inférieur<span style='letter-spacing:-.35pt'> </span>à 1<span style='letter-spacing:-.05pt'> </span>est<span style='letter-spacing:-.1pt'> </span>en<span style='letter-spacing:-.1pt'> </span>faveur<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.1pt'> </span>docétaxel+cisplatine+5-FU</p>
<p class=AmmCorpsTexte style='margin-bottom:0cm;margin-bottom:.0001pt'>*<span style='letter-spacing:-.3pt'> </span>Modèle<span style='letter-spacing:-.3pt'> </span>de<span style='letter-spacing:-.1pt'> </span>Cox<span style='letter-spacing:-.15pt'> </span>(Ajuste<span style='letter-spacing:-.1pt'>m</span>ent<span style='letter-spacing:-.3pt'> </span>sur<span style='letter-spacing:-.1pt'> </span>le Perfor<span style='letter-spacing:-.1pt'>m</span>ance<span style='letter-spacing:-.25pt'> </span>Status<span style='letter-spacing:-.25pt'> </span>(échelle<span style='letter-spacing:-.3pt'> </span>OMS),<span style='letter-spacing:-.25pt'> </span>la localisation<span style='letter-spacing: -.4pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la tu<span style='letter-spacing:-.1pt'>m</span>eur pri<span style='letter-spacing:-.1pt'>m</span>itive<span style='letter-spacing:-.1pt'> </span>et le stade<span style='letter-spacing: -.2pt'> </span>clinique<span style='letter-spacing:-.3pt'> </span>T<span style='letter-spacing:-.05pt'> </span>et N)</p>
<p class=AmmCorpsTexte style='margin-bottom:0cm;margin-bottom:.0001pt'><span lang=EN-GB>**<span style='letter-spacing:-.35pt'> </span>Test<span style='letter-spacing:-.1pt'> </span>Log rank</span></p>
<p class=AmmCorpsTexte><span lang=EN-GB>***<span style='letter-spacing:-.4pt'> </span>Test<span style='letter-spacing:-.1pt'> </span>du<span style='letter-spacing:-.1pt'> </span>Chi²</span></p>
<p class=AmmCorpsTexte><i>Paramètres<span style='letter-spacing:-.75pt'> </span>de<span style='letter-spacing:-.1pt'> </span>qualité<span style='letter-spacing:-.3pt'> </span>de<span style='letter-spacing:-.1pt'> </span>vie</i></p>
<p class=AmmCorpsTexte>Les<span style='letter-spacing:-.4pt'> </span>patients<span style='letter-spacing:-.3pt'> </span>traités<span style='letter-spacing:-.25pt'> </span>par<span style='letter-spacing:-.15pt'> </span>le TPF<span style='letter-spacing:-.15pt'> </span>ont<span style='letter-spacing:-.15pt'> </span>présenté<span style='letter-spacing:-.35pt'> </span>significati<span style='letter-spacing: .05pt'>v</span>e<span style='letter-spacing:-.1pt'>m</span>ent<span style='letter-spacing:-.4pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>o</span>ins<span style='letter-spacing:-.1pt'> </span>de<span style='letter-spacing:-.1pt'> </span>détérioration<span style='letter-spacing: -.45pt'> </span>de<span style='letter-spacing:-.1pt'> </span>leur<span style='letter-spacing:-.15pt'> </span>état de<span style='letter-spacing:-.1pt'> </span>santé général<span style='letter-spacing:-.3pt'> </span>par<span style='letter-spacing:-.15pt'> </span>rapport<span style='letter-spacing:-.3pt'> </span>à ceux<span style='letter-spacing:-.2pt'> </span>traités<span style='letter-spacing:-.25pt'> </span>par<span style='letter-spacing:-.15pt'> </span>PF<span style='letter-spacing:-.1pt'> </span>(p<span style='letter-spacing:-.1pt'> </span>=<span style='letter-spacing:-.05pt'> </span>0,01,<span style='letter-spacing:-.2pt'> </span>échelle<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.1pt'> </span>l’EORTC<span style='letter-spacing:-.4pt'> </span>QLQ<span style='letter-spacing:-.2pt'> </span>C30).</p>
<p class=AmmCorpsTexte><i>Paramètres<span style='letter-spacing:-.75pt'> </span>de<span style='letter-spacing:-.1pt'> </span>bénéfices<span style='letter-spacing:-.35pt'> </span>cliniques</i></p>
<p class=AmmCorpsTexte>Les<span style='letter-spacing:-.4pt'> </span>para<span style='letter-spacing:-.1pt'>m</span>ètres<span style='letter-spacing:-.3pt'> </span>de<span style='letter-spacing:-.1pt'> </span>bénéfices<span style='letter-spacing:-.4pt'> </span>cliniques<span style='letter-spacing:-.35pt'> </span>de<span style='letter-spacing:-.1pt'> </span>l<span style='letter-spacing:.05pt'>’</span>échelle<span style='letter-spacing:-.05pt'> </span>d<span style='letter-spacing:.05pt'>’</span>évaluation de<span style='letter-spacing:-.1pt'> </span>l<span style='letter-spacing:.05pt'>’</span>état ph<span style='letter-spacing:.1pt'>y</span>sique<span style='letter-spacing: -.1pt'> </span>PSS<span style='letter-spacing:-.15pt'> </span>HN,<span style='letter-spacing:-.15pt'> </span>spécifique des<span style='letter-spacing: -.4pt'> </span>cancers<span style='letter-spacing:-.3pt'> </span>des<span style='letter-spacing:-.15pt'> </span>voies<span style='letter-spacing:-.2pt'> </span>aéro-digestives<span style='letter-spacing:-.6pt'> </span><span style='letter-spacing:.05pt'>s</span>upérieures<span style='letter-spacing:-.05pt'> </span>et <span style='letter-spacing:-.1pt'>m</span>esurant<span style='letter-spacing:-.1pt'> </span>l’intelligibilité<span style='letter-spacing: -.4pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la voix,<span style='letter-spacing:-.2pt'> </span>la capacité<span style='letter-spacing: -.3pt'> </span>de<span style='letter-spacing:-.1pt'> m</span>anger<span style='letter-spacing:-.2pt'> </span>en public<span style='letter-spacing:-.25pt'> </span>et à s’ali<span style='letter-spacing:-.05pt'>m</span>enter<span style='letter-spacing:-.15pt'> </span>nor<span style='letter-spacing:-.1pt'>m</span>ale<span style='letter-spacing:-.05pt'>m</span>ent,<span style='letter-spacing:2.25pt'> </span>étaient<span style='letter-spacing:.05pt'> </span>significative<span style='letter-spacing: -.05pt'>m</span>ent<span style='letter-spacing:-.5pt'> </span>en<span style='letter-spacing:-.1pt'> </span>faveur<span style='letter-spacing:-.25pt'> </span>du<span style='letter-spacing:-.1pt'> </span>bras<span style='letter-spacing: -.15pt'> </span>TPF<span style='letter-spacing:-.15pt'> </span>par<span style='letter-spacing:-.15pt'> </span>rapport au<span style='letter-spacing: -.1pt'> </span>bras<span style='letter-spacing:-.15pt'> </span>PF.</p>
<p class=AmmCorpsTexte>Le<span style='letter-spacing:-.35pt'> </span>te<span style='letter-spacing:-.05pt'>m</span><span style='letter-spacing:.05pt'>p</span>s<span style='letter-spacing:-.05pt'> </span><span style='letter-spacing:-.1pt'>m</span>édian<span style='letter-spacing:2.3pt'> </span>avant<span style='letter-spacing:-.2pt'> </span>détérioration<span style='letter-spacing:-.45pt'> </span>de<span style='letter-spacing:-.1pt'> </span>l’état<span style='letter-spacing:.05pt'> </span>g<span style='letter-spacing:-.1pt'>é</span>néral<span style='letter-spacing:-.05pt'> </span>(échelle<span style='letter-spacing:-.25pt'> </span>OMS)<span style='letter-spacing:-.25pt'> </span>était significative<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.5pt'> </span>plus<span style='letter-spacing:-.15pt'> </span>long<span style='letter-spacing:-.2pt'> </span>dans le bras<span style='letter-spacing:-.15pt'> </span>TPF<span style='letter-spacing: -.15pt'> </span>par<span style='letter-spacing:-.15pt'> </span>rapport<span style='letter-spacing:-.3pt'> </span>au<span style='letter-spacing:-.1pt'> </span>bras<span style='letter-spacing:-.15pt'> </span>PF.<span style='letter-spacing:-.15pt'> </span>Le<span style='letter-spacing:-.1pt'> </span>score<span style='letter-spacing:-.2pt'> </span>d’intensité<span style='letter-spacing:-.4pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la douleur<span style='letter-spacing:-.3pt'> </span>était a<span style='letter-spacing:-.1pt'>m</span>élioré<span style='letter-spacing:-.05pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>deux<span style='letter-spacing:-.2pt'> </span>bras, ce qui <span style='letter-spacing:-.1pt'>m</span>ontre une<span style='letter-spacing:-.15pt'> </span>prise<span style='letter-spacing:-.2pt'> </span>en<span style='letter-spacing:-.1pt'> </span>charge<span style='letter-spacing:-.25pt'> </span>adéquate<span style='letter-spacing:-.3pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la douleur.</p>
<p class=AmmListePuces1 style='text-align:justify;page-break-after:avoid'><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>                   </span></span>Chi<span style='letter-spacing:-.1pt'>m</span>iothérapie<span style='letter-spacing:-.1pt'> </span>d’induction<span style='letter-spacing: -.4pt'> </span>suivie<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.1pt'> </span>chi<span style='letter-spacing:-.05pt'>m</span>io radiothérapie<span style='letter-spacing:-.05pt'> </span>(TAX324)</p>
<p class=AmmCorpsTexte>L<span style='letter-spacing: .05pt'>’</span>efficacité et la tolérance<span style='letter-spacing:-.35pt'> </span>du<span style='letter-spacing:-.1pt'> </span>docétaxel<span style='letter-spacing:-.4pt'> </span>en<span style='letter-spacing:-.1pt'> </span>tr<span style='letter-spacing: -.15pt'>a</span>ite<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.15pt'> </span>d<span style='letter-spacing:.05pt'>’</span>induction<span style='letter-spacing:-.05pt'> </span>des<span style='letter-spacing:-.15pt'> </span>patients<span style='letter-spacing:-.3pt'> </span>présentant<span style='letter-spacing: -.4pt'> </span>un<span style='letter-spacing:-.1pt'> </span>carcino<span style='letter-spacing:-.05pt'>m</span>e épider<span style='letter-spacing:-.05pt'>m</span><span style='letter-spacing:.05pt'>o</span>ïde<span style='letter-spacing:-.25pt'> </span>locale<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.25pt'> </span>avancé<span style='letter-spacing:-.3pt'> </span>des<span style='letter-spacing:-.15pt'> </span>voies<span style='letter-spacing:-.2pt'> </span>aérodigestives<span style='letter-spacing: -.55pt'> </span>supérieures<span style='letter-spacing:-.45pt'> </span>(VADS)<span style='letter-spacing:-.35pt'> </span>ont<span style='letter-spacing:-.15pt'> </span>été évaluées<span style='letter-spacing:-.35pt'> </span>au cours<span style='letter-spacing:-.5pt'> </span>d<span style='letter-spacing:.05pt'>’</span>une<span style='letter-spacing:-.05pt'> </span>étude<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span>phase<span style='letter-spacing:-.25pt'> </span>III<span style='letter-spacing:-.1pt'> m</span><span style='letter-spacing:.05pt'>u</span>lticentrique,<span style='letter-spacing:-.05pt'> </span>rando<span style='letter-spacing:-.15pt'>m</span>isée,<span style='letter-spacing:-.25pt'> </span>en<span style='letter-spacing:-.1pt'> </span>ouvert<span style='letter-spacing:-.25pt'> </span>(TAX324).<span style='letter-spacing: -.45pt'> </span>Dans<span style='letter-spacing:-.2pt'> </span>cette<span style='letter-spacing:.05pt'> </span>étude,<span style='letter-spacing:-.25pt'> </span>501<span style='letter-spacing:-.15pt'> </span>patients présentant<span style='letter-spacing:-.4pt'> </span>un<span style='letter-spacing:-.1pt'> </span>carcino<span style='letter-spacing:-.05pt'>m</span>e<span style='letter-spacing:-.3pt'> </span>épider<span style='letter-spacing:-.05pt'>m</span><span style='letter-spacing:.05pt'>o</span>ïde<span style='letter-spacing:-.25pt'> </span>locale<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.25pt'> </span>avancé<span style='letter-spacing:-.3pt'> </span>des<span style='letter-spacing:-.15pt'> </span>VADS<span style='letter-spacing:-.25pt'> </span>et un<span style='letter-spacing:-.1pt'> </span>état général<span style='letter-spacing:-.3pt'> </span>(échelle<span style='letter-spacing:-.3pt'> </span>OMS) de<span style='letter-spacing:-.1pt'> </span>0<span style='letter-spacing:-.05pt'> </span>ou<span style='letter-spacing: -.1pt'> </span>1, étaient<span style='letter-spacing:.05pt'> </span>rando<span style='letter-spacing:-.1pt'>m</span>isés<span style='letter-spacing:-.25pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>l<span style='letter-spacing:.05pt'>’</span>un<span style='letter-spacing:-.05pt'> </span>des<span style='letter-spacing:-.2pt'> </span>deux<span style='letter-spacing:-.2pt'> </span>bras<span style='letter-spacing:-.15pt'> </span>de<span style='letter-spacing:-.1pt'> </span>traite<span style='letter-spacing:-.05pt'>m</span>ent.<span style='letter-spacing:-.3pt'> </span>La<span style='letter-spacing:-.1pt'> </span>population<span style='letter-spacing:-.4pt'> </span>de<span style='letter-spacing:-.1pt'> </span>l<span style='letter-spacing:.05pt'>’</span>étude<span style='letter-spacing:-.05pt'> </span>incluait<span style='letter-spacing:.05pt'> </span>des<span style='letter-spacing:-.15pt'> </span>patients<span style='letter-spacing:-.3pt'> </span>dont<span style='letter-spacing:-.2pt'> </span>la tu<span style='letter-spacing:-.1pt'>m</span>eur<span style='letter-spacing: -.15pt'> </span>était<span style='letter-spacing:.05pt'> </span>techn<span style='letter-spacing:-.05pt'>i</span>que<span style='letter-spacing:-.1pt'>m</span>ent<span style='letter-spacing:-.3pt'> </span>non<span style='letter-spacing:-.15pt'> </span>résécable,<span style='letter-spacing:-.4pt'> </span>des<span style='letter-spacing:-.15pt'> </span>patients<span style='letter-spacing:-.3pt'> </span>avec<span style='letter-spacing:-.2pt'> </span>une<span style='letter-spacing:-.15pt'> </span>faible<span style='letter-spacing:-.25pt'> </span>probabilité de<span style='letter-spacing:-.1pt'> </span>curabilité<span style='letter-spacing:-.35pt'> </span>chirurgicale<span style='letter-spacing: -.45pt'> </span>et des patients<span style='letter-spacing:-.3pt'> </span>destinés<span style='letter-spacing:-.3pt'> </span>à une<span style='letter-spacing:-.15pt'> </span>préservation<span style='letter-spacing:-.5pt'> </span>d<span style='letter-spacing:.05pt'>’</span>organe.<span style='letter-spacing:-.05pt'> </span>L<span style='letter-spacing:.05pt'>’</span>évaluation<span style='letter-spacing:-.05pt'> </span>de l<span style='letter-spacing:.05pt'>’</span>efficacité<span style='letter-spacing:-.05pt'> </span>et de<span style='letter-spacing:-.1pt'> </span>la tolérance<span style='letter-spacing:-.35pt'> </span>s<span style='letter-spacing: .05pt'>’</span>est<span style='letter-spacing:-.05pt'> </span>intéressée <span style='letter-spacing:.05pt'></span>e<span style='letter-spacing:-.1pt'>x</span>clusive<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.05pt'> </span>aux<span style='letter-spacing:-.15pt'> </span>critères<span style='letter-spacing:-.3pt'> </span>de<span style='letter-spacing:-.1pt'> </span>survie<span style='letter-spacing:-.25pt'> </span>; le succès<span style='letter-spacing: -.25pt'> </span>d<span style='letter-spacing:.05pt'>’</span>une<span style='letter-spacing:-.05pt'> </span>préservation d<span style='letter-spacing: .05pt'>’</span>organe<span style='letter-spacing:-.05pt'> </span>n<span style='letter-spacing:.05pt'>’</span>a<span style='letter-spacing:-.05pt'> </span>pas<span style='letter-spacing:-.15pt'> </span>été for<span style='letter-spacing:-.1pt'>m</span>elle<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.2pt'> </span>évalué.<span style='letter-spacing:-.3pt'> </span>Les patients<span style='letter-spacing: -.3pt'> </span>du<span style='letter-spacing:-.1pt'> </span>bras<span style='letter-spacing:-.15pt'> </span>docétaxel<span style='letter-spacing: -.35pt'> </span>ont<span style='letter-spacing:-.15pt'> </span>reçu<span style='letter-spacing:-.15pt'> </span>du<span style='letter-spacing:-.1pt'> </span>docétaxel<span style='letter-spacing:.05pt'> </span>(T)<span style='letter-spacing:-.15pt'> </span>75<span style='letter-spacing:-.1pt'> m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.1pt'>m<sup>2</sup></span><sup> </sup>en<span style='letter-spacing:-.35pt'> </span>perfusion<span style='letter-spacing: -.4pt'> </span>intraveineuse<span style='letter-spacing:-.5pt'> </span>à J1<span style='letter-spacing:-.1pt'> </span>suivi<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span>cisplatine<span style='letter-spacing: .05pt'> </span>(P)<span style='letter-spacing:-.1pt'> </span>100<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.1pt'>m<sup>2</sup></span><sup> <span style='letter-spacing:.7pt'></span></sup>ad<span style='letter-spacing: -.1pt'>m</span>inistré en<span style='letter-spacing:-.35pt'> </span>perfusion<span style='letter-spacing:-.4pt'> </span>intraveineuse<span style='letter-spacing: -.5pt'> </span>d’une<span style='letter-spacing:-.25pt'> </span>durée<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span>30<span style='letter-spacing:-.1pt'> m</span>inutes<span style='letter-spacing:-.3pt'> </span>à 3<span style='letter-spacing:-.05pt'> </span>heures,<span style='letter-spacing:-.3pt'> </span>suivi<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span>5-fluoro-uracile(F)<span style='letter-spacing: -.1pt'> </span>1000<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.1pt'>m<sup>2</sup></span>/jour en<span style='letter-spacing:-.1pt'> </span>perfusion<span style='letter-spacing:-.4pt'> </span>intraveineuse<span style='letter-spacing:-.5pt'> </span>continue<span style='letter-spacing:-.35pt'> </span>de<span style='letter-spacing:-.1pt'> </span>J1<span style='letter-spacing:-.1pt'> </span>à J4.<span style='letter-spacing:-.1pt'> </span>Les<span style='letter-spacing:-.15pt'> </span>c<span style='letter-spacing:.1pt'>y</span>cles<span style='letter-spacing:-.05pt'> </span>étaient répétés<span style='letter-spacing: -.3pt'> </span>toutes<span style='letter-spacing:-.25pt'> </span>les<span style='letter-spacing:-.1pt'> </span>3<span style='letter-spacing:-.05pt'> </span>se<span style='letter-spacing:-.1pt'>m</span>aines à raison<span style='letter-spacing: -.25pt'> </span>de<span style='letter-spacing:-.1pt'> </span>3 c<span style='letter-spacing:.1pt'>y</span>cles.<span style='letter-spacing:-.05pt'> </span>Tous<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>patients<span style='letter-spacing:-.3pt'> </span>n<span style='letter-spacing:.05pt'>’</span>a<span style='letter-spacing:.1pt'>y</span>ant<span style='letter-spacing:-.05pt'> </span>pas<span style='letter-spacing:-.15pt'> </span>présenté<span style='letter-spacing:-.35pt'> </span>de<span style='letter-spacing:-.1pt'> </span>progression<span style='letter-spacing:-.45pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la <span style='letter-spacing:-.1pt'>m</span>aladie<span style='letter-spacing: -.25pt'> </span>devaient recevoir<span style='letter-spacing:-.35pt'> </span>une chi<span style='letter-spacing:-.05pt'>m</span>io radiothérapie<span style='letter-spacing:-.05pt'> </span>(CRT)<span style='letter-spacing:-.25pt'> </span>confor<span style='letter-spacing:-.1pt'>m</span>é<span style='letter-spacing:-.1pt'>m</span>ent<span style='letter-spacing:-.4pt'> </span>au<span style='letter-spacing:-.1pt'> </span>protocole<span style='letter-spacing:-.4pt'> </span>(TPF/CRT).<span style='letter-spacing:-.5pt'> </span>Les<span style='letter-spacing:-.15pt'> </span>patients du<span style='letter-spacing: -.1pt'> </span>bras<span style='letter-spacing:-.15pt'> </span>co<span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>p</span>arateur<span style='letter-spacing:-.1pt'> </span>ont<span style='letter-spacing:-.15pt'> </span>reçu du<span style='letter-spacing:-.1pt'> </span>cisplatine<span style='letter-spacing: -.35pt'> </span>(P)<span style='letter-spacing:-.1pt'> </span>100<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.1pt'>m<sup>2</sup></span><sup> </sup>à<span style='letter-spacing:-.25pt'> </span>J1<span style='letter-spacing: -.1pt'> </span>en<span style='letter-spacing:-.1pt'> </span>perfusion<span style='letter-spacing:-.4pt'> </span>intraveineuse<span style='letter-spacing: -.5pt'> </span>de 30<span style='letter-spacing:-.35pt'> </span><span style='letter-spacing:-.1pt'>m</span>inutes<span style='letter-spacing:-.3pt'> </span>à 3<span style='letter-spacing:-.05pt'> </span>heures,<span style='letter-spacing: -.3pt'> </span>suivi<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span>5-fluoro-uracile(F)<span style='letter-spacing: -.1pt'> </span>1000<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.1pt'>m</span>²/jour<span style='letter-spacing:-.55pt'> </span>en<span style='letter-spacing:-.1pt'> </span>perfusion<span style='letter-spacing:-.4pt'> </span>intraveineuse<span style='letter-spacing: -.55pt'> </span>continue de<span style='letter-spacing:-.1pt'> </span>J1<span style='letter-spacing:-.1pt'> </span>à J5.<span style='letter-spacing:-.1pt'> </span>Les<span style='letter-spacing:-.15pt'> </span>c<span style='letter-spacing:.1pt'>y</span>cles<span style='letter-spacing:-.05pt'> </span>étaient répétés<span style='letter-spacing: -.3pt'> </span>toutes<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>3<span style='letter-spacing:-.05pt'> </span>se<span style='letter-spacing:-.1pt'>m</span>aines<span style='letter-spacing:-.1pt'> </span>à raison<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing: -.1pt'> </span>3<span style='letter-spacing:-.05pt'> </span>c<span style='letter-spacing:.1pt'>y</span>cles.<span style='letter-spacing:-.05pt'> </span>Tous<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>patients n<span style='letter-spacing:.05pt'>’</span>a<span style='letter-spacing:.1pt'>y</span>ant<span style='letter-spacing:-.05pt'> </span>pas<span style='letter-spacing:-.15pt'> </span>présenté de<span style='letter-spacing:-.1pt'> </span>progression<span style='letter-spacing: -.45pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la <span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:-.05pt'>a</span>ladie<span style='letter-spacing:-.25pt'> </span>devaient<span style='letter-spacing:-.35pt'> </span>recevoir<span style='letter-spacing:-.35pt'> </span>une<span style='letter-spacing:-.15pt'> </span>chi<span style='letter-spacing:-.1pt'>m</span>io radiothérapie<span style='letter-spacing:-.1pt'> </span>(CRT) confor<span style='letter-spacing:-.1pt'>m</span>é<span style='letter-spacing:-.1pt'>m</span>ent<span style='letter-spacing:-.4pt'> </span>au<span style='letter-spacing:-.1pt'> </span>protocole (PF/CRT).</p>
<p class=AmmCorpsTexte>Les<span style='letter-spacing:-.4pt'> </span>patients<span style='letter-spacing:-.3pt'> </span>des<span style='letter-spacing:-.15pt'> </span>deux<span style='letter-spacing:-.2pt'> </span>bras<span style='letter-spacing:-.15pt'> </span>de<span style='letter-spacing:-.1pt'> </span>traite<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.3pt'> </span>devaient<span style='letter-spacing:-.35pt'> </span>recevoir<span style='letter-spacing:-.35pt'> </span>7<span style='letter-spacing:-.05pt'> </span>se<span style='letter-spacing:-.1pt'>m</span>aines<span style='letter-spacing:-.1pt'> </span>de<span style='letter-spacing:-.1pt'> </span>CRT<span style='letter-spacing:-.2pt'> </span>à l<span style='letter-spacing:.05pt'>’</span>issue<span style='letter-spacing:-.05pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la chi<span style='letter-spacing:-.05pt'>m</span>iothérapie<span style='letter-spacing:.05pt'> </span>d’induction,<span style='letter-spacing: -.45pt'> </span>avec<span style='letter-spacing:-.2pt'> </span>un<span style='letter-spacing:-.1pt'> </span>intervalle<span style='letter-spacing: -.35pt'> </span><span style='letter-spacing:-.1pt'>m</span>ini<span style='letter-spacing:-.1pt'>m</span>um<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span>3<span style='letter-spacing:-.05pt'> </span>se<span style='letter-spacing:-.1pt'>m</span>aines<span style='letter-spacing:-.1pt'> </span>et pas<span style='letter-spacing:-.15pt'> </span>plus<span style='letter-spacing: -.15pt'> </span>de<span style='letter-spacing:-.1pt'> </span>8<span style='letter-spacing:-.05pt'> </span>se<span style='letter-spacing:-.1pt'>m</span>aines<span style='letter-spacing:-.1pt'> </span>après<span style='letter-spacing:-.2pt'> </span>le début<span style='letter-spacing:-.2pt'> </span>du<span style='letter-spacing: -.1pt'> </span>dernier<span style='letter-spacing:-.3pt'> </span>c<span style='letter-spacing:.1pt'>y</span>cle (de<span style='letter-spacing:-.15pt'> </span>J22<span style='letter-spacing:-.15pt'> </span>à J56<span style='letter-spacing:-.15pt'> </span>du<span style='letter-spacing:-.1pt'> </span>dernier<span style='letter-spacing:-.3pt'> </span>c<span style='letter-spacing:.1pt'>y</span>cle).<span style='letter-spacing:-.05pt'> </span>Durant<span style='letter-spacing:-.3pt'> </span>la radiothérapie,<span style='letter-spacing:-.5pt'> </span>du<span style='letter-spacing:-.1pt'> </span>carboplatine<span style='letter-spacing: -.5pt'> </span>(AUC 1,5)<span style='letter-spacing:-.15pt'> </span>était<span style='letter-spacing:.05pt'> </span>ad<span style='letter-spacing:-.1pt'>m</span>inistré<span style='letter-spacing:-.3pt'> </span>de<span style='letter-spacing:-.1pt'> </span>façon hebdo<span style='letter-spacing:-.1pt'>m</span>ada<span style='letter-spacing: -.05pt'>i</span>re<span style='letter-spacing:-.25pt'> </span>en<span style='letter-spacing:-.1pt'> </span>perfusion<span style='letter-spacing:-.4pt'> </span>intraveineuse<span style='letter-spacing:-.5pt'> </span>d’une<span style='letter-spacing:-.25pt'> </span>heure<span style='letter-spacing:-.2pt'> </span>pour<span style='letter-spacing:-.2pt'> </span>un<span style='letter-spacing:-.1pt'> m</span>axi<span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>u</span>m<span style='letter-spacing:-.15pt'> </span>de<span style='letter-spacing:-.1pt'> </span>7<span style='letter-spacing:-.05pt'> </span>doses.<span style='letter-spacing:-.25pt'> </span>L<span style='letter-spacing:.05pt'>’</span>irradiation était<span style='letter-spacing:.05pt'> </span>délivrée<span style='letter-spacing:-.35pt'> </span>au <span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing: .05pt'>o</span><span style='letter-spacing:.1pt'>y</span>en<span style='letter-spacing:-.15pt'> </span>d<span style='letter-spacing:.05pt'>’</span>un<span style='letter-spacing:-.05pt'> </span>équipe<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.35pt'> </span>à <span style='letter-spacing:-.1pt'>m</span>égavoltage<span style='letter-spacing:-.4pt'> </span>utilisant un<span style='letter-spacing: -.35pt'> </span>fractionne<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.5pt'> </span>conventionnel<span style='letter-spacing: -.5pt'> </span>(2<span style='letter-spacing:-.1pt'> </span>Gy par<span style='letter-spacing:-.15pt'> </span>jour,<span style='letter-spacing:-.2pt'> </span>5<span style='letter-spacing:-.05pt'> </span>jours<span style='letter-spacing:-.2pt'> </span>par<span style='letter-spacing:-.15pt'> </span>se<span style='letter-spacing:-.1pt'>m</span>aine<span style='letter-spacing:-.1pt'> </span>pendant<span style='letter-spacing:-.3pt'> </span>7<span style='letter-spacing:-.05pt'> </span>se<span style='letter-spacing: -.1pt'>m</span>aines<span style='letter-spacing:-.1pt'> </span>et pour<span style='letter-spacing:-.2pt'> </span>une<span style='letter-spacing:-.15pt'> </span>dose totale<span style='letter-spacing:.05pt'> </span>70-72<span style='letter-spacing: -.25pt'> </span>G<span style='letter-spacing:.1pt'>y</span>).<span style='letter-spacing:-.05pt'> </span>La<span style='letter-spacing:-.1pt'> </span>chirurgie<span style='letter-spacing:-.35pt'> </span>du<span style='letter-spacing:-.1pt'> </span>site pri<span style='letter-spacing:-.1pt'>m</span>itif<span style='letter-spacing: -.1pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la tu<span style='letter-spacing:-.1pt'>m</span>eur<span style='letter-spacing:-.15pt'> </span>et/ou<span style='letter-spacing:-.2pt'> </span>du<span style='letter-spacing:-.1pt'> </span>cou<span style='letter-spacing:-.15pt'> </span>pouvait<span style='letter-spacing:-.3pt'> </span>être<span style='letter-spacing:-.15pt'> </span>envisagée<span style='letter-spacing:-.35pt'> </span>à tout<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing: .05pt'>o</span><span style='letter-spacing:-.1pt'>m</span>ent<span style='letter-spacing:-.15pt'> </span>à l’issue de<span style='letter-spacing: -.1pt'> </span>la CRT.<span style='letter-spacing:-.2pt'> </span>Tous<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>patients<span style='letter-spacing:-.3pt'> </span>du<span style='letter-spacing:-.1pt'> </span>bras<span style='letter-spacing:-.15pt'> </span>docétaxel<span style='letter-spacing: -.35pt'> </span>de<span style='letter-spacing:-.1pt'> </span>l’étude<span style='letter-spacing:-.3pt'> </span>ont<span style='letter-spacing:-.15pt'> </span>reçu<span style='letter-spacing:-.15pt'> </span>une<span style='letter-spacing:-.15pt'> </span>proph<span style='letter-spacing:.1pt'>y</span>laxie<span style='letter-spacing:.05pt'> </span>antibiotique.<span style='letter-spacing:-.45pt'> </span>La<span style='letter-spacing:-.1pt'> </span>survie globale<span style='letter-spacing:.05pt'> </span>(SG),<span style='letter-spacing: -.2pt'> </span>c<span style='letter-spacing:-.05pt'>r</span>itère<span style='letter-spacing:-.05pt'> </span>d’évaluation<span style='letter-spacing: -.45pt'> </span>principal<span style='letter-spacing:-.3pt'> </span>de<span style='letter-spacing:-.1pt'> </span>cette<span style='letter-spacing:.05pt'> </span>étude,<span style='letter-spacing:-.25pt'> </span>était significative<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.5pt'> </span>plus<span style='letter-spacing:-.15pt'> </span>longue<span style='letter-spacing:-.25pt'> </span>(test<span style='letter-spacing:-.15pt'> </span>du<span style='letter-spacing:-.1pt'> </span>log-rank,<span style='letter-spacing:-.35pt'> </span>p =<span style='letter-spacing:-.05pt'> </span>0,0058)<span style='letter-spacing:-.3pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>le bras<span style='letter-spacing:-.15pt'> </span>contenant<span style='letter-spacing:-.35pt'> </span>le docétaxel<span style='letter-spacing: 2.15pt'> </span>que<span style='letter-spacing:-.15pt'> </span>dans le bras<span style='letter-spacing:-.15pt'> </span>PF<span style='letter-spacing:-.1pt'> </span>(SG<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span>édiane<span style='letter-spacing:-.3pt'> </span>: 70,6<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing: .05pt'>o</span>is<span style='letter-spacing:-.1pt'> </span>versus<span style='letter-spacing:-.25pt'> </span>30,1<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>o</span>is respective<span style='letter-spacing:-.05pt'>m</span>ent),<span style='letter-spacing:-.4pt'> </span>avec<span style='letter-spacing:-.2pt'> </span>une<span style='letter-spacing:-.15pt'> </span>réduction<span style='letter-spacing: -.4pt'> </span>de 30%<span style='letter-spacing:-.45pt'> </span>du<span style='letter-spacing:-.1pt'> </span>risque<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.1pt'> m</span><span style='letter-spacing: .05pt'>o</span>rtalité<span style='letter-spacing:-.05pt'> </span>co<span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>p</span>aré<span style='letter-spacing:-.1pt'> </span>au<span style='letter-spacing:-.1pt'> </span>bras<span style='letter-spacing:-.15pt'> </span>PF<span style='letter-spacing:-.1pt'> </span>(risque<span style='letter-spacing:-.35pt'> </span>relatif<span style='letter-spacing:-.25pt'> </span>(RR)<span style='letter-spacing:-.2pt'> </span>=<span style='letter-spacing: -.05pt'> </span>0,70,<span style='letter-spacing:-.2pt'> </span>intervalle<span style='letter-spacing:-.35pt'> </span>de<span style='letter-spacing:-.1pt'> </span>confiance<span style='letter-spacing:-.4pt'> </span>à 95%<span style='letter-spacing:-.45pt'> </span>(95%<span style='letter-spacing:-.2pt'> </span>IC)<span style='letter-spacing:-.15pt'> </span>=<span style='letter-spacing:-.05pt'> </span>0,54-0,90)<span style='letter-spacing: -.4pt'> </span>et<span style='letter-spacing:.05pt'> </span>un<span style='letter-spacing:-.1pt'> </span>suivi<span style='letter-spacing:-.2pt'> </span>global<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:-.1pt'>m</span>édian<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.1pt'> </span>41,9<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>o</span>is.<span style='letter-spacing:-.1pt'> </span>La<span style='letter-spacing:-.1pt'> </span>survie<span style='letter-spacing:-.25pt'> </span>sans<span style='letter-spacing:-.15pt'> </span>progression<span style='letter-spacing:-.45pt'> </span>(SSP),<span style='letter-spacing:-.25pt'> </span>critère d<span style='letter-spacing:.05pt'>’</span>évaluation secondaire,<span style='letter-spacing:-.45pt'> </span>a <span style='letter-spacing:-.1pt'>m</span>ontré<span style='letter-spacing:-.1pt'> </span>une<span style='letter-spacing:-.15pt'> </span>r<span style='letter-spacing:-.1pt'>é</span>duction de<span style='letter-spacing:-.1pt'> </span>29%<span style='letter-spacing: -.2pt'> </span>du<span style='letter-spacing:-.1pt'> </span>risque<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.1pt'> </span>progression<span style='letter-spacing:-.45pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>de<span style='letter-spacing:-.1pt'> </span>décès<span style='letter-spacing:-.2pt'> </span>et une a<span style='letter-spacing:-.1pt'>m</span>élioration<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing:-.1pt'> </span>22<span style='letter-spacing:-.1pt'> m</span><span style='letter-spacing:.05pt'>o</span>is<span style='letter-spacing:-.1pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la SSP<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span>édia<span style='letter-spacing:-.05pt'>n</span>e<span style='letter-spacing:-.2pt'> </span>(35,5<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>o</span>is<span style='letter-spacing:-.1pt'> </span>pour<span style='letter-spacing:-.2pt'> </span>TPF<span style='letter-spacing:-.15pt'> </span>et<span style='letter-spacing:.05pt'> </span>13,1<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>o</span>is<span style='letter-spacing:-.1pt'> </span>pour<span style='letter-spacing:-.2pt'> </span>PF).<span style='letter-spacing:-.15pt'> </span>La<span style='letter-spacing:-.1pt'> </span>significativité<span style='letter-spacing:.05pt'> </span>statistique<span style='letter-spacing: -.4pt'> </span>était atteinte<span style='letter-spacing:.05pt'> </span>avec<span style='letter-spacing:-.2pt'> </span>un<span style='letter-spacing:-.1pt'> </span>RR<span style='letter-spacing:-.2pt'> </span>=<span style='letter-spacing:-.05pt'> </span>0,71<span style='letter-spacing:-.15pt'> </span>;<span style='letter-spacing:.05pt'> </span>95<span style='letter-spacing:-.05pt'>%</span>IC<span style='letter-spacing:-.1pt'> </span>0,56-0,90<span style='letter-spacing:-.4pt'> </span>;<span style='letter-spacing:.05pt'> </span>log-rank<span style='letter-spacing:-.3pt'> </span>test,<span style='letter-spacing:-.1pt'> </span>p<span style='letter-spacing:-.05pt'> </span>=<span style='letter-spacing:-.05pt'> </span>0,004.<span style='letter-spacing:-.25pt'> </span>Les résultats<span style='letter-spacing: -.35pt'> </span>d<span style='letter-spacing:.05pt'>’</span>efficacité<span style='letter-spacing:.05pt'> </span>sont<span style='letter-spacing:-.15pt'> </span>présentés<span style='letter-spacing:-.35pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>le tableau<span style='letter-spacing:-.3pt'> </span>ci-dessous.</p>
<p class=AmmCorpsTexte style='margin-bottom:0cm;margin-bottom:.0001pt'><u>Efficacité<span style='letter-spacing:.05pt'> </span>du docétaxel<span style='letter-spacing: .05pt'> </span>en traite<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.1pt'> </span>d<span style='letter-spacing:.05pt'>’</span>induction des patients présentant un carcino<span style='letter-spacing:-.05pt'>m</span>e épider<span style='letter-spacing:-.05pt'>m</span><span style='letter-spacing: .05pt'>o</span>ïde</u> <u>locale<span style='letter-spacing:-.05pt'>m</span>ent avancé des VADS</u></p>
<p class=AmmCorpsTexte><u><sub>(Anal<span style='letter-spacing:.1pt'>y</span>se en intention de traiter)</sub></u></p>
<table class=AmmCorpsTexteTable border=1 cellspacing=0 cellpadding=0
style='margin-left:17.7pt;border-collapse:collapse;border:none'>
<thead>
<tr style='height:11.5pt'>
<td width=227 valign=top style='width:6.0cm;border:solid windowtext 1.0pt;
border-bottom:none;padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmTableauTitre1 align=left style='margin:0cm;margin-bottom:.0001pt; text-align:left'>Critère d'évaluation</p>
</td>
<td width=199 valign=top style='width:149.6pt;border-top:solid windowtext 1.0pt;
border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmTableauTitre1 align=center style='margin:0cm;margin-bottom:.0001pt; text-align:center'>Docétaxel + Cis + 5-U</p>
</td>
<td width=207 valign=top style='width:155.15pt;border-top:solid windowtext 1.0pt;
border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmTableauTitre1 align=center style='margin:0cm;margin-bottom:.0001pt; text-align:center'>Cis + 5-FU</p>
</td>
</tr>
<tr style='height:23.5pt'>
<td width=227 valign=top style='width:6.0cm;border:solid windowtext 1.0pt;
border-top:none;padding:0cm 3.5pt 0cm 3.5pt;height:23.5pt'>
<p class=AmmTableauTitre1> </p>
</td>
<td width=199 valign=top style='width:149.6pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:23.5pt'>
<p class=AmmTableauTitre1 align=center style='margin:0cm;margin-bottom:.0001pt; text-align:center'>n=225</p>
</td>
<td width=207 valign=top style='width:155.15pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:23.5pt'>
<p class=AmmTableauTitre1 align=center style='margin:0cm;margin-bottom:.0001pt; text-align:center'>n=246</p>
</td>
</tr>
<tr style='height:11.5pt'>
<td width=227 valign=top style='width:6.0cm;border-top:none;border-left:
solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>Survie globale médiane (mois)</p>
</td>
<td width=199 valign=top style='width:149.6pt;border:none;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'>70,6 (49,0-NA)</p>
</td>
<td width=207 valign=top style='width:155.15pt;border:none;border-right:
solid windowtext 1.0pt;padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'>30,1 (20,9-51,5)</p>
</td>
</tr>
<tr style='height:11.5pt'>
<td width=227 valign=top style='width:6.0cm;border-top:none;border-left:
solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>(95 % CI)</p>
</td>
<td width=199 valign=top style='width:149.6pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'> </p>
</td>
<td width=207 valign=top style='width:155.15pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'> </p>
</td>
</tr>
<tr>
<td width=227 valign=top style='width:6.0cm;border-top:none;border-left:
solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>Risque relatif (95 % IC)</p>
</td>
<td width=406 colspan=2 valign=top style='width:304.75pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'>0,70 (0,54-0,90)</p>
</td>
</tr>
<tr>
<td width=227 valign=top style='width:6.0cm;border:solid windowtext 1.0pt;
border-top:none;padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>*valeur de p</p>
</td>
<td width=406 colspan=2 valign=top style='width:304.75pt;border-top:none;
border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'>0,0058</p>
</td>
</tr>
<tr style='height:11.5pt'>
<td width=227 valign=top style='width:6.0cm;border-top:none;border-left:
solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>Médiane de survie sans</p>
</td>
<td width=199 valign=top style='width:149.6pt;border:none;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'>35,5</p>
</td>
<td width=207 valign=top style='width:155.15pt;border:none;border-right:
solid windowtext 1.0pt;padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'>13,1</p>
</td>
</tr>
<tr style='height:11.5pt'>
<td width=227 valign=top style='width:6.0cm;border-top:none;border-left:
solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>progression (mois) (95 % IC)</p>
</td>
<td width=199 valign=top style='width:149.6pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'>(19,3-NA)</p>
</td>
<td width=207 valign=top style='width:155.15pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'>(10,6-20,2)</p>
</td>
</tr>
<tr>
<td width=227 valign=top style='width:6.0cm;border-top:none;border-left:
solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>Risque relatif (95 % IC)</p>
</td>
<td width=406 colspan=2 valign=top style='width:304.75pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'>0,71 (0,56-0,90)</p>
</td>
</tr>
<tr>
<td width=227 valign=top style='width:6.0cm;border-top:none;border-left:
solid windowtext 1.0pt;border-bottom:solid black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>**valeur de p</p>
</td>
<td width=406 colspan=2 valign=top style='width:304.75pt;border-top:none;
border-left:none;border-bottom:solid black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'>0,004</p>
</td>
</tr>
<tr style='height:11.5pt'>
<td width=227 valign=top style='width:6.0cm;border-top:none;border-left:
solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>Réponse objective à la</p>
</td>
<td width=199 valign=top style='width:149.6pt;border:none;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'>71,8</p>
</td>
<td width=207 valign=top style='width:155.15pt;border:none;border-right:
solid windowtext 1.0pt;padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'>64,2</p>
</td>
</tr>
<tr style='height:11.5pt'>
<td width=227 valign=top style='width:6.0cm;border-top:none;border-left:
solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>chimiothérapie (RC + RP) (%)</p>
</td>
<td width=199 valign=top style='width:149.6pt;border:none;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'>(65,8-77,2)</p>
</td>
<td width=207 valign=top style='width:155.15pt;border:none;border-right:
solid windowtext 1.0pt;padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'>(57,9-70,2)</p>
</td>
</tr>
<tr style='height:11.5pt'>
<td width=227 valign=top style='width:6.0cm;border-top:none;border-left:
solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>(IC 95 %)</p>
</td>
<td width=199 valign=top style='width:149.6pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'> </p>
</td>
<td width=207 valign=top style='width:155.15pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'> </p>
</td>
</tr>
<tr>
<td width=227 valign=top style='width:6.0cm;border:solid windowtext 1.0pt;
border-top:none;padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>***valeur de p</p>
</td>
<td width=406 colspan=2 valign=top style='width:304.75pt;border-top:none;
border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'>0,070</p>
</td>
</tr>
<tr style='height:11.5pt'>
<td width=227 valign=top style='width:6.0cm;border-top:none;border-left:
solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>Réponse objective au traitement</p>
</td>
<td width=199 valign=top style='width:149.6pt;border:none;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'>76,5</p>
</td>
<td width=207 valign=top style='width:155.15pt;border:none;border-right:
solid windowtext 1.0pt;padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'>71,5</p>
</td>
</tr>
<tr style='height:11.5pt'>
<td width=227 valign=top style='width:6.0cm;border-top:none;border-left:
solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>(RC + RP) [chimiothérapie +/-chimioradiothérapie]( %)(IC 95 %)</p>
</td>
<td width=199 valign=top style='width:149.6pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'>(70,8-81,5)</p>
</td>
<td width=207 valign=top style='width:155.15pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'>(65,5-77,1)</p>
</td>
</tr>
<tr>
<td width=227 valign=top style='width:6.0cm;border:solid windowtext 1.0pt;
border-top:none;padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>***valeur de p</p>
</td>
<td width=406 colspan=2 valign=top style='width:304.75pt;border-top:none;
border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'>0,209</p>
</td>
</tr>
</thead>
</table>
<p class=AmmCorpsTexte style='margin-bottom:0cm;margin-bottom:.0001pt'>Un<span style='letter-spacing:-.4pt'> </span>risque<span style='letter-spacing:-.25pt'> </span>relatif<span style='letter-spacing:-.25pt'> </span>inférieur<span style='letter-spacing:-.35pt'> </span>à 1<span style='letter-spacing:-.05pt'> </span>est<span style='letter-spacing:-.1pt'> </span>en<span style='letter-spacing:-.1pt'> </span>fav<span style='letter-spacing:-.1pt'>e</span>ur<span style='letter-spacing:-.15pt'> </span>de<span style='letter-spacing:-.1pt'> </span>docétaxel<span style='letter-spacing:-.4pt'> </span>+cisplatine+5-fluoro-uracile</p>
<p class=AmmCorpsTexte style='margin-bottom:0cm;margin-bottom:.0001pt'>*<span style='letter-spacing:-.3pt'> </span>test<span style='letter-spacing:.05pt'> </span>du<span style='letter-spacing:-.1pt'> </span>log-rank<span style='letter-spacing:-.3pt'> </span>non<span style='letter-spacing:-.15pt'> </span>ajusté</p>
<p class=AmmCorpsTexte style='margin-bottom:0cm;margin-bottom:.0001pt'>**<span style='letter-spacing:-.35pt'> </span>test Log-rank<span style='letter-spacing: -.35pt'> </span>non<span style='letter-spacing:-.15pt'> </span>ajusté,<span style='letter-spacing:-.25pt'> </span>non<span style='letter-spacing:-.15pt'> </span>ajusté<span style='letter-spacing:-.25pt'> </span>pour<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>co<span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>p</span>araisons<span style='letter-spacing:-.1pt'> m</span><span style='letter-spacing:.05pt'>u</span>ltiples</p>
<p class=AmmCorpsTexte style='margin-bottom:0cm;margin-bottom:.0001pt'>***<span style='letter-spacing:-.4pt'> </span>test du<span style='letter-spacing:-.1pt'> </span>Chi²,<span style='letter-spacing:-.2pt'> </span>non<span style='letter-spacing:-.15pt'> </span>ajusté<span style='letter-spacing:-.25pt'> </span>pour<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>co<span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>p</span>araisons<span style='letter-spacing:-.1pt'> m</span><span style='letter-spacing:.05pt'>u</span>ltiples</p>
<p class=AmmCorpsTexte>NA<span style='letter-spacing:-.4pt'> </span>Non<span style='letter-spacing:-.15pt'> </span>atteint</p>
<p class=AmmCorpsTexte style='margin-top:.8pt;line-height:12.0pt;text-autospace: none'><u><span style='font-size:10.0pt;font-family:Arial'>Population pédiatrique</span></u></p>
<p class=AmmCorpsTexte>L’Agence<span style='letter-spacing:-.7pt'> </span>du<span style='letter-spacing:-.1pt'> </span>Médica<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.3pt'> </span>Européenne<span style='letter-spacing: -.5pt'> </span>a dérogé<span style='letter-spacing:-.25pt'> </span>à l’o<span style='letter-spacing:.05pt'>b</span>ligation<span style='letter-spacing:-.1pt'> </span>de<span style='letter-spacing:-.1pt'> </span>sou<span style='letter-spacing: -.1pt'>m</span>ettre<span style='letter-spacing:-.15pt'> </span>les<span style='letter-spacing:-.1pt'> </span>résultats<span style='letter-spacing:-.35pt'> </span>des<span style='letter-spacing:-.15pt'> </span>études<span style='letter-spacing:-.25pt'> </span>avec docétaxel<span style='letter-spacing: -.55pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>sous-populations<span style='letter-spacing: -.7pt'> </span>pédiatriques<span style='letter-spacing:-.5pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>le cancer<span style='letter-spacing:-.25pt'> </span>du<span style='letter-spacing:-.1pt'> </span>sein,<span style='letter-spacing:-.2pt'> </span>cancer<span style='letter-spacing:-.25pt'> </span>du<span style='letter-spacing:-.1pt'> </span>sein,<span style='letter-spacing:-.2pt'> </span>le cancer<span style='letter-spacing:-.25pt'> </span>du pou<span style='letter-spacing:-.1pt'>m</span>on<span style='letter-spacing:-.15pt'> </span>non<span style='letter-spacing:-.15pt'> </span>à petites<span style='letter-spacing:-.25pt'> </span>cellules,<span style='letter-spacing:-.3pt'> </span>le cancer<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la<span style='letter-spacing: -.15pt'> </span>prostate,<span style='letter-spacing:-.35pt'> </span>le cancer<span style='letter-spacing:-.25pt'> </span>gastrique,<span style='letter-spacing: -.4pt'> </span>le cancer<span style='letter-spacing:-.25pt'> </span>des<span style='letter-spacing:-.15pt'> </span>voies aéro-digestives<span style='letter-spacing:.05pt'> </span>supérieures,<span style='letter-spacing: -.5pt'> </span>n’incluant<span style='letter-spacing:-.35pt'> </span>pas<span style='letter-spacing:-.15pt'> </span>les<span style='letter-spacing:-.1pt'> </span>cancers<span style='letter-spacing:-.3pt'> </span>naso-pha<span style='letter-spacing:.1pt'>r</span>yngés<span style='letter-spacing:-.35pt'> </span>t<span style='letter-spacing:.1pt'>y</span>pe<span style='letter-spacing:-.05pt'> </span>II<span style='letter-spacing:-.05pt'> </span>et III<span style='letter-spacing:-.1pt'> m</span><span style='letter-spacing: .05pt'>o</span>ins<span style='letter-spacing:-.1pt'> </span>différenciés<span style='letter-spacing:.05pt'> </span>(voir<span style='letter-spacing:-.2pt'> </span>rubrique<span style='letter-spacing:-.35pt'> </span>4.2<span style='letter-spacing:-.15pt'> </span>pour une<span style='letter-spacing:-.15pt'> </span>inf<span style='letter-spacing: .05pt'>o</span>r<span style='letter-spacing:-.1pt'>m</span>ation<span style='letter-spacing:-.05pt'> </span>sur<span style='letter-spacing:-.1pt'> </span>l’utilisation<span style='letter-spacing:-.4pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>populations<span style='letter-spacing: -.45pt'> </span>pédiatriques).</p>
<p class="AmmAnnexeTitre2"><a name="RcpPropPharmacocinetique">5.2. Propriétés pharmacocinétiques</a></p>
<p class=AmmAnnexeTitre3><a name="_Toc142278934">Absorption</a></p>
<p class=AmmCorpsTexte>Les<span style='letter-spacing:-.4pt'> </span>para<span style='letter-spacing:-.1pt'>m</span>ètres<span style='letter-spacing:-.3pt'> </span>phar<span style='letter-spacing:-.1pt'>m</span>acocinétiques<span style='letter-spacing: -.15pt'> </span>du<span style='letter-spacing:-.1pt'> </span>docétaxel<span style='letter-spacing:-.4pt'> </span>ont<span style='letter-spacing:-.15pt'> </span>été évalués<span style='letter-spacing:-.3pt'> </span>chez<span style='letter-spacing: -.2pt'> </span>des<span style='letter-spacing:-.15pt'> </span>patients<span style='letter-spacing:-.3pt'> </span>cancéreux<span style='letter-spacing:-.4pt'> </span>après<span style='letter-spacing:-.2pt'> </span>ad<span style='letter-spacing:-.1pt'>m</span>inistration<span style='letter-spacing: .05pt'> </span>d<span style='letter-spacing:-.05pt'>'</span>une<span style='letter-spacing:-.05pt'> </span>dose<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span>20<span style='letter-spacing:-.1pt'> </span>à 115<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing: -.1pt'>m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.1pt'>m<sup>2</sup></span>,<span style='letter-spacing: -.35pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>des<span style='letter-spacing:-.15pt'> </span>essais<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.1pt'> </span>phase<span style='letter-spacing:-.25pt'> </span>I.<span style='letter-spacing:-.05pt'> </span>La<span style='letter-spacing:-.1pt'> </span>cinétique<span style='letter-spacing:-.35pt'> </span>du<span style='letter-spacing:-.1pt'> </span>docétaxel<span style='letter-spacing:-.4pt'> </span>est<span style='letter-spacing:-.1pt'> </span>indépendante<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la dose et correspond<span style='letter-spacing:-.45pt'> </span>à un<span style='letter-spacing:-.1pt'> m</span>odèle<span style='letter-spacing:-.1pt'> </span>à trois<span style='letter-spacing:-.2pt'> </span>co<span style='letter-spacing: -.1pt'>m</span><span style='letter-spacing:.05pt'>p</span>arti<span style='letter-spacing:-.05pt'>m</span>ents,<span style='letter-spacing:-.1pt'> </span>avec<span style='letter-spacing:-.2pt'> </span>des<span style='letter-spacing:-.15pt'> </span>de<span style='letter-spacing:-.1pt'>m</span>i-vies<span style='letter-spacing:-.3pt'> </span>de<span style='letter-spacing:-.1pt'> </span>4<span style='letter-spacing:-.05pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>n</span>, 36<span style='letter-spacing:-.35pt'> </span><span style='letter-spacing:-.1pt'>m</span>n<span style='letter-spacing:-.05pt'> </span>et 11,1<span style='letter-spacing:-.15pt'> </span>heures<span style='letter-spacing:-.25pt'> </span>pour<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>phases<span style='letter-spacing:-.25pt'> </span>&#945;,<span style='letter-spacing:1.0pt'> </span>ß<span style='letter-spacing:-.05pt'> </span>et &#947;,<span style='letter-spacing:-.35pt'> </span>respective<span style='letter-spacing: -.05pt'>m</span>ent.<span style='letter-spacing:-.4pt'> </span>La<span style='letter-spacing:-.1pt'> </span>phase<span style='letter-spacing:-.25pt'> </span>tardive<span style='letter-spacing:-.3pt'> </span>est<span style='letter-spacing:-.1pt'> </span>due<span style='letter-spacing:-.15pt'> </span>en<span style='letter-spacing:-.1pt'> </span>partie<span style='letter-spacing:-.25pt'> </span>à une<span style='letter-spacing:-.15pt'> </span>sortie relative<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.3pt'> </span>lente<span style='letter-spacing:-.2pt'> </span>du<span style='letter-spacing:-.1pt'> </span>docétaxel<span style='letter-spacing:-.35pt'> </span>du<span style='letter-spacing:-.1pt'> </span>co<span style='letter-spacing: -.1pt'>m</span><span style='letter-spacing:.05pt'>p</span>arti<span style='letter-spacing:-.15pt'>m</span>ent<span style='letter-spacing:-.1pt'> </span>périphérique.<span style='letter-spacing:-.5pt'> </span></p>
<p class=AmmAnnexeTitre3>Distribution</p>
<p class=AmmCorpsTexte>Après<span style='letter-spacing:-.25pt'> </span>ad<span style='letter-spacing:-.1pt'>m</span>inistration<span style='letter-spacing: -.45pt'> </span>d<span style='letter-spacing:-.05pt'>'</span>une<span style='letter-spacing:-.05pt'> </span>dose<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:.05pt'> </span>100<span style='letter-spacing:-.1pt'> m</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.1pt'>m<sup>2</sup></span>, sous<span style='letter-spacing:-.2pt'> </span>for<span style='letter-spacing: -.1pt'>m</span>e<span style='letter-spacing:-.1pt'> </span>d<span style='letter-spacing:-.05pt'>'</span>une<span style='letter-spacing:-.05pt'> </span>perfusion<span style='letter-spacing:-.4pt'> </span>d<span style='letter-spacing:-.05pt'>'</span>une<span style='letter-spacing:-.05pt'> </span>heure,<span style='letter-spacing:-.25pt'> </span>la<span style='letter-spacing:-.05pt'> </span>concentration<span style='letter-spacing:-.5pt'> </span>plas<span style='letter-spacing:-.1pt'>m</span>atique<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>o</span><span style='letter-spacing:.1pt'>y</span>enne<span style='letter-spacing:-.2pt'> </span>atteint 3,7<span style='letter-spacing: -.4pt'> </span><span style='letter-spacing:-.05pt'>µ</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.1pt'>m</span>l,<span style='letter-spacing:-.05pt'> </span>avec<span style='letter-spacing:-.2pt'> </span>une<span style='letter-spacing:-.15pt'> </span>aire<span style='letter-spacing:-.15pt'> </span>sous<span style='letter-spacing:-.2pt'> </span>la courbe<span style='letter-spacing:-.25pt'> </span>(AUC)<span style='letter-spacing:-.3pt'> </span>de<span style='letter-spacing:-.15pt'> </span>4,6<span style='letter-spacing:-.15pt'> </span>h.<span style='letter-spacing:-.05pt'>µ</span><span style='letter-spacing:.05pt'>g</span>/<span style='letter-spacing:-.1pt'>m</span>l.<span style='letter-spacing:-.05pt'> </span>Les<span style='letter-spacing:-.15pt'> </span>valeurs<span style='letter-spacing:-.3pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing: .05pt'>o</span><span style='letter-spacing:.1pt'>y</span>ennes<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la clairance<span style='letter-spacing:-.35pt'> </span>totale<span style='letter-spacing:.05pt'> </span>et du volu<span style='letter-spacing: -.1pt'>m</span>e<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span>distribution<span style='letter-spacing: -.45pt'> </span>à l<span style='letter-spacing:-.05pt'>'</span>équilibre<span style='letter-spacing:-.3pt'> </span>étaient<span style='letter-spacing:.05pt'> </span>respective<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.4pt'> </span>égales<span style='letter-spacing:-.25pt'> </span>à 21<span style='letter-spacing:-.1pt'> </span>l/h/<span style='letter-spacing:-.2pt'>m</span><sup><span style='letter-spacing:-.1pt'>2</span> </sup>et<span style='letter-spacing:-.25pt'> </span>113<span style='letter-spacing:-.15pt'> </span>l.<span style='letter-spacing:-.05pt'> </span>Les<span style='letter-spacing:-.15pt'> </span>variations interindividuelles de la clairance totale étaient approximativement de 50%. Le docétaxel se lie à plus de 95% aux protéines plasmatiques.</p>
<p class=AmmAnnexeTitre3>Elimination</p>
<p class=AmmCorpsTexte>Une<span style='letter-spacing:-.45pt'> </span>étude<span style='letter-spacing:-.2pt'> </span>portant<span style='letter-spacing:-.3pt'> </span>sur<span style='letter-spacing:-.1pt'> </span>le docétaxel<span style='letter-spacing:-.35pt'> </span><span style='letter-spacing:-.1pt'>m</span>arqué<span style='letter-spacing:-.25pt'> </span>au<span style='letter-spacing:-.1pt'> </span><span style='letter-spacing:-.05pt'>C<sup>14</sup></span><sup><span style='letter-spacing: 1.75pt'> </span></sup>a<span style='letter-spacing:-.25pt'> </span>été <span style='letter-spacing:-.1pt'>m</span>enée<span style='letter-spacing:-.2pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>trois<span style='letter-spacing:-.2pt'> </span>sujets<span style='letter-spacing:-.25pt'> </span>cancéreux.<span style='letter-spacing: -.45pt'> </span>Le<span style='letter-spacing:-.1pt'> </span>docétaxel<span style='letter-spacing:-.4pt'> </span>a été éli<span style='letter-spacing:-.05pt'>m</span>iné<span style='letter-spacing:-.1pt'> </span>en<span style='letter-spacing:-.1pt'> </span>sept<span style='letter-spacing:-.15pt'> </span>jours<span style='letter-spacing:-.2pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>l<span style='letter-spacing:.05pt'>’</span>urine<span style='letter-spacing:-.05pt'> </span>et les<span style='letter-spacing:-.1pt'> </span>fèces,<span style='letter-spacing:-.25pt'> </span>après<span style='letter-spacing:-.2pt'> </span>un<span style='letter-spacing:-.1pt'> </span>processus<span style='letter-spacing:-.4pt'> </span>de<span style='letter-spacing:-.1pt'> m</span>étabolis<span style='letter-spacing:-.05pt'>m</span>e<span style='letter-spacing:-.35pt'> </span>ox<span style='letter-spacing:.1pt'>y</span>datif<span style='letter-spacing:-.1pt'> </span>lié au c<span style='letter-spacing:.1pt'>y</span>tochro<span style='letter-spacing: -.05pt'>m</span>e<span style='letter-spacing:-.05pt'> </span>P-450<span style='letter-spacing:-.25pt'> </span>du<span style='letter-spacing:-.1pt'> </span>groupe<span style='letter-spacing:-.1pt'>m</span>ent<span style='letter-spacing:-.35pt'> </span>ester<span style='letter-spacing:-.2pt'> </span>tert-but<span style='letter-spacing:.1pt'>y</span>lique.<span style='letter-spacing:-.3pt'> </span>L<span style='letter-spacing:.05pt'>’</span>excrétion urinaire<span style='letter-spacing:-.3pt'> </span>et fécale<span style='letter-spacing:-.2pt'> </span>correspondait respective<span style='letter-spacing:-.05pt'>m</span>ent à 6<span style='letter-spacing:-.05pt'> </span>et 75%<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la radioactivité<span style='letter-spacing: -.45pt'> </span>ad<span style='letter-spacing:-.1pt'>mi</span>nistrée.<span style='letter-spacing:-.4pt'> </span>Environ<span style='letter-spacing:-.3pt'> </span>80%<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing: -.1pt'> </span>la radioactivité<span style='letter-spacing:-.45pt'> </span>retrouvée<span style='letter-spacing:-.4pt'> </span>dans les fèces<span style='letter-spacing: -.2pt'> </span>est<span style='letter-spacing:-.1pt'> </span>excrétée<span style='letter-spacing:-.35pt'> </span>au<span style='letter-spacing:-.1pt'> </span>cours<span style='letter-spacing:-.2pt'> </span>des<span style='letter-spacing:-.15pt'> </span>48<span style='letter-spacing:-.1pt'> </span>pre<span style='letter-spacing:-.1pt'>m</span>ières<span style='letter-spacing:-.15pt'> </span>heures<span style='letter-spacing:-.25pt'> </span>sous<span style='letter-spacing:-.2pt'> </span>for<span style='letter-spacing:-.1pt'>m</span>e<span style='letter-spacing:-.1pt'> </span>de<span style='letter-spacing:-.1pt'> m</span>étabolites<span style='letter-spacing: -.4pt'> </span>inactifs<span style='letter-spacing:-.3pt'> </span>(un<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span>étabolite<span style='letter-spacing:-.25pt'> </span>principal et trois<span style='letter-spacing: -.2pt'> </span><span style='letter-spacing:-.1pt'>m</span>étabolites<span style='letter-spacing:-.4pt'> </span>secondaires)<span style='letter-spacing: -.55pt'> </span>et de<span style='letter-spacing:-.1pt'> </span>très<span style='letter-spacing:-.15pt'> </span>faibles<span style='letter-spacing:-.25pt'> </span>quantités<span style='letter-spacing:-.35pt'> </span>de<span style='letter-spacing:-.1pt'> </span>produit<span style='letter-spacing:-.3pt'> </span>inchangé.</p>
<p class=AmmCorpsTexte><b><u>Populations particulières</u></b></p>
<p class=AmmCorpsTexte style='margin-bottom:0cm;margin-bottom:.0001pt'><u>Age et sexe</u></p>
<p class=AmmCorpsTexte>Une<span style='letter-spacing:-.45pt'> </span>anal<span style='letter-spacing:.1pt'>y</span>se<span style='letter-spacing:-.15pt'> </span>phar<span style='letter-spacing:-.1pt'>m</span>acocinétique<span style='letter-spacing: -.15pt'> </span>a été réalisée<span style='letter-spacing:-.3pt'> </span>sur<span style='letter-spacing:-.1pt'> </span>une<span style='letter-spacing:-.15pt'> </span>population<span style='letter-spacing:-.45pt'> </span>de<span style='letter-spacing:-.1pt'> </span>577<span style='letter-spacing:-.15pt'> </span>patients.<span style='letter-spacing: -.35pt'> </span>Les<span style='letter-spacing:-.15pt'> </span>para<span style='letter-spacing:-.1pt'>m</span>ètres phar<span style='letter-spacing: -.1pt'>m</span>acocinétiques esti<span style='letter-spacing:-.05pt'>m</span>és<span style='letter-spacing:-.15pt'> </span>à l'aide<span style='letter-spacing:-.2pt'> </span>du<span style='letter-spacing:-.1pt'> m</span>odèle<span style='letter-spacing:-.1pt'> </span>étaient très<span style='letter-spacing: -.15pt'> </span>proches<span style='letter-spacing:-.3pt'> </span>de<span style='letter-spacing:-.1pt'> </span>ceux<span style='letter-spacing:-.2pt'> </span>qui<span style='letter-spacing:-.15pt'> </span>avaient<span style='letter-spacing:-.3pt'> </span>été déduits<span style='letter-spacing:-.3pt'> </span>des<span style='letter-spacing:-.15pt'> </span>essais de phase<span style='letter-spacing: -.25pt'> </span>I.<span style='letter-spacing:-.05pt'> </span>Les<span style='letter-spacing:-.15pt'> </span>para<span style='letter-spacing:-.1pt'>m</span>ètres<span style='letter-spacing:-.3pt'> </span>phar<span style='letter-spacing:-.1pt'>m</span>acocinétiques<span style='letter-spacing:-.2pt'> </span>du<span style='letter-spacing:-.1pt'> </span>docétaxel<span style='letter-spacing:-.4pt'> </span>n'ont<span style='letter-spacing:-.2pt'> </span>pas<span style='letter-spacing:-.15pt'> </span>varié<span style='letter-spacing:-.2pt'> </span>en<span style='letter-spacing:-.1pt'> </span>fonction<span style='letter-spacing:-.35pt'> </span>de<span style='letter-spacing:-.1pt'> </span>l'âge<span style='letter-spacing:-.2pt'> </span>ni du<span style='letter-spacing:-.1pt'> </span>sexe.<span style='letter-spacing:-.2pt'> </span></p>
<p class=AmmCorpsTexte style='margin-bottom:0cm;margin-bottom:.0001pt'><u>Insuffisance hépatique</u></p>
<p class=AmmCorpsTexte>Chez quelques<span style='letter-spacing:-.35pt'> </span>sujets<span style='letter-spacing:-.25pt'> </span>(n<span style='letter-spacing:-.1pt'> </span>=<span style='letter-spacing:-.05pt'> </span>23)<span style='letter-spacing:-.15pt'> </span>présent<span style='letter-spacing:.05pt'>a</span>nt<span style='letter-spacing:-.3pt'> </span>une<span style='letter-spacing:-.15pt'> </span>élévation<span style='letter-spacing: -.3pt'> </span><span style='letter-spacing:-.1pt'>m</span>odérée<span style='letter-spacing:-.1pt'> </span>des<span style='letter-spacing:-.15pt'> </span>taux<span style='letter-spacing:-.15pt'> </span>d'ALAT<span style='letter-spacing:-.35pt'> </span>et/ou<span style='letter-spacing:-.2pt'> </span>d'ASAT (&#8805;<span style='letter-spacing:-.05pt'> </span>1,5<span style='letter-spacing:-.15pt'> </span>fois<span style='letter-spacing:-.15pt'> </span>la LSN)<span style='letter-spacing:-.2pt'> </span>et des<span style='letter-spacing:-.15pt'> </span>taux<span style='letter-spacing:-.15pt'> </span>de<span style='letter-spacing:-.1pt'> </span>phosphatases<span style='letter-spacing:-.55pt'> </span>alcalines<span style='letter-spacing: -.35pt'> </span><span style='letter-spacing:-.05pt'>(</span>&#8805;<span style='letter-spacing:-.05pt'> </span>2,5<span style='letter-spacing:-.15pt'> </span>fois<span style='letter-spacing:-.15pt'> </span>la LSN),<span style='letter-spacing:-.25pt'> </span>la clairance<span style='letter-spacing:-.35pt'> </span>corporelle<span style='letter-spacing:.05pt'> </span>totale<span style='letter-spacing:.05pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>o</span><span style='letter-spacing:.1pt'>y</span>enne<span style='letter-spacing:-.2pt'> </span>a di<span style='letter-spacing:-.1pt'>m</span>inué<span style='letter-spacing: -.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span>27% (voir rubrique<span style='letter-spacing:-.05pt'> </span>4.2).<span style='letter-spacing:-.2pt'> </span></p>
<p class=AmmCorpsTexte style='margin-bottom:0cm;margin-bottom:.0001pt'><u>Rétention hydrique</u></p>
<p class=AmmCorpsTexte>La<span style='letter-spacing:-.1pt'> </span>clairance<span style='letter-spacing:-.3pt'> </span>du<span style='letter-spacing:-.1pt'> </span>docétaxel<span style='letter-spacing:-.4pt'> </span>n'était pas<span style='letter-spacing: -.15pt'> </span><span style='letter-spacing:-.1pt'>m</span>odifiée chez<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>sujets<span style='letter-spacing:-.25pt'> </span>présentant<span style='letter-spacing: -.4pt'> </span>une<span style='letter-spacing:-.15pt'> </span>rétention h<span style='letter-spacing:.05pt'>y</span>drique<span style='letter-spacing:-.05pt'> </span>faible<span style='letter-spacing:-.25pt'> </span>à <span style='letter-spacing:-.1pt'>m</span>odérée<span style='letter-spacing:-.1pt'> </span>et il n<span style='letter-spacing:.05pt'>’</span>y<span style='letter-spacing: .05pt'> </span>a aucune<span style='letter-spacing:-.3pt'> </span>donnée<span style='letter-spacing:-.3pt'> </span>disponible chez<span style='letter-spacing: -.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>sujets<span style='letter-spacing:-.25pt'> </span>a<span style='letter-spacing:.1pt'>y</span>ant<span style='letter-spacing:-.05pt'> </span>une<span style='letter-spacing:-.15pt'> </span>rétention<span style='letter-spacing:-.35pt'> </span>h<span style='letter-spacing:.1pt'>y</span>drique sévère.</p>
<p class=AmmCorpsTexte><b><u>Chimiothérapie associée</u></b></p>
<p class=AmmCorpsTexte style='margin-bottom:0cm;margin-bottom:.0001pt'><u>Doxorubicine</u></p>
<p class=AmmCorpsTexte>Utilisé<span style='letter-spacing:-.55pt'> </span>en<span style='letter-spacing:-.1pt'> </span>association,<span style='letter-spacing: -.45pt'> </span>le docétaxel<span style='letter-spacing:-.35pt'> </span>ne<span style='letter-spacing:-.1pt'> m</span>odifie<span style='letter-spacing:-.1pt'> </span>ni<span style='letter-spacing:-.1pt'> </span>la clairance<span style='letter-spacing:-.3pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la doxorubicine,<span style='letter-spacing:-.55pt'> </span>ni<span style='letter-spacing:-.1pt'> </span>le niveau plas<span style='letter-spacing: -.1pt'>m</span>atique<span style='letter-spacing:.05pt'> </span>du<span style='letter-spacing:-.1pt'> </span>doxorubicinol<span style='letter-spacing: -.5pt'> </span>(un<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span>étabolite<span style='letter-spacing:-.35pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la doxorubicine).</p>
<p class=AmmCorpsTexte>Les<span style='letter-spacing:-.4pt'> </span>para<span style='letter-spacing:-.1pt'>m</span>ètres<span style='letter-spacing:-.3pt'> </span>phar<span style='letter-spacing:-.1pt'>m</span>acocinétiques<span style='letter-spacing: -.15pt'> </span>du<span style='letter-spacing:-.1pt'> </span>docétaxel,<span style='letter-spacing:-.4pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la doxorubicine<span style='letter-spacing:-.5pt'> </span>et du<span style='letter-spacing:-.1pt'> </span>c<span style='letter-spacing:.1pt'>y</span>clophospha<span style='letter-spacing:-.05pt'>m</span>ide<span style='letter-spacing:-.15pt'> </span>ne<span style='letter-spacing:-.1pt'> </span>sont<span style='letter-spacing:-.15pt'> </span>pas <span style='letter-spacing:-.1pt'>m</span>odifiés<span style='letter-spacing: -.1pt'> </span>par<span style='letter-spacing:-.15pt'> </span>leur<span style='letter-spacing:-.15pt'> </span>co-ad<span style='letter-spacing:-.1pt'>m</span>inistration.</p>
<p class=AmmCorpsTexte style='margin-bottom:0cm;margin-bottom:.0001pt'><u>Capécitabine</u></p>
<p class=AmmCorpsTexte>Une<span style='letter-spacing:-.45pt'> </span>étude<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span>phase<span style='letter-spacing:-.25pt'> </span>I<span style='letter-spacing:-.05pt'> </span>évaluant<span style='letter-spacing:-.35pt'> </span>l'effet<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la capécitabine<span style='letter-spacing:-.15pt'> </span>sur<span style='letter-spacing:-.1pt'> </span>la phar<span style='letter-spacing:-.1pt'>m</span>acocinétique<span style='letter-spacing:-.15pt'> </span>du<span style='letter-spacing:-.1pt'> </span>docétaxel<span style='letter-spacing:-.35pt'> </span>et réciproque<span style='letter-spacing: -.05pt'>m</span>ent, n<span style='letter-spacing:-.05pt'>'</span>a<span style='letter-spacing:-.05pt'> </span>dé<span style='letter-spacing:-.1pt'>m</span>ontré<span style='letter-spacing:-.1pt'> </span>aucun<span style='letter-spacing:-.25pt'> </span>effet<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la<span style='letter-spacing:-.05pt'> </span>capécitabine<span style='letter-spacing: -.45pt'> </span>sur<span style='letter-spacing:-.1pt'> </span>la phar<span style='letter-spacing:-.1pt'>m</span>acocinétique<span style='letter-spacing: -.15pt'> </span>du<span style='letter-spacing:-.1pt'> </span>docétaxel<span style='letter-spacing:-.4pt'> </span>(C<sub><span style='letter-spacing:-.1pt'>m</span>ax<span style='letter-spacing:1.8pt'> </span></sub>et<span style='letter-spacing:-.25pt'> </span>ASC)<span style='letter-spacing:-.25pt'> </span>ni<span style='letter-spacing:-.1pt'> </span>d’effet<span style='letter-spacing:-.25pt'> </span>du docétaxel<span style='letter-spacing:-.35pt'> </span>sur<span style='letter-spacing:-.1pt'> </span>la phar<span style='letter-spacing:-.15pt'>m</span>acocinétique<span style='letter-spacing:-.15pt'> </span>du<span style='letter-spacing:-.1pt'> </span>5’<span style='letter-spacing:-.1pt'> </span>DFUR,<span style='letter-spacing:-.3pt'> </span>un<span style='letter-spacing:-.1pt'> m</span>étabolite<span style='letter-spacing: -.35pt'> </span>significatif<span style='letter-spacing:-.45pt'> </span>de la capécitabine.</p>
<p class=AmmCorpsTexte style='margin-bottom:0cm;margin-bottom:.0001pt'><u>Cisplatine</u></p>
<p class=AmmCorpsTexte>La<span style='letter-spacing:-.35pt'> </span>clairance<span style='letter-spacing:-.35pt'> </span>du<span style='letter-spacing:-.1pt'> </span>docétaxel<span style='letter-spacing:-.4pt'> </span>associé<span style='letter-spacing:-.3pt'> </span>au<span style='letter-spacing:-.1pt'> </span>cisplatine<span style='letter-spacing:-.4pt'> </span>est<span style='letter-spacing:-.1pt'> </span>si<span style='letter-spacing:-.1pt'>m</span>ilaire<span style='letter-spacing:-.05pt'> </span>à celle observée<span style='letter-spacing:-.35pt'> </span>en<span style='letter-spacing:-.1pt'> m</span>onothérapie.<span style='letter-spacing: -.1pt'> </span>Le<span style='letter-spacing:-.1pt'> </span>profil phar<span style='letter-spacing:-.1pt'>m</span>acocinétique<span style='letter-spacing: -.15pt'> </span>du<span style='letter-spacing:-.1pt'> </span>cisplatine<span style='letter-spacing:-.35pt'> </span>ad<span style='letter-spacing:-.1pt'>m</span>inistré<span style='letter-spacing:-.3pt'> </span>peu<span style='letter-spacing:-.15pt'> </span>après<span style='letter-spacing:-.2pt'> </span>la perfusion<span style='letter-spacing: -.4pt'> </span>de<span style='letter-spacing:-.1pt'> </span>docétaxel<span style='letter-spacing:-.4pt'> </span>est<span style='letter-spacing:-.1pt'> </span>si<span style='letter-spacing:-.1pt'>m</span>ilaire<span style='letter-spacing:-.05pt'> </span>à celui<span style='letter-spacing:-.2pt'> </span>observé avec<span style='letter-spacing:-.2pt'> </span>le cisplatine<span style='letter-spacing: -.4pt'> </span>seul.</p>
<p class=AmmCorpsTexte style='margin-bottom:0cm;margin-bottom:.0001pt; page-break-after:avoid'><u>Cisplatine et 5-fluorouracile</u></p>
<p class=AmmCorpsTexte>L<span style='letter-spacing: .05pt'>’</span>association<span style='letter-spacing:-.05pt'> </span>du<span style='letter-spacing:-.1pt'> </span>docétaxel<span style='letter-spacing:-.4pt'> </span>avec<span style='letter-spacing:-.2pt'> </span>le cisplatine<span style='letter-spacing:-.35pt'> </span>et<span style='letter-spacing:-.1pt'> </span>le 5-fluoro-uracile chez<span style='letter-spacing:-.2pt'> </span>12<span style='letter-spacing:-.1pt'> </span>patients<span style='letter-spacing:-.3pt'> </span>présentant<span style='letter-spacing:-.4pt'> </span>des<span style='letter-spacing:-.15pt'> </span>tu<span style='letter-spacing:-.1pt'>m</span>eurs solides<span style='letter-spacing:-.3pt'> </span>n<span style='letter-spacing: .05pt'>’</span>a<span style='letter-spacing:-.05pt'> </span>pas<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span>ontré<span style='letter-spacing:-.1pt'> </span>d<span style='letter-spacing:.05pt'>’</span>influence<span style='letter-spacing:-.05pt'> </span>sur<span style='letter-spacing:-.1pt'> </span>le<span style='letter-spacing:.05pt'> </span>profil<span style='letter-spacing:-.2pt'> </span>phar<span style='letter-spacing:-.1pt'>m</span>acocinétique<span style='letter-spacing: -.15pt'> </span>de<span style='letter-spacing:-.1pt'> </span>chacun<span style='letter-spacing:-.3pt'> </span>des<span style='letter-spacing:-.15pt'> </span>produits.</p>
<p class=AmmCorpsTexte style='margin-bottom:0cm;margin-bottom:.0001pt'><u>Prednisone et dexamethasone</u></p>
<p class=AmmCorpsTexte>L’effet<span style='letter-spacing:-.55pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la prednisone<span style='letter-spacing: -.45pt'> </span>sur<span style='letter-spacing:-.1pt'> </span>la<span style='letter-spacing:-.05pt'> </span>phar<span style='letter-spacing:-.1pt'>m</span>acocinétique<span style='letter-spacing:-.15pt'> </span>du<span style='letter-spacing:-.1pt'> </span>docétaxel<span style='letter-spacing:-.35pt'> </span>ad<span style='letter-spacing:-.1pt'>m</span>inistré<span style='letter-spacing:-.3pt'> </span>avec<span style='letter-spacing:-.2pt'> </span>une<span style='letter-spacing:-.15pt'> </span>pré<span style='letter-spacing:-.1pt'>m</span>édication<span style='letter-spacing:-.15pt'> </span>standard de<span style='letter-spacing: -.1pt'> </span>dexa<span style='letter-spacing:-.05pt'>m</span>éthasone<span style='letter-spacing:-.5pt'> </span>a été étudié<span style='letter-spacing: -.25pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>42<span style='letter-spacing:-.1pt'> </span>p<span style='letter-spacing:-.05pt'>a</span>tients.<span style='letter-spacing:-.05pt'> </span></p>
<p class=AmmCorpsTexte style='margin-bottom:0cm;margin-bottom:.0001pt'><u><span style='letter-spacing:-.05pt'>Prednisone</span></u></p>
<p class=AmmCorpsTexte>Aucun<span style='letter-spacing:-.25pt'> </span>effet<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.15pt'> </span>la prednisone<span style='letter-spacing:-.45pt'> </span>sur<span style='letter-spacing:-.1pt'> </span>la phar<span style='letter-spacing:-.1pt'>m</span>acocinétique<span style='letter-spacing:-.15pt'> </span>du docétaxel<span style='letter-spacing: -.35pt'> </span>n<span style='letter-spacing:.05pt'>’</span>a<span style='letter-spacing:-.05pt'> </span>été observé.</p>
<p class="AmmAnnexeTitre2"><a name="RcpSecuritePreclinique">5.3. Données de sécurité préclinique</a></p>
<p class=AmmCorpsTexte><a name="_Toc142278935">Le potentiel carcinogène du docétaxel n’a pas été étudié.</a></p>
<p class=AmmCorpsTexte>Le docétaxel s’est révélé mutagène dans les tests du micronoyau et d’aberration chromosomique in vitro sur des cellules CHO K1 ainsi que dans le test du micronoyau in vivo chez la souris. Ni le test d’Ames ni l’essai de mutation génique CHO/HGPRT n’ont mis en évidence un effet mutagène du produit. Ces résultats concordent avec l’activité pharmacologique du docétaxel.</p>
<p class=AmmCorpsTexte>Des anomalies portant sur les testicules ont été observées dans les études chez les rongeurs et suggèrent que le docétaxel pourrait altérer la fertilité chez l’homme.</p>
<p class="AmmAnnexeTitre1"><a name="RcpDonneesPharmaceutiques">6. DONNEES PHARMACEUTIQUES</a></p>
<p class="AmmAnnexeTitre2"><a name="RcpListeExcipients">6.1. Liste des excipients</a></p>
<p class=AmmCorpsTexte style='margin-bottom:0cm;margin-bottom:.0001pt'><a name="_Toc142278937">Polysorbate 80, éthanol à 96 %, acide citrique monohydraté.</a></p>
<p class="AmmAnnexeTitre2"><a name="RcpIncompatibilites">6.2. Incompatibilités</a></p>
<p class=AmmCorpsTexte><a name="_Toc142278938">Ce<span style='letter-spacing: -.35pt'> </span><span style='letter-spacing:-.1pt'>m</span>édica<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.25pt'> </span>ne<span style='letter-spacing:-.1pt'> </span>doit<span style='letter-spacing:-.15pt'> </span>pas<span style='letter-spacing:-.15pt'> </span>être<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span>élangé<span style='letter-spacing:-.3pt'> </span>avec<span style='letter-spacing:-.2pt'> </span>d<span style='letter-spacing:.05pt'>’</span>autres<span style='letter-spacing:-.05pt'> </span><span style='letter-spacing:-.1pt'>m</span>édica<span style='letter-spacing:-.05pt'>m</span>ents<span style='letter-spacing:-.25pt'> </span>à l<span style='letter-spacing:.05pt'>’</span>exception<span style='letter-spacing: -.05pt'> </span>de<span style='letter-spacing:-.1pt'> </span>ceux<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:-.1pt'>m</span>entionnés<span style='letter-spacing:-.4pt'> </span>dans la rubrique<span style='letter-spacing: -.35pt'> </span>6.6.</a></p>
<p class="AmmAnnexeTitre2"><a name="RcpDureeConservation">6.3. Durée de conservation</a></p>
<p class=AmmCorpsTexte><a name="_Toc142278939"><u>Flacon</u></a></p>
<p class=AmmCorpsTexte>24 mois.</p>
<p class=AmmCorpsTexte><u>Après ouverture du flacon</u></p>
<p class=AmmCorpsTexte>Chaque flacon est à usage unique et doit être utilisé immédiatement après ouverture. En cas d’utilisation non immédiate, les durées et conditions de conservation sont de la responsabilité de l’utilisateur.</p>
<p class=AmmCorpsTexte><u>Après addition dans la poche de perfusion</u></p>
<p class=AmmCorpsTexte>D'un point de vue microbiologique, la reconstitution/dilution doit être réalisée dans des conditions contrôlées et aseptiques et le médicament doit être utilisé immédiatement. En cas d’utilisation non immédiate, les durées et conditions de conservation sont de la responsabilité de l’utilisateur.</p>
<p class=AmmCorpsTexte>Une fois introduite comme recommandé dans la poche de perfusion (PP) ou le flacon de perfusion (PE), la solution pour perfusion de docétaxel, si elle est conservée à une température ne dépassant pas 25°C, reste stable pendant 8 heures dans le flacon de perfusion et pendant 6 heures dans la poche de perfusion. Elle doit être utilisée dans les 6–8 heures (en comptant l’heure nécessaire pour l’administration IV de la perfusion).</p>
<p class=AmmCorpsTexte>De plus, la stabilité physico-chimique en condition d’utilisation de la solution pour perfusion, préparée selon les recommandations, a été démontrée dans des poches exemptes de PVC, jusqu’à 48 heures conservées entre 2 et 8°C.</p>
<p class=AmmCorpsTexte>La solution pour perfusion de docétaxel est hyper-saturée, et peut par conséquent cristalliser dans le temps. En cas d’apparition de cristaux, la solution ne devra plus être utilisée et devra être jetée.</p>
<p class="AmmAnnexeTitre2"><a name="RcpPrecConservation">6.4. Précautions particulières de conservation</a></p>
<p class=AmmCorpsTexte><a name="_Toc142278940">A conserver au réfrigérateur (entre </a>2°C et 8°C).</p>
<p class=AmmCorpsTexte>A conserver dans l’emballage extérieur d’origine, à l’abri de la lumière. </p>
<p class=AmmCorpsTexte>Pour les conditions de conservation du médicament dilué, voir rubrique 6.3.</p>
<p class="AmmAnnexeTitre2"><a name="RcpEmballage">6.5. Nature et contenu de l'emballage extérieur</a></p>
<p class=AmmCorpsTexte><a name="_Toc142278941">Flacon de 2 ml en verre incolore de type I, fermé par un bouchon gris de </a>13 mm en caoutchouc chlorobutyle et un capuchon vert amovible constitué d’un opercule en aluminium et d’un cerclage amovible en plastique vert. Le bouchon en caoutchouc est enrobé d’un film protecteur en Teflon®.</p>
<p class=AmmCorpsTexte>Chaque boîte contient un flacon avec un volume de remplissage de 1 ml.</p>
<p class="AmmAnnexeTitre2"><a name="RcpPrecEmpl">6.6. Précautions particulières d’élimination et de manipulation</a></p>
<p class=AmmCorpsTexte><a name="_Toc142278942">Le<span style='letter-spacing: -.35pt'> </span>docétaxel est un agent antinéoplasique et, comme tous les autres composés potentiellement toxiques, doit être manipulé et préparé avec précautions. L’usage de gants est recommandé.</a></p>
<p class=AmmCorpsTexte>En cas de contact cutané avec la solution à diluer ou la solution pour perfusion de docétaxel, il convient de rincer immédiatement et soigneusement la peau à l'eau et au savon. En cas de contact d'une muqueuse avec la solution à diluer ou la solution pour perfusion de docétaxel, il convient de laver immédiatement la région souillée, à grande eau.</p>
<p class=AmmCorpsTexte><u>Préparation pour l’ad<span style='letter-spacing:-.05pt'>m</span>inistration<span style='letter-spacing: -.4pt'> </span>intraveineuse</u></p>
<p class=AmmCorpsTexte><i><u><sub>Préparation de la solution pour perfusion</sub></u></i></p>
<p class=AmmCorpsTexte><b>NE PAS utiliser d’autres médicaments contenant du docétaxel se présentant sous plusieurs flacons (solution à diluer et solvant) avec ce médicament (DOCETAXEL SEACROSS 20 mg/1 ml, solution à diluer pour perfusion, composé de seulement 1 flacon).</b></p>
<p class=AmmCorpsTexte><b>DOCETAXEL SEACROSS 20 mg/1 ml, solution à diluer pour perfusion<span style='letter-spacing:-.4pt'> </span>ne requiert<span style='letter-spacing:-.35pt'> </span>PAS<span style='letter-spacing:-.2pt'> </span>de dilution<span style='letter-spacing:-.35pt'> </span>préalable<span style='letter-spacing:-.4pt'> </span>avec un solvant<span style='letter-spacing: -.3pt'> </span>et est prêt<span style='letter-spacing:-.2pt'> </span>à<span style='letter-spacing:-.05pt'> </span>être<span style='letter-spacing:-.15pt'> </span>ajouté<span style='letter-spacing:-.25pt'> </span>à<span style='letter-spacing:-.05pt'> </span>la solution<span style='letter-spacing:-.35pt'> </span>pour<span style='letter-spacing: -.2pt'> </span>perfusion.</b></p>
<p class=AmmCorpsTexte>Chaque<span style='letter-spacing:-.6pt'> </span>flacon<span style='letter-spacing:-.25pt'> </span>est à usage<span style='letter-spacing: -.25pt'> </span>unique<span style='letter-spacing:-.25pt'> </span>et doit<span style='letter-spacing:-.15pt'> </span>être<span style='letter-spacing:-.15pt'> </span>utilisé<span style='letter-spacing:-.25pt'> </span>immédiate<span style='letter-spacing: -.05pt'>m</span>ent.</p>
<p class=AmmCorpsTexte>Laisser le nombre de boîtes nécessaire de DOCETAXEL SEACROSS, solution à diluer pour perfusion reposer à une température inférieure à 25°C pendant 5 minutes avant utilisation.</p>
<p class=AmmCorpsTexte>Plus<span style='letter-spacing:-.45pt'> </span>d<span style='letter-spacing:.05pt'>’</span>un<span style='letter-spacing:-.05pt'> </span>flacon<span style='letter-spacing:-.2pt'> </span>de DOCETAXEL SEACROSS<span style='letter-spacing:-.55pt'> </span>solution<span style='letter-spacing:-.3pt'> </span>à diluer<span style='letter-spacing:-.3pt'> </span>pour<span style='letter-spacing:-.2pt'> </span>perfusion<span style='letter-spacing:-.4pt'> </span>peuvent<span style='letter-spacing:-.25pt'> </span>être nécessaires<span style='letter-spacing:-.35pt'> </span>pour<span style='letter-spacing:-.2pt'> </span>obtenir<span style='letter-spacing:-.3pt'> </span>la dose prescrite<span style='letter-spacing: -.35pt'> </span>à un patient.<span style='letter-spacing:-.3pt'> </span>Extraire<span style='letter-spacing:-.3pt'> </span>de façon<span style='letter-spacing:-.3pt'> </span>aseptique<span style='letter-spacing:-.4pt'> </span>la quantité<span style='letter-spacing:-.25pt'> </span>requise<span style='letter-spacing:-.3pt'> </span>de DOCETAXEL SEACROSS,<span style='letter-spacing:-.55pt'> </span>solution<span style='letter-spacing:-.3pt'> </span>à diluer<span style='letter-spacing:-.25pt'> </span>pour perfusion<span style='letter-spacing:-.4pt'> </span>à l’aide<span style='letter-spacing:-.2pt'> </span>d’une<span style='letter-spacing:-.25pt'> </span>seringue<span style='letter-spacing:-.35pt'> </span>graduée<span style='letter-spacing:-.3pt'> </span>adaptée.</p>
<p class=AmmCorpsTexte><b>Dans<span style='letter-spacing:-.5pt'> </span>un flacon<span style='letter-spacing:-.25pt'> </span>de DOCETAXEL SEACROSS<span style='letter-spacing:-.55pt'> </span>20 mg/1<span style='letter-spacing:-.2pt'> </span>ml,<span style='letter-spacing:-.15pt'> </span>la concentration<span style='letter-spacing:-.6pt'> </span>de docétaxel<span style='letter-spacing:-.4pt'> </span>est de 20 mg/ml.</b></p>
<p class=AmmCorpsTexte>Le volume requis de DOCETAXEL SEACROSS, solution à diluer pour perfusion doit être injecté en une injection unique (en une seule fois) dans une poche ou un flacon de perfusion de 250 ml contenant soit une solution glucosée à (5 %) soit une solution de chlorure de sodium à 9 mg/ml (0,9 %).pour injection. </p>
<p class=AmmCorpsTexte>Si<span style='letter-spacing:-.35pt'> </span>une<span style='letter-spacing:-.15pt'> </span>dose<span style='letter-spacing:-.2pt'> </span>supérieure<span style='letter-spacing:-.4pt'> </span>à 190<span style='letter-spacing:-.15pt'> </span>mg<span style='letter-spacing:-.05pt'> </span>de docétaxel<span style='letter-spacing: -.35pt'> </span>est requise,<span style='letter-spacing:-.05pt'> </span>utiliser<span style='letter-spacing:-.25pt'> </span>un volume<span style='letter-spacing: -.2pt'> </span>plus<span style='letter-spacing:-.15pt'> </span>important de véhicule<span style='letter-spacing:-.3pt'> </span>de perfusion<span style='letter-spacing:-.4pt'> </span>de sorte<span style='letter-spacing:-.2pt'> </span>que<span style='letter-spacing:-.15pt'> </span>la concentration<span style='letter-spacing:-.5pt'> </span>en docétaxel<span style='letter-spacing: -.4pt'> </span>de 0,74<span style='letter-spacing:-.15pt'> </span>m<span style='letter-spacing:.05pt'>g</span>/ml ne soit<span style='letter-spacing: -.15pt'> </span>pas<span style='letter-spacing:-.15pt'> </span>dépassée.</p>
<p class=AmmCorpsTexte>Mélanger<span style='letter-spacing:-.65pt'> </span>manuelle<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.4pt'> </span>la poche<span style='letter-spacing:-.25pt'> </span>ou le f<span style='letter-spacing: -.05pt'>l</span>acon<span style='letter-spacing:-.05pt'> </span>de perfusion<span style='letter-spacing:-.4pt'> </span>par<span style='letter-spacing:-.15pt'> </span>rotation<span style='letter-spacing:-.25pt'> </span>manuelle.</p>
<p class=AmmCorpsTexte>La<span style='letter-spacing:-.35pt'> </span>poche<span style='letter-spacing:-.25pt'> </span>de solution<span style='letter-spacing: -.3pt'> </span>pour<span style='letter-spacing:-.2pt'> </span>perfusion<span style='letter-spacing:-.4pt'> </span>doit<span style='letter-spacing:-.15pt'> </span>être utilisée<span style='letter-spacing:-.35pt'> </span>dans<span style='letter-spacing: -.2pt'> </span>les 8<span style='letter-spacing:-.05pt'> </span>heures<span style='letter-spacing:-.25pt'> </span>à une<span style='letter-spacing:-.15pt'> </span>te<span style='letter-spacing:-.05pt'>m</span><span style='letter-spacing: .05pt'>p</span>érature<span style='letter-spacing:-.05pt'> </span>ne dépassant<span style='letter-spacing:-.4pt'> </span>pas 25°C incluant<span style='letter-spacing:-.25pt'> </span>l’heure<span style='letter-spacing:-.3pt'> </span>de perfusion<span style='letter-spacing:-.4pt'> </span>au patient.</p>
<p class=AmmCorpsTexte>Comme<span style='letter-spacing:-.15pt'> </span>pour<span style='letter-spacing:-.2pt'> </span>tous<span style='letter-spacing:-.15pt'> </span>les médica<span style='letter-spacing:-.05pt'>m</span>ents<span style='letter-spacing: -.25pt'> </span>administrés<span style='letter-spacing:-.35pt'> </span>par<span style='letter-spacing:-.15pt'> </span>voie<span style='letter-spacing:-.15pt'> </span>parentérale,<span style='letter-spacing:-.4pt'> </span>la solution<span style='letter-spacing: -.3pt'> </span>pour<span style='letter-spacing:-.2pt'> </span>perfusion<span style='letter-spacing:-.4pt'> </span>de DOCETAXEL SEACROSS<span style='letter-spacing:1.5pt'> </span>doit<span style='letter-spacing:-.15pt'> </span>être<span style='letter-spacing:-.15pt'> </span>contrôlée<span style='letter-spacing: -.3pt'> </span>visuelle<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.4pt'> </span>avant<span style='letter-spacing:-.2pt'> </span>toute<span style='letter-spacing:-.2pt'> </span>utilisation<span style='letter-spacing: -.35pt'> </span>; les solutions<span style='letter-spacing:-.35pt'> </span>contenant<span style='letter-spacing:-.35pt'> </span>un précipité<span style='letter-spacing: .05pt'> </span>doivent<span style='letter-spacing:-.3pt'> </span>être<span style='letter-spacing:-.15pt'> </span>éli<span style='letter-spacing:-.05pt'>m</span>inées.</p>
<p class=AmmCorpsTexte>Tout<span style='letter-spacing:-.45pt'> </span>produit<span style='letter-spacing:-.3pt'> </span>non<span style='letter-spacing:-.15pt'> </span>utilisé<span style='letter-spacing:-.2pt'> </span>ou déchet<span style='letter-spacing:-.2pt'> </span>doit<span style='letter-spacing:-.15pt'> </span>être<span style='letter-spacing:-.15pt'> </span>éli<span style='letter-spacing:-.05pt'>m</span>iné conformément<span style='letter-spacing:-.4pt'> </span>à la régle<span style='letter-spacing:-.05pt'>m</span>entation<span style='letter-spacing:-.15pt'> </span>en vigueur.</p>
<p class="AmmAnnexeTitre1"><a name="RcpTitulaireAmm">7. TITULAIRE DE L’AUTORISATION DE MISE SUR LE MARCHE</a></p>
<p class=AmmTitulaireNom style='margin-right:18.3pt'><a name="_Toc142278943"><span lang=DE style='text-transform:none'>SEACROSS PHARMACEUTICALS LTD</span></a></p>
<p class=AmmTitulaireAdresse><span lang=EN-GB>LANDMARK HOUSE</span></p>
<p class=AmmTitulaireAdresse><span lang=EN-GB>17 HANOVER SQUARE</span><span lang=EN-GB>, MAYFAIR</span></p>
<p class=AmmTitulaireAdresse>W1S 1HU LONDON</p>
<p class=AmmTitulaireAdresse>ROYAUME UNI</p>
<p class="AmmAnnexeTitre1"><a name="RcpPresentation">8. NUMERO(S) D’AUTORISATION DE MISE SUR LE MARCHE</a></p>
<p class=AmmListePuces1 style='text-align:justify'><a name="_Toc142278944"><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>582 289-9 ou 34009 582 289 9 5 : 1 flacon(s) en verre de 1 ml.</a></p>
<p class="AmmAnnexeTitre1"><a name="RcpPremiereAutorisation">9. DATE DE PREMIERE AUTORISATION/DE RENOUVELLEMENT DE L’AUTORISATION</a></p>
<p class=AmmCorpsTexte><a name="_Toc142278945">[à compléter par le titulaire]</a></p>
<p class="AmmAnnexeTitre1"><a name="RcpDateRevision">10. DATE DE MISE A JOUR DU TEXTE</a></p>
<p class=AmmCorpsTexte><a name="_Toc142278946">[à compléter par le titulaire]</a></p>
<p class="AmmAnnexeTitre1"><a name="RcpDosimetrie">11. DOSIMETRIE</a></p>
<p class=AmmCorpsTexte>Sans objet.</p>
<p class="AmmAnnexeTitre1"><a name="RcpInstPrepRadioph">12. INSTRUCTIONS POUR LA PREPARATION DES RADIOPHARMACEUTIQUES</a></p>
<p class=AmmCorpsTexte>Sans objet.</p>
<div style='border:none;border-top:solid windowtext 1.0pt;padding:1.0pt 0cm 0cm 0cm'>
<p class="AmmAnnexeTitre"><a name="RcpCondPrescription">CONDITIONS DE PRESCRIPTION ET DE DELIVRANCE</a></p>
</div>
<p class=AmmCorpsTexte>Liste I.</p>
<p class=AmmCorpsTexte>Médicament soumis à prescription hospitalière.</p>
<p class=AmmCorpsTexte>Prescription réservée aux spécialistes en oncologie ou en hématologie ou aux médecins compétents en cancérologie.</p>
<p class=AmmCorpsTexte>Médicament nécessitant une surveillance particulière.</p>
<b><span style='font-size:12.0pt;font-family:Arial;color:#0B3D92;text-transform:
uppercase'><br clear=all>
</span></b>
</BODY>
</HTML>
